<SEC-DOCUMENT>0000950170-25-107279.txt : 20250812
<SEC-HEADER>0000950170-25-107279.hdr.sgml : 20250812
<ACCEPTANCE-DATETIME>20250812160325
ACCESSION NUMBER:		0000950170-25-107279
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250812
DATE AS OF CHANGE:		20250812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Solid Biosciences Inc.
		CENTRAL INDEX KEY:			0001707502
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				900943402
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38360
		FILM NUMBER:		251206536

	BUSINESS ADDRESS:	
		STREET 1:		500 RUTHERFORD AVENUE
		STREET 2:		3RD FLOOR
		CITY:			CHARLESTOWN
		STATE:			MA
		ZIP:			02129
		BUSINESS PHONE:		617-337-4680

	MAIL ADDRESS:	
		STREET 1:		500 RUTHERFORD AVENUE
		STREET 2:		3RD FLOOR
		CITY:			CHARLESTOWN
		STATE:			MA
		ZIP:			02129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Solid Biosciences, LLC
		DATE OF NAME CHANGE:	20170524
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sldb-20250630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-08-12T15:25:36.0428+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:sldb="http://www.solidbio.com/20250630" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_f5ded806-230b-4664-8011-753569c38b74" name="dei:EntityCentralIndexKey" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55">0001707502</ix:nonNumeric><ix:nonNumeric id="F_13f7ae0a-ea3f-46eb-a941-70f57ddc3a47" name="dei:AmendmentFlag" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55">false</ix:nonNumeric><ix:nonNumeric id="F_8a6adb43-91a2-481d-877d-ef5fce7f1ff4" name="dei:CurrentFiscalYearEndDate" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55">--12-31</ix:nonNumeric><ix:nonNumeric id="F_baff5ccb-e6a8-4cf7-a384-1b3280c8fc2a" name="dei:DocumentFiscalPeriodFocus" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55">Q2</ix:nonNumeric><ix:nonFraction id="F_7ed96db2-e2ed-4040-b7b9-483f0b1967e0" name="us-gaap:CommitmentsAndContingencies" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_29f36a27-1849-4abf-89d8-42fbc895f4a4" name="us-gaap:CommitmentsAndContingencies" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_fd6a424f-9e78-46d4-9165-086964b4e16b" name="us-gaap:PreferredStockValue" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_3f4e1821-c913-4d84-8c0a-80ca54685688" name="us-gaap:PreferredStockValue" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_48d73115-07e5-48ba-9dc8-452243c36a43" name="sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1" contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c" unitRef="U_USD" decimals="INF" scale="3">0</ix:nonFraction><ix:nonFraction id="F_08ff9217-3602-4409-8438-1bc1896ee246" name="sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" unitRef="U_USD" decimals="INF" scale="3">0</ix:nonFraction><ix:nonFraction id="F_1be8fb40-e397-4eaf-b81b-88444ec1c2a6" name="sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1" contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c" unitRef="U_USD" decimals="INF" scale="3">0</ix:nonFraction><ix:nonFraction id="F_f576a497-b1ba-43df-9267-28b759106728" name="sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" unitRef="U_USD" decimals="INF" scale="3">0</ix:nonFraction><ix:nonFraction id="F_7f2d05a5-0a5c-4f59-b707-ed7bd008cae6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" unitRef="U_USD" decimals="INF" scale="3">0</ix:nonFraction><ix:nonFraction id="F_0a9b999f-ba3c-4c75-85b3-624f3daa13ec" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c" unitRef="U_USD" decimals="INF" scale="3">0</ix:nonFraction><ix:nonFraction id="F_3c78939b-2f88-43de-94c1-2b2dca662653" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" unitRef="U_USD" decimals="INF" scale="3">0</ix:nonFraction><ix:nonFraction id="F_5fe053a6-d452-4df1-bff8-51707a501d58" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c" unitRef="U_USD" decimals="INF" scale="3">0</ix:nonFraction><ix:nonFraction id="F_2eb056d4-25d3-4b79-9779-b2b71429c937" name="sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" unitRef="U_USD" decimals="INF" scale="3">0</ix:nonFraction><ix:nonFraction id="F_38c85a03-f1da-4bb9-bee4-e34e8e64f14b" name="sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2" contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c" unitRef="U_USD" decimals="INF" scale="3">0</ix:nonFraction><ix:nonFraction id="F_981c76c5-7e07-41ab-a103-d0737a7932bd" name="sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" unitRef="U_USD" decimals="INF" scale="3">0</ix:nonFraction><ix:nonFraction id="F_81ea4290-b268-4d22-8def-51b3d1505ec7" name="sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2" contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c" unitRef="U_USD" decimals="INF" scale="3">0</ix:nonFraction><ix:nonFraction id="F_3a22dccf-9544-457d-a4be-457034ddacdf" name="sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" unitRef="U_USD" decimals="INF" scale="3">0</ix:nonFraction><ix:nonFraction id="F_cb4f10ce-e1bf-4e65-ab4b-c31784741e94" name="sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1" contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c" unitRef="U_USD" decimals="INF" scale="3">0</ix:nonFraction><ix:nonFraction id="F_4ad198f7-47e2-4a32-bdfc-243a9a08f8d7" name="sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" unitRef="U_USD" decimals="INF" scale="3">0</ix:nonFraction><ix:nonFraction id="F_d2f01e79-37d9-4163-914f-7030affd467c" name="sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1" contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c" unitRef="U_USD" decimals="INF" scale="3">0</ix:nonFraction><ix:nonNumeric id="F_1cf5d347-81ef-4291-87b4-2b55905c5532" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sldb-20250630.xsd"/></ix:references><ix:resources><xbrli:context id="C_80913da5-18e0-4e2d-9932-f1f9a150ed8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81638abc-ed31-43b9-98ef-a8496af60b08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8254bb6c-0764-44d8-a999-479ae11715b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8353f2de-6a98-4421-bb84-ff19b77babb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sldb:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83ce3b1a-e318-4538-962e-ec2695fed38c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:ProbabilityOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8466f2d9-6b68-47d7-ba93-53848911d53e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_852de8fa-b9b7-41ee-aac7-7d5c2c175c8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sldb:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:February2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86fa028f-2418-4cf6-b959-b70470ee2aa9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_888d7863-e043-4b8e-9a9c-902e9e4efb65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_889a20b7-df33-41ee-923b-1fa83b319dc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8930ba8b-d153-4438-8796-eeb7f6030e7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b6d4398-1614-4734-94af-3cd9579e2b1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:InternalResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8bdf85e3-0c40-4066-9f25-f31d21aef5df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:TimingOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8bf9e100-f231-4586-b5dd-838b0884dd87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sldb:OfficeAndLaboratoryLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d226a90-397f-41ab-935f-5aab9dd4c71c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8db1bca0-aca7-44cf-ac19-c26a69173dfc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sldb:UnvestedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e05825b-3564-43f0-9df6-8e98b1d7be91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e9b54e8-5db3-4a2c-8d9c-a1cdfcf765d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ebf87b6-992f-494c-8560-27ee2a653d27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8fe8d85b-2d6f-43f1-b624-cffb99addfa2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sldb:AccruedMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9123b419-0bc2-4374-94a6-007cd47c652a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9357a2d9-9713-42be-ad31-6036ccaefd7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sldb:Fa212LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_944b7695-ad9e-4285-960c-d72aec8f998b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:SGT003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9611295f-24d3-4b23-a0ec-62392a8b5c79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96ed23d1-a1e6-4659-bc21-14e675a602f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96fa1fb9-5125-47c5-9d54-82197981893e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sldb:GovernmentBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98efec03-6261-4884-8666-bf6095a4bb0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sldb:Fa212LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99ed3715-c191-4bd1-af0a-a1b55b1bcf04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sldb:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a0af20a-6059-403f-91cf-5541fbb0763d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a594a20-a7ac-4b49-ae92-d855f2517334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a88d8b1-f41f-4be3-91c2-23b45a6dd969"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9afdb802-6737-49db-88fa-ef76a745ff30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sldb:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b1b1aff-b775-4fdd-b8ca-07668edaa8ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b696383-da9c-41fe-9065-748e255e49a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sldb:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9bea4674-820e-4575-bad5-37c016a585cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sldb:GovernmentBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d8cd037-690b-4ca0-a376-cbffcf5bfa7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e42e73a-a6c9-4461-a752-a23c4b0480e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sldb:Fa212LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1407b45-da9f-427b-a243-aed2688829bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:SGT003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a14e5cf5-aed7-466a-9751-7832ebbdde1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4cf9151-2ea2-4600-8153-d60667cae2dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sldb:Fa212LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a537fa02-a1f1-49bd-84cb-8936826a3d3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a698c408-5f01-47f3-97e9-aa9f2ef0cb86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a77281d0-83e9-4ceb-b6cd-ee4c4377550d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sldb:Fa212LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a81e0a2f-1838-4bd5-b00c-b952678b1b8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:SGT501Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a91acc16-ec5d-42f1-ae23-d52f464888f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-11</xbrli:startDate><xbrli:endDate>2024-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a99a7b4d-7291-4c75-bfcd-d11cbca34f46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa5bd7ea-c156-4475-926c-e8eddecefd5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_abb48ec4-81de-4bdb-9fa1-14513edb7132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac9669fb-6c3b-47fb-90e4-6286c0192e44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad417689-b70e-4fdd-8ee9-88aa9781e90b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sldb:TreasuryBillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af5ce639-0ee4-4ebc-b2dc-3c8e938ebf5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af67bb44-76aa-4851-ada3-634e88aa092e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b0005526-5d37-401c-9d72-c06da6f9106f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b09c9e6d-7e59-4302-a92f-007cfefb2664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:TimingOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1b96c09-b829-40e0-9943-61aa3ed9067c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1d34379-d268-419a-8067-a8edfa178a20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:ExternalGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1dca8da-6809-47a8-bc34-ba283cb61a5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:TimingOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4ad5fd9-ef1a-4596-931b-e54dc3cf2c0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:ExternalResearchAndDevelopmentOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5119432-e3f6-4b09-b1da-c2228aab8045"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b83fb99f-5542-4814-ad4c-4ef8642b65e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:ExternalGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8a19bcd-ecaa-4d90-ba75-094d33c6ca5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:February2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-19</xbrli:startDate><xbrli:endDate>2025-02-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b9aed1ea-13eb-4016-bc97-d2029636fac4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdad8e63-34f9-4989-b0b3-c9137d6a4917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be22b5d9-efe2-482f-aa0b-2ae151a5a94d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be43a57e-e5c9-467b-9ef0-ad48c48eb300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be626f41-f068-4534-943f-caf740d9baca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sldb:AccruedResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bef71313-6e23-4dd9-8241-70fe0eb1517e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sldb:AccruedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c267e437-1d14-4b97-ac07-f8b08257fa7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c465dc2b-b8fb-4093-a52c-31899dca9507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c599352c-a66b-417c-85ef-0627fd3a2f3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sldb:TreasuryBillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c96a2be2-695f-4030-9b68-3a5f63eb3737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:InternalResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb1343da-e01f-4ce0-adcf-425c15f992be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sldb:UnvestedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbf823b0-60bc-410a-aeb8-2f8b923dc7c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc190b1a-b3c2-4730-8745-e9776ccd432e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:TimingOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc99c4e5-1df8-4c44-830a-6d130cb72576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd72c633-01e1-43fb-bc8c-26f766ba3391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfc39ec9-d790-474a-94f7-86f38a3344d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfc4b4a2-204b-43b5-a661-f05441902b21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cff1f316-69c3-4b3f-a8d5-620b81ea7de8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3cfa6b7-1a5b-468f-8cdb-18aa29db656f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sldb:AccruedResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d565f4e4-dbfe-4ca6-945a-b8666899b153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8ff73cd-5ef2-4164-872f-1f12e3c684c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:ExternalGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9216090-1e30-4279-8a28-35be3c27b884"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d97c1211-c3a9-4ea5-91b7-040fde3392b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9af6823-a26b-4885-a9fb-907deb94d20c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc97493b-5647-4a4b-aaa6-bd066ad9125f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:TimingOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dca2999e-bb17-4181-8e87-86f8da45617b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd44ede6-4ec4-41dd-9ad2-bab26319cb0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sldb:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ddbae127-0489-4e1a-9f96-5243dd079a21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de18e3d4-4b86-42dc-b5ca-c6702ad6d2fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de9d66b8-e543-4914-8cdd-a9d5b58ab10c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df55ee2b-223d-4c46-ab63-80dcac637cef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e13de2f2-ceab-4e18-9846-718dd592da8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1fc1533-e5f3-4a29-a6a7-15d22fa44a9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e39737d4-96a5-4208-8dd7-4b8993b23f93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e445144a-7061-4fa5-ae92-64b3821a428b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e481b2b4-78e4-493a-b1a7-9caece635448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e604e914-7ff0-4f04-b45a-8f2f9ce0c9bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6208aaa-c289-4498-b410-b580516620c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6263d79-32c5-4715-9a16-d2aa12863296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e87fa31e-fdf3-4012-9418-bb7b976dcee5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea7a5a80-b49b-47e8-a532-b9e2fbc30677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sldb:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1fd8b2d-e76f-4251-951c-312c4df54169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2a02817-6c5e-449e-a477-05d0a714df5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sldb:TwoThousandAndTwentyFourInducementStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2feab69-5f72-4f85-8dcc-ead4e1b51215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sldb:AccruedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f540fe1f-6760-4c9b-902f-500441ab7298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f578dfc8-5ea5-41f0-905c-c47b2fe1a24b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:ProbabilityOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6440943-092c-4f4b-8ccf-fb54b31a4a23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f72bf3d9-6c7b-4a2b-a09e-4c623d761a64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f86d33b7-2665-4a04-943a-c562c8410bd5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb4b367c-a294-43f5-af08-b0aea809fc01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sldb:OfficeAndLaboratoryLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbba6851-1a6e-4905-b021-c0bc7d5f40f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sldb:AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-11</xbrli:startDate><xbrli:endDate>2024-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fbce7cd5-1b2d-4126-b546-1df19016fd56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fde676d0-416a-44d0-990b-c79ab2d42ba2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe6f9f56-6572-4eb9-ab24-7440ff654b29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_004daa09-8340-480a-b520-e166a80e5304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00a86f62-54eb-4a64-af3c-51b16552e396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_020b0edf-b857-4f10-ac8b-229a8c436b55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04579f4c-0d92-4807-b526-47e70d33525d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_067da7b3-96d4-4d90-9b0a-89c4f29d4125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sldb:AccruedExpensesOtherAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07264e86-c26a-42ce-a8e5-89f7da5029a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a6c72f5-7161-423a-a27c-3a3a231889bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0afad434-c6ec-493a-ad86-7a15c47c34be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b47160b-f65e-4831-8696-c2c52dd0bc33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:ProbabilityOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ba68b2f-2dd1-4b87-be43-3f478cee6225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:SGT501Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0bea57c3-1523-47ea-b446-8474ebbcbd5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:ExternalResearchAndDevelopmentOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c822986-4362-4137-a232-16bb78f035a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0dbb79eb-088e-4b58-8b14-1c279ad90bd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:InternalGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0dfd0d13-a826-4ebd-b93f-49699f6c04b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e4f4078-c836-4440-84d7-12e84fc594a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f922a3e-5746-46b4-a40a-2a645e0ec579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0fbb6db9-57f0-4f7f-b13e-14af89636f51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:SGT003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1159e041-c22c-4bf8-b89b-c533c983f202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:InternalGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11726ae9-e40d-4c5b-83b8-8005c97ded06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11a10128-fba6-447d-a976-5fa084bf9295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_121327c9-aee0-4ee4-85a3-a872dfee9989"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sldb:AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-12</xbrli:startDate><xbrli:endDate>2025-06-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1289e95b-8da8-4d52-8d1f-4b8964a89bb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12e60ca8-b4cb-4f88-953a-ab24ae966a5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sldb:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_14340f1e-e345-45e4-974c-789fb31cb960"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15fd7743-86bb-49ec-b84d-abc109f772fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-11</xbrli:startDate><xbrli:endDate>2024-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1679319c-e556-4669-b19c-516102e53d80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_176c63c3-fc59-41a1-a932-f7bf7ba8d013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18030d3f-b395-4cc3-997d-b26bfd8329d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a3c625c-1186-436d-91aa-d8d2544b7b4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e06cedf-6a5d-4473-b93f-a7e7df103a67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e60639d-8283-41ae-8cd9-7b46f80766be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_201319f1-99d0-4366-bfc4-d818dfd528d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2161a6b4-6f9c-4f31-a82d-4f7221bf0362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:February2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-19</xbrli:startDate><xbrli:endDate>2025-02-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_232dc221-d840-420d-bab1-6b1e75c2fc36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_253f834d-9848-47a4-80e2-b6033edab9fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27139884-7a96-4e34-a577-e29115f6dc2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2724230e-7cdb-46f3-a217-d029bcdf1d1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28011c1d-5f4c-4932-ad90-695a175099ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ab7d9ae-f3fe-411e-aa31-941b38ba994f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:ProbabilityOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ad125fb-5eec-4263-bb8f-8a0e750525f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e4a7c1b-d7cd-41ff-9b20-980516f53df2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f3b7b59-d24f-40f5-8461-a913f95f8f17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fba1c08-32ae-4049-8fbf-3094c4c366bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:February2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3189d97a-043c-49ab-94df-6b80295ced76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:ExternalGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32a641e0-2697-41b7-a866-ce0eb5498572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_360e00c1-d83f-408a-8983-fda0502e6613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a78b22e-0dc9-4c13-a887-682de9fd6013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:SGT501Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b99cdb3-b726-4538-afce-a3801788fd13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3bc4e127-2055-433c-a159-d00bb0f66d84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:InternalGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3bd6d252-5e42-42c5-8ae2-0186828da84b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sldb:TwoThousandAndTwentyFourInducementStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c01f597-7579-48d0-bd5e-4b0f4f5104a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d8b7096-5d1f-45b8-b514-de72cd28a61a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sldb:TreasuryBillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40de0e1b-6102-4d68-a514-295bf97cabb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41f2e884-47b6-44f0-b8af-b6fb07efc6e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43201d5f-3fb8-4b8f-bcc4-042087291ecb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43934480-1ee4-495d-8199-c3e8feb3750c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sldb:Fa212LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-19</xbrli:startDate><xbrli:endDate>2024-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_467782df-d0fd-4099-acab-ff5bc1e9ec7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47b90c1a-3b38-4665-b877-e9472f8c44fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_486f1e6a-12ec-4d97-ab93-1669ee41521b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_491fb316-de76-4866-ae64-7e0adfba538c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a834eb1-0754-4f74-8286-ff19658ed3c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f06942d-922b-469e-b680-72ee9ddfb246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:ExternalResearchAndDevelopmentOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4fd6bf31-bc0e-49ed-9f27-784e94385c06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_509be445-ad50-4826-9d85-bc19b599ef83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:TimingOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50c05ebc-0ef9-47a4-a21f-7d16f9e48827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:InternalResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5102f076-6976-4786-8570-ddc9fcaa4fda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51655aef-3697-4608-9eff-6b7264ab13cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:ExternalResearchAndDevelopmentOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53878ad7-f60d-4fe9-9496-c94de89a86d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:ProbabilityOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55f5bc14-0f86-46cb-af50-0c8b568c21fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56e1e286-3df8-4b2c-bde0-b81555ab2370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sldb:TreasuryBillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_583384bc-be95-42dd-89bf-a2fab8449504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_583bdf28-4c22-41d2-bf7a-5f216b481995"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a01998c-63bd-4627-945b-11d0879cf70c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a879064-7c82-4954-9b22-68f6cb214734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sldb:AccruedExpensesOtherAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b2c2df1-3cdd-4a8f-b2dd-15e41f28a290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sldb:GovernmentBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5dadfd3e-8058-4606-b32d-a0cfe60eb067"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60238495-82b4-4a9e-8f0c-dec2e85bad33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60a0c528-a68d-432e-aab7-f31907efd67f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6402365a-b943-488b-9bd3-756393cdd6c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sldb:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64acb9d0-11e7-4835-9467-65098353bd5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:SGT003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6573f6ee-fbf9-4133-87fb-c760c893c038"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_674b0646-86dc-4ece-b574-7ef26e78d9f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_67fc3ae3-0a38-4bcf-a5f8-68d2ff13b334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69be95bd-262a-441d-b2bd-98d19efe9bd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b0dcf24-e56b-4005-a22c-bc5fb3b0c9b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b51695d-2c24-4616-9d6b-cb74e1484c1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b940487-af87-4229-a014-aac844c38125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6cd19d05-d8a7-4151-a703-c33e74dfa457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sldb:Fa212LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d1d0185-6a08-4a4d-bf78-3cf596bda452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d7a65a2-794d-4455-9e96-273e3ca49062"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:InternalGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6da01f39-bdb4-4e8f-b42c-7df09d145c96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6fc1a0fa-31ae-4532-816a-741e0211781d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sldb:GovernmentBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ff04018-2bea-4ce0-9148-099fbf986bc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71f48d56-146a-435b-9b14-f7e66b80f25a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72a44744-a858-4632-9155-e3c3f22a4ca6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75db7873-c2fc-46ea-9e70-df62f468e4fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7621a0fc-5398-41ee-bdd0-b6ec3eec8693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77693677-27d9-4472-b43c-7dbe442a2eb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:InternalResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_78d04ead-7986-4a8d-8aac-14a63c569702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7aca4bd1-bcd1-48cc-9174-dd70c602d117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sldb:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ad823ef-64bf-4820-ae9b-3a36a9790d50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:SGT501Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b3b5780-a030-4090-8d67-27c854d7392e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d4b4b58-8e68-4c67-aaf1-47f818c7a79f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sldb:Fa212LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-28</xbrli:startDate><xbrli:endDate>2025-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ff2cf9c-d175-4659-8c95-55b9ec8a0868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001707502</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:ProbabilityOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Y"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>sldb:Segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.14in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#1a1915;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">			 	  </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:1.5pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, DC 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:17pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e15066a-70da-4663-9669-32cfbe205d12" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-Q</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de0fbd29-bb7c-4fff-b496-61c9ac711a0e" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1882ff9-f1bb-4740-a162-637230c0b28e" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32929bba-e059-4bf6-9e8e-569dbd587654" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50169f3f-0f42-47be-88d8-59be20e7aad1" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from _________ to _________</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_afec392a-2f00-4bc3-a74d-d31c078f0dd8" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-38360</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img247595994_0.jpg" alt="img247595994_0.jpg" style="width:89px;height:89px;"/></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e3cc7a5d-6a8b-465b-ba16-73f52ae50368" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Solid Biosciences Inc.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:49%;box-sizing:content-box;"/>
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:49%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7f03510d-3476-4716-ab2f-e45d242a94d8" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_367eff5f-14cd-4794-8537-d0b6e8e3b250" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">90-0943402</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6d014bc0-1bc9-4565-a9dc-13cdf577f204" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">500 Rutherford Avenue</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_822bc2e0-bba9-4980-9841-a83d306739a0" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:EntityAddressCityOrTown" continuedAt="F_822bc2e0-bba9-4980-9841-a83d306739a0_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Third Floor</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:continuation id="F_822bc2e0-bba9-4980-9841-a83d306739a0_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Charlestown</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_36ddcffc-8224-4e75-9bd6-0b3136d70a5c" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3084a607-7c50-4016-8b8f-b82f49c3b412" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">02129</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_69a05166-7e07-475a-9442-5fb65986f577" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">617</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6c2feb1-ef77-48c0-ba04-ae6e949ca771" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">337-4680</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:4pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:33.32%;box-sizing:content-box;"/>
     <td style="width:33.34%;box-sizing:content-box;"/>
     <td style="width:33.34%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Symbol</span></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ed4bd3c9-d068-4721-b3b6-4952a5c1c2f5" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_31d26746-9a2e-44b5-8a65-76cedad3737c" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SLDB</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_62031173-5122-4d86-96c6-999ae561c509" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3f41a032-89c5-4c3e-b9e2-9ea40cfe445f" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;    No  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2ea3c317-6fe9-418d-9566-590b0ab2020a" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;     No  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:26.75pt;margin-right:0.083%;text-align:center;margin-left:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.227%;text-indent:-43.707%;padding-left:28.52%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left; margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.14in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#1a1915;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">			 	  </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:17.78%;box-sizing:content-box;"/>
     <td style="width:3.34%;box-sizing:content-box;"/>
     <td style="width:53.32%;box-sizing:content-box;"/>
     <td style="width:22.54%;box-sizing:content-box;"/>
     <td style="width:3.02%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_35307faa-5ec5-47fd-a7e2-b841990cf334" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8de1dabd-b5af-4cd8-9639-496067ef6a5d" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c3c817e6-b800-42b1-9af8-91de2e44798d" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ee34f28-4e27-4fc7-bc6a-bf52cf30f11c" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    No  &#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of August 7, 2025, the registrant had </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf03a9aa-1737-48e8-9bb7-249be2bc21d6" contextRef="C_6b51695d-2c24-4616-9d6b-cb74e1484c1c" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">77,869,071</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, $0.001 par value per share, outstanding.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:26.75pt;margin-right:0.083%;text-align:center;margin-left:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.227%;text-indent:-43.707%;padding-left:28.52%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left; margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOLID BIOSCIENCES INC.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:9.84%;box-sizing:content-box;"/>
     <td style="width:84%;box-sizing:content-box;"/>
     <td style="width:6.16%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.741%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#cautionary"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART I.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ifinancial_information"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">FINANCIAL INFORMATION</span></a><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_condensed_consolidated_financial_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements (Unaudited)</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:36pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Balance Sheets at June 30, 2025 and December 31, 2024</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:36pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_operat"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:36pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:36pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_compre"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2025 and 2024</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:36pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_change"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity for the three and six months ended June 30, 2025 and 2024</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:36pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_cash_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;text-indent:36pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_condensed_consolidated_financia"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to the Condensed Consolidated Financial Statements</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_quantitative_qualitative_disclosu"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART II.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iior_information"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">OTHER INFORMATION</span></a><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_unregistered_sales_equity_securit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">SIGNATURES</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="cautionary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Quarterly Report on Form 10-Q includes forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;seek,&#8221; &#8220;predict,&#8221; &#8220;aim,&#8221; &#8220;continue,&#8221; &#8220;possible,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would&#8221; or &#8220;should&#8221; or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Quarterly Report on Form 10-Q. We derive many of our forward-looking statements from our operating budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and, of course, it is impossible for us to anticipate all factors that could affect our actual results. All forward-looking statements are based upon information available to us on the date of this Quarterly Report on Form 10-Q.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, progress, design and results of ongoing and planned preclinical studies and clinical trials for our neuromuscular (e.g., SGT-003, SGT-212), cardiac (e.g., SGT-401, SGT-501, SGT-601) or other future candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish or maintain collaborations or strategic relationships;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain U.S. and foreign regulatory approval of our neuromuscular (e.g., SGT-003, SGT-212), cardiac (e.g., SGT-401, SGT-501, SGT-601) or other future candidates, and the timing and scope thereof; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and outcomes of regulatory interactions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size of the patient populations and potential market opportunity for our neuromuscular (e.g., SGT-003, SGT-212), cardiac (e.g., SGT-401, SGT-501, SGT-601) or other future candidates, if approved for commercial use;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our manufacturing capabilities and strategy, including capacity constraints and the scalability and commercial viability of our manufacturing methods and processes;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans to develop and commercialize our neuromuscular (e.g., SGT-003, SGT-212), cardiac (e.g., SGT-401, SGT-501, SGT-601) or other future candidates, if approved; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the pricing and reimbursement of our neuromuscular (e.g., SGT-003, SGT-212), cardiac (e.g., SGT-401, SGT-501, SGT-601) or other future candidates we may develop, if approved; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the establishment of sales, marketing and distribution capabilities and entry into agreements with third parties to market and sell our neuromuscular (e.g., SGT-003, SGT-212), cardiac (e.g., SGT-401, SGT-501, SGT-601) or other future candidates, if approved; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rate and degree of market acceptance and clinical utility of our neuromuscular (e.g., SGT-003, SGT-212), cardiac (e.g., SGT-401, SGT-501, SGT-601) or other future candidates, if approved; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans to develop our platform technologies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations related to our use of capital resources; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates regarding expenses, ongoing losses, future revenue, capital requirements, and need for and ability to obtain additional financing; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our intellectual property position; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitive and market position; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments relating to our competitors and our industry; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to continue as a going concern; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of laws, regulations, and global political and economic developments, including the imposition of tariffs or other trade restrictions, on our business, operations, strategy and goals. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.139%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition, business and prospects may differ materially from those made in or suggested by the forward-looking statements contained in this Quarterly Report on Form 10-Q. In addition, even if our results of operations, financial condition, business and prospects are consistent with the forward-looking statements contained in this Quarterly Report on Form 10-Q, those results may not be indicative of results to be expected in subsequent periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.389%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. The forward-looking statements contained in this Quarterly Report on Form 10-Q are made as of the date of this Quarterly Report on Form 10-Q, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.389%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Quarterly Report on Form 10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities based on our analysis of these data, research, surveys and studies. All of the market data used in this Quarterly Report on Form 10-Q involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our candidates include a number of key assumptions based on our industry knowledge, industry publications and third-party research, surveys and studies, which may be based on a small sample size and fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.139%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As used in this Quarterly Report on Form 10-Q, the terms &#8220;Solid,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Solid Biosciences Inc., and its consolidated subsidiaries, unless the context indicates otherwise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ifinancial_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I&#8212;FINANCIA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">L INFORMATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_condensed_consolidated_financial_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. F</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inancial Statements (unaudited)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOLID BIOSCIENCES INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONDENSED CONSOLIDA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TED BALANCE SHEETS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:68.187%;box-sizing:content-box;"/>
     <td style="width:1.601%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.305%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.601%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.305%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc137035-7d99-435a-a38a-dbaaf0e59c0b" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,933</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eefbf9f1-d469-4629-abca-d66fffc4af6c" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,235</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffa49c0a-0a0a-4822-97f8-45bb0de2f69a" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,177</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28aac1e0-fa62-4dbd-a8e6-e601bc409fc2" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,685</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1852fa52-0738-4876-bd93-834e249d35e1" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,530</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_387ca047-3663-4ad7-95e1-1e3d9cc784fa" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,382</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d77fc629-dfc9-4304-aa55-54bb6302592a" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">278,640</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a14e2b4-3029-49f1-b2c5-dd7a38f8aea2" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,302</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current assets:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease, right-of-use assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee5378a4-c79c-4cb6-8b92-ed23242a01bf" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,133</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2d8fccb-b22a-4def-9444-e61fa9035bca" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,295</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72fd1024-ddf7-4c26-b0aa-7f49fbc285b8" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,317</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b83d3796-7ec1-4b6a-b691-097b0676abda" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,747</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20055164-7f9d-4774-8a74-f9a8c9010984" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">278</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e81bb6a-8beb-4a14-b048-b6420eba9d5c" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">366</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed73422e-a8e8-439d-beff-3e2abf6f2de6" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,924</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbd6c758-bf02-451b-bbc0-26a6c7b4e289" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,952</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total non-current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6872eeea-8832-42e1-b91e-15050a2b6308" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,652</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1c3c8ee-e795-4f43-a12e-cab86aacaa38" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,360</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74985eae-459b-45d7-b0d6-135639c29600" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">308,292</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5640f9d-2777-46e0-a3b3-cc77329a3935" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,662</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d06bd60d-bf9c-4a82-860d-ff765e101fcd" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,704</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cfdc32c-f343-400f-b02f-571403cba4d8" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,237</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a9d4822-8a46-4eb6-aaaa-5d1befafb5b4" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,546</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6436dc68-c83a-4e9c-bba4-b58587bae3cd" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,852</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e889e131-96bf-482b-91c6-9407021b5cee" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,943</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73aeffe7-7fe7-4892-a983-8fda45e1bfde" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,787</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_261c4b4d-c903-4ade-8567-b05547ad105f" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">953</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_674a0ec5-ffc8-4b91-8015-eab86c5c80c6" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,231</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0affe51-c35b-4c38-bc4c-81c9986e440f" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:DerivativeLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,700</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fc99fbe-bc42-40bd-a0e3-cc0cd9194207" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:DerivativeLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,150</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a05c06b-0e53-4556-bf15-8b57e51ce47d" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,846</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c696cc4-50f9-4293-910f-a737d647d61d" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,257</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, excluding current portion</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11cc434d-6429-490c-b3f4-e4a743c65bf6" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,155</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f72a0eee-7906-4c33-b740-b64ea615b7a1" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,159</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total non-current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76b8d1e3-0a14-4ffa-947f-9aae8628b243" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,155</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8e471b7-495e-4d28-bcb0-9e9c09383de8" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,159</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4.627%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b731415e-61b4-4838-9155-827916608689" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,001</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c0901fb-234e-4401-8dbb-b9903389d250" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,416</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_7ed96db2-e2ed-4040-b7b9-483f0b1967e0;"><span style="-sec-ix-hidden:F_29f36a27-1849-4abf-89d8-42fbc895f4a4;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;(Note 9)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders' equity:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Preferred stock, $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51f67fbf-9993-49ff-8cdf-722be1c0ca75" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c82094c2-94e6-44db-b17c-17d09b1b2c00" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;par value &#8212; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6344a8f5-f36c-45b0-b376-bbecd54c919e" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b58fb8fe-47ad-4153-baf1-8d4941de9f46" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares authorized; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d347513-81a4-4242-98b4-31321ea05cc8" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5cdfcde9-6495-497d-aed4-0f21cac0e0dc" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d995a80b-2b5c-426e-83ea-05de2dbd2f07" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3b771784-dd53-4128-94be-a01242dae4b2" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares issued or outstanding at June 30, 2025 and December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_fd6a424f-9e78-46d4-9165-086964b4e16b;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_3f4e1821-c913-4d84-8c0a-80ca54685688;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa3e691c-6867-492c-a0ed-876ba3cb82be" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9425cc57-b673-435d-a4bf-c47d8176591b" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;par value &#8212; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19908f63-bac3-4727-bdeb-451e6d85d6f2" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">240,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8af4f9f9-e9de-442e-86ea-e1f69be9db24" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">120,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares authorized at June 30, 2025 and December 31, 2024, respectively; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e79b779e-6e79-4442-8e40-cff5000445b7" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_63484ed9-d240-4d40-955a-5cc73ff8f7bb" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">77,602,741</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_037759d2-b4e5-4a37-b181-443f47e741a2" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ec1a7021-a4f3-4a5c-8dbb-697708d1a34d" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">40,468,141</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b896f63-61b9-4196-99f9-c2c9f2cb5a1d" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abce63ab-22f7-46a7-9f37-e2dac9bf6e72" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bc9a2bc-9331-4a91-8ae8-e84b77aa9dfa" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,120,463</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_815baf88-27c4-4033-8c41-7b9324fccc2f" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">920,609</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8186a5c9-a550-42b4-a931-983140defc4e" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">38</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c28470ba-8fb8-466a-92ef-2a07751c5f1b" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cd01681-e6eb-414a-809a-326acb49aa8a" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">862,212</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a267f88-8b63-4c95-bf90-8ac43adb3ee8" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">783,450</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4.627%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccddce9e-e6b3-4e14-8cfd-d751db9dcea5" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,291</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd47a363-28d7-4e78-bd67-13785e21ca8f" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137,246</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e4a53a3-404f-4549-b2ec-1d1f8e985ba4" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">308,292</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd37ea1c-1721-4b77-81ee-2b09edc2cec0" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,662</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOLID BIOSCIENCES INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_operat"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONDENSED CONSOLIDATED S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TATEMENTS OF OPERATIONS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:43.6%;box-sizing:content-box;"/>
     <td style="width:1.28%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.82%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.28%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.82%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.28%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.82%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.28%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.82%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1673457-524c-4e11-b85b-b2fe15a43459" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,415</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_015e77c3-be4d-4b69-ba23-b3d331e2a40a" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,461</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e06014cc-5c91-451a-82c1-589fb9d9719d" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,329</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a1c9ec1-fb00-46b1-82f8-f6d238202233" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,334</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee46a6ba-eb33-48e3-a40a-7c3488aa655b" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,278</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_635bac91-facd-4d36-a04b-67bff6a32575" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,327</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b3d65be-398f-4e9f-962a-a41ac7c6ce80" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,416</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cbefc35-d72b-4348-8c54-baf067e90c1d" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,316</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c98e8f5-0793-4c78-a8b4-7b66762331b9" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,693</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d503c23e-9929-4fe5-b352-feff387358d2" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,788</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bda55a0a-dbde-49fa-9320-2f7e6a791345" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,745</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d792b26c-e4df-4daf-bf30-147c650311b0" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,650</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e8518f5-38bc-4db6-89f6-660947b6ecab" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,693</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_946c41a9-f619-42c6-bf5f-1492a33b89f3" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27,788</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7419d01-f03c-497d-b559-7dba2d84d601" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">81,745</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71b6f884-1177-45b3-affa-a5ef6eb5e9cd" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,650</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6bc8e1d-564e-4fff-92e2-954331ed2085" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,966</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e404325-92b3-4354-a161-d68c7292ba7c" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,565</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1f60782-28e2-45f3-b86c-28134c9a2058" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,266</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cd7b290-6deb-4156-8fac-c341d189c950" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,216</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ada6d0c9-6eec-43d3-a436-e454bce91992" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7528715-c380-43a6-968c-b1a5fc0f9706" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7caf4138-2f67-4e4b-ba0e-5b0d2200f0e9" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">128</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_798845da-15a0-4061-8f25-6f77a25a399b" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of derivative liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_124c15d4-1903-4bc3-9673-ca8cd5bb39ff" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">900</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_865897ef-5488-416f-a3ad-3e5fbb852bd6" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,550</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c075f8b9-c71e-428e-9d0b-17e925773c0f" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb92755b-df27-4497-8432-9b75e6218f11" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_568b55ee-3f25-4cdc-ad74-49346252a321" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">395</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cb3acf5-66f4-40ed-998c-6d33a9e10caf" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">242</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f90e3bd9-8834-48b1-99c5-621eec5744bd" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,213</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7f62bbe-4f5b-472e-9cd2-ac41cc8779d3" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,716</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5f6304e-d26e-47d7-a41e-3892ce3a8db3" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,983</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5a19c9e-db46-486f-8621-c34f6b69bf78" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,275</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f9cfdbc-f898-444e-aa01-e933776afa35" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,480</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d03f2c4-f300-42ca-990d-59eb18de297f" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,072</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_653993c8-03a0-43e0-ba1c-bfca1a969b95" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,762</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64ef396d-ac8f-4689-ab8e-8ff68b99ad65" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49,375</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b3d9672-3fd8-4d96-acd5-8e76ded05503" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c0440a03-3bca-4cd3-a442-2a2ffc17ade9" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.42</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22bcb14d-8938-4dd3-a083-127d265c2512" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3c3e88ac-d667-49db-89dc-fe71799513dd" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.61</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b25c427-f8f8-438c-940f-7c7e94dc0264" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2bb9a5f2-60a1-4b35-8830-ab80372f91dd" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.98</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8c2893e-edd4-4c9a-a40f-164235c17bf6" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_13fd5eef-063b-4246-9551-6bc3f3392fb2" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.25</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average shares of common stock outstanding, used to <br/>&#160;&#160;&#160;compute basic and diluted net loss per share</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d61751ce-7ddf-4177-bfaa-30c6b8ba52b1" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_860015b8-9da5-404a-801c-548ee0fc0c48" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">94,140,286</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aec6f4f7-89de-4d8c-9b4c-eafce7c4d279" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8c0e2d39-8350-42ea-9a5c-eb7d4a283edf" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">40,934,361</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0eec50fc-d9ab-4fd4-8419-0b375aae0849" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4e42f12b-e3d0-4839-987f-8c474b56e703" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">80,317,588</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd662e65-28ae-4541-8ae8-1c268274d06c" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bde22ef9-0ab4-47de-aec4-d8c80302c9db" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">39,544,867</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOLID BIOSCIENCES INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_compre"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONDENSED CONSOLIDATED ST</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATEMENTS OF COMPREHENSIVE LOSS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:43.6%;box-sizing:content-box;"/>
     <td style="width:1.28%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.82%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.28%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.82%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.28%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.82%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.28%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.82%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb9e43df-f54c-4243-8a6c-d05d4d4e3ac0" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,480</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43a90bd1-3bdc-457a-aef3-9e8e913dcea2" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,072</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00c8fb4f-5d97-4667-96e9-453180d440ca" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,762</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cac23818-f2fc-4a39-98d4-b17cef1d8a7c" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49,375</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized loss on available-for-sale securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3213a7bb-84fd-47e1-9b4f-2719892b3e19" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05e617a0-c67b-4e0f-bccc-9a35a38aa73a" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc6e1215-cc99-4897-bd66-0568f0f82505" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8943b831-9a3e-4f8a-9b01-20ab95001d0e" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddeb7f51-b1bd-44c2-a6a7-a5594c3f99bb" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,520</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21ae2302-26b2-438b-9cc3-b3ba213b5832" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,083</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45bb94d7-a4be-44df-98c0-35c4fdad6eb9" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,847</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81276fd3-2070-4d0d-a868-18957c489972" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49,405</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOLID BIOSCIENCES INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_change"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONDENSED CONSOLIDATED STATEMENTS O</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F CHANGES IN STOCKHOLDERS&#8217; EQUITY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:33.86%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.14%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="22" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended <br/>June 30, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common<br/>Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-in</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Stockholders'</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Income (Loss)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at January 1, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abb170d3-a7a4-4aa7-88d9-3c6a27a88517" contextRef="C_69be95bd-262a-441d-b2bd-98d19efe9bd0" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">40,468,141</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6e3adea-e500-4ae0-8f54-40d555d7cc2a" contextRef="C_69be95bd-262a-441d-b2bd-98d19efe9bd0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bab68d28-f007-4bce-831a-3ff94a21c911" contextRef="C_b9aed1ea-13eb-4016-bc97-d2029636fac4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">920,609</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_447fa5f6-10ca-452d-b230-cb935986b9e9" contextRef="C_cff1f316-69c3-4b3f-a8d5-620b81ea7de8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21a37dc2-f4fc-4b5c-9f61-aeb27a583b35" contextRef="C_e1fc1533-e5f3-4a29-a6a7-15d22fa44a9a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">783,450</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_420a5bea-299a-43b5-a7dd-b2268675fa8d" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137,246</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Issuance of common stock in public offering, net of issuance costs of $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0386487-aa4a-4500-9c8e-b0213f2c3a62" contextRef="C_0c822986-4362-4137-a232-16bb78f035a6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,665</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3c84ead-bcc3-4e87-ac58-e1903a88334a" contextRef="C_9123b419-0bc2-4374-94a6-007cd47c652a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">35,739,810</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a211662-e070-4d82-a4e0-f83b3042e42e" contextRef="C_9123b419-0bc2-4374-94a6-007cd47c652a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b284523-affa-4760-a05c-4f4af73a4eb2" contextRef="C_80913da5-18e0-4e2d-9932-f1f9a150ed8a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135,331</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f70cff0-33b0-4d90-bfe9-8df31d226d73" contextRef="C_0c822986-4362-4137-a232-16bb78f035a6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135,367</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Issuance of pre-funded warrants in public offering, net of issuance costs of $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_086c2c4c-211e-49e9-b460-2008d157e8be" contextRef="C_0c822986-4362-4137-a232-16bb78f035a6" name="sldb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,366</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79b9a69c-527e-4edb-8a4b-dd67338bb48c" contextRef="C_80913da5-18e0-4e2d-9932-f1f9a150ed8a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,590</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_948ff807-e1d2-4b4a-9562-d781965c7a3a" contextRef="C_0c822986-4362-4137-a232-16bb78f035a6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,590</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock in private placement for payment of developmental milestone consideration</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39f30175-342b-4023-b131-8027ade10a0f" contextRef="C_9123b419-0bc2-4374-94a6-007cd47c652a" name="sldb:IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">975,496</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62609475-550c-48e7-acbd-82d1194ba5ab" contextRef="C_9123b419-0bc2-4374-94a6-007cd47c652a" name="sldb:IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f91837a7-36ab-4619-80f8-5608cb132a8e" contextRef="C_80913da5-18e0-4e2d-9932-f1f9a150ed8a" name="sldb:IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,999</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54cd9b93-ae79-47f3-9d3f-51619612d58e" contextRef="C_0c822986-4362-4137-a232-16bb78f035a6" name="sldb:IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Issuance of common stock in at-the-market public offering net of sales commissions of $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e8f9594-11f5-4c68-a77d-9ad42d3045bf" contextRef="C_0c822986-4362-4137-a232-16bb78f035a6" name="sldb:AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3b09dae-7f3d-4cb9-a431-467db17a8316" contextRef="C_d97c1211-c3a9-4ea5-91b7-040fde3392b0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">61,542</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d9b6120-50c9-43b0-b945-be4bb40f5214" contextRef="C_cfc4b4a2-204b-43b5-a661-f05441902b21" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_596500ea-217d-4901-97da-fcc82cc80d72" contextRef="C_11a10128-fba6-447d-a976-5fa084bf9295" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a888fdf1-614b-48ec-ab18-ec3ffdbab577" contextRef="C_9123b419-0bc2-4374-94a6-007cd47c652a" name="sldb:VestingOfRestrictedStockUnits" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">247,970</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized loss on available-for-sale securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_872fbe4a-d612-450d-a604-6b6890c4194a" contextRef="C_8d226a90-397f-41ab-935f-5aab9dd4c71c" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93d48180-4813-4dea-a68f-f8dc7a4e61a2" contextRef="C_0c822986-4362-4137-a232-16bb78f035a6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3159eb15-a9e6-4f8a-a2e1-46d391bf0351" contextRef="C_80913da5-18e0-4e2d-9932-f1f9a150ed8a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,341</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00afc5c3-7ae5-4fed-808c-e49467fed75e" contextRef="C_0c822986-4362-4137-a232-16bb78f035a6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,341</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecaf500b-79e9-46cb-bf87-0c9bd7ffff1a" contextRef="C_fde676d0-416a-44d0-990b-c79ab2d42ba2" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,282</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01c5a599-91e0-482e-a8eb-e8de1f9f509f" contextRef="C_0c822986-4362-4137-a232-16bb78f035a6" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,282</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at March 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7001778-b8c4-43a9-aee6-60c1756311c2" contextRef="C_e6263d79-32c5-4715-9a16-d2aa12863296" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">77,492,959</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_405119df-2ea1-430e-b2ae-15a069709efe" contextRef="C_e6263d79-32c5-4715-9a16-d2aa12863296" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_728453f5-c5fa-42d8-a04b-5a48c6f0ce89" contextRef="C_9a0af20a-6059-403f-91cf-5541fbb0763d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,117,116</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c18a84f9-8d3b-4258-9dd1-1743297dba45" contextRef="C_e445144a-7061-4fa5-ae92-64b3821a428b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_716d0ca2-ad8a-4366-9071-ddb58d1fd345" contextRef="C_360e00c1-d83f-408a-8983-fda0502e6613" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">822,732</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8fedf1f-50ab-4c3f-aa86-23bce8fd3e7b" contextRef="C_1289e95b-8da8-4d52-8d1f-4b8964a89bb2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">294,463</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26e2ab69-9aac-498e-909c-5cafc68f7f41" contextRef="C_aa5bd7ea-c156-4475-926c-e8eddecefd5c" name="sldb:VestingOfRestrictedStockUnits" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">32,189</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0c9b481-2de0-4a38-80d6-f59378c10f35" contextRef="C_aa5bd7ea-c156-4475-926c-e8eddecefd5c" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">74,860</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_718ead90-ad4e-4199-96a3-c9e9e1f42805" contextRef="C_aa5bd7ea-c156-4475-926c-e8eddecefd5c" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad1fa47c-5a74-4af9-b833-c3b0df3259ba" contextRef="C_cbf823b0-60bc-410a-aeb8-2f8b923dc7c7" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">196</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e19f3ca4-59e8-4cd8-b474-c9ae70b05b7d" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">197</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercises of common stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a961e4d-fb6d-457a-b95c-bbc2f1329233" contextRef="C_aa5bd7ea-c156-4475-926c-e8eddecefd5c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,733</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09556609-581a-4fa1-9e8e-c95ffc935315" contextRef="C_cbf823b0-60bc-410a-aeb8-2f8b923dc7c7" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2db018d3-b313-4631-80e6-5566b36760f3" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized loss on available-for-sale securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa7561cb-231a-431b-96a4-6eea6ac8edb9" contextRef="C_df55ee2b-223d-4c46-ab63-80dcac637cef" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85041128-b935-48a4-afe1-31290bf543f8" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcbd4864-7c84-4bfd-9a9d-816858674c6c" contextRef="C_cbf823b0-60bc-410a-aeb8-2f8b923dc7c7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,145</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3026e75a-afc3-4e50-80ac-94d856a600b4" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,145</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27391452-aaa0-408f-a465-e474789f0500" contextRef="C_f86d33b7-2665-4a04-943a-c562c8410bd5" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,480</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0fc0507-17db-45b9-8e45-ac035a71453d" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,480</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at June 30, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf17f70b-5c5c-4281-93dd-00b61927f884" contextRef="C_8466f2d9-6b68-47d7-ba93-53848911d53e" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">77,602,741</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9285f8b6-4c53-4772-ad4a-fe0a3b896a32" contextRef="C_8466f2d9-6b68-47d7-ba93-53848911d53e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f53b4008-ba4f-49a4-92ea-2a20128189d5" contextRef="C_af67bb44-76aa-4851-ada3-634e88aa092e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,120,463</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bf6b6bd-c2fb-4084-a4d7-a13d54e182d6" contextRef="C_8ebf87b6-992f-494c-8560-27ee2a653d27" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">38</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c5d57d1-39d1-4029-8dd3-01040cc5118f" contextRef="C_ac9669fb-6c3b-47fb-90e4-6286c0192e44" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">862,212</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1802014e-9373-42b7-8fc0-778d43814456" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,291</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOLID BIOSCIENCES INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:33.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.02%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="22" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended <br/>June 30, 2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common<br/>Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-in</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Stockholders'</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Income (Loss)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at January 1, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1265827-268a-448d-aa2f-43ae3b5823c7" contextRef="C_f72bf3d9-6c7b-4a2b-a09e-4c623d761a64" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,386,606</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95a64ba1-3e09-4271-9eea-bd58aa2a5579" contextRef="C_f72bf3d9-6c7b-4a2b-a09e-4c623d761a64" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a26f9860-ede9-4946-8836-49cae154e4f4" contextRef="C_32a641e0-2697-41b7-a866-ce0eb5498572" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">785,199</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bfe00c0-6ede-4754-a274-50c24c9bb561" contextRef="C_60238495-82b4-4a9e-8f0c-dec2e85bad33" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6909b3bb-fdb0-4159-8a4f-e81adf88a4a8" contextRef="C_5dadfd3e-8058-4606-b32d-a0cfe60eb067" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">658,753</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b451f7d6-e660-4c6f-a786-ee2f49932548" contextRef="C_72a44744-a858-4632-9155-e3c3f22a4ca6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,481</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Issuance of common stock in private placement, net of issuance costs of $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58f2848d-c84d-4167-8200-c0feb8d087d4" contextRef="C_8e05825b-3564-43f0-9df6-8e98b1d7be91" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,407</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1406d483-8b9d-4194-a9d7-53233b565560" contextRef="C_e13de2f2-ceab-4e18-9846-718dd592da8e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,973,103</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52dad432-c442-4d7a-b608-a830179e5094" contextRef="C_e13de2f2-ceab-4e18-9846-718dd592da8e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2142b5e1-4511-46d4-919f-d4e03a4d3875" contextRef="C_674b0646-86dc-4ece-b574-7ef26e78d9f8" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,437</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6659c3e5-87d9-4bc6-b5e3-050108e5f7c7" contextRef="C_889a20b7-df33-41ee-923b-1fa83b319dc5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,454</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Issuance of pre-funded warrants in private placement, net of issuance costs of $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_390914c9-621f-486c-8708-e0f8e9c57b94" contextRef="C_8e05825b-3564-43f0-9df6-8e98b1d7be91" name="sldb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">704</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa8821d0-219f-4df7-ab98-4fc48f9486bb" contextRef="C_28011c1d-5f4c-4932-ad90-695a175099ce" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,293</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c701b104-abd2-45cd-b730-c3d105d64a76" contextRef="C_8e05825b-3564-43f0-9df6-8e98b1d7be91" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,293</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Issuance of common stock in at-the-market public offering net of sales commissions of $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eaac730c-f788-49c2-8fa8-b557fa97bd9c" contextRef="C_8e05825b-3564-43f0-9df6-8e98b1d7be91" name="sldb:AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f75277d4-2bc1-4c6d-8522-dca3b88c551f" contextRef="C_5102f076-6976-4786-8570-ddc9fcaa4fda" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">350,664</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdb1602a-c379-4a23-96e9-fe8a8c46aead" contextRef="C_5102f076-6976-4786-8570-ddc9fcaa4fda" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c684042f-7a0c-4e64-9432-7e3bb5280ba4" contextRef="C_0dfd0d13-a826-4ebd-b93f-49699f6c04b8" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,055</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95a5e72b-d1b3-4036-8ff6-67cb87f9e38b" contextRef="C_1e60639d-8283-41ae-8cd9-7b46f80766be" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,056</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90ac8cad-41fd-4e7b-b6c3-3734159f3b68" contextRef="C_d9216090-1e30-4279-8a28-35be3c27b884" name="sldb:VestingOfRestrictedStockUnits" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">98,677</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercises of common stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3b5b796-8658-4f7b-b98c-f32d83b17c0e" contextRef="C_d9216090-1e30-4279-8a28-35be3c27b884" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">24,639</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7665ecc-4377-4da8-86a2-f133b25590ad" contextRef="C_28011c1d-5f4c-4932-ad90-695a175099ce" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">151</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e916482-3345-4f23-8eb6-386ea924c3ff" contextRef="C_8e05825b-3564-43f0-9df6-8e98b1d7be91" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">151</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized loss on available-for-sale securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_201d83bc-f35e-4fee-b56a-98244a5db99f" contextRef="C_8254bb6c-0764-44d8-a999-479ae11715b9" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cdf95dc-44ec-45ea-aae6-a8c95fc98176" contextRef="C_8e05825b-3564-43f0-9df6-8e98b1d7be91" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3dd8962f-ced3-4d31-b70d-060709019f80" contextRef="C_28011c1d-5f4c-4932-ad90-695a175099ce" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,611</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2276179-9aaa-4646-887a-a7aeee70acf2" contextRef="C_8e05825b-3564-43f0-9df6-8e98b1d7be91" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,611</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5850f591-0bdc-4e53-a536-4a4b1678dfc4" contextRef="C_18030d3f-b395-4cc3-997d-b26bfd8329d0" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">24,303</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d250068-fa24-4753-b899-9469498dd39e" contextRef="C_8e05825b-3564-43f0-9df6-8e98b1d7be91" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">24,303</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at March 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a543ded3-ed1a-4dd1-82a5-cd0fc2996302" contextRef="C_ddbae127-0489-4e1a-9f96-5243dd079a21" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,833,689</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff2acd5c-25f7-4ee4-a017-9305e656a0be" contextRef="C_ddbae127-0489-4e1a-9f96-5243dd079a21" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e859c34e-ddd5-4669-8259-3ee0f0ad0929" contextRef="C_2e4a7c1b-d7cd-41ff-9b20-980516f53df2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">893,746</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b9a1260-0d19-4e8a-973d-b9cd0e7fe726" contextRef="C_af5ce639-0ee4-4ebc-b2dc-3c8e938ebf5d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f046481-8303-4ce4-8daf-10cdb6effa55" contextRef="C_86fa028f-2418-4cf6-b959-b70470ee2aa9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">683,056</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5af20fd1-bb1c-4a6d-a117-534a5de336b2" contextRef="C_004daa09-8340-480a-b520-e166a80e5304" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210,724</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Issuance of common stock in at-the-market public offering net of sales commissions of $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cedd105e-b66e-4da3-8b9d-63a623643dc8" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="sldb:AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a81f8081-342d-4388-a132-f983f2739be1" contextRef="C_be22b5d9-efe2-482f-aa0b-2ae151a5a94d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">526,953</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b94ce68a-1664-493e-a0be-49561a0be7c0" contextRef="C_be22b5d9-efe2-482f-aa0b-2ae151a5a94d" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e598aaf-c937-43b1-b266-778914ad683a" contextRef="C_1679319c-e556-4669-b19c-516102e53d80" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,356</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_236f0240-73db-4feb-8192-cfa46eb9f245" contextRef="C_04579f4c-0d92-4807-b526-47e70d33525d" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,357</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f0a1dda-e8ba-4c24-95ef-418fa1df516f" contextRef="C_07264e86-c26a-42ce-a8e5-89f7da5029a5" name="sldb:VestingOfRestrictedStockUnits" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">131,859</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1173f76-d27c-444a-b23c-c3d14745f48b" contextRef="C_07264e86-c26a-42ce-a8e5-89f7da5029a5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">56,855</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_670640e8-f93b-41b1-9c1a-bb55fdeeaae0" contextRef="C_dca2999e-bb17-4181-8e87-86f8da45617b" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24dc3ada-9efa-49f4-9bf6-18dba328b1b1" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercises of common stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a637c0b3-24b3-4f22-96cd-a69b771a3915" contextRef="C_07264e86-c26a-42ce-a8e5-89f7da5029a5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,703</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_900efdd6-d00b-4da4-8aa4-b634d4fa4003" contextRef="C_dca2999e-bb17-4181-8e87-86f8da45617b" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_183e993d-2da7-4d0e-9151-6a97cdb03df2" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized loss on available-for-sale securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_601be6d4-faef-43c5-809f-33615b8c6c27" contextRef="C_1a3c625c-1186-436d-91aa-d8d2544b7b4a" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d77c37e1-a699-4e4b-9661-ec0e98393951" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28f4770d-45a3-4122-909f-1f4177e4d93e" contextRef="C_dca2999e-bb17-4181-8e87-86f8da45617b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,092</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c411364-cd84-4b85-b8b6-d929030c454c" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,092</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74bbd04c-2c0a-469e-945c-e373f2fa5b38" contextRef="C_b1b96c09-b829-40e0-9943-61aa3ed9067c" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,072</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b15f4b04-0fdc-4daa-9117-0ec061a55ac0" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,072</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at June 30, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cc47fd5-e036-442e-be6a-1329bb7f594f" contextRef="C_6d1d0185-6a08-4a4d-bf78-3cf596bda452" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">38,551,059</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7816a6db-2965-46cd-9d63-feccfe9c4b43" contextRef="C_6d1d0185-6a08-4a4d-bf78-3cf596bda452" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f61b84d-db5d-4a42-b4d7-fe3ee0df0fac" contextRef="C_d9af6823-a26b-4885-a9fb-907deb94d20c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">901,349</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_470f4420-c1de-4683-b5ef-dbe510dea15b" contextRef="C_7621a0fc-5398-41ee-bdd0-b6ec3eec8693" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93475c55-63bd-4811-8ecd-5ff7b15a23dd" contextRef="C_888d7863-e043-4b8e-9a9c-902e9e4efb65" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">708,128</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_958f1384-aef6-4d84-a94d-5ef5a27db9c5" contextRef="C_11726ae9-e40d-4c5b-83b8-8005c97ded06" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,245</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOLID BIOSCIENCES INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_cash_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONDENSED CONSOLIDATED S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TATEMENTS OF CASH FLOWS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:70.88%;box-sizing:content-box;"/>
     <td style="width:1.56%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.56%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44758709-26ef-49af-b61d-d632743851d0" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,762</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e268c6db-04fc-4b14-8502-4b465bf742a5" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49,375</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of discount on available-for-sale securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a85ec5b8-6ecf-47f5-9601-f003e700ed7a" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">800</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30448f7e-8201-4c70-a26e-58892d9ef085" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,581</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb350e9c-0f3e-45e8-aaf5-102025aeaf43" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,486</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39ae56a6-7c3b-4bff-bfc7-b8740f5fd11c" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,703</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b0faaa0-ddde-4703-a214-07e28cdaff97" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">793</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46502047-4b51-4dde-81e6-c8ea94c8bb38" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,562</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash lease expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae0c3435-5ada-4fe3-8b18-e5894be01ff9" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="sldb:NonCashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,162</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e66fbbb6-0358-485e-bd07-8298d260f2ff" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="sldb:NonCashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,241</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of derivative liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adc93b1b-0a16-4b67-8baa-e705a6cbcce5" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="sldb:ChangeInFairValueOfDerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,550</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf7bfd9d-3f9d-4562-ae49-691cc96e92aa" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="sldb:ChangeInFairValueOfDerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7a7860f-3c1b-465e-b62c-08a419fd9a4a" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">55</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28562620-118f-41f5-a84e-903707a8e809" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d8e44c6-c77a-4b4b-89ed-ee23f87a224d" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,060</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebf5f78d-381e-4c67-95f7-9b29d8e6f5e4" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,556</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48e8ee1e-e858-4374-b863-a8ae3f5edccc" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">467</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57b04278-7567-4804-882c-498c14ece90d" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">472</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_479327cf-e08c-4c84-9f5b-5dedfc859902" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">848</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ef33a4c-70d8-4edb-a40b-1a1c4d57eb5b" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">864</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6c4f6de-05ae-4994-b9dc-9a0d2cc4ebef" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,695</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c424c8b-d778-4ed2-bdb6-134bb3594db9" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">167</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4.627%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e1a3b43-37b3-4376-b82d-2c4eb4836dbb" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">69,262</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd4ae9a5-63c9-4ccf-8d8f-a7ce306ba70f" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">46,659</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c6e8f9a-4c31-4777-85b3-303392f982aa" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">503</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e478161c-64ba-404a-b879-694391a1cd91" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">435</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from maturities of available-for-sale securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be2ac74d-4c08-44e0-9351-0686310e423a" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">69,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a46cc4ef-e83f-4418-b6b2-67045d3330c6" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">60,300</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of available-for-sale securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79b83879-68da-4ef4-81ff-d7a9e264659e" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">128,777</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f54aa0eb-f8f1-45ae-a3ae-c41fa7c70d52" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,536</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0dde2bb-20ae-4180-a5f5-5d6311b94241" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6eb0ef95-656b-4086-a60a-2f07fc48b369" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4.627%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c985bb5-5268-41a2-95d3-0ae239e8cc91" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">60,195</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f739e8a0-e7a2-4851-a868-ff49a4f8a8cd" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">43,666</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock and pre-funded warrants in public offering, net of underwriting discounts and commissions</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c3978f2-86bd-4553-89be-6588a199072a" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="sldb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">189,637</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a532fbc0-18b7-43bf-ab95-49499ffec96e" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="sldb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments of common stock and pre-funded warrants issuance costs in public offering</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b622c692-1a07-46b7-b8a6-e07e0e4278c7" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="sldb:PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,681</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d9389f2-b513-45d0-ae05-a27d142395b8" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="sldb:PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock and pre-funded warrants in private placement</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14649455-3ce7-4686-a76d-c3dc98d0eecb" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="sldb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44a82ea7-ceee-4ef6-82df-dd6d4ab2b065" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="sldb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,858</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments of common stock and pre-funded warrants issuance costs in private placement</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3aae34ab-985c-46db-ba1f-a053595037f7" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3b998ea-df33-4d7d-a0f4-3b145a969c07" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,111</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock in at-the-market public offering, net of sales commissions</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31a2e7be-5fd4-478f-a98b-4c5fad678451" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="sldb:ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f635c565-e137-4634-a8e2-f9d5a2784418" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="sldb:ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,414</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercises of common stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c7be9fc-448c-4800-8c9b-0f8026c7ebfd" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdd27d54-06d2-4a40-90e8-84f354b29310" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan purchases</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfcf9175-cfba-4e96-8c16-197672ce29c2" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">196</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e464993-9522-4d1e-9877-e35e70e5a8e2" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments of principal portion of finance lease obligations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d920269b-56fd-45be-981d-fb3fcdb45023" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e80f7591-27de-4694-a763-5bb8803180e8" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4.627%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_464ec563-995c-4e32-ab33-ef6bd2ccee8f" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,127</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21e501a4-f9d9-4f07-980a-5b3a160aa650" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,241</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net increase in cash, cash equivalents, and restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36a93ede-2d2c-4e12-9f41-b5af3ce9de7e" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,670</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5bfdc61-6f60-4e87-9363-b88c5adbf4a3" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,916</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents, and restricted cash at beginning of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdae07c5-7090-4370-be9d-31027b3b97bd" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,187</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ed1e7db-7b9b-4d7c-8edf-1ad1926f212a" contextRef="C_72a44744-a858-4632-9155-e3c3f22a4ca6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,848</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents, and restricted cash at end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b79f99c7-5c43-4c2d-90dd-3f388dad0d5e" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140,857</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f5a0ce1-89c2-4c4f-a87f-f17e6f088621" contextRef="C_11726ae9-e40d-4c5b-83b8-8005c97ded06" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,764</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:69.446%;box-sizing:content-box;"/>
     <td style="width:1.64%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.638%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.64%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.638%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of cash flow information:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for interest</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7a94b15-bae2-43b0-8d70-dfa0d4e537df" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">128</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b121b1d8-3cc9-4137-b3ce-9efce09ce388" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of non-cash investing and operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock issued as payment for developmental milestone consideration</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc4df418-07b3-45fe-a620-4cf0f7fa7cb5" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="sldb:CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ab6098a-36dd-457b-a659-cc9b442c0f84" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="sldb:CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets acquired through operating leases</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_690e7086-c380-49d4-b276-f134a960c5dd" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51688c29-636b-4ba5-9494-2ccac2459b07" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">407</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Decrease in right-of-use assets due to lease termination</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dd444fe-bd94-4e88-b36e-817507435070" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="sldb:IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c024dc2-1ece-4b43-a7af-0540efe3e9ce" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="sldb:IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">197</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment purchases included in accounts payable and accrued expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_625a291c-edc8-4cbd-a06d-417ba6912bb7" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_764cc880-993b-4236-8e3d-6f9b46aa41cf" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the amounts reported in the condensed consolidated statements of cash flows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:69.44%;box-sizing:content-box;"/>
     <td style="width:1.8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.88%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.48%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.4%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c271aa81-89fe-477f-8948-b54e6b89c092" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,933</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89064947-5a14-4a39-a034-4c31b7a6e0cf" contextRef="C_11726ae9-e40d-4c5b-83b8-8005c97ded06" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,854</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash, non-current</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bab2deb3-2739-4ba5-937a-84fbc6bbbf91" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,924</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30c2fa49-b96b-4251-8b7d-093f4d6c5273" contextRef="C_11726ae9-e40d-4c5b-83b8-8005c97ded06" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,910</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents, and restricted cash, as reported in<br/>&#160;&#160;&#160;the condensed consolidated statements of cash flows</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0b0760a-ee9a-40d0-a95b-f5c296614a75" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140,857</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d358abf-c55c-4542-9d64-272369c88ef2" contextRef="C_11726ae9-e40d-4c5b-83b8-8005c97ded06" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,764</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOLID BIOSCIENCES INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_condensed_consolidated_financia"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONDENSED CONSOLID</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATED FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(amounts in thousands, except share and per share data and where otherwise noted)</span></p><div><ix:nonNumeric id="F_9161644a-60c0-4b9e-bc1c-5210040d5700" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true" continuedAt="F_9161644a-60c0-4b9e-bc1c-5210040d5700_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Nature of the Business and Basis of Presentation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Solid Biosciences Inc. was organized in March 2013 under the name SOLID Ventures Management, LLC and operated as a Delaware limited liability company until immediately prior to the effectiveness of its registration statement on Form S-1 on January 25, 2018, at which time it completed a statutory corporate conversion into a Delaware corporation and changed its name to Solid Biosciences Inc. (the "Company").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates (collectively "Candidates"), including SGT-003 for the treatment of Duchenne muscular dystrophy ("Duchenne"), SGT-212 for the treatment of Friedreich&#8217;s ataxia ("FA"), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia ("CPVT"), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases, at different stages of development with varying levels of investment. The Company is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management and care. Patient-focused and founded by those directly impacted by Duchenne, the Company&#8217;s mission is to improve the daily lives of patients living with these devastating diseases.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on licenses, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting capabilities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Candidates are in development. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from, among others, other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, partners, and consultants.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based upon its current operating plan, the Company expects that its cash, cash equivalents and available-for-sale securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59938593-a977-4a7d-991c-abad97147d24" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">268.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million excluding restricted cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a307bbf1-f3ab-4012-b779-799dcc535f90" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, as of June 30, 2025, will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of issuance of these condensed consolidated financial statements. However, the Company has based this estimate on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to it. As a result, the Company could deplete its capital resources sooner than it currently expects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Through June 30, 2025, the Company has funded its operations primarily with the proceeds from the sale of redeemable preferred units and member units as well as the sale of common stock and pre-funded warrants to purchase shares of its common stock in private placements (including the January 2024 Private Placement (as defined below)) and the sale of common stock in its initial public offering, follow-on public offerings in March 2021 and February 2025 and under its at-the-market sales agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects to continue to generate operating losses for the foreseeable future and to finance its future cash needs through a combination of equity offerings, debt financings, collaborations, strategic partnerships and alliances or licensing arrangements. If the Company is unable to obtain funding, the Company would be forced to delay, reduce or eliminate some or all of its research and development programs, preclinical and clinical testing or commercialization efforts, which could adversely affect its business prospects.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_9161644a-60c0-4b9e-bc1c-5210040d5700_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") along with the rules and regulations of the Securities and Exchange Commission for interim financial information and include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from the Company&#8217;s audited financial statements but does not include all disclosures required by GAAP to constitute a complete set of financial statements. These condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for a fair statement of the Company&#8217;s financial position at June 30, 2025 and its results of operations, changes in stockholders&#8217; equity, and cash flows for the interim periods ended June 30, 2025 and 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These unaudited condensed consolidated interim financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024. The results of operations for the three and six months ended June 30, 2025 are not necessarily indicative of the operating results to be expected for the year ending December 31, 2025, for any other interim period, or for any other future year.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant Judgments and Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, estimates related to the recognition of research and development expenses, equity-based compensation, and derivative liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from the Company&#8217;s estimates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no changes to the significant accounting policies disclosed in the Company's most recent Annual Report on Form 10&#8209;K.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_448a6369-a0e5-410e-966b-75e12564ccba" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="sldb:RecentlyIssuedAccountingPronouncementsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This ASU updates income tax disclosure requirements primarily by requiring specific categories and greater disaggregation within the rate reconciliation and disaggregation of income taxes paid by jurisdiction. This ASU is effective for annual periods beginning after December 15, 2024 and is applicable to the Company&#8217;s fiscal year beginning January 1, 2025, with early application permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disaggregation of Income Statement Expenses (Topic 220)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The requirements in this ASU may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures.</span></p></ix:nonNumeric></div></ix:continuation></div><div><ix:nonNumeric id="F_a6a06271-7b10-49aa-883f-773ed53bc3b4" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:AssetAcquisitionTextBlock" escape="true" continuedAt="F_a6a06271-7b10-49aa-883f-773ed53bc3b4_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. FA212 Asset Acquisition</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_977a4ee1-93db-40cf-b1db-9d71286c7372" contextRef="C_43934480-1ee4-495d-8199-c3e8feb3750c" name="us-gaap:AssetAcquisitionDateOfAcquisitionAgreement" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 19, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company entered into an asset purchase agreement with FA212 LLC ("FA212") for the purchase of certain intellectual property, including patents and assigned licenses related to a preclinical drug candidate, which the Company now refers to as SGT-212, assigned manufacturing contracts as well as research and development materials such as manufactured materials and samples.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a6a06271-7b10-49aa-883f-773ed53bc3b4_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid FA212 an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61e8cca3-f573-43de-9b4a-62cc85a8b58a" contextRef="C_98efec03-6261-4884-8666-bf6095a4bb0d" name="sldb:AssetAcquisitionUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the third quarter of 2024. Additionally, the Company agreed to pay FA212 development milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ebf0aed-dade-403a-9b46-cfc3f4489480" contextRef="C_6cd19d05-d8a7-4151-a703-c33e74dfa457" name="sldb:DevelopmentMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">34.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, cumulative sales milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbe8e722-5b8e-4687-9070-008949991760" contextRef="C_6cd19d05-d8a7-4151-a703-c33e74dfa457" name="sldb:CumulativeSalesMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and tiered royalties on net sales in the low-single-digits. The Company also assumed from FA212 contingent development milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_619ac4b7-7d99-4104-a7e8-592f4fd50bb7" contextRef="C_a77281d0-83e9-4ceb-b6cd-ee4c4377550d" name="sldb:AssetAcquisitionAssumedContingentDevelopmentMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, regulatory milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3498c045-f732-4302-8e48-1c5e36ee8336" contextRef="C_a77281d0-83e9-4ceb-b6cd-ee4c4377550d" name="sldb:AssetAcquisitionAssumedRegulatoryMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">13.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, cumulative sales milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a727363b-00c7-4278-9f3f-a35038797f83" contextRef="C_a77281d0-83e9-4ceb-b6cd-ee4c4377550d" name="sldb:AssetAcquisitionAssumedCumulativeSalesMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">27.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and tiered royalties on worldwide net sales in the mid-single digits payable to the University of Pennsylvania.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain development milestone payments to FA212 are payable in either cash, equity, or a combination of both, at the Company's discretion. Such contingent payments were determined to be derivative liabilities and were initially recorded at their fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02cee115-e8e5-4e45-a75f-f41817a97a1d" contextRef="C_a4cf9151-2ea2-4600-8153-d60667cae2dc" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined that the FA212 agreement represented an asset acquisition of in-process research and development assets with no alternative future use and recognized the aggregate acquisition cost of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17a0abb8-f164-482e-b780-5028b3b9cd21" contextRef="C_98efec03-6261-4884-8666-bf6095a4bb0d" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as research and development expense in the third quarter of 2024, which included the upfront payment, initial recognition of the derivative liability and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7514b33-a560-41e6-82c4-07dec80845de" contextRef="C_98efec03-6261-4884-8666-bf6095a4bb0d" name="sldb:AssetAcquisitionTransactionCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in transaction costs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> submitted an investigational new drug application ("IND") for SGT-212 for the treatment of FA to the U.S. Food and Drug Administration ("FDA"), which was cleared in December 2024. Upon clearance of the IND, the first development milestone of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91901942-feaa-4307-80c8-68b30c0f0af3" contextRef="C_9e42e73a-a6c9-4461-a752-a23c4b0480e5" name="sldb:FirstDevelopmentMilestonePayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million became payable to FA212. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4757028-6bac-425f-84f6-faba5d4e1f72" contextRef="C_9e42e73a-a6c9-4461-a752-a23c4b0480e5" name="sldb:MilestoneLiabilityPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment is included in Accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheet as of December 31, 2024. On February 28, 2025, the Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">made the first development milestone payment in the form of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23e7ae13-767b-4940-a56f-a6f39a7255e5" contextRef="C_7d4b4b58-8e68-4c67-aaf1-47f818c7a79f" name="sldb:FirstDevelopmentMilestonePaymentInShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">975,496</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The derivative liabilities for the remaining contingent payments were recorded at a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41721cec-7452-4baa-9c33-72844314e97c" contextRef="C_9357a2d9-9713-42be-ad31-6036ccaefd7e" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c34c8a4-5216-4eb2-9bfd-9d4015d8ef11" contextRef="C_9e42e73a-a6c9-4461-a752-a23c4b0480e5" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2025 and December 31, 2024, respectively. See Note 3 -</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_f687c476-b2f0-4131-ac4a-96ef7b8f46a9" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" escape="true" continuedAt="F_f687c476-b2f0-4131-ac4a-96ef7b8f46a9_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_580b497f-ea45-4c89-9e24-47d2a3d11430" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true" continuedAt="F_580b497f-ea45-4c89-9e24-47d2a3d11430_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:32.48%;box-sizing:content-box;"/>
         <td style="width:1.7%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.7%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.7%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.7%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93c43fec-4fe8-4d1a-9b0b-08c0393aa439" contextRef="C_0f922a3e-5746-46b4-a40a-2a645e0ec579" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,331</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ab12053-1f1f-429a-ae75-81f4b5ad416f" contextRef="C_e481b2b4-78e4-493a-b1a7-9caece635448" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,331</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48bb5fe2-18c8-48a6-a39d-ec88d94a60a3" contextRef="C_3c01f597-7579-48d0-bd5e-4b0f4f5104a5" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,331</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72c75212-5fee-4f4c-8313-8a58ec31bf84" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,331</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities (Note 4):</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury bills</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8940870b-9413-4c2d-bc56-60013ca18e87" contextRef="C_56e1e286-3df8-4b2c-bde0-b81555ab2370" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,287</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30a86583-2a28-475e-99eb-115988eea4c5" contextRef="C_3d8b7096-5d1f-45b8-b514-de72cd28a61a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,287</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52c21f62-1b26-439b-8948-fcd56226ece6" contextRef="C_6fc1a0fa-31ae-4532-816a-741e0211781d" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,890</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6e4b5b4-8ae0-4247-b65c-41d78fdfc7c8" contextRef="C_5b2c2df1-3cdd-4a8f-b2dd-15e41f28a290" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,890</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total available-for-sale securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a492eceb-a38f-4694-905f-8bfbe0ca87c5" contextRef="C_3c01f597-7579-48d0-bd5e-4b0f4f5104a5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,177</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d28de46-6274-4642-b1b3-548b5188948d" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,177</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5d42f37-cb4c-4c86-a7aa-d17f925c55f9" contextRef="C_3c01f597-7579-48d0-bd5e-4b0f4f5104a5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">259,508</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89331459-909c-47bc-a021-ddb5569d5213" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">259,508</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities (Note 2):</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_184a3021-5188-48d6-bff6-411ea42df5dd" contextRef="C_40de0e1b-6102-4d68-a514-295bf97cabb8" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,700</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20d1dd10-a9b0-484e-9f5d-b2369d41add6" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,700</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f47802d-f921-4612-a457-2e8fe2c2b118" contextRef="C_40de0e1b-6102-4d68-a514-295bf97cabb8" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,700</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b359e37-fbb6-482a-a7da-141b4cea234b" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,700</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:continuation id="F_580b497f-ea45-4c89-9e24-47d2a3d11430_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:33.44%;box-sizing:content-box;"/>
         <td style="width:1.68%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.96%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.68%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.96%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.68%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.96%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.68%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.96%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61eebad7-c14c-41ba-9f5b-a29bab7c10da" contextRef="C_e604e914-7ff0-4f04-b45a-8f2f9ce0c9bd" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,088</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5846dedf-a04f-4be7-a898-fc34a441cc75" contextRef="C_f6440943-092c-4f4b-8ccf-fb54b31a4a23" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,088</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury bills</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdea4d0e-be0d-4505-8aec-d23e4bf3f4c8" contextRef="C_c599352c-a66b-417c-85ef-0627fd3a2f3e" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,434</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_900b6a14-98d2-4510-bba2-6ecf7b797f85" contextRef="C_ad417689-b70e-4fdd-8ee9-88aa9781e90b" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,434</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_612c872f-5305-4a4a-8859-0f16aa96af91" contextRef="C_9d8cd037-690b-4ca0-a376-cbffcf5bfa7e" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,522</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14f81a41-6dec-42e9-ab78-bf13a8f7b984" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,522</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities (Note 4):</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury bills</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbc6f6ba-06c6-45a6-b8dd-ab23203b7920" contextRef="C_c599352c-a66b-417c-85ef-0627fd3a2f3e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,895</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b8d0258-3068-4d7e-bf19-7df2b868666f" contextRef="C_ad417689-b70e-4fdd-8ee9-88aa9781e90b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,895</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8837ef66-3cbb-4375-8db8-d206b33be958" contextRef="C_9bea4674-820e-4575-bad5-37c016a585cb" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,790</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e3d55d2-61e4-43a7-ae7b-a4e663a68381" contextRef="C_96fa1fb9-5125-47c5-9d54-82197981893e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,790</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total available-for-sale securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83ed8e69-d146-4749-b66c-15f258e42a01" contextRef="C_9d8cd037-690b-4ca0-a376-cbffcf5bfa7e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,685</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_334e769d-0e13-4c63-a9da-70dddff6f0b4" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,685</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcac6d21-8466-4f7a-b1ff-1e6bb8185c92" contextRef="C_9d8cd037-690b-4ca0-a376-cbffcf5bfa7e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,207</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01df38fc-10f4-4498-b05c-271861bd9bb2" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,207</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities (Note 2):</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b358ecec-3df3-4389-b2a1-f6454710fde4" contextRef="C_de9d66b8-e543-4914-8cdd-a9d5b58ab10c" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,150</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_919466e6-681d-467a-baa3-fc8df98e2380" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,150</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0caadd7-6413-4c22-ba05-c2eca456367a" contextRef="C_de9d66b8-e543-4914-8cdd-a9d5b58ab10c" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,150</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69bce532-787d-4289-a541-e10be74bbe3c" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,150</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_f687c476-b2f0-4131-ac4a-96ef7b8f46a9_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025 and December 31, 2024, the fair values of the Company&#8217;s cash equivalents and available-for-sale securities were determined using Level 2 inputs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimated the fair value of the derivative liabilities by using a Monte Carlo simulation forecasting the timing and likelihood of certain development milestone events being achieved and discounting the probability adjusted payments using an appropriate discount rate based on market interest rates. The main assumptions when determining the fair value of the derivative liabilities are the timing and probability of achieving certain milestones, the estimated volatility of the Company&#8217;s common stock, and the discount rate. The estimated fair value presented is not necessarily indicative of an amount that could be realized in a current market exchange. The use of alternative inputs and estimation methodologies could have a material effect on these estimates of fair value.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e9d17f6-a563-49ea-8c8a-ebf30d5e3167" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant unobservable inputs used in valuing the developmental milestone derivative liabilities at each measurement date are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:27.267%;box-sizing:content-box;"/>
         <td style="width:1.01%;box-sizing:content-box;"/>
         <td style="width:17.168%;box-sizing:content-box;"/>
         <td style="width:1.01%;box-sizing:content-box;"/>
         <td style="width:17.168%;box-sizing:content-box;"/>
         <td style="width:1.01%;box-sizing:content-box;"/>
         <td style="width:17.047%;box-sizing:content-box;"/>
         <td style="width:1.01%;box-sizing:content-box;"/>
         <td style="width:17.31%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unobservable Input</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Range</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Range</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of achieving certain development milestones</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4daaa50-ea22-4abb-be21-daf556726b99" contextRef="C_0b47160b-f65e-4831-8696-c2c52dd0bc33" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">28.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78c618c8-3fef-4e64-b4df-920ed0b07576" contextRef="C_7ff2cf9c-d175-4659-8c95-55b9ec8a0868" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">70.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_665c1328-0890-4c62-af15-5bbdf7659027" contextRef="C_f578dfc8-5ea5-41f0-905c-c47b2fe1a24b" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">49.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47d5b89d-2b05-45f6-b396-b18f16b20918" contextRef="C_2ab7d9ae-f3fe-411e-aa31-941b38ba994f" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">28.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b10531f-12c5-4f5d-ad11-76153d76603d" contextRef="C_83ce3b1a-e318-4538-962e-ec2695fed38c" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">70.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6627e314-ecc8-4bbc-a4da-9befc56c2702" contextRef="C_53878ad7-f60d-4fe9-9496-c94de89a86d4" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">49.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa6bd80c-20aa-4400-8829-0e74d78fde89" contextRef="C_81638abc-ed31-43b9-98ef-a8496af60b08" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">93.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c55606d-2e46-452d-8fd8-c30d1c31ad8c" contextRef="C_f1fd8b2d-e76f-4251-951c-312c4df54169" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">93.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a535531-e89a-41a2-920d-041d30f5b2a3" contextRef="C_60a0c528-a68d-432e-aab7-f31907efd67f" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">85.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3297411-8abd-4aa1-911b-10de5f6c107e" contextRef="C_201319f1-99d0-4366-bfc4-d818dfd528d0" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">85.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discount Rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cba8cd2c-b373-42ab-8c64-342356dee76d" contextRef="C_9a88d8b1-f41f-4be3-91c2-23b45a6dd969" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">3.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3cb5ff2-7525-461d-ad74-08258854182e" contextRef="C_9b1b1aff-b775-4fdd-b8ca-07668edaa8ff" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0881df4c-9870-44b9-afd5-e77e1dcc8569" contextRef="C_6b940487-af87-4229-a014-aac844c38125" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_314fdeab-d8d6-44f2-b959-2c5a5a10f3a2" contextRef="C_b5119432-e3f6-4b09-b1da-c2228aab8045" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1a2e673-f91a-463f-81c2-85f6156e1db8" contextRef="C_6da01f39-bdb4-4e8f-b42c-7df09d145c96" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2606a329-d0af-4031-8198-d13767e0d441" contextRef="C_67fc3ae3-0a38-4bcf-a5f8-68d2ff13b334" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Timing of achieving certain development milestones</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25c853ae-a865-4ca8-a447-fe1853ffe0e3" contextRef="C_b09c9e6d-7e59-4302-a92f-007cfefb2664" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_Y" decimals="INF" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e448aaa-34f3-4667-9458-a65e415163bf" contextRef="C_509be445-ad50-4826-9d85-bc19b599ef83" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_Y" decimals="INF" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7b15bb3-318a-41bc-bf98-9133e0ce0e92" contextRef="C_8bdf85e3-0c40-4066-9f25-f31d21aef5df" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_Y" scale="0" decimals="1" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b799ff7-e9e4-48e7-b2f5-23d1031274aa" contextRef="C_b1dca8da-6809-47a8-bc34-ba283cb61a5e" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_Y" decimals="INF" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e141e16-e3a7-4531-8dc8-8a90945178ce" contextRef="C_dc97493b-5647-4a4b-aaa6-bd066ad9125f" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_Y" decimals="INF" format="ixt:num-dot-decimal">3.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af8c77a3-7d64-4b37-a7d6-5bdf089d9543" contextRef="C_cc190b1a-b3c2-4730-8745-e9776ccd432e" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_Y" scale="0" decimals="1" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2e8e70a-c63d-4f36-a868-212ae28dff2b" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" escape="true"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents a roll forward of activity associated with the Company&#8217;s derivative liabilities measured using Level 3 inputs:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:78.54%;box-sizing:content-box;"/>
         <td style="width:2.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.28%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Developmental Milestone Derivative Liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of derivative liabilities as of January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e11bb2b4-270a-4e59-b527-8bed2f265e5e" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,150</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of derivative liabilities</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39a01517-633b-4fba-be48-777494dd63d8" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="sldb:ChangeInFairValueOfDerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,550</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of derivative liabilities as of June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_372140de-2112-4a9f-866a-879f358d184b" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,700</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized loss</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">es of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4540bf90-f8a3-4f3a-95d7-8091063bd027" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4904a5d-fb8f-4f9a-9715-db487b696816" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the change in fair value of the derivative liabilities during the three and six months ended June 30, 2025, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3d6d6b0-9534-41d3-b4b1-bca30a335ee5" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9a18399c-006a-4f92-8c1f-a83caaf346f3" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gain or loss was recognized during the three or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is the Company's policy to recognize transfers between levels of the fair value hierarchy, if any, at the end of the reporting period. During the six months ended June 30, 2025, and the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01cdfaeb-103a-46fe-ba5a-7b76e0a7f1eb" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_be148fb4-4cbc-47e4-b8d2-3e80a0f0dea9" contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0c3cc998-3928-40ee-942b-46b5ef43316f" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_10af4575-5cdf-4c8e-8e13-1adcb308dcb8" contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3e7525bc-a221-45d3-b627-8b430af58d43" contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c" name="sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_32da3084-c042-4b88-9e95-d043945bbcc3" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e765419d-8bdd-4dbf-b497-cfebe69c35bb" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8712b1f8-d71e-43af-876f-73d9afd038df" contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c" name="sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_48d73115-07e5-48ba-9dc8-452243c36a43;"><span style="-sec-ix-hidden:F_08ff9217-3602-4409-8438-1bc1896ee246;"><span style="-sec-ix-hidden:F_1be8fb40-e397-4eaf-b81b-88444ec1c2a6;"><span style="-sec-ix-hidden:F_f576a497-b1ba-43df-9267-28b759106728;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">between</span></span></span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7f2d05a5-0a5c-4f59-b707-ed7bd008cae6;"><span style="-sec-ix-hidden:F_0a9b999f-ba3c-4c75-85b3-624f3daa13ec;"><span style="-sec-ix-hidden:F_3c78939b-2f88-43de-94c1-2b2dca662653;"><span style="-sec-ix-hidden:F_5fe053a6-d452-4df1-bff8-51707a501d58;"><span style="-sec-ix-hidden:F_2eb056d4-25d3-4b79-9779-b2b71429c937;"><span style="-sec-ix-hidden:F_38c85a03-f1da-4bb9-bee4-e34e8e64f14b;"><span style="-sec-ix-hidden:F_981c76c5-7e07-41ab-a103-d0737a7932bd;"><span style="-sec-ix-hidden:F_81ea4290-b268-4d22-8def-51b3d1505ec7;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1</span></span></span></span></span></span></span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3a22dccf-9544-457d-a4be-457034ddacdf;"><span style="-sec-ix-hidden:F_cb4f10ce-e1bf-4e65-ab4b-c31784741e94;"><span style="-sec-ix-hidden:F_4ad198f7-47e2-4a32-bdfc-243a9a08f8d7;"><span style="-sec-ix-hidden:F_d2f01e79-37d9-4163-914f-7030affd467c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2</span></span></span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and Level 3.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company's accounts payable, accrued expenses, and other current liabilities approximated their estimated fair values due to the short-term nature of these financial instruments.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_d092a821-f972-4f0d-a349-38048bb5656f" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true" continuedAt="F_d092a821-f972-4f0d-a349-38048bb5656f_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Available-for-Sale Securities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_21117239-cecd-49c9-a9ff-ab38b46c74a8" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the Company's available-for-sale securities is presented below:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:49.39%;box-sizing:content-box;"/>
         <td style="width:1.239%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.093%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.279%;box-sizing:content-box;"/>
         <td style="width:1.239%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.093%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.239%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.093%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.239%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.093%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="15" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury bills maturing in one year or less</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55cbc64c-c79e-4a81-96c0-0f524688ca46" contextRef="C_3d8b7096-5d1f-45b8-b514-de72cd28a61a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,290</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2675e865-5e7f-4484-9afa-481cc8b437b9" contextRef="C_3d8b7096-5d1f-45b8-b514-de72cd28a61a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa37df58-9173-42f1-a9ab-dde8df79c38f" contextRef="C_3d8b7096-5d1f-45b8-b514-de72cd28a61a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,287</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds maturing in one year or less</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e9d3d95-5fc5-4844-b29d-8abc4c247ea6" contextRef="C_5b2c2df1-3cdd-4a8f-b2dd-15e41f28a290" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,925</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7768a0ee-2094-4ff3-a3a2-5fd816f2d17c" contextRef="C_5b2c2df1-3cdd-4a8f-b2dd-15e41f28a290" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8a611e4-c06a-4c4a-9a9e-136660e6cc17" contextRef="C_5b2c2df1-3cdd-4a8f-b2dd-15e41f28a290" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_befcd9c3-d7b0-408e-bcb4-4979c40a5cc0" contextRef="C_5b2c2df1-3cdd-4a8f-b2dd-15e41f28a290" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,890</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total available-for-sale securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5a6d730-1fc8-44b9-be91-1015abe121d1" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,215</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3481dd95-70f7-40f8-af26-c1989022029c" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab3f612c-13e3-4eaf-94f9-7022a96d864d" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51055e9a-cce2-48e3-83d9-fcd8a02bad65" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,177</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.03%;box-sizing:content-box;"/>
         <td style="width:1.259%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.232%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.259%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.232%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.259%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.232%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.259%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.232%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury bills maturing in one year or less</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37c36b2d-27bb-48ca-8a93-208711dcde74" contextRef="C_ad417689-b70e-4fdd-8ee9-88aa9781e90b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,879</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99f8d656-f55f-4b02-9b22-b1261baaf781" contextRef="C_ad417689-b70e-4fdd-8ee9-88aa9781e90b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0efe2f9d-9c11-4cf0-8d9e-13142d8d2fb4" contextRef="C_ad417689-b70e-4fdd-8ee9-88aa9781e90b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,895</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds maturing in one year or less</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc9983ce-fdf5-4607-8170-17f2ef0373b0" contextRef="C_96fa1fb9-5125-47c5-9d54-82197981893e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,759</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc982fc2-eeaa-46bc-86db-2b40f0fc0a34" contextRef="C_96fa1fb9-5125-47c5-9d54-82197981893e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06a766b2-092b-4de8-9d45-64c607c28578" contextRef="C_96fa1fb9-5125-47c5-9d54-82197981893e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,790</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total available-for sale securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a551901-55cc-46f8-85c3-630dfaa9c601" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,638</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ed5609f-0a3a-4384-8f4f-e84c9c514a01" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8074b2f4-d5f6-473e-a940-f4f73db9937d" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,685</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d092a821-f972-4f0d-a349-38048bb5656f_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average contractual maturity of the Company&#8217;s available-for-sale securities was approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_35dcdc6d-c7fd-494d-b422-4049550fb15b" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="sldb:AvailableForSaleSecuritiesWeightedAverageMaturityPeriod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">0.6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8c15ef8-d2fe-4701-8ad6-1b7d8b41a069" contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c" name="sldb:AvailableForSaleSecuritiesWeightedAverageMaturityPeriod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">0.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d6edc11c-a2a9-4e50-876c-e3a84cfc2e26" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="sldb:PrepaidExpensesAndOtherCurrentAssetsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Prepaid Expenses and Other Current Assets</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_839dcbd8-9252-41f3-9d24-32ccc7543d88" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66%;box-sizing:content-box;"/>
         <td style="width:3%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.899999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, <br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70ef1c0a-46ae-4154-a8f6-83444128a02f" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="sldb:PrepaidResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,235</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57ea9529-b60b-4a71-8c16-bad4ec88cee0" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="sldb:PrepaidResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,731</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid other and other current assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dadd220b-b03e-4f69-bc3d-605286d2f5f6" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="sldb:PrepaidOtherAndOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,295</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50857f5e-11f3-4062-b402-d1ef4ba41ee9" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="sldb:PrepaidOtherAndOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,651</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_377b95e2-e6bc-4d9f-b97b-714b11df1036" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,530</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c29032e-324a-40ad-b7d2-c796cbe6183a" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,382</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b890e920-9a30-4437-a750-6cf23b80dcd2" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62a5ffee-d989-4fda-89da-c2ca16f58e29" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="sldb:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.72%;box-sizing:content-box;"/>
         <td style="width:1.72%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.92%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.72%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.92%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, <br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_726faf82-6990-4b5f-82f6-0cde43a6e3e5" contextRef="C_be626f41-f068-4534-943f-caf740d9baca" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,944</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7de5e0f-63de-4e74-b013-1e049152e676" contextRef="C_d3cfa6b7-1a5b-468f-8cdb-18aa29db656f" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,268</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cddd90d0-25bb-45d4-ac40-f8b42b7a9bcb" contextRef="C_f2feab69-5f72-4f85-8dcc-ead4e1b51215" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,618</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf91d6ac-5dd7-46ae-b5ce-322af6982350" contextRef="C_bef71313-6e23-4dd9-8241-70fe0eb1517e" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,221</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued milestone payment (Note 2)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e6af3be-3598-482b-a901-3fc3fca39029" contextRef="C_8fe8d85b-2d6f-43f1-b624-cffb99addfa2" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdd72b60-4c0c-4b08-b6a0-a6e573d32825" contextRef="C_067da7b3-96d4-4d90-9b0a-89c4f29d4125" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,984</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34316ac8-76fc-4fa8-b40d-547d71385b6c" contextRef="C_5a879064-7c82-4954-9b22-68f6cb214734" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,363</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_412b40a4-53e1-40df-9cbf-fde9f48bca13" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,546</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7090c17f-8e68-4f25-8058-b4cf47ff5f55" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,852</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e6cc974-2767-4a03-b818-3e05eb15ad36" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Stockholders' Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 11, 2024, the Company issued and sold in a private placement </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9474361a-6e76-4eca-8127-ba2e762a595d" contextRef="C_15fd7743-86bb-49ec-b84d-abc109f772fc" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,973,103</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock at a price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40899468-77da-492a-a00b-24df62220a10" contextRef="C_71f48d56-146a-435b-9b14-f7e66b80f25a" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">5.53</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and, to one investor in lieu of shares of common stock, pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8185fa8e-0f59-4e2d-be4b-c93cf8569394" contextRef="C_ea7a5a80-b49b-47e8-a532-b9e2fbc30677" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,712,478</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c32435c-b06e-4e2b-b805-4ad913fb7932" contextRef="C_ea7a5a80-b49b-47e8-a532-b9e2fbc30677" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">5.529</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant, (the "January 2024 Private Placement"). The Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07651602-9d6b-4d4a-a70c-68c3b0333942" contextRef="C_a91acc16-ec5d-42f1-ae23-d52f464888f9" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">103.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of net proceeds from the January 2024 Private Placement after deducting offering costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 19, 2025, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_727a2822-3a1d-4e70-818a-64fa9954345d" contextRef="C_b8a19bcd-ecaa-4d90-ba75-094d33c6ca5e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">35,739,810</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock at a price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de0f1f0f-d9b2-4c9d-9511-cfce19af884c" contextRef="C_2fba1c08-32ae-4049-8fbf-3094c4c366bc" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">4.03</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and, to certain investors in lieu of shares of common stock, pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24d92b83-b0d9-4aee-98bb-68bca9ccac08" contextRef="C_852de8fa-b9b7-41ee-aac7-7d5c2c175c8c" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,888,340</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a409e44b-f3b8-4aaa-b8cf-4c8e074d4851" contextRef="C_852de8fa-b9b7-41ee-aac7-7d5c2c175c8c" name="sldb:ClassOfWarrantOrRightPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">4.029</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant (the "February 2025 Offering"). The Company received approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd872122-e65f-4231-b46c-1eddb426b7f5" contextRef="C_2161a6b4-6f9c-4f31-a82d-4f7221bf0362" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">188.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of net proceeds from the February 2025 Offering after deducting underwriting discounts and commissions and offering costs.<br/><br/>The Company determined the pre-funded warrants met the criteria for equity classification. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b7d9c74-b4bb-4509-878a-b36b18635ac8" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="sldb:ClassOfWarrantOrRightsExercised" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants were exercised during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_a23cc27a-3132-4af2-8396-e14a18d74490" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_a23cc27a-3132-4af2-8396-e14a18d74490_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Equity-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity-Based Compensation Expense</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_22c70847-7870-4282-9908-c9f4dcc27a38" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has classified equity-based compensation expense in its condensed consolidated statements of operations as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:43.4%;box-sizing:content-box;"/>
         <td style="width:1.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.48%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.48%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.3%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.3%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2837cc85-269d-4249-963b-bba923152a2c" contextRef="C_0a6c72f5-7161-423a-a27c-3a3a231889bb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,116</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39d92011-b27f-4052-a6be-5782c217701d" contextRef="C_9611295f-24d3-4b23-a0ec-62392a8b5c79" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">832</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a84f5de-a20b-4f6d-b851-6edeefdda9e1" contextRef="C_43201d5f-3fb8-4b8f-bcc4-042087291ecb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,218</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d90ab604-8ce5-4cfd-8beb-d67a64816dd8" contextRef="C_de18e3d4-4b86-42dc-b5ca-c6702ad6d2fd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,380</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99f72d5d-21b8-4aa4-86b9-4b8fc87ef0d4" contextRef="C_232dc221-d840-420d-bab1-6b1e75c2fc36" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,029</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_156c270e-b81b-4e96-9402-a0220e718a4e" contextRef="C_fbce7cd5-1b2d-4126-b546-1df19016fd56" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,260</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12632dc6-e6f0-4adf-b676-c3155298c4d9" contextRef="C_6b0dcf24-e56b-4005-a22c-bc5fb3b0c9b1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,268</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8712d9d3-d292-4d52-b5ee-e250dc550397" contextRef="C_b0005526-5d37-401c-9d72-c06da6f9106f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,323</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3031335f-15a8-4732-a40f-0719dc04f94c" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,145</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d3eaee8-69ad-47e2-8b42-c7c5faf88ed0" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,092</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2439ddb3-0e71-448f-997d-15fb0980f98b" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,486</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c183a77b-7e69-4125-8427-4cffe9f94f1c" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,703</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_a23cc27a-3132-4af2-8396-e14a18d74490_1" continuedAt="F_a23cc27a-3132-4af2-8396-e14a18d74490_2"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Incentive Plans</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, the Company&#8217;s approved equity incentive plans include: the 2018 Omnibus Incentive Plan (the "2018 Plan"); Amended and Restated 2020 Equity Incentive Plan, as amended (the "2020 Plan"); the Amended and Restated 2021 Employee Stock Purchase Plan; and the 2024 Inducement Stock Incentive Plan (the "2024 Plan"). These plans are administered by the Board of Directors (the "Board") and permit the granting of stock options, stock appreciation rights, restricted stock, restricted stock units (the "RSUs"), performance awards, and other stock&#8209;based or cash-based awards. Upon the adoption of the 2020 Plan, the Company no longer grants new equity awards under its 2018 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated 2020 Equity Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 12, 2025 and June 11, 2024, the Company's stockholders approved amendments to the 2020 Plan to increase the number of shares of common stock reserved for issuance under the plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16f50379-1f0b-4c04-94d1-eaab2868a495" contextRef="C_121327c9-aee0-4ee4-85a3-a872dfee9989" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68a26beb-160a-4d6d-b787-ac06426f69a4" contextRef="C_fbba6851-1a6e-4905-b021-c0bc7d5f40f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, there </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a040b587-9c5d-4134-a69f-a18f7ce4c540" contextRef="C_6402365a-b943-488b-9bd3-756393cdd6c8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,450,074</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock options outstanding, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bf27b1f-3b36-4593-8c77-0f884fb9bd26" contextRef="C_9b696383-da9c-41fe-9065-748e255e49a0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,433,589</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs outstanding, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3d433f7-ed7d-4ee6-889f-22285b4608d4" contextRef="C_12e60ca8-b4cb-4f88-953a-ab24ae966a5e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,074,188</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> performance stock units outstanding, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6946bb10-bac4-4150-80ca-6b2acf044b95" contextRef="C_f2a02817-6c5e-449e-a477-05d0a714df5a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,173,225</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remained available for future issuance under the 2020 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 Inducement Stock Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, the Board approved the 2024 Plan, which provides for the reservation of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad34b0ac-2718-49b8-b2c5-d83b37db2973" contextRef="C_3bd6d252-5e42-42c5-8ae2-0186828da84b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock for equity granted as an inducement material to the individual&#8217;s entering into employment with the Company and in accordance with the requirements of Nasdaq Stock Market Rule 5635(c)(4). As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb8cb85d-2717-4ab2-a0bc-f64e488422b3" contextRef="C_f2a02817-6c5e-449e-a477-05d0a714df5a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">100,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock options outstanding, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7e92b38-4ba4-48d7-b3e8-7e94d474ca94" contextRef="C_f2a02817-6c5e-449e-a477-05d0a714df5a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">492,256</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs outstanding, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba056263-c65b-4e35-9e99-b4f319cd3fc5" contextRef="C_99ed3715-c191-4bd1-af0a-a1b55b1bcf04" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">386,111</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remained available for future issuance under the 2024 Plan.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fcb7ce95-713a-4460-8fd9-3857466c0948" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below summarizes the activity with respect to stock options for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.91%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.002%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.002%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:6.841%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.24%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining Contractual Life (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56bee5c9-6f40-471b-815f-d236a4c18ec5" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,927,937</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a26701a-ffd8-4b06-b37b-fd4265cb0efe" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.22</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><ix:nonNumeric id="F_e7437aaa-59a4-4817-a1f4-a2125b65bed2" contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.01</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_044bacf3-18ce-480e-b41a-50204f766053" contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09f842b3-f962-432b-ba8d-6bd002d04ac5" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">642,148</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3fff342-c67a-41b6-aebe-40c0c7b8471b" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.56</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5caf50cf-1775-43e3-99e9-92ddf070ef6b" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,733</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17106c48-1f3c-425e-9154-1113c80dfa66" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.35</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76aa5d34-88c7-4e74-b031-55153e271acf" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">139,165</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7612f1a7-2bf6-46b4-9a94-797116c0dcdc" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">67.13</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeitures</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae2d121c-548f-41fc-8475-0f8606dd78c9" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">103,882</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d062735-cb33-4042-a54c-04d8b5059eb5" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.09</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3355c3b-e197-4170-8e7c-63a9f463dc59" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,324,305</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce88f8eb-a8f6-471c-9c28-1b6b2c000480" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.93</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><ix:nonNumeric id="F_c48e0f62-bc6a-4c1a-b954-d15ac500d7c3" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.14</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf6fc7a1-1590-4d64-8bbe-b91fd7765675" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">467</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest at June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_238d0eb2-77ea-4b6f-850c-4f3a69a31f23" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,324,305</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3b87de6-87e2-45bf-8d2d-8b9f94979936" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.93</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><ix:nonNumeric id="F_858c7314-3d86-4d33-9653-7a2025b6ea56" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.14</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18505c20-c077-4829-a704-367510d1ced9" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">467</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bad18198-5a2b-4554-969e-0c850a801472" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,668,986</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_815eb63b-dd25-451e-b4d8-425100dafe2f" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">21.64</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><ix:nonNumeric id="F_bf5287b5-36a5-4c19-95c0-bf98b5119faa" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.41</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c80a1859-4c1a-40f0-b858-aa6835261717" contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0cbda973-ba65-4162-bff6-31f5d64da29c" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in the Black-Scholes option-pricing model for all stock options granted during each period presented are as follows:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:44.4%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:13.14%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:13.14%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:12.42%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:12.42%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0a2e61c-e5d7-4c44-a11f-805f811a98a3" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.58</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f367e450-6dfa-4e25-b129-c1e2d5b4694e" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.51</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3eef135-1fc5-4245-8f37-35ca0ee3b7fe" contextRef="C_e6208aaa-c289-4498-b410-b580516620c2" name="sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dce78b4e-dbbe-4369-8899-9d139f81e3ef" contextRef="C_6ff04018-2bea-4ce0-9148-099fbf986bc0" name="sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.58</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c382993-3efa-44d7-8469-039179b5d7d0" contextRef="C_4fd6bf31-bc0e-49ed-9f27-784e94385c06" name="sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.76</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85835563-4eb3-48b0-9de7-6610dca44722" contextRef="C_a537fa02-a1f1-49bd-84cb-8936826a3d3b" name="sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.85</ix:nonFraction></span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01fd11b9-33d1-4b31-8cc7-54b266b88995" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">114.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9584163f-b856-440b-bde4-dd4d9233b6ae" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">122.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4ef685c-4889-4610-85ee-722cce83f2d6" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">112.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e28d381-166e-4376-bfea-6ae92279eda0" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">114.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3bec24d-714c-488d-a6d7-dce305523f90" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">122.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a45647d-2714-43f8-ad1e-a1b3cfcf5248" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">128.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividends</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bb6775b-d42f-47f3-8931-880066c045f0" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9be38802-6592-4cf5-8ca8-467e98e8f36b" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed27de38-b230-42ac-bce6-ca2a1ca66d1e" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8032eb1-f543-4df9-a827-c9457a030fd8" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_5e1ab501-bb80-4f48-bec4-ec2ec792d8f1" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_d025f403-1182-462f-a7a7-012b98ed6f7b" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_d934ba21-f70f-4d88-83c7-73875340c64b" contextRef="C_e6208aaa-c289-4498-b410-b580516620c2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><ix:nonNumeric id="F_8284f44e-5eb4-45c1-b20f-77952a48b9c6" contextRef="C_6ff04018-2bea-4ce0-9148-099fbf986bc0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_b78a5e4f-deb0-40e5-befc-96a579ee8ea8" contextRef="C_4fd6bf31-bc0e-49ed-9f27-784e94385c06" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><ix:nonNumeric id="F_2338e74f-bea7-48dd-b78c-6e2aecb8af8a" contextRef="C_a537fa02-a1f1-49bd-84cb-8936826a3d3b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.25</span></ix:nonNumeric></span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da6d0952-25bd-4f7e-80c2-453e766661ae" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2909fd3-e92e-4ec7-a23d-f3b0dd6d6479" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d23889b0-03eb-480e-9a8d-1ba5445735cc" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20f2e557-4e67-4e67-8ba0-6988910b4e67" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6604bb0f-0fa3-4f82-b303-a6e8bfc8c51d" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df27fe7e-8151-43d5-ba80-b7f6ffead346" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average grant date fair values of stock options granted during the three months ended June 30, 2025 and 2024 were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79c5cb56-e927-46af-8a06-04f8dc28035f" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.84</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0470835-cf70-49d7-bb48-d5ff5c230e52" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.52</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and the weighted average grant date fair values of stock options granted during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dadc3720-2e31-4c48-9d8b-803390d5160b" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.83</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b5d8922-3ba6-4275-93fc-f12af3541362" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.91</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, resp</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognize</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c14a6c8-522f-418e-b1c6-91f27fc5a577" contextRef="C_a99a7b4d-7291-4c75-bfcd-d11cbca34f46" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2822216-5324-4765-be49-c4ce720e585d" contextRef="C_0e4f4078-c836-4440-84d7-12e84fc594a9" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion of equity-based compensation expense in connection with stock options during the three months ended June 30, 2025 and 2024, respectively. During the six months ended June 30, 2025 and 2024, the Company recognized equity-based compensation expense in connection with stock opt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_033af1b2-0680-491e-b94e-9a5f94f50cdd" contextRef="C_8e9b54e8-5db3-4a2c-8d9c-a1cdfcf765d7" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19db7b38-ce6d-47d4-8fbe-ea57acd6576a" contextRef="C_e87fa31e-fdf3-4012-9418-bb7b976dcee5" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, respectively. As of June 30, 2025, there was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e6ec7a0-dc43-4df4-b2b6-378eb2e09dcf" contextRef="C_8db1bca0-aca7-44cf-ac19-c26a69173dfc" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion of total unrecognized equity-based compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f34e3a42-aa76-415b-8e1e-f74cd139af05" contextRef="C_cb1343da-e01f-4ce0-adcf-425c15f992be" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a23cc27a-3132-4af2-8396-e14a18d74490_2"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4fcd5acc-34df-44bb-806f-e67cea6a3c17" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes activity with respect to RSUs during the six months ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67%;box-sizing:content-box;"/>
         <td style="width:1.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.58%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.92%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Units</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested RSUs at January 1, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f2e69d1-0776-4512-8025-ea4d91063284" contextRef="C_583384bc-be95-42dd-89bf-a2fab8449504" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,480,272</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcd82b0a-0016-449c-a6d7-e71e9c1f2a08" contextRef="C_583384bc-be95-42dd-89bf-a2fab8449504" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.50</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03ddc33e-f486-4614-87d0-6dce0403acb0" contextRef="C_14340f1e-e345-45e4-974c-789fb31cb960" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,188,256</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e198101-81f3-44c5-a27b-523b6dc3f781" contextRef="C_14340f1e-e345-45e4-974c-789fb31cb960" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.23</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c2ffef2-25d9-4889-9dc7-119ecec030f4" contextRef="C_14340f1e-e345-45e4-974c-789fb31cb960" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">280,159</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42e50e08-4c30-491d-97c8-80701a6cb73e" contextRef="C_14340f1e-e345-45e4-974c-789fb31cb960" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.76</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeitures</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a30b2a0-30ff-4258-9b9f-307186d76edf" contextRef="C_14340f1e-e345-45e4-974c-789fb31cb960" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">286,245</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5b3eb25-57b5-4074-b915-9fcd9f3520c5" contextRef="C_14340f1e-e345-45e4-974c-789fb31cb960" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.73</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested RSUs at June 30, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31b3a0fc-d4b1-4747-9fe9-ed980eb8c150" contextRef="C_75db7873-c2fc-46ea-9e70-df62f468e4fd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,102,124</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e3d81f9-7ed2-4680-b8b4-c9a55ed7c7a6" contextRef="C_75db7873-c2fc-46ea-9e70-df62f468e4fd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.72</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e26019a1-0381-49fa-b146-5dafc34c4c7f" contextRef="C_d565f4e4-dbfe-4ca6-945a-b8666899b153" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e4beb6f-b7ec-47d9-9454-51fd3ac80998" contextRef="C_486f1e6a-12ec-4d97-ab93-1669ee41521b" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of equity-based compensation expense in connection with RSUs during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended June 30, 2025 and 2024, respectively. During the six months ended June 30, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized equity-based compensation expense in connection with RSUs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d9b8044-3bd1-47fb-ba42-b2aad380eca5" contextRef="C_14340f1e-e345-45e4-974c-789fb31cb960" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48189a59-36ca-416b-866f-b919675c53fa" contextRef="C_abb48ec4-81de-4bdb-9fa1-14513edb7132" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b4b42a0-1316-4d04-b206-22bcee181fd6" contextRef="C_75db7873-c2fc-46ea-9e70-df62f468e4fd" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of total unrecognized equity-based compensation expense related to nonvested RSUs, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54450cb7-e36c-4232-8391-b26cc869b180" contextRef="C_14340f1e-e345-45e4-974c-789fb31cb960" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Stock Units</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, the Board approved a grant of performance-based restricted stock unit awards ("PSUs" or "Performance Awards") to the Company&#8217;s executive team. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ac1b0f7-86ce-4ef1-bc7c-9ddec8303ded" contextRef="C_c465dc2b-b8fb-4093-a52c-31899dca9507" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each PSU represents the contingent right to receive one share of the Company&#8217;s common stock.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> These Performance Awards provide for the vesting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3da6f3e-4bbe-4083-913e-0570de154717" contextRef="C_491fb316-de76-4866-ae64-7e0adfba538c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee&#8217;s continued service with the Company (the "Approval Conditions").</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Performance Milestones are tied to the achievement of certain business objectives and are non-market and non-financial in nature. The Board will determine that all Approval Conditions have been satisfied and the number of units that will ultimately vest on the 2026 Evaluation Date, which will occur in the first quarter of 2026, and the 2027 Evaluation Date, which will occur in the first quarter of 2027. A maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2d94816-f255-4f50-9ec5-b18186ce050d" contextRef="C_491fb316-de76-4866-ae64-7e0adfba538c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the target number of RSUs may vest at the 2026 Evaluation Date and the percentage of the target number of RSUs allocable to any Performance Milestone that has not been achieved on or prior to the 2027 Evaluation Date shall be cancelled.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8027ca1b-8c30-4b47-a073-f77aa702b73b" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes activity with respect to PSUs during the six months ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67%;box-sizing:content-box;"/>
         <td style="width:1.06%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.44%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.54%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.96%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Units</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested PSUs at January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2616b747-073f-4c7f-a7bd-51229824fc77" contextRef="C_41f2e884-47b6-44f0-b8af-b6fb07efc6e9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,165,325</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c6eb90b-b0a2-491e-9593-f68eaeb12f9c" contextRef="C_41f2e884-47b6-44f0-b8af-b6fb07efc6e9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.51</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeitures</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b4672b0-e4b8-4df0-8d96-c3b453a32d48" contextRef="C_c465dc2b-b8fb-4093-a52c-31899dca9507" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">91,137</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d7d0061-3f9d-459a-9091-c278b1b4d74f" contextRef="C_c465dc2b-b8fb-4093-a52c-31899dca9507" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.51</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested PSUs at June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b06a00a6-a81c-4d67-8a5f-15a9be59768b" contextRef="C_2ad125fb-5eec-4263-bb8f-8a0e750525f8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,074,188</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24edfb14-71a6-4f45-95ed-24aab36c10ac" contextRef="C_2ad125fb-5eec-4263-bb8f-8a0e750525f8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.51</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64f89125-eef0-47ba-959d-2b32f317603d" contextRef="C_2f3b7b59-d24f-40f5-8461-a913f95f8f17" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85c48285-000c-43b3-a335-f09ad234c352" contextRef="C_47b90c1a-3b38-4665-b877-e9472f8c44fd" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">equity-based compensation expense in connection with PSUs during the three months ended June 30, 2025 and 2024, respectively. During the six months ended June 30, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized equity-based compensation expense in connection with PSUs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab266467-608c-4c0a-8175-4088c962f5d4" contextRef="C_c465dc2b-b8fb-4093-a52c-31899dca9507" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be585ba4-e217-454e-b1b4-e40122c1dbfe" contextRef="C_00a86f62-54eb-4a64-af3c-51b16552e396" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de12b510-0a05-4a8d-92fc-cead7dcfcbab" contextRef="C_2ad125fb-5eec-4263-bb8f-8a0e750525f8" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized equity-based compensation expense related to nonvested PSUs based on the achievement of all Performance Milestones, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9a3cf54-b412-45f1-9cbc-e50c6a6527d0" contextRef="C_c465dc2b-b8fb-4093-a52c-31899dca9507" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_b983c86a-f948-4a41-89e9-73f4e9e3be43" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_b983c86a-f948-4a41-89e9-73f4e9e3be43_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Letter of Credit</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had an outstanding letter of credit in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18ec3cd7-3014-4a85-bb8b-2ac6babe07d3" contextRef="C_fb4b367c-a294-43f5-af08-b0aea809fc01" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee08599b-85a4-45d1-9cfe-5b2a9442cb8f" contextRef="C_8bf9e100-f231-4586-b5dd-838b0884dd87" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at June 30, 2025 and December 31, 2024, respectively, which is required as a condition of the Company&#8217;s office and laboratory lease.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b983c86a-f948-4a41-89e9-73f4e9e3be43_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with its executive officers and members of its Board that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as executive officers or directors of the Company. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification arrangements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of June 30, 2025 and December 31, 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which the Company is focused. The Company is not aware of any material legal proceedings or claims as of June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_2625c529-f4e6-4d7c-a2ed-fb21ff0dbc94" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Net Loss Per Share</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17288e05-e2de-4397-953a-e0e71b1aaa13" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of the Company's basic and diluted net loss per share:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:42.4%;box-sizing:content-box;"/>
         <td style="width:1.24%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.24%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.24%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.24%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9984bfba-9706-43eb-92c2-7017bed768fb" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,480</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21bee669-8edb-4632-ae3e-f59fd0d7bba7" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,072</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44f2c5ad-eb53-42aa-a7c5-06c4c17977e2" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,762</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfe6e9ab-4544-4b80-af5c-9dcedb6ed904" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49,375</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares used to compute net loss per share, basic and <br/>&#160;&#160;&#160;diluted</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average shares of common stock <br/>&#160;&#160;&#160;outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1e6318d-5aff-4984-97c4-0b02053b43bf" contextRef="C_aa5bd7ea-c156-4475-926c-e8eddecefd5c" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f10af600-4828-4a24-b98c-e2c41d0c5d92" contextRef="C_aa5bd7ea-c156-4475-926c-e8eddecefd5c" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">77,539,468</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a52403e-64a5-4aca-9c52-0fd2789f15ae" contextRef="C_07264e86-c26a-42ce-a8e5-89f7da5029a5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5ba97e2d-35f0-4678-b814-022abdc85762" contextRef="C_07264e86-c26a-42ce-a8e5-89f7da5029a5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">38,221,883</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4b407a5-5faf-4c59-a61e-3f956a1d1b3e" contextRef="C_6573f6ee-fbf9-4133-87fb-c760c893c038" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6444e267-77b4-41c1-9bd5-61a4829b989b" contextRef="C_6573f6ee-fbf9-4133-87fb-c760c893c038" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">67,476,597</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87b100d6-6df8-4029-999d-9af57245fe0a" contextRef="C_7b3b5780-a030-4090-8d67-27c854d7392e" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1a604e4b-f43e-4afa-975a-4adf2851527f" contextRef="C_7b3b5780-a030-4090-8d67-27c854d7392e" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">36,981,426</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average shares of pre-funded warrants to <br/>&#160;&#160;&#160;purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_371965e6-2c42-44f3-8ea3-4871f2644358" contextRef="C_9afdb802-6737-49db-88fa-ef76a745ff30" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d23eb371-19a5-478e-af53-73ee937c9f3d" contextRef="C_9afdb802-6737-49db-88fa-ef76a745ff30" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">16,600,818</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f34e7078-ac73-4e72-b62e-6f28baa33cdb" contextRef="C_8353f2de-6a98-4421-bb84-ff19b77babb2" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c24fc963-11fc-4042-a66f-9744ba7ec738" contextRef="C_8353f2de-6a98-4421-bb84-ff19b77babb2" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,712,478</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01417785-92e6-46f0-a2a6-65d27e3e19fd" contextRef="C_7aca4bd1-bcd1-48cc-9174-dd70c602d117" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c84a9568-f0c2-4fc7-ae37-14cabd672da7" contextRef="C_7aca4bd1-bcd1-48cc-9174-dd70c602d117" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">12,840,991</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7215235a-bfe4-47b3-8bde-740d0ac8cdcc" contextRef="C_dd44ede6-4ec4-41dd-9ad2-bab26319cb0f" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fff0958a-9967-4944-8dee-256395c965d5" contextRef="C_dd44ede6-4ec4-41dd-9ad2-bab26319cb0f" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,563,441</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average shares of common stock <br/>&#160;&#160;&#160;outstanding used to compute basic and diluted <br/>&#160;&#160;&#160;net loss per share</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92b3ba36-eef2-430d-8109-5684deb7f0f5" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_136f44e0-4706-4b3a-ae8e-37be384df7a8" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">94,140,286</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc418fe8-d8ee-49c6-ac28-16ac9301df9d" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c6bccac1-1f05-47b4-bb92-758cb76a3de2" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">40,934,361</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_868e13a2-bea5-48ec-a378-9c662cc17e19" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3b0b4ef2-0809-43f7-aef3-3f6e621f0208" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">80,317,588</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f2c074a-98e0-4607-9bbd-e22cab09728b" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_85f79d0f-f51a-4df9-8ef9-adf77e53e08c" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">39,544,867</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb1e9320-e860-42b5-9e54-70eadf3f4b2d" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_09c44849-9bd3-43ea-a472-682ceef0760d" contextRef="C_0c822986-4362-4137-a232-16bb78f035a6" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.42</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b21749b-8f15-47b5-994e-87dc4803f6ed" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bd3b303e-c397-4b8c-8d7c-8b93d5b733d9" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.61</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ea5ac8a-a58c-4126-a573-cef4d5589f8e" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6d48da99-786f-4a14-8741-85ed6289946d" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.98</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62e4f518-d87b-4eb2-9504-e1de7aa9904b" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_de6f7b60-bb51-49bc-8a4f-ff259759a8ee" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.25</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included within weighted average shares of common stock outstanding for the three and six months ended June 30, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d64ae1c0-7bc4-4f1d-9561-9bc1148b95f1" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="sldb:CommonStockIssuableUponExerciseOfPrefundedWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,600,818</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea135f90-6c89-4e71-ac49-02ae352ecdf8" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="sldb:CommonStockIssuableUponExerciseOfPrefundedWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,712,478</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock issuable upon the exercise of the pre-funded warrants, respectively. The pre-funded warrants are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd8d6e92-48fb-4c03-97b4-f103d27c6750" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_fd8d6e92-48fb-4c03-97b4-f103d27c6750_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The outstanding securities presented below were excluded from the calculation of net loss per share because the inclusion of such securities would have been anti-dilutive due to the Company&#8217;s net loss per share during the periods presented.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.552%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16.903%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16.903%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three and Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0474c261-e7de-47d9-a646-ec2e06d62ad4" contextRef="C_3b99cdb3-b726-4538-afce-a3801788fd13" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8d2c1eb5-bb42-47a6-bec6-49745163cfd5" contextRef="C_e39737d4-96a5-4208-8dd7-4b8993b23f93" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,324,305</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92df6ff6-8265-467d-ac19-db3445baee42" contextRef="C_78d04ead-7986-4a8d-8aac-14a63c569702" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b2a787c3-d400-4db6-9f8b-51023d455996" contextRef="C_176c63c3-fc59-41a1-a932-f7bf7ba8d013" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,890,045</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested restricted stock units</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca1ec4c0-b2e5-4f1a-9868-45ec41de0af3" contextRef="C_467782df-d0fd-4099-acab-ff5bc1e9ec7f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8c721f50-413c-4ff1-bf11-e72f6b40b407" contextRef="C_a14e5cf5-aed7-466a-9751-7832ebbdde1c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,102,124</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba1914db-8523-4129-9e1d-4add5b9a790d" contextRef="C_55f5bc14-0f86-46cb-af50-0c8b568c21fb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_09f2ae1f-ce53-4fc6-bf83-e36d906ec7a8" contextRef="C_4a834eb1-0754-4f74-8286-ff19658ed3c2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,397,063</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested performance stock units</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfeb0b60-8084-4e81-9649-281426e4680a" contextRef="C_bdad8e63-34f9-4989-b0b3-c9137d6a4917" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c015a2c6-abee-4201-8438-85f9226efcb7" contextRef="C_2724230e-7cdb-46f3-a217-d029bcdf1d1f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,074,188</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb1821ec-b29c-4111-bb1f-138d1a1c6fea" contextRef="C_27139884-7a96-4e34-a577-e29115f6dc2f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_858d7f62-72ed-49e1-8b9f-b4712e6665fe" contextRef="C_a698c408-5f01-47f3-97e9-aa9f2ef0cb86" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,165,325</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares subject to employee stock purchase plan</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f481283-5528-4fee-ae5f-e275460b395d" contextRef="C_cfc39ec9-d790-474a-94f7-86f38a3344d7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d98505ea-3f9f-40c7-97be-2b11a4e39805" contextRef="C_be43a57e-e5c9-467b-9ef0-ad48c48eb300" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">216,802</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee645c94-473b-4060-87fa-6007621da35a" contextRef="C_f540fe1f-6760-4c9b-902f-500441ab7298" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_74a47298-98fb-4a67-913e-ded32c5a26af" contextRef="C_5a01998c-63bd-4627-945b-11d0879cf70c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">250,188</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23c7e743-8a68-43cf-bb44-a14018ba5289" contextRef="C_1e06cedf-6a5d-4473-b93f-a7e7df103a67" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ee0684d7-ed0f-42d2-ac72-2e77635039b8" contextRef="C_8930ba8b-d153-4438-8796-eeb7f6030e7f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,563</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_919b8c95-662d-4c4a-ba35-32608b096664" contextRef="C_cc99c4e5-1df8-4c44-830a-6d130cb72576" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_84dc57db-eedd-4aba-b69d-0360f4f432b0" contextRef="C_fe6f9f56-6572-4eb9-ab24-7440ff654b29" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,230</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_664fab99-4741-45d3-977c-8057180aab7d" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ee157183-566d-4467-94d5-02cfb3d51952" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,719,982</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3162e0ba-03a6-4df5-8216-ea960fecc45b" contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_432aa69f-6320-4b1a-9737-4846d28fd443" contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,711,851</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_fd8d6e92-48fb-4c03-97b4-f103d27c6750_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e36c46e-950c-457f-84ef-35af221e2199" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Segment Reporting</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#2d2d2d;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f94fdb48-74a3-4424-b60d-c07b4d40f000" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable and </span><span style="font-size:10pt;font-family:Times New Roman;color:#2d2d2d;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_215f1864-17fc-420e-b501-76419930b86d" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment and manages its business activities primarily in North America and on a consolidated basis. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. All of the Company&#8217;s tangible assets are held in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting policies of the Company are the same as those described in the summary of significant accounting policies.</span><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s chief operating decision maker ("CODM") is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1cf5d347-81ef-4291-87b4-2b55905c5532;"><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief executive officer</span></span></span><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_52aa506c-ec71-417c-9c37-cf9483397723" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription"><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM assesses performance for the Company and decides how to allocate resources based on net loss as reported on the condensed consolidated statements of operations. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The annual budgeting process is the primary mechanism used to make these decisions.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The financial information also helps in making performance assessments using budgeted versus actual results.</span><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19264942-c904-4880-a469-940fad2f6bc6" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents segment expenses, other segment items, and segment net loss for the periods presented:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.05%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.402%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.402%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.402%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.742%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Segment expenses:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-003</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7459fdda-7bce-4879-8600-a821268514f1" contextRef="C_944b7695-ad9e-4285-960c-d72aec8f998b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,219</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afabd80b-4adf-494c-9493-aecc3cb69ab2" contextRef="C_0fbb6db9-57f0-4f7f-b13e-14af89636f51" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,434</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5645fc3-0f3b-45df-8fe9-f0b658cfff4f" contextRef="C_a1407b45-da9f-427b-a243-aed2688829bf" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,385</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bdc08e2-015e-4f7c-bc53-828543afa10b" contextRef="C_64acb9d0-11e7-4835-9467-65098353bd5a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,340</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-501</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d0b7667-2f19-4135-956b-cb89ceb55c6a" contextRef="C_a81e0a2f-1838-4bd5-b00c-b952678b1b8f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,223</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd34f12b-a8d4-4db8-bbe2-d17c3870aaf2" contextRef="C_0ba68b2f-2dd1-4b87-be43-3f478cee6225" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,422</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b144290-8ec8-4a6f-b7db-0fd4ce90439f" contextRef="C_7ad823ef-64bf-4820-ae9b-3a36a9790d50" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,689</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e157846f-1643-4225-82e3-6ad4d481fa0e" contextRef="C_3a78b22e-0dc9-4c13-a887-682de9fd6013" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,229</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External R&amp;D other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0f3808c-eee7-4914-89dc-62a3b26682a8" contextRef="C_4f06942d-922b-469e-b680-72ee9ddfb246" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,116</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7aa4532e-66ee-44c5-9191-d258d65f8070" contextRef="C_0bea57c3-1523-47ea-b446-8474ebbcbd5b" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,845</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0c89137-4bf5-4df2-b701-09ff167d2cde" contextRef="C_51655aef-3697-4608-9eff-6b7264ab13cf" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,886</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b6423eb-cbbe-4e80-a654-b174678e6acc" contextRef="C_b4ad5fd9-ef1a-4596-931b-e54dc3cf2c0f" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,573</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal R&amp;D expense</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd0488a2-5982-4c0d-8427-7cd764b1afaa" contextRef="C_8b6d4398-1614-4734-94af-3cd9579e2b1f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,765</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7803374c-5d25-4f3d-842d-d0c64bcd986d" contextRef="C_c96a2be2-695f-4030-9b68-3a5f63eb3737" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,921</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fdbb3f3-306e-4a07-872a-ef5e8888e888" contextRef="C_77693677-27d9-4472-b43c-7dbe442a2eb4" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,608</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e814cac-ab32-4e76-abde-3b3858347347" contextRef="C_50c05ebc-0ef9-47a4-a21f-7d16f9e48827" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,298</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External G&amp;A expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3b5628e-baee-4939-bdb8-43490a8af74c" contextRef="C_b83fb99f-5542-4814-ad4c-4ef8642b65e7" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,279</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_065e0b9f-c216-48e8-a982-0a3351d043c4" contextRef="C_b1d34379-d268-419a-8067-a8edfa178a20" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,449</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_197f461c-18fd-41a3-9dc4-66095d8f35e6" contextRef="C_3189d97a-043c-49ab-94df-6b80295ced76" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,156</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf1ab42d-5a25-4c15-9742-06b22d4b47d9" contextRef="C_d8ff73cd-5ef2-4164-872f-1f12e3c684c1" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,883</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal G&amp;A expense</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc3b7589-324b-4fc5-935a-9ea4f75dbd7a" contextRef="C_6d7a65a2-794d-4455-9e96-273e3ca49062" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,360</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fa2a1c1-f4c7-485e-9cfd-c80a924130fb" contextRef="C_3bc4e127-2055-433c-a159-d00bb0f66d84" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,037</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb7956d3-803a-40b6-9b94-a33c7013c2a1" contextRef="C_1159e041-c22c-4bf8-b89b-c533c983f202" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,823</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df3340fb-8bbd-4a63-a6d4-485e71013839" contextRef="C_0dbb79eb-088e-4b58-8b14-1c279ad90bd4" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,003</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e808d49-9bf4-474c-b7b5-953f005e5ca6" contextRef="C_cd72c633-01e1-43fb-bc8c-26f766ba3391" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,731</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_934fd9bd-c27c-4de6-9da1-3c287bc2738a" contextRef="C_0afad434-c6ec-493a-ad86-7a15c47c34be" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,680</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e836d7f-60dc-40af-81c0-d5cf21feed01" contextRef="C_253f834d-9848-47a4-80e2-b6033edab9fc" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,198</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a443cd96-bd52-4a95-ae9b-d6a38df5d2fc" contextRef="C_96ed23d1-a1e6-4659-bc21-14e675a602f3" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,324</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1726ca6-d014-4e93-94b0-08241bbf416c" contextRef="C_cd72c633-01e1-43fb-bc8c-26f766ba3391" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,213</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_085df943-29d9-44d2-8b6e-fca459e21eb8" contextRef="C_0afad434-c6ec-493a-ad86-7a15c47c34be" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,716</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f462104b-98e6-46d9-8aad-46ae9d64b4d6" contextRef="C_253f834d-9848-47a4-80e2-b6033edab9fc" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,983</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c362931-d495-46af-bcdc-601c8576a63a" contextRef="C_96ed23d1-a1e6-4659-bc21-14e675a602f3" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,275</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Condensed consolidated net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a04a2774-3018-4a26-8cef-f5ea4f2fbbbe" contextRef="C_cd72c633-01e1-43fb-bc8c-26f766ba3391" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,480</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c03a103b-6ac8-4ede-852d-1e8deaa2b34d" contextRef="C_0afad434-c6ec-493a-ad86-7a15c47c34be" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,072</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_699a386a-fa15-4918-b656-d06668a2633b" contextRef="C_253f834d-9848-47a4-80e2-b6033edab9fc" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,762</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cda64691-eb27-4149-8bf7-6999ad7f7e24" contextRef="C_96ed23d1-a1e6-4659-bc21-14e675a602f3" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49,375</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:4.86%;box-sizing:content-box;"/>
         <td style="width:95.14%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal expenses consisted primarily of payroll and related costs, temporary services, and travel and entertainment.</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items primarily included other program costs, equity-based compensation expense, and depreciation and amortization expense.</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The measure of segment assets is reported on the balance sheet as total condensed consolidated assets.</span><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fcc499b8-43a9-4433-a575-04dc61a9d9fb" contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Subsequent Events<br/><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 4, 2025, the One Big Beautiful Bill Act (the "OBBBA") was enacted in the United States. The OBBBA includes significant changes to federal tax law and other regulatory provisions that may impact the Company. As this legislation was not signed into law until the third quarter of 2025, the impacts are not included in the Company's operating results for the three and six months ended June 30, 2025. The Company will evaluate the impact of the newly enacted tax law and its impact on the Company's forecasted annual effective tax rate in subsequent periods as required.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Management&#8217;s Discussion and Analysis of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Financial Condition and Results of Operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes appearing elsewhere in this quarterly report on Form 10-Q and our audited financial statements and related notes for the year ended December 31, 2024 included in our annual report filed on Form 10-K on March 6, 2025.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Some of the statements contained in this discussion and analysis or set forth elsewhere in this quarterly report on Form 10-Q, including information with respect to our plans and strategy for our business, constitute forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). We have based these forward-looking statements on our current expectations and projections about future events. The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this quarterly report on Form 10-Q particularly including those risks identified in Part II, Item 1A &#8220;Risk Factors&#8221; and our other filings with the Securities and Exchange Commission (the "SEC").</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this quarterly report on Form 10-Q. Statements made herein are made as of the date of the filing of this Form 10-Q with the SEC and should not be relied upon as of any subsequent date. Even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this quarterly report on Form 10-Q, they may not be predictive of results or developments in future periods. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, which we refer to collectively as our Candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy ("Duchenne"), SGT-212 for the treatment of Friedreich's ataxia ("FA"), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia ("CPVT"), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy ("TNNT2 DCM"), and additional assets for the treatment of genetic cardiac and neuromuscular diseases, at different stages of development, with varying levels of investment. We are advancing our diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management and care. Patient-focused and founded by those directly impacted by Duchenne, our mission is to improve the daily lives of patients living with these devastating diseases.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Solid was purpose-built to advance the best science and accelerate the discovery and development of treatments that may benefit all patients with Duchenne. As we expand to bring meaningful treatments to patients living with other neuromuscular and cardiac diseases, the values and guiding principles that drive us continue. Our corporate vision is to build an innovation platform enabling the discovery and development of high-value genetic medicines for neuromuscular and cardiac diseases by integrating internal capabilities, including a vector core, use of validated animal models, optimized expression cassettes, novel capsids and regulatory expertise, and collaborations with leaders in related clinical and research fields. Our mission, which guides our operations, is to treat and change the course of neuromuscular and cardiac diseases at all stages. Underscoring this mission, our disease-focused business model is founded on the following fundamental principles:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identify and develop meaningful therapies for underserved patients with sometimes fatal neuromuscular and cardiac diseases;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">build innovative libraries of delivery capsids and other enabling technologies with the potential to have broad impact on the gene therapy field at large; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bring together the leading experts in neuromuscular and cardiac diseases, science, technology, disease management and care; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be guided by the needs of these patients. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are continuing to advance our pipeline of Candidates. The U.S. Food and Drug Administration (the "FDA") has granted Fast Track, Orphan Drug, and Rare Pediatric Disease designations for SGT-003 for Duchenne. The FDA has granted Fast Track designation for SGT-212 for the treatment of FA. The FDA has granted Fast Track, Orphan Drug and Rare Pediatric Disease designations to SGT-501 for the treatment of CPVT.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we continue to pursue opportunities in both the U.S. and international markets, we remain attentive to evolving global economic conditions, including uncertainties related to international trade policies, tariffs, and supply chain dynamics. Although these factors have not had a material impact on our operations to date, future changes in trade regulations, tariff structures, or logistical constraints could influence the cost, availability, or timing of materials and components used in our manufacturing processes. We continue to monitor these developments closely.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SGT-003</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participant dosing in the Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 began in the second quarter of 2024. The INSPIRE DUCHENNE trial is a Phase 1/2 first-in-human, open-label, single-dose, multicenter trial designed to evaluate the safety, tolerability and efficacy of SGT-003 in pediatric participants with Duchenne at a dose of 1E14vg/kg. SGT-003 is administered as a one-time intravenous infusion. In September 2024 and June 2025, we amended the INSPIRE DUCHENNE clinical trial protocol to increase the anticipated participant enrollment size, expand the participant cohort age groups, and extend the timepoints of certain secondary objective measurements. In connection with the expanded clinical trial, we have initiated work for additional GMP batches of SGT-003.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 18, 2025, we announced positive initial data from the Phase 1/2 INSPIRE DUCHENNE trial as of the data cutoff date of February 11, 2025. Interim biopsy data reported in the first three participants showed an average microdystrophin expression of 110%, as measured by western blot, and improvements in multiple biomarkers that are indicators of muscle integrity, health and resilience. For a full description of the initial results from the INSPIRE DUCHENNE trial, see Part I, Item I, &#8220;Business&#8221; appearing in our Annual Report on Form 10-K for the year ended December 31, 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of August 12, 2025, 15 participants have been dosed in the INSPIRE DUCHENNE trial and SGT-003 has been well tolerated as of such date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enrollment and dosing in the INSPIRE DUCHENNE trial is ongoing, with at least 20 total participants anticipated to be dosed by year-end 2025.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The INSPIRE DUCHENNE trial currently has 10 active sites across the U.S., Canada, Italy and the United Kingdom, with additional sites expected to be activated by the end of 2025. A meeting with the FDA to discuss potential regulatory pathways for SGT-003 is anticipated to occur in the fourth quarter of 2025.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we intend to initiate a separate randomized, double-blind, placebo-controlled trial evaluating SGT-003 outside of the United States, also expected in the fourth quarter of 2025, with the aim of supporting potential global regulatory authorizations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SGT-212</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, we announced that the FDA cleared our investigational new drug ("IND") for SGT-212 for the treatment of FA. We anticipate initiating an open-label, multi-center Phase 1b clinical trial of SGT-212 in the fourth quarter of 2025. The trial is expected to enroll non-ambulatory and ambulatory adult participants living with FA in up to three cohorts and is designed to evaluate the safety and tolerability of systemic and bilateral IDN administration of SGT-212. The FDA has granted Fast Track designation to SGT-212 for the treatment of FA.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SGT-501</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2025, we announced that the FDA cleared our IND and that Health Canada approved our clinical trial application ("CTA") for SGT-501 for the treatment of CPVT. We anticipate initiating an open-label, multi-center Phase 1b clinical trial of SGT-501 in adult participants with CPVT in the fourth quarter of 2025. The FDA has granted Fast Track, Orphan Drug and Rare Pediatric Disease designations to SGT-501 for the treatment of CPVT.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Cardiac Programs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently developing a preclinical stage product candidate, SGT-601, for the treatment of TNNT2 DCM. Efficacy studies in mice suggest that SGT-601 treatment resulted in a restoration of ejection fraction function and a stabilization in cardiac function over time.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capsids</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AAV-SLB101, Solid's proprietary, rationally designed capsid used in SGT-003, has been well tolerated as of August 12, 2025 (N=15), in the INSPIRE DUCHENNE trial as well as in non-human primates ("NHP") and mouse studies.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are focused on developing transformative treatments to improve the lives of patients with rare neuromuscular and cardiac diseases. The majority of our current programs are designed to treat these diseases with gene transfer products. Gene transfer, a type of gene therapy, is designed to address diseases caused by mutated genes through the delivery of functional versions of genes, called transgenes. The transgenes are then utilized by the body to produce desired proteins that act therapeutically to treat the condition. In addition to a transgene, our gene transfer Candidates include a viral capsid or vector (a protein shell utilized as a vehicle to deliver a transgene to cells in the body) and a promoter (a specialized DNA sequence that directs cells to produce the protein in specific tissues). The capsid is modified to no longer self-replicate yet still retains its ability to introduce new genetic material directly into patients&#8217; cells. Adeno-associated virus ("AAV") capsids have been approved for use to deliver transgenes to patients, including via systemic delivery as well as stereotactic neurosurgical administration to the brain. The use of AAV capsids to deliver gene therapies has also been extensively studied by third parties in human clinical trials for multiple disease indications, and in certain of these trials AAV was delivered systemically to the participant.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are building multiple cardiac and neuromuscular next-generation capsid and promoter libraries with final capsid selection from the first cardiac capsid library anticipated in the fourth quarter of 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Operations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to our significant research and development expenditure, licensing and patent investment, and general and administrative costs associated with our operations, we have generated substantial operating losses in each period since our inception. Our net losses were $39.5 million and $78.8 million for the three and six months ended June 30, 2025, respectively, and $25.1 million and $49.4 million for the three and six months ended June 30, 2024, respectively. As of June 30, 2025, we had an accumulated deficit of $862.2 million. We expect to incur significant expenses and operating losses for the foreseeable future.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we seek to develop and commercialize our Candidates, we anticipate that our expenses will increase significantly and that we will need substantial additional funding to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity financing, debt financings or other sources, which may include licensing agreements or strategic collaborations. We may be unable to raise additional funds or enter into such agreements or arrangements when needed on favorable terms, if at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development or commercialization of our Candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or determine when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, we had cash, cash equivalents, and available-for-sale securities of $268.1 million, excluding restricted cash of $1.9 million. We believe that our cash, cash equivalents, and available-for-sale securities as of June 30, 2025 will enable us to fund our operating expenses and capital expenditure requirements into the first half of 2027. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently anticipate.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Operations Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not generated any commercial product revenue to date and do not expect to generate any product revenue from the sale of our products for the foreseeable future, if ever. If our development efforts for our Candidates are successful and result in marketing approval, we may generate commercial product revenue in the future.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We classify our operating expenses into two categories: research and development and general and administrative expenses. Personnel costs, including salaries, benefits, bonuses, and equity-based compensation expense comprise a significant component of both expense categories. We allocate expenses associated with personnel costs based on the nature of work associated with these resources.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and clinical and preclinical development activities for our Candidates and include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred under agreements with third parties, including contract research organizations ("CROs") that conduct research, preclinical and clinical activities on our behalf, as well as contract development and manufacturing organizations ("CDMOs") that manufacture SGT-003, SGT-212, SGT-501, and other Candidates for use in our preclinical studies and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">salaries, benefits and other related costs, including equity-based compensation expense, for personnel engaged in research and development functions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs of outside consultants engaged to assist in our research and development activities, including their fees, equity-based compensation and related travel expenses;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs incurred in seeking regulatory approval of our Candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred under our intellectual property licenses; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">facility-related research and development expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development activities are central to our business model. We are still in the early stages of development of our Candidates. Candidates in later stages of clinical development generally have higher development costs than those in preclinical development or in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase for the foreseeable future if and as we conduct clinical trials for SGT-003, initiate clinical trials for our other Candidates, including our planned Phase 1b clinical trials of SGT-212 and SGT-501, and continue to identify and develop additional Candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We typically use our employee and infrastructure resources across our Candidates. We track outsourced development costs and milestone payments made under our licensing arrangements by Candidate, but we do not allocate personnel costs, license payments made under our licensing arrangements or other internal costs to Candidates on a program-specific basis. These costs are included in unallocated research and development expenses in the table below.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development expenses by Candidate for the respective periods (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:46.251%;box-sizing:content-box;"/>
     <td style="width:1.36%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.078%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.36%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.078%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.36%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.078%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.36%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.078%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocated research and development expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-001</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">236</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">494</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-003</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,318</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,435</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,616</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,341</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-501</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,223</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,422</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,689</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,229</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-212</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,145</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,970</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-601</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,268</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,422</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">411</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other development programs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,154</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,611</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,481</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,592</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total allocated research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,300</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,015</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,528</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,240</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unallocated research and development expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel related expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,160</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,850</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,150</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,917</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,955</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,596</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,651</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,177</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total unallocated research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,115</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,446</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,801</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,094</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,415</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,461</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,329</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,334</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot determine with certainty the duration, costs, and timing of ongoing and planned clinical trials of SGT-003, SGT-212, SGT-501 or our other Candidates, or if, when, or to what extent we will generate revenue from the commercialization and sale of any of our Candidates for which we obtain marketing approval or our other research and development expenses. We may never succeed in obtaining marketing approval for any of our Candidates. The duration, costs, and timing of clinical trials and development of our Candidates will depend on a variety of factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, rate of progress, expense, and results of any clinical trials of our Candidates and other research and development activities that we may conduct;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the imposition of regulatory restrictions on clinical trials, including full and partial clinical holds and the time and activities required to lift any such holds;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">uncertainties in clinical trial design and participant enrollment or drop out or discontinuation rates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant and changing government regulation and regulatory guidance;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential additional studies or clinical trials requested by regulatory agencies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and receipt of any marketing approvals; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of salaries and other related costs, including equity-based compensation, for personnel in our executive, finance, business development and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters, professional fees for accounting, auditing, tax and consulting services, insurance costs, travel expenses, and facility-related expenses.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that our general and administrative expenses will increase in the future as we support our research and development activities and activities related to our INSPIRE DUCHENNE trial, our planned Phase 1b clinical trials of SGT-212 and SGT-501, and any other planned or future clinical trials for and potential commercialization of our Candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income, net consists primarily of interest income. Interest income consists of income earned on our cash and cash equivalents, available-for-sale securities, and restricted cash.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management's discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ materially from these estimates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2025, there were no material changes to our critical accounting policies. Our critical accounting policies are described under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Critical Accounting Policies and Use of Estimates&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2024 and the notes to the unaudited condensed consolidated financial statements included in Part I, Item 1, &#8220;Financial Statements (unaudited),&#8221; of this Quarterly Report on Form 10-Q. We believe that of our critical accounting policies, the following accounting policies involve the most judgment and complexity:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accrued research and development expenses;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">equity-based compensation; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">derivative liabilities.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, we believe the policies set forth above are critical to fully understanding and evaluating our financial condition and results of operations. If actual results or events differ materially from the estimates, judgments and assumptions used by us in applying these policies, our reported financial condition and results of operations could be materially affected.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Three Months Ended June 30, 2025 and 2024</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the periods indicated (in thousands, except percentages):</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$ Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">% Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,415</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,461</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,954</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66.6</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,278</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,327</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">951</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.4</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,693</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,788</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,905</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(41,693</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(27,788</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,905</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,966</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,565</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">401</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.6</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(60</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(88</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(31.8</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of derivative liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(900</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(900</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(100.0</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(32</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13.4</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,213</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,716</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(503</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(18.5</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(39,480</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(25,072</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14,408</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57.5</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development expenses by Candidate for the periods indicated (in thousands, except percentages):</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:46.251%;box-sizing:content-box;"/>
     <td style="width:1.36%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.078%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.36%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.078%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.36%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.958%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.558%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$ Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">% Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocated research and development expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-001</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">236</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(44</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(18.6</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-003</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,318</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,435</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,883</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">405.9</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-501</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,223</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,422</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,199</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(35.0</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-212</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,145</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,020</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">816.0</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-601</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,268</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,082</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1119.4</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other development programs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,154</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,611</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,457</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(55.8</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total allocated research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,300</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,015</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,285</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114.1</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unallocated research and development expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel related expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,160</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,850</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,310</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39.5</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,955</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,596</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">359</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.8</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total unallocated research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,115</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,446</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,669</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.6</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,415</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,461</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,954</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66.6</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses for the three months ended June 30, 2025 were $ 32.4 million, compared to $19.5 million for the three months ended June 30, 2024. The increase of $13.0 million in research and development expenses was primarily due to a $9.9 million increase in costs for SGT-003 primarily related to manufacturing, regulatory, and clinical costs, a $2.3 million increase in personnel related expenses, a $2.1 million increase in costs for SGT-601 primarily related to manufacturing costs, a $1.0 million increase in costs for SGT-212 primarily related to clinical and research costs, partially offset by a $1.5 million decrease in costs for other development programs primarily related to lower research costs, and a $1.2 million decrease in in costs for SGT-501 primarily related to lower research and manufacturing costs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses were $9.3 million for the three months ended June 30, 2025, compared to $8.3 million for the three months ended June 30, 2024. The increase of $1.0 million was primarily related to a $1.2 million increase in personnel related costs, partially offset by a $0.3 million decrease in consulting fees.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income, Net</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income, net was $2.2 million for the three months ended June 30, 2025 compared to $2.7 million for the three months ended June 30, 2024. The decrease of $0.5 million was primarily related to the change in fair value of derivative liabilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Six Months Ended June 30, 2025 and 2024</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the periods indicated (in thousands, except percentages):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$ Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">% Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,329</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,334</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,995</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.2</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,416</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,316</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,100</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.9</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,745</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,650</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,095</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.6</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(81,745</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(54,650</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(27,095</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.6</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,266</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,216</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(128</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(183</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(30.1</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of derivative liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,550</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,550</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(100.0</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">395</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">242</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63.2</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,983</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,275</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,292</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(43.5</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(78,762</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(49,375</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(29,387</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59.5</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development expenses by Candidate for the periods indicated (in thousands, except percentages):</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50.05%;box-sizing:content-box;"/>
     <td style="width:1.26%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.238%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.26%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.238%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.26%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.998%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.698%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$ Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">% Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocated research and development expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-001</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">494</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(144</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(29.1</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-003</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,616</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,341</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,275</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">397.9</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-501</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,689</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,229</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(540</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(7.5</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-212</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,970</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,797</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1038.7</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-601</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,422</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">411</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,011</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">975.9</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other development programs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,481</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,592</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,111</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(46.0</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total allocated research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,528</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,240</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,288</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117.7</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unallocated research and development expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel related expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,150</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,917</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,233</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.5</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,651</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,177</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">474</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.2</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total unallocated research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,801</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,094</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,707</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.3</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,329</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,334</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,995</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.2</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses for the six months ended June 30, 2025 were $63.3 million, compared to $38.3 million for the six months ended June 30, 2024. The increase of $25.0 million in research and development expenses was primarily due to a $17.3 million increase in costs for SGT-003 primarily related to manufacturing and clinical costs, a $4.2 million increase in personnel related expenses, a $4.0 million increase in costs for SGT-601 primarily related to manufacturing and research costs, a $1.8 million increase in costs for SGT-212 primarily related to clinical and research costs, offset by a $2.1 million decrease in other development programs primarily related to lower research and manufacturing costs, and a $0.5 million decrease in costs for SGT-501 primarily related to lower manufacturing and study costs partially offset by an increase in clinical, regulatory and licensing fees.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses were $18.4 million for the six months ended June 30, 2025, compared to $16.3 million for the six months ended June 30, 2024. The increase of $2.1 million was primarily related to a $3.0 million increase in personnel related costs, partially offset by a $0.7 million decrease in legal and consulting fees.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income, Net</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income, net was $3.0 million for the six months ended June 30, 2025 compared to $5.3 million for the six months ended June 30, 2024. The decrease of $2.3 million was primarily related to the change in fair value of derivative liabilities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of Liquidity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have financed our operations primarily through the sale of redeemable preferred units and member units, the sale of securities in private placements and follow-on offerings, the sale of common stock in our initial public offering, and sales of common stock under our "at-the-market offering" sales agreement with Jefferies LLC ("Jefferies") (the "ATM Sales Agreement"). Through June 30, 2025, we raised an aggregate of $144.6 million of gross proceeds from our sales of preferred units prior to the completion of our initial public offering, and an aggregate of $857.1 million of net proceeds from the sale of our common stock through public offerings, including our IPO and follow-on public offerings, private placements, the ATM Sales Agreement, and pursuant to the stock purchase agreements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 13, 2019, we entered into the ATM Sales Agreement, which was amended and restated in March 2024, under which we may offer and sell, from time to time, shares of our common stock through Jefferies as sales agent. Any such sales being made by any method that is deemed an &#8220;at-the-market offering&#8221; as defined in Rule 415 promulgated under the Securities Act. We will pay Jefferies a commission of up to 3% of the gross proceeds of any sales of common stock pursuant to the ATM Sales Agreement. During the year ended December 31, 2024, we sold 2,212,937 shares pursuant to the ATM Sales Agreement resulting in net proceeds of $18.4 million. During the six months ended June 30, 2025, we sold 61,542 shares pursuant to the ATM Sales Agreement resulting in net proceeds of $0.2 million. We sold no shares pursuant to the ATM Sales Agreement during the three months ended June 30, 2025.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 11, 2024, we issued and sold 16,973,103 shares of our common stock at a price per share of $5.53 and, to one investor in lieu of shares of common stock, pre-funded warrants to purchase 2,712,478 shares of common stock at a price of $5.529 per pre-funded warrant, in a private placement we refer to as the January 2024 Private Placement. We received $103.7 million of net proceeds from the January 2024 Private Placement after deducting offering costs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 19, 2025, we issued and sold in an underwritten offering (the "February 2025 Offering"), 35,739,810 shares of our common stock at a price of $4.03 per share and, to certain investors in lieu of shares of common stock, pre-funded warrants to purchase 13,888,340 shares of common stock at a price of $4.029 per pre-funded warrant. We received approximately $188.0 million of net proceeds from the February 2025 Offering, after deducting underwriting discounts and commissions and offering costs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, we had cash, cash equivalents, and available-for-sale securities of $268.1 million, excluding restricted cash of $1.9 million, and had no debt outstanding.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of Cash Flows</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our sources and uses of cash for each of the periods presented (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.78%;box-sizing:content-box;"/>
     <td style="width:1.66%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.940000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.66%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.96%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash used in operating activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(69,262</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(46,659</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash used in investing activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(60,195</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(43,666</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash provided by financing activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188,127</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,241</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase in cash, cash equivalents, and restricted cash</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,670</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,916</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Activities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2025, operating activities used $69.3 million of cash, primarily resulting from our net loss of $78.8 million partially offset by changes in our operating assets and liabilities of $0.7 million and non-cash charges of $10.2 million. Net cash used by changes in our operating assets and liabilities during the six months ended June 30, 2025 consisted of an increase in prepaid expenses and other assets of $2.1 million, a decrease in the operating lease liability of $0.8 million, offset by an increase in accrued expenses and other liabilities of $1.7 million, and an increase in accounts payable of $0.5 million. Non-cash activities were driven by equity-based compensation of $6.5 million, a change in the fair value of derivative liabilities of $2.6 million, non-cash lease expense of $1.2 million, depreciation and amortization expense of $0.8 million, partially offset by amortization of available-for-sale securities of $0.8 million.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2024, operating activities used $46.7 million of cash, primarily resulting from our net loss of $49.4 million and changes in our operating assets and liabilities of $2.1 million, partially offset by non-cash charges of $4.8 million. Net cash used by changes in our operating assets and liabilities during the six months ended June 30, 2024 consisted of an increase of $1.6 million in prepaid and other assets, a decrease in the operating lease liability of $0.9 million, a decrease in accrued expenses and other liabilities of $0.2 million, offset by an increase in accounts payable of $0.5 million. Non-cash activities were driven by equity-based compensation of $3.7 million, depreciation and amortization expense of $1.6 million, and non-cash lease expense of $1.2 million, partially offset by amortization of available-for-sale securities of $1.6 million and a gain on lease termination of $0.1 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing Activities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2025, investing activities used $60.2 million of cash, resulting from the purchases of available-for sale securities of $128.8 million and the purchases of property plant and equipment of $0.5 million, partially offset by the maturity of available-for sale securities of $69.0 million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2024, investing activities used $43.7 million of cash, resulting from the purchases of available-for sale securities of $103.6 million and the purchases of property plant and equipment of $0.4 million, partially offset by the maturity of available-for sale securities of $60.3 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Activities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2025, financing activities provided $188.1 million of cash, resulting from the net proceeds from the issuance and sale of common stock and pre-funded warrants to purchase shares of common stock of $188.2 million, and proceeds from the issuance of shares of $0.2 million under the Company's Amended and Restated 2021 Employee Stock Purchase Plan, or ESPP, offset by payments of the principal portion of finance lease obligations of $0.3 million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2024, financing activities provided $112.2 million of cash, resulting from the net proceeds from the issuance of common stock and pre-funded warrants to purchase shares of common stock of $112.2 million, proceeds from the exercise of common stock options for $0.2 million, and proceeds from the issuance of shares of $0.1 million under the ESPP offset by payments of the principal portion of finance lease obligations of $0.2 million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Funding Requirements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our expenses to increase substantially in connection with our ongoing development activities related to our Candidates. In addition, we have incurred and expect to continue to incur costs associated with operating as a public company. We expect that our expenses will increase substantially if and as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to enroll participants in our INSPIRE DUCHENNE trial and advance clinical development of SGT-003;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance our other Candidates into clinical trials, including our planned Phase 1b clinical trials of SGT-212 and SGT-501; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue research and preclinical development of our Candidates and adjacent technologies such as assays; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek to identify additional candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage in regulatory interactions with the FDA and other regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submit regulatory filings relating to the development of our Candidates and seek marketing approvals for our Candidates that successfully complete clinical trials, if any; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">scale up our manufacturing processes and arrange manufacturing for larger quantities of our Candidates for preclinical and clinical development and potential commercialization; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, expand, protect and enforce our intellectual property portfolio; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hire and retain additional clinical, quality control and scientific personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">build out new facilities or expand existing facilities to support our activities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire or in-license other drugs, drug candidates, technologies and intellectual property; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">add operational, financial and management information systems and personnel.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, we had cash, cash equivalents and available-for-sale securities of $268.1 million, excluding restricted cash of $1.9 million. Based on our current operating plan, we believe that our cash, cash equivalents and available-for-sale securities as of June 30, 2025 will be sufficient to fund our operating expenses and capital requirements into the first half of 2027. As a result, in order to continue to operate our business beyond that time, we will need to raise additional funds. However, there can be no assurance that we will be able to generate funds on terms acceptable to us, on a timely basis, or at all. In addition, we have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently anticipate.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the numerous risks and uncertainties associated with the development of our Candidates and because the extent to which we may enter collaborations with third parties for development of our Candidates is unknown, we are unable to estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our Candidates. Our future capital requirements will depend on many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the progress, costs and results of the INSPIRE DUCHENNE trial, our planned clinical trials of SGT-212 and SGT-501, and any future clinical trials of our Candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of regulatory review of our Candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of discovery, laboratory testing, manufacturing, preclinical development and clinical trials for our Candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with manufacturing and use of third-party manufacturers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the revenue, if any, received from commercial sale of our Candidates, should any of our Candidates receive marketing approval; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining, defending and enforcing our intellectual property rights and defending intellectual property-related claims; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcome of any lawsuits filed against us; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms of our current and any future license agreements and collaborations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain additional strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the payment or receipt of milestones, royalties and other collaboration-based revenues, if any;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or in-license other candidates, technologies and intellectual property; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.559494254318427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if and as we need to adapt our business in response to public health emergencies or pandemics and collateral consequences related thereto.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are supplying, and expect to continue to supply, our ongoing and future preclinical and clinical development programs with drug product produced at a cGMP compliant facility located at one of our CDMOs. We intend to establish the capability and capacity to supply Candidates at commercial scale from multiple sources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval for any Candidates or generate revenue from the sale of any products for which we may obtain marketing approval. In addition, our Candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adequate additional funds may not be available to us on acceptable terms, or at all. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity securities, our existing stockholders&#8217; ownership interest may be diluted. Any debt or preferred equity financing, if available, may involve agreements that include restrictive covenants that may limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, which could adversely impact our ability to conduct our business, and may require the issuance of warrants, which could potentially dilute existing stockholders&#8217; ownership interests.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise additional funds through licensing agreements and strategic collaborations with third parties, we may have to relinquish valuable rights to our technology, future revenue streams, research programs, or Candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds, we may be required to delay, limit, reduce and/or terminate development of our Candidates or any future commercialization efforts or grant rights to develop and market Candidates that we would otherwise prefer to develop and market ourselves.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual Obligations and Commitments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2025, there were no material changes to our contractual obligations and commitments from those described in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of significant recent accounting pronouncements that we expect to adopt is included in Note 1 &#8211; Nature of the Business and Basis of Presentation to our condensed consolidated financial statements (See Part I, Item 1 &#8211; Financial Statements, of this Quarterly Report on Form 10-Q).</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Off-Balance Sheet Arrangements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_quantitative_qualitative_disclosu"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Quantitative and Qualitati</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ve Disclosures About Market Risk.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Rate Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to market risk related to changes in interest rates. As of June 30, 2025, our cash equivalents consisted of money market funds and treasury bills that have contractual maturities of less than 90 days from the date of acquisition. As of June 30, 2025, our investments consisted of treasury bills and government bonds that have contractual maturities of less than one year. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. However, because of the short-term nature of the investments in our portfolio, an immediate 10% change in market interest rates would not have a material impact on the fair market value of our investment portfolio or on our financial position or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inflation Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inflation generally affects us by increasing our cost of labor and research, manufacturing and development costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations in the last two years. However, our operations may be adversely affected by inflation in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Controls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Procedures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our President and Chief Executive Officer and our Chief Financial Officer (our principal executive officer and principal financial and accounting officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2025. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected. Based on the evaluation of our disclosure controls and procedures as of June 30, 2025, our President and Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were designed and operating effectively.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that have occurred during the three months ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iior_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II&#8212;OTHER</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> INFORMATION</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceedings.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ris</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">k Factors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should carefully consider the following risk factors, in addition to the other information contained in this Quarterly Report on Form 10-Q, including the section of this report titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our financial statements and related notes. If any of the events described in the following risk factors and the risks described elsewhere in this Quarterly Report on Form 10-Q occurs, our business, operating results and financial condition could be seriously harmed and the trading price of our common stock could decline. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Quarterly Report on Form 10-Q. The risks and uncertainties described below are not the only ones we face. Additional risks not presently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair our business operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISK FACTOR SUMMARY</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is subject to a number of risks that if realized could materially affect our business, operating results and financial condition and the trading price of our common stock could decline. These risks are discussed more fully below. These risks include the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant net losses since inception and anticipate that we will continue to incur net losses for the foreseeable future and may never achieve or maintain profitability.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never generated revenue from product sales and do not expect to do so for the foreseeable future, if ever.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our limited operating history may make it difficult for our stockholders to evaluate the success of our business to date and to assess our future viability.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unfavorable global economic conditions could harm our business, financial condition or results of operations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our pipeline of gene transfer candidates, which we refer to collectively as our Candidates, utilize novel technology, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval. To our knowledge, only a limited number of gene transfer products have been approved for commercialization in the United States and the European Union.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of our prior clinical trials had been placed on clinical hold by the FDA in the past, and we cannot guarantee that similar events will not happen in ongoing, planned and future clinical trials for our Candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never completed a clinical trial and may be unable to do so for any Candidate, including SGT-003, SGT-212, SGT-501 and other Candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Candidates may cause one or more adverse events or other undesirable side effects or have properties that could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay, denial or withdrawal of regulatory approval by the FDA or other comparable foreign regulatory authorities, limit the Candidates commercial potential or result in significant negative consequences following any potential marketing approval.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Success in preclinical studies or early clinical trials may not be indicative of results obtained in later trials.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preliminary or interim data that we announce or publish from time to time may change as more data becomes available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may find it difficult to enroll participants in our clinical trials, which could delay or prevent us from proceeding with clinical trials of SGT-003, SGT-212, SGT-501 or our other Candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize our Candidates and the approval may be for a narrower indication than we seek.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition and our competitors may achieve regulatory approval before us or develop therapies that are more advanced or effective than ours, which may adversely affect our ability to develop, successfully market or commercialize our Candidates. Changes within the competitive landscape could lead us to alter our regulatory and/or clinical trial strategy, baseline eligibility criteria or make other modifications to clinical trial designs.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be successful in finding strategic collaborators for continuing development of our Candidates or platform technologies, or for successfully commercializing or competing in the market for certain indications.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited gene therapy manufacturing experience and could experience production problems and delays in obtaining regulatory approval of our manufacturing processes, which could result in delays in the development or commercialization of SGT-003, SGT-212, SGT-501, or our other Candidates. In addition, changes to manufacturing sites or processes, or formulations for our Candidates may result in additional cost or delay.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to utilize third parties to conduct our product manufacturing for the foreseeable future. Therefore, we are subject to the risk that these third parties may not perform satisfactorily or meet regulatory requirements.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our gene transfer approach utilizes capsids derived from a virus, which may be perceived as unsafe or may result in unforeseen adverse events. Negative public opinion and increased regulatory scrutiny of gene therapy may damage public perception of the safety of gene transfer Candidates and adversely affect our ability to conduct our business or obtain regulatory approvals for our Candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We heavily rely on certain in-licensed patents and other intellectual property rights in connection with our development of our Candidates and may be required to acquire or license additional patents or other intellectual property rights to continue to develop and commercialize our Candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our Candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our Candidates may be adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our intellectual property licenses with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The price of our common stock has been, and in the future is likely to be, volatile and fluctuate substantially, which could result in substantial losses for holders of our common stock.</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Financial Position and Need for Capital Requirements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred significant net losses since inception and anticipate that we will continue to incur net losses for the foreseeable future and may never achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, we have incurred significant net losses. Our net loss was $78.8 million for the six months ended June 30, 2025. Our net losses were $124.7 million and $96.0 million for the years ended December 31, 2024 and 2023, respectively. As of June 30, 2025, we had an accumulated deficit of $862.2 million. Prior to our acquisition of AavantiBio, Inc. in December 2022 (the "Acquisition") we devoted substantially all of our efforts to research and development, including clinical development of SGT-001, which we are no longer developing, and preclinical development of SGT-003, as well as to building out our management team and infrastructure. Following the Acquisition, we also began devoting efforts to preclinical development of our other Candidates, clinical development of SGT-003, as well as building out our management team. We expect that it could be several years before we have a commercialized product, and we may never have a commercialized product. We expect to continue to incur significant expenses and see continued operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if, and as, we:</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to enroll participants in our INSPIRE DUCHENNE trial and advance clinical development of SGT-003;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance our other Candidates into clinical trials, including our planned Phase 1b clinical trials of SGT-212 and SGT-501;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue research and preclinical development of our Candidates and adjacent technologies such as assays; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek to identify additional Candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage in regulatory interactions with the FDA and other regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submit regulatory filings relating to the development of our Candidates and seek marketing approvals for our Candidates that successfully complete clinical trials, if any;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">scale up our manufacturing processes and arrange manufacturing for larger quantities of our Candidates for preclinical and clinical development and potential commercialization;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, expand, protect and enforce our intellectual property portfolio;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hire and retain additional clinical, quality control and scientific personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">build out new facilities or expand existing facilities to support our activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire or in-license other drugs, drug candidates, technologies and intellectual property; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">add operational, financial and management information systems and personnel.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To become and remain profitable, we must develop and eventually commercialize one or more Candidates with significant market potential. This will require us to be successful in a range of challenging activities, and our expenses will increase substantially as we continue to enroll participants in and conduct the INSPIRE DUCHENNE trial, initiate enrollment in our planned Phase 1b clinical trials of SGT-212 and SGT-501, and continue to develop our pipeline and complete ongoing and planned preclinical studies and clinical trials of our Candidates, obtain marketing approval for our Candidates, develop adjacent technologies such as assays, develop and validate commercial-scale manufacturing processes, manufacture, market and sell any future Candidates for which we may obtain marketing approval and satisfy any post-marketing requirements. Moreover, the manufacturing process requires materials which may fluctuate in cost or be limited or unavailable to us, as well as relationships with CDMOs to facilitate the manufacturing process. We may never succeed in any of these activities and, even if we do, we may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause stockholders to lose all or part of their investment.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, conduct clinical trials of, and seek marketing approval for our Candidates. In addition, if we obtain marketing approval for our Candidates, we expect to incur significant expenses related to product sales, marketing, manufacturing and distribution. We also expect to continue to incur additional costs associated with operating as a public company. While we believe that our cash, cash equivalents and available-for-sale securities as of June 30, 2025, will be sufficient to fund our operating expenses and capital requirements into the first half of 2027, we have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently anticipate. In order to continue to operate our business beyond that time, we will need to raise additional funds. However, there can be no assurance that we will be able to generate funds on terms acceptable to us, on a timely basis, or at all. In addition, we anticipate that we will need additional funding to complete the development of our Candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the progress, costs and results of the INSPIRE DUCHENNE trial, our planned Phase 1b clinical trials of SGT-212 and SGT-501 and any future clinical trials of our Candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of regulatory review of our Candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of discovery, laboratory testing, manufacturing, preclinical development and clinical trials for our Candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with manufacturing and use of third-party manufacturers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the revenue, if any, received from commercial sale of our Candidates, should any of our future Candidates receive marketing approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining, defending and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcome of any lawsuits filed against us;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms of our current and any future license agreements and collaborations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain additional strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the payment or receipt of milestones, royalties and other collaboration-based revenues, if any;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or in-license other candidates, technologies and intellectual property; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if and as we need to adapt our business in response to public health emergencies or pandemics and collateral consequences related thereto. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identifying potential candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to submit a Biologics License Application ("BLA") or obtain marketing approval and achieve product sales. In addition, our Candidates, if approved, may not achieve commercial success. Our product revenue, if any, will be derived from or based on sales of our Candidates that may not be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all, and may be impacted by the economic climate and market conditions. Our ability to raise additional funds may be adversely impacted by general economic conditions, both inside and outside the U.S., including disruptions to, and instability and volatility in, the credit and financial markets in the U.S. and worldwide, heightened inflation, interest rate and currency rate fluctuations, global trade programs, tariffs and economic slowdown or recession as well as concerns related to public health emergencies or pandemics and geopolitical events, including civil or political unrest. In addition, market instability and volatility, high levels of inflation and interest rate fluctuations may increase our cost of financing or restrict our access to potential sources of future liquidity. Alternatively, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or Candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership of our common stock will be diluted and the terms may include liquidation or other preferences that adversely affect the rights of our current stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or Candidates, or grant licenses on terms unfavorable to us.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have never generated revenue from product sales and do not expect to do so for the foreseeable future, if ever.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with collaborative partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize our Candidates. We do not anticipate generating revenue from product sales for the foreseeable future, if ever. Our ability to generate future revenue from product sales depends heavily on our success in:</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completing research and development of our Candidates in a timely and successful manner; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seeking and obtaining regulatory and marketing approvals for any of our Candidates for which we complete clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">launching and commercializing Candidates for which we obtain regulatory and marketing approval by establishing a sales force and marketing and distribution infrastructure or, alternatively, collaborating with a commercialization partner; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining and enhancing a commercially viable, sustainable, scalable, reproducible and transferable manufacturing processes for our Candidates that is compliant with cGMPs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate, in terms of cost, amount and quality, products and services to support clinical development and the commercial demand for our Candidates, if approved; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining market acceptance, if and when approved, of our Candidates as a viable treatment option by patients, the medical community and third-party payors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">qualifying for coverage and adequate reimbursement by government and third-party payors for our Candidates both in the U.S. and internationally; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effectively addressing any competing technological and market developments; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations under such arrangements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining, protecting, enforcing and expanding our portfolio of intellectual property rights, including patents, trademarks, trade secrets and know-how; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">avoiding and defending against intellectual property infringement, misappropriation and other claims; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implementing additional internal systems and infrastructure, as needed; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attracting, hiring and retaining qualified personnel.</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our limited operating history may make it difficult for our stockholders to evaluate the success of our business to date and to assess our future viability.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, acquiring rights to our technology, conducting research and development activities, establishing research and development collaborations, identifying and acquiring Candidates, establishing manufacturing arrangements and undertaking preclinical studies and clinical trials. As a company, we have limited experience in clinical development. We have not yet demonstrated the ability to complete clinical trials of any Candidate, obtain marketing approvals, manufacture at commercial-scale or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions our stockholders make about our prospects may not be as accurate as they could be if we had a longer operating history or prior experience integrating acquired businesses into our existing business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unfavorable global economic conditions could harm our business, financial condition or results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our results of operations could be harmed by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn, including the impact of increased interest rates and inflation, and global trade programs and tariffs, could result in a variety of risks to our business, including weakened demand for our Candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could strain our manufacturers, possibly resulting in manufacturing disruption, or cause delays in payments for our services by third-party payors or our future collaborators. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could harm our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We hold a portion of our cash and cash equivalents that we use to meet our working capital and operating expense needs in deposit accounts that could be adversely affected if the financial institutions holding such funds fail.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We hold a portion of our cash and cash equivalents that we use to meet our working capital and operating expense needs in deposit accounts at multiple financial institutions. The balance held in these accounts may exceed the Federal Deposit Insurance Corporation ("FDIC") standard deposit insurance limit of $250,000. If a financial institution in which we hold such funds fails or is subject to significant adverse conditions in the financial or credit markets, we could be subject to a risk of loss of all or a portion of such uninsured funds or be subject to a delay in accessing all or a portion of such uninsured funds. Any such loss or lack of access to these funds could adversely impact our short-term liquidity and ability to meet our operating expense obligations, including payroll obligations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, on March 10, 2023, Silicon Valley Bank ("SVB") and Signature Bank, were closed by state regulators and the FDIC was appointed receiver for each bank. The FDIC created successor bridge banks and all deposits of SVB and Signature Bank were transferred to the bridge banks under a systemic risk exception approved by the United States Department of the Treasury, the Federal Reserve and the FDIC. If financial institutions in which we hold funds for working capital and operating expenses were to fail, we cannot provide any assurances that such governmental agencies would take action to protect our uninsured deposits or investments in a similar manner.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also maintain investment accounts with other financial institutions in which we hold our investments and marketable securities and, if access to the funds we use for working capital and operating expenses is impaired, we may not be able to sell investments or transfer funds from our investment accounts to other operating accounts on a timely basis sufficient to meet our operating expense obligations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Development of our Candidates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our pipeline of gene transfer Candidates utilize novel technology, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval. To our knowledge, only a limited number of gene transfer products have been approved for commercialization in the United States and the European Union.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future success depends on our successful development of our Candidates. Our risk of failure is high. We have experienced problems and delays in developing SGT-001, which we are no longer developing, and may in the future experience problems or delays in developing Candidates. Any such problems or delays would cause unanticipated costs, and any development problems may not be solved. For example, we or another party may uncover a previously unknown risk associated with our Candidates, the AAV capsid, construct or other issues resulting in toxicity or lack of efficacy that may be more problematic than we currently believe and this may prolong the period of observation required for obtaining, or result in the failure to obtain, regulatory approval or may necessitate additional clinical testing.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our ability to conduct and complete our preclinical development testing and studies is contingent on our ability to source animals and other supplies required for the conduct of such testing and studies and the performance of animal models. If we are unable to obtain all necessary animals and other supplies required for the conduct of our preclinical testing and studies, or the animal models do not perform as expected, we may be unable to complete such preclinical development testing and studies in a timely manner or at all. For example, some of our IND-enabling toxicology and other studies require certain NHPs that may be imported from countries in which trade relation with the U.S. are or may become challenging or through vendors who may not be able to timely source certain NHPs or at all, which may impair our ability to complete preclinical development testing and studies to support IND or similar applications or delay submission of such applications. Additionally, we may fail to demonstrate adequate Candidate efficacy and/or safety as required by regulatory authorities. We may fail to access relevant, adequate, or necessary animal models, including genetic models of disease and non-human primates in particular, for use in such studies as requested by regulatory authorities. We may also experience substantial delays as a result of our reliance on CROs to conduct all animal model experimentation necessary to assess the efficacy and safety of our Candidates. Any of these factors may result in delays to Candidate progression, inability to obtain regulatory approval, and/or substantial increases in Candidate development costs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the product specifications and the clinical trial requirements of the FDA, the European Commission, the European Medicines Agency (the "EMA") and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of such product candidate. The regulatory approval process for novel product candidates such as ours is unclear and can be more expensive and take longer than for other, better known or more extensively studied product candidates. To our knowledge, only a limited number of gene transfer products have been approved for commercialization in the United States and the European Union. As a result, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our gene transfer Candidates in either the United States or the European Union, if at all. Approvals by the European Commission may not be indicative of what the FDA may require for approval and vice versa.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our gene transfer Candidates may cause undesirable side effects or have other properties that could delay or prevent their clinical development, regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are conducting our INSPIRE DUCHENNE trial for SGT-003, which commenced participant dosing in the second quarter of 2024. Our other current Candidates have not yet been studied in human patients. During the conduct of clinical trials, participants may experience changes in their health, including illnesses, injuries, discomforts or a fatal outcome. Often, it is not possible to determine whether the Candidate being studied caused these conditions. For instance, we reported a serious adverse event in IGNITE DMD, which resulted in a clinical hold in November 2019, which has since been resolved. In April 2021, a participant treated with SGT-001 in IGNITE DMD experienced a systemic inflammatory response classified as a serious adverse event and considered by the investigator to be drug related.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, it is possible that as we test Candidates in larger, longer and more extensive clinical programs, or as use of these Candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier clinical trials, as well as conditions that did not occur or went undetected in previous clinical trials, will be reported by subjects. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that a Candidate has side effects or causes serious or life-threatening side effects, the development of the Candidate may fail or be delayed, or, if the Candidate has received regulatory approval, such approval may be withdrawn.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been several significant adverse side effects in gene therapy treatments in the past, including reported cases of leukemia and death seen in other clinical trials. The FDA convened the Cellular, Tissue, and Gene Therapies Advisory Committee in September 2021 to discuss toxicity risks of AAV based gene therapy products and discussed risks including oncogenicity risks due to capsid genome integration, hepatotoxicity, thrombotic microangiopathy, and neurotoxicity (especially related to dorsal root ganglion toxicity). While new recombinant capsids have been developed with the intent to reduce these side effects, gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. There have been reports of significant adverse side effects, including muscle weakness, myocarditis, and acute liver injury, in clinical trials of other gene therapy treatments for Duchenne that may be related to the type and location of the specific gene mutation causing the disease. In another gene therapy treatment, there have been reports of AAV mediated acute liver failure leading to death in non-ambulatory boys with Duchenne in the setting of commercially available product. There also is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. Possible adverse side effects that may occur with treatment with gene therapy products include an immunologic reaction early after administration that could substantially limit the effectiveness of the treatment or represent safety risks for patients. Additionally, in previous clinical trials involving AAV capsids for gene therapy, some subjects experienced the development of a positive ELISPOT test associated with T&#8209;cell responses, which is of unclear clinical translatability. If T-cells are activated, the cellular immune response system may trigger the removal of transduced cells. If our gene transfer Candidates demonstrate a similar effect or other undesirable side effects, we may decide or be required to halt or delay further clinical development of our Candidates involving AAV capsids for gene therapy.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse side effects may be observed following administration of any AAV gene therapy, including SGT-003 or other Candidates. Not all contemplated AAV delivery systems have been validated in human clinical trials previously, such as AAV&#8209;SLB101, which is a novel capsid. If a delivery system does not meet the safety criteria or cannot provide the desired efficacy results, then we may be forced to suspend or terminate our development of SGT-003 or other Candidates. If certain adverse side effects were to occur in the future and we are unable to demonstrate that they were not caused by the administration process or related procedures, the FDA, the European Commission, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, SGT-003 or other Candidates for any or all targeted indications. Even if we are able to demonstrate that any serious adverse events are not product-related, such occurrences could affect participant recruitment or the ability of enrolled participants to complete the clinical trial. Participants will also create antibodies to the AAV capsid and a second administration of gene transfer might not be safe or successful.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, if one or more of our Candidates receive marketing approval, the FDA could require us to adopt a Risk Evaluation and Mitigation Strategy ("REMS") to ensure that the benefits outweigh the risks, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients and a communication plan to health care practitioners. Furthermore, if we or others later identify undesirable side effects caused by our Candidates, several potentially significant negative consequences could result, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may suspend or withdraw approvals of such a Candidate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require additional warnings on the label;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to change the way a Candidate is administered or conduct additional clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to patients; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer.</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">One of our prior clinical trials had been placed on clinical hold by the FDA in the past, and we cannot guarantee that similar events will not happen in ongoing, planned and future clinical trials for our Candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2019, the FDA placed a clinical hold on SGT-001 following a serious adverse event in IGNITE DMD. The third participant in the 2E14 vg/kg cohort of IGNITE DMD, dosed in late October 2019, experienced a serious adverse event deemed related to the study drug that was characterized by complement activation, thrombocytopenia, decrease in red blood cell count, acute kidney injury, and cardio-pulmonary insufficiency. In April 2021, an eighth participant was treated with SGT-001. The participant experienced a systemic inflammatory response which has since fully resolved. The event was classified as a serious adverse event and considered by the investigator to be drug related. While SGT-003 utilizes a different capsid than SGT-001 and includes other changes to the construct and manufacturing process to help avoid or mitigate any such events, we cannot guarantee that similar serious adverse events or clinical holds will not happen in ongoing and future clinical trials of SGT-003. We also cannot guarantee that similar serious adverse events or clinical holds will not happen in planned and future clinical trials of any of our other Candidates.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delays in the completion of, or our inability to conduct, any clinical trial of SGT-003 or any other Candidate, as a result of similar serious adverse events or clinical holds or otherwise, will increase our costs, slow down or cease our Candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of SGT-003 or other Candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have never completed a clinical trial and may be unable to do so for any Candidate, including SGT-003, SGT-212, SGT-501 and other Candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are early in our development efforts and we have never completed a clinical trial. In the second quarter of 2024, participant dosing commenced in our INSPIRE DUCHENNE trial. Our other current Candidates are still in preclinical development. Preclinical studies involve a lengthy and expensive process with an uncertain outcome. There are many potential preclinical models to test for different disease states, and we could fail to choose the best or a predictive preclinical model to determine proof of concept and potential safety and efficacy of our Candidates. We may decide to suspend further testing on our Candidates or technologies if, in the judgment of our management and advisors, the preclinical test results do not support further development.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need to successfully initiate our planned clinical trials and complete our ongoing clinical trials in order to obtain FDA approval to market SGT-003, SGT-212, SGT-501 and other Candidates. We have limited experience in preparing, submitting and prosecuting regulatory submissions, and have not previously submitted a BLA for any Candidate. We cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin or to begin as proposed, or that, once begun, issues will not arise that suspend or terminate such clinical trials. Carrying out later-stage clinical trials and the submission of a successful BLA is a complicated process. This may be particularly true for design of a pivotal trial for the treatment of Duchenne as the FDA has not given clear guidance as to the necessary endpoints for approval of a treatment for Duchenne. In addition, we cannot be certain how many clinical trials of SGT-003, SGT-212, SGT-501 or other Candidates will be required or how such trials should be designed. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to BLA submission and approval of SGT-003, SGT-212, SGT-501 or other Candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of Candidates that we develop. Failure to commence or complete, or delays in, clinical trials, could prevent us from or delay us in commercializing SGT-003, SGT-212, SGT-501 and other Candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Success in preclinical studies or early clinical trials may not be indicative of results obtained in later trials.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results from preclinical studies or early clinical trials are not necessarily predictive of results from future clinical trials and are not necessarily indicative of final results. Our preclinical studies for certain Candidates in animals have been limited. There is a high failure rate for gene therapy and biologic products proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical studies and clinical trials are subject to varying interpretations, which may delay, limit or prevent regulatory approval. We also may experience regulatory delays or rejections as a result of many factors, including due to changes in regulatory policy during the period of our Candidate development. Our Candidates may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies. This failure could cause us to abandon any of our Candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preliminary or interim data that we announce or publish from time to time may change as more data becomes available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may announce or publish preliminary or interim data from clinical trials. Positive preliminary or interim data may not be predictive of such trial&#8217;s subsequent or overall results. Preliminary or interim data are subject to the risk that one or more of the outcomes may materially change as more data becomes available. Additionally, preliminary or interim data are subject to the risk that one or more of the biologic or clinical outcomes may materially change as participant enrollment continues and more participant data becomes available. Therefore, positive preliminary or interim data in any ongoing clinical trial, including the INSPIRE DUCHENNE trial, may not be predictive of such results in the completed trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. As a result, preliminary or interim data that we report may differ from future results from the clinical trials, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Preliminary or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary or interim data we previously published. As a result, preliminary or interim data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to preliminary or interim data could significantly harm our business prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining marketing approval from regulatory authorities for the sale of our Candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the Candidate for its intended indications. Clinical testing is expensive, time consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in obtaining animals in sufficient quantities to run our preclinical studies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching a consensus with regulatory authorities on trial design;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching agreement with the appropriate external parties on dose escalation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in enrolling participants in clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in opening clinical trial sites or obtaining required institutional review board or independent ethics committee approval at each clinical trial site;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in recruiting suitable subjects to participate in our clinical trials, including because such trials have restrictive eligibility criteria or may be placebo-controlled trials and participants are not guaranteed to receive treatment with our Candidates, or as a result of alternative therapies or competing trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty in finding suitable animal models to demonstrate a disease specific phenotype;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to perform in accordance with FDA good clinical practices ("GCPs") or applicable regulatory guidelines in the European Union and other countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in the testing, validation, manufacturing and delivery of our Candidates to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in subjects completing participation in a trial or returning for post-treatment follow-up;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trial sites or subjects dropping out of a trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, or after an inspection of our clinical trial operations, trial sites or manufacturing facilities or otherwise;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays as a result of public health emergencies or pandemics or other global instability; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, if the results of any clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our Candidates, we may:</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interrupt or halt clinical development;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be delayed or fail in obtaining marketing approval for our Candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as we intended or desired;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to changes in the way our products, if approved, are administered;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a modified REMS;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be sued and held liable for harm caused to participants; or</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">experience damage to our reputation.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product development costs will increase if we experience delays in testing or marketing approvals. In addition, if we make manufacturing or other changes to our Candidates, we may need to conduct additional studies to bridge our modified Candidates to earlier versions. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. We may also determine to change the design or protocol of one or more of our clinical trials, which we have done in the past and which could result in delays. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our Candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our Candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our third-party clinical trial vendors fail to comply with strict regulations, any clinical trials for our Candidates may be delayed or unsuccessful.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have the personnel capacity to conduct or manage the clinical trials that will be necessary for the development of our Candidates. For our INSPIRE DUCHENNE trial we are relying, and for any planned and future clinical trials we expect we will rely, on third parties to assist us in managing, monitoring and conducting our clinical trials. If these third parties fail to comply with applicable regulations or do not adequately fulfill their obligations under the terms of our agreements with them, we may not be able to enter into alternative arrangements without undue delay or additional expenditures and, therefore, clinical trials for SGT-003 or other Candidates may be delayed or unsuccessful.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, the FDA can be expected to inspect some or all of the clinical sites participating in our clinical trials to determine if our clinical trials are being conducted according to GCPs. If the FDA determines that these clinical sites are not in compliance with applicable regulations, we may be required to delay, repeat or terminate the clinical trials.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may find it difficult to enroll participants in our clinical trials, which could delay or prevent us from proceeding with clinical trials of SGT-003, SGT-212, SGT-501 or our other Candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identifying and qualifying participants to participate in any clinical trials of SGT-003, SGT-212, SGT-501 and our other Candidates are critical to our success. Because of our primary focus on rare diseases, we may have difficulty enrolling a sufficient number of eligible participants. The timing of any clinical trials depends on our ability to recruit participants to participate as well as complete required follow-up periods. If participants are unwilling or unable to participate in our gene therapy clinical trials, including because of negative publicity from adverse events related to our Candidates, other approved therapies, or due to competitive clinical trials or approvals for similar participant populations, clinical trials in products employing our capsid or our platform or for other reasons, the timeline for recruiting participants, conducting clinical trials and obtaining regulatory approval of SGT-003, SGT-212, SGT-501 or other Candidates may be delayed. We may also experience delays if participants withdraw from the clinical trial or do not complete the required monitoring period. Furthermore, we may face difficulties in recruiting participants to enroll in, or once enrolled, retaining participants in future clinical trials if they or their caretakers are affected by public health emergencies or pandemics or are fearful of traveling to, or are unable to travel to, our clinical trial sites because of public health emergencies or pandemics or other unforeseen events. These delays could result in increased costs, delays in advancing SGT-003 or other Candidates, delays in testing the effectiveness of our Candidates or termination of clinical trials altogether.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to identify, recruit and enroll a sufficient number of participants, or those with required or desired characteristics, to complete any clinical trials in a timely manner. Participant enrollment and trial completion is affected by many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">size of the participant population and the process for identifying subjects;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">design of the trial protocol;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eligibility and exclusion criteria, including age, size and functional ability and pre-existing antibodies to AAV capsids that preclude subjects from being able to receive AAV-mediated gene transfer;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on our ability to conduct clinical trials, including full and partial clinical holds on ongoing or planned clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perceived risks and benefits of the Candidate under study;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perceived risks and benefits of gene therapy-based approaches to the treatment of diseases;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">release or disclosure of data from our completed or ongoing clinical trials;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">availability of competing therapies and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">severity of the disease;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proximity and availability of clinical trial sites for prospective subjects;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ability to obtain and maintain subject consent;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk that enrolled subjects will drop out before completion of the trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient referral practices of physicians;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ability to monitor subjects adequately during and after treatment; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the case of pivotal trials, the risk that participants may opt not to enroll because they are not assured treatment with our Candidate.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted. For example, in December 2022, with the passage of the Food and Drug Omnibus Reform Act ("FDORA"), Congress required sponsors to develop and submit a diversity action plan for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse participant populations in late-stage clinical trials of FDA-regulated products. In June 2024, as mandated by FDORA, the FDA issued draft guidance outlining the general requirements for DAPs. Unlike most guidance documents issued by the FDA, the DAP guidance when finalized will have the force of law because FDORA specifically dictates that the form and manner for submission of DAPs are specified in FDA guidance. On January 27, 2025, in response to an executive order issued by the President earlier in January 2025 on Diversity, Equity and Inclusion programs, the FDA removed the draft DAP guidance from its website. That action, along with similar actions by the current U.S. presidential administration to remove many other healthcare webpages, is currently the subject of ongoing litigation. In late July 2025, the FDA restored the draft DAP guidance to its website with a statement that &#8220;information on this page may be modified and/or removed in the future subject to the terms of the court&#8217;s order and implemented consistent with applicable law." Accordingly, in light of these ongoing actions, there is considerable uncertainty surrounding the draft DAP guidance and how the FDA will consider diversity action plans in connection with its review of marketing applications.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We plan to conduct clinical trials at sites outside the United States. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to conduct clinical trials, including the INSPIRE DUCHENNE trial, with one or more trial sites that are located outside the United States. Although the FDA may accept data from clinical trials conducted at sites outside the United States, acceptance of these data is subject to conditions imposed by the FDA. For example, where data from foreign clinical trial sites are not intended to serve as the sole basis for approval in the United States, the FDA will not accept the data as support for a marketing application unless the clinical trial was well designed and conducted in accordance with GCP requirements. The FDA must also be able to validate the data from the trial through an onsite inspection, if necessary. Where data from foreign clinical trial sites are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, these clinical trials are subject to the applicable local laws of the jurisdictions where the trials are conducted. There can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and could delay or permanently halt our development of the applicable product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, conducting clinical trials outside the United States could have a significant adverse impact on us. Risks inherent in conducting international clinical trials include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical practice patterns and standards of care that vary widely among countries; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">non-U.S. regulatory authority requirements that could restrict or limit our ability to conduct our clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with foreign manufacturing, customs, shipment and storage requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">administrative burdens of conducting clinical trials under multiple non-U.S. regulatory authority schema; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign exchange fluctuations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diminished protection of intellectual property in some countries; and</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruptions or delays resulting from geopolitical events, such as wars. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The EU Clinical Trials Regulation ("CTR") which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. The CTR aims to simplify and streamline the authorization, conduct and transparency of clinical trials in the European Union. We have only recently secured authorization to conduct clinical trials in the European Union pursuant to the CTR and, accordingly, there is a risk that we may be delayed in commencing any such studies. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize our Candidates and the approval may be for a narrower indication than we seek.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot commercialize our Candidates until the appropriate regulatory authorities have reviewed and approved the Candidate. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and local statutes and regulations require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals. Even if our Candidates meet their safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA advisory committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in regulatory authority policy during the period of product development, clinical trials and the regulatory review process.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, under the Pediatric Research Equity Act of 2003, a BLA or supplement to a BLA for certain biological products must contain data to assess the safety and effectiveness of the biological product in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective, unless the sponsor receives a deferral or waiver from the FDA. A deferral may be granted for several reasons, including a finding that the product or therapeutic Candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The applicable legislation in the European Union also requires sponsors to either conduct clinical trials in a pediatric population in accordance with a Pediatric Investigation Plan approved by the Pediatric Committee of the EMA or to obtain a waiver or deferral from the conduct of these studies by this Committee. For any of our Candidates for which we are seeking regulatory approval in the U.S. or the European Union, we cannot guarantee that we will be able to obtain a waiver or alternatively complete any required studies and other requirements in a timely manner, or at all, which could result in associated reputational harm and subject us to enforcement action, invalidation of the marketing application, and/or financial penalties. Our collaborators are also subject to similar requirements outside of the United States and the European Union and thus the attendant risks and uncertainties.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we receive regulatory approval, regulatory authorities may approve a Candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a REMS. Regulatory authorities may require precautions or contra-indications with respect to conditions of use or they may grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of our Candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our Candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval for a Candidate, our Candidates will remain subject to regulatory oversight.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain any regulatory approval for any of our Candidates, we will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information. Any regulatory approvals that we receive for our Candidates may also be subject to a REMS, limitations on the approved indicated uses for which the product may be marketed or conditions of approval, or requirements for potentially costly post-marketing testing and surveillance to monitor the safety, purity, and potency of the biologic product. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may have various consequences, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on such products, manufacturers or manufacturing processes; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions and warnings on the labeling or marketing of a product; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on product distribution or use; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warning letters or untitled letters; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of the products from the market; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recall of products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, restitution or disgorgement of profits or revenues; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or withdrawal of marketing approvals; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">damage to relationships with any potential collaborators; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unfavorable press coverage and damage to our reputation; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to permit the import or export of our products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties; or </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">litigation involving patients using our products.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs applicable to drug manufacturers or quality assurance standards applicable to medical device manufacturers, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, any contract manufacturers we may engage in the future, our future collaborators and their contract manufacturers will also be subject to other regulatory requirements, including submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements regarding the distribution of samples to clinicians, recordkeeping, and costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product such as the requirement to implement a REMS.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, our ability to develop and market new drug products may be impacted by litigation challenging the FDA&#8217;s approval of another company&#8217;s drug product. In April 2023, the U.S. District Court for the Northern District of Texas invalidated the approval by the FDA of mifepristone, a drug product which was originally approved in 2000 and whose distribution is governed by various measures adopted under a REMS. The Court of Appeals for the Fifth Circuit declined to order the removal of mifepristone from the market but did hold that plaintiffs were likely to prevail in their claim that changes allowing for expanded access of mifepristone, which the FDA authorized in 2016 and 2021, were arbitrary and capricious. In June 2024, the Supreme Court reversed that decision after unanimously finding that the plaintiffs did not have standing to bring this legal action against the FDA. On October 11, 2024, the Attorneys General of three states filed an amended complaint in the U.S. District Court for the Northern District of Texas challenging the FDA&#8217;s actions. On January 16, 2025, the District Court agreed to allow these states to file an amended complaint and continue to pursue this challenge. Depending on the outcome of this litigation our ability to develop new drug Candidates and to maintain approval of existing drug products could be delayed, undermined or subject to protracted litigation.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-compliance with European Union requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the European Union&#8217;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions. Further, similar restrictions apply to approved products in the European Union. The holder of a marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: compliance with the EU&#8217;s stringent pharmacovigilance or safety reporting rules, which can impose post-authorization studies and additional monitoring obligations; the manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory; and the marketing and promotion of authorized drugs, which are strictly regulated in the European Union and are also subject to EU Member State laws.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, assuming we, or our collaborators, receive marketing approval for one or more of our Candidates, we, and our collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we, and our collaborators, are not able to comply with post-approval regulatory requirements, our or our collaborators&#8217; ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any regulatory approval to market our products will be limited by indication. If we fail to comply or are found to be in violation of FDA regulations restricting the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulations relating to the promotion of products for unapproved uses are complex and subject to substantial interpretation by the FDA, EMA, Medicines and Healthcare products Regulatory Agency ("MHRA"), and other government agencies. In September 2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a drug product. Physicians may nevertheless prescribe our products off-label to their patients in a manner that is inconsistent with the approved label. We intend to implement compliance and training programs designed to ensure that our sales and marketing practices comply with applicable regulations. Notwithstanding these programs, the FDA or other government agencies may allege or find that our practices constitute prohibited promotion of our products for unapproved uses. We also cannot be sure that our employees will comply with company policies and applicable regulations regarding the promotion of products for unapproved uses.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the regulatory restrictions on off-label promotion, the FDA and other regulatory authorities allow companies to engage in truthful, non-misleading, and non-promotional scientific communications concerning their products in certain circumstances. For example, in January 2025, the FDA published final guidance outlining its policies governing the distribution of scientific information to healthcare providers about unapproved uses of approved products. The final guidance calls for such communications to be truthful, non-misleading and scientifically sound and to include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use of the approved product. If a company engages in such communications consistent with the guidance&#8217;s recommendations, the FDA indicated that it will not treat such communications as evidence of unlawful promotion of a new intended use for the approved product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we could be adversely affected by several significant administrative law cases decided by the U.S. Supreme Court in 2024. In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Loper Bright Enterprises v. Raimondo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for example, the court overruled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">., which for 40 years required federal courts to defer to permissible agency interpretations of statutes that are silent or ambiguous on a particular topic. The Supreme Court stripped federal agencies of this presumptive deference and held that courts must exercise their independent judgment when deciding whether an agency, such as the FDA, acted within its statutory authority under the Administrative Procedure Act (the "APA"). Additionally, in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corner Post, Inc. v. Board of Governors of the Federal Reserve System</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the court held that actions to challenge a federal regulation under the APA can be initiated within six years of the date of injury to the plaintiff, rather than the date the rule is finalized. The decision appears to give prospective plaintiffs a personal statute of limitations to challenge longstanding agency regulations. Another decision, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Securities and Exchange Commission v. Jarkesy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, overturned regulatory agencies&#8217; ability to impose civil penalties in administrative proceedings. These decisions could introduce additional uncertainty into the regulatory process and may result in additional legal challenges to actions taken by federal regulatory agencies, including the FDA and CMS, that we rely on. In addition to potential changes to regulations as a result of legal challenges, these decisions may result in increased regulatory uncertainty and delays and other impacts, any of which could adversely impact our business and operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In recent years, a significant number of pharmaceutical and biotechnology companies have been the target of inquiries and investigations by various federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for unapproved uses and other sales practices, including the Department of Justice and various U.S. Attorneys&#8217; Offices, the Office of Inspector General of the Department of Health and Human Services ("HHS"), the FDA, the Federal Trade Commission ("FTC"), and various state Attorneys General offices. These investigations have alleged violations of various federal and state laws and regulations, including claims asserting antitrust violations, violations of the Federal Food, Drug, and Cosmetic Act, the False Claims Act, the Prescription Drug Marketing Act and anti-kickback laws and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement. Many of these investigations originate as &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; actions under the False Claims Act. Under the False Claims Act, any individual can bring a claim on behalf of the government alleging that a person or entity has presented a false claim or caused a false claim to be submitted to the government for payment. The person bringing a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> suit is entitled to a share of any recovery or settlement. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Qui tam </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suits, also commonly referred to as &#8220;whistleblower suits,&#8221; are often brought by current or former employees. In a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">qui tam </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suit, the government must decide whether to intervene and prosecute the case. If it declines, the individual may pursue the case alone.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA or any other governmental agency initiates an enforcement action against us or if we are the subject of a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> suit and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects and reputation.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain and maintain approval of one or more of our Candidates from the FDA, we may never obtain approval for our Candidates outside of the United States, which would limit our market opportunities and adversely affect our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we receive FDA approval of one or more of our Candidates in the United States, approval of a Candidate in the United States by the FDA does not ensure approval of such Candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Future sales of our Candidates outside of the United States will be subject to foreign regulatory requirements governing clinical trials, manufacturing and marketing approval. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that country. If we submit a marketing authorization application ("MAA") to the EMA for approval of SGT-003, SGT-212, SGT-501 or other Candidates in the European Union, obtaining such approval from the European Commission following the opinion of the EMA is a lengthy and expensive process. Regulatory authorities in countries outside of the United States and the European Union also have requirements for approval of product candidates with which we must comply prior to marketing in those countries. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our Candidates in certain countries.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for our Candidates may be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced, and our ability to realize the full market potential of our Candidates will be harmed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we could face heightened risks with respect to obtaining marketing authorization in the United Kingdom as a result of the withdrawal of the United Kingdom from the European Union, commonly referred to as Brexit. The United Kingdom is no longer part of the European Single Market and EU Customs Union. As of January 1, 2025 the MHRA is responsible for approving all medicinal products destined for the UK market (i.e., Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. On April 28, 2025, the United Kingdom Parliament adopted amendments to improve and strengthen the United Kingdom&#8217;s clinical trials regulatory regime, which are scheduled to take effect on April 28, 2026. Any delay in obtaining, or an inability to obtain, any marketing authorizations, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our Candidates, which could significantly and materially harm our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, foreign regulatory authorities may change their approval policies and new regulations may be enacted. For instance, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (including potentially reducing the duration of regulatory data protection, revising the eligibility for expedited pathways, etc.) was published on April 26, 2023 with several amendments requested in April 2024. The proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revisions may, however, have a significant impact on the pharmaceutical industry and our business in the long term. On June 4, 2025, after almost two years of negotiations among the EU Member States, the Council of the European Union adopted its position on the proposed overhaul of the EU general pharmaceutical legislative framework, which is known as the new Pharma Package. This proposal will now be the subject of additional negotiations and technical meetings, with the objective of reaching agreement on issues such as the regulatory data protection framework and the access and supply obligations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that we will be subject to additional risks in commercializing any of our Candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce uncertainty in countries where labor unrest is more common than in the United States.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be materially adversely affected by the imposition of duties and tariffs and other trade barriers and retaliatory countermeasures implemented by the U.S. and other governments.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently there have been significant changes to U.S. trade policies, sanctions, legislation, treaties and tariffs, including, but not limited to, trade policies and tariffs affecting products from outside of the U.S. For example, the current U.S. presidential administration has announced or initiated a series of tariff-related actions against U.S. trading partners, including Mexico and Canada, which has in certain instances resulted in U.S. trading partners announcing or initiating retaliatory tariff-related actions in response. The extent and duration of tariff-related actions and the resulting impact on general economic conditions and on our business are uncertain and depend on various factors, such as negotiations between the U.S. and its trading partners, the responses of other countries or regions, exemptions or exclusions that may be granted, availability and cost of alternative sources of supply, and demand for our products in affected markets. Any new or additional tariff-related actions impacting goods imported to the U.S. from Mexico, Canada, or other countries, or products imported into the European Union or other non-U.S. markets, could also increase the cost of some of our products and reduce our margins. The imposition of additional tariffs or other trade barriers could increase our costs in certain markets. Other countries have changed, and may continue to change, their own policies on trade as well as business and foreign</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investment in their respective countries. Additionally, it is possible that U.S. policy changes and uncertainty about such changes could increase market volatility and currency exchange rate fluctuations. As a result of these dynamics, we cannot predict the impact to our business of any future changes to the U.S. or other countries&#8217; trading relationships or the impact of new laws or regulations adopted by the U.S. or other countries.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory requirements governing gene therapy products are periodically updated and may continue to change in the future.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory requirements governing gene therapy products have changed frequently and will likely continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of gene therapy products. For example, in the United States, the FDA has established the Office of Therapeutic Products within the Center for Biologics Evaluation and Research ("CBER") to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical trials may also be subject to review and oversight by an institutional biosafety committee, a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical trial, even if the FDA has reviewed the trial and approved its initiation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has issued various guidance documents regarding gene therapies, including final guidance documents released in January 2020 relating to chemistry, manufacturing and controls information for gene therapy INDs, gene therapies for rare diseases and gene therapies for retinal disorders, a final guidance in October 2022 for Human Gene Therapy for Neurodegenerative Diseases, as well as a draft guidance in July 2023 on comparability requirements for manufacturing changes in gene therapy products. In December 2023, a draft guidance on potency assurance for cellular and gene therapy products was released. Although the FDA has indicated that these and other guidance documents it previously issued are not legally binding, we believe that our compliance with them is likely necessary to gain approval for any gene therapy Candidate we may develop. The guidance documents provide additional factors that the FDA will consider at each of the above stages of development and relate to, among other things, the proper preclinical assessment of gene therapies; the chemistry, manufacturing, and control information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA application; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. Further, for AAV capsids specifically, the FDA typically recommends that sponsors continue to monitor participants for potential gene therapy&#8209;related adverse events for up to a 5-year period. Other types of gene therapy or gene editing products may require longer follow up, potentially up to a maximum 15-year period.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly, the EMA may issue new guidelines concerning the development and marketing authorization for gene therapy products and require that we comply with these new guidelines. The grant of marketing authorization in the European Union for gene therapy products is governed by Regulation 1394/2007/EC on advanced therapy medicinal products, read in combination with Directive 2001/83/EC of the European Parliament and of the Council, commonly known as the Community code on medicinal products. Regulation 1394/2007/EC includes specific rules concerning the authorization, supervision, and pharmacovigilance of gene therapy medicinal products. Manufacturers of advanced therapy medicinal products must demonstrate the quality, safety, and efficacy of their products to the EMA, which provides an opinion regarding the MAA. The European Commission grants or refuses marketing authorization in light of the opinion delivered by the EMA.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, ethical, social and legal concerns about gene therapy, genetic testing and genetic research could result in additional regulations or prohibiting the processes we may use. Federal and state agencies, congressional committees and foreign governments have expressed their intentions to further regulate biotechnology. More restrictive regulations or claims that our Candidates are unsafe or pose a hazard could prevent us from commercializing any products. New government requirements may be established that could delay or prevent regulatory approval of our Candidates under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we advance our Candidates through clinical development, we will be required to consult with these regulatory and advisory groups, and comply with applicable guidelines. These regulatory review committees and advisory groups and any new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of Candidates or lead to significant post-approval limitations or restrictions. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to obtain orphan drug exclusivity for one or more of our Candidates, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. A similar regulatory scheme governs approval of orphan products by the EMA in the European Union. Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from approving another marketing application for a similar product for the same therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has granted orphan drug designation to SGT-003 for the treatment of Duchenne and to SGT-501 for the treatment of CPVT.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order for the FDA to grant orphan drug exclusivity to one of our products, the FDA must find that the product is indicated for the treatment of a condition or disease with a patient population of fewer than 200,000 individuals annually in the United States. The FDA may conclude that the condition or disease for which orphan drug exclusivity is sought does not meet this standard. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, under the FDA September 2021 guidance for interpreting sameness of gene therapy products under the orphan drug regulations, even after an orphan drug is approved, the FDA can subsequently approve a similar product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA Reauthorization Act of 2017 ("FDARA") requires that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. FDARA reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and Congress may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11th Circuit in September 2021 finding that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221; Thus, the Court of Appeals concluded that orphan drug exclusivity applies to the entire designated disease or condition rather than the &#8220;indication or use.&#8221; Although there have been legislative proposals to overrule this decision, they have not been enacted into law. In January 2023, the FDA announced that, in matters beyond the scope of that court order, FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved. We do not know if, when, or how the FDA or Congress may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA or Congress may make to its orphan drug regulations and policies, our business could be adversely impacted.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek a breakthrough therapy designation for one or more of our Candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek a breakthrough therapy designation for one or more of our Candidates; however, we cannot assure our stockholders that one or more of our Candidates will meet the criteria for that designation. A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies and biologics that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of participants placed in ineffective control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review if supported by clinical data at the time the BLA is submitted to the FDA.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our Candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive breakthrough therapy designation, the receipt of such designation for a Candidate may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our Candidates qualifies as a breakthrough therapy, the FDA may later decide that the Candidate no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accelerated approval by the FDA, even if granted for one or more of our Candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our Candidates will receive marketing approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek approval of one or more of our Candidates using the FDA&#8217;s accelerated approval pathway. A product may be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate or intermediate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality ("IMM") that is reasonably likely to predict an effect on IMM or other clinical benefit. The FDA or other applicable regulatory agency makes the determination regarding whether a surrogate or intermediate endpoint is reasonably likely to predict long-term clinical benefit. Given that expression of microdystrophin has not yet been established to predict long-term clinical benefit, it is not currently accepted, and it is possible the FDA and/or other applicable regulatory agencies could decide never to accept it, as a surrogate endpoint for the accelerated approval pathway for the treatment of Duchenne.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a condition of approval, the FDA may require that a sponsor of a drug or biologic product candidate receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. These confirmatory trials must be completed with due diligence and may be required to be initiated prior to submission of the BLA. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Further, with passage of FDORA in December 2022, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA to: require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded, require a sponsor of a product granted accelerated approval to submit progress reports on its post-approval studies to FDA every six months (until the study is completed) and use expedited procedures to withdraw accelerated approval of a BLA after the confirmatory trial fails to verify the product&#8217;s clinical benefit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that the FDA or comparable foreign regulatory agencies will agree with our surrogate endpoints or intermediate clinical endpoints in any of our clinical trials, or that we will decide to pursue or submit any additional application for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that, after feedback from the FDA or comparable foreign regulatory agencies, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval. Furthermore, for any submission of an application for accelerated approval or application under another expedited regulatory designation, there can be no assurance that such submission or application will be accepted for filing or that any expedited development, review or approval will be granted on a timely basis, or at all.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A failure to obtain accelerated approval or any other form of expedited development, review or approval for our Candidates, or withdrawal of a Candidate, would result in a longer time period until commercialization of such Candidate, could increase the cost of development of such Candidate and could harm our competitive position in the marketplace.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A potential regenerative medicine advanced therapy designation by the FDA for our Candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our Candidates will receive marketing approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek a regenerative medicine advanced therapy designation for some of our Candidates. A regenerative medicine advanced therapy is defined as cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products. Gene therapies, including genetically modified cells, that lead to a durable modification of cells or tissues may meet the definition of a regenerative medicine therapy. The regenerative medicine advanced therapy program is intended to facilitate efficient development and expedite review of regenerative medicine advanced therapies, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition. A BLA for a regenerative medicine advanced therapy may be eligible for priority review or accelerated approval through (1) surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit or (2) reliance upon data obtained from a meaningful number of sites. Benefits of such designation also include early interactions with the FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A regenerative medicine therapy that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence, clinical trials, patient registries, or other sources of real world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post-approval monitoring of all participants treated with such therapy prior to its approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designation as a regenerative medicine advanced therapy is within the discretion of the FDA. Accordingly, even if we believe one of our Candidates meets the criteria for designation as a regenerative medicine advanced therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a regenerative medicine advanced therapy designation for a Candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our Candidates qualify as regenerative medicine advanced therapies, the FDA may later decide that the biological products no longer meet the conditions for qualification.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek PRIME Designation in the EU for one or more of our Candidates, but we might not receive such designations and, even if we do, such designations may not lead to a faster development or regulatory review or approval process.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, we may seek PRIME designation for our Candidates in the future. PRIME is a voluntary program aimed at enhancing the EMA&#8217;s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet medical needs. The program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the EU or even if such a method exists, it may offer a major therapeutic advantage over existing treatments. PRIME is limited to medicines under development and not authorized in the EU and the sponsor intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for PRIME, a product candidate must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation based on information that is capable of substantiating the claims.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The benefits of a PRIME designation include the appointment of a Committee for Medicinal Products for Human Use rapporteur to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME enables a sponsor to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME designation for any of our Candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA&#8217;s grant of a marketing authorization.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek a Rare Pediatric Disease Designation for our Candidates. However, a BLA for such Candidates may not meet the eligibility criteria for a priority review voucher upon approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With enactment of the Food and Drug Administration Safety and Innovation Act in 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications that meet the criteria specified in the law. This provision is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to receive a priority review voucher upon BLA approval, the product must receive designation from the FDA as a product for a rare pediatric disease prior to approval of the marketing application. A &#8220;rare pediatric disease&#8221; is a disease that is serious or life-threatening, in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years and affects fewer than 200,000 people in the United States, or affects more than 200,000 people in the United States but there is no reasonable expectation that the cost of developing and making available in the United States a product for such disease or condition will be recovered from sales in the United States of such product. In addition to receiving rare pediatric disease designation, in order to receive a priority review voucher, the BLA must be given priority review, rely on clinical data derived from studies examining a pediatric population and dosages of the product intended for that population, not seek approval for a different adult indication in the original rare pediatric disease product application and be for a product that does not include a previously approved active ingredient.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the current statutory sunset provisions for the Rare Pediatric Disease Priority Review Voucher Program, after September 30, 2024, the FDA may only award a voucher for an approved rare pediatric disease product application if the sponsor has rare pediatric disease designation for the drug, and that designation was granted by September 30, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After September 30, 2026, the FDA may not award any rare pediatric disease priority review vouchers. If we do not obtain approval of a BLA by these dates, and if the Rare Pediatric Disease Priority Review Voucher Program is not further extended by congressional action, we may not receive a Priority Review Voucher.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has granted rare pediatric disease designation to SGT-003 for the treatment of Duchenne and SGT-501 for the treatment of CPVT.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek a fast track designation for one or more of our Candidates. However, such designation may not actually lead to a faster development or regulatory review or approval process. We might not receive such designation for one or more of our Candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a therapy is intended for the treatment of a serious condition and non-clinical or clinical data demonstrates the potential to address unmet medical need for this condition, a drug sponsor may apply for FDA fast track designation. However, fast track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe. The FDA has broad discretion with respect to whether or not to grant fast track designation to a product candidate, so even if we believe a particular</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Candidate is eligible for such designation, the FDA may decide not to grant it. Moreover, we may not experience a faster development or regulatory review or approval process with fast track designation compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program or if the unmet need has been fulfilled with the approval of another product. Fast track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has granted fast track designation to SGT-003 for the treatment of Duchenne, to SGT-212 for the treatment of FA and to SGT-501 for the treatment of CPVT.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek priority review designation for one or more of our Candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. We may request priority review for our Candidates, however, we cannot assume that one or more of our Candidates will meet the criteria for that designation. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular Candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily mean a faster development or regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions and delays at the FDA and other government agencies from funding cuts, personnel losses, regulatory reform, government shutdowns and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical development program and develop and secure approval of our Candidates in a timely manner, which would negatively impact our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and comparable regulatory agencies in foreign jurisdictions play an important role in the development of our Candidates by providing guidance on our clinical development programs and reviewing our regulatory submissions, including INDs, requests for special designations and marketing applications. If these oversight and review activities are disrupted, then correspondingly our ability to develop and secure timely approval of our Candidates could be impacted in a negative manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, there is substantial uncertainty as to how measures being implemented by the US government administration will impact the FDA, CMS and other federal agencies with jurisdiction over our activities. For example, the recent loss of FDA leadership and personnel could lead to disruptions and delays in FDA guidance, or review and approval of our Candidates. Pursuant to an executive order issued by the President, the Secretary of HHS announced on March 27, 2025, a reorganization and reduction in force across HHS of approximately 20,000 employees, with FDA&#8217;s workforce of approximately 20,000 to decrease by 3,500 full-time employees. Subsequently, the FDA indicated that roughly a quarter of those employees who received RIF notices had been reinstated. Shortly thereafter, thousands of employees at the FDA were terminated on April 1, 2025. On July 14, 2025, following litigation reaching the U.S. Supreme Court, the administration began to carry out these layoffs across the HHS, including the FDA. There are also ongoing deliberations within the administration and Congress over potentially substantial proposed cuts to the overall budget for HHS and funding of the FDA for the 2026 federal fiscal year. Similarly, efforts by the new administration to substantially reduce or delay research funding by the National Institutes of Health of medical research could have substantial direct or indirect impacts on our research activities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions and could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the same time, disruptions at the FDA and other government agencies may result from public health events similar to the COVID-19 pandemic. For example, during the pandemic, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. In the event of a similar public health emergency in the future, the FDA may not be able to continue its current pace and review timelines could be extended. Regulatory authorities outside the United States facing similar circumstances may adopt similar restrictions or other policy measures in response to a similar public health emergency and may also experience delays in their regulatory activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, if any of the foregoing developments and others impact the ability of the FDA to provide us with guidance regarding our clinical development programs or delay the agency&#8217;s review and processing of our regulatory submissions, including INDs and BLAs, our business would be negatively impacted. Further, any future government shutdown could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face significant competition and our competitors may achieve regulatory approval before us or develop therapies that are more advanced or effective than ours, which may adversely affect our ability to develop, successfully market or commercialize our Candidates. Changes within the competitive landscape could lead us to alter our regulatory and/or clinical trial strategy, baseline eligibility criteria or make other modifications to clinical trial designs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate in a highly competitive segment of the biopharmaceutical market. We face competition from many different sources, including larger and better-funded pharmaceutical, specialty pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions. Our Candidates, if successfully developed and approved, will compete with established therapies as well as with new treatments that may be introduced by our competitors. There are a variety of product candidates, including gene therapies, in development for Duchenne, CPVT, other cardiomyopathies or FA. Many of our competitors have significantly greater financial, product candidate development, manufacturing and marketing resources than we do. Large pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for their products, and mergers and acquisitions within these industries may result in even more resources being concentrated among a smaller number of larger competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, enrolling participants in clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware of a number of companies and research institutions developing gene transfer programs progressing in Duchenne. For example, in June 2023, Sarepta Therapeutics, Inc. ("Sarepta") announced that it had received accelerated approval for its gene therapy candidate ELEVIDYS</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.035pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne. In June 2024, Sarepta announced an expanded US approval of ELEVIDYS</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.035pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for patients who are at least 4 years of age including full approval for ambulatory Duchenne patients and accelerated approval for non-ambulatory Duchenne patients. We are also aware of several companies and research institutions conducting clinical trials of product candidates focused on systemic gene transfers for Duchenne, including Genethon, with product candidate GNT0004 currently being evaluated in a Phase 1/2/3 clinical trial, REGENXBIO Inc., with product candidate RGX-202 currently being evaluated in a Phase 1/2/3 clinical trial and Insmed Incorporated, with product candidate INS1201 currently being evaluated in a Phase 1 clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are other approaches to treat Duchenne that are either currently marketed or in development including antisense oligonucleotides ("ASOs"), histone deacetylase ("HDAC") inhibitors, myosin inhibitors, cell therapies and gene editing. Notably, Sarepta has received accelerated approval for three therapies including Exondys 51, Vyondys 53 and Amondys 45 targeting exons 51, 53 and 45, respectively; Nippon Shinyaku received accelerated approval for Viltepso to treat exon 53 amenable patients; Avidity Biosciences is developing Del-zota to treat exon 44; Wave Life Sciences is developing WVE-N531 to treat exon 53 amenable patients; Dyne Therapeutics is developing DYNE-251 to treat exon 51 amenable patients; BioMarin Pharmaceutical is developing BMN 351 to treat exon 51 amenable patients; and Entrada Therapeutics is developing ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51 for exon 44, 45, 50 and 51 amenable patients, respectively. Italfarmaco received FDA approval for its HDAC inhibitor, Givinostat, in Duchenne patients who are at least 6 years of age. Edgewise Therapeutics is developing Sevasemten, a fast skeletal myosin inhibitor, for Duchenne and Becker muscular dystrophies. Capricor Therapeutics is developing Deramiocel, an allogeneic cardiosphere-derived cell therapy product candidate. Precision BioSciences is in preclinical development for gene editing product candidate, PBGENE-DMD.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also aware of a number of companies and research institutions developing gene transfer programs in FA. For example, Lexeo Therapeutics is developing an IV</span><span style="color:#d13438;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gene therapy to treat the</span><span style="color:#d13438;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cardiac manifestations of FA. Other competitors currently developing gene therapies to treat FA are in preclinical development, including Neurocrine Biosciences in collaboration with Voyager Therapeutics and Capsida Biotherapeutics. We are also aware of other companies developing non-gene therapies for FA, such as Design Therapeutics, Larimar Therapeutics, and PTC Therapeutics. Biogen&#8217;s SKYCLARYS</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(omaveloxolone) was approved for the treatment of FA in adults and adolescents aged 16 and older by the FDA and the European Commission in February 2023 and February 2024, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also aware of several companies and research institutions conducting clinical trials in small molecule product candidates focused on CPVT, including Cardurion Pharmaceuticals Inc., with an orally administered CAMKII-delta inhibitor candidate in a Phase 2 clinical trial.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are first to market or are safer, more effective, have fewer or less severe side effects, have broader market acceptance, are more convenient or are less expensive than any Candidate that we may develop. Changes within the competitive landscape could lead us to alter regulatory and/or clinical trial strategy, baseline eligibility criteria or make other modifications to clinical trial designs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware of several companies focused on developing gene therapies in various indications, as well as several companies addressing other methods for modifying genes and regulating gene expression. Any advances in gene therapy technology made by a competitor may be used to develop therapies that could compete against Candidates we develop.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may fail to capitalize on other potential Candidates that may represent a greater commercial opportunity or for which there is a greater likelihood of success.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of our business depends upon our ability to develop and commercialize our Candidates. Because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or Candidates or for indications that later prove to have greater commercial potential than our Candidates. For example, in September 2022, we announced that we would be pausing activities for SGT-001, which we are now no longer developing.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our spending on current and future research and development programs may not yield any commercially viable Candidates. If we do not accurately evaluate the commercial potential for a particular Candidate, we may relinquish valuable rights to that Candidate through strategic collaborations, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such Candidate. Alternatively, we may allocate internal resources to a Candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement. If any of these events occur, we may be forced to abandon our development efforts with respect to a particular Candidate or fail to develop a potentially successful Candidate.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Manufacturing and Commercialization of our Candidates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have entered into, and may in the future enter into, collaborations with third parties for the development or commercialization of our Candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these Candidates and our business could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have retained all necessary rights to and are developing on our own SGT-003, SGT-212, SGT-501 and other Candidates, we may in the future enter into development, distribution or marketing arrangements with third parties with respect to SGT-003, SGT-212, SGT-501 or other Candidates. Our likely collaborators for any such sales, marketing, distribution, development, licensing or broader collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. If we enter into any such arrangements with any third parties in the future, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our Candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborations that we enter into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators. Collaborations pose a number of risks, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not perform their obligations as expected; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not pursue development of our Candidates or may elect not to continue or renew development programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not pursue commercialization of any Candidates that achieve regulatory approval or may elect not to continue or renew commercialization programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that may divert resources or create competing priorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a Candidate, repeat or conduct new clinical trials or require a new formulation of a Candidate for clinical testing; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not have access to, or may be restricted from disclosing, certain information regarding Candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such Candidates on a discretionary basis; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators could develop products that compete directly or indirectly with our Candidates and products pursuant to the collaboration;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our Candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our Candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a Candidate or product; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator with marketing and distribution rights to one or more of our Candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disagreements with collaborators, including disagreements over intellectual property or proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of Candidates, might lead to additional responsibilities for us with respect to Candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not properly obtain, maintain, enforce, defend or protect our intellectual property or proprietary rights or may use our proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may infringe, misappropriate or otherwise violate the intellectual property or proprietary rights of third parties, which may expose us to litigation and potential liability; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborations may be terminated for the convenience of the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable Candidates. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration agreements may not lead to development or commercialization of Candidates in the most efficient manner, or at all. If any collaborations that we enter into do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our Candidates could be delayed and we may need additional resources to develop our Candidates. All of the risks relating to product development, regulatory approval and commercialization described herein also apply to the activities of our collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, subject to its contractual obligations to us, if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any Candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in finding strategic collaborators for continuing development of our Candidates or platform technologies, or for successfully commercializing or competing in the market for certain indications.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek to establish strategic partnerships for developing Candidates or platform technologies due to capital costs required to develop, manufacture and commercialize our Candidates or platform technologies. We may not be successful in our efforts to establish strategic partnerships or other alternative arrangements because, among other things, our research and development pipeline may be insufficient, Candidates or platform technologies may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view our Candidates or platform technologies as having the requisite potential to demonstrate safety and efficacy. We cannot be certain that, following a strategic transaction, we will achieve an economic or business benefit that justifies such transaction. If we seek to but are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms or at all, we may have to curtail, reduce or delay the development of a Candidate, delay its potential commercialization, reduce the scope of any sales or marketing activities or increase our expenditures and undertake development, manufacturing or commercialization activities independently. If we elect to fund our own independent development or commercialization activities, we will need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development, manufacturing and commercialization activities, we may not be able to further develop our Candidates or platform technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have limited gene therapy manufacturing experience and could experience production problems and delays in obtaining regulatory approval of our manufacturing processes, which could result in delays in the development or commercialization of SGT-003, SGT-212, SGT-501, or our other Candidates. In addition, changes to manufacturing sites or processes, or formulations for our Candidates may result in additional cost or delay.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited experience manufacturing SGT-003, SGT-212, SGT-501 and our other Candidates. The manufacturing process we have used historically and the manufacturing process we plan to use in the future to produce product for our Candidates are complex and our processes have not been validated for commercial use. As Candidates progress through preclinical studies and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to enhance safety, quality, efficacy, yield, manufacturing batch size, minimize costs and achieve consistent results. For example, we have moved to a transient transfection-based manufacturing process for SGT-003 and while we have observed early positive results in preclinical studies and in our ongoing INSPIRE DUCHENNE trial using this new manufacturing process, any further changes in manufacturing or formulation may result in effects and results that are different from those observed in our completed studies to date. Similarly, in the future we may further alter our existing process or introduce an alternative process or formulation of one or more of our Candidates during the course of our planned preclinical studies or clinical trials. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our Candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay initiation or completion of clinical trials, require the conduct of bridging studies or clinical trials or the repetition of one or more studies or clinical trials, increase development costs, delay approval of our Candidates and jeopardize our ability to commercialize our Candidates, if approved, and generate revenue.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The production of SGT-003, SGT-212 and SGT-501 uses a transient transfection-based process which requires processing steps that are more complex than those required for most chemical pharmaceuticals. We also intend to use transient transfection manufacturing for our other Candidates. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a gene therapy candidate such as ours generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product will perform in the intended manner. Accordingly, we have and will continue to employ multiple steps to control our manufacturing processes to assure that the process works and that SGT-003, SGT-212, SGT-501 and our other Candidates are made strictly and consistently in compliance with such processes. We must supply all necessary documentation in support of an IND, BLA or MAA on a timely basis and must adhere to the FDA&#8217;s and the European Union&#8217;s cGMP requirements before we can obtain marketing approval for SGT-003, SGT-212, SGT-501, and other Candidates. In order to obtain approval, we will need to ensure that all of our processes, methods and equipment are compliant with cGMP requirements, by performing extensive audits of contract laboratories, manufacturers and suppliers.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently rely on multiple third-party manufacturers for supply of SGT-003, SGT-212 and SGT-501 and plan to rely on third-party manufacturers for our other Candidates. In order to produce sufficient quantities of Candidates for clinical trials and initial U.S. commercial demand, we have and will continue to further optimize and increase the capacity of our manufacturing process at our third-party manufacturers. We may need to make changes to our manufacturing processes, beyond implementation of a transient transfection-based manufacturing process. We may not be able to produce sufficient quantities of drug product due to several factors, including capacity constraints, equipment malfunctions, facility contamination, material shortages or contamination, natural disasters, a public health issue (for example, an outbreak of a contagious disease such as the COVID-19 pandemic), disruption in utility services, human error or disruptions in the operations of our suppliers. We may experience variability with respect to the success and yield between lots that will require continued engagement in process development activities to improve the reproducibility, reliability, quality and consistency of yields of the manufacturing process. Additional manufacturing runs will be required to produce necessary or adequate supply for our future clinical trials and there is no guarantee that all of those runs will be within specifications or produce adequate supply. If we are not able to produce sufficient supply on the timeline expected, our overall development schedule for SGT-003, SGT-212, SGT-501 and other Candidates could be delayed, and we could incur additional expense. Any such failure could delay or prevent development and commercialization of SGT-003, SGT-212, SGT-501 or other Candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If supply from a manufacturing facility is interrupted, including as a result of capacity constraints, equipment malfunctions, facility contamination, material shortages or contamination, natural disasters, public health emergencies or pandemics, such as the recent COVID-19 pandemic, disruption in utility services or human error, there could be a significant disruption in supply of SGT-003 or other Candidates. In such instance, we may need to locate appropriate replacement third-party manufacturers, and we may not be able to enter into arrangements with such additional third-party manufacturers on favorable terms or at all. Use of new third-party manufacturers could increase the risk of delays in production or insufficient supplies of our Candidates as we transfer our manufacturing technology to these manufacturers and as they gain experience manufacturing our Candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the BLA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory authority may impose restrictions relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA, the EMA and other foreign regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other foreign regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Lot failures or product recalls could cause us to delay or abandon clinical trials or product launches.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to oversee our manufacturing and quality control process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any problems in our manufacturing process or facilities could make us a less attractive collaborator for potential partners, including biotechnology and pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in our manufacturing process or facilities also could restrict our ability to meet market demand for our Candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect to utilize third parties to conduct our product manufacturing for the foreseeable future. Therefore, we are subject to the risk that these third parties may not perform satisfactorily or meet regulatory requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not independently manufacture material for our ongoing or planned clinical programs and we are utilizing and expect to utilize materials manufactured by cGMP-compliant third-party suppliers. If these third-party manufacturers do not successfully carry out their contractual duties, meet expected deadlines or manufacture our Candidates in accordance with quality and regulatory requirements or if there are disagreements between us and these third-party manufacturers, we may not be able to complete, or may be delayed in completing, the clinical trials required for approval of our Candidates. In such instances, we may need to locate an appropriate replacement third-party relationship, which may not be readily available or on acceptable terms, which would cause additional delay or increased expense prior to the approval of our Candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we rely on our third-party manufacturers for their compliance with the cGMP and their maintenance of adequate quality control, quality assurance and qualified personnel. Furthermore, all of our third-party suppliers and manufacturers are engaged with other companies to supply and/or manufacture materials or products for such companies, which exposes them to regulatory risks for the production of such materials and products. FDA inspections may identify compliance issues at third-party manufacturer facilities or at the facilities of third-party suppliers that may disrupt production or distribution, or require substantial resources to correct and prevent recurrence of any deficiencies, and could result in fines or penalties by regulatory authorities. In addition, discovery of problems with a product or the failure to comply with applicable requirements may result in restrictions on a product, manufacturer or holder of an approved BLA, including withdrawal or recall of the product from the market or other voluntary, FDA&#8209;initiated or judicial action, including fines, injunctions, civil penalties, license revocations, seizure, total or partial suspension of production or criminal penalties, any of which could significantly and adversely affect supplies of our Candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we do not currently have long-term supply or manufacturing arrangements in place for the production of our Candidates at commercial scale. Although we intend to establish additional sources for long-term supply, from one or more third-party manufacturers, if the gene therapy industry were to grow, we may encounter increasing competition for the materials necessary for the production of Candidates. We may experience difficulties in scaling up production beyond clinical batches. Furthermore, demand for third-party cGMP manufacturing facilities may grow at a faster rate than existing manufacturing capacity, which could disrupt our ability to find and retain third-party manufacturers capable of producing sufficient quantities of our Candidates for future clinical trials or to meet initial commercial demand in the United States. We currently rely, and expect to continue to rely, on additional third parties to manufacture materials for our Candidates and to perform quality testing. We intend to maintain third-party manufacturers for these materials, as well as to serve as additional sources of our Candidates, which will expose us to risks including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced control of manufacturing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability of certain CDMOs to produce our Candidates in the necessary quantities, or in compliance with current cGMP or in compliance with pertinent regulatory requirements and within our planned time frame and cost parameters;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability of our CDMOs to pass regulatory inspections and supply commercial material, which could impact our commercialization timelines;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination or nonrenewal of manufacturing and service agreements with third parties in a manner or at a time that is costly or damaging to us; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruptions to the operations of our third-party manufacturer and our and their suppliers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier, natural disasters or public health issues.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could lead to clinical trial delays or failure to obtain regulatory approval or impact our ability to successfully commercialize our Candidates. Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of product manufacture.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to establish sales, distribution and marketing capabilities or enter into agreements with third parties to market and sell our Candidates, we will be unable to generate any product revenue.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have no sales, distribution or marketing organization. To successfully commercialize any Candidate that may result from our development programs, we will need to develop these capabilities, either on our own or with others. The establishment and development of our own commercial team or the establishment of a contract sales force to market any Candidate we may develop will be expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to successfully develop this capability. We may enter into collaborations regarding our Candidates with other entities to utilize their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If any future collaborators do not commit sufficient resources to commercialize our Candidates, or we are unable to develop the necessary capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We compete with many companies that currently have extensive, experienced and well-funded sales, distribution and marketing operations to recruit, hire, train and retain marketing and sales personnel. We will also face competition in our search for third parties to assist us with the sales and marketing efforts of any future products. Without an internal team or the support of a third party to perform marketing and sales functions, we will be unable to compete successfully against these more established companies.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to establish medical affairs capabilities, we will be unable to establish an educated market of physicians to administer any future products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have no medical affairs team. If we are unable to successfully build a medical affairs team to address scientific and medical questions and provide expert guidance and education in the application, administration and utilization of any future products to physicians, we may not be able to establish an educated market for our products. The establishment and development of our own medical affairs team will be expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to successfully develop this capability.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the market opportunities for any of our future products are smaller than we believe they are, our revenue prospects may be adversely affected and our business may suffer.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently focus our research and product development on treatments for rare genetic neuromuscular and cardiac indications. Our understanding of the patient population with these diseases is based on estimates in published literature and by disease-focused foundations. These estimates may prove to be incorrect and new studies may reduce the estimated incidence or prevalence of these diseases. The number of patients in the United States, the European Union and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our Candidates or patients may become increasingly difficult to identify and access.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, there are several factors that could contribute to reducing the actual number of patients who could receive our Candidates less than the potentially addressable market. These include the lack of widespread availability of, and limited reimbursement for, new therapies in many underdeveloped markets. Further, the severity of the progression of a degenerative disease such as Duchenne and FA up to the time of treatment will likely diminish the therapeutic benefit conferred by a gene therapy due to irreversible cell damage.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Certain patients&#8217; immune systems might prohibit the successful delivery of certain gene therapy products, thereby potentially limiting the population of patients amenable to gene transfer.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As with many AAV-mediated gene therapy approaches, certain patients&#8217; immune systems might prohibit the successful delivery of certain gene therapy products, thereby potentially limiting the population of patients amenable to gene transfer. While we are working to better understand the prevalence of antibodies to AAV, or seroprevalence, as it relates to gene therapy, the exact seroprevalence is currently unknown and varies by AAV serotype and age. We may not be able to address these potentially limiting factors for gene therapy as a treatment for certain patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The commercial success of any of our Candidates, if approved, will depend upon market acceptance by physicians, patients, third&#8209;party payors and others in the medical community.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even with the requisite approvals from the FDA in the United States, the European Commission in the European Union and other regulatory authorities internationally, the commercial success of our Candidates will depend, in part, on the acceptance of physicians, patients and health care payors of gene therapy products in general, and, in particular for each of our current and future Candidates, as medically necessary, cost-effective and safe. Any product that we commercialize may not gain acceptance by physicians, patients, health care payors and others in the medical community due to ethical, social, medical and legal concerns. If our products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of gene therapy products and, in particular, our current and future Candidates, if approved for commercial sale, will depend on multiple factors, including:</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efficacy and safety of our current and future Candidates as demonstrated in clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efficacy and potential and perceived advantages of our Candidates over alternative treatments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of treatment relative to alternative treatments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical indications for which our Candidates are approved by the FDA, the European Commission or other regulatory authorities, as applicable; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of physicians to prescribe new therapies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of the target patient population to try new therapies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any side effects; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product labeling or product insert requirements of the FDA, the EMA or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relative convenience and ease of administration; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the strength of marketing and distribution support; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of market introduction of competitive products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of products to meet market demand; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publicity concerning our Candidates or competing products and treatments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any restrictions on the use of our products together with other medications; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">favorable third-party payor coverage and adequate reimbursement.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a potential Candidate displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be fully known until after it is launched.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our efforts to educate the medical community and third-party payors on the benefits of our Candidates may require significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our potential Candidates. If our Candidates are approved but fail to achieve market acceptance among physicians, patients or third-party payors, we will not be able to generate significant revenue from any such product.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our gene transfer approach utilizes capsids derived from a virus, which may be perceived as unsafe or may result in unforeseen adverse events. Negative public opinion and increased regulatory scrutiny of gene therapy may damage public perception of the safety of gene transfer Candidates and adversely affect our ability to conduct our business or obtain regulatory approvals for our Candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gene transfer remains a novel technology that faces many challenges imposed by the humoral immune response. The immunogenicity of AAV gene transfers is a very complex process that we and others continue to work understand through the extensive clinical experience that now exists over a broad spectrum of therapeutic areas and indications. Marked inflammatory toxicities have been observed, including complement activation, cytopenias, severe hepatotoxicity as well as transgene related toxicities representing part of the continuum of diverse aspects of clinical immune responses that can be observed post gene transfer.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular, our success will depend upon physicians who specialize in the treatment of our pipeline indications, prescribing treatments that involve the use of viral capsids in lieu of, or in addition to, other treatments with which they are more familiar and for which greater clinical data may be available. More restrictive government regulations or negative public opinion may delay or impair the development and commercialization or demand for any Candidate we may develop. A public backlash developed against gene therapy following the death of a participant in 1999 during a gene therapy clinical trial of research subjects with ornithine transcarbamylase ("OTC") deficiency, a rare disorder in which the liver lacks a functional copy of the OTC gene. The death of the clinical trial subject was due to complications of adenovirus capsid administration. Dr. James M. Wilson, former chair of our Scientific Advisory Board, was a co-investigator of the 1999 trial while he was Director of the Institute for Human Gene Therapy of the University of Pennsylvania. Serious adverse events in our clinical trials, including the events that led to the previously-lifted clinical holds on IGNITE DMD or other clinical trials involving gene transfer products or our competitors&#8217; products, even if not ultimately attributable to the relevant Candidates, and the resulting publicity, could result in increased government regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our Candidates, stricter labeling requirements for our Candidates, if approved, and a decrease in demand for our Candidates.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any contamination in our manufacturing process, shortages of materials or failure of any of our key suppliers to deliver necessary components could result in interruption in the supply of our Candidates and delays in our clinical development or commercialization schedules.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the nature of biologics manufacturing, there is a risk of contamination in our manufacturing processes. Any contamination could materially adversely affect our ability to produce our Candidates on schedule and could cause reputational damage.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of the materials required in our manufacturing process are derived from biologic sources. Such materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our Candidates could adversely impact or disrupt the manufacturing or the production of clinical material, which could materially and adversely affect our development timelines.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our Candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is significant uncertainty related to third-party coverage and reimbursement of newly approved products. We expect the cost of a single administration of gene transfer products, such as those we are developing, to be substantial, when and if they achieve regulatory approval. We expect that coverage and reimbursement by government and private payors will be essential for most patients to be able to afford these treatments. Accordingly, sales of our future products, if approved, will depend substantially, both domestically and abroad, on the extent to which the costs of such Candidates will be paid by health maintenance, managed care, pharmacy benefit and similar health care management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors. Coverage and reimbursement by a third-party payor may depend upon several factors, including the third-party payor&#8217;s determination that use of a product is:</span></p><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a covered benefit under its health plan;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safe, effective and medically necessary;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">appropriate for the specific patient;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cost-effective;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">durable and a one-time treatment, as applicable; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">neither experimental nor investigational.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining coverage and reimbursement for a product from third-party payors is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data. If coverage and reimbursement are not available, or are available only at limited levels, we may not be able to successfully commercialize our future products, if approved. Even if coverage is provided, the approved reimbursement amount may not be adequate to realize a sufficient return on our investment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To our knowledge, only a limited number of gene transfer products have been approved for coverage and reimbursement by the Centers for Medicare &amp; Medicaid Services ("CMS"), the agency responsible for administering the Medicaid program. It is difficult to predict what the CMS will decide with respect to coverage and reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these types of products either in the United States or the European Union. For example, several cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement in certain European Union member states and vice versa. It is difficult to predict what third-party payors will decide with respect to the coverage and reimbursement for our future products, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, international operations generally are subject to extensive government price controls and other market regulations, and increasing emphasis on cost-containment initiatives in the European Union, Canada and other countries may put pricing pressure on us. In general, the prices of therapeutics outside the United States are substantially lower than in the United States. Other countries may allow companies to fix their own prices for therapeutics, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulations could restrict the amount that we are able to charge for our Candidates. Accordingly, in markets outside the United States, the reimbursement for our Candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable product revenue.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, in countries where the pricing of gene therapy products is subject to governmental control, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our Candidate to other available therapies. Reimbursement of our products may be unavailable or limited in scope or amount, which would adversely affect our revenue, if any.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we obtain approval to commercialize our future products outside of the United States, in particular in the European Union, a variety of risks associated with international operations could materially adversely affect our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that we will be subject to additional risks in commercializing our future products, if approved, outside the United States, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">different regulatory requirements for approval of therapeutics in foreign countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced protection for intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the existence of additional third-party patent rights of potential relevance to our business;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign reimbursement, pricing and insurance regimes;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production shortages resulting from any events affecting material supply or manufacturing capabilities abroad; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods and fires.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure to comply with applicable foreign regulatory requirements may result in, among other things, fines, suspension, variation or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we engage in future acquisitions or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic collaboration may entail numerous risks, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased operating expenses and cash requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the assumption of additional indebtedness or contingent liabilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the diversion of our management&#8217;s attention from our existing Candidates and initiatives in pursuing such acquisition or strategic collaboration;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or collaboration or even to offset transaction costs.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">locate suitable acquisition or collaboration opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Business Operations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent on members of our executive team, the loss of whose services may adversely impact the achievement of our objectives. While we have entered into employment agreements with certain of our executive officers, any of them could leave our employment at any time. We currently do not have &#8220;key person&#8221; insurance on any of our employees. The loss of the services of one or more of our current key employees might impede the achievement of our research, development and commercialization objectives.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recruiting and retaining other qualified employees, consultants and advisors for our business, including scientific and technical personnel, also will be critical to our success. There currently is a shortage of skilled individuals with substantial gene therapy experience, which is likely to continue. As a result, competition for skilled personnel, including in gene therapy research and capsid manufacturing, is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for individuals with similar skill sets. In addition, the failure to succeed in preclinical or clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to manage growth in the scale and complexity of our operations, our performance may suffer.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are successful in executing our business strategy, we will need to expand our managerial, operational, financial and other systems and resources to manage our operations, continue our research and development activities and, in the longer term, build a commercial infrastructure to support commercialization of our current and future Candidates and products that are approved for sale. Future growth would impose significant added responsibilities on members of management. It is likely that our management, finance, development personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively manage our operations, growth and any future Candidates requires that we continue to develop more robust business processes and improve our systems and procedures in each of these areas and to attract and retain sufficient numbers of talented employees. We may be unable to successfully implement these tasks on a larger scale and, accordingly, may not achieve our research, development and growth goals.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. This could include violations of the federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance or codes of conduct. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our Candidates and may affect the prices we may set.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business and financial prospects could be affected by changes in health care spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws or judicial decisions, or new interpretations of existing laws or decisions, related to health care availability, the method of delivery or payment for health care products and services could negatively impact our business, operations and financial condition.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, in the United States there is significant interest in promoting health care reform, as evidenced by the enactment of the Patient Protection and Affordable Care Act and the companion Health Care and Education Reconciliation Act (the "Health Care Reform Law"). The Health Care Reform Law increased federal oversight of private health insurance plans and included a number of provisions designed to reduce Medicare expenditures and the cost of health care generally, to reduce fraud and abuse, and to provide access to increased health coverage.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Health Care Reform Law also imposed substantial changes to the U.S. system for paying for health care, including programs to extend medical benefits to millions of individuals who have lacked insurance coverage. Generally, implementation of the Health Care Reform Law has thus far included significant cost-saving, revenue and payment reduction measures with respect to, for example, several government health care programs that might cover our products in the United States, should they be commercialized, including Medicaid and Medicare. Additional downward pricing pressure associated with the Health Care Reform Law includes that the Health Care Reform Law established and provided significant funding for a Patient-Centered Outcomes Research Institute to coordinate and fund Comparative Effectiveness Research, as those terms are defined in the Health Care Reform Law. While the stated intent of Comparative Effectiveness Research is to develop information to guide providers to the most efficacious therapies, outcomes of Comparative Effectiveness Research could influence the reimbursement or coverage for therapies that are determined to be less cost-effective than others. Should any of our products be approved for sale, but then determined to be less cost-effective than alternative therapies, the levels of reimbursement for these products, or the willingness to reimburse at all, could be adversely impacted.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to legislative changes resulting from the passage of the Health Care Reform Law, other legislative changes have been proposed and adopted since the Health Care Reform Law was enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which will remain in effect through the first half of 2032. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2029 unless additional Congressional action is taken. The Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act") suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2020, and extended the sequester through 2031. These Medicare sequester reductions were suspended through June 2022, with the full 2% cut resuming thereafter. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our Candidates for which we may obtain regulatory approval or the frequency with which any such Candidate is prescribed or used.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since enactment of the Health Care Reform Law, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017 ("TCJA"), Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision of the Health Care Reform Law, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, on December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the Health Care Reform Law is an essential and inseverable feature of the Health Care Reform Law, and therefore because the mandate was repealed as part of the TCJA, the remaining provisions of the Health Care Reform Law are invalid as well. The U.S. Supreme Court heard this case on November 10, 2020 and on June 17, 2021, dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality of the statute. It is unclear how such litigation and other efforts to repeal and replace the Health Care Reform Law will impact the Health Care Reform Law and our business. Litigation and legislation over the Health Care Reform Law are likely to continue, with unpredictable and uncertain results.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax laws or in their implementation or interpretation could adversely affect our business and financial condition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income, sales, use or other tax laws, statutes, rules, or regulations could be enacted or amended at any time, which could affect our business or financial condition, including causing potentially adverse impacts to our effective tax rate, tax liabilities, and cash tax obligations. For example, the Inflation Reduction Act (the &#8220;IRA&#8221;), was signed into law in August 2022, and the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;), was signed into law in July 2025. The IRA introduced new tax provisions, including a 1% excise tax imposed on certain stock repurchases by publicly traded companies. The 1% excise tax generally applies to any acquisition of stock by the publicly traded company (or certain of its affiliates) from a stockholder of the company in exchange for money or other property (other than stock of the company itself), subject to a de minimis exception. Thus, the excise tax could apply to certain transactions that are not traditional stock repurchases. The OBBBA contains numerous tax provisions that we are currently in the process of evaluating, and which may significantly affect our business or financial condition. The recent changes under the OBBBA include tax rate extensions and changes to the business interest deduction limitation, the expensing of domestic research and development expenditures (in contrast to the continued capitalization and amortization of foreign research and development expenditures), the bonus depreciation deduction rules, and the international tax framework. Regulatory guidance under the IRA, the OBBBA, and other tax-related legislation is and continues to be forthcoming, and such guidance could ultimately increase or lessen the impact of these</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws on our business and financial condition. In addition, it is uncertain if and to what extent various states will conform to changes to federal tax legislation.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Current and future legislative efforts may limit the prices for our products, if and when they are licensed for marketing and that could materially impact our ability to generate revenues.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The costs and prices of prescription pharmaceuticals have been the subject of considerable discussion in the United States. To date, there have been several U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, Congress and the current administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in October 2020, the HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program to import certain prescription drugs from Canada into the United States. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America ("PhRMA"), but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue HHS. Several states have passed laws allowing for the importation of drugs from Canada. Certain of these states have submitted Section 804 Importation Program proposals and are awaiting FDA approval. Florida now has authority to import certain products from Canada for a period of two years once certain conditions are met. Florida will first need to submit a pre-import request for each product selected for importation, which must be approved by the FDA. Florida will also need to relabel the products and perform quality testing of the products to meet FDA standards. On May 21, 2025, the FDA announced that it would offer individual states the opportunity to submit a draft proposal for pre-review and meet with the agency to obtain initial feedback from the FDA prior to formally submitting their section 804 importation program (&#8220;SIP&#8221;) proposal. The intent of these meetings is to assist states in developing their proposals by further clarifying requirements, enhancing the quality of proposals submitted to the FDA and ultimately shortening the review timeline. Further, the HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, on November 20, 2020, the HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which has been delayed until January 1, 2032, by the IRA.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IRA has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation; and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single&#8209;source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition. With passage of the OBBBA in July 2025, Congress extended this exemption to drugs and biologics with multiple orphan drug designations. The first cycle of negotiations for the Medicare Drug Price Negotiation Program commenced in the summer of 2023. On August 15, 2024, HHS published the results of the first Medicare drug price negotiations for ten selected drugs that treat a range of conditions, including diabetes, chronic kidney disease, and rheumatoid arthritis. The prices of these ten drugs will become effective January 1, 2026. In August 2024, HHS published the results of the first Medicare drug price negotiations for ten selected drugs that treat a range of conditions and the prices will become effective January 1, 2026. In January 2025, CMS announced the next 15 drug and biologic prices that will be subject to the IRA&#8217;s price negotiation provisions. This second cycle of negotiations with participating drug companies will occur during 2025, and any negotiated prices for this second set of drugs will be effective starting January 1, 2027. CMS issued a public statement on January 2025, declaring that lowering the cost of prescription drugs is a top priority of the new administration and CMS is committed to considering opportunities to bring greater transparency in the negotiation program.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $2,000 a year beginning in 2025.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IRA includes a provision exempting orphan drugs from Medicare price negotiation but this exclusion has been interpreted by CMS in final guidance issued in July 2023 to apply only to those orphan drugs with an approved indication (or indications) for a single rare disease or condition. The final guidance clarifies that CMS will consider only active designations/approvals when evaluating a drug for the exclusion, such that designations/indications withdrawn before the selected drug publication date will not be considered. CMS also clarified that, if a drug loses its orphan drug exclusion status, the agency will use the earliest date of approval/licensure to determine whether the product is a qualifying single source drug subject to price negotiations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2023, Merck filed a lawsuit against HHS and CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the Constitution. Subsequently, a number of other parties, including pharmaceutical companies, also filed lawsuits in various courts with similar constitutional claims against HHS and CMS. There have been various decisions by the courts considering these cases since they were filed. The HHS has generally won the substantive disputes in these cases or succeeded in getting claims dismissed for lack of standing. Most of these cases are now on appeal. In October 2024, the U.S. Court of Appeals for the Third Circuit heard oral argument in three of these cases. In May 2025, the Third Circuit rejected a pharmaceutical company&#8217;s challenge to the Medicare price negotiation program, finding that the program did not violate the company&#8217;s due process rights under the U.S. Constitution since there is no protected property interest in selling goods to Medicare beneficiaries at a price higher than what the government is willing to pay in reimbursement. We expect that litigation involving these and other provisions of the IRA will continue with unpredictable and uncertain results. Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2025, the President issued an executive order directing the HHS to take steps to reduce the prices of pharmaceutical products, repeating many of the proposals advanced during the first Trump Administration, including directing the FDA to streamline and improve its existing drug importation program so as to make it easier for states to obtain approval without sacrificing the safety or quality of drug products. Other provisions of the executive order relate to the 340B program. Specifically, one provision calls on the Secretary of HHS to determine the hospital acquisition cost for covered outpatient drugs at hospital outpatient departments and to consider and propose any appropriate adjustments for Medicare payment. The other provision directs HHS to condition grant funding to certain health centers on those centers passing through the 340B discounts they receive on insulin and injectable epinephrine products to patients who meet certain requirements. With respect to the IRA&#8217;s Medicare drug pricing program, the executive order, among other things, calls for alignment in &#8220;the treatment of small molecule prescription drugs with that of biological products, ending the distortion that undermines relative investment in small molecule prescription drugs, coupled with other reforms to prevent any increase in overall costs to Medicare and its beneficiaries.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 12, 2025, the President issued an additional executive order calling on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in the United States. The executive order directs the Secretary of HHS to communicate most-favored-nation (&#8220;MFN&#8221;), price targets to pharmaceutical manufacturers to bring prices in line with comparably developed nations. The executive order further provides that if such actions do not lower the costs of pharmaceuticals, the Secretary of HHS would pursue other actions, including proposing a rulemaking that imposes MFN pricing in the United States. Subsequently, on May 20, 2025, HHS indicated that the proposed MFN pricing will apply only to brand products without generic or biosimilar competition and the referenced foreign countries will include only those in which the branded product similarly does not have generic or biosimilar competition. Second, HHS indicated that the MFN target price will be the lowest price in a country that is a member of the Organization for Economic Co-operation and Development (&#8220;OECD&#8221;) with a gross domestic product (&#8220;GDP&#8221;) per capita of at least 60% of the U.S. GDP per capita. Based on previous estimates, there are likely at least 22 OECD countries that would satisfy this criterion. The implications of these actions remain unclear and are likely to result in litigation if the administration pursues an MFN regulatory pricing requirement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states, for example, require drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers, wholesale distributors, to disclose information about pricing of pharmaceuticals. This is increasingly true with respect to products approved pursuant to the accelerated approval pathway. State Medicaid programs and other payers are developing strategies and implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA&#8217;s standards for accelerated approval. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, if approved, or put pressure on our product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our Candidates or additional pricing pressures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is likely that federal and state legislatures within the United States and foreign governments will continue to consider changes to existing health care legislation. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of the government, insurance companies, managed care organizations and other health care payors of to contain or reduce costs of health care may adversely affect:</span></p><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the demand for any Candidates for which we may obtain regulatory approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to set a price that we believe is fair for our products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain coverage and reimbursement approval for a product;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of taxes that we are required to pay.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, in the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our Candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our Candidates, restrict or regulate post-approval activities and affect our ability to commercialize our Candidates, if approved.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States, the European Union or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our Candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our relationships with customers, physicians and third-party payors will be subject, directly or indirectly, to federal and state health care fraud and abuse laws, false claims laws, health information privacy and security laws, and other health care laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we obtain FDA approval for our current or future Candidates and begin commercializing one or more of those products in the United States, our operations will be directly or indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations, including, without limitation, the federal Health Care Program Anti-Kickback Statute, the federal civil and criminal laws and the Physician Payment Sunshine Act and regulations. These laws will impact, among other things, our proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct our business. The laws that will affect our operations include, but are not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Health Care Program Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal health care program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers on the other. The Health Care Reform Law amended the intent requirement of the federal Anti-Kickback Statute. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government payors that are false or fraudulent. The Health Care Reform Law provides and recent government cases against pharmaceutical and medical device manufacturers support the view that Federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may implicate the False Claims Act;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, which created new federal criminal statutes that prohibit a person from knowingly and willfully executing a scheme or from making false or fraudulent statements to defraud any health care benefit program, regardless of the payor (e.g., public or private);</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act ("HITECH"), and its implementing regulations, and as amended again by the final HIPAA omnibus rule, Modifications to the HIPAA Privacy, Security, Enforcement, and Breach Notification Rules Under HITECH and the Genetic Information Nondiscrimination Act; Other Modifications to HIPAA, published in January 2013, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses and health care providers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal transparency laws, including the federal Physician Payment Sunshine Act, that require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the CMS information related to: (i) payments or other &#8220;transfers of value&#8221; made to physicians, other healthcare professionals and teaching hospitals and (ii) ownership and investment interests held by physicians and their immediate family members;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">state and foreign law equivalents of each of the above federal laws, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other health care providers or marketing expenditures and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts in certain circumstances, such as specific disease states; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment and the curtailment or restructuring of our operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that we may run afoul of one or more of the requirements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies, contractual obligations and failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the United States, EU and UK. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of our business activities now or in the future.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to properly protect the privacy and security of protected health information, we could be found to have breached our contracts. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. HHS enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2018, California passed into law the California Consumer Privacy Act ("CCPA") which took effect on January 1, 2020 and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#8217;s requirements are similar to those found in the General Data Protection Regulation ("GDPR"), including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of &#8220;sales&#8221; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. In November 2020, California voters passed a ballot initiative for the California Privacy Rights Act ("CPRA"), which went into effect on January 1, 2023, and significantly expanded the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created a new enforcement agency &#8211; the California Privacy Protection Agency &#8211; whose sole responsibility is to enforce the CPRA and other California privacy laws, which will further increase compliance risk. The provisions in the CPRA may apply to some of our business activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to California, several other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime over the next several years. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data (which includes health data in some cases). Some of the provisions of these laws may apply to our business activities. There are also states that are strongly considering privacy laws that will go into effect over the next several years. Other states will be considering these laws in the future, and Congress has also been debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plaintiffs&#8217; lawyers are also increasingly using privacy-related statutes at both the state and federal level to bring lawsuits against companies for their data-related practices. In particular, there have been a significant number of cases filed against companies for their use of pixels and other web trackers. These cases often allege violations of the California Invasion of Privacy Act and other state laws regulating wiretapping, as well as the federal Video Privacy Protection Act. The rise in these types of lawsuits could create potential risk for our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar to the laws in the United States, there are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the European Economic Area ("EEA"), and the processing of personal data that takes place in the EEA, is regulated by the GDPR, which went into effect in May 2018 and which imposes obligations on companies that operate in our industry with respect to the processing of personal data and the cross-border transfer of such data. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and policies. If our or our partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The GDPR places restrictions on the cross-border transfer of personal data from the EU to countries that have not been found by the European Commission to offer adequate data protection legislation, such as the United States. There are ongoing concerns about the ability of companies to transfer personal data from the EU to other countries. In July 2020, the Court of Justice of the European Union (the "CJEU") invalidated the EU-U.S. Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the U.S. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the U.S. While we were not self-certified under the Privacy Shield, this CJEU decision may lead to increased scrutiny on data transfers from the EEA to the U.S. generally and increase our costs of compliance with data privacy legislation as well as our costs of negotiating appropriate privacy and security agreements with our vendors and business partners.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the withdrawal of the UK from the EU, the UK Data Protection Act 2018 applies to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, through separate &#8220;adequacy&#8221; decisions, that data transfers between the two jurisdictions are in compliance with the UK Data Protection Act and the GDPR, respectively. The UK and the U.S. have also agreed to a U.S.-UK &#8220;Data Bridge&#8221;, which functions similarly to the EU-U.S. Data Privacy Framework and provides an additional legal mechanism for companies to transfer data from the UK to the United States. In addition to the UK, Switzerland is also in the process of approving an adequacy decision in relation to the Swiss-U.S. Data Privacy Framework (which would function similarly to the EU-U.S. Data Privacy Framework and the U.S.-UK Data Bridge in relation to data transfers from Switzerland to the United States). Any changes or updates to these developments have the potential to impact our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, in October 2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which serves as a replacement to the EU-U.S. Privacy Shield. The European Commission initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework in December 2022 and the European Commission adopted the adequacy decision on July 10, 2023. The adequacy decision permits U.S. companies who self-certify to the EU-U.S. Data Privacy Framework to rely on it as a valid data transfer mechanism for data transfers from the EU to the U.S. However, some privacy advocacy groups have already suggested that they will be challenging the EU-U.S. Data Privacy Framework. If these challenges are successful, they may not only impact the EU-U.S. Data Privacy Framework, but also further limit the viability of the standard contractual clauses and other data transfer mechanisms. The uncertainty around this issue has the potential to impact our business internationally.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following Brexit, the UK Data Protection Act 2018 applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the United Kingdom and the EU have determined, through separate &#8220;adequacy&#8221; decisions, that data transfers between the two jurisdictions are in compliance with the UK Data Protection Act and the GDPR, respectively. Any changes or updates to these adequacy decisions have the potential to impact our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and the sale and distribution of commercial products, through increased compliance costs, costs associated with contracting and potential enforcement actions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we continue to address the implications of the recent changes to data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and our efforts to comply with the evolving data protection rules may be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. We must devote significant resources to understanding and complying with this changing landscape. Failure to comply with laws regarding data protection would expose us to risk of enforcement actions taken by data protection authorities in the EEA and elsewhere and carries with it the potential for significant penalties if we are found to be non-compliant. Similarly, failure to comply with federal and state laws in the United States regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, be precluded from developing manufacturing and selling certain products outside the United States or be required to develop and implement costly compliance programs, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations are subject to anti-corruption laws, including the U.K. Bribery Act 2010 ("Bribery Act"), the U.S. Foreign Corrupt Practices Act ("FCPA"), and other anti-corruption laws that apply in countries where we do business and may do business in the future. The Bribery Act, FCPA and these other laws generally prohibit us, our officers, and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. Compliance with the FCPA, in particular, is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may in the future operate in jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the Bribery Act,</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. If we expand our operations outside of the United States, we will need to dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws. In addition, various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and Candidates outside of the United States, which could limit our growth potential and increase our development costs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. The Securities and Exchange Commission also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by United Kingdom, U.S. or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any Candidate that we may develop.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face an inherent risk of product liability exposure related to the testing of SGT-003 and any of our current and future Candidates in preclinical studies and clinical trials and may face an even greater risk if we commercialize any Candidate that we may develop. If we cannot successfully defend ourselves against claims that our Candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></p><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for any Candidate that we may develop;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to trial participants or patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant time and costs to defend the related litigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize any of our Candidates; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation and significant negative media attention.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we commence additional clinical trials and if we successfully commercialize any Candidate. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the generation, handling, use, storage, treatment, manufacture, transportation and disposal of, and exposure to, hazardous materials and wastes, as well as laws and regulations relating to occupational health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and viruses and other biologic materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages. We also could incur significant costs associated with civil or criminal fines and penalties. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Although we maintain workers&#8217; compensation insurance for certain costs and expenses, we may incur due to injuries to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our internal computer systems, or those of our collaborators, contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite the implementation of security measures, our internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such systems are also vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors and/or business partners, or from cyber-attacks by malicious third parties. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyber-attacks also could include phishing attempts or e-mail fraud to cause payments or information to be transmitted to an unintended recipient.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we are not aware of any such material system failure, accident, cyber-attack or security breach to date, if such an event were to occur and cause interruptions in our or our collaborators&#8217;, contractors&#8217; or consultants&#8217; operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from preclinical studies or clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our current and other future Candidates could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We heavily rely on certain in-licensed patents and other intellectual property rights in connection with our development of our Candidates and may be required to acquire or license additional patents or other intellectual property rights to continue to develop and commercialize our Candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to develop and commercialize our Candidates is heavily dependent on licenses to patent rights and other intellectual property granted to us by third parties. In particular, we have licensed certain patents and patent applications from the University of Missouri, the University of Washington and others that are important or necessary to the development of SGT-003, our other Candidates and other elements of our gene transfer program. We have further licensed certain intellectual property from the University of Pennsylvania and others that are important or necessary to the development of SGT-212 and from ICS Maugeri that are important or necessary to the development of SGT-501. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, development and commercialization obligations, milestone payments, royalties and other obligations on us. If we fail to comply with our obligations under our agreements, we may be subject to damages, which may be significant, and the licensor may have the right to terminate the license, in which event we may not be able to develop or market Candidates or technologies covered by the license. In addition, certain of these license agreements are not assignable by us without the consent of the respective licensor, which may have an adverse effect on our ability to engage in certain transactions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under certain of our existing license agreements, we do not have, and under future license agreements we may not have, the right to control the preparation, filing and prosecution of patent applications, or the maintenance, enforcement and defense of the patents and patent applications that we license from third parties. For example, under our inbound license agreements with the University of Missouri and the University of Washington, each of the applicable licensors controls the prosecution of patent applications and the maintenance of patents and patent applications. Therefore, we cannot be certain that the licensed patents and applications will be prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. If our licensors fail to maintain, enforce or defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our Candidates that are the subject of such licensed rights could be adversely affected. For more information, see Part I, Item 1, &#8220;Business&#8212;Strategic Partnerships and Collaborations/Licenses&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2024.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, licenses to additional third-party intellectual property, technology and materials may be required for our development programs but may not be available in the future or may not be available on commercially reasonable terms. For example, third parties may claim that the constructs containing the gene or protein of interest and the AAV capsids we are developing for use in product candidates are covered by patents held by them. We believe that we would have valid defenses to any such claims; however, if any such claims were ultimately successful, we might require a license to continue to use and sell Candidates and such AAV capsids. Such licenses may not be available on commercially reasonable terms, or at all. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign license rights to us. We also may be unable to license or acquire third&#8209;party intellectual property rights on terms that would allow us to make an appropriate return on our investment. Moreover, even if we are able to obtain such licenses, they may only be non-exclusive, which could permit competitors and other third parties to use the same intellectual property in competition with us.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may collaborate with non-profit and academic institutions to accelerate our preclinical research or development under written agreements with these institutions. These institutions may provide us with an option to negotiate a license to any of the institution&#8217;s licensable rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the required timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to successfully obtain rights, or successfully challenge such rights, to any third-party intellectual property rights that are required for the development and commercialization of our Candidates, and such third-party intellectual property rights are successfully asserted against us, we may be liable for damages, which may be significant, and we may be required to cease the development and commercialization of our Candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our Candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our Candidates may be adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends, in large part, on our and our licensors&#8217; ability to seek, obtain, maintain, enforce and defend patent rights in the United States and other countries with respect to our Candidates and our future innovation related to our manufacturing technology. Our licensors and we have sought, and we intend to continue to seek, to protect our proprietary position by filing patent applications in the United States and, in at least some cases, one or more countries outside the United States related to our Candidates that are important to our business. However, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents or whether the claims of any issued patents will provide us with a competitive advantage.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, although we have pending patent applications in the United States and abroad, we cannot predict whether or in which jurisdictions the pending applications will result in issuance of patents that effectively protect any of our Candidates or will effectively prevent others from commercializing competitive products. Further, each of the provisional patent applications is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of the filing date of each provisional patent application. If we do not timely file a non-provisional patent application in respect of a provisional patent application, we may lose our priority date with respect to such provisional patent application and any patent protection on the inventions disclosed in such provisional patent application. While we intend to timely file non-provisional patent applications relating to our provisional patent applications, we cannot predict whether such future patent applications will result in the issuance of patents that effectively protect any of our Candidates or will effectively prevent others from commercializing competitive products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, foreign regulatory authorities may change their approval policies and new regulations may be enacted regarding non-patent exclusivity. For example, EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products, which may reduce the duration of regulatory data protection and exclusivity periods for orphan drugs, and revise the eligibility for expedited pathways in addition to other changes, was published on April 26, 2023. On April 10, 2024, the European Parliament adopted a position on the proposal requesting several amendments to the package. The proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revisions may, however, have a significant impact on the pharmaceutical industry and our business in the long term.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to file, prosecute, maintain, enforce, defend or license all patents that are necessary to our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent prosecution process is expensive, time-consuming and complex, and we and our licensors may not be able to file, prosecute, maintain, enforce, defend or license all necessary or desirable patents and patent applications at a reasonable cost or in a timely manner.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is also currently unknown what claims may, if ever, issue from pending applications included in our patent rights. Additionally, certain of our in-licensed U.S. patent rights lack corresponding foreign patents or patent applications, and therefore we will be unable to obtain patent protection for our Candidates in certain jurisdictions. We or our licensors may not be able to obtain or maintain patent protection with respect to our Candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain and enforce our intellectual property rights, and more generally, could affect the value of our intellectual property rights or narrow the scope of our licensed patents or future owned patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Patent applications included in our current and future patent rights may not result in patents being issued that protect our Candidates, effectively prevent others from commercializing competitive products or otherwise provide any competitive advantage. In fact, patent applications may not issue as patents at all. Even assuming patents issue from patent applications in which we have rights, changes in either the patent laws or interpretation of the patent laws in the United States and other jurisdictions may diminish the value of our patents or narrow the scope of our patent protection.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other parties have developed products that may be related or competitive to our own and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our patent applications or issued patents. We may not be aware of all third-party intellectual property rights potentially relating to our Candidates. In addition, we cannot provide any assurances that any of the inventions disclosed in our patent applications will be found to be patentable, including over third-party or our own prior art patents, publications or other disclosures, or will issue as patents. Even if our patent applications issue as patents, we cannot provide any assurances that such patents will not be challenged or ultimately held to be invalid or unenforceable. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and in other jurisdictions are typically not published until 18 months after filing, or, in some cases, at all. Therefore, we cannot know with certainty whether the inventors of our licensed patents and applications were the first to make the inventions claimed in those patents or pending patent applications, or that they were the first to file for patent protection of such inventions. Similarly, should we own any issued patents or patent applications in the future, we may not be certain that we were the first to file for patent protection for the inventions claimed in such patents or patent applications. Furthermore, given the differences in patent laws in the United States, Europe and other foreign jurisdictions, for example, the availability of grace periods for filing patent applications and what can be considered as prior art, we cannot make any assurances that any claims in our pending and future patent applications in the United States or other jurisdictions will issue, or if they do issue, whether they will issue in a form that provides us with any meaningful competitive advantage. Similarly, we cannot make any assurances that if the patentability, validity, enforceability or scope of our pending or future patents and patent applications in the United States or foreign jurisdictions are challenged by any third party, that the claims of such pending or future patents and patent applications will survive any such challenge in a form that provides us with any meaningful competitive advantage. For example, we are aware of certain third-party patents and publications related to certain microdystrophin constructs. While we believe that our owned or in-licensed patents and patent applications claim novel and non-obvious features of microdystrophin constructs that are not described in such third-party patents or publications, such third-party patents and publications may have earlier priority or publication dates and may be asserted as prior art against our owned or in-licensed patents and applications. Any such challenge, if successful, could limit or eliminate patent protection for our products and Candidates or otherwise materially harm our business. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights cannot be predicted with any certainty.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or may own in the future do issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Any patents that we license or may own in the future may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether any of our Candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative products in a non-infringing manner.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of patent protection we require to successfully compete in the marketplace may be unavailable. We cannot provide any assurances that any of the patents or patent applications included in our patent rights include or will include claims with a scope sufficient to protect our Candidates or otherwise provide any competitive advantage. In addition, the laws of foreign countries may not protect our proprietary rights to the same extent as the laws of the United States. Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally twenty years after it is filed. Certain extensions may be available, however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new Candidates, patents protecting such Candidates might expire before or shortly after such Candidates are commercialized. As a result, our patent rights may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar or identical to our Candidates, including biosimilar versions of such products.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our licensed patents, and any patents we may own in the future, may be challenged, narrowed, invalidated or held unenforceable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we acquire patent protection that we expect should enable us to maintain some competitive advantage, third parties, including competitors, may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. In litigation, a competitor could claim that our in-licensed patents or any patents we may own in the future are not valid or enforceable for a number of reasons. If a court agrees, we would lose our rights to those challenged patents. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such proceedings could result in the revocation or cancellation of or amendment to our licensed patents and any patents we may own in the future in such a way that they no longer cover our Candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if issued, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our current and future patent rights may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third-party submission of prior art to the U.S. Patent and Trademark Office ("USPTO") challenging the validity of one or more claims of patents included in our patent rights. Such submissions may also be made prior to a patent&#8217;s issuance, precluding the granting of a patent based on one of the pending patent applications included in our patent rights. We may become involved in opposition, derivation, revocation, reexamination, post-grant and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review, or interference proceedings challenging one or more patents included in our patent rights. For example, competitors may claim that they invented the inventions claimed in patents or patent applications included in our patent rights, such as the microdystrophin we use in SGT-003, prior to the inventors of such patents or patent applications, or may have filed one or more patent applications before the filing of the patents or patent applications included in our patent rights. A competitor who can establish an earlier filing or invention date may also assert that we are infringing their patents and that we therefore cannot practice our technology related to our Candidates as claimed in the patents or patent applications included in our patent rights. Competitors may also contest patents or patent applications included in our patent rights by showing that the claimed subject matter was not patent-eligible, was not novel or was obvious or that the patent claims failed any other requirement for patentability or enforceability. In addition, we may in the future be subject to claims by our or our licensors&#8217; current or former employees or consultants asserting an ownership right in the patents or patent applications included in our patent rights as an inventor or co-inventor, as a result of the work they performed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar therapeutics, without payment to us, or could limit the duration of the patent protection covering our Candidates. Such challenges may also result in our inability to manufacture or commercialize our Candidates without infringing third&#8209;party patent rights, and we may be required to obtain a license from third parties, which may not be available on commercially reasonable terms or at all, or we may need to cease the development, manufacture and commercialization of one or more of our Candidates. In addition, if the breadth or strength of protection provided by the patents and patent applications included in our patent rights is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future Candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if they are unchallenged, the patents and pending patent applications included in our patent rights may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our patent rights by developing similar or alternative therapeutics in a non-infringing manner. For example, a third party may develop a competitive therapeutic that provides benefits similar to one or more of our Candidates but that uses a capsid or an expression construct that falls outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we license or pursue with respect to our Candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our Candidates could be negatively affected.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our intellectual property licenses with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently depend, and will continue to depend, on our license, collaboration and other similar agreements. Further development and commercialization of our Candidates and platform technologies may require us to enter into additional license, collaboration or other similar agreements. The agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, impact our ability to sublicense the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected Candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our licenses or material relationships are terminated or breached, we may:</span></p><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lose our rights to develop and market our Candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lose patent protection for our Candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">experience significant delays in the development or commercialization of our Candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not be able to obtain any other licenses on acceptable terms, if at all; or </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur liability for damages.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These risks apply to any agreements that we may enter into in the future for our Candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have certain obligations under licensing agreements with third parties that include annual maintenance fees and payments that are contingent upon achieving various development, commercial and regulatory milestones. Pursuant to many of these license agreements, we are required to make milestone payments if certain development, regulatory and commercial sales milestones are achieved, and may have certain additional research funding obligations. Also, pursuant to the terms of many of these license agreements, when and if commercial sales of a licensed product commence, we must pay royalties to our licensors on net sales of the respective licensed products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into, or plan to enter into, license agreements with third parties and may need to obtain additional licenses from one or more of these same third parties or from others to advance our research or allow our commercialization of our Candidates. It is possible that we may be unable to obtain such licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign Candidates or the methods for manufacturing them or to develop or license replacement products, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize our Candidates. We cannot provide any assurances that third-party patents or other intellectual property rights do not exist that might be enforced against our manufacturing methods, Candidates or any technologies we may develop, resulting in either an injunction prohibiting our manufacture or sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The majority of our existing license agreements provide the licensor sole control of patent prosecution of the licensed technology, and we may be required to reimburse the licensor for their costs of patent prosecution. Future license agreements may require the same. If our licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual property. Further, in certain of our license agreements our licensors have the first right to bring any actions against any third party for infringing on the patents we have licensed. Our license agreements also require us to meet development thresholds to maintain the license, including establishing a set timeline for developing and commercializing Candidates. Disputes may arise regarding intellectual property subject to our licensing agreements, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which our products or processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sublicensing of patent and other rights under our collaborative development relationships;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inventorship or ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the priority of invention of licensed patented inventions.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize our Candidates. In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby resulting in disputes or litigation, which could cause us to incur substantial costs and distract management&#8217;s time, and if we are unsuccessful, we could lose our ability to develop and commercialize products covered by these license agreements. If these licenses are ultimately terminated by the licensor, or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends upon our ability and the ability of our future collaborators to develop, manufacture, market and sell our Candidates without infringing, misappropriating or otherwise violating the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We or our licensors may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our Candidates, including interference proceedings, post grant review and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review before the USPTO. Our competitors or other third parties may assert infringement claims against us, alleging that, among other things, our therapeutics, manufacturing methods, formulations or administration methods are covered by their patents.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the vast number of patents in our field of technology, we cannot be certain or guarantee that a court would hold that any of our Candidates do not infringe an existing patent or a patent that may be granted in the future. Many companies and institutions have filed, and continue to file, patent applications related to gene therapy and related manufacturing methods. Some of these patent applications have already been allowed or issued and others may issue in the future. Since this area is competitive and of strong interest to pharmaceutical and biotechnology companies, there will likely be additional patent applications filed and additional patents granted in the future, as well as additional research and development programs expected in the future. Furthermore, because patent applications can take many years to issue, may be confidential for 18 months or more after filing and can be revised before issuance, there may be applications now pending that may later result in issued patents that may be infringed by the manufacture, use, sale or importation of our Candidates and we may or may not be aware of such patents. If a patent holder believes the manufacture, use, sale or importation of one of our Candidates infringes its patent, the patent holder may sue us even if we have licensed other patent protection for our Candidates. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our licensed patent portfolio may therefore have no deterrent effect.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is also possible that we have failed to identify relevant third-party patents or applications for which we may need a license to develop and commercialize our Candidates. For example, applications filed before November 29, 2000, and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to our Candidates because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patent applications may issue with claims of relevance to our Candidates. In addition, we may be unaware of one or more issued patents that would be infringed by the manufacture, sale or use of a current or future Candidate, or we may incorrectly conclude that a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our Candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent or other intellectual property rights against us. For example, third parties may claim that gene or protein of interest, such as microdystrophin, or the AAV capsids we are developing for use in our Candidates are covered by patents held by them. Even if we believe such claim, or other intellectual property claims alleged by third parties, are without merit, there is no assurance that we would be successful in defending such claims. A court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize our Candidates covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Similarly, there is no assurance that a court of competent jurisdiction would find that our Candidates did not infringe a third-party patent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent and other types of intellectual property litigation can involve complex factual and legal questions, and their outcome is uncertain. If we are found, or believe there is a risk that we may be found, to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, and we are unsuccessful in demonstrating that such intellectual property rights are invalid or unenforceable, we could be required or may choose to obtain a license from such third party to continue developing, manufacturing and marketing our Candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing Candidate. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement, misappropriation or other violation of intellectual property rights, or claims that we have done so, could prevent us from manufacturing and commercializing our Candidates or force us to cease some or all of our business operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time-consuming. Competitors may infringe patents that we may own in the future or the patents of our licensing partners or we may be required to defend against claims of infringement. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing or misappropriating or successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our licensed patents and applications and any patents and patent applications we may own in the future. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable intellectual property law firms and other professionals to help us comply and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could have a material adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Some intellectual property that we have in-licensed may have been discovered through government-funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. manufacturing. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of the intellectual property rights we have licensed, including such rights licensed from the University of Missouri, the University of Washington and the University of Florida, are stated to have been generated through the use of U.S. government funding</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and may therefore be subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future Candidates pursuant to the Bayh-Dole Act of 1980 ("Bayh-Dole Act"). These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention, (ii) government action is necessary to meet public health or safety needs or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting, maintaining, enforcing and defending patents on Candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. Although our license agreements grant us worldwide rights, certain of our in-licensed U.S. patents lack corresponding foreign patents or patent applications. For example, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States even in jurisdictions where we and our licensors pursue patent protection. Consequently, we and our licensors may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in jurisdictions where we and our licensors pursue patent protection, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our inventions in jurisdictions where we and our licensors have not pursued and obtained patent protection to develop their own products and may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as it is in the United States. These products may compete with our Candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property rights, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents, if pursued and obtained, or the marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could (i) result in substantial costs and divert our efforts and attention from other aspects of our business, (ii) put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and (iii) provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of the discovery and development processes of our Candidates or technology platforms that involve proprietary know&#8209;how, information or technology that is not covered by patents. Aspects of our manufacturing process are protected by trade secrets. However, trade secrets can be difficult to protect and some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We seek to protect our proprietary know-how, trade secrets and processes, in part, by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our employees, consultants, scientific advisors, CROs, manufacturers and contractors. These agreements typically limit the rights of third parties to use or disclose our confidential information. However, we may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements, despite the existence generally of confidentiality agreements and other contractual restrictions. We cannot guarantee that we have entered into such agreements with each party that may have or have had</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">access to our trade secrets or proprietary processes. Monitoring unauthorized uses and disclosures is difficult and we do not know whether the steps we have taken to protect our proprietary know-how and trade secrets will be effective. If any of our employees, collaborators, CROs, manufacturers, consultants, advisors and other third parties who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. As a result, we could lose our trade secrets. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these security measures, they may still be breached, and we may not have adequate remedies for any breach.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our trade secrets may otherwise become known or be independently discovered by competitors. Competitors could purchase our Candidates, if approved, and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe, misappropriate or otherwise violate our intellectual property rights, design around our protected know-how and trade secrets, or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate such trade secrets, from using that technology or information to compete with us. If our trade secrets are not adequately protected so as to protect our market against competitors&#8217; products and technologies, our competitive position could be adversely affected.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors, as well as our academic partners. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. An inability to incorporate such technologies or features would have a material adverse effect on our business and may prevent us from successfully commercializing our Candidates. Moreover, any such litigation or the threat of such litigation may adversely affect our ability to hire employees or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our Candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Moreover, individuals executing agreements with us may have preexisting or competing obligations to a third party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our Candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in either the patent laws or the interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. On September 16, 2011, the Leahy-Smith America Invents Act (the "Leahy-Smith Act") was signed into law. The Leahy-Smith Act includes several significant changes to U.S. patent law. Prior to March 2013 in the United States, assuming that other requirements for patentability are met, the first to make the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the invention. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and may also affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent through various post-grant proceedings administered by the USPTO. The USPTO developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business as, among other reasons, the USPTO must still</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implement various regulations. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent positions of companies engaged in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Two cases involving diagnostic method claims and &#8220;gene patents&#8221; have been decided by the U.S. Supreme Court. On March 20, 2012, the U.S. Supreme Court issued a decision in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mayo Collaborative Services v. Prometheus Laboratories, Inc. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">("Prometheus"), a case involving patent claims directed to a process of measuring a metabolic product in a patient to optimize a drug dosage for the patient. According to the U.S. Supreme Court, the addition of well understood, routine or conventional activity such as &#8220;administering&#8221; or &#8220;determining&#8221; steps was not enough to transform an otherwise patent-ineligible natural phenomenon into patent-eligible subject matter. On July 3, 2012, the USPTO issued a guidance memo to patent examiners indicating that process claims directed to a law of nature, a natural phenomenon or a naturally occurring relation or correlation that do not include additional elements or steps that integrate the natural principle into the claimed invention such that the natural principle is practically applied and the patent claim amounts to significantly more than the natural principle itself should be rejected as directed to patent-ineligible subject matter. On June 13, 2013, the U.S. Supreme Court issued its decision in Association for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Molecular Pathology v. Myriad Genetics, Inc. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">("Myriad"), a case involving patent claims held by Myriad Genetics, Inc. relating to the breast cancer susceptibility genes BRCA1 and BRCA2. Myriad held that an isolated segment of naturally occurring DNA, such as the DNA constituting the BRCA1 and BRCA2 genes, is not patent-eligible subject matter, but that complementary DNA may be patent-eligible.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2014, the USPTO issued a guidance to its patent examiners for evaluating claims for patent subject matter eligibility under the relevant statute (35 U.S.C. &#167; 101). This guidance was in response to a series of decisions from the U.S. Supreme Court on patent claims reciting judicial exceptions, including Abstract Ideas, Laws of Nature/Natural Principles, Natural Phenomena and/or Natural Products. Based on judicial decisions and public feedback, several supplements to this guidance and additional memoranda and materials have since been issued and are continually being issued, while the current eligibility guidance has been incorporated into the latest (10th) edition of the MPEP (Manual for Patent Examination Procedure), last revised in June 2020. The current subject matter eligibility guideline instructs USPTO examiners to follow a two-part test, set forth in the U.S. Supreme Court decisions Alice/Mayo, as the only test that should be used to evaluate the eligibility of claims under examination, including claims directed to natural products and principles including all naturally occurring nucleic acids. Certain claims of our licensed patents and patent applications contain, and any future patents we may obtain may contain, claims that relate to specific recombinant DNA sequences that are naturally occurring at least in part and, therefore, could be the subject of future challenges made by third parties. In addition, the current USPTO subject matter eligibility guidance and the constantly evolving case law, together with contemplated congressional action, could all impact our ability to pursue similar patent claims in patent applications we may prosecute in the future.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure our stockholders that our efforts to seek patent protection for our Candidates will not be negatively impacted by the decisions described above, rulings in other cases or changes in guidance or procedures issued by the USPTO. We cannot fully predict what impact the U.S. Supreme Court&#8217;s decisions in Prometheus and Myriad may have on the ability of life science companies to obtain or enforce patents relating to their products in the future. These decisions, the guidance issued by the USPTO and rulings in other cases or changes in USPTO guidance or procedures could have a material adverse effect on our existing patent rights and our ability to protect and enforce our intellectual property in the future.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, although the U.S. Supreme Court has held in Myriad that isolated segments of naturally occurring DNA are not patent-eligible subject matter, certain third parties could allege that activities that we may undertake infringe other gene-related patent claims, and we may deem it necessary to defend ourselves against these claims by asserting non-infringement and/or invalidity positions, or paying to obtain a license to these claims. In any of the foregoing or in other situations involving third-party intellectual property rights, if we are unsuccessful in defending against claims of patent infringement, we could be forced to pay damages or be subjected to an injunction that would prevent us from utilizing the patented subject matter.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not obtain patent term extension for patents relating to our Candidates, our business may be materially harmed.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and specifics of any FDA marketing approval of our Candidates, one or more U.S. patents that we license or may own in the future may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (the "Hatch-Waxman Amendments"). The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process based on the first regulatory approval for a particular drug or biologic. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. In addition, to the extent we wish to pursue patent term extension based on a patent that we in-license from a third party, we would need the cooperation of that third party. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may be able to enter the market sooner.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition and our business may be adversely affected.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have registered trademarks with the USPTO for the marks &#8220;SOLID BIOSCIENCES&#8221;, and &#8220;SOLID BIOSCIENCES&#8221; logo and registered marks in foreign jurisdictions for &#8220;SOLID BIOSCIENCES&#8221;, &#8220;SOLID GT&#8221; and &#8220;SOLID BIOSCIENCES&#8221; logo. Once registered, our trademarks or trade names may be challenged, infringed, diluted, tarnished, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement, dilution or tarnishment claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights and regulatory exclusivity rights do not necessarily address all potential threats.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make gene therapy products that are similar to our Candidates but that are not covered by the claims of the patents that we license or may own in the future;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our current or future license partners or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent applications that we license or may own in the future;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our current and future license partners or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative products or duplicate any of our processes without infringing our owned or licensed intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may circumvent our regulatory exclusivities, such as by pursuing approval of a competitive product candidate via the traditional approval pathway based on their own clinical data, rather than relying on the abbreviated pathway provided for biosimilar applicants;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our pending licensed patent applications or those that we may own in the future will not lead to issued patents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we hold rights to now or in the future may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may have access to the same intellectual property rights licensed to us;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents or other intellectual property rights of others may have an adverse effect on our business; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may choose not to file a patent for certain trade secrets or know how, and a third party may subsequently file a patent covering such intellectual property.</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If approved, our Candidates that are licensed and regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009 ("BPCIA") was enacted as part of the Health Care Reform Law to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, a reference biological product is granted 12 years of regulatory exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reference product. In addition, the licensure of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still develop and receive approval of a competing biologic, so long as its BLA does not reply on the reference product, sponsor&#8217;s data or submit the application as a biosimilar application.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2022, Congress clarified through FDORA, that the FDA may approve multiple first interchangeable biosimilar biological products so long as the products are all approved on the same first day on which such a product is approved as interchangeable with the reference product and the exclusivity period may be shared amongst multiple first interchangeable products. More recently, in October 2023, the FDA issued its first interchangeable exclusivity determination under the BPCIA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that any of the Candidates we develop as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject Candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing. Nonetheless, the approval of a biosimilar to our Candidates would have a material adverse impact on our business due to increased competition and pricing pressure.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Ownership of our Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our executive officers, directors and principal stockholders maintain the ability to control or significantly influence all matters submitted to our stockholders for approval.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our executive officers and directors and principal stockholders, in the aggregate, beneficially own shares representing a significant percentage of our capital stock. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This concentration of voting power may:</span></p><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay, defer or prevent a change in control;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">entrench our management and our Board of Directors; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay or prevent a merger, consolidation, takeover or other business combination involving us on terms that other stockholders may desire.</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A significant number of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is performing well.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Our outstanding shares of common stock may be freely sold in the public market at any time to the extent permitted by Rules 144 and 701 under the Securities Act of 1933, as amended (the "Securities Act"), or to the extent such shares have already been registered under the Securities Act and are held by non-affiliates of ours. Moreover, holders of a substantial number of shares of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2020, in connection with the execution of our collaboration and license agreement with Ultragenyx, we issued and sold 521,719 shares of our common stock to Ultragenyx. For the ten-year period after date of such sale, subject to specified conditions, we have agreed to file a registration statement in order to register all or a portion of the shares sold to Ultragenyx.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, in connection with the execution of our collaboration, patent and know-how license agreement with Mayo Foundation for Medical Education and Research ("Mayo"), we issued 364,990 shares of our common stock to Mayo in a private placement. In February 2025, we made the first milestone payment of 975,496 shares of our common stock to FA212 following the FDA's clearance of our IND for SGT-212 for the treatment of FA. We have filed resale registration statements to register all of the shares issued to Mayo and FA212.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2019, December 2020 and January 2024, we completed private placements of shares of our common stock and pre&#8209;funded warrants to purchase shares of our common stock to several accredited investors. In December 2022, we also issued shares of our common stock in the Acquisition and in a related private placement to several accredited investors. We have filed registration statements covering the resale of these shares by the purchasers in these private placements, and the stock consideration issued in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acquisition, and have agreed to keep such registration statements effective until the date the shares covered by the respective registration statement have been sold or can be resold without restriction under Rule 144 of the Securities Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we have filed registration statements registering all shares of common stock that we may issue under our equity compensation plans. These shares can be freely sold in the public market upon issuance, subject to black-out periods and volume limitations applicable to affiliates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have on file with the SEC universal shelf registration statements which allow us to offer and sell registered common stock, preferred stock, debt securities, depositary shares, warrants and/or units from time to time pursuant to one or more offerings at prices and terms to be determined at the time of sale.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The price of our common stock has been, and in the future is likely to be, volatile and fluctuate substantially, which could result in substantial losses for holders of our common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stock price has been, and in the future is likely to be, volatile. The stock market in general and the market for biopharmaceutical or pharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, our stockholders may not be able to sell their shares of common stock at or above the price they paid for their shares. The market price for our common stock may be influenced by many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully implement our proposed business strategy;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results of or developments in preclinical studies and clinical trials of our Candidates or those of our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of competitive products or technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of public health emergencies or pandemics on both the healthcare system and the patient population;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory or legal developments in the United States, the European Union and other countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the recruitment or departure of key personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of expenses related to any of our Candidates, or our clinical development programs and our commercialization efforts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of our efforts to discover, develop, acquire or in-license additional Candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated changes in our development timelines;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to raise additional capital;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to obtain or delays in obtaining adequate product supply for any approved product or inability to do so at acceptable prices;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our Candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of health care payment systems;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, industry and market conditions; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the liquidity for our stock and daily share volumes transacted;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain our listing on the Nasdaq Global Select Market; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation often has been instituted against that company. We and certain of our executive officers and board members have previously been named as defendants in purported class action lawsuits. Any such litigation instituted against us could cause us to incur substantial costs to defend such claims and divert management&#8217;s attention and resources.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">An active trading market for our common stock may not be sustained.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although our common stock is listed on the Nasdaq Global Select Market, given the limited trading history of our common stock, there is a risk that an active trading market for our shares may not continue to develop or be sustained. If an active market for our common stock does not continue to develop or is not sustained, it may be difficult for our stockholders to sell shares without depressing the market price for the shares, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are a &#8220;smaller reporting company&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a smaller reporting company, and we will remain a smaller reporting company so long as the market value of our common stock held by non-affiliates is less than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100 million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter. Smaller reporting companies are able to provide simplified executive compensation disclosure and have certain other reduced disclosure obligations, including, among other things, being permitted to provide only two years of audited financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of reduced reporting burdens in our filings with the SEC. We cannot predict whether investors will find our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we incur significant legal, accounting and other expenses. Those expenses will increase if we do not remain a smaller reporting company. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 404 of the Sarbanes-Oxley Act ("Section 404"), we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain a smaller reporting company with less than $100 million in annual revenue, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in our certificate of incorporation and our bylaws and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our Board of Directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors. Among other things, these provisions:</span></p><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a classified Board of Directors such that not all members of our board are elected at one time;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allow the authorized number of our directors to be changed only by resolution of our Board of Directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limit the manner in which stockholders can remove directors from the board;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our Board of Directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limit who may call stockholder meetings;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authorize our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4961660705107365%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require the approval of the holders of at least two-thirds of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our certificate of incorporation or bylaws.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law ("DGCL") which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, is the only sole source of gain for an investment in our common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for an investor for the foreseeable future.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for such disputes with us or our directors, officers or employees.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, our certificate of incorporation or our bylaws or (iv) any action asserting a claim governed by the internal affairs doctrine. We do not intend to have this choice of forum provision apply to, and this choice of forum provision will not apply to, actions arising under the Securities Act or the Exchange Act. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_unregistered_sales_equity_securit"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Unregistered Sales of Equit</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">y Securities and Use of Proceeds.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We did not sell any securities during the three months ended June 30, 2025 that were not registered under the Securities Act of 1933, as amended (the "Securities Act"), and that have not otherwise been described in a Quarterly Report on Form 10-Q or in a Current Report on Form 8-K.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Other Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) None of our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> directors or officers </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f803b07-bebc-4c3f-86b4-f9ca688b392d" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_eb7ef3cb-7af6-4b0b-a350-712b07fdc236" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7225c11b-390e-4c31-b799-d859f72e3c34" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_6fa49657-f60c-4268-832d-a0ef4d25e08d" contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defin</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ed in Item 408(c) of Regulation S-K) during second quarter of 2025.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="tx567579_16"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. Ex</span><span id="item_6_exhibits"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hibits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:15.28%;box-sizing:content-box;"/>
     <td style="width:84.72%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1707502/000095017025086128/sldb-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Incorporation of Solid Biosciences Inc., as amended (incorporated herein by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-8 (File No. 333-288022) filed with the Securities and Exchange Commission on June 13, 2025).</span></a></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:5.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1707502/000095017025086128/sldb-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated 2020 Equity Incentive Plan, as amended (incorporated herein by reference to Exhibit 99.1 to the Registrant's Registration Statement on Form S-8 (File No. 333-288022) filed with the Securities and Exchange Commission on June 13, 2025).</span></a></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sldb-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sldb-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1**</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sldb-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2**</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sldb-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> * Filed herewith.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ** Furnished herewith.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">URES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:51.12%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:3.34%;box-sizing:content-box;"/>
     <td style="width:44.44%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Solid Biosciences Inc.</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: August 12, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Alexander Cumbo</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Alexander Cumbo</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: August 12, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Kevin Tan</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Kevin Tan</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>sldb-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and 15d-14(a), as adopted pursuant to Section 302 of Sarbanes-Oxley Act of 2002</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="mypage"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Alexander Cumbo, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Solid Biosciences Inc.; </font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">internal control over financial reporting</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (as defined in </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Act</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">internal control over financial reporting</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or caused such </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">internal control over financial reporting</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Alexander Cumbo</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alexander Cumbo</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: August 12, 2025</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>sldb-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and 15d-14(a), as adopted pursuant to Section 302 of Sarbanes-Oxley Act of 2002</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Kevin Tan, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Solid Biosciences Inc.; </font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">internal control over financial reporting</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (as defined in </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Act</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">internal control over financial reporting</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or caused such </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">internal control over financial reporting</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Kevin Tan</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kevin Tan</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: August 12, 2025</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>sldb-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Quarterly Report on Form 10-Q of Solid Biosciences Inc. (the &#x201c;Company&#x201d;) for the quarter ended June 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned, Alexander Cumbo, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.1%;box-sizing:content-box;"></td>
     <td style="width:2.34%;box-sizing:content-box;"></td>
     <td style="width:40.56%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: August 12, 2025</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Alexander Cumbo</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alexander Cumbo</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>sldb-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Quarterly Report on Form 10-Q of Solid Biosciences Inc. (the &#x201c;Company&#x201d;) for the quarter ended June 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned, Kevin Tan, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.1%;box-sizing:content-box;"></td>
     <td style="width:2.34%;box-sizing:content-box;"></td>
     <td style="width:40.56%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: August 12, 2025</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Kevin Tan</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kevin Tan</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img247595994_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img247595994_0.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"!*!$GX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/^#.0?\ EH)*YVZ_X*<_M@W&[R?'NA6.0H'V7P'X/?:5.25^VZ1><N/E;=N
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M'3<6NB6/J6))[YR:^<J*VCQ5Q/#X.(\^CLO=SC,(Z+9:8A;=#FGX>\ U/XG
M_"%35OW^&LEEJ]W[V">KLKOK8^H(OVU?VK87WI\>/B$6 (Q+JXG3!Z_NYX9(
MR?0E<CL16M!^W=^US;!!'\<O%C>6VY?/@T*Z).[=AS=:1,95SQLD+IM^3;MX
MKY)HKHAQKQE3_A\6\30_P9]FL?\ TG%KLON.&KX5>%]96K>&_ 55;6J\'\/5
M%;73WLN?=_>^Y]G0_P#!0K]L: ,$^->J,&()\[POX#N2,?W3<>%92HYY"D ]
M2"0*W+;_ (*4?MF0']Y\6K>\ *D"Y^'WPU PO5,VOA"V8A^C$L7[JZGFOA6B
MNNGXB>(%+^'QSQA!=H\2YRH]=X_7>5[O='FUO!+P9Q"?MO"7PSJ-_:EP)POS
M=-IK*U);):-:*VQ^A=K_ ,%0OVN[?;YOBWPM>X8L?M7@;P\FX$8"-]BM;3Y0
M>05VOGJQ'%=!:_\ !5O]JJWV^:?AM?8!!-UX/N$W$G(9OL6N68!4?*-H5<?>
M5F^:OS4HKNI^*WB32^'CGB=_]?,WQ=;_ -/5)]OZNSR:_P!'?P*Q%_:>$O 4
M;[^PX<R[#=]OJU&E;?I;IV1^JMG_ ,%>?VCH2!>>"?@Q>H,\KH'C2UF)+ X+
MIX^DAVA=R@"W!R0Q8X(;K++_ (+#_%>/;_:/PC^'EU@_-]BU+Q)89&_.%\^[
MU+:=GRY.[Y_GQC]W7X_45Z='QK\4Z%N3C3-)6_Y_0P6(V[_6,+5O\[WZGA8G
MZ*OT>L7?VOA;P_"__0-5S7!?=]3S&A;Y6/VNLO\ @LIKL>W^T?@!I-UC;N^Q
M?$:\L,@$[MOG^#-2VY&T*3NVD$D," O667_!930I-O\ :/P!U:TSMW?8OB-9
MZAMX.[;Y_@S3-V&VA<[-P))VD!6_"6BO4H_2"\7*-E_K7[6*^S6R3AZ=_67]
ME*I_Y/\ B?/XGZ&/T;L3=_\ $._J\W]O#<5<:4K>E/\ UAE17_@H_H'LO^"P
M_P )Y-O]H_"3XAVN1\WV+4?#=_@[,_+Y]YINX;_ER=GR?/C/[NNST[_@KI^S
M9=;5OO"7QBTM_P")Y?#OA*ZMQP3\LEIXYEG;H <VJ\LN,C<5_G%HKU:'TD_%
M.DTZF8Y5B;;JODV#BGZ_5HX=_<T?/8OZ"OT>\0FJ.2<0X"][/"<49G-Q]/KT
ML8M/[REYW/Z>-._X*C?LCWNW[3XF\7:/N."=1\$:W+LYQEO[)CU0D8Y^0,<'
MIG(KO=-_X*'_ +'&J;1!\:+"W=L IJ7A/Q]I>QB%RK2:AX5MH>-P!=96C)#;
M7(5B/Y2J*]K#_2G\0Z5E6RSA/%+JYY?F=*;])4<YA!/_ +AM>1\IC/V>W@KB
M+O"Y]XBX"7V52SG(*])>L<3PO5JR2\J\7YG]>6G?MD?LKZIM^S?'OX9Q;NG]
MH^)K+1\<$_-_:S6.W[I^]CG ZLH/?:=\>O@9K&W^R?C1\)]4WG"_V=\1?!]]
MN.<87[-K$N3GCC//%?QGT5[F'^EEQ'&WUKA/)*W?ZOC,?AK^GM'B[?.Y\IC?
MV<O ]2_]G>(W%>%_E^NY9E&/MZ^P66\WRY3^V[3/$GAW6MO]C:]HNK;AE?[,
MU2QO]PVA\K]EGER-A#9'&TANA!K:K^'@$J0RDA@0002""#D$$<@@\@CD&NRT
MGXC?$+0-O]A>//&>B[-H3^R?%&MZ;L"?="_8[Z';M_AQC;VQ7O87Z6U-V6-X
M%G'O4PO$,9W]*57)J=OG6?\ G\AC_P!F[65Y97XN4I_RT<?P5*E;UQ&'XGK7
MOY856MUOI_:K17\?&D_M7_M-:)M_L_X^?%O8ARD5]X\\1:K G&-JV^JW][ J
M=3L$83<2VW<<UZ=I/_!0K]L31MHMOC3JERBA04U;PUX(UK>J]FEU7PS=SY/\
M3K*LA_OYYKZ/"_2NX.G;Z[PYQ+AWU^K+*\8E\ZN/P3:^2?D?#YA^SJ\3J7-_
M9?'' F-M\/U^7$&6N7JL/D^:I-KS:OI>VI_5S17\RFD_\%4/VL=.V_;-4\":
M_M//]K>"[:'?QC#?V%>:+@=_DV')ZXP*].TG_@L!\=(-@USX;?"C4PH 8Z;;
M^+M'D<#J2UQXGUJ-78=2L03<250+A!]'A?I->&&(M[6MGN!OO]:RASMZ_4L1
MC/PN?#YA] OQ]P?-]6PW".;6V_L_B2-/F_P_VK@LLWW][E\[/0_H=HK\.M$_
MX+)ME(_$?P!!''F7>B?$4@CUV:??>#CGU&[4QZ'UKU[1/^"OWP(NMBZ_\._B
MKHSM@%].M?"FMV\9/4O)+XFT>XV#GYH[21SQ^[Y)'T^#\=O"C&V5+B_"TI/1
MQQF!S; \K[.>+P%&GZM3<?,^!S/Z(GTBLIYG7\-,QQ,(WM/+,VX<S;G2ZQIY
M=G&)KZ](RI1G_=/UGHK\]]$_X*?_ +(>K;/MWC'Q-X:+8R-;\#>))]F?[Y\.
MV>OKQW*%Q[XYKU_1/VW_ -DWQ!Y?V#XZ^!H/,QM_MN[O/#6,]/,_X2.RTKRO
M?S=FWOBOJ\'XA\!9A98/C/A>O*5K4XY[EL:VNUZ,\3&JK^<%KIN?G>9^"OC!
MDW,\S\+O$#"4XWYJ\^$<]EAM-[8JE@9X>5NO+59]4T5YKHGQG^#WB4H/#GQ7
M^&NOF3!C&B^.O"^JE\]-HL=4G+9R.@->C12Q3QI-!+'-%(-T<L3K)&ZGHR.A
M*L/=217U&&QN#QD.?!XO#8J'\^&KTJ\/_ J4YKJNO4_/\=EF9994]EF67X[+
MZMVO98["8C"5+K=<F(ITY7756)****Z3A"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*XX_#4))WTLU<VJ***]4^>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8_!OPX^(OBJ:/(675WT#PII\Y!.&BGCU#Q%?B,C'S3Z5#("2/*X!;Y@\6_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2*_A\KO/!OQ2^)?P[F6?P%\0/&G@V17\PCPSXFUG1(I&)RPF@T^\MX;A'/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.+J/<L=WK=SIG@O1IFY"R0S ^(]7>,<,5N-&LI#]P!<[Q_/317XSGOTH./\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<>)_8U\[PF1\#8&IRSE/B#,X8G,72E]JEEF21S*<:R_Z!\PKY=-6?.X.R?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"Q:7EW87,%[8W5Q97EK(LUM=VD\MM<V\R'
M*2P3PLDL4B'E7C=64\@BOL+X9?M^?M4?"[[/;Z?\3=0\6:1;[1_8OQ"B3QC:
MR1IC9#_:>I-_PDMK B_NTAT_7;.-8\(% 2/9\:T5[&3\09[P_7^LY%G&9Y17
MNG*IEV-Q&$<[=*JH5(1JP>SA44X25U*+3:/F>)N"^$>-,']0XNX9R'B7!\LH
MPH9WE6"S*-+FWEAY8JC5GAZB?O1JT)4ZL))2A.,DFOW8^&7_  6%TB?[/9_&
M'X3WNG/\BW&O_#O4HM1MV9N&<>&?$,UE<6T,9^9BOB?49BA(2%G0+)^AOPR_
M;1_9E^+/V>#PM\6?#5KJUSL1- \53R>#];:X?_EUM[/Q''IR:G<#N-'FU&,@
M$I(P5B/Y&J*_<>'/I,^(63^SI9NLMXFPT;1D\=AE@L=R+90QF7JA3YK:.IB<
M'BIRWDW*[?\ )G&_T#/!;B7VV(X;>>\!XZ?-*"RG'RS3*/:RU<JV69T\77Y+
MZQHX',\OI0^&"C!**_N'5E=5=&5T90RLI#*RL,JRL,@J00002"#D<4M?QR?#
M3]I#XZ_!YH!\.?BEXN\.65NRM'HJ:F^I>&R5/!D\,ZPNH>'Y3C*[I--9@I*@
M@$U^C/PM_P""O7Q&T?[-8_%WX>>'_&EHNV.77/"ES-X4UT)U>YN=/N%U71-1
MGZ@06D?AZ C'SJ5)?][X;^D_P+FOLZ6?83,^&<1*RE4JTWFN71D[*RQ6!IK&
M/7>53+*<$O>E-*]OX[XZ^@%XN</*MB>$,QR'CW!0YG3H8>NN'L\G&.KE++\V
MK/+%[NT*.>UZLI)QC2;<>;^@*BOAWX6_\%$_V6/BA]FMO^$\_P"%?ZS<;!_8
M_P 2;5?#.QVPN#K_ )][X2/SG8B_V^LS\-Y*@\?:UAJ%AJMG;ZCI=]9ZEI]Y
M&LUI?V%S#>6=U"WW9;>ZMWD@GC;!VR1.RG'!K]YR3B3A_B2A]9R#.LLS>C92
ME++\90Q,J5[>[7ITYRJT)JZ3IUH4YQ;M**9_'_%7 O&? V,^H<8\+9]PUBG*
M4:=/.<LQ>!AB.7>6$K5Z4:&+I63<:V%J5J4EK&;6I<HHHKVSY0**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO&/BC^T/\$O
M@Q#))\3/B7X6\+W,<8E&C3WXO_$D\97<'M?#&E)?>(+I""O[R#39(P73<XWK
MG\T?BO\ \%?/!>E_:=/^#7PYU;Q5=+OCB\1>-KE?#VBAQG;<6VAZ<]]K&I6S
M\8CO+WPY<C+%D7 #?#<3^)? W!ZG'/N),NPN)IIWR^C4>.S*_1/+\%'$8JGS
M/2,ZM*G2O=RJ12DU^M\!>!/BWXF.E/@_@?.LPP%9KESG$T(Y5D2C]J2SG-)X
M/+JSA'WI4L/B*U=JRA1G*4(R_96O%OBA^T7\#_@S%(WQ*^)OA7PS=QQ^;_8T
MVH#4/$DL>-P>W\,:2E_X@N$/ \R'37C!907!9<_S3?%7]O7]J+XM?:;;5?B1
M?^%-$N-X/A[X>H?!^GK%)D26\M]I\K>([^VD7Y'M]5UR_A9 5*89]WQ[+++/
M+)//))---(\LTTKM)+++(Q>2221R7>1V)9W8EF8DL2237\[\3?2NP=+VE#A#
MANMBI*ZAF&?U5AZ*:T4HY;@:E2M6IR>L7/,,)444N:FFVH_VQP%^SKS2O['%
M>)?'.&R^F^657)N#L/+&XIQE9N$\\S:C0PV&K07NR5+)LQHN3;A6E&*<_P!]
M_BG_ ,%?/ 6DFYL/A!\.-<\7W2[XHM>\8W<7AC15<9VW-MI5E_:FLZE;,,#R
M;N7P[<<DG;M ?\W/BE_P4)_:G^*?VFVG^(4O@;1KC>#HGPWMV\*0HC\-'_;4
M,]SXKFC=/D>&Y\030.NX&+YWW?$]%?SUQ+XS^(_%/M*>.XDQ>"PE2Z^H9,UE
M.%4);TIO!\F)Q--]8XS$XGULDE_:? GT7/ [P^]A6RG@7+<TS*CRR6<<4)\1
MY@ZL;<N(I+,E6P&!KJVD\LP."L[M)-MNS>7EYJ-U/?:A=7-]>W4K375Y>3RW
M-U<S.<O-/<3.\LTKGEI)'9V/))-5J**_+FW)N4FY2DVY2;;;;=VVWJVWJV]6
MS^@(QC",80C&$(1480BE&,8Q5HQC%)*,8I)))))*R5@HHHI%!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7I/P]^,?Q5^$]Y]N^&_Q!\6>#93
M()9H=#UJ]M-.O'&,#4=)$K:7J:< ^5J%G<Q$A24RH(\VHKHPN,Q>!KT\5@<5
MB,'BJ3YJ6)PM>KAZ]*7\U.M1E"I!^<9)G%F.6Y=F^#K9?FV P6:8#$QY,1@<
MQPM#&X.O#^2MAL33JT:L?[LX27D?J]\+?^"MGQM\,?9K+XG^%O"WQ.TZ/8LV
MHVJ_\(5XHD'"O(]UI=M>>')=J_.L,?AFS:1]RM=(KAH_T@^%O_!37]E_XB?9
MK37-?U?X7:U-LC-EX[TTPZ6TY W^3XDT>35-&BM5).VYUF?16=1DP1M\M?S
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MQU-6?[W!XBO3=I)3;3MI4445[Y\:%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB?(>&35[>>?Q3>0R)B.6"]U^XMI$W P 22!OBRBOYPXH\:/$;BSVE/'<0XG
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBW_\)!\/? ^N^;_K/[9\)Z!J?F=/O_;=/GW]!][/05Y5K/[(/[+NN^8;_P"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?LX<%CLXXBX9E.RMGO#>-JJ$G:T9SX?EGU..KLY.?(M7*2CJ?A'17ZB>*_\
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MQV'ET5;"XNG2K4[[Q<H)26L6UJ%%%%=IY84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=R(O<BO[+:*_,LW^BIP?BN:639]GV4SE>T,2L'FN&AV4*?LL#B&EU4\9-O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=>=,GP\F\%:A/NSJ'@/7-2T+R]W(\G1[B74?#,6TDE=FA#^ZVY JCXH\?_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KVWX-_M%_&3X!ZI_:
M7PP\;ZKH,$LZSZAH$CKJ/A?5R-JM_:GAZ^$^F7$KQ*85OD@BU*WC9OL=[;/A
MQXE179E^8X_*L71Q^68W%Y=CL/+GH8O!8BKA<32EWIUJ,X5(W6CM))IM.Z;1
MYF<Y)D_$66XG)\_RK+LZRG&P]GB\MS7!X?'X'$PWY:V%Q5.K1J)/6/-!N,DI
M1:DDS^A/X _\%8/AYXN^Q:!\=M";X<:])Y<!\6:''>:OX'O)FPIEN[/_ $K7
M_#8DD941&&OV4:AY[S5;.(87]7/#_B+P_P"+-'L?$'A?6])\1Z%J<(GT_6=#
MU"TU72[V$DCS+6^L99[:= 05)CD;:P*MA@0/XD*]E^#W[0/Q?^ VL?VO\+_&
MVK>'/-F274-'$BWWAS6=@"[=7\/7RSZ5?.8@88[J2V%_:HS&RN[:0B0?T]P+
M])_/,K]C@>-\%_;^"CRP_M7 QHX;.:,%9<U:A^ZP.8<L59+_ &&O)MSJXBM/
M1_P'XN?0"X2S_P"LYOX49I_J=FLN>K_J[FU3$X_AC$U'=\F&Q?\ M&;9-SR;
ME)O^UL+%*%*A@\+37,O[(Z*_(;]G_P#X*P> /%GV'P_\>=#_ .%=Z[)Y<'_"
M7Z%'>ZKX(O)CA?-O;#-WKWAOS'944?\ $_L4 >XN]2L81M7]8/#_ (C\/^+-
M'L?$/A;6])\1Z#J<(GT_6=#U"TU72[V$DCS+6^LI9[:=0P*L8Y&VL&5L,"!_
M8/"?'7"G&V$^M\-YSA<PY8*5?"*3HYAA+V5L5@*RABJ*4GR*K*FZ%22?L:M2
M/O/_ #.\1?"/Q$\*<Q_L[CKAC,,F]I4E3P>8N"Q639CRIROEV;X5U<!BI."5
M25"%=8JA&26)P]"=X+9HHHKZT_-PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGHT]4S^@HRC.,9PDI1DE*,HM2C*,E=2BU=------IIW04444AA1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ***^ /VD?\ @HG\$_@1]O\ #^A72?%+XB6W
MFP'PWX8OH?[&TB[3*F/Q-XH1+JQL7BD5XY].TV+5M7AF3R;RRL5<3KX7$/$V
M0\*9?/-.(<UPF58*%TJN)J6G6FE?V6%H04\1BZ[6L:&&I5:LE=J#2;/KN"^
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M&495@:2H8++<LPE# X'"T8[4\/A<-"G1I0NV^6$(IMMN[;84445RGHA1110
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M0\;<.Y;Q#EE3F<*6.HWKX2I./*\1EV-I.GC<MQ7+[JQ6 Q&'Q"C>/M.5M/\
MKO\ @#^UQ\$?VC;*/_A O%$=MXF6W,]_X$\1>3I/B^P")OG9-.:>6'5[2!<-
M+J.A76IV,(9%N)X)B85^F:_B"L+^_P!*O;74M+O;O3=1L9XKJQO["YFL[VSN
MH'$D-S:W5N\<]O/"ZAXIH9$DC<!D8$ U^K?[-_\ P50^(?@/[!X8^.ME=?$W
MPK%Y5NGBNT:"#X@:5 ,+YEV\S0:=XM2)% QJ$FFZQ*S23W.N7KA8&_L?P_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?_+RI6PJA3Q<ULOKU+%12^SHK?NOAW])/QF\,?84.'>-,PQ.4T.6,>'\_?\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ZWP3X\\9_#;Q#9>+/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J6
MHZEIVCV%YJNKW]EI>F:?;RW=_J6HW4%C86-I ADFN;R\N9(K>VMX4!>6::1(
MXT!9V !-?&/[2W[>7P7_ &<TO=$EOAX]^),*ND7@/PU>0/+I]R 2@\5ZT%N+
M+PW&#M,EM)'>ZX4DBEAT:6W<SI_/I^T-^U_\:?VDK^5?&OB!M-\(QW'G:9X
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M!RRC@\')QA.K1JUDZLBBBBOST_:0HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M***],\ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML.^:#G[*?ML/*:HXNCA\0I4HOHHHKZ@_/PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#EV78:MC,;B\1/X*.'PV'A4K5JCLWRP@VDG)V2;7K)( ))P!R2>@'J:_+_\
M:J_X*6_#WX0?VCX,^$0TSXF_$>'SK6YU&*X:?P+X5NTW(ZZAJ%G*C^(M2MW
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% ']L/@FX^U^#/"-UG/VGPQH-QGU\[2K23/X[JZ>N/^'D1M_ '@: YS#X/
M\,Q'/7,>BV2'/O\ +S785_L=@6Y8+!N7Q/"X=R]72@W^)_S#9K&,<TS*,/@C
MC\9&'^%8BHH_@D%%%%=1P!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7Q]^WW(8_V0/C>P."?#VD1Y]I?%GA^)A^*N0?8U]@U\;_\% PQ
M_8\^-H7K_8OA\G_='C3PT6_\=!KY/CYM<"\:-;KA/B-KU63XP_1O!U*7BYX6
M1>TO$;@A.^UGQ-EB=S^3^BBBO\DS_I""BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K[L_9<_;Y^+?[.4ECX=O9I?B#\+8W2.7P7K=[(+K1;8L/,?P=K4BSSZ*R??
M&ES1W>A2DS;=/M;NX;4(_A.BO:X?XCSSA;,J.;\/YEB<KS"AI&OAIV52#:<J
M.(HR4J.)P\W%>TP^(IU:,[+F@[*WRO&7!'"?B#D6)X;XRR+ 9_DV*5YX7'4N
M:5&JHRC#%8+$TW#%8#&TE*7L<9@JU#%4N:2IU8J4D_[$?@1^TA\)OVC/#G]O
M_#7Q'%>7-M%$VN>%]1\NQ\5>')9< 1:QHYED=(6DW1P:E9R7FD7CI(MG?SM%
M*J>[U_%!X,\;^+OAUXCT[Q=X&\1:MX6\2Z3+YMAK&C7<EI=PYQYD+E#LN;2X
M4>5=V-TDUG>0,]O=030.\;?O!^RK_P %1O#/C/\ LWP1^T/]@\&>*7\JTLOB
M':QBU\&ZW*=L:'Q#;@L/"E_,VUI;Y"_AN21III6\/VZ16[_W)X9?2,R7B7ZO
MD_&/U;A_/)<E*EF',Z>29C4=DKU*DI/+,1-_\NL3.6%FU^[Q4)SAAU_DMX]?
M0@XJX%^N\3>&/U[C/A*G[3$8C)N15N*\CHJ\I6H4*<8Y_@J2_P"7^!HT\PI0
M:5;+ZE*C6QTOU_HJ&WN+>\MX+NTGANK6ZACN+:YMY4GM[BWF19(9X)HF:.6&
M6-EDCEC9DD1E96*D&IJ_IE--)IIII--.Z:>J::T::V9_!;3BW&2<91;4HM--
M-.S33U33T:>J84444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIC<33^LR****_-C]T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KY&_;QA-Q^R)\<8P-Q7PM:38QGBV\0Z-<$_\!$18
MGL!GM7US7SC^U]8?VE^RY\?;?;N\OX5^,;_&,_\ (*T>YU3=_P !^Q[L]L9[
M5\UQG2=?@_BN@E=UN&L]I)+5MU,KQ4$DO5GW?A=B8X/Q-\.L7+X<+QWPCB9=
M/=H<09?5>OI$_D%HHHK_ ",/^DT**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ^XOV6?V[OBO\ LV7%IH,DTGCOX7&8?:O VLWDBOI44C[IKCP?JSK<
M2Z#<;F>5K Q7.B73O,\VG1WDPU"'^C#X$?M'_"?]HSPT/$/PV\11WEQ;1Q-K
MGAC41'9>*O#<THP(=9TCS972)GW1P:E9RWFD7KI(MEJ%PT4H3^.VNL\$>.O&
M/PV\2Z=XP\!^(]5\*^)=)D\RQU?1[I[:YC!QYL$H&Z&[LKE1Y5Y87D4]E>P%
MH+NWFA=HS^[^&/CQQ)P(\/E>9.KQ!PQ!QIK 5ZO^W9;2NDY95BZE^6$%JL!B
M'+"RY>2C+!RG.L?R%X]_1!X'\7HXSB#(EA^#./JBG5>;X3#K^R<\KV<E'B++
MJ*CSUJLKQEG&#4,P@Y^UQ4,SA2I89?VN45^2/[)__!3SPG\0CIO@7X^MIO@7
MQI)Y5G8>.(B+/P3XDG.(T_M;S&*>$=4G)!>2>1O#MQ*)72ZT??:Z:WZV(Z2H
MDD;K)'(JO'(C!T=' 9'1E)5E92&5E)# @@D&O[WX2XTX<XXRR.:\.9C2QM#W
M8XB@_P!WC<#6DF_J^.PDG[7#U5:7*Y)TJRBZF'JUJ3C4?^.WB1X6<<>$V?U.
M'N.,DKY5BW[2>"Q<;U\JS?#0DH_7,IS&"]AC<.^:'.HN.(PTIJCC*&&Q"E1B
MZBBBOJC\]"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX>A!?]?)9HH6_O'[_4445_J<?\]P4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M445XQ]0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **I:C
MJ6GZ/87NJZM?V>EZ7IMK/>ZAJ6HW,-E86%G;1M-<W=Y=W+QV]M;6\2-+-/-(
MD44:L[LJ@D?A3^V/_P %-KS6O[5^&G[-NH7.FZ03-8:[\5HUDM=4U->8I[7P
M/'(J3Z58D;D;Q+,D>J7))?1HM.CB@U.]^'XZ\0N&O#W*WF.?8NU:K&:R_*\.
MX5,QS*K!:PPU!RC:G%N*K8FM*GAJ'-%5*BG.G"?ZSX1>"W'/C3Q!'(^#\N<L
M-0E2EG.?XQ5*.29%AJDFE6Q^+C"?-6G&,WAL!AHUL=BW";HT'2I5ZM+[0_:_
M_P""@G@3]GJ+4/!?@G^S_'GQ?$<D+Z3'.9?#W@V9EPD_BV[M95>6^C)$D?AF
MQFCU"15SJ-SH\4MK+=?SC_$KXG>._B]XMU'QQ\1?$FH>)_$FIM^]O;Z0>5:V
MZL[0Z?IEG$([/2],M=[BUTZP@M[2 ,YCB#N[-PTLLL\LD\\DDTTTCRS32NTD
MLLLC%Y)))')>221R6=V)9F)9B22:CK_.WQ'\5N)?$C'<V8U?J.34*KGE^0X6
MI/ZGAMXQK8B3498[&\C:EBJT4H<U2.%HX:E4E3?^V?@=]';@3P-RGV>2X=9M
MQ1C*$:6=<7YA0IK,\;?EE4PN"IIU(Y3E7M(J4,OPU24JG)2GC\3CJ]*%=%%%
M%?F)^^!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445E:YKN
MC>&='U+Q!XBU73]#T/1[2:_U75]5NX+'3M/LK=2\US>7=R\<$$,:C+/(ZC.
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MK!9WDF:4'A\=EN/HQK8>O3;4HNSM*G6I34:N'Q%&5/$8:M"G7H5:=:G"<?[
MOV=?VF_AC^TOX27Q%X#U/R=6L8H%\3^#=2DAC\1^%[R4$".]MD8BZTZ=U?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% #D1Y'2.-&DDD941$4L[NQ"JB*H+,S,0%4 DD@ $FOZN_V%OV=Q^SO\"M
M$TC5[-8/'OC(Q>+_ !X[H!<6NIW]M&-/\/.Q!94\-Z9Y-A-"'>#^UVUB[MR$
MO37XX?\ !,[]FL_%_P"+@^)?B6P\[P!\)+NRU0+<1;K77?')(N?#NE . D\.
MD%!XAU-5,@1K?2+.ZA:WU;-?TM5_:_T7_#YX?#XOQ!S.@U5Q<:V6\/1J1LXX
M6,^3,<Q@FMZ]6'U'#U%:2IT<:M:=>+?^5/T_?&>.-QV7>#&0XOFP^6SPV>\:
MSHS]VIF$Z2JY)DE1Q:NL'AZO]KXRE+GIRK8K*I)QKX.I%%%%%?V"?YFA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% 'Y@_\%0/V='^*?PC@^*OANP\_QG\(H;N^OT@BW76K> +@
MB;7[8[ &E?P]+&GB*V\QBEO8Q:^L*-/>J#_-K7]P<\$-S#-;7,,5Q;W$4D$\
M$\:2PSPRH8Y89HI R212(S))&ZLCHQ5@02*_DZ_;:_9SN/V</C=K6@:?:RIX
M#\4F?Q3\/KHAVB71+RX?[3H)F;<&NO#-\9-+='D>XDL%TO49PG]HQBOXD^D_
MX?/#8S"^(&6T/W&.='+N(8TXZ4L9""IY?F$[7M'%48+!5IOEA&MA\(O>JXIL
M_P!7/H!>,ZQ^69AX,Y[BE]<RF.*SS@N=:?O5\KJU76SK):3DTI3P&+JRS7"T
MH\]6IAL9F+M##Y?%+Y!HHHK^0C_2P**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5D:_K^B>%=%U/Q'XDU;3]
M"T'1;.;4-6UC5;J&RT_3[*W4O-<W5U.R10Q(HZLPW,510795/*?%'XI^!/@U
MX,U7Q[\1-?M?#_AS2D^>><[[J^NW5VMM+TFR3-QJ>JWI1DM+&U1YI-LDK".W
MAFFC_F5_:\_;9\>?M/ZU)I-O]K\)?";2[PRZ!X)AN!YNHR0L1!KGBZ>!O*U/
M6&'SVUFK/I>B*WD6 GN3=ZI?_E'BAXM9#X;9?:NX9CQ#BJ3EEF1TJBC4FG>,
M<7CYQ4GA,!&2:YY1=7$SC*EAH3<*U2A_1?@!]'#B_P =<YYL)&IDG!>7XB%/
M/>+,10E.A3:Y9SRW**4G".99O.G*,G1A-8? TYTZ^/JTE4PU'%>X?ML_\%#]
M<^,[ZK\,?@[=:AX;^%&Z6RUC70)K#Q!\0H@625)5/EW.C^%)P,1Z21'J&K0'
M?K?DPSOHUO\ EG117^<?%G%V?<:YQ7SOB#&SQ>+K7C2IJ\,+@L.I-T\)@</S
M..'PU*[Y8)N<Y.5:M.K7J5*L_P#<'PY\->#_  JX9PG"G!F54\MRW#I5,16E
MRU<PS7&N$8ULRS;&<L:F-QU?E7-4DHTZ-.,,-A:6'PE&CAZ91117S1]X%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %=3X)\&>(OB)XN\.>!O"6GR:IXD\5:O9:+H]
MC'D>;>7LRQ(\TF"MO:6ZEKF]NY,0V=I#/=3LD,,CKRU?OW_P2T_97/A;0&_:
M-\;:;L\0>*K*>P^&MG=PXETGPK< Q7_B<1RKNAO/$VUK32Y55'7PZDUQ#+-:
M>(=J??>&W N-\0N*\#D.&52G@TUB\XQL%=8'*Z,X?6:R;3C[:JY0PV$C)-2Q
M-:ESI4U4E'\=\=?%S*O!;P[S?B_&^QKYFXO+N&<KJ2L\VX@Q5.I]2P[BI1G]
M5PZA4QV8SBU*G@,+B/9MUY4:<_TC_9Z^"?A[]GSX3>%?ACX>\N<:/:?:==U8
M1"*7Q!XFO@DVN:W.#EQ]KN@8K*&5Y'LM+M[#3UD>.SC->U445_J=EV7X/*L!
M@\LR^A#"X'+\-0P>#P]-6A1P^'IQI4:<;W;4812NVY2=Y2;DVW_SV9UG.9\0
MYOF>?9UC*V89OG&.Q699ECJ\N:MBL;C:T\1B:\VDHIU*M24E&*C"":A",814
M44445V'F!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M99%FM%5\OS3"5<)B8:*2A47NU:4FGR5Z%10KX>HDW2KTZ=2/O11])PAQ7G/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '3^#?&?BKX>^)M(\8^"M=U'PUXGT
M*Z6\TK6-+G,%U;3*"KJ<AHKBVN(F>WO+*YCFL[VUEFM+R">VFEB?^D7]B_\
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M  4@M_%!TCX2?M#:O!9>)6\C3O"OQ-OGCMK#Q WRQ6VE>,9CL@L-<8[8[7Q
M_EV6KDK'JAM=4 O-7_9BO]'^"^-^'^/<FI9SP_BU6I/EAB\)5Y88[+L2X\TL
M+CJ"E)TJBU<)Q<Z->"]KAZM6FU(_PX\4O"CC/P?XGK\+\99<\-77/5RW,J'/
M5RG/,#&?+#,,IQDH05>A*\55I3C3Q6$J/V&,H4*Z=,****^N/S8**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS7(ZU2,L3A).T77P\K1>+P$YM*GBH07*Y1IXBG1K24'_ (:^/'T?>,/ K/\
MZIFT)9KPOF%:HN'N+,+0G# YC"/--83&0O4679Q2I)RKX"K4DIQC.O@JV*PT
M958]/1117Z:?@@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHJO>7EII]I=7]_=6]C8V5O-=WM[>3Q6UI:6EM&TUQ=75S,R0V]O!"CRS32ND
M<4:,[LJJ2$VHIRDU&,4W*3:222NVV]$DM6WHD5&,IRC"$93G*2C&,4Y2E*3M
M&,8J[<FVDDDVV[+4G)"@LQ"JH)9B0  !DDD\  <DG@"OP^_;H_X*-;3K/P<_
M9WUOYAY^F>,?BGI<_P!TC=#>:)X%O(6Y/WH;WQ7 ^!^\C\/N3Y>KCRW]NO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 445\O_M=_M%Z7^S3\'-;\;.;>Y\6:D6\
M/^ ='G(<:CXHO8)6M[FXA!#/I>B0)+J^J',:2P6J:>LT5UJ%IO\ -SC-\OR'
M*L?G.:XB.%R_+,+5Q>+KRUY*5&+DU&.]2K-VIT:4;SJU9PI04ISBG[O#/#><
M<8<0Y/POP_@YX_.L^S##99EV%AI[3$XFHJ<95)V<:5"DG*MB<1.U+#X>G5KU
M91ITYR7YV?\ !43]KEK""?\ 9I^'FJE;R\AAG^+.K6$Y5[>RG1+BQ\"QS1MD
M27\3Q:CXE5"H%BUAI#O*E[K%I'^%5:>M:SJOB+6-5U_7+^YU76M;U&]U;5]3
MO9#-=ZAJ6HW$EW>WMS*W,D]S<RR32N?O.[' Z5F5_EAXA<<9EX@<3X[B#'N=
M.E.7U?+,"Y\U/+LLI2E]6PL/LN=I2K8FI%)5L55K54HQE&$?^A3P6\)LC\&>
M LIX-R=4Z^)I06,S_-E34*V=Y[B*<%CLPJ77-&C>$,-@*$G)X;+\/AJ$I5*D
M)U:A1117Q!^KA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC0A>>/RJ'NTZ.:QA%U<QR>%KI3QV6QE@UB,-EWR31117\^']H!1110 4444
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M$EBE19(W5U!']#O["?\ P4&L?BU'I7PC^-&HVFF?%"-(K'PUXJG,5GIOQ"V
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU**AG5"2Y:D6%%%%?QJ?Z@A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110![[^S+\=-9_9U
M^,?A3XE:9Y]QIUG<?V9XMTB!]O\ ;OA'4GBCUO3=K,L;7"1)'J.F&4^5#K%A
MIUQ(&2%E;^O;0=<TGQ-HFC^)-!OH-3T37]+L-9T?4;9MUO?Z9J=K%>V%Y Q
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 445XQ\=_CQ\/_ -G?P%?^/OB!J7D6T6^V
MT71;5HWUOQ/K+1L]MHVB6CNGGW,NW?<3N4M-/M5DO;Z:&VB=ZX\PS#!95@L5
MF698JA@L!@J,\1BL7B:D:5"A1IJ\ZE2<FDDEHEJY2:C%.32?IY-DV:\0YKE^
M1Y'E^*S7-\UQ5+!9=EV"HRKXK%XJO)0I4:-*";E*3=VW:,(J4YRC",I*Y\:_
MC;\/_@#X$U+X@?$35ET_2[,&#3["#RY=8\0ZL\;O::)H5B\D9O=1N_+8@%X[
M:TMTFOK^XM;"VN+F+^6C]IW]J'X@?M/^.)/$GBJ9M,\-Z9)<0>#?!-I<22:1
MX9TV5QDY*QC4-:O4CB?5]:FA2:\E1(8(K/3K:RL+7+_:._:0^('[2_CRX\8^
M-+HVVG6AGM?"?A*SGE?1?">D22!A9V2.$^TW]R$BDU?6)HDN]4N(T++;V5O8
MV-G\^U_G=XR>-..\0,54R;)IU\#PAA:UZ=%\U+$9U5I2O#&YA&Z<:$9)3P>!
ME[M-\N(Q"EB53CAO]L?HP?19RGP:R^AQ1Q13PN;>)>886U;$KDKX/A7#XB%J
MN5Y/-IQGC)PDZ69YM#WJZ<\'@I0P+K5,<4445^"']B!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>[
M? ']G3XF_M'^,(_"?P\T@RPV[02>(?$]^);?PWX6L)G91>:Q?I')B20)+]BT
MVU2?4]1>*46=K(D-Q+#[E^R%^PWX^_:;U.#7]1^V>#?A%97935?&,UN!=ZVU
MO)MN=(\&VUPACU"^WJUO=:K*CZ1H[B0W!O;V%-)N?Z6_A9\*/ /P7\':;X$^
M''AZS\.^'M.7=Y4"^9>:C>NB)<:KK%_)NNM4U6[\M#<7UW))*52*"/RK:"""
M+^AO"/P)S/CF6'SWB!8C*>$U*-2D[.EC\\2=^3 *<7['!2M:IF$XM37[O!PJ
MR=2MA_XK^DE]+S(/"6GC>$>"Y8/B3Q%<)T:\>95\FX3G)6]KF\J4U];S2-[T
M<EI5(RI27M<SJ8>"HX;&^/?LP_LD_#+]E_PU]A\+VHUKQEJ=M%'XI\?ZI;1+
MK>M."DDEG9H&E71- 2=5>VT:SE=3Y<$VHW.I7T?VQOJ:BBO[_P GR;*^'\NP
MN49-@</EV78.FJ>'PF&@H4X+>4I/6=2K4E>=:M5E.M6J2E4JSG4E*3_QIXFX
MGX@XRSS'\2<49MC<[SS,ZSKXW,<?5=6O5E91A"*2C3H8>C!1I8;"T(4L-A:$
M(4,/2I480A$HHHKTSP0KYK_:-_94^$_[3/A[^S?'&D_8O$=C;R1>'/'6CQP0
M>)M!<EG2);ED*:GI#2NSW.B:B)K*3S)9;;[%?F*^A^E**\[-<IRS/<OQ.59Q
M@<-F.78N'L\1A,72C5HU(WNGRR5XU(22G2JP<:M*I&-2G.$XQDO;X=XDS[A+
M.<#Q#PSFV.R/.LMJJM@LRRZO/#XFC/:4>:#M4HU8-TZ^'JQG0Q%&4Z->G4I3
MG"7\D7[2W['WQ;_9DUB0>*M-.N^"+JZ,&A?$/1+>:3P_J(<DV]MJ*GS)O#VL
MO&#OTK4F EDCG.EWFJVL#79^5*_MTUO1-&\2:3J&@^(=*T[7-$U:UELM4TC5
MK.WU#3=0M)AMEMKRRNXY;>Y@D'WHY8W4X!QD U^*7[4O_!*O>VI>-OV:)E4D
MS7EY\*=9O=JY.7=/!FOWTN%R<>7HOB"X"#,AMM<51;:=7\1>)OT;<SR=XC..
M U7SG*US5:N13?M,WP,=9-8*6CS3#PU4*22S"*Y(*&-ESUE_J]X"?3HR#B:.
M#X8\8)83ACB!JGA\-Q=2C[#AK-JFD(RS6"NN'\94=I5*[;R6<G5J.IE5-4L-
M+\.**V?$'AW7O">LZCX=\4:-JGA[7])N'M-3T;6;&YTW4["Y3!:&ZLKN.*>%
M\%64.@WHRNI9&5CC5_+%2G4I5)TJL)TJM.<J=2G4C*%2G.#<9PG"24HSC).,
MHR2<6FFDT?Z%T:U'$T:6(P]6E7P]>G"M0KT:D:M&M1JQ4Z=6E5@Y0J4ZD)*<
M)PDXSBU*+::84445!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M17;_  ]^&WCOXK>)K+P=\._"VK>+?$=^<PZ=I-N93%"&5)+R_N7,=GIFG0%T
M^TZEJ-Q:V%J&#7%Q&I!K]X_V6/\ @EYX.\ ?V=XU^/K:=X_\8Q^5=V?@F#=<
M>!M F&'1=5\U$;Q??PD*)(KF*'P]%(9H38ZPJV]_7Z'P%X8<6>(>+5+),$Z>
M7TZBAC,[QJG1RO";.476Y)/$XA1::PF%C5K^]&52-*DW5C^*^,'C[X=>"N6O
M$<5YK&OG5:BZN6<*Y7*EBL_S)NZIS6%=2,<#@I2C)2S',)X;">Y.%&=?$*.'
MG^;/[*?[ OQ1_:-FL/$VKQW/P_\ A.TJ22^+M3M&_M'Q#;HP\V#P9I4WEMJ1
MDP8O[;N?*T.V;S6CGU*[M9-,?^CCX,? SX9_ +PE!X-^&7ARWT73QY4FIZA)
MMN==\0WT:%#J?B#5G1;C4;QMSF,-Y=G9(YMM-M+*S6.V3UB&&*WBB@@BC@@@
MC2&&&%%CBABC4)'%%&@5(XXT4(B(H5% 50  *DK_ $ \-_"'ACPXPRJ8.E_:
M6?5:?)C,_P 92A]:DI*U2C@:2<XY?A).]Z5*4ZU566*Q&(Y(<G^-/CE])7C_
M ,<<;*AFE?\ L+A"A7]KEO!^65ZCP$'"5Z.)S;$-4ZF=9C!)-8C$TZ>&P\^>
M6 P6"]K550HHHK]5/YW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\5_:+^*<7P5^"'Q
M+^)C211WGAGPQ>RZ(LP5HIO$NH[-)\,6\B-D/%/K]_IT4RA6(A:1MK!2*X\Q
MQ^&RO 8[,\;4]E@\NP>)QV+JO_EWAL)1GB*\]6D^2E3E*UU>VYZ>291C^(,Y
MRG(<KHO$9GG>9X#*,NH*]ZV.S+%4L'A*5TFU[2O6IPND[7O9G\[O_!2'XUO\
M7/VD/$&C:?>?:/"GPI23P%HB1ONMY-5L9C)XOU$*"R>?-X@\_2S-&Q6XL-$T
MU^",5\!U/<W-Q>W-Q>7<\MS=7<\MS<W,[M+-<7$\C2S3S2.2\DLLCM)([$L[
ML68DDFH*_P D.)\_Q?%/$.<<0XYOZSF^/Q&,E%R<E1IU)OV&&@WK[+"X=4L-
M272E2@NA_P!(_ /!V7>'_!?#'!>51C]1X;R;!97"I&"@\56H4E]<QU2*T5?,
M,9+$8[$-?%7Q%274****\(^N"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ%_97^,US
M\!?CMX ^(HGDBT>RU>/2O%L*;BMUX0ULKIWB!'B7_7R6EG,=5LHF&W^TM/LI
M.#&"/GJBN_*LRQ>39GE^;X"JZ.-RS&8;'X2JK^YB,+6A6I-I-7CSP2E&]I1;
MB]&SQ^(<BRWBC(LYX;SB@L5E6?97CLHS'#NW[W!YAAJF%Q$8MI\L_959.G-*
M].:C./O13/[A(9H;B&*XMY8YX)XTFAFA=9(IH95#QRQ2(2DD<B,KHZDJRD,I
M((-25\0?\$\OBX_Q:_9?\$R7]U]J\0> 6N/AQKKN^Z5F\-16W]@S2EB9)'G\
M*WFA-/<2%C<7BW;EV</C[?K_ %OX<SO#<29#D^?X/3#9OEV$Q].%U)TOK-&-
M2=";5OWF'J.=&HK:5*<ET/\ FXXWX4Q_ W&'$W!V9ZX[AK.\QR>O447".(^H
MXFI1I8NE%Z^PQE&-/%4'=\U&M3EU"BBBO:/E@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\^/VMO^"?OP[_:)BO\
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MZ?L\$HTYE%%%?AI_6P4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI6C*M@JJ]CBZ*DIO"YA@JL:F#S'!RDE*6$QU"OAY249^SYXQDOX^OCO^R_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG&E%I1S#,(J-;,:T;+DP<*-%%%%%?AY_6(4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV+R;%K#YM@U;KBL'25TTF[.W*T445\L?H04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !117K/PS^!/QB^,=TMK\,_ASXJ\7
M*9?)DU#3M,ECT.UESMV7_B*]^RZ#IQS_ ,_VHV_1O[K8ZL%@<;F.(IX/+\'B
ML?BZSM2PN"P]7%8BJ^U.A0A4JS?E&+9Y^:9ME61X*MF>=9GE^3Y=AH\V(S#-
M,;ALOP5"/\U;%XNI1H4HZ/6=2*T/)J<JL[*B*SN[!41069F8@*JJ 2S,2
M220 ,U^R7P>_X)#^,M6^RZG\;O'VG^$K-MDDWA?P0B:]X@:,XWV]UK]['%H.
ME7*\GS+*S\46S#;A\D[/U=^#'[(7[/OP'6VN? ?P_P!,/B&W5<^,?$0_X2+Q
M8TJC#30:MJ*R?V0T@QYL.@6^DVCE5)MMPS7[SPE]&[C[B%TJ^<4\/PIE\^64
MJF9OV^92INUW2RK#S]I"HM;TL?7P$E9^5_X_\1_IS>#G!<<1A.&JV-\1,YI<
MT(4<A7U3(XUHWM'$<0XVE[&=*2LU7RC!YQ!W2T][E_GT^!W_  3T_:-^-+6F
MHR^&3\-_",YCD;Q-\0(KK1WGMFPQDTGPX86\0:F9(CYEI.UC9:3<Y4?VM$K;
MQ^S'P'_X)L?L_?!U[+6?$=A+\7/&-MLE&K>,[6W;P]:7*8/FZ3X-1I]+B4,J
MR1-KDWB&\MYE\VUO(#@#]"J*_JO@KP%X!X/='%5,"^(LVI<LEF.=QIXBG2JJ
MSY\)ERBL#A^624J4ZE/$8JDTG'%-ZG^=_BI],+QB\35B<OI9O'@KARNITWDG
M"DZ^"JXBA*\73S'.Y3>:XSG@W3Q%&C7P67XB,FIX"SL,CC2)$BB1(XHT6...
M-0B1H@"HB(H"JBJ JJH 4    4^BBOVI))62LEHDMDNQ_+#;;;;;;=VWJVWN
MV^K84444""BBB@ HHHH **** "BBB@ HHHH *X;XC_#7P1\6O".J^!?B%X>L
M?$OAG6(MES87J'=#,H807^GW492ZT[4[-F,EEJ-E+!=VLGS0RKE@>YHK#$X;
M#XS#UL)BZ%'%87$TIT,1AL13A6H5Z-2+A4I5J512A4ISBW&<)Q<91;333.K
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M27%OCIF[HU75R+@?+\1*ID?"M&NY0<H\T(9GG=6#C#,,VG!M0;7U7+J<Y8?
MTU*>*Q6,****_6S^;@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8:>Y5I1XAUR+6M:\ENCVVE>%1K%JTN"&-OJ&KZ6ZC*R%)!LK^EL
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MX@^%>KS%Y!+X0U1KK1'G;.&N/#WB!=4MHK=<C%IHESH<8VKM*_.'_/;XD_\
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M:[G^3333::::=FGHTUNFNC04444""BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ***\X^+/Q7\$?!3P+K?Q#^(.K
MQZ3X>T6')QMDO]4OY0WV+1M'LRZ/?ZMJ,JF*TM495&)+BYEM[*WN;F'GQ>+P
MN PN(QN-Q%'"8/"4:F(Q.)Q%2-*A0H48.=6K5J3:A"G3A%RE*3223;9VY=EV
M/SC'X+*LJP>)S',LQQ5#!8# 8.C/$8O&8O$U(TJ&&P]"E&52K6K5)1A3A"+E
M*322,WXU_&KP)\ _ &K?$3X@:F++2M/7R+&Q@,<FK>(-8FCD:QT+0[1WC-WJ
M5Z8W*J62"UMH[B_OIK:PM+JYB_E4_:2_:0\>?M,?$"Y\:>,)S9Z;:^?9^$?"
M5K/))I'A317D#K9VH98Q=:A=;(IM8U>2*.XU.Z13LM[*WL+"SU/VH_VGO&_[
M4'C^;Q1XC>33/#.EM<VG@GP;!<-+IWAK299%)9B B7NN:B(H9M:U=XDDNYHX
MK>%+?3K.PLK;YGK_ #K\:?&7%>(&.GDN35*N%X/P->]&FU*E5SK$4I>[C\;!
MVE'#QDN; X.:3IJV(Q$?K,H4\-_MM]%CZ+^7^#64TN*>*:&&S#Q+S;"VQ%9<
MF(P_"N"Q$$YY/E=5<T)XV<7R9OF=)M5I<V!P<W@85*V/****_ S^Q0HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **FM[>>[G@M;6":YN;F:.WMK:WC>:>XGF=8X8((8U:26:61ECCCC5G=V5
M54L0*_>[]AG_ ()SP>$_['^,/[0.D0W?BH>1J7A#X;:A$D]IX9;Y9K76?%UN
MX:*[\0J=LMCH4@>UT)@L^HK/K.RUT7[G@+P^X@\0\YAE624.6C2<)YEFE>,E
M@<LPTI->UQ$TO?JS2DL-A:;=;$SC)14:4*U:E^2>,7C/P;X*<,5.(>*L7SXJ
MNJM+(L@PLZ;S;/\ '4XI_5\'2D_W6'I.=.6.S"LEA<%2G!S<Z]7#8;$>,_L.
M_P#!.2Z\8_V/\7OV@=)GL?")\C4O"?PXO4DMK_Q2GRS6NK^*X3LGL/#CC;+9
MZ*XCO==4K-?"VT8I#K7[YVMK:V-K;65E;06=G9P0VMI:6L,=O:VMK;QK#!;6
MUO"J10001(D4,,2+'%&JHBJJ@">BO])> ?#WA[P[R>.5Y)0YJ]50GF6:5XQ>
M.S/$137M*\TO<HP;DL-A*;5'#PE+E4JLZU:K_A=XQ>-/&?C7Q-/B#BK%^SPF
M'=6ED7#^$G4649!@JDDW0P=*3_>XFLH4Y8[,:R>*QM2$.>5/#T<-AL.4445]
MT?D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB@#\Z_\ @J2KM^R3X@*GY4\9>"6D]T.JL@!_[:-&?J!7\Q=?U&_\%-;%[O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'JIPJ03M<HHHKQCZ@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX3P=>%XX[&4IKW>(\52DTJ4ESY-AYNE+ES&K7A@RBBBOY;/]! HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPX*X[='!T\4\CSVIRQ_L;-ITZ4Z]5V7)EV,3CAL?=W5.G%TL9))RE@X1U/\
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MYHT445_ Q_L6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA9(HHHK\C/Z2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I(I98)8YH9)
M(9H9$EBEB=HY8I8V#QR1R(0Z2(X#(ZD,K ,I! -1T4)M.Z=FM4UNGW$TFFFD
MTTTTU=-/1IIZ--;H_4;]F?\ X*>?$_X5_P!G^%?C E]\5O D/E6\>JSW"?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG2RO,%1R;BN%/W\OE4MA,S<(WJ5\HJU).4W9.I4P%64L50AS.$L51I5*\?\
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MZ5$JQ^)#ONK15U\RQ:Y^ DD<D,DD,T;Q2Q.\<L4B,DD<B,5>.1& 9'1@5=&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"AA\-AL/3C2H8?#T:48TZ-&C2A&G2I4XQA3A&,(Q44D%%%%9FX4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\TO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOY[@*$%S<\I/]YFF#IJ^(U]IB\/%XNTZE+%U%_C7],3Z,:\.,QK>)/ N <>
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M:6&RK.L34:C2SY+EI83'UI*GG5HTL1..;N$LT_)FBBBOY-/]&PHHHH ****
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M/VN*X?S&5.CGF6QE=SI)VACL)&34(X_!J4I4[N,<12=3#5)052%6C_.WTCO
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M5IPQ.,KH****_,S]Y"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY\'^T*22LE9+1);)=@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KV
M7X"_&_QC^SW\2]!^)/@RX/VK39?LVL:/+,\>G^)?#]Q)&=4T#4U0,&MKV.-7
M@F,<DFGW\-GJ5LHNK.%AXU177@,?C<JQV$S++L35P>.P.(I8K"8JA+DJT,11
MFITJD)=XR2=FG&2O&2<6T_-SG)\KXARK,<CSK X?,LHS;!XC+\QP&*@JF'Q>
M#Q5.5*O0JP>\9PDU>+4X.TX2C.,9+^SWX0_%CP?\;?A[X<^)/@>^^V:%XALU
MF\F0H+[2=0B_=ZCHFJPHSBVU/2KL26MW$&:-RBW%M)/9SV]Q+Z77\O'[ /[6
MLW[.?Q&'AOQ7?2_\*C^(%[:VOB9)&9X?"^LMLM=.\9VT63Y<=NOEV7B)80'N
MM&"7)2ZN='TZW/\ 4'#-%<113P2QSP3QI-#-"ZR1312*'CEBD0LDD<B,'1T8
MJZD,I((-?Z=^$OB1A/$CAFGCFZ5#/,O]GA,^P,'94L4X-T\70@VY+!8^,)5<
M.W=4ZD:^%<ZDL-*<O\"_I'^!N9>!O'E?*(K$8KA/.?;YCP?F]5<SQ.7*I%5L
MMQ=6*4'FF3SJ4\-C$N5UZ4\)F"I4:>.A1IR4445^I'\^A1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***SM7U?2] TK4M<UO4+32M&T>QN]3U74[^>.VLM/TZQ
M@>YO+V[N)66."WMK>.2::5V"I&C,3@5,YPIQE.<HPA",ISG.2C&$(IN4I2;2
MC&*3<I-I))MNQ=.G4K5*=*E3G5JU9QITJ5.,IU*E2<E&%.G"*<ISG)J,8Q3E
M*322;:1Q'Q;^*W@WX*> /$'Q'\=ZB-/T#P_:F5D38]]JE_+E-/T72;=WC^UZ
MKJESLMK.#>D89FGN9;>S@N+B'^3/]HCX^^,OVCOB9J_Q$\7RM DQ-CX;\/Q3
MO-I_A;PY!+(]AHUCN"!V02/<ZC>^5$^HZE/=7KQ0B5((O;OVX/VNM5_:<^(!
MM-$FN[#X2^#KNYM_!6CR>9 VK3_-;W/C'6+<X)U+5(P4TZVF7.C:2Z6B)'>7
M.K3WGP[7^=OCMXN3XYS1Y!D>(DN$\IQ#Y:E.3BL\Q].\)8^HM+X.B^:&74VO
M>BYXRI[]:E3P_P#MG]$3Z-M/PDR"/&7%N#A+Q&XDP4.>C5C&4N%,GKJ%6.3T
MF[\N:8JU.KG5>+_=SC3RVB_9X?$5L:4445_/9_:04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5[%\"_@=X[_:#^(6
MD_#SP%8>??7I^TZKJMPL@TCPUHD4D:WVNZU<(K>196HD1(XQFXOKR6VT^RCF
MO+J")\/X4?"KQM\:?'>A_#OP!I,FK>(=<N B [H[+3;*,J;W6=7NPCK8Z3IL
M+>?>73JQ"A8;>.>[FM[>;^J[]E[]F3P3^S#\/8/"?AQ(]2\1ZDMM>^-O&,UN
ML6H>)M9CC8 @9=[/1=.,LT&B:2LCQV5O)+-*]QJ-YJ%[=?M'@]X28[Q(S7ZS
MC%6P?"F6UH_VICXIPGBZL>6:RO+YM-2Q-6#B\162E#!4)JK-.K4P]*M_+7TF
M_I(Y3X'</?4,LEALS\1,\PM1Y!E$VJE++:$G*D^(,YIQ:E# T*BE'!863A4S
M7%TY4*3CAZ&-Q&&Z+]GS]G_P)^SA\/-/\ ^"+3>5V7GB/Q%<Q1IJ_BO76B5+
MK5]3D3=M!QY6GV"2/;Z99+%:0%RLL\WN5%%?Z1Y=EV!RC 83+,LPM'!9?@:%
M/#83"X>"A2H4::Y80A'=]Y2DW.<G*<Y2G*4G_AAG>=YOQ)F^8Y]GV88K-<YS
M;%U<=F.8XRHZN)Q>*KR<JE6I-Z+I&$(*-.E3C"E2A"G"$(E%%%=IY84444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)7Q"5_=PF$J5%BL;4=GRTL)1K596:C!V9\&UZ;\,?@U\4OC-K(T'X8^!]?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI8G#5:^$Q&'Q%4HHHKYL^Y"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /V._X)J_MI?\(AJ&F_L\?%+5MOA75[SR/A
MIXBU"?">&]9O9BP\)7T\K8CT/6;J1FT:9F TS6)VLWW6.I1/I?[]5_#P"000
M2"#D$<$$="#V(K^C3_@G-^VB/B_H%M\%OB7JH?XH^%].(\.:Q?S9N/'WAJPB
MR1+-(VZZ\4Z#;1XU+<3<ZMI<:ZP?M-S:ZW<)_:7T=O%_VT<+X>\2XK][!*EP
MOF&(G_%@E[N1UZDG_$@O^17*3]^"> BU*&#I5/\ +#Z;/T:?JT\P\:.!,O\
M]FJR>(X_R7!TK>PK3E[W%F$H4U;V-:37^L$*<4Z55K.)1E"KF=>C^J=%%%?V
M,?YC!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M74J6WE16-H4?;0:UC4I.<)1:E&3BTW8HHHKUSYL**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBO5****^D/APHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_(Z<,;@VHU\NS*E!MN-#,LOK87'4(M\T:6(C&5I)I%%%%?1'Q(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M23<*M*I'EJX>O2E.CB*%2G7H3J4:D)R****]$\4**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(ZDN63A)\E7.\TA"4J=3-LPC%-Q3G3R["N&!P\ZDEBL5C"BBBOUL_F\****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ )
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,P*KY>E7K4\LHT_Z0:***_T!/\9PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K^6G_@I!\56^)O[4GC&RM;GS]#^&
ML%I\.=*56S&MSHC37'B5BBDH)U\4WVL6;R#+R06-JKD"-$3^EGXI^.K'X8_#
M;QW\0]1V&T\%^$]=\1M%(VT74NE:=<75K8J<@F6_NHX;*! 0SS3QHI!85_&'
MJNJ7^MZIJ6M:I<R7FIZO?WFJ:C>2G,MU?W]Q)=WES*>,R3W$LDKG'+,37\D_
M2LXE>&R;AWA2A4M/,\96S?'1B[2^JY=#V&$IU%UIU\5B:M6*M_$P$7=6L_\
M2']G;P(L=Q1QKXBXJCS4L@RS#<-93.<;Q>89U4^N9E6HRM[M;!Y?@,/AYNZ_
M<YO*-FI-QH4445_#I_K.%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% ']'7_!)SXJMXO\ @/KOPWOK
MHS:G\*?$TL5E$S;GC\*^+S<ZSI>2Q+MY>N0^*(0.4BMTM8EPH51^IU?S(_\
M!+SXG'P)^T[IOAFZN?)TCXH^'M7\(3I(^VW76+6(>(= N&&>;E[K29]'M.OS
MZVZ8^?<O]-U?Z6?1^XE?$?AIE%.M4]IB^'ZE;A[$MN\N3 JG4R_1ZJ,<LQ&#
MI)[2E2G9Z-+_  B^F;P(N"/'CB6MAZ/L<MXRHX7C/ J,;1]KFSK4<X]Y)1<Y
MY]@LSQ#BK2A3Q%+F3NI2****_;#^5 HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]$YOENK-E%%%?B9_584444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<7=U(GVS1117]Q'^3 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E7QI^#G@OX\?#O7OAM
MX[L?M6D:S#OM;R%8QJ6@ZQ K_P!FZ_HT\BN+;4]-E<O$Q#17,#W%A>1SV%Y=
MVTWJM%<N-P6$S'!XG 8_#TL7@L90JX;%86O!5*-?#UH.G5I5(2NI0G"3C)=G
MI9ZG?E6:9CD>98#.,HQN(R[-,KQ>'Q^7X_"594<3@\9A:L:V'Q%"K!J4*E*K
M",XM=5JFKH_C>^/GP,\:?L\?$G6OAQXUM\W-BWVO1=:@BDCTWQ/X?N))%T[7
MM+9RV;>Z6)X[BW\QY=/OX;O3KEOM%I+7C%?UM?M=_LM^&OVHOAM/X?NOLNE^
M.= 6ZU'X?^*I8SNTK5GC7S=-U"2)'GD\/ZV(H;;58$61H62UU."&:[T^"-_Y
M3/&?@WQ+\/?%6O>"O&.DW6A>)O#6HSZ7K&EWBA9K:Z@(Y5U+17%M/&T=S9WE
MN\EK>V<T%W:RRVT\4K_YI^,7A9B_#?/>;"QJXCAC-:E2IDV-E><J#7OU,JQE
M2VF*PL7>E4E;ZYADJ\/WD,33H?[N_1C^D+EWCEPDJ>83PV"X_P"'J%&EQ1E5
M/EI0QD':E1XARRC?7+L?-)8BC"[RS'2EA*B]A4P-?%<Q1117XZ?TX%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5])_LK?M
M'>)/V9?BKI?CC2OM%_X<O?+TGQUX:CE"Q>(/#4TRM.D:NRQ)J^F-_P 3#1+M
MBAAO8C;S2'3[V_@G^;**]'*<US#(\SP.<95B:F#S'+L33Q6$Q%-^]3K4I75T
M[QG"2O"K2FI4ZM*4Z52,H3E%^)Q)P[DW%N0YMPSQ#@*.9Y)G>!KY?F6"KIN%
M?#5XN,K234Z5:G+EJX?$4I0K8;$4Z5>A.%:G"<?[8_!OC#PYX_\ "N@>-?".
MJ6^L^&O$VF6NKZ-J=L28[FSNXPZ;D8"2"XA;=!=VLZQW-G=136MS%%<0R1KT
MM?SL?\$T/VN_^%8^*8?@5\0-4\OX?>-M3!\(:G>S8M_"'C*^=8ULWED8"VT+
MQ3,4AF&?L]AKIMK[9;PZCK%X/Z)Z_P!1?#/Q P'B+PQA<ZPWLZ&84>7"YUE\
M97E@<QA!.HHJ3<WA<0G[?!U6Y<]&7LYR]O1KPA_S]^//@UG/@CQ]C^%L=[;%
M9-B>?,.%LZG!*&;Y)5J25&4Y0C&G',,%*^#S.A%0]GBJ?MJ</JF)PM2J4445
M^A'XL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'DKX3&82K*C7HU$FTW"I!I3@Y0G&TZ<I0E&3****[#S HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>)/[.^ 7@;PU%)LF\2_%"QNID#8\[3M \.>()9T*_P 2KJ&H:3*3R%:-<C+
MCX#Q4S)Y3X<<:8V,N6:X?S#"TIWLX5LPHO+Z,D_YHU<5"4?[R6^Q^R?1YR)<
M1^.'A9E4X>TI2XTR7'UZ;5U4PV38J.<XJG)?R3P^7U83_N.3NMS^=6BBBO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+FVMKVVN+.\MX
M+NSNX);:ZM;F*.>VN;:>-HI[>X@E5XIH)HG>.6*16CDC9D=65B#_ #'_ +?O
M['%S^SKXT/C7P58S2_!SQKJ$ITG8))AX+UZ827,_A*]E.YA8R(DUUX9NIV\R
M>PBN-/G::ZTN2[O?Z=ZXKXB_#WPG\5?!7B+X?^-]+BUCPQXGT^73M3LY,+(J
ML5DM[RSGVLUIJ.GW20WVG7L0\VSO;>"YB(>,5^8^*OAME_B1P[4P%3V6'SK
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MW=1117]UG^104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5^%7_!9+7C)JWP&\,))@
M6FG>/M>N8@>'.HW/A;3[*1E_Z9_V7J"H?^FL@K]U:_G*_P""NNL&]_:,\'Z2
MCYBT7X1Z'O3.0EYJ/BKQC<S''0;[1+#/<X&>,5^%?2.QCPOA3G-%.SS#'Y+@
M^S:CF5#'-+U6"=[;QNGHV?US]!W*UF'TB.&,2X\RR7*.*,TU5TG/(L9E,9/T
MEFD6F]I<K6J1^5E%%%?YN'^YX4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_7U^R#K
MQ\2?LO? ;4S)YKI\,/"FDRR$[F>;P]IL/A^=G;DLYFTQ_,)Y+[B><U]'5\(_
M\$UM7.J_L=?#")G+RZ->>.-(E8G) B\<^(;VW0^@CL[ZVC4=D5:^[J_UMX$Q
MCS'@C@_'2=YXOAC(:]1WO^]J97A954WWC4<HOS3/^;OQ=RM9+XK>)>41CRT\
MNX^XOP=%6LO84,_S"G0DETC*BJ<H^304445]6?G84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4Z?:KV=F\?HHK_+O'X[%YGC<7F.88BIB\=CL16Q>+Q-:7-5KXBO4E5K59O\
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M39S34Z%?/ZR32G@Z495<-D<))N.%G7QTG&IF#H8<HHHK]^/XV"BBB@ HHHH
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M$W/7%.>6\/9#E,9VUC'.LRQF,G%.UTIO((-J^K@FT[*W-4445_#Y_K*%%%%
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MU3^HUL7!-?SV>C9^_-%%%?Z8G^#04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_+_
M /\ !4#43??M>>,;4ON_L?PSX&TX#/W!+X:LM7V#TR=5+X]7)[U_4!7\I?\
MP41NS>_MD?&F4MN\N^\(6@] +'X>^$K/:/3!@.??).223_-/TJ*[I^'F5TD]
M<1Q;E\)><*>59U5?_D\*?](_N_\ 9Z815_&KB#$26F"\.,YJ1?:K6XAX5PZM
MVO2J5M?EU9\5T445_GZ?[,A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '])_\ P29U
M$WW[+NI6I?=_8_Q6\6:<%S]P2Z+X3U?;[9;5&?\ X&3WK].:_)+_ ((^W9?X
M&_$NQW96V^*\]V%SP#>^$/"\+-C_ &A8*">^T>E?K;7^IG@U7>(\+^"JC=W'
M):5#Y8:K6PR7R5)+RL?\^/TH,(L%](#Q4HI)*?%.(Q=DK:X_#87'2?JY8AMO
MJW<****_3#\%"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _ ;_@IG^Q
MS_PB>J7W[1?PUTO;X8UV]5_B=HEC#B/0-?OYECC\6VT,2[8])U^[D6+65VJ+
M+79H[P-)%K$BV'XX5_;MK&CZ5XATG4]!US3[35M&UFPN]+U;3+^%+FRU#3K^
M"2VO+*[MY T<UO<V\LD,T;@JZ.P/6OY6?VV?V4=5_9A^)<D&FQ7=[\+_ !?+
M=ZCX!UJ7?,UM$CA[SPKJEPP.=7T(RQHDSL3JFF26>HJ1</?6UG_!_P!(CPE_
ML'&U>.N'L-;)<RKWSS"48>YE>95YV6,A&*M# YC5E::MR8?'2Y5)4\70I4O]
M?/H3_2._UORO#^$?&F/YN*<CP;7"698JI^\X@R+!T[RRNK4F[U<VR3#PO1=W
M4QN44_:2BZV78K$8CXOHHHK^5S_0P**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K]B_^"7?[6/_  B>O1_LY>/-2V>&O%-]
M+<?#34+R;$6B^*KQS)=^%C)(=L6G^)Y2UQI<89$B\1F2WBBFG\0L\/XZ5-;W
M$]I/!=6L\UM=6TT=Q;7-O(\,]O/"ZR0SP31LLD4T4BK)')&RO&ZJRL& -?6\
M#\89GP+Q+E_$>5R<JF$J<F*PKDXTLPR^JXK%X&M9-<E>FKPFXR=#$0HXB$74
MHPM^;^+/AED/B[P+G7!&?P4*.8T?:Y=F$:<:F(R;.</&<LNS;"IN+]KA:TFJ
MM.,Z?UK!U<5@JDU1Q-2_]P5%?#'[!O[4\'[27PIBMO$-Y#_PM/P%%9Z/XVMR
M4CEUB!HVCTGQA;PKA3%K<4$B:DL2JEKKEM?*L-O9W&G"7[GK_5'AW/\ +.*<
MDRW/\HKJOE^9X:&(H2T4X-WC5P]:*<E3Q&&K1J8?$4[OV=:G.%W:[_YZ.-N#
M<]\/^*\\X-XEPCP>=9!CJF"Q=/WG2JJ*53#XS"SE&+K8+'8:='&8*ORQ5;"U
MZ52RYK(HHHKVCY8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***\U^+_Q4\*_!3X<^*?B9XRN?(T3
MPQITEVT$;HMWJM_(1!I>BZ<LA"R:CJ]_);V%HK$1I).)IWBMHII8^?%XO#8#
M"XG'8VO3PV#P="KBL5B*TE"E0P]"G*K6K5)O2,*=.,IR;V29VY;EN/SC,<!E
M.5X2OC\SS/&8;+\OP.&@ZN(QF-QE:&'PN&H4XZSJUZU2%.G%;RDD?$W_  4;
M_:M_X47\-_\ A7G@[4O(^*?Q+T^ZMK:>UFVW?A/PA(9+/5?$>Z-O-MM0U!A/
MH_AV4>4Z70U'5+>99M%6.7^9JO3OC'\6/%?QO^)'BCXF>,KGSM9\2W[W"VL;
MNUGH^FP@0:5H>FJYS'I^DV,<-G;@_O)A&UU<M+=SSS2>8U_E[XL>(>*\1N*L
M1F:=2GDV"Y\%D.#G=>QP,9W>)J0VCB\?-+$8EZR@G1PW/.GAJ;/]_P#Z.?@K
M@/!#P\P60N-"OQ/FOLLUXPS.DE+ZUF]2E:."H5K<T\NR>E)X+ KW85)+$X]4
MJ5;'UXA1117YB?O@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7[P_\$Q?V//['L[']I/XDZ5C5=2MW;X4:)?PX;3M+N8VB
MF\<W$$J[A=ZI \EMX:#JHATN2?64$QU+2[BT^)O^"?\ ^R++^T5\03XK\86$
MO_"H/ -];SZ^94=(?%NNJ([JQ\'6TOR[[=D,=]XDDA+/;:4T%D6MKC6K*YB_
MI[@@AMH8;:VABM[>WBC@@@@C2*&"&)!'%##%&%2.*-%5(XT541%"J  !7]<_
M1R\)UF%>CX@\08:^"PE9_P"K6#K0]W%8RC/EGF]2,E9T,'4BZ>!5G[3&1GB%
MR+"TG6_S8^G!](S^Q\)BO!?@S'6S7,</!<=YGA:MI9?EF)IJI3X:HU(/FCB\
MTH3A6S9IQ]EEE2G@G[1YCB8X:6BBBO[?/\G@HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,+Q1>/
MIWAGQ%J$;;9+#0M7O(VZ;7M=/N)U;/;#(#7\2E?VJ_$;>/A[X\,?^L_X0SQ1
MY?\ O_V'?;?_ ![%?Q55_%7TMIMXS@6GKRQPW$,UVO.KD\96\[4XW^1_JE^S
M=IQ66>+E96YYX[@NG)]>6EA^)Y1OY7K3MYMA1117\>'^FP4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5^IO\ P2+O'@_:4\6VH;]W??!OQ&C*>AD@\7^
M[B-A_M*J2J/]EVXZ$?EE7Z;_ /!)O?\ \-1ZAL^[_P *J\6^9_N?VQX5Q_Y$
M\NOTCP?FX>)W!,HWN\^PL--[5.>G+Y<LG?RN?A?TF:<:O@%XK1FDTN$<?45]
MN:C*E6@_53IQ<?[UK']*-%%%?ZH'_/6%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5_-7_P %)_VJO^%T?$8?"WP;J7G_  S^&6HW,$UQ:R[[3Q7X
MWB$MGJ>L!T/EW.G:(C7&BZ)(N^.1FU?48)IK74[7ROTR_P""CG[57_"C/AG_
M ,*^\'ZEY'Q1^)MA=6EI-;2[;OPKX0<O9ZOXCW1GS;:^OSYNC>'I1Y3K='4=
M3MIA-HGER?S,U_&OTF/$WE2\.\EQ&LE1Q/$]>C/:/NUL'D_,GO+]WC<;%?9^
MJ4>9J6)I'^H/T#_ 7GD_&WBG!>[!XG < X3$T])37/A<SXFY)+50?MLJRJ3O
M[_\ :6*Y%*& KA1117\8G^HX4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7L?P%^"7B[]H+XF^'_AIX.A(N]5F^T:OJTD3R
MV/AOP]:O&=6\0:EM* 6UC#(JPPF2-[^_FLM,MW^U7L"MY1I^GW^K7]CI6EV=
MSJ.IZG>6VGZ=I]E#)<WE]?7DR6]I9VEO$KRSW-S<21PP0Q*TDLKJB*68 _U1
M_L._LI6'[,OPPB_MFWMKCXI^-(;34_'FIIY<QT\JADL/".GW"%E.GZ$LTBW4
ML+NFI:O)>W@DDM!IT5K^M>#_ (:8GQ'XEA0KQJTN'<KE2Q6?8R%XMT7)NCEV
M'J+;%X]PG",D[T,/"OB?>E2ITZG\X?29\>,#X'<"U,9A9T,1QKQ!'$9?PAEM
M3EG&.)C"*Q.=8RBW>679/&K3JS@TUB\94P>!O"&(JUZ'TG\)?A9X1^"WP^\-
M?#;P18BRT#PU8I;1.X0WFI7DA,NHZSJ<R(@N-4U:\>:]O9@B1^=*8X(X;:.&
M"/T:BBO]-L)A,-@,+AL%@Z%+"X3"4*6&PN&HP5.C0P]"$:5&C2A%)0ITZ<8P
MA%*RBDC_  3S',<?F^88[-<TQ=?'YEF6+Q&/Q^.Q525;$XS&8NK.OB<37JS;
ME4K5ZTYU*DY-N4I-O<****Z#B"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P?%-F^H>&/$=A&N^
M2^T'5[.-?[SW.GW$*KW^\S@=.]?Q*U_<17\37C#1W\.^+O%/A^1/*DT/Q'K>
MCR1XQY;Z9J=U9,F,#&QH"N,#ITK^-/I;X=VX$Q23Y4^(\/-]$W_8E2DO5J-7
M_P !TZG^H?[-W&Q4O%[+I-*<EP1C:2OJXQ?%5"N[;VBYX972WGKTOSE%%%?Q
MD?ZBA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7ZF?\$C+-Y_VE?%=R%_
M=V/P;\22.W8//XN\"6Z*/]IA)(0./E1CVP?RSK]C?^".NCO/\2/C)X@"9CTS
MP1H&CM)CA'US7I;V-,X_Y:+X=D;&>?*/!QQ^I>"F'>*\5.#*44VXYI/$:=L'
M@L5BY/T4:#;[)-G\^?2KQL<!]'KQ1KS:2J9!1P2;=ES9EFV79=!>LIXJ,4NK
M:74_?NBBBO\ 48_Y^@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPC.=?&5XPA];Q]?%8IPI^V5.!1117VA^6A1110 4444 %%%% !1110 4444
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M7_@FMX-?PC^R/X!GGA\B\\8ZCXG\972%<,R:CK=SIVES$\;OM&A:1I5PC?\
M/.5%_AK^A/HS97+'^)M'&\K<<ER3-<>Y6TC/$0I93&-]E*4<RJ.*W<8S:TB[
M?Q=]/3B".4> N)ROG2J<5<5</9.J=_>G3P=6OQ'4ERWNX0GD=%2E:T9SIIZR
MB?>=%%%?Z*'^) 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&4T^:I4PO*E>IC,'>IB,#:\ZL95\(HU)U</[+^W_ *&?TAGX8\3K@+BK'<G
M?%V.IQH8G$5+4.&>(Z_LZ%#,'.3Y*.69GRT<'FSERTL/..$S&4Z-+#8SV_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?C7_P6
M%\ /?^!?A+\3;:WW'PUXEUGP?JDT8RWV7Q5I\.JZ:\^,D06MWX9O(8W.$2?4
MQ&Q+SQBOV4KYE_;&^&+_ !<_9J^+/@ZUMOM6K_\ ",S>(= B5=T\FN^$YH?$
MFG6UL<$K/J,NF'2@1@-'?21L0CM7P'BGP_+BCP^XKR:G!U,16RJMBL'3BKRG
MC<ME#,L'3CU4JV)PE.C==*C6J;3_ &3Z/G&<. /&CP[XGK550P6%XBPV S.M
M*7+"EE.>PJY'FE>I=I.&'P.8U\3:6G-1BU:237\B-%%%?Y3'_1(%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOZY/\V@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/GBBBBOYG/[R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5,;BZGO*E232IX?!X6G*4G1P6!PT*.#P5!2DJ.%H4J:;Y;LHHHKVCY8****
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M.K.U'!<78=.GEC3;M3CG5"<\JJ<J<JV.63Q;4*<FOP<HHHK_ #\/]G HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *_H#_ ."/G@4Z;\,OBK\19X=DGBSQCI?A
M>SD=?G>Q\':4U]++"2.()KWQ9-!(RG$DU@58$P+C^?ROZW/V(OA\WPT_99^#
MOA^>#R-0O_"\?B[559=L_P!O\:W-QXI:*Y& 1<65MJMMISJ>8ULTB.?+S7]&
M_1BR-YEXB5,UG"]'A[)L;BXU&KQCC,?R990AY2GAL3CIQ?:E+J?Q!]/KBU9'
MX*4>':=6V)XTXGRK+IT5*TIY;D[J9]BZMMY0I8[ 932FEUQ,+Z;_ %91117^
MA9_BL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI*."X@H4HW;Q635*U2=6,(SGB<NK8W#0A*O/#SI?Q^T5T?B[PGX@\">*-?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!VC%K#T6ZF)JPA36*QU;%XR5.$\3-!1117V!^9A1110 4444 %%%% !1110
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M"!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVWJVV]6V]6WN?[R1C&,8QC%1C%*,8Q248Q2LHQ2LDDDDDE9+1!1112&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7[-_P#!+/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML&3H<TA::]\8>'[2%<G197+W'B#3(4SH\K2:K:I_9#WD>C_BW7^8'''!.=\
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M_P %/&WQ_P#B+HOPX\"67GZEJ;^?J.I3I)_9?AW1('C&HZ_K,\:MY&GV*2(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF&B\-B(VA46&Q<:^$H8E%%%?GQ^T!1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*ME]6*R****_A _U\"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8S@3BO->',7SSIX6M[7+\5*-EC<LQ#<\%BE9*+E.E^[KJ%XT\52KT4VZ;/\
MHD\&?$[+/%[PZX>XXR[V5*MC\,L-G6 IRYGE6?X-1I9ME\DVYJ%/$?O\'*HH
MSKY?B,'BG%1KQ04445\8?J04444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M17RQ^A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M##X+,4N?#X^+91117\AG^E84444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#A/B=\.?#/Q;\
M ^*OAQXPLQ>>'O%NDW&EWR*$\^V=]LMEJ5D[JZPZCI-_%;:GITY5A!?6D$I5
M@A4_R _&;X3^)O@A\3/%OPQ\61;=5\+ZG):I=I&\=MK&F2JMQI&N6(<DFRU?
M3I;:^@4LTD(F:VGV7,$T:?V<U^6'_!3[]F/_ (6A\.(_C/X2T[SO'7PMT^=M
M=AMHMUSK_P /E>2[U!&"@M+<^%)Y)]<M 64+ID^OIB:=[.-?YU^D1X<?ZV\,
M_P"LF68?GS_ABC5K.-.-ZN/R6[JXW"V2YJE3!OFQV%BVVDL71I0E5Q2/[:^A
M/XX?\0XX\_U'S[&>RX.X^Q6'PL9UJG+A\GXI?+A\KS&\GR4:&9+DRG,)VC%N
M66XJO5A0R^5_YQJ***_SQ/\ :X**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#^AC_@E5^T<?&W@'4?@-XGO_ #?$OPWMSJ7@
M][B3=/J7@*ZN5CEL$+EGED\*:K<I;+N8"/2-5TBTMHA#ILK+^N%?QE?!3XL>
M(?@?\4?!WQ0\,N3J/A;5HKN>R,K10ZQI,RM:ZUHETR@XMM7TN>[L9'VLT!F6
MYB GAB=?["? ?C;P]\2/!GAGQYX4O!?^'?%NC6.N:3<_*)#:WT"RB&YC5G\B
M]M'+VE]:LQDM+R">VE DB<#_ $,^CEX@?ZT<*/AO,*_/G7"L*6&@YRO4Q>22
M]S+ZZO9SE@G%Y?6Y4^2G3P<ZDG/$:_XJ?3@\&?\ B'_B*N.<FPGLN%O$.KB,
M=4C1A:AEO%5.U3.<(^5.-.&:<\<YPW/*+JUJV9TJ,%1P6G64445_1A_$0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8
M_B+Q!H_A/0-:\3^(;^#2]!\.Z5?ZWK.I7+%8+'3-,M9;R^NI2 6V06T,DA"A
MG;;M168@'8K\<?\ @K!^T5_PCOA31OV>O#-_LUCQG';^(_'SV\N)+/PG9W9;
M1=%E9#E)-?U>U:^N8]R2)I^CQ12I)::P-WQ_'G%V#X&X5S?B3%\DW@L.XX+#
M2E9XS,:_[K X16:DU5KRBZTH7E2P\:U>SC2D?IG@_P"&V9^+7B)PWP-EOM*<
M<UQD9YKCJ<.997D>$_VC-LQE=."EA\'"HL-"HXPKXVIA<+S*=>%_QY_:1^-N
ML?M"?&+Q?\3=5\^"TU6]-EX:TN9]W]A^$]-+V^@Z4%5FB6:.T'VO46AQ%<:O
M=ZA>*H-RPKPNBBO\I,RS'&9OF&.S7,*\\3CLQQ5?&XNO/XJN(Q-256K-]$G.
M;M%6C%6C%**27_1/D6299PWDN5</Y+A*>!RC),OPF5Y;@Z2M##X+ T(8?#TD
M]Y.-*G%2G)N=25YS<I2;91117$>J%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $D,,UQ-%;V\4D\\\B0P00HTLTTTK!(XHHT#/))(
M[*B(BEG8A5!) K^K7]AC]FJ']F_X+Z=I^K6D<?Q&\:BT\3?$"YVJ9[:^E@)T
MOPP)5W9M_"]E.]HZ+)+"^L7&LWMN_DWB*OY+_P#!+[]F;_A9OQ)E^-'BO3_-
M\$?"R_A.@Q7,6ZVUWXA"..ZT\+N&V6#PG!)!KES@J4U2?P^,2PF[C']&]?VW
M]&/PY^JX6MXA9K0MB,;&M@>'*=6/O4L&I.ECLSBI+W9XN<98/#37+)8:GBI+
MFHXN$G_E']/?QN_M',<+X+\.XR^"RJIALVXWJT)^YB<T<(U\HR*<HM*=/+J4
MX9GCJ;<Z<L;7R^#]GB<MJQ"BBBOZ]/\ -,**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HJ.::*WBEN+B6."""-YIIIG6**&*)2\DLLCE4CCC16=W=@J*"S$
M $U^1_[4W_!4;PCX$.I>"OV?X]/\>>+8C-9WGCJZ#3^!]"F&Z-VT9(WCD\77
MT+!C'<120>'8W\F>.[UR+S[,?*<7<;<-<#Y:\SXCS*E@J4N=8;#K][CL=5@D
MW1P.$@_:XB>L5.44J-%2C/$5:5.\U^A^&_A7QUXLYY'(.!\BQ.:XF+IRQV,:
M]AE.48>I)I8K-LRJ)8;!T;1FZ<)2EB<2X2I8/#XFORTI?I5\4?C!\-/@MX<E
M\5_$[Q?I'A+1U\Q+=K^9GO\ 4YXU#M9Z-I-JD^J:S>A6#FTTRSNITC)FD1(5
M>1?Q6_:!_P""L_BK6FO?#_[/7A\>$=,)DA_X3SQ9:6>I>)KE>5\_1_#S-=Z)
MHRDC='-JK:]/-"ZL;/3;A2J_E%\0OB7X]^*_B2Z\7?$;Q7K'B[Q#>9#ZAJ]T
M9O(AW,ZV>GVJ".RTO3XF9C!IVFVUI86X8B"WC!(KAZ_B3C[Z27%7$<J^!X54
M^%<GES05>E.,\^Q5-W7-4QL;PR_F5I*GE_+7I2O%X^M!G^KW@[]!?P\X(AA<
MW\0I4O$+B:')5>#Q%*=+A# 5DD^2AE=2U7.>27-"5?.7+"8B'+-9/A:D;OJ_
M&7CKQG\1-<N?$OCOQ1KOB[7[OB;5?$&IW>J7GEAF9+>*2ZED^SVD18B"SMQ%
M:VZ8C@ACC 4<I117\Y5Z];$UJF(Q-:KB*]:<JE:O7J3JUJM23O*=2I4<ISG)
MZRE*3DWJVS^W\+A,+@<-0P>!PV'P>#PU*%'#87"T:>'PV'HTURPI4*%&,*5*
ME"*2A3IPC&*5DD@HHHK(Z HHHH **** "BBB@ HHHH **** "BBB@#8T'Q#K
MWA75K/7O#&MZMX=US3I1-8:QH>HW>E:I93 8\RUO[&:"ZMWP2"T4JD@D'()%
M?J5\ /\ @JQ\4O!#V>A?&W3%^*7AE/+A/B&Q2STCQYI\"X7S&=$M]%\2"*-0
M%AU"+2]1N9"TUUK\C95OR=HKZKA;C?BG@O%K%\-YSC,MDYJ=;#0G[7 8JUE;
M%X"LJF$Q'NKE4JE)U*:UI3A)*2_._$'PG\/?%++GEW'/"V69Y&-.5/"XZK2>
M'S?+U*[YLNSC"NCF."M-J<J=#$QHU6E&O2JTW*#_ +'/@M^T1\(?V@=%;6?A
M?XPL-;>WBCDU709]VG^)]#+X7;J^@W?EWUM'YI,,=_''/I=W(CBQO[I%+U[9
M7\2_A?Q7XF\$Z[I_B;P?K^K^&?$.E3"?3]9T._N=-U&TD'#>5=6LD<H21<QS
M1%C%/$SPS))$[(?VP_9:_P""J<%R=.\%?M+Q);7!,5I9?%71K$+:RL<(C>,M
M L(L6K%LB36M MC:Y:,7.B6D4=SJ)_L[PY^DIDF?RP^5<:4J'#N:SY:=/-*<
MI?V%BZCLE[6564ZN53DWI]8J5\)I*4\91O"D?Y<^-WT%.+.#J>,XA\+<1B^-
M^'J7/6K9!6IP_P!;LNHJ[?U>GAX4\/Q%2II-OZE1PN9>]"%/+,4HU,0?MQ16
M=I&KZ5K^F6&MZ%J=AK.CZI:PWVF:KI=W;W^G:A9W""2"ZLKVUDEM[FWF0AXY
MH9'C=3E6(K1K^GH3A4C&<)1G"<8SA.$E*,X22<91DFU*,DTXR3::::=C^!*E
M.I1J5*56G.E5I3E3JTJD90J4ZD).,Z=2$DI0G"2<91DE*,DTTFF@HHHJB HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /YL_
M^"DW[)O_  IKQ\?BUX)TWROAG\1]3GDOK2TAVVOA#QM<"6\OM,"(/+M]*U]4
MN=6T5%*Q6\Z:KID<5M:V>GK/^8=?VG_$OX<^%/BUX%\2_#OQMIZZGX;\4Z;+
MIVH0?*L\#$K+::A8S,C_ &;4M,O(X-0TVZ",UM>VT$P5MA4_R0?M#_ CQ9^S
MI\4=>^&_BJ-YELY#?>'-<6%H;/Q/X9NI91I6N68)=5\Y(GM[^V624Z?JEM?:
M>\LC6QD?_/?Z0?A8^$LZEQ5DN&Y>&\^Q,I5Z5&%J>49O5YJE7#\L5RT\'CFI
MXC!VM"E46(PJC3A3PRJ?[1_0N^D''Q(X6AX>\4X[GXYX0P-.&#Q&)J7K\2<-
M8?DH8?&<\GS5LRRE2I8+,N;FJUZ+P>82G6JUL;*CX?1117\WG]RA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 Y$>1TCC1I))&5(XT4N[NY"J
MB*H+,S,0%4 DD@ $FOZ@?^"?7[**?L\?#(>)O%FGK%\6/B+:6E_XC$\8-SX8
MT/BYTGP?&Q&Z&>'<M_XA$>P3:PZ6<AN(=&L9S^?O_!,?]D(^-==MOVA_B'I1
M;PAX7OV'PXTN]A_=>(_%5A,4E\221RC$VD>%[F,II[!6CO/$<982J-"N8+G^
M@>O[:^C;X6/!T8>(>>X:V)Q5*=/AC#5H6E0PE6+IU\XE&2O&IBX.5# -I6PD
MJV(7/#%8></\I/IT?2#CFF*J^"O"..YL!E^(I5N/<?AJB<,7F.'G&MA.&85(
M/EE1RVM&&+S=)ROF4,+@I.E4R_&4JA1117]?'^:04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !117Y<?M8?\%+? WP?DU+P
M/\'TTSXC_$:#SK2^U?SVG\#^$KM<H\=U=6<J/XDU:W<;9=+TNY@LK27?'?ZM
M'=VT^F/\UQ5Q?P]P7ED\VXCS*CE^%BW&C&5YXG&5DKK#X+"PO6Q-=Z-QIQ:I
MQO4K2ITHSJ1^[\/?#7C7Q2S^EPWP1D>*SG,)*-3$U*:5+ 99A92Y7C<UQ]5Q
MPN PD7=*I7J1E6FE0PT*^(G3HS_0/XF_%GX<_!OPW/XM^)GB[2/"6B0[UBFU
M*<_:]0N$3>;+1],@6;4M9ORGSK8Z7:7=T4#2&(1J[K^(O[0W_!6'QCXC:_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#+ZW-E?#$Y/&N$KT\3GU6'+7YK:2664)/!PO:5/$U<P@[KE9_LE]!#P=7!_
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M<1+GKXO'8VM/$8K$UIZ<U2M7J3J3=DN:3LDK(****Z3@"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M88J;EB<?CJRA'VV+Q=6K7FHQBYJ$(0B4445X1]<%%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBO%/J@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*LX9;GV7PFW[*LHJ:P^.PZG4GEV94Z<Z^"K3FG"OA*^+PF)_AZHK]H/VZO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M445[A\F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@<KI+FJXIW^M:***_L _S/"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.6X>K[+/,WH\R:Y\;C*;RC#U8\M6E2P&9T]:.-U****_D _TN"BBB@ HHHH
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MV.+PTZN&K6U=*K.VMF?'^('!64^(O!?$G!.>0YLNXCRO$9?4J*"G4PE>257
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >*?M$_&
M32O@'\'/&_Q0U/R9IM TIX]"TZ9MHUCQ/J#"Q\/:7A6$K17.ISP-?-"&DMM-
MBO;S:4MG(_CXU[7-6\3ZYK'B37KV;4M;U_5+_6M8U&Y8-<7^J:I=2WM_>3,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH4I/(,UK<J<G]9P=*ME.(K3<:=/ZCE-&-ZF(U^M:***_L(_S+"BBB@ HHHH
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M8>;3C&5OR+\2>(=8\7>(=<\5>(;V74M>\2:OJ.NZSJ$YS+>ZGJMW+?7UR^.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)J5#':S4445_;Q_D^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?F2GQIX&6VT;4+FZ?+&?6],$$FB:\TLFTW5Q?6']K2Q*8H-5M=V\?C)\<?\
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MN)\1]5X?R7,LWK)J,U@<+5K4Z/-M+$5XQ]AAH;?O,14IP5U>2N?(<7<?\$\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4GALTE%-ZNM)I*SO[+1117]HG^684444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!^0O\ P6%W_P#"G_A3C_5_\+*NM_\ O_\ "+ZKY?\ X[YM?SXU
M_1'_ ,%?[-Y/@'\.K\+E+7XO6%JY_NM>^#?&,J9] ?L+#)[X'4U_.Y7^<'TD
MH./BIF<G>U3+,FG&_98&G3T\N:$OG<_W'^@O4C/Z/60QC:]'/^**<[;J3S:K
M65_/DJQ?HT%%%%?@Q_8(4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_2[
M_P $I-__  RM\_W?^%E>,/*_W/LNA9_\B>97\T5?TY?\$M;-[;]DK09G7"ZC
MXT\;7D1_O(FIIIY;_OY8R+_P&OZ+^B_"4O$JK)7M3X:S6<O*+Q.6T]?+FG%>
MMC^(OI_5(P\"<-&5KUN.^'J<+[N2P&>5G;SY*4GZ7/T6HHHK_0T_Q4"BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK_5\HX>RO&9MCZGN\[H8.C*JZ5&,G%5,3B)1CA\+13YJV(JTJ4+SG%/]R_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV8;?Q]X;\$_$FQ3;YUR;2;P=X@GQPV+_ $43:#%N')QX5;#<@A?D/WQ\-/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8VO._LHV_F4HHHK_ #:/]T0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLVFL9F-"MF=:E)1J4_[,RZHKTL3K+1117]MG^484444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !17QA^T-^W;\!_V>A>:1J>N'QKX\MP\8\"^#IK;4-1M
M+E<@1^(=3,G]E^'%1]GGP7T[ZPL+B>UT>\08K\.?C]_P41_: ^-[7NDZ=K!^
M%W@BY\R(>&/!%W<VM_>6KY7RM>\5CR-9U0O&SQ7-O9G1]'NXFVSZ0Q&X_CO'
M?CCP/P,ZV$JXUYWG=+F@\GR>5.O4HU5IR8_&.7U3 \KLJE.=2IC()\T<)-']
M-^$7T3?%GQ:6%S+#Y6N%.%<1R5%Q-Q+"MA*.)H2L_:91EJC_ &CFW/"[HUZ5
M&CEE247">94I'[N_'3]M[]GKX!&[T[Q/XPC\0^+K4.I\#^"E@\0>(HYTR#;Z
MF8[B'2= E!VEH==U/3KIHF$MO;7 X/XZ?&W_ (*J?'#Q\UYI7PNL=.^$7AR7
M?$EY:&+Q!XUN8&RA:77+^U33M,,J;71='T>WO[*1F6+6)]JRU^79))))))))
M).22>223R23R2>M)7\?\9_2%X^XJ=7#8#%QX6RN;E&.%R6I.&.G3>RQ.;RY<
M9*:3<9/!_4*,XNTZ$K7/],?"[Z%G@[X>K#XW.,OGXA<04E&<LQXIHTJN54JR
MM>6!X;@YY;3IMJ,H+,WF^)I33=/%Q3LMKQ!XD\0^+=6N]>\4Z[K'B37+]_,O
MM8U[4KS5]4NY.?GN;^_FN+J9ADX,DK8' P*Q:**_#*E2I6J3JU:DZM6I*4ZE
M2I*4ZE2<FW*<YR;E*4FVY2DVVVVW<_K>C1HX:C2P^'HTJ%"A3A2HT*-.%*C1
MI4XJ,*=*E!1A3IPBE&$(148Q2222L%%%%0:A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110![=\(_VC_C9\#+M)
M_AC\0]>\/6?G>=<: TZZGX7O7+9D:\\-:HEYHLLLJ[D-VMFE]&KN;>ZA<AQ^
MN7P/_P""NFB7_P!CT7X_>"I-"N6V0OXW\!QSW^D$G"FXU3PK>3S:M8QJ%,D\
M^D:CK<DLC[;?2+>-<#\'Z*_0N$/%/CG@B5..1YYB/J,&F\HQ[>.RJ<;WE".$
MKR:PW/ISU,#/"UVDE[6Q^*^)?T>O"7Q8IUZG%G">"_M>M%\O$F41CE'$5.=K
M1J3S+"0B\?[--^SH9M2S#"Q;;^KN6I_:7\._BE\._BSH4?B7X;>,M!\9:,X0
M276BWT=Q+9R2+O6VU.Q;9?Z3>[1N:QU.UM+Q!R\"UWM?Q2>"O'GC7X<:[;>)
MO 7BG7?"&OVN!%JGA_4KK3;HQ[E9[>=K:1%NK.8J!<65TLUI<IF.XADC)4_K
MQ^S]_P %:M<TTV/AW]HCPT-?LQY<!^(/@ZUM[+6HEX7[1KOA8-;Z7J.6;S+B
MZT*;1WA@C(@T6_G;#?UOP/\ 2<X9SIT<#Q?A7PSF$^6'U^DZF+R2M-Z<TIJ,
ML7E_-)JT:\,1AZ<4Y5<=%(_S<\6?H$<><*K$YMX:YA'CW)J?/5_LBO&CEW%>
M%I+WN6G1<XY=G7LX)N4\'5P6-K3<88;*:DF?O'17G?PT^+/PW^,7AZ+Q3\,_
M&&B^+]%?8LL^EW.;JPFD4NMIJ^F3K#J>C7VP;S8ZK9V=V$P_D[&5CZ)7]+X7
M%X7'8>CC,%B:&,PF(@JN'Q6%K4\1AZ].7PU*-:E*=.I"724)2B^C/X0S#+LP
MRG&XG+<UP.,RS,<%5E0QF S##5L'C<)7A\='$X7$0IUZ%6/VJ=6G&<>J0444
M5T'&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!^,'_!8SP@;GP?\%O'L<) T?Q)XG\(W<ZK][_A)-,L
M-8T^*5O^F?\ PBVI-"#CF:<\YX_!:OZJ?^"BO@,^//V2_B6L$!GU#P<FD>/-
M/PN[R1X;U*"36I^ 2!'X8N==RPQM!RQV!@?Y5J_SK^DQDTLM\2ZN/4+4L_R?
M+<P4DK1=;#4YY35A?9SC'+Z52:72M"3UD?[;?0-XGCGG@1A\FE4YJ_!_$V>Y
M*Z<I7G'#8ZM3XCP]2V_LIU,ZQ-&FWIS8>I!:02"BBBOY[/[2"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /V._X([^$3>?$;XP>.WB)7P_X+T/PK#,R_*)
M?%FMOJLJQL1@R+'X.3>5^9$E4-A90&_?JOS$_P""4'@,^&?V:[[Q=<0%+OXC
M>.M<U6WG9-K2Z)X?CMO#%E$"1ETAU;3/$$B-G&;E@!P2?T[K_3OP*R:62^%O
M"U*I'EK8_#5\XJNUN99KBJV+PLFO^P&IA8WZ\M]FD?X%?2ZXGCQ3](/Q"Q%&
MI[3"Y/CL'PSATGS*G+A[+L+EN/@GM_R-J.83:7PN;CJTVRBBBOUT_FP****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW'^S3:YI589W@)323ER8925HQFSY.HHHK^(C_5\**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH [CX9>$9O'_P 1_ /@:W1Y)?&'C+PSX954R& UO6;/3G<L
M/N)%'<-))(2%BC1I&*JI(_M-CCCACCBB18XHD6..-%"I'&BA41%& JJH"JH
M   '%?R]?\$S?A^_CC]J_P (ZE);^?IOP\T;Q#XYU#<O[M9+:Q.A:,Q8\"6+
M7M>TR\B4'<WV1R!M1RO]1%?W?]%+)7A>%>(L]G!QEF^<T<%2;6L\-D^%YHU(
MNVL'B<RQ5+?XZ,TUHF_\@_VB7%4<Q\0^"N$:513APSPQBLTQ$8RNJ6.XFQZA
M.C.-]*BP.1Y?7U7\/$TVGJPHHHK^J3_/,**** "BBB@ HHHH **** "BBB@
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M9O2IF>:XF5+ 8&#C>4(U\1"K7Y7##TJU2T'^IVJZMI>AZ=>:OK>I:?H^DZ?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7!TZ:NIYEAIXG++1C/$5L%4K0PR^VZ***_<3^2PHHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHJQ9VEUJ%W:V%C;RW=[>W$%I9VL"-+/<
MW5S*L-O;PQJ"TDLTKI'&B@L[LJ@$D4TG)J,4Y2DTHQ2;;;=DDEJVWHDM6Q2E
M&$93G*,(1BY2E)J,8QBKRE*3LE%)-MMI)*[T/WT_X) _#%])\ ?$OXM7UMLF
M\8:_8>$="EE7#_V1X5@DO-4N;9N]M?ZOK,=I*<DFYT KA?+R_P"QE>,_L\_"
MV#X*_!/X;?#*-(5N?"WABR@UEX-IAN/$E\7U7Q-=Q,O#176OWVI3Q$ECY4B
MLV,GV:O]7_#;AG_5#@;AK()PY,3@\MIU,?&RNLQQLIX[,(M[R5/&8FM3@WK[
M.$%HDDO^='QUX\7B7XM\=<94JKJX',\\KT,HG=V>1Y5"GE.334=H.MEN!PU>
MI&.GMJM25Y.3DRBBBON#\F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBO+_ (M?&;X:_ [PM/XP^)OBG3_#6D1^
M9'9QSN9M4UF\1-XT[0M)@$E_JU^X()@LX9!!&3<W;V]I'+<1\V,QF$R["U\=
MC\5A\%@\+3E6Q.+Q5:GA\/0I05Y5*U:K*-.G"/64Y)>9W99E>99UF&$RG)\!
MC,TS3,*\,-@<NR_#5L9C<9B*CM"AAL+AX5*U:K)_#"G"4G9NUDSU"O@;]IC_
M (*%?!GX ?VAX<T>XC^)GQ*MO-@;PKX=OH1I>BWB979XK\1HES::;)"ZLLVE
MV,6I:U'(BQ7=C8QRK=+^47[4?_!2KXG?&4ZCX2^%YU#X6_#>8RVTLEI="/QS
MXFLVRC?VSK%G(5T6RN8\>9HVA3 E'FM=0UC5K67RE_,TDDDDY)Y)/4GU-?R%
MXC_2<ITG7RGP[I1K37-2J<2XZ@W2B]4Y95E]:*]JT]8XK,(*E=24<#6A*%8_
MTL\#OH$5<1'!\1^->(GAJ4O9XBAP)E.*2Q,XNTE#B+.,--_5U)753+\GJNNE
M*+GFV'JQJX4^E?C]^UI\;/VCM0=_'WB>2#PW'<>?IO@7P_YVE>$--*MNA;^S
M5GEEU6[A))CU+7+G4]0BWR)!<0P,(5^:J**_C[-<WS3/,=6S/.,PQ>9X_$2Y
MJV+QM>IB*\[7Y8\]24G&G!/EITH\M.G%*%.,8I)?Z9\/<-Y!PEE.%R+AC)LN
MR')\%#DPV797A*.#PM*Z7-/V=&,5.M5:YJU>ISUZ]1NI6J3J2<F4445YQ[84
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !6YX;\3^(_!VMV'B3PGKNK>&_$&ES"X
MT[6=#U"ZTS4K*8<;[>\LY8IX]RDI(H?9)&S1R*R,RG#HJZ=2I1J4ZU&I.E5I
M3C4I5:<Y0J4ZD)*4)TYQ:E"<))2C*+4HR2:::,J]"ABJ-;#8FC2Q&'Q%.=&O
MAZ].%:C6HU8N%2E6I5%*G4IU(-PG3G&49Q;C)--H_:K]FK_@J]JFGM8>%/VD
MM-;5[#]U;0_$WPW81QZM;#A!-XH\-6:1VVI1#):?4?#T5I>1Q1@#0M4N9'FK
M]M/!?CGP?\1O#MAXL\">)-'\5^'-23=9ZOHE[#>VCL IDMY6B8O;7EN6"7=C
M=)#>6DN8;J"&560?Q0U[/\%?V@?BO^S]XC7Q)\,?%-WHTDSQ?VMHL^;WPUXA
M@B/%MKFB3-]DO5V%XX;M!!J=BLLCZ=?6<S>:/Z:\.?I)Y_D#H99QG&MQ'D\>
M6G',4XO/L%#1<TJM24:>:TXI-N.*G3Q<FW)XZ:C&B_X+\;OH+<'<8QQF?>%T
M\+P/Q+)3K3R.49KA#-*KUY*="C"I6X>JS>D9Y?3K9;%1C!952<YXE?V0T5^>
M7[*__!1#X6_'\:=X3\7&T^&GQ3G\JWCT/4KP?\(YXGNVP@/A/6[DQJ;JXDP8
M_#VJ&'5 \J6VG3:YY4UT/T-K^W>'.)\AXMRREF_#V9X;,\#5LG.A*U2A4LI.
MAB\/-1KX3$133E0Q%.G42<9<KA*,G_E!QQP#QAX;Y]B.&^-<BQV0YMA[R5'%
MP3H8NAS.,<7E^,I.IA,PP5246H8O!UJU!RC*FYJI"<(E%%%>\?'A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% %34+"RU6PO=+U*U@OM.U*TN;"_LKF-9;:\LKR%[>Z
MM;B)P5E@N())(I8V!5XW92"":_D#_:B^"=[^S[\;_&_PVF2=M)L-0.I^$KV?
M<S:CX0U@M>:#<^:V!//;VSG2]0E7Y!JNGW\8_P!77]@]?DO_ ,%7_@/_ ,)E
M\+]#^-FAV7FZ_P##"<:9XC:&/=-=^!M<NTC6:3:&DE'A[7YK>XB15"6]CK.M
MWDS+'"2/Y]^D9P0N)^"*F<X2CSYMPG*KF5-QC>I5RJ<8QS>AI]FG2ITLPN[M
M+ SA!7JN_P#9OT(?%=\ >*]'A?,L3[+AWQ&CA\BKJI/EHX?B&E.I+AO&--V4
MJ^(K8C)K*R;S:G4J/EP\;?SOT445_G2?[=A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 =.E?UH_L0_'#_A?/[._@OQ-?W?VKQ7X?
MA/@GQLSOON'\1>'8+>'^T;@GEIM>TF;2]>E8*(UGU*:%!^Y('\EU?J;_ ,$J
M/C=_P@GQJU/X5:O>>5X>^+FG+%IRROB&W\;>'HKJ^TAE9SLA_M72GUC3'"!7
MO;\Z+ 2QBB6OW?Z//&3X6X_PN Q%7DROBF,,EQ2E*T(8Z<W/*,0UHG-8R3P2
M<GRPI8^M)ZI6_D+Z:OA?_P 1!\',PSC X;VV?^'M2KQ1E[A#FK5,IITE3XEP
M<79R5*66P6:2A%.56OD^&IJW,S^CNBBBO](3_#0**** "BBB@ HHHH ****
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M,J5&:34X+.,WI4X4YQ;C4P^59CAZD7"MKT5%%%?WD?X_!1110 4444 %%%%
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MZ+_$E7U5^S)^UY\5/V8=?6?PQ>MKO@F^NDF\1_#W5[F;^PM54[4FN]/<"5]
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M=AHNBZ3:37^J:MJEW!8Z=I]E;(9)[J\O+EXX+>WA0%I)99%10.37X'_MC?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 *"0002""""#@@CD$$<@@\@CI7ZK_LE_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAA\SO3CI1AC)>RS3"TKMPP6/PJ;NV%%%%?GY^S!1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2=#'8K'+E4IR;****_%C^IPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_0S+/:;M*G0O4P&5U%SQ^MXZ-&O@BBBBOY5/]#@HHHH **** "BBB@ HHHH
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MX4HHHK^.C_3D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC)----IIW3L%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M< HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'&\ZV,R6FN:>)P#]IB\J@G6HNOERJ1RW]@Z***_K$_SF"BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0^"]:\?_ ! UNVT'PUH=N9;JZG.Z:YG?*VNFZ;:J?.U#5+^4""QL;=7FN)F
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M*48Z***_-3]V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(*]7%9_D&%I1]V$?>K9KE5&/+"//CL%",(UZ"_;JBBBO[*/\O@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *\._:1^#MC\>?@KX\^&-VL"WFNZ/+-X=O)P NF^*M,9=1\.7QDQOB
MACU6WMX;XQ%7FTV:]MBVR=P?<:*XLRR_"9ME^.RO'THU\%F.$Q&!Q=&6U7#8
MJE.C6@WTYJ<Y)-:Q=FM4CU,CSG,>',ZRGB#*,1+"9KDF98+-LMQ4/BP^.R_$
MT\7A:J5U?DK4H2<7I))Q>C9_$)J6FW^CZCJ&D:I:36&IZ5>W6FZC8W*&.XL[
M^QGDM;RTN(SS'-;W$4D,J'E9$93R*I5^EO\ P5#^!_\ PK/X]_\ "P-)L_(\
M+_&.TG\1!HDVP6_C+3F@M?%UJ, _O+YY]-\122.VZ:ZUN]5%"6YQ^:5?Y+\7
M\.8OA'B;.N&\9S.ME..JX:-22Y?K&&=JN#Q272&+PE2AB8+I&JD[--'_ $>>
M&O'&7>)/ ?"W'.5\D<-Q'E&&QU2A"?/]2QR3H9GETI?:J9=F5'%X&H]G/#R:
M;33"BBBOG#[@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK3I)1117Q9^IA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM\&M,O=NK^)3'Y-_XFEMI,7&@^$%GC9)[AF4V^H:VT<NG:/^]!%YJ,:Z<_\
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M7Q;-'N7[-X1T,?VEKS&9>;>6]M(#I-E,>%U+4;)<$N ?GJOW]_X)'?!/^PO
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5_8!_F>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MON)L-:LI+;[1$K%/M6GW/SV>J6+L"(M0TVXNK*;&8;AQS7]J%<-\0?AE\/\
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M67QO*-&GR8#.*4%JU/"5ZKP^)Y59*6%Q<JU9IN.$IW43_33PQ^GIX8<5PP^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\.6UM>6S8&(O$LP^;(V_D!7^<?TC>*O]8?$/%9=0J<^!X7P\,FI*+O"6.O\
M6,TJ6Z5(XFHL#4VO]0AIU?\ N)]"#P\_U*\%,!G>+H>RS?Q QM7B?$2G&U6.
M4\JP7#]!RLN:A/ T99M0WM_:]376R****_ S^Q HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHKZW_8>^"_\ PO']H_P'X:O;3[7X9\/W
M1\<>,5=/,@;P_P"&)K>Z^Q72X^:WUK6)-)T"895A'JCNI!3->KD>3XSB#.<K
MR/ 1Y\9FV/PN PZ:;C&IBJT*2J3M\-*DI.I5GM"G"<VTHMGSW%O$N6\&<,<0
M<69Q4]GEG#N48_.,:TTIRH8##5,1*C2OI*O7<%0P]-7E4KU*=.*<I)/^AO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<_XK\4:'X(\,Z_
MXP\37\6E^'O#&D:AKFLZA,?DM=.TRVDN[J7:/FDD$43"&&,-+/*4AB5Y9$4Y
MU:M.A2J5JU2%*C1ISJU:M22A3ITZ<7.I4J3DU&$(13E*4FE&*;;21MA\/7Q>
M(H87"T:N(Q.)K4L/A\/0A*K6KUZTXTZ-&C2@I3J5:M2484X03E.<E&*;:1\
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M _>$'B/Q%)8+ 5Y"M)X6N-^=Q5-NUOW2HK]%R7Z-7AGE<H3QF'S;/ZD6I?\
M"KF4J='F5GI1RJEEJE"__+NM*LFM)\Z/Q'BGZ=OCSQ!"I1RS'<.<'49J4/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0$C"^3XDC*J2"7;#+^L%%?>Y1X!>%F42A47#<<RK0M^]S?&XS'J5OY\+.M'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+#1?LZ,$BBBBOEC]""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=6>!3J2]ZK5R^I#$93BJK2=7%Y?7J**A.#91117Z(?B84444 %%%% !1110
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M^(5=<\.(,H?U#,YU(K^']=JT8YG1IMMQPN.P[;=[A1117Y^?LP4444 %%%%
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MZ@_>O[N'1117\*'^NH4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%8OB3Q#I'A+P]KOBK7[R/3]"\-Z/J6NZQ?2_ZN
MSTO2;.:_OKE^Y$-M!+)M'+;=HR2!45*E.C3G5JSC3I4H2J5*DY*,*=.$7*<Y
MRDU&,8Q3E*3:22;;LC6A0K8FM1PV'I5*^(Q%6G0H4:4)5*M:M5FJ=*E3IQ3E
M.I4G*,(0BG*4FDDVT?C'_P %</CR;>R\(_L\Z#>D27_V?QUX^6"0C%G!++!X
M2T2YV$JRSWD5[KUW:R[7C:Q\/W:@I,K5^%M>H_&KXH:O\:/BMXZ^)^MF1;SQ
MAX@O-2@M9'\PZ;I*%;30](1\G=%H^BVUAID39):.T5B2S$GRZO\ *?Q-XQJ\
M=<:9UG[E-X.I7>$RFG*Z]CE.#;HX**@]:<JT%+%UX;+$XFNUHS_HA\!/#&AX
M1^%?"W!RITXYI1P:S+B2M#E;Q/$>9QAB<UDZD=*T,+4<,MPE71RP.!PJ:O$*
M***^"/V(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS*G327)"&'SVCFM&E2AI3P\*&D5)111117[$?S(%%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1YO5P^8*G)-5</EN*CIJU\04445_FR?[IA1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMHU%7L[I%%%%?LA_,(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$9HW'Y85_4I_P3?^$@^%O[,'A._O+80:_P#$V>?XC:LS)B7[%K,4%OX7@#L
MY@_X1FSTN_2(@)%=:E>E%)D=Y/W#Z/?"O^LOB/EN(K4^? \-TYY_B>9>ZZ^%
MG"GEL+O3G68UL/B5%W<J>&JV5DVOY-^FCXA?ZB^!V>X+"U_99MQS7I<'8%1E
M:HL)F%.K7SVJXIJ3I/)<-C,%*::5.MC\/=MR49?>E%%%?Z4'^%(4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHQA"$5&,4DHQ225D%%%%2:!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'IWP6^'%[\7?BQ\/OAI8>:)/&7BK2='N9X1N>RTN6Y676M2Q@Y
M72]'BOM1DX/[NU?@]*_LNT[3[+2-/L-*TVVBL].TRSM=/L+.%=L-K964"6UK
M;1+D[8H((HXHUR<(H&:_GW_X)&?"C_A(?BOXU^+E_;;[#X=^'DT+1)9$P!XF
M\8^=#-<6SGAI+'PY8ZK:W*+RB:[;,Q =0W]"E?W[]%WAC^R^#,?Q'6I\N)XF
MS%QH2:U>690ZN%H-7U7/CJF8N5O=G"%&6ME;_&W]H#Q__K!XHY/P/A:_/@>
M\EC+&4XRO%9_Q)&AF&+4E%\LO9912R2,'*\J52IBH6CS23****_IL_@D****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1O X3,Z=M&U-ZV33^?Z***_@4_V-"BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4JU*;IU:52+LXSISC*$XM7C)-/5!1115F04444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %?K1_P2"\1&R^.GQ$\,
M.^R'Q!\+Y]352>)+WP]XGT".!,=W%IK>H2 XX5']>?R7K[]_X)DZXVD?M@>
M;/=L3Q)HGCG0Y3G *IX1U;78U;D9W7&B0JH.<N4P,XK]%\(\<\O\3.",0I./
M/Q#@,$VM/=S*I_9TD_*4<6XOR;/Q'Z264K.O ;Q7P;AS^RX,S?-5&U_>R*DL
M\A)+O">71FNMXJVI_471117^J9_SRA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5Y?\ &[Q"WA+X,_%KQ2C^7)X=^&GCK6X7!VD3
MZ9X8U2\@"G@[VFA14 Y+E0.2*]0KY'_;PUMO#_[(OQQOU?89_"MKHF<XROB7
MQ!HWAQDS_P!-%U4ICONQWKP>*<<\LX8XCS)/E>7Y#F^.4OY7A,OQ%=/Y>SN?
M7^'N5+/N/N!\CE'G6<\7\-94X-74UF.=8+!N+77F5:UO,_DOHHHK_(4_Z60H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5_+A_P4F^%'_"LOVH?%6HV=MY&A_$
MZTM/B)IA1,1"^U9Y[/Q/$9  C7#^)=/U/4Y8P \<&J6I<$2)(_\ 4?7Y1?\
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M*,:5#/(YMA*48>[&GAXI*/P1****_73^; HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K\]?\ @J#JIT_]D3Q=:!MHUWQ1X&TIAG&\0^(K76]OOAM'5L?[
M.>U?H57Y<_\ !7"_-I^S-X:ME/\ R$_C%X8M'&>L</A3QSJ!)]0)+*(?4J:_
M//%K$/#>&G'%1.W-PYF6'OY8NA+"M?\ ;RK6^9^U?1QP2Q_COX3T)+F5/CC(
ML;9]\NQ<,PB_^W98527FC^;VBBBO\JC_ *'@HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#[G_X)N:H=,_;'^%"%ML6J1>.-+FYQD3^ /$\\"^^;RVM>/Q'(%?U0U_)
M%^P]?G3OVL_@5<*<&3QO;V&<XXU2PO\ 3&'_  );LKCOG%?UNU_?/T4\0Y\"
MY[AF[^PXKQ-1>4<1E.4*WIS49OU;/\<_VB."5+Q=X2QT4DL9X=X&A)K[53!\
M1\22<GY^SQ5*-^T4N@4445_3Y_ 84444 %%%% !1110 4444 %%%% !1110
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M5W:X4445X1]>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>A_"&Y-E\6/AA> X-I\0_!5R".H,'B73)01]-E>>5V/P[?R_B!X%D'\'C'P
MP_\ WSK=BW]*[<MFZ>8X":T<,;A9I]G&O3:_(\K/::K9'G-*2O&KE68TY+NI
MX2M%K[F?VKT445_L6?\ ,8%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7Y)_\%@;@K\#/AI:=I_BQ!<$=LVOA#Q1$/R^V''U-?K9
M7Y!_\%AF(^$7PG3G#?$B\8^F4\,:D!^/SG'XU^5^-TN3PJXS??+:,?\ P/,,
M'!_^E']"_11IJI](;PNBU=+/<34^=+)\SJQ?RE!/Y'\^=%%%?Y=G_0&%%%%
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MXS@3/9RPE-RNX9%Q*Z^8X1)-\SY<WHY[S->["$Z$;)VO7HHHK^93^]0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]O\ _@CQ\2]L_P 6
M_@]=W'$L>E_$?0;8M@!HF@\->*9 I/+.LGA$#8,@1R%LC!'X@5];_L+_ !+_
M .%6?M2?"G7)[C[/I.N:X/!&N%WV0-IWC.)M!BEN7R MOI^JW>FZL[$A5.GJ
MSY16!_1_"3B+_5?Q%X6S2=3V>&EF5/+L;)NT%@LUC++J]2IWAAXXE8JW25",
MEK%'X=])+@G_ %_\$O$'(*5'VV.IY'6SO*H1CS599IP[.&=X2C0ZJKC)8&6
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M$-*7DW@\FKV_\!K)_,****_G8_MH**** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7Y$?\%A(R?@W\+)<'"?$V:,GL#+X5UE@#[GR3CZ&OUWK\H_\ @KY:
MF3]GCP#> 9^S?&;1H"0,[5N_!/CQR3Z M:H,],E1U(K\M\:X.IX6<:16MLKA
M/Y4L;A:C^Y0N?T#]%:JJ/TA/"V;VEQ#4I?/$99F%!?C41_.G1117^7)_T#A1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'O7[*\9E_:9_9]4 G'QH^&<F!Z1>,='E)^
M@"$GV%?V'5_(9^QO:_;/VI_@)#C=L^)OAFZQU_X\;Y+W/_ ?L^[VQFOZ\Z_N
MOZ)]-KA?BFKTGG]"G\Z>749/_P!.H_R*_:,55+Q \/J'6GP=C*K]*V=8F"_'
M#L****_JT_SL"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *]^_93T_P#M3]IGX VA7<O_  N#X>W;KC(:/3O%&F:A*I']TQVK!O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*/\ GR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3E>ZO1X?R[%XB*[>SQF-Q--K^:$GU"BBBOVT_E(**** "BBB@ HHHH ****
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MV5S=ZU-86JY!&Z8?*WW3ZQ7Y<_\ !63XB?\ "+_L[Z1X&MI]E]\3?&FFV=S
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7\E'[<_A3_A#OVM/CAI8B\J
M.^\8/XJCPNU7'C73K#Q?)(F!A@T^MRAB,XD5U/S*P']:]?SD_P#!6_P=_8O[
M0OA;Q;#%LMO&WPYTTSR[<>;K'AS5=4TN[^8##>7I+Z O.6&<'Y=M?S;]*+*G
MC?#W"9C"-YY-Q!@J]2=K\N%QF'Q>!J+R4L36P>NUXI6;::_NC]G[Q"LK\:<R
MR6K.U+B?@O-<)1IWMSX_+,9EV;496ZN&!PN9JV]IMWLFG^5M%%%?Y\G^T 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7]#?_!(+PI_9WP3^(_C"2/9-XH^(XTF-B,--8>%
MO#^F202!L<QB^\0ZI"HSQ)%+P,Y/\\E?U=_\$^_!W_"%_LC_  AM9(O+N]?T
MK4O&-VY7:9_^$KUO4=8TZ4CVT2YTN%6_B2%&Z&OZ+^C#E3QWB/4Q[C>&2Y#F
M.+4VM(U\5/#9;""?24Z.,Q,EWC"9_$/T_.(5E/@=1R>-2U7BGC#),NE23LYX
M3+Z6.SVM4:ZPIXK+<#%]5.K3TM=K[-HHHK_0T_Q5"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^[O^";WQ$_X5_\
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MZ-IT1GU#5K^STRQ@7[TUY?W$=K:Q#KS)/*B#@\M7]JO@WPU9^"_"'A7P=IP
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)))62LEHDMDNQ_S:MMMMMMMW;>K;>[;ZMA1110(**** "BBB@ HHHH ****
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /ZGO^"</Q"/C_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=#!TD]$U"Z25DBBBBOK#\Y"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\4L8X).<HGXO4445_G>?[8!1110 4444 %%%% !1110 4444 %%%% !1110
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MYTZD90J0E*$X33C.$XMQE&46DXRC)-232::::N%%%%,D**** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>V4445_?I_C<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA[1HX'+Z$I)2>&RW TL-@,-S>][##T^9N5VRBBBO?/C@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#^2K]N;P#_P *Y_:J^,>BQ0^38ZKXG?QG
MINU=L+6OC>UM_%,BVZX $-I?ZI>Z>JJ L;V;QH-J"ODROV(_X+!^ _[.^)7P
MJ^)$$.V'Q5X0U3PI>R(OR&_\(:J-0@DG('$]Q9>*TAC+',D.G;5X@;'X[U_E
M/XJY&N'?$3B[*HP]G2IYSB<7AH6LH83,^7,\)".WNT\/C*<$^T>]S_HB^CQQ
M7_KKX)>&O$$ZOML15X7P.68ZJW>53,<@Y\@S&K/5M3JXW+*]62?6=UHT%%%%
M?GY^S!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'ZD?\$E
M_'/_  CW[16N>#IYMMK\0? .K6MO!NV^;K?AJZM-?LWQT<PZ-!XC&T#<!*6!
M"JP;^D"OX^OV4/&__"NOVD?@MXM>;[/;67C_ $+3]2GW;1#HWB*X_P"$;UN0
MG(RJ:1J]ZS*2 Z@H2 QK^P6O] /HM9S]>X$S'*)SYJN1Y[75.%_@P694*.*I
M:=.;&1S!]GZW/\:/V@O"_P#9/B]DG$M*GRT.+.$<'*M4M;VN:9%B\3EV)UVE
MR9;+)EK[RO9Z<H4445_3!_!P4444 %%%% !1110 4444 %%%% 'X^?\ !83Q
MM_9WPO\ A3\/XIMDOBGQMJ?B>XC1OF>R\':,; 1R@?\ +&2\\76\RAL!YK16
M7)A.W^?JOU)_X*T^-?[?_:+T'PC!+NM? 7P]TBVN(=V?*UGQ'>ZAKMV^ <*9
M=(F\/C!&X^6&)*LH'Y;5_F-X\9Q_;/BGQ1.,N:CEU?#9/15[\G]FX2CA\3'_
M ,+EBY-=')IZIG^^/T0.&/\ 5?Z/G -*I3Y,5G>$QW$^*=K>U_MW,<3C,!4M
MO_R)Y9;33;?,J:DK)I(HHHK\@/Z7"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /:_V</ 7_"S_ (\_"3P(\/VBT\0>._#\.K1;=^[0;.^C
MU+Q VT@AO+T.RU"3#?*=GS$+DC^QVOYLO^"3_@?_ (2/]I6^\630[K7X>> M
M>U6"<KN$6L:_):>%[2(''RO-I6J:\ZMD';;R+_%7])M?WW]%C)/J7!.;9U.'
M+5SS/*D*<K?'@LJH4Z%%WZ\N,KYC&VRMW;2_QO\ VA/%;S7Q7X=X6I5>?#<)
M<*4:M6GS7]EFO$.+JXS%+EV7/EF$R6=]&[J^BBV4445_3I_ X4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4=>M%% '\N'_!0K]F<_ #XS7.L>
M';#[/\-?B9)?>(_"H@BVV>BZGYR/XC\*+M 2)-,N[F*]TN%56./1=2L;6-I9
M;&Z9?@:O[!/VH/@%HG[1_P '_$?PYU/[/:ZM)'_:_@W6YD+'0?%VGQ3'2;\L
MJO(+.X\V;2]62-6DETB_ODA"W!ADC_D8\3^&M<\&^(M<\)^)M.N-(\0^'-4O
M=&UG3+I=D]EJ.GW#VUU X!*MLEC;9)&S12QE98G>-T<_YN^/?AP^".*YYEEU
M#DX<XDJ5L;@/9PM2P.-NIX_+'9*-.,*D_K.#@E&/U2M&C3YGA:K7^YGT._'&
M/BQX=TLCSK&>UXWX&HX7*\W=:IS8G-\I4'2RC/O>;G6J5:5)X',ZC<ZG]H8:
M6*KNFLPP\985%%%?A)_7@4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !117Z!?\ !/3]EYOC_P#%N'Q%XGTXS_"_X:7%GK7B07$6;/Q#
MK8?SM!\) N#'<174T)U'6XMLB#1K22RN#!)JUE(WN\,\.YEQ9GV6</932]KC
MLSQ,,/3NG[.C#6=?%5W%-QP^%H1J8BO))N-*G-I.5D_D>/.-LC\.N$,^XTXC
MQ'L,IR# 5<9747%5L555J>$R_"1FXQGC<PQ<Z&"PE-RC&>(KTU*48<TH_K!_
MP36_9G_X4Q\(Q\0_$^G_ &?XA_%BULM5FCN(MMWH'@L#[3X=T0AQYEM<ZBLG
M]OZO&#$YDN=,L+R$7&C U^DU       & !P !T '8"BO]6N%.&LNX0X>RKAS
M*X<N$RS"PH*HXJ-3$UVW4Q.,K<NCKXO$3JXBK;W5.HXP2A&,5_SM>(G'>=^)
M?&G$/&_$%3GS+/\ 'U,5*C&4IT<#A8J-' 9;A7+WEA<MP5.A@L/S>_*E0C.H
MY593E(HHHKZ$^*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX2N=8^+>NV^^,1^$(4M?#27"9Q'<>*M5\BVG@88*W?A^Q\00'< &)#A?S/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110!^:/\ P57\!_\ "4_LQ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>:3#/-'+JWAV[SJ'A77E3"[-8T&=_LD\AB!ACU"W^RZO:1.XL-0M'8O7]/<
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M=:M1<E*FYJI"<(E%%%>^?'!1110 4444 %%%% !1110 4444 %%%% !1110
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MAHVV?+EN+SF=]6N6R5G)K\RJ***_@0_V/"BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSJ5<,WS/"UXXG 5*E6>&5>O0HHHK\J/Z'"BBB@ HHHH **** "BBB@ HHHH
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MKIR]IE.7YC!I;*3DTU%I_J;1117^EA_A&%%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]V$<TP,)-R>#KS:C5IWE/!8B2HU)2IU,-6K_ .%GTF?HZYKX%\31K8'ZSF7
M&?5ZLN&\YJQYZN$JI2JU,@S>I"*A',L)33EAZ]H4\TP<'BJ$85J..PV$["BB
MBOV,_F(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJUGJ%%%%>4?1!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M HHHH **** "BBB@ HHHH *[CX<_#CQE\6?&6B^ O .B76O^)]>N1;V-C;*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOTA\T_M+Q4SZG&7-2RO#Y7E=)WNE[+ 4,37CY<F+Q6)@UWBWNS_=KZ%/#_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK!8[!5Z6*PF+PU>"J4<1AL11E.C7HU:<HSIU:<Y0G%J49--,****Q.H****
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MZ%"G3HTX0B4445WGC!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2E-Y/*^=8=SDXT,/3S:%.#JXQ']!-%%%?Z$G^+04444 %%%% !1110 4444
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MM1\773E=K3_\)9KFIZ[82L,#.-(O-.A1OXHH8SDYS7V37^K'A5E7]B^'/!F
M<>2:R# XNK"UG'$9E3_M+$1:_FC7Q=12[R3>NY_SN?2&XA_UI\</%'.%4]K2
MGQAFV78:K>ZJ8/(ZW]AX*<7K[D\)EM&4%T@XJRM9%%%%?H!^-!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!X)^T!^S;\+OVD?";>&?B'HP>\M4F;P[XKTX16WB;PO>3*-UQI
M6H-')NMY65#>Z5>)<:9?B.-KFU:>"VG@_FH_:?\ V-_BK^S#K#OK]H?$G@"]
MNC!H/Q$T>UE&CW9<L8+'6K<M-+X=UMHQDZ?>RR6]RRS'2=0U.*">6/\ K2K*
MUS0]%\3:1J.@>(M)T[7=#U:UDLM4TC5[.WU#3=0M)AB6VO+*ZCEM[B%QC,<L
M;+D XR 1^.^)W@SPYXC49XMJ.4<2TZ?+AL[PU*+==0C:G0S2A%P6-H))1A4<
MH8K#Q451K>RC*A4_IOP#^E%QQX(8JGEL93XEX$KUW/'<*8[$2BL(ZD^:MC.'
M\9*-5Y5C&W*I4H*%3+\;*4WB<,L1*GC*'\1E%?MC^U?_ ,$M+RQ;4O'?[-"/
M?6/[Z\U'X4W]V7O[11EY6\%:M>R$ZA"%RRZ!J]P+]0CKI^IZC+-;:9'^+FIZ
M7J6BZC>Z1K.GWVDZKIMS+9ZCIFIVD]AJ%A>6[F.>UO;*ZCBN;6YAD4I+!/&D
ML;@JZ@@BO\^^-. >)^ LQ>7<19?.@IRDL'F%'FK9;F$(_P#+S!8M1C"I[KC*
M="HJ>*HJ457H4FTG_L[X6>,7 /C%D<<ZX)SFGBY4H4WF>38KDPV>Y+6J+2AF
MF7.I.I23DI0I8NC*OE^*<)O!XO$1A)JC1117QI^H!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%>Y? O]G3XL?M$^)!X=^&GAN;4(K>2)
M=:\27Q>Q\+>'(93D3ZUK+1210N4#R0:?:I=ZM>I')]@T^Z,;A>W+LMQ^;XW#
MY=E>#Q.88_%U%2PV$P=&IB,16F]>6%*G&4G9)RD[<L(J4I-1BVO+SO/,GX;R
MO&YWG^:8')LGRZC+$8[,LRQ5'!X/"THV7/6KUY0IQYI.,(1YN:I4E&G3C*<H
MQ?BEK:W-[<V]G9V\]W>7<\5M:VMK%)<7-S<SR+%!;V\$2O+-/-*RQQ11HTDD
MC*B*6(!_:3]D#_@F#>ZFVE?$;]I2SFT_31Y-_H_PG$CPZE?@[98)_'-S"ZR:
M9:XVN?#-I(NI2EECUFYTXPW6DW/WO^RK^P?\+/V;+>T\07,</CSXJ&$&Z\;:
MM9HL&C22Q[)K7P=I4C3QZ+ %9X7U-WGUN\1YQ)>VUE<?V;#]S5_:WA9]&_"Y
M8\-GOB!"AC\?'DK8;AR$HULOPDU:499I5BW3S"O%VOA*3E@(--5:F-C/EI_Y
M5?2%^G+F&?QQW"'@S5Q>3Y--5<-C^.*D*F%SK,J;O"<.'J$U&MDV$J1NUF5>
M,,XJ*47AZ653I.=>EINF:=HVGV6DZ1866E:5IMK!8Z=ING6L%E86%E;1K#;6
MEG9VR16]M;6\2+'#!#&D44:JB*J@"KM%%?UG&,81C"$8PA"*C"$4HQC&*M&,
M8I)1C%))))))62L?YQ3G.K.=2I.52I4E*=2I.3G.<YMRG.<I-RE*4FY2E)MR
M;;;;844451(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %>,?'#X!?#+]H7PA-X.^)6@QZE;IYTNCZU:F
M.U\1>&K^5 O]HZ!JOE226<^4C,]O(D^G:@D4<&IV5Y;KY5>ST5QYAE^!S7!8
MG+LRPF'Q^ QE*5'%83%4H5\/7I2WA4I5%*,E>S5U>,DI1:DDUZ63YSFW#V:8
M'.\BS'&Y1F^6XB&*P&99?B*N%QF$Q%/X:M"O1E"I"5FXRM*TX2E":E"4HO\
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MEF$YG*& RK P?L,#@Z;=U3I1YZU1RQ&)J5\54JUZA1117TI\(%%%% !1110
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M4445J<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M***XSTPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDP-56:]AA*JYL=4IRORXC'1]F[1J4\%AZL5,_P IO&[Z;O'?B''&9!P'#$\
M<)5O:4:F(P^(3XLS;#RO%K&9GAY<F4T:L;.>"RB?MDG4HULUQE"HZ9%;V\%K
M!#:VL,5M;6T4=O;V]O&D,$$$*+'####&JQQ111JJ1QHJHB*JJH4 5+117]&I
M)))))))))622T226B26R/X?;<FY2;E*3;E)MMMMW;;>K;>K;U;"BBBF(****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*:[I&C22,J(BL[N[!41%!9F9F("JH!+,2  "2<"G5\P?MG?$=OA9^S'\7_%5
MO.;?4I?"MQX9T:1&VSQZOXQG@\+65S;<@F;3WU9M3&,A4LGD8%$8'S<YS/#Y
M)E&:9SBG;#95EV-S+$:V?L<%AJF)J)-]7"FTO-I69[O"^08SBKB7A_AC+U?'
M\19WE>1X/1R2Q.:XZA@:$I)6]V-2O&4M4E%-MI*Y_,/^TI\4I/C1\=?B=\2?
M->:Q\0^*+T:$7)S'X9TH1Z-X8B*GA730=/T_S@H53.97 !8UX=117^0V98_$
MYKF&/S3&3]KC,QQF)Q^*J._OXC%UIXBM/5M^]4J2>[W/^E?(\GP/#N2Y1D&5
MTE0RW(\KP&49?15OW6"RW"TL'A:>B2]RA1IQ;25VKV04445Q'J!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGR0Q7$E+(*EW:,H<3X7$\.I3Z.*GFD)*^BG&,M'%-?S!T445_EL?]!@4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA7?X5N;:YLKB>TO+>>TN[:5X+FVN8I(+BWFB8I)#/#*J212QN"KQR*KHP*L
M017\RY[PSQ!PQBG@N(,GS#*,1>2A#'8:K1A64=YX>M*/L<33[5</4JTWTDS^
M]>$>/.#./<O6:<&<3Y+Q+@N6#J5,IQ]#%5,,YJ\:>-PT)_6L!7MOA\;1H5X_
M:IH@HHHKPSZP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OZ._^"2GCEO$'[//B+P;<2E[GX?\ C_4H;6/=D1:)XGL[36[3
M )RI?6F\1,0 %/!&6+X_G$K]C_\ @CKXL:T^(OQC\#%SLU[P7H7BM(R> _A/
M7)-(D9%/1F7QF@<KRP1-V0BX_;?H\YM+*O%/(J;GR4<VH9EE-?6W-&O@JN)P
M\'WYL=A,(K/K9[I'\H_35X<CQ!]'KBZLJ:J8GAO&9%Q'A%:_)+"YKA\!C:B?
MV7#*<RS%W6ZO':3/WYHHHK_2L_PE"BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?GO$DU-U*5#,<?5G@,+-W3>"RRFZ>6X%.[O'!X6A'5^[JPHHHKZ0^&"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5@G_+*:ZL^;****_@D_V'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]Z6+P5=R723:Z!1117PI^NA1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN*KWUUUOJ%%%%>N?-A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>T^'OAM\.O"+(WA3P#X*\,-'CRV\/>%="T5H]OW=ATVPMBN.VTC':NUHKZ;
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M3J*,H-%RBBBOZ5/X3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(K5/9X7.,?C.&<0K\JJ2XAR[%Y9E]-M_]3:OE\TOM."BM6FOYM:***_S$/\
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M\,O#O)7'DEE/ _"F73BU9^TP>18##U'+O*52G*4WNY-MZL****^:/O HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K=AJ%_
MI5[:ZEI=[=Z;J-C/'=66H6%S-9WMG<PL'AN+6ZMWCGMYXG >.:&1)$8!E8$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5Q'FT(2O#^T,]J1PN7T*T;Z5\'E^7U<3!67[G-XN[YK1****_K4_S@"BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF74-[I^H6-U&LUM=V=Y;/)!<VT\3+)%-%(\;HP96(-?Q#U]Z_L;_ +<WC/\
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MC"K0KT:D94ZM*I"-2G.,HSBI)H****V.8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K\6/^"LO[.LFJ:3H7[1GABPWW6@16OA3
MXCI;Q_/)HT]SL\,>(I@@ /\ 9VH7,FA7]P_F3R0:EHB#;:Z<[)^T]87B?PUH
MGC+PYKOA+Q+I\.J^'_$NDW^B:SIUP"8;W3=3MI+2\MW((9"\,KA)$99(GVRQ
M.DB*P^,\0.#L)QWPGFW#>*<:<\71]K@,3)7>#S+#OVN"Q*LG+DC62IUXPM*I
MA:E>BFE49^H^#/B;F7A#XC<.\<9>JE:EEV*]AG& A+E_M3(L:E0S7 .[4'4J
M8:3K8.52\*&/H83$N+=!(_B4HKWW]ICX#:_^SE\7?$GPWUGSKFPMI?[4\):W
M+'L3Q#X2OY9CI&J+A5C^T*L4NGZI%'F.VU>QO[:-GCB21_ J_P J,SRW&Y/F
M.-RK,L//"X_+L56P>,P]1>_2Q%"<J=2#:O&2YHMQG%N$XN,X2E"2;_Z(<ASW
M*N)\ERKB+(\92S#)\ZP&%S/+<;1=Z>(P>,I1K4:B3M*$N2:52E-1J4JBG2J1
MC4A******X3U@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ K^@_P#X)2?LZR>#_ ^L?'OQ-8>3
MK_Q#A;1O!27$>V>Q\#V5TKWNI(KA7B/BC6+:-H]R_/I>BZ?>6\C6^J-N_(W]
MDC]G;5OVE?C'H7@B)+BW\*Z>R:_X^UF$,@TSPK93Q"ZAAGP5CU36I7CTC25
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M445ZQ\Z%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+B:LG+_5_&5IW=52=VLKQ%23>,I?#AJDGC:2C?%1K_PO]+OZ+U'Q.RW$^(7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMI5_>^#]-N(R9%D7R?$%]']B(FTR#4([G^B%555"J JJ JJH 55 P  .  .
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M^(W2Y:^:8^$6UAL,YKVE#)\ YU*6783W=)5,57B\7B:\Y%%%%?FI^[A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% ']5G_!.?5_[8_8Y^$#N^Z;3H?&&D3#
M.=G]G>._$T%LF>O_ !X?9&QQC=@< $_;E?FC_P $HM7_ +2_97>RW;O^$?\
MB9XOTC&<[//L] U[;CMG^V]^/]K/>OTNK_5WPOQ7UWPYX'KWN_\ 5?):$G>[
M<\+@*.%J-ONYT9-^=S_G5\?\N_LOQO\ %C"*/)'_ (B!Q3BJ<=E&EF&;XK,*
M,5_=5+%04?[M@K^2K]NO53K/[7'QSNRV_P GQ>FE9SG T+1M*T,+_P  &G!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHHKH.(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP&;1;TNXK&8#)6D]6HMMK1.3^(_C^HK^L"\_X)^?L>7TADG^"6BHQ.<6>O\
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MJLIU*LY?:G.4I/JPHHHK4P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'M2_LK]K/X%76[;YOC>WTW.<9_MFPOM'V_\  _MVS'?=CO7];M?WU]%/$<_
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M[JWA?7=&\2Z!?3:9KGA_5+#6M'U&V8+<6.J:7=17MC=PD@@26]S!%*FX%25
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTO/M6@7\@Q\^I>'-02[T+47P-HDO-.FD12PC=,DU^LWP,_X*Z$M::)^T%X*
M!*0GQSX B/R]$$VK^$K^Z8D?\M;N\T75,@;A:: 3MCK^C^#_ *3'!6?2I87B
M"AB>%,=4M'VN)E]>RB4WHDLPH4Z=:A=W;EB\%0H4TUS8F6K/X<\3/H&^*G"$
M,1F'!F*P/B+E-)2G[# P_LGB6G2C[S<LFQ=>KAL6XJT8PRW-,7BZ\DW# PNH
MG[B45YS\,_B[\-/C'H">)OAEXST3QAI!\L3R:7=9O-.EE4LEMK&E7"P:KHUX
MR@N+/5;*SN2F'$10ACZ-7]$83%X3'X:CC,#B</C,)B(*I0Q6%K4\1AZ].7PU
M*-:C*=.I!])0DXOHS^*,QR[,,HQN)RW-<!C,LS'!594,9@,PPM?!8W"5H?%1
MQ.%Q,*=>A5C]JG5IQFNJ"BBBN@X@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'AS*\'F\W+.:TJ<E#$86KE*J153":%%%%?S@?W(%%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $MO-);3
MPW$1VRV\L<T;?W9(G61#^#*#7]O5G=1WMG:7L7,5W;0749SG,=Q$LJ<]_E<<
MU_$!7]I_PPOO[3^&OP\U+=N_M#P-X2OMW7=]KT#3[C=GW\S-?V+]$BO;$\=X
M:_\ $H<.UTO^O-3.J;:]?;QOIT79'^8W[2+"<V!\(L<EK1Q?&V$;[_6J/"U:
M*?>WU237:\K;L_'7_@LMJ'R_L]:6K=3\4-0F7/3 \ VULV/?==C)Z8XZFOPZ
MK]E_^"QMWO\ '?P2L<_\>WA+Q9=[?3[;K&F0Y_'[!C_@/M7XT5^-^/M9U_%O
MBZ5](5<HHI=E1R#*J32_[>C)OS;/Z?\ H<X987Z-_AK!*SJX?B3$R?63Q7&'
M$.(3?_;E2*7]U(****_'C^F@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?!<^7*6'R[]DZ***_K@_S;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0R#):U\?6H3LG[/,<[Y\/7BVUSY%1DK7=RBBBOY1/]% HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%LE>56O7J.]3$XO%593Q&,Q=:4Z^*Q-2I7K3G4G*3****\D^D"BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.)23U25:A-)/5=0HHHKO/'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M $=/\.PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_AP_UI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!R.\;JZ,R.C*Z.C%71U(*LK @JRD
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_&_^T7\06^*GQV^*
M_C\3&>U\1>.-=GTF0G<?[ M+Q]-\.QELD-Y.A66G0Y&%/EY4!< ?U@_M ^-/
M^%=? [XM>-DF\BY\.?#[Q7J&G2;MN=7&CW<6BQAOX6GU:6SA4]0T@(!. ?XU
MJ_C3Z6>=22X0X=IS]UO,<ZQ5.^\HJC@<!.WDI9E&[[Z6UO\ ZA?LX^%HN?B7
MQM6I>_&.2<+9?6MM&;Q.;9Q2YO-T\CG9/[-Y?9"BBBOXR/\ 48**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^CO_@D
M5<>=^S3XNA)YM/C1XEB [A)/!GP^N ?8%YG ]P:_G$K^A[_@C]<;O@3\2;3/
M$/Q:NKC'8?:O!WA.,G\?L@S]!7[[]&JIR>*6"C_S]R?.*?K;#QJ_^X[G\;_3
MMH^U^C]FL_\ H'XFX9K>G-C9X?\ ]SV/R1_;GF\_]K;XZ/G.WQD8?_ ?2=,M
M\?AY6*^3Z^F_VSIO/_:J^/+YSM^(^OPY_P"O:=;?'X>5C\*^9*_)^-)^TXQX
MLJ?S\2Y[/_P+-,5+]3^C/"RG['PQ\.:.WLN ^$*=NW)P_ET?T"BBBOFC[P**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#Z@_8M\9?\()^U1\#]>:7R(9O'.G^&KJ0MMC2T\:17'@^Y>4G@11PZZ\LA;A
M%3?P5!']=%?Q#:5J5WHVJ:;K%A(8;_2K^SU*RF&<Q7=C<1W5M(,$'*31(PP0
M>."*_MET/5K;7M%T?7;,YM-:TO3]6M3D-FVU&TAO(#N'!S%,IR.#UK^W?HF9
MJZF4\89'*6F#S'+<UI1;W>8X:OA*\HK^[_9>'4O\<-^G^3_[1SAZ-#B3PTXK
MA!.69Y)GG#V(J):Q61X_"9CA(S?]_P#U@QCIK_IW4VT-2BBBOZ[/\UPHHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *<K,C*Z,R.K!E925964Y5E88(8$ @@@@C(YIM%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH _.G_@J1XS;PM^RAK6D1R&.;Q_XQ\(^$5*'$AA@NY_&%R
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MG5RCCO#X1NVL<+FV1YPZSOT3Q.7X*+6B=T_LH^_J***_O@_QU"BBB@ HHHH
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M"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'XZ_\%?_ (D'2_AW\,?A7:3E
M9_%WB;4/%NK)&V&_LKPE9K8V-O<+W@OM4\0?:HA@YGT3.1Y>&_ &OT>_X*F>
M.CXL_:GU+P_%,7M/ASX/\,>%413F'[;?6TWB^_E4?=,V?$L%G.PY!L4B;F'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_HU_P""16L?
M;?V=/&.DN^9=%^+FM[%S]RSU'PKX.N8N.HW7:7Y]#VYS7\Y5?O9_P1POFD\%
M?'#32Y*6GBCP=?*F>%;4-)UJW9P.Q<:8@)[^6/2OW?Z-^)=#Q5RFDGIC<NSK
M#/S4,OK8RWGKA$_E<_D+Z<N CB_H\<1XB23>5YWPMCX-])5,ZPV6-KL^3,9+
MT;74_9RBBBO](3_#0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ3]I/4SHW
M[/'QVU16VR67P?\ B1-"<X_TC_A$-86V&>VZX:-<]LYKVNOFO]L:;R/V6?CV
M^<;OACXIA_\  G3Y+?'X^;BO"XHJRP_#7$5>+M*CD6;U8OM*GE^(FG\G$^NX
M PT<9QYP3A)KFABN+N&\-./>-?.<%2DOFI-'\A=%%%?Y"'_2T%%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *"< D]!R:*@NG\NUN9/^><$S_\ ?,;-_2DW9-]DW]PXKFE&*WDTE\W8
M_B,U.]?4M2U'49,[[^^N[U\]=]U<23MGWS(<U1HHK_&F4G.4IR=Y2DY2?=R=
MV_FV?]0E.$:4(4X+EA3A&$(K91@E&*^2204444BPHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OVT_X(U'_ (FO[0:^
MNG_#$_E<^/!_[-^M?B77[8?\$:S_ ,3K]H =CI?PV/Y7?C8?^S&OV+P!=O%S
MA#_KYG*^_AW-T?S'],A7^C;XEK_ISPN_NXVX;?Z'Y0_'([OC7\8&_O?%+X@G
MUZ^+-7/7O7EM>I_'-/+^-GQBC_YY_%/X@I_WSXMU=?Z5Y97Y?G5_[8S:^_\
M:>/OZ_6JI^_<+6_U8X<MM_8.46]/[/P]@HHHKS3W@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OVM_X(V+G7OC\_\
M=TCX=+_WU>>,C_[)7XI5^W__  1ILV,_[0^H'(1(OA;9IZ,TC_$&:7\4$47_
M '\K]C\ (.?BYPBDKVGG,WY*'#N;R;?W??9'\Q?3)J1I_1M\2G)VYJ7"U-><
MJG&W#<$EWNW\E=O1,_<FBBBO]-3_  4"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .
M/^(<)N/ 'CF 9S/X/\30C'7,FBWJ#'O\W%?Q3U_;QJUBNIZ5J>FL<+J&GWEB
MQ]%N[:2W)_ 29K^(J2-X9)(I%*21.T<B'@JZ,592.Q5@0?<5_%GTMZ36)X$K
M6]V=#B.DGYTJF23:\M*JMWU['^I_[-W$1E@/%W"W]^EB^"<0X]>6O1XIIIKO
MKAVGVTONAE%%%?QT?Z<A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Z=?
M\$F83)^U%JCC.+?X3^+)C]&USPE!S[9G'7OCOBOS%K]7?^"0FFM/^T)X]U0@
MF/3O@_JUL#CA9]1\8^"FC)/J8;&Y '?)/:OTKP=I.KXG\$PBKM9YAZMO*C"I
M6D_E&FW\C\(^D[B(X;P!\5:DW92X4Q>'3_O8NM0PL%_V].M&/S/Z*Z***_U.
M/^>X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '[!?\ !'B#=\5_BY<X_P!5\/=-@SZ?:/$E
MI)C\?LWZ5_0-7X3?\$;-+\W7/C[K17_CRTKX=:6CD=?[3N_&-W(H/?']D1%@
M.F5SU&?W9K_2CZ.E&5+PFX?FU98C%9Y6CYQ6=8ZA?_P*A(_PH^FYB8XCZ1O&
M=*+N\%@.$\-/RE+A;*,7;_P'%1?JV%%%%?N!_)P4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !5#5=PTO4BH+-]@O-JCJ6^SR8 ]R< >]7Z1E#*58 JP*L#R"",$$>A'!J9Q
MYH2C>W-&4;]KIJ_R+ISY*E.;5^2<9V[\LD[?.UC^'BBK5];FSO;RT;.ZUNKB
MW.>N8)7B.??*\^]5:_QJDG&3BU9Q;379IV:^\_Z@X2C.,9Q=XSC&47WC))I_
M-,****104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCHYGPSP[F4'>.89%E&.B][QQ>7X?$1=_-5$PHHHKS3W0HHHH **** "BBB@
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MH\O$G$$=N7/,VC;TQ^(1^Z\ RY^!>"Y_S\)<.2_\"R?!O]0HHHKQ#ZP****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV-X3Q=W;VDL^PE7#Y93NVE[V>1RK1WO:R]ZQ_-Y1117^9)_O:%%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=T)*4E9A1117[&?S$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M._G=M/L]PHHHKY _2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ^$M4D_X2GP%</O9)?"FL3SO:V0E?)EFT&\BO- N'<^9,^FB[952ZBW?Q/\
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M->G5RC-ZG+T5-X;(XW5[^UL[<L;^54445_'!_IX%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_1-_P2 M]O[/_ ,0[
MO'^O^,6IV^?7[+X*\$28_#[7^M?SLU_2'_P2/M_(_9D\22XQ]L^,?BFXSZ[?
M"G@2TS_Y*X_"OW_Z-%/G\4<)+_GUDN<5/2]&G2_]R6^9_&OT[ZWLOH_YC"_^
M\<4<,T?7EQ-;$6_\H7^1^6__  4UM_)_;$^(DF,?:]&\!7'3KM\$Z%:9]_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *_FI_X*L?#QO"?[2Z>+X(-EA\
M3?!VAZVTZKMB;6M!C;PKJ=N. #+'8:5HEY,1]XZ@K,2[.:_I6K\I?^"MGPS;
MQ-\#/"OQ'L[?S;WX9>+DAOY@O,'AKQK'!I-[(S@$_P#(PV?A6)5/R8FD;(8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X3XF_#?PI\7/
M ?B;X=>-M/&H^&_%.FRZ??1#:MQ;.2LMGJ5A,Z2"VU/2[V.WU#3KK8_V>]MH
M92CJI1OY)OVBO@'XO_9Q^)^M?#KQ7&UQ' QO_#7B".%X;'Q1X:N995T[6;,,
M7$;N(WMM1LQ)*VGZG;W=D99EA2>7^Q2OEK]K/]E[PK^U%\.)O#6I&WTKQEH@
MNM0\ ^+&B+2:)K$D2B2SO#&K33^']9\F"VUFT0.=L=MJ%O&U]I]H1^&^-WA1
M3\0\DCC\KITX<5Y-2F\NJ-QIK,L)=U*N4XBH[)<\G*K@*E1\E#%2E"4J5'%8
MBI'^M?HH?2)K>"O%4\GX@KUJOAWQ1B:,,[I14ZSR+,+1H8?B3"48\TI*E!0P
M^;T*,75Q>7QA5A"OB<!@Z$_Y'**Z_P ?> _%?PQ\8:]X$\;Z/<Z%XG\-W\NG
MZIIURO*2)AHKBWE7,5W87L#17>GWUNTEK?64\%U;220RHYY"O\WJ]"OA:];#
M8FC5P^)P]6I0Q%"M"5*M1K4IN%6E5IS49TZE.<90G"24HR3C))IH_P!R\'C,
M)F&$PN/P&)H8W XW#T<7@\9A:M.OAL5A<13C6P^)P]>E*5.M0KTIPJ4JM.4H
M5*<HSC)Q:84445D= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %?M;_P3%_8[DU&]T[]I7XD:85TZPED?X3Z
M'?0_\?\ J$3-#+XZN8)1@6FG2"2#PP'4M/J"RZY&(4L-)N;OY<_8._8PU#]H
M_P 6KXP\9VEW9?!GPE?QC6+C][;2>,]7@V3IX3TFX78ZVRJT4OB/4+=Q)9V4
MD=E;20W]_#<V?].=A86.E6-EI>F6=MI^FZ;:6UAI]A901VMG8V-G"EO:6=I;
M0JD-O;6T$<<,$$2)'%$BQHJJH _K/Z//A#/-,5AN/N),*UE>#JJKP[@:\+?V
MAC:,_<S2K"2UP6#J1;PB:_VG%P5;2CATL3_G']-;Z2M+(,OQ_@[P-F"EG^9T
M'A^-\VPE1/\ L7*\33]_A_#U8/3-,TH32S*2?^PY;4>&L\5C92P-NBBBO[E/
M\DPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA3C##X+!4%)QP^"PE*CA</%N-*E!-W****]D^8"BBB@ HHHH **** "BBB@
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M4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "O'OC#\ OA)\>=$&A_%'P7I?B2.".1--U1D:S\0Z*TOS-)HVOV30:I
MI^9 DLMO%<_8KMHT6^M;J(&,^PT5R8[ 8',\)6P.98/"X_!8F#IXC"8RA2Q.
M&K0;ORU:%:,Z<U=)I2B[-)K5)GI91G&;9!F.%S?(\SQ^3YK@:JK8+,LKQ=?
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MP].=;E4Z\ZM2\V4445]0? !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?V@T5_+5X&_X*4_M:^"FBCN?'>G>.+&(@K8>.?#FF:DK8/(EU32H]$\0RAP
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MZK\-8KDD'&U7O+3QO:!<#.YEL6W9&$7&#^WE%?G^-\#/"G'R<JW!V"I2>O\
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MHXB\8_%?BR-2EQ%XC<9YKAJJ:J8+$<0YG'+Y)[K^SJ.(I8%7ZVPZNDD[I(0
M* J@*J@!5    &  !P !P . *6BBOKC\V"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOP]_X*O?LTLW]F_M*^$M.SM6P\-?%**VBYVCR['PMXLG"CD#,/AC4YW;@?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 445W/PU^'7BOXL^.?#7P[\$Z<^I^)?%.I1:=I]N-RPPA@TMUJ
M%],J/]ETW3+..?4-2NV5EM;&VGG8,$VG;#8:OC,10PF%HU,1BL56I8?#8>C"
M52M7KUIQIT:-*G%.4ZE2I*,(0BFY2DDDVSEQV.P>68+&9EF.*H8++\OPM?&X
M[&8JK"CAL)A,+2E7Q.)Q%:HXPI4:%&$ZE6I-J,(1E*323/K']@K]EBX_:/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYU)RIT,YI45R87,)PK*%##9AA*,?.Z***_"S^N0HHHH **** "BBB@ HHHH
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ME.K5FY5:U6<ZU:=2K4G.11117">L%%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7P]^VY^R!I'[3_@47FC)9Z9\6O"-I<2^#-<EV0Q:K;DM//X0URXP"=+U&
M7<^GW4A8Z)JDGVR(BTNM5MKW[AHKQN(>'\JXHR?'Y#G6%CB\NS&BZ->D])Q=
MU*G7HU+-TL1AZD85J%:/O4ZL(S6UG]1P7QEQ%X?\3Y1Q?PKF%3+<\R7%1Q.$
MQ$+RIS5G"OA,51NHXG!8RA*IAL9AJG[NOAZM2G+25U_$=K^@:UX6UO5O#?B/
M3+S1=>T*_NM+U?2=0@>VO=/U"RF:"ZM+F%P&26&5&5AR#@,I92&.17]*'[?W
M[#MM\=]'NOBG\,]/@MOC%H-@/MVGP+'!'\1M'L8L1Z=<-E(U\46%N@CT+49"
M/ML")H=^Y@73+G2_YMKJUNK&ZN;*]MI[.]LYYK6[M+J&2WNK6ZMY&AN+:YMY
ME26">"5'BFAE19(I%9'564@?YC>)GAOF_AOGT\MQJGB<LQ3J5LES:,'&CF&$
MC)>[*UXTL;AE*$,9AKWIS<:D.;#UJ-2?^^'@/XY<-^.?!]+/<K=/ Y]@(T<+
MQ3PY*JIXG)\QG!OGI\UIXC*L<X5*N68[EY:U.-2A5]GC,-BJ%*"BBBOSD_<
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M]N/C_I X/ZYX3<465YX7^R<9#R]AG67^U?RP\JW_  US],^AGF?]F_2-\/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.+]R:2@\5E^(E"I++LSI4XT<72C*$X8?&4<5A,/5HHHK\_/V8**** "BBB@
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MKQ!X:U:PUS1M1MR!+9ZEIES'=VDZ@@JX2:)"\4BM%,FZ*5'C=E/VOA[QIC>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#^I^7'%J%C+E=XVQ7=E*3::C:V=['+;1_P"<WBEX/Y]X;XR5=JIF?#.(J\N
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M:S>IAJU7#U%*.(P&#Q]-Q<>9KX4HHHK_ #2/]WPHHHH **** "BBB@ HHHH
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MJTJM-RA4IU(2C.%2$I1G%J46TTPHHHJ#4**** "BBB@ HHHH **** "BBB@
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M*JX\LI9'P[.ME. IN_O669_V[7C+2,Z=>FTFDI2****_FL_NL**** "BBB@
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MK+ IU)8?.,-!J4O;Y;5KSITN6>,H8.<U27A]%%%?F!^_!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7[M?\$;M \K
M0OCOXH=,_;M6\":!;R$?=_LJS\3:C=HI_P"FG]LV32#_ *9QGCO^$M?TB_\
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M,KE9%BN)])TZ1M+L'< J=5UNX\C1M(1MRXEU._M(CN4;\D9Z<)@\9F&(I8/
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M1U8!E96!#*0"""" 13:_)=MS^D$TU=.Z>J:V:[A1110 4444 %%%% !1110
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M4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS+\YG+_M^>/E*_6]WN%%%%?J)_/P4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"BBBM#$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBBO\A#_ *60HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKZGMNO?M*_M#>)MXUWXX?%?4(I,E[1_'WB>*PYSG;I]OJ4-BF0<'9;KQA>@
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MZ?:^:!U#MX/F\*,"1P2A4]^M?G/17U>7^(?'>5./]G\8\2X:,=J4<YQ\\/\
M/#5:\\/+_MZF^Q^=9UX*^$/$2G_;/AEP+C:DTU+$RX7R>EC==^7'8?"4L9"_
M]RO'6SW29^UWA'_@L=KL311>//@EI-^K;1/?>$?%MYI+1_WGBTK6=*UH39Z+
M&^LP8ZF5NE?5O@K_ (*L_LO>)3%#XC/CSX>SMM6:;Q!X8_M;3D<]?*N?"%[X
MBOI(AQF272[9NN8@!D_S245^AY3](WQ2RQP5?-L#G-.%K4LVRO"2NETE6R^.
M7XJ=^LIUY3O]H_%.(_H0?1\S]5)83AW-^%Z]2_-B.'.(,Q@XR>TJ>%SJ>=9?
M3MTA3P<*?>#;;/[(/ ?[1GP(^)K0P^!?BWX"\0WMQM\K2;;Q'I]OKK;\;,Z!
M?S6FM)N)VC?8+E@4^\I ]HK^'>O=?AY^TY^T#\*F@'@/XN>-]$M+;;Y.D2:Q
M-K'AY-F-O_%-ZZ-3T%L !?FTYB5^0_+Q7ZSD?TLHWA3XEX2:5U[3%Y'CE)VZ
M\F78^,;M;KFS17V=OB/YRXM_9R32JUN!/$B,I6?L<MXMREP5_L^USK)IU&D]
MGR9 [?$K_"?V)T5_/%\-?^"NGQDT!H+7XF^!_"/Q"L$V++?Z2]SX+\1.#Q)-
M+-;IJ^@S,H^=((- TY78,AG175HOT/\ A=_P4Y_9@^(36]EKVMZU\+M8FV1_
M9O'.F%-)>=L;A#XCT675=*AMER2+K6GT4, =T:-A3^W\.>.7AGQ*Z=*AQ%0R
MO%U+)8//H2RFHI2TC!8G$/\ LZI.3]V,*&-JR<K)*[C?^3N-_HE>/' L:U?&
M<$8O/\NH\S>9\(58<1490CK.H\#@U_;5"E"/O2JXK*L/",;R<DHRY?T.HK$\
M/^)?#GBW3(-;\*Z_HOB;1KH9MM6\/ZK8ZSIEP,!LP7^G3W-K+PRGY)6X(/<5
MMU^LTZE.M3A5I5(5:52*G3J4Y1G3G"2O&4)Q;C*,EJI1;36J9_.=>A6PU:KA
M\31JX>O1G*G6H5Z<Z5:E4@[3IU:511G3G%IJ4)14HM6:3"BBBK,@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]M_\ @CAXLV:E\<?
MTTN?M-CX.\6:?#G&S[#/K6CZO*%SD^9_:.AHQ ^7RE!)W#'XD5^CG_!+'Q9_
MPCO[5^E:.TNQ/'7@CQAX8VDX226SM;;QC$"#QO'_  BKA#][+,B_?(/ZCX*Y
MI_9'BCP;B7+ECB,T_LR6ME+^V,/7RN$7T?[S%P:3^THM:I'\^_2IX?\ ]9/H
M_>)^!4.>>#X?_M^G97E!\,X[!\05)QZI^PRVK&36].4XO233_ILHHHK_ %'/
M^?D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "HIX(KF":VG198+B*2":-AE9(I4,<B,.
MZNC%2.X)J6BDTFFFDTU9IZII[IKJF--Q:E%M23333:::=TTUJFGJFM4S^*#Q
MQX:G\&>-?&'@^ZW?:?"GBGQ!X:N-XP_GZ%JUWI<V\8&&\RU;<,#!SQ7+5]G_
M /!07P,W@3]K7XLVR1%++Q-J=CXYL)"NT7"^+=-M=5U.51T(3Q!)K%L6YW-
MS'DD#XPK_(3B;*I9%Q'GV2SBXO*<XS++TG_+A,96H0DGUC.$(RC+:46I)M-,
M_P"EO@+B*'%W _!_%-.<9QXBX8R+.G*.RJ9EEF&Q=6#7V9TZM6=.<&DX3C*+
M2::"BBBO#/K HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQS7%XK#1BGJH0H5:<(+[,(Q70****^@/C HHHH **** "BBB@ HHHH ****
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MVVVW=MZMM[MOJV?T4DHI1BE&,4E&*2222LDDM$DM$EHD%%%% PHHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/#_DQ)^[TZ\F.&_JO@KZ3O"V<NE@^+,)5X8QT^6'UVFZF.R:K-V7-*I"'US
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBJ&JZKI>AZ=>ZQK>I6&CZ1IMM+>:CJFJ7EO8:=86D"EYKJ]O;N2*VM;>%
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M@W^_P&98>5"KR-R4*]">M'%86MRMT,9A:E;"XB"YZ%:I!J04445ZQ\X%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB-IIM----IIJS36C33U33W04444""BBB@ HHHH **** "BBB@ HHHH ****
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M[PBOA.8%LO$W@K4;[PE%'("25/V;1H)$#8+0R1N/E=2?K.ORD_X)%^,?[8^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5^ ?\ P6(\7"]^(_P?\"I+D>'?!>N>*9HE/"R>
M+M;CTN,R '&\1^#25#?,B2;@ LN6_?ROY7O^"CWB_P#X2[]KKXE+%+YMEX5B
M\-^$+(YSY?\ 9'A_3YM3BQDA?+UZ^U=<#ZD!BP'\]?2:S7ZAX9U,$I6EG>=Y
M7@'%/65/#RK9M.5OY8U,NI)O92G!=4?VI] KAW^V?'BCFLH7APIPIQ!G,:C5
MXPKXR.%X<IQ3V52=+/,1**W<*=1K2+/ABBBBO\[#_;0**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *_=3_ ((X>%/+TKXX^.)8L_:]0\&^
M%+"8C&S^SK;6]7U>(-W\S^U-$=AGY?*4G[PQ^%=?TV?\$L?"G_"._LH:5K#1
M;'\<^-_&/B?>1AI([.[MO!T9)/.P?\(HVP?=Y9U'SDM^]_1LRO\ M#Q2R_$N
M/-')LJS?,Y75TN?#+*H2?3W:F9P<6]I*+6J1_'GTZ<__ +&^C]G.!4^2?%'$
M'#>00L[2DJ>.?$-6$6M?>HY#4C-=:;G%Z-I_HY1117^CI_AT%%%% !1110 4
M444 ?SU_\%@/"7]G?&/X9>-(XO+B\4_#RXT.1@,+-?>$M?O+B:4GO*++Q1IL
M+<\1Q0C Y)_(NOZ$O^"P/A+^T?@]\,/&J1;Y?"WQ"NM"D<#+0V7B[0+NYFD)
M[1&\\*Z="W/,DL(P>H_GMK_,WQ_RO^R_%7B3ECRTLQ_L_-*.EN;ZYE^&^L2\
M[XVGBM?+76Y_O-]#7B'_ %@^CSP-SSY\3DG]L\/8G6_)_9N<XWZE#NN7*JV7
MZ/:^GNV"BBBOQD_J(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3I583IU:<Y4ZE.I%PJ4YP;C.$X22E&<9)QE&23BTTTF@HHHJB HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRJ<T\DXJP.=P@W>4*'$651P:44]J?MN'*T[+13J2;UGK'1117\HG^BH4444
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MKX?$4*L85:->C5A*G5I5(QG3G&4)Q4DT%%%%:G.%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ]:*TIPYIQP>"I-87 T9.G1@YSKUJQ1117Q1^JA1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM:L4445\4?J@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5])?LP?M->-_V8OB#;^+/#4D
MFH^'M1:WL_&O@Z>X>+3?$^CQR,=IX=+/6=/$DL^B:ND3RV-P\D4J7.G7FH6-
MW\VT5Z&4YMF.19E@\WRG%UL#F.7UX8C"8JA+EJ4JL/)IQG"<7*G5I5(RI5J4
MITJL)TYRB_%XCX=R3BW(\SX;XCRW#9ODF<82I@LQR_%PYZ.(H5+/=-3I5:4U
M"MA\11E3KX;$4Z6(P]2G6I4ZD?[0?A-\5_!/QK\":)\1/A_JR:KX>UN#<NX+
M'?Z9?1!1?:-K%H'D:QU;396\F\M69U_U=Q;2W%E<6US-Z/7\G?[''[6OB7]E
MSQ\MT_VS6?AIXEGMK?QWX4BD!9X4/EP^(M$25UAA\0Z3&S-$&:*#5K/S=+O)
M(M]I?:?_ %1>$?%OASQWX9T3QCX1U>TUWPUXCTZWU31M6L7+V]Y9W*[D<!@L
MD4L;!H;FVG2.YM+F.:UNHH;B&6)/]+/"/Q4P'B5DG-4]EA.),MITX9UEL6U%
MM^[#,<%&3<IX'$R3]URE/"5KX>M*2="OB/\ "+Z27T>\Y\"N*_9T?K&9<#9Y
M6K5>%L]J14IJ,?WE3),UG",:=/-L!!KWU&G2S+"J..PT(26+PN#Z*BBBOUP_
MFX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ***"0 23@#DD] /4T ?S ?\%//&G_"6_M9^*--CF\ZU\!>&O"?@VW96S&&
M&FGQ1?H@[-!J?B>]MI> ?.@<<A0:_/:O4?C=XT/Q%^,7Q1\="7SH/%?C[Q7K
M=DV=P73;[6KR72X4/.8[?3C:P19)/EQ+DD\UY=7^1W&N<?V_Q?Q-G2ESPS+/
M,SQ5!WNEAJF+JO"P3ZQAAU2A%]8Q1_TE>%?#/^IOAIP%PLZ?LJV1<)9!E^+C
M;E;Q]'+<.LPJ25E:=;'/$59JR]^;"BBBOF#[X**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH _H+_P""/G@[^SOA/\5/'<D6R7Q5X[T[P[$[
M##367@[0X[V.1#WB^V>+[Z$$<&6"53RE?K[7QC_P3Y\&_P#"%_LC_"*VDB\J
M\\0:7J?C*\;;M,__  E6MZCJVFRD8[:'/I4*MSN2)6!P0!]G5_JMX3Y1_8GA
MOP;E[CR3_L+"8VM"UG#$9JI9IB(R7\T:^,J1E_>3/^>#Z1?$G^MGCEXH9S&I
M[6D^+<QRO#5;W53!\/RAP_@ZD'=_NYX7*Z,J?]QQT6R****_0C\6"BBB@ HH
MHH **** "OQ'_P""QO@W?I_P2^(,,6/LUYXK\&ZE/MR&^VP:9K>B1%NWE_8/
M$#A23N\PD8V-N_;BOSW_ ."GG@S_ (2O]DOQ3J20^=<^!/$OA+QC;J%W.H&I
M_P#"+WLB<<"#3/$][/*<@"&*0\X /Y?XT91_;7A?QCA5'FG0RJ6:4[*\E+)J
M]'-6X];RIX.<';6492CKS6?[]]%OB3_5;Q^\,<QE4]G2QG$4.'ZUW:$H<3X7
M$\/152^G)&MF=*K>6D94XST<4U_+_1117^6Y_P!!04444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5]J_P#!/3QM_P (1^UO\*9I9O*L?$U[
MJO@F^4MM$_\ PE&CWMAI4.>G/B$Z-(%(.XQA1AF##XJKI?!?B:[\%^,?"?C&
MPW?;O"?B70O$MEM;:WVO0M4M=4M]K<;3YUJF#G@\U[G#&;2R'B3(,[BVGE.<
MY;F+MUA@\91KU(-=8SA"4)1^U&3B]&?)<?<-PXPX'XPX4G&,EQ'PSGF21YK6
MC5S++<3A*-1-Z1E2JU8583TY)PC)--7/[8Z*I:;J%IJVG6&JV$RW%AJ=E:ZA
M93K]V>TO8([FVF7_ &9(94<>S"KM?Z]1E&<8SA)2C.*E&46G&49*\91:T:::
M::T:U1_S33A.G.=.I&4*E.4H3A-.,H3BW&491=G&49)IIJZ::844451(4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3E*<Y.4I-RE*3<I2E)W<I-W;;;;;;;;=V%%%%,04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>8_&+XN>#?@=\/?$'Q)\=7_ -CT
M/0;;<EO$8VU#6=3FW)IVAZ1;NZ"ZU34[@""VBW)%$OFWEW+;V-M=7,/H&IZG
MIVBZ;J&L:O?6NF:5I5E=:EJ>HWT\=M96&GV4#W-Y>7=Q*RQ06UM;Q233S2,J
M1Q(SNP4$U_++^W%^UKJ?[3?Q&>VT6XNK3X3>#;JZL_!&DOYD']JRY,%WXQU6
MW;:QU'5U4C3X)T5M(T<PV:QQWEQJLUY^4>+GB;@_#;AV6)@Z6(X@S)5</D6
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M$PT%3I4J<;MNT5>4YRE4JS<JE6<ZDY291117&>H%%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *\4_:1\;_P#"N/@'\7_&J3?9
M[K0_A]XFETR7=MVZW=Z9/IVA+NZCS-9N[&/(RPW?*"< ^UU^:?\ P57\;_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7S2BZ>3NI7A.I3S=*B4445_)9_H\%%%% !1110 4444 %%%% !1110 4444
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M5K.RN)$EA2:"7]?\&O$NOX=<34ZF*J5)\-YO*EA,\PRYI*E#F:H9I1@KMXC
M2G*<HQBY5\+/$4%%U)TIT_YH^E!X#X3QNX#K4L!1HT^.>&Z>)S#A+'3Y:;Q%
M5PC+&9!B:TK)8/.(4:=.$IRC#"YA3P>+E-4:>(IUO["Z*YCP7XQ\._$+PGX>
M\;^$M2AU;PWXHTJTUG1]0A/RSV=Y$)$66,_/;W4#%K>\M)0L]G=Q3VMPD<\,
MB+T]?Z:4:U'$T:6(P]6G6H5Z5.M0K4IQG2JT:L5.G5ISBW&=.I"49PG%N,HM
M--IG^"N*PN)P6)Q&"QE"MA<7A*];"XK"XBG.CB,-B</4E2KT*]*HHU*5:C5A
M*G5ISC&<)QE&23304445J8!1110 4444 %%%% !1110 4444 %%%% !1110
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M?Y>^-^3?V)XH\6X>,.6EC<?#.*+M:,UG&'I9A6E'RCBL1B*3MIS4Y):'^_\
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MUI<F65,DCJW)7L_=Y0HHHK^F3^# HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "OG?]J3X_P"B?LW?![Q%\1-1^SW.M!/[&\%Z
M).Y']N^+M0AF_LNS959)#96@BGU75G1D>/2K"\\EC<M!')]#D@ DD  $DDX
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M<(J,(148I))!1114&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '[&_\$L/VHV\,>(Y?V<O&>I;?#WBRZN-1^&UU=RXBTGQ7(#-J/AI
M))6VQ6?B:-&O-.A#)&GB""6""&:\\0LR_OW7\06GW]]I5_9:IIEW<6&I:;=V
MU_I]]:2O;W=E?6<R7%I=VL\962&XMIXXYH98V5XY$5T(90:_K3_8Y_:)LOVD
M_@KH7B^::W3QGHP3PW\0=.AV1FV\36$$1DU&*W7'E:?X@M6AUFQ"*88/M-QI
MJ2RS:=<%?[G^C/XCRS3+JO .;8CFQV4498G(*M6=YXC*E)>WR].3O*IELY*I
MAXIN3P-5TX0C2P+;_P D/IY>!L<@SNAXQ<.8/DRGB3$T\#QC0H4[4\#Q%*#^
MJ9PXP5H4<\I4Y4L94<8P6;4%6JU*F)S=)?55%%%?UB?YS!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !M&C#15E%4<@SRMRK_EY"*R3%U9M14J>2TH1<ZE23^Y:***_L@_S!"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]M#,\91@Z&52GJ_99)@_98#V<9RHO&QQ^+I6^N3N4445^4']%!1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8;V_#?A]"AQ+F*J0YJ&)S95I1X;R^I=.+=3'TJF9RISC*G7PV48FA45JJO\
M+-%%%?YO'^Y84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7'7W=?>TN?QVT445_DR?]' 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MZ(?\$S_C8WPJ_:+TSPMJ5YY'A;XO6\7@K4DD?;;Q>(O->X\%WY7(#7!U9Y=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)K5.::3>A_2\         !@ #@  <  =!2T45_K8?\W@4444 %%%% !1110
M4444 %%%% !1110 4$ @@C(/!!Z$>AHHH _C5^/_ ("/PP^-OQ4\ K#Y%MX8
M\=>(]/TQ-NS=HAU*>XT*8+_"+C1I["=5&0HE !8 $^0U^G'_  5=\ _\(O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 1S30V\,MQ<2QP001R33S2NL<4,,2EY)99'(1(XT5
MG=V(55!9B ":_CM_:4^+$_QO^.7Q(^)3RR26.O\ B*ZCT!)-P-OX7TE4TCPS
M!Y;8$<BZ)8V+W*JJA[R2XF*AY7)_I&_X* ?%=OA-^RY\0K^SN?LVN^,X(?AS
MH#*_ER&[\6+/;:K) X(>.XM/"\&OW]M)'\\=Q:Q,I3'F+_*/7\4?2MXI=7&\
M.\&X>I^[PM&>?YE"+O%U\0ZN"RV$K?#4HT(8ZHXN[<,72G9)IO\ U5_9V^'T
M:&6<;>)^,H+VV/Q-+@[)*LXVG'!X-8?-,\J4VU[U+%8JKE%&,XM)5<MQ$'=I
MJ)1117\?'^F84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%+X0\0.',WG5]E@YXV.79FV[0_L[,O\ 8\1.KJKPPOM88U*_\3#0>MK'X?\
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M4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME=XW'Y;PEEM5QLXPR^A_:^;QBWK*%:>89->VBEAFM7=1****_CX_TS"BBB@
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MS2W^LI/W6T_J^BBBO]##_%4**** "BBB@ HHHH **** "BBB@ HHHH ****
M/R+_ ."OG@'^V/A#\.?B+;P>9<^"/&MUH5Y(J_-#H_C33-\L\K <Q1ZMX;T>
MV0,3MEOAL WN3_/77]>7[8GP^_X6=^S+\9?"D4'VB^;P;?>(-)B5=TLFL>$'
MA\5Z7! 0-RS7=YHT5D""-RW+QN?+=P?Y#:_SX^E!D7]G>(&&SB$+4>(<FPM>
M<[64L;ESEEU>/9N&$I9?)O?]XDUI=_[0_0!XN_MOP:QW#56KS8G@OBC,,)2I
M-W=/*L[C3SK"3[Q53,L1G45&UOW+:>K2****_FX_N<**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ?'))#(DL3O'+$ZR1R1L4DCD1@R.CJ0
MRNC ,K*058 @@BO[+_@7\0(_BK\'/AE\1%D22;Q;X+T#5M0V8VQ:S+80QZY:
M_+\N;/6(KZT;  W0G '2OXS:_I%_X)._$3_A*?V==5\#W,^^^^&7C34[&W@+
M;FB\/^*5'B/3I#D[E$NM7'B:)5QM"VPVL<LJ?T]]%G/_ *AQIFV0U)\M'/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2CAWS+:4?V"HHHK_ $&/\7PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK?%687CRU)U^)JT\VPZJQLG&KA\LQ& P<HR7-'ZLHR]Y,****_*C^B HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME3'\-8U3E6J22_B3P&=X"A&[UIX1<J]V18HHHK^JC_/(**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *QO$>O:=X6\/:[XGU>7R-)\.:-JFO:I/Q^YT[2+&?
M4+V7D@?N[:WE?D@?+R0.:V:^$_\ @H_\2/\ A7?[*7CN&"?R-4^(%QI?PZTS
MYMID37YI+G7HMH(9UE\*:9KT) . TJ%\KE&\+BC.J7#?#F>Y]6Y>3*,JQV8*
M,G95*F&P]2I1HK57E7K1IT8*ZO.<5=7/K_#_ (5Q'''''"/!^&4_:<2\193D
M\IP5Y4*&.QM&ABL4]':&$PTJV)J2L^6G2E*SM8_F(\9^*-1\<>,/%7C35VWZ
MKXN\1ZWXFU)MQ;-]KNI7.IW6&/)43W3A>!\H' Z5S5%%?Y$5JM2O5JUZTY5*
MU:I.K5J3=Y5*E23G.<GUE*4G)OJVS_I2PN&H8+#8?!X6E"AA<)0I8;#4::M"
MC0H4XTJ-*"Z0ITX1A%=$D@HHHK,W"BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!_,S_ ,%4O&/_  DO[5-[H22[X? '@?PGX9,:
MG,:75_!=>,9VP#M\UH_%%M%*P^;$$<;<Q #\W:]__:K\5_\ ":_M)?&_Q&LG
MG077Q*\565C+NW"33-$U2?0]*<'^ZVFZ;:E0"0H(4$@9/@%?Y+>(&:O.^..+
M<UYN:&,X@S6=!WO_ ++#&5:6$C?KRX:G2C?1.VB2T7_1[X,\/+A3PF\..'N3
MV=7+>#.'J6+C;E_X4*N68?$9C.W1U,?6Q-1IZIRLVW=A1117R!^EA1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?V*_LR>,?^$__ &>O@QXM>7S[K5?ASX674I=V[?K&G:7;
MZ5K1SDGC5K&]&"2PQAOF!KW.OSI_X):^*_\ A(OV3=#TII/,?P/XS\9>%F!.
M61;B_A\81(<\X6/Q6H3/ 0*J\* /T6K_ %KX"S5YYP3PIFTI<]7'</Y36Q$K
MW_VKZE1CBE?KRXF-6-WKIJD]#_F]\8.'EPGXJ^(O#D(>SH93QGQ%A<'&UO\
M8%FF)J9?)+HIX&>'FELE*R;6H4445]:?G(4444 %%%% !1110 4444 %%%%
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M$;1CC,DQ'U_+YUG:SK8O"9KBJ5-W;=+*^5V4(W[6BBBOZW/\W HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K[>_X)RZR=&_;%^$3%]D&IR>,-&N!G'F#4/ OB6.V3/\
MV$%LWQW*8')!'Q#7TE^QYJ1TK]J7X!W0?89?BAX4TW.<9&LZE#H[)_VT6^*8
M[[L5]3P-BG@N-N#\8G;ZKQ1D%=_X:6:X2<D_)Q336S3:9^>^+>7K-?"KQ+RQ
MI2^O\ <882*M>T\1P]F-*$E_>C.491:U4DFM4?U[4445_K>?\W(4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "NP^'F[_A/_ ^W[W_"8>&=O^]_;5EC]:X^
MN[^%L+7/Q.^'-NHRT_COPA"H]6E\0:>@'XEJ[,NBY9A@(K>6,PL5ZNO!(\S.
MY*&2YO.5N6&5X^3OM:.$JMW\K+4_M-HHHK_8P_YB@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *_(+_@L,I/PB^$[]E^(]ZI^K>&
M=1(_1#^=?K[7Y)?\%@K<M\#OAG=_PP_%>&W/UNO"'B>1?TM&K\K\;HN7A5QF
MEK;+:,OE#,,')_<HMG]#?11FJ?TAO"Z3=D\\Q,->]3)LSII?-S27FS^>2BBB
MO\NS_H""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /=/V7E+?M+?L]@=1\;OA6WX)X
MYT)F_P#'0:_L4K^/O]DRW-S^T]^S_&O5?B]X N/PM/$NG73?^.PFO[!*_NCZ
M)T6N&N*Y])9YA8KUC@(M_P#I:/\ (_\ :,S3XZ\.Z=]8\)YC-KJE4SB<4_FZ
M;^YA1117]8'^<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*&:8C5>YE47=VY9?O'1117^C!_B&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YY?\%1+,W7[(WB
MF<+D:=XL\#WC'^Z'UZ'3]WM\U\%[?>QWP?YA*_JQ_P""B>FG5/V./C+"B;I+
M6T\(:DAQDH-,^('A2]G<?2U@G4G^ZS5_*=7^?GTIZ#I>(F65;>[B>$\OG?\
MO4\TSJC)>JC"#_[>1_LW^SVQ:K^"F?89M<V!\1LZI<O54ZW#_"V)A*W12G5J
MI><&%%%%?S4?W:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5ZY\ +-M1^/'P3T]5W-??%S
MX;V:K_>-SXRT:$#\2^*\CKZ3_8ZTPZM^U-\ [55WF+XG^%=3QC.!HNHQZPS=
M_N+8%\]MN>,9KV^&:#Q7$G#^&2N\1G>54$N[JX_#TTOGS'RG'F+67\#\9X^3
M26"X4XBQ;;=DEALHQE9MOHDH7N?UZT445_KZ?\T04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %?EO_P5QL6NOV9_#%RHS_9OQC\,
MW3G'2*;PGX[L2,]@9;N'\0*_4BOSR_X*B:6VH?LC>*KL+N&A^*_ ^J,<9V+-
MKT&B!O;+:PJ9X^]COBOSOQ:P[Q/AGQO32OR\.YCB/EA*+Q3?R5%OY'[7]'#&
M+ ^/'A/7;45/C?(\'=NVN8XJ.7I>LGBE%+JVD?S"4445_E6?]#H4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%-/ZIX=X*O)+[,\9Q'Q)%Q?9\F$IR])1?5!1117]/G\!!1110 4444 %%%%
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M=*<)QE*,DV4445ZAX 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY+ZI9OEV.PG-;LWDC5_[NO0;1117\CG^DH4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME32=^1U<LAG;CY/_ (6%)K^\%%%%?O9_'H4444 %%%% !1110 4444 %%%%
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M*,DVI1DFFFFTTTT[!1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /VE_X) ?%@6/B+XE_!74+G;!KMC;?$#PU"[[8QJ>DF#1?$L,2D
MXDN;_3;C0[D(H#"VT*YD.Y5.W]XZ_CH_9K^*DOP4^.GPS^)7FR16/A[Q-9C7
MA'N+2^&-5$FC>)H@BY$DC:%?WY@5@P%RL+XW(I']BD4L4\4<T,B30S1I+%+$
MZO'+%(H>.2-U)5T=2&1U)5E(()!!K_0CZ,?%']L\"U\AKU.?%\+8^>'A%OFE
M_9F92J8W!2DW[UHXG^T,/!.ZA2P].,79*,?\7/I[^'_^K'BYA.,,+0]GEWB#
MD]+&5)QCRT_[>R*-#*\UIQ27*G/ _P!BXRI+253$8RO.2<FY2?1117]('\-!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7\9?QS\,GP9\:OBWX3\ORD\._$GQMI$"8VJ;2Q\2:C!9R(./
MW<MJD,L1QS&ZGO7]FE?RN?\ !1WPF?"O[7GQ.9(O*L_$R>&?%EEQCS!JWAK2
MX]2E]#OUVSU;D>F#E@37\K?2NRQU^$^&\VC'F>79_4P<FEK"EF> K5)2;Z1]
MKEM&#_O2@C_0S]G7GJPGB/QSPY*?+'.N#J.:0BW95*^0YQA:$817VIJAGF)J
M);J%.H]DSX:HHHK^$#_7P**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]O?^"-WAHM<_';Q
MC+%A8X/ WAJQFQ]XS2>)-4U6(-VV"WT9B!G/F G&T9_$*OZ3_P#@D[X3.A?L
MR7_B"6+;-XV^(_B35H9B,&73M)L]'\-01J?XHX=0T?5F4]1)-*.@%?NOT<<L
M>8>*F45W'FAE& S?,ZBM=)?4:F74Y2[<M?,*,HO^=1/Y%^G#GRR;Z/7$F$4^
M2KQ)G'#>0T7>TFUFU#.Z\(ZZ^TPF2XF$UK>G*>G5?IS1117^D9_AB%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDM$DM$EHD?\ .1*4IRE.<G*4FY2E)N4I2D[N4F[MMMMMMMMN["BBBF(****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
ME4_X*&_"S_A5O[4WCZ.UMOL^B^/7MOB3HN$V(Z>*6G?7 @ "*L?BRT\011HG
M"0+",+G:/B*OZ ?^"O7PL_MCX=_#SXO6%MNN_!>OW/A/798T^<Z#XJB%SIUS
M<OC_ (]]-UO2ULX "")_$3_*P8E/Y_J_RZ\:.&?]5?$?B/ TZ?L\'CL5_;6
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M SVCS6?+0A@,2LTK[7_LJGKI9_T!T445_HZ?X=A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X"?\%A_!
MALOB-\(OB!'#B/Q%X-UGPG<3(ORF?PEK*ZK")2.!+)#XP=8V;YI([8JI98,)
M^_=?F)_P5@\#'Q)^S58^+((=]S\._'FA:K<3A=QBT;7XKOPO>1$_PI-JVJ:
M[-ZVZ CYLC\B\=<F>=>%O%-*$.:M@,-0SBBTKN"RK%4<7B96_P"P&GBHMJUE
M)MZ)I_TG]$7B=<+?2"\/L15J<F&SG'XOAC$IRY54?$. Q.6X"FW_ -C:MEU1
M+[4H*.C::_FRHHHK_,0_WU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\\?_!7OP6V
MD_&KX=^.8H?+M?&7P_?2)7"\3ZMX/UJZ-U(6[NNE^(M#A*_PI#&?XJ_).OZ,
M?^"M_@-M?^ ?A/QQ;P^9=?#_ ,>VJ74NW/D:%XML;C2[QMP!*[];M?#4>#A6
MW<G<$!_G.K_,_P"D#DSR?Q2X@<8<E#-HX'.</I;F6,PM.&*GV=\PH8S5=K/5
M,_WB^AEQ0N)_H^<&QG453%\-U,VX7QEG?V;RS,*U7+Z;6\7')<9E>C[W5HM)
M%%%%?BY_4P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ&/Q>*QV*J.KBL;B:^+Q-67Q5,1B:LJU:H_.=2<I/S84445L<P4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >"_M1?#UOBI^SU\7O L,'VF^UCP3JUQH\&S>9O$&AQKX@\/1@<D
M%]<TO3UW*"R9W*K, I_CQK^XBOX\OVHOAJWPB_:"^+'@%8/LUCH_C#4KK1(0
MNU4\-ZZ4\0>&U4 !3LT/5-/1RF$\Q' "XVC^,_I8Y _^,4XIIPT_VO(,94MM
MOF.6POY_\*LM?*W4_P!1/V<W&2_XV)X?5ZJ4G_9W&.64;ZM+ER3/:O*^W_&/
M137=\VT3P2BBBOXS/]1 HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *_7G_@D'\/&UCXL?$?XE7$&
M^T\$^#K7P]8R.N%36O&>HB430,<;I;?2/#FIVTP4D1Q:FAD ,L1/Y#5_3?\
M\$N_AJW@;]E_3/$5W!Y6I_$_Q)K7C&0NNV=-)MWC\.:'"QQS!+;:++J]KR?W
M>L%\@N57]Q^CQP^\\\3LIKS@YX;(,/C,\Q&GNJ6'IK"X+WME*./Q>%JQ6[5*
M5MFU_)GTU^,EPEX"<1X2E55+'<8XW+.$L':7ORIXVM+'YJN5:RA/)LMS##SE
M\,98B',[RC&7Z,T445_I.?X5!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7Y[?\%,?BZ/AG^S-KN@6-SY
M.O\ Q6OX/ =@J/B9=&N$>_\ %ESLR"]K)HEI+HEP<_))KML2#FOT)K^:_P#X
M*I?%W_A//V@[;P!I]UYVA_"+0HM'=$??"WBOQ"EMK/B*>-@=NZ*S_L#1[A,%
MH;O2+I&;.53\>\=>*O\ 57PXSNI2J>SQV=1CP_@+.TO:9E"I'%SBU[T94<MI
MXVK"<=8U8TM8MIK^FOHB^'G_ !$/QQX5H8FA[;*.%9SXSSB\>:G['(JE&IEM
M&I%^Y.GB<]K95AZU*>E3#5*_NRC&43\QZ***_P R#_>X**** "BBB@ HHHH
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M&[M1CA,;++:#TO\ V745KQ;91117X$?V,%%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"AW0-#TSPQH6B^&]%MEL]'\/:3INAZ3:)]RUTS2;.&PL+9, #;!:V\42X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP#G['*\!S)R3CE^6TL)@H/F?N8>.KW"BBBOI#X8**** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)UG1]2\/:QJN@:S9S:?K&AZE?:1JMA<+MGL=2TVZELKZTG4$A9;:ZAEAD )
M=& )K-K]1?\ @J=\"#\._C3:?%71K,Q>&/B_;RWM\8H\067CG1X[>WUV)M@*
MQ?VU9OI^N1M*PDO-0GUUT4I;.1^75?Y,<9<,XO@[BC.N&\9S.IE>-J4:564>
M7ZSA)I5L#BTME'%8.I0Q"2^'VCB]8M+_ *.?"[CW+O$[@#A;CG+'"-'B#*J&
M*Q&'IRYE@<SI\V&S;+I-MMRR_,J.*P;D_C5%5%>,XME%%%?,GWP4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM92=VY9)AZ4%S5M?RLHHHK^%#_74**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K]L_^"17P.^TZCXV_: UJSS#I
MJ2> ?!#S)PU_=1VU]XLU6#> 0UK9/I>CVUS$7CD74M<M6(>!Q7XS>&_#VL>+
MO$.A>%?#]E)J.N^)-7T[0M&L(1F6\U/5;N&QL;9.P,US/&FYL*H8LQ"@D?V+
M? SX4:/\$/A-X&^%VB^7);^%-#M[2]O8T\O^U=;N"][K^L.I 8-JNLW-]?!&
MR88YT@4[(E _I#Z-/!3S_C*IQ)BZ7-EO"E*.(I.4;PK9SBHSIX""NK2^JTHX
MC'.47S4:]'!N2M53/X:^G=XIK@[PPH\#9=B?9Y[XBUYX.NJ<K5</POETZ-?.
M*LG%MP685YX+*HQG%1Q.$Q.9*$N:A)+UBBBBO]"#_%P**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_"?_
M (*^?&/[5JOP[^!6EW68=+AD^(?BV*-]RG4+U;O1_"EI-M(V36EB->OI8)-V
MZ'5=-G 7",W[F:CJ-CI&GW^K:G=0V6FZ99W6HZA>W#!(+2QLH'N;NZG<\)#;
MP122R,>%1&/:OXX_C]\5+WXV?&3XA_$^],H3Q7XCN[K2X)SF6Q\/6@33?#>G
M/R1OL-!L].M)"N%>6%Y H+D5_-OTF^+?[$X)H</8>KRXWBK%JA447:<<IRZ5
M+%8V2:UC[7$/ X9IV52C6Q$;M*2?]T?0)\./]:O%;&<:XW#^TRKP]RUXJA.<
M.:E/B+.H5\!E4&I+ED\/@HYMCXR3<J&)PV"J63E"2\?HHHK_ #Y/]H HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /F3]KWX$6_[0_P)\7^ XH8G\36T \2^!KF
M38IMO%^B13RZ;$)7^2"+6();SP_=S-D0V6K7$X4R1(1_(Q<VUQ9W%Q:7<$MM
M=6LTMM<VUQ&\,]O<02-%-!-%(%>*6*16CDC=5='5E8 @BO[@J_FP_P""G_[.
M_P#PJSXQ)\4O#UCY/@OXORW>IW0@CVVVE>/;?;)XCM&V@B)=>62+Q';-*RM<
MWMUKL<$8@T_C^1?I1<"/%X# <>Y?1O7RQ4\KSU0CK/ 5JO\ PGXV=DO]UQ=6
M>$JS?-.4,9AE=4\/I_I-^S^\7HY;G.<>#^<XKEPF?2K<0<(NK/W:><X7#K^V
M<KIN3;7]H9=AZ>88>FN2E"KEF-:YJ^-2E^8U%%%?Q"?ZQ!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ+>'S3+*ST?M,!CZ5?#\\HQ]M3A3Q$$Z5:$F4445\N??A1110 4444 %%%%
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M<O=2A.WL<;6QGNQE.=RBBBOQD_J,**** "BBB@ HHHH **** "BBB@ HHHH
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MVWNV^K84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %>-_M!?%BQ^"'P9^(7Q/O#"TOA?P_=3:1;3D>7?^([YD
MTWPUI[C(8QWNNWEA;SE S1VSS3;2L;5[)7X=?\%>OC1EOA_\!=)N^ #\1/&4
M<3]S]KTCPCI\Q0]A_;NIW-I+_>T6["?ZEZ^ \3^+8\$\#Y]GT9QAC:6%>$RM
M.UYYICG]6P3C%_&J%2I];JPZT,/5=U:Y^Q^ /AQ/Q5\6>#^#ZE*53*Z^8QS'
MB&2NHT^'\I7U_-8SFOX3Q="C_9V'J.Z6+QN'5GS6?XD:CJ-]J^H7^K:G=37N
MI:G>76HZA>W#%Y[N^O9WN;NZG<\O-<3RR2R,>6=V/>J=%%?Y3RE*<I3G)RE)
MN4I2;E*4I.[E)N[;;;;;;;;NS_HCA"%.$*=.$:=.G&,*=.$5"$(02C&$(Q2C
M&,8I*,4DDDDDD@HHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% #XXY)I(XHHWEEE=8XHHU9Y))'8*D<:*"SN[$*JJ"S,0 "2!7]A/[+
M_P )8_@A\!OAK\.&A2'5-'\/6]WXD*A29/%6MN^M>)"T@YF2'5[ZZM+:1R6%
ME;6T0"I&B+_.3_P3]^#W_"X?VF_!%K>VOVGPYX$D?XB^)-Z;X6MO#,]M)H]I
M,K#RY8]0\37&B6EQ;N?WUB]ZVR18G4_U95_:WT4^%/983B#C/$4K3Q52.0Y9
M.2L_J]!TL9F=2-U[U.M7>!HQFK6GA*\'=W2_RJ_:(^(JQ&9<&^%N!KWIY=2J
M<89_3A*\7C,7&OEN0T*B5N6MAL)'-L3.G*[=+,L)42BK.11117]A'^9@4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-</@,94492I4*E./._2:***_0S\5"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *R]<T32?$NBZMX=UZPMM5T/7=-O='UC3+
MR,2VNH:9J5M):7UG<1G&^&YMII(9%R"5<X(."-2BIG"%2$Z=2$:E.I&4*E.<
M5.$X33C*$XR3C*,HMJ46FFFTTTS2E5JT*M.O0J5*-:C4A5HUJ4Y4ZM*K3DIT
MZE.I!J<*D)I2A.+4HR2E%II,_D7_ &N?V<M7_9G^,&L>"Y5N;KPEJ?F:[X U
MR<%O[4\,W4[B&VN)PJQOJVB3!]*U9 L;//!'J"016FH69?Y?K^MC]L7]F?2?
MVG/A)J'AA4M;7QSX?^T:Y\.]<G 3[%KR0;9-*N[@ NFC>(H8TT[4U^:.&06.
MJF&>?2K:,_R=ZYHFK^&M9U7P]K^GW6DZYH>H7FDZOI=]$T%YI^I:?<26MY9W
M,3<QS6]Q%)%(ISAE."1@G_-#QL\-*GA[Q/.>!I2_U:SN=;%Y-52DX867,I8K
M*:DGM/!3FG0YFW5P4Z$W.=6-=0_WA^BGX[T?&C@&E2S;$T_]>^%*>&RWBB@W
M&-3,(<CA@.(Z--63I9K3I26,4(QCA\THXNFJ=/#U,&ZN71117XP?U&%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !2JK,RJJEF8A5502S,3@*
MH&2220  ,D\"DK]7_P#@F5^R9_PLWQ@GQT\=Z89/ /@+4T'A*QO(?]'\5>-[
M-DFBN]CC%QH_A-_*NYFP(+O76L;4/<16&KV@^HX-X3S3C;B++N',IA?$8ZJO
M:UY1E*C@<'3M+%8[$-6M1PU*\FKJ56HZ="G>M5IQE\!XG^(V0>%'!.=\;\1U
M;8+*<._JV#A.,,5FV9UKPR_*<$I7YL5CL1RTU+EE##T56QE?EPV&K5(?I-_P
M3V_98'[/GPJ7Q'XJT\0?%/XDV]EJOB1+B,"Z\-Z(%,^B>$5+#?!/;),=0UY%
M",^L7!LIO/CT>REK] Z**_U3X9X=RWA/(LMX>RBE[+ Y9AHT*=[>TK3NYU\5
M7E%)3Q&*KRJ8BO-)*56I)QC&-HK_ )Y>/>-L^\1N+\]XTXDQ'UC-\^QU3%U^
M7F]AAJ24:6#P&$A)RE3P67X2G0P6$IN4I0P]"FISG/FG(HHHKW3Y **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGPV3X;EP62X22>TL+E.&P="=DE*I"<^5.304445]8?G(4444 %%%% !1110
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M@MJ?PIU>\\WQ#\)-06+35E?,]SX)\0S75[I+*7/F3?V3JJ:OI;A T=E8?V)
M2@DB6OYQ*^N/V(/C=_PHC]HKP3XEOKO[)X5\0SGP1XU9Y/+MT\/>(Y[>#^T+
MDYP(-"U>+2]>E8*SF#398D&92#^J^#'&7^I7'^3X^O5]EEF8S_L7-VW:$<#F
M%2G".(J/90P6+AA<;-V<O9T*D8_&S^>/I2>&'_$5?!SB7)\)A_;Y_DE-<4\-
M*,>:M+-<FI5JE3!T4E>53-,MJ8_*Z4;J/M\71J2O[)']:%%%%?ZAG_/\%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7<H*VNJ07%Q:Z57ZJ @@$$$$9!'((/0@]P:_AWK].OV.?^"BOB[X(OIGP_\
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MHRE[#'X"NIX?$TN:47**JT9U</4HUJA1117SY]F%%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#2U6C^TJ***_TC/\, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*G.5Y2R/.*RIYGAZ,.E++\ZY<55DTKU<^BDW;3RZBBBOY./]&@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _J\_8+^-W_"\?V<?!
M^J:A>?:O%G@R/_A ?%YD??<2ZEX>M[>/3M3G+'S)'UK0)M*U*XN"JI)J,VH0
MQEC;N1]F5_-?_P $M/C?_P *Y^.T_P -]6O/)\-?&&QCT>%99-L%MXTT<7-[
MX9GRQ(5M1AEU70%CC4/<WVJ:8'?;;J*_I0K_ $^\$^,O]=/#_*,77J^US3*H
M_P!AYLY.]26*P%.G&CB9MZREC,%/"XJI.RBZ]2M"-_9L_P !?I5^&'_$+?&7
MB3+<)A_89!Q#/_6OAQ1ART89?G%:M/$X&DDN6$,KS6GC\OHTN9SCA*&%J3M[
M:(4445^M'\XA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7E_QD^$/@SXY_#SQ!\-O'5C]KT37;?$5S$(U
MU'1=4@#-INNZ/<.CBVU33+@B:"0JT4T9FLKN*XL;JZMIO4**YL;@\+F.$Q.
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MHK[L_(0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7H+^R/:4\K_4VBBBOZP/\YPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHK)U[7M&\+:)JOB/Q%J=GHV@Z'876J:OJVH3I;V6GZ?90O/=
M7=S,Y"QQ0Q(SL>2<;5#,0#%2I"E"=6K.%.G3A*I4J5)*$*<()RG.<Y-1C",4
MY2E)I12;;21I1HU<15I4*%*I7KUZD*-&C1A*I5K5:DE"G2I4X*4ZE2I.2A"$
M(N4Y-1BFVD5O%/BGP[X)\/:OXL\6ZS8>'_#>@V4VHZOK&ISK;V5C9PCYY)9&
MY9G8K%!!$KSW-Q)%;6T4L\L<;_S2_MJ_MW^*/VC-3O?!/@J:_P##'P6L+O%O
MINYK75?'$UK+NAUCQ1Y;;DL1*BW&E>'0[6]JPBO-1^U:E';_ -GY?[;_ .VK
MKG[3'B9_#/A>:^T;X->&[YVT'2'+VUSXJOX"\2^*O$4 (/F.I?\ L72I=RZ3
M:2%Y%_M&YNF7X$K^!_&WQRK\45<5PKPEBJF'X9I2E0S#,J,I4ZV?SBW&=.G)
M<LJ>4)IJ--6ECTO:5O\ 9Y1HO_8KZ*/T2L'X?X;+_$3Q(P%+&<>8BG3Q>39'
MBH0K8;@ZG-*=*M6IRYJ=;B1Q:E.JTX9.W['#+ZY"IB8E%%%?S$?WT%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?7W
M[)O[87C_ /9<\3JUA)/XB^&^L7D4GBWP'<W#+:W .R*36= DD+1Z1XC@@556
MY1?LVI1116>JQ31Q6D]E_4+\*OBMX&^-'@G2/B!\/-;@UOP[K$?RR+B.]TZ]
MC5#=Z1K%D6:73M6L'=8[NSF^9=T<\+S6D]O<3?Q>5]3_ +*/[5/C3]ESQY'K
MNCM/K'@O6I;:V\<^"WN#'::YI\;D+>V6\F*R\0Z8CR2:5J(4?>DL;OS+"ZN(
MS_0_@OXVXS@?$T.'^(:U;&<(8BJH0E)SK8CA^I4EKB<)%<TYX"4Y.>+P,4W&
M\L3@XJO[:CB_XI^E)]%++/%K XOC+@O#87*_$K!8=U*E."I8;!\94:$%RX+,
MIODI4<XA3BJ>6YM4<54M# 9E-X7ZMBLM_KAHK@_AG\2O!OQ>\$:#\0O 6KQ:
MUX9\0V@N;.Y0;)[>528[O3M1MB3)9:GIURLEI?V4O[RWN8G3+)L=N\K_ $*P
MV)P^-PU#&82O2Q.%Q5&GB,-B:%2-6C7H5H*I2K4JD&X5*=2$HSA.+<91::;3
M/\6,?@,;E>-Q>6YEA,1@,PR_$U\'CL%BZ-3#XK"8O#5)4<1AL30JQC4HUZ%6
M$Z=6E4C&<)QE&23304445N<@4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 <CX]\">%?B;X/\ $'@/QMI-OKGACQ-I\NFZMIUP"!)#
M(5>*>"5<2VM]9W"17FGWL#)<V-[!!=VTD<\,;K_*/^UA^S!XK_9>^)%SX7U3
M[1JGA#6&N=0\!>+6A"P:]HR2*&MKIHU6"#7]'\V&UUJR4)MD>"_MXQI^H64D
MG]<U>,_'GX&>!_VAOAUJ_P ._'-GOM;P&ZT;6;>.,ZKX9UV&.1+#7=(E<?N[
MJU,CQSP%A!J%E+<Z?=!K:YE4_C?C'X4X3Q(R55,(J.&XHRNE4EE&.G:$<1#6
M<\JQLTKO"XB5W1J2N\'B9>VA^ZJ8FE6_J#Z,7TB<R\#>*G0S&6)Q_A_Q!B*,
M.)<JIWJ5,#5]VE2XARNDW99A@Z:4<50BXQS3 Q^K5?W]' 5\+_&[17LOQX^!
M?CK]GGXAZK\//'=CY5W:$W6CZQ;I)_9/B?0Y99$L==T>=P/-M;D1LDT+'[18
M7D=QI]XD=U;2H/&J_P ULPP&-RK&XK+<QPM;!8_!5ZF&Q>%Q$'3K4*]*3C.G
M4@]4TUNKJ2M*+<6F_P#=;)\XROB'*LOSS),?ALTRC-<)1QV79A@ZL:V%Q>$Q
M$%4HUJ-2.CC.+5T[2A*\)QC.,HHHHHKD/2"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBB@ HHHH **** "BBN2\>>.?#/PT\'>(_'GC+4HM(\,^%M+N-6U>^EP2EO
M$@MX\AKF^O)WBLM/LXLSWM]<6]I KS31J<J]>CA:%;$XFK3H8?#TJE>O7JSC
M3I4:-&$JE6K5J2:C"G3A&4YSDU&,4Y-I(Z,)A,5C\7AL#@</6Q>-QN(HX3!X
M3#4YUL1BL5B:D:.'P]"C34JE6M6JSA3I4X1E.I.48Q3DTCPG]K3]ISPU^R_\
M,;KQ7?BVU3QAK)N-+\ ^%992KZWK:Q*SW5VD3+/'H.BI+%>:U=(8_D>UTZ*>
M*^U.RW?RC^._'/BKXE>+M>\=>-=7N==\3^);^74=6U*Z8;Y9I J1PPQ*!%:V
M5I D5I865ND=K8V4$%I:Q100QQKZG^TO^T%XI_:2^*>M?$'Q"\UKII=]-\(>
M'&F,MMX8\+V\TC:?ID6/W;WDN]KW5[Q57[;JEQ<S(L5O]FMX/G^O\T_&;Q3Q
M/B+GTJ."J5:7"V4U:E/)\*^:'UNHKTZF;XJF[-U\2KK#0FD\)A'&DHPK5,5*
MK_NY]%SZ/> \$>#X8K-*&'Q/B%Q)AJ-?B7,$H57EM&7+6H\-9?65U'!X&7++
M'5:4G',<QC*O*=3#8?+X8<HHHK\8/ZD"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K1TC5]4T#5=-US1-0O-
M)UG1[ZUU/2M3T^XDM;[3]0LIDN+2\M+F%DE@N;:>-)898V5TD164@BLZBJA.
M=.<9PE*$X2C.$X2<9PG%IQE&2:<91:3C)---)IW(J4Z=:G4I5:<*M*K"5.K2
MJ1C.G4ISBXSIU(23C.$XMQE&2<91;333:/ZG/V%_VOK#]IOP&^F>(YK.R^+O
M@RUMX?%VFQ".W37K'Y+>U\9:3:KM5;2^E*P:Q:VR^5I.KN(_+M['4-*67[LK
M^,#X1?%;Q?\ !/XA>'/B3X'OS9:[X=O5G$3ES9:K82?N]1T35849?M.EZK:&
M2TNXMRR*KK/;207<%O/%_7)\#OC)X3^/?PS\-?$WP=.#I^N6H6_TV25)+[P_
MKEL%35_#^I! NR]TVZ)CWE$2\M7M=1M@UG>VTDG^B?@-XL?Z]91+(L[KI\59
M)0@ZM6;2GG.6Q<:5/,4M&\50E*G0S%)-2J3HXI/_ &F=.C_B3],#Z.B\(^)8
M<7<*8.4?#SBK&5%0H4HR=/AC/)QG7K9))ZJ. Q4(UL5DDFTX4:6)P$H_[#2K
M8KUNBBBOZ#/XP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0D $
MD@  DDG  ')))X  ZFOYQO\ @HG^VI-\8O$%[\&?AIJO_%J?#&HB/7]6L)CY
M7Q!\1:?-DR">,[;CPKHMW'C2HT+6VK:A"=<9KF"+19+;[)_X*;?M=O\ #SP[
M)\ ?A[JI@\<>+].$GCO5+&;%SX7\(7T9":-'+&VZVUGQ5 Q\W)$]EX=:27RU
M;6M/NX?YZ*_B_P"D9XM3E4Q'AYP[B7&G"T.*<=0GK4FTI+(Z52+TA!-3S1Q=
MYS<<#*45#&T9_P"I7T(/HX4HT<%XU\;8"-2K5;J>'V4XNE>-&G&3B^+<11J+
M6K4DI4^'^=6ITU4S>G&4JN5XFD4445_&Y_I\%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]R_L0?M?Z
MQ^S'X[73];GN]0^$7B^^MXO&6BKYD[:-<MLMH?&6B6XW%=2TZ((FIVL*_P#$
M[TJ+[)(CWEII-Q9?U)Z1JVF:_I6FZYHE_::KH^L6-IJ>E:G83QW-EJ&GWT"7
M-G>VEQ$S1SVUS;RQS0RHQ5XW5E)!K^(>OV=_X)@?M=OH.J6O[-WQ#U4G0]:N
M9&^%>JWTWR:3KES(\USX,>64[4L==F>2ZT%"R"#6VN-.C69]:M([;^K/H[^+
M4\FQN'X#XAQ3>3YC6Y,@Q=>>F69C7EIE\Y2?NX+,*LK4%?EP^.FO=]GBZLZ/
M^=OTV/HWTN)\JQGB_P %X",>)<EPOM>,<NPM*TL_R7"TTGG-.$%[^:Y+AX7Q
M3<>?&Y33DW/VV74*6)_>NBBBO[L/\B0HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /G#]IS]FCP/^T[\/I_"'BA%T[7-/\^]
M\&>,+>W2;4_"^LR1A?-0%HVO-(O_ "XH-;T=YHX=0MXXI$DMM1L]/O[/^5;X
MP_![QU\"_'FL?#SXA:2^F:YI3^9!/'ODTS6]+E>1;'7-#O&CC6^TG4%C=H)P
MB2PRI/97L-KJ%K=VD']G%?,_[4'[+O@+]J#P-)X;\3Q+I?B;2TN+CP7XUM;=
M)=5\-:E*@RK M&VH:)?/'$FKZ-+*D5W$B3P2VFHVUE?6WX!XT^#&%X_PD\[R
M2%'"<7X.C:$FXTJ&>8>E'W,%C)NT88JG%<N!QLVE'3#8F7U=TZN%_LCZ+/TH
M\?X-9E3X4XKJXK,?#3-,4YU:<5/$8OA3&XB:]IFN64DW.IE]6;]IFV5TDW4?
M-C\##ZZJ]#,/Y#Z*]6^,WP7\?_ ;QUJ?P_\ B)H[Z9J]@QFL[N+?+I.OZ4\D
MB6FN:%?-'&M_I=Z(V\N0)'/;3)-8W]O::A;75K#Y37^>&-P6+RW%XG 8_#5L
M'C<'6J8?%87$TY4J]"M2DXU*56G-*4)QDFFFO-:69_MCE6:Y;GF6X'.,GQV%
MS/*LRPU'&Y?F&"K4\1A,9A:\%4HU\/7I2E"I3J0::E%OL[--(HHHKE.\****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8X3 U$ITWF6(Q%6$J>*RJ#4%%%%?PZ?ZSA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Z&_\
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M!J-; YCAE+WGA,RP-7#X["N5I^PQ%/G49\T44445[Y\<%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG3KW_A+O&H9"\ \*^&Y(;R\M+G&2L.MWK:?X=#@9276(WX"DC^N$
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M"$5S5<3F.$YG:FC\'Z***_SR/]K HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ]T_9K^,E]\!/C7X#^)MJTS6.B:O';^)+.#);4?"
MFJ*=.\160BSLEF;3+B>XL%D#)%J=O97(7? A']A&G:C8ZOI]AJVF74-]INJ6
M=KJ.GWMLXEM[RQO8$N;2ZMY%^62&XMY8YHG'#HZL.#7\0=?TH?\ !+GX]?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XW_;J^/S
M?L_? #Q'K6DW?V;QMXO8^"O YC?;<6NK:O;7!O==B .]#X>TB*]U*WGV/"NJ
MII=M. MVN?Y0"2Q+,26))))))).223R23R2>2:_2'_@I[\;G^)W[05SX%TV[
M\[PM\'+:7PO;)')N@G\67A@N_&-[@'Y9[:ZBLO#DR,/DD\/2.G$S%OS=K_-?
MQ_XVEQ=Q[C<)AZSGE'##JY+@(QE>G/$TI_\ "KBTM8N5;&P>'C4BW&KAL'A9
MIZG^ZWT-?"J'AMX/97F.-PRH\2<>JAQ3F\Y1M7I8#$T;\.Y=-M*<887*ZD<9
M.A.*GA\?F>/IR6@4445^'G]9!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_2+_P2V_:
M ?XE_!RZ^%6OWAF\5?!\VEAI[SR;I]0\!ZB9O^$?==Q#2'0)X+K0)%B7R[33
M8= 61C+<\_S=5]3_ +&/QMD^ G[0G@;QA<W1MO#.J7B^$/&P9RD#>%/$<]O:
MWMW<8(W1Z'>)8>(E4$%Y=(CC)VNP/ZIX-<:RX'X[RG'UJSIY5F,UD^=)NU-8
M'&U(0CB9W=DL!BE0QKDDY^RHU:<=*LD_YY^E#X50\6?"'B+*,-AE7XBR2E+B
M7A:48WKO-LJI5:D\#2:5V\WP$L7ED8.2I_6,3AZ\[O#P:_KAHH!! ((((R".
M00>A![@T5_J(?\_H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!DZ[H6B^)]'U+P]XCTK3]<T+6+2:PU72-5M(;[3M0
MLKA2DUM=VEPDD,\,BGE)$(R PPP!'X"_MC?\$T-<\ '5?B1^S[9ZAXG\$)YU
M]K/P_4S:CXH\*P\R2SZ"Q\R[\3:# -P-JQF\0:="(VD_MF 75]:?T(45\#Q_
MX;\->(N6?4L[PW)BZ$9_V=G&&C".8Y=4EK^ZJ--5</.5G7P=;FH55[R5.M&E
M6I_L7@YXY<=^"6??VKPIC_:Y;BZE+^W.&L=*I4R7.Z%-VMB*$9)X?&TX.2PN
M9X5T\7AFW!RJX6=?"UOX>""I*L"&!((((((.""#R"#P0>0:2OZ8/VN/^"=/@
M/X[G4O''PX;3?AY\5YO-NKJ5+=H?"7C.Z8%V_P"$BLK.-WTW59Y/F;Q'IEO+
M/,[ROJVGZK+)'<6O\\/Q.^%/Q!^#?BN]\%?$GPQJ/A?Q!9$O]FO8U:VOK4NR
M1ZCI.H0-+8:MID[(XAO]/N+BU=TDB\P312QI_GCXB>%/%'ASC'',\.\9D]6J
MX8'/L'3G+ XE.[A3KKWI8'&.*?-A<0_>E&H\-5Q-*#JO_:WP3^D1X?\ CAED
M9Y#C%E?$V'H*KF_!^95J<<WP+BHJK7PC2A#-\LC.24,PP<+0C.DL=A\#B*BP
MZ\]HHHK\S/WD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC&M2RJA)Y=A*BIN;Q^)P]+',HHHK]P/Y."BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /@__@HE\=O^%*_L[Z[9:5>?9O&7Q.,_@3PWY4FRZM;._MG/BG6H@I65!IVA
M--9PW4++)::MJVD2@YK^6>OOG_@HS\>!\:/VA=8TK2+W[3X,^%:W'@;P_P"5
M)OM;O5+6Y+>+=9B +1L;W6HVTV&XB=HKO2]$TNX0C>:^!J_S.\=^-O\ 7+CW
M'K"UO:Y1P_S9)EG+*]*H\-4E]?QD+-QE]:QKJJG5C?VN$HX1WM%6_P!Y/HA>
M%7_$+_!W)Y8_#>PXDXS]GQ7GWM(<M>@L=0I_V/EE3F2J0^H94L/*MAYV=#,<
M5F*23G*Y1117XP?U(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBBM3G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\T89]Q%[?+L!*S]U^SRNCGE1/65.M'#U(VDE)>44445_G^?[,!1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/3H[A;?4/%-^ITOPCI+9!D^WZ_=JMF9XD/FMIUB;W5I8P3;:?.?E/[A? ?\
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MUT"BBBOYQ/[C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Z@?^"8_Q ?Q
MO^REX:TRYG\^_P#AWX@\1>!KAG;,OV:"XB\0Z0K*3D16^C^(;'3[<@!3'9!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M75LHX[)\?AL?0C-I2=*K+#U)NA7@G:IAZZIUZ4KPJ4X232****\L^@"BBB@
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MER(HHHK],/P8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_\ "T_V@[7QIJMGY_A7X.VT'BVZ:2/=;S^*[B26W\&63'!VS07L-YXCA8$
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M553IS2E%I%%%%>>>R%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG4PM5PAB*#DDYX7%TO9XK"5;6K8:M2JQO&:84445ZY\V%%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7#XR$6^J@\_FTNCF^X4445_*)_HH%%%% !1110 4444 %%%% !1110 4444
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M_4  * J@!0      !@  <  < #@"EHHK_4(_Y_PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _)C_ (*P
M? K_ (3'X6Z%\:M%L_,U[X7W0TWQ$T,>9KKP/K]U%$)I2H:24>']?DM9X4 $
M=O9:SK=W*RI$2/YWJ_MK\4>&M&\9>&M?\)>(;--0T'Q/HVI:!K-E)]VZTS5K
M.:QO8"<':9+>>15<#=&Q#KAE!K^.3XT_"[6?@M\5/''POUT.U]X0UZZTZ&Z>
M/RAJ>E/MN]$UB-/X8=8T:XL=3B7JB72HV'5@/X0^E#P5_9G$&7\:8.CRX/B"
M$<#F;C&T*><8*BE0J3:247CLOIQ48J[E4R_$U9/FJ:_Z]_L_O%3^WN#<Y\+<
MSQ//F7!M:>;9#&I.]2MPSFN)<L50IIMRE'*<YK3=24FE"EG&"H4XJ%'3R^BB
MBOY6/]#0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ^_O^"<O[0'_  I/X^Z;HFLWOV;P/\5OL?@SQ#YLFRUL=8EN&_X1#79<E43[
M%JUP^EW%Q*ZPVNE:YJ=U)DP)C^HJOX> 2I#*2K*058$@@@Y!!'((/((Y!K^L
M3]AKX_#]H+X ^&M=U.\%SXV\*!?!GCL.X:YGUK2+> 6NMR@D.P\1Z5)9:M+,
M$2 ZE-J=I!D63X_M/Z+?'7M*.9< X^M[]#VN<9#SRWHSE%9I@:=VE^[JRIX^
ME3BG*7ML?4?NT]/\L/V@OA)['%9'XQY/AOW>,^K\,\8>RAI'$TJ<GP_FU;E3
M;]MAZ=7)\37J.,(?5<GH1O.MK]AT445_8I_F,%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKB?T4.+;Z<3<.M=&X9FG]RPCM][/4C^T7\.++FX#XV3ZJ-7(I)>C>8Q;_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /:_P!FN\?3_P!HGX#7L;;3;_&3X9.3V,?_
M  FFBK*I_P!EXBZ-_LL>17]CM?QF? K?_P +O^#?E_ZS_A:OP\\O_?\ ^$NT
MC9_X]BO[,Z_N+Z)DV\BXPIZ\L<VRV:[7J8.M&5NE[4XW^5^A_DS^T<I17%OA
MG627/4X=SVE)]>6EF6$E!/R3K3MYMA1117];'^;H4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /@#_ (*<7KVO['WCZ!6PNHZ[X#LI!_>1/&.CZ@%]_P!Y81M_P'/:OY=J
M_IS_ ."I6_\ X9*U_;]T^,_!/F?[G]J,1_Y$\OK7\QE?Y[_2DFY>)&"B[VI\
M*Y9"-^SS#.*FGES5)?.Y_M'^S[I1I^!V:2BE>MXAY]5G;=R62\,T4WY\E*"]
M$@HHHK^;S^Y0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI.];%<+8SVD\DK+F:<UETJ6)R>4:<7'#X7"9;[27/B5?%HHHK^<C^X HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^W?V!/VA?^%
M?'G1I=9OOLO@'X@?9_!OC7S9-EI917ER/["\1S9(C0^']6D22YN6#-#HEYK:
M1C?.*_JKK^'>OZD/^"=O[0O_  O/X#Z=I6MWWVGQ[\+19>#_ !/YTF^[U#3(
M[=AX4\0RY+2.=2TNV>PN[B5VFNM8T;5;E]JS1Y_LGZ+G'G+/'^'^85M)^VS?
MA_VDOMI*6:9?3O\ S12S&C3BDER9C4DVY(_S _:!^#_/3R?QFR7"^]2^K<-\
M9JE#>G*3AP_G-;E27N3E+),36FW*2J9+0@E&$F??%%%%?V>?Y;!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-<S16]O&\T\\L<,,,:EY)9I7"1QQHH+,[NRJJ@$LQ  R:_M,^&?A-/ ?PX\
M>"$5%7P?X*\+^%P(R"F=!T2QTMF##AMS6I8OSO)+$DDFOZO^B?E<JW$O%.<N
M+<,!D>&RWF:T53-<=#$JS_FY,HFM-5%M;2U_SI_:,<01PW GA]PNII5,XXKQ
MV>."?O2H\/934P,FU>_)[3B2F]59RBFM8Z=O1117]TG^1H4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7X5^!_A?H(1[+PAH5KI\UVD?E'4]5D+W>N:Q(G\,VL:S<WVIRITC>Z,:X1%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBTTVFF%%%%26%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT;=<2;KK5_ \H:+PQJ0+D--)I*0R>'+THK^3%8Z3<W4K3ZH,_I;7^L/"7$N
MXPX<RGB/+9?[-FF$A7]FY*4\-B$W3Q>#JM))U<)B85</4:24I4W*-X2BW_SG
M^(_ F<>&?&_$? ^>P:Q_#^8U<)[=0=.GCL')1KY=F>'C)MK#YE@*N'QM!-N4
M*==0G:I&<44445]$?$A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=; 9?R32G1Q&(>89G1FFZ>8QB^1!))))R3R2>I/J:***_$S^K0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *Z?P?XU\7_#[7K3Q/X'\2ZWX3\06)S:ZOH&HW6F7R*65G
MA::UDC,UK-M"W%I/YEM<QYBN(9(RR'F**THUJV'JTZ^'JU*%>C.-2C6HU)4J
MM*I!J4*E.I!QG"<)).,XR4HM)IIF&*PN%QV&KX/&X:AC,)B:4Z&)PN*HT\1A
ML11J1<:E&O0JQG2JTJD6XSIU(RA*+:DFG8_:/]GG_@K/KNF-9>'/VB] _P"$
MAL?W<"_$/PC9VUGKD X7S]?\,1FVTO4URV^>[T)M)FA@C(BT;4KA^?VF^&_Q
M3^'GQ>\.0>*_AKXNT;Q?H4Q5&N])N0\UE.R!_L>JZ?,L6HZ/?JA#OI^J6EG>
MHC*[P!64G^+:N^^''Q2^(7PB\1V_BSX;>+=9\(:];[5-WI5R4BO(%</]CU2P
ME673]7T]W :33]4M;NRD8*SP,RJ1_2/ /TE.*.'G0P'%D)\4Y3'EA];G.,,^
MPM-67-'%SM3S)15Y.&.MB*LK)YA3BN4_AGQC^@KP!QK'%9QX<U:7A]Q'-3J_
MV?2I3K<(8^L[ODGEU/FKY(YOEBJN4<V#H03:R>M4DY']I5%?C[^S/_P54\)>
M+?[/\)?M"V5KX'\0OY5K!X_TF*=O!FIRG$:/KEAFXO?"]S*Q3S+N)K_0R[37
M%Q)H5I&L8_7;3]1T_5[&TU32KZSU/3-0MXKRPU'3[F"]L;VTG02075I=VSRV
M]S;S1LLD4\,CQ2(P9&92#7]K<(\<\,<<X!9APWFE'&QA&+Q.%D_8YA@9R6E/
M&X.=JU!W4HQJ<LJ%9QE*A6JP7,_\J_$GPEX_\)<X>3<<\/XK*JE2518#,(KZ
MSDV;4Z;5ZV5YI14L+BXJ,H3J45.&+PRJ0AC,-AZK]FKE%%%?6GYP%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7\Q?\ P5"^'[^#?VJ-;UV*W\K3_B1X9\.>+[9D7$!NX+,^%]6C5@,?:'O?
M#S:A<H26!U&.4X69*_ITK\AO^"O'PQ?7?A7\/_BI8VWF7/@'Q-=:!K$L:_-'
MH/C*" 0W-PX'S0VFNZ/IMG"&.4FUM]@_>R&OP[Z1'#\L]\,<UK4H.IB,@Q6#
MSZC&*O+V>&E/"XYWW4*67XS%8B?1JBK[)K^M/H4<9PX1\>^'L-B*JHX+C+ 9
MEPAB92E:/ML?"EF&51Y7HZE?.<KR_"4_M+ZU)*Z;C+^?"BBBO\V#_=0****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ^F/V.?A^_Q,_:<^#7A<P?:+-?&FG>
M(]6B9<Q/HW@_S/%6J13DC"Q75IH\ED22"SW*1(?,D0'^O"OP*_X) ?#%]1\<
M_$WXNWEMFS\,:!9^"=%FD7*/J_B2ZCU35I;9NUQIVEZ/:6\Q)&(-?50&\QBG
M[ZU_H7]&+A^65>'];-ZU-QK<29MB<73DU9O 8%1R_#)IZV^LT<?5BWI*%:+B
MK>]+_%?Z?/&<>(?&;#\-8>JIX7@;AW 9=6C&7-&.;YNWG6.FFGRI_4L5E&'J
M16L*N&G&;YDXP****_HT_A\**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%BE4GS5\7P_.G-\.8]W?-)4L-0K9/4?O2Y\KC6JM2Q4;TJ***_ #^R@HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7]9G^<84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>K"4J5?!97AL52:6)E<HHHK]V/Y$"BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$4I5*&)H3IU\/5JT:D*DBBBBO0/%"BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0J)8CA_(JCEA\?GL^1^TH8FLO:X#)97IR>,>(QU&<GE=2E/V(         #
M '   X  X '2EHHK_1D_Q!"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG7AKF5H.IF'#F,JQEFF2RJ6BV^6+QV7RF^7#X^G!)7]VCBX1C1Q*]VA6P_\
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ME)4:MTE%8BBT\/C*<4E3Q%.?*G1G2G/_ *#O OQ@R7QKX RSBS+G1P^9PC'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%>:?&+XI^'/@K\-/%_Q.\52[=(\)Z3-?&V618[C5-0=EMM)T6S9P5^
MVZSJ<UIIMJ6!CCEN5EF*PQR.O-C,7ALOPF*QV-KT\-@\%AZV*Q6(JRY:5##X
M>G*K6K5)=(4Z<)3D^B3.[+,MQ^<YC@,HRO"UL=F>:8W"Y=E^"P\7.OB\;C:T
M,/A<-1@OBJUZ]2%.$>LI)'Y5?\%7_P!I#^Q]#TG]G'PM?[=1\11V?B7XCRVT
MOSVN@P3^=X=\-RLA.V35[^W&M7\#&*:.QT[20PDL]7=6_!>NV^)'Q \1_%3Q
MYXK^(GBVZ^V>(?%VLW>LZC("WDPM</BWL;1'9VAT_3;1+?3M.M]Q%M8VMO I
M*QBN)K_*WQ+XVQ/'_%^9\05>>&#E/ZIE&&F]<)E.&E..$I.-VHU:O-/%XE)N
M/UK$5N5\G*E_T,^!'A3@?!OPUR'@W#JC4S.%+^TN)<=26F8\1XZ%.68UU.R<
MZ&'Y*678&4E&7]GX+"J:]ISME%%%?!'["%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &AI.E:EKVJZ9H>CV<^HZOK.H6>E:7I]JAD
MN;[4=0N8[2RL[>,<R3W-S-%#$@Y:1U7O7]?7[,7P1T[]GOX*^#/AK:+!)J=A
M8C4O%FH0 ;=6\7ZJJ7.O7OF8#2P17)73=->0>8FD6&GP-S#7XJ_\$JOV>_\
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MI2JTJD5.G4IU(-PG3G!J4)Q;C*+4HMIIA1114EA1110 4444 %%%% !1110
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M*PU6EB,/4J4:L)R****],\$**** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO+Z_O;J58;:TL[2W22>YN;B9TB@@AC>661E1%9F /9_#+X6^/?C%XNT[P/\
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M;#4E*EEV4X"$I2P^695A'.:PN"P_/)J/-.M7JRJXK%UL1BZ]>O4****^H/@
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MK".RHT74KU%+&8O&5JQ1117YV?MH4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ IK,J*SNRHB*6=V(55502S,Q("JH!))(
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MC=)I2LTFF@HHHKE/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#]G/\ @E/^TU_8>MWW[.'B[4-ND^(Y[S7?AI<74N(['Q"(VN-=
M\,1NY(C@URVB?5]-A#11+JUIJ,4:S7NN1J?WLK^(K1=9U7PYK&E>(-#OKC2]
M:T/4;+5](U*SD,5UI^IZ=<QWEC>VT@Y2>VN88IHG_A=%.#TK^N/]E#]H'2OV
MD?@SX<\?V[6\'B*%!H7CG2("!_9/B[3H81J*QQ99H[#4XY(-9TH%I"NG:A;P
M22-<P7"I_=GT9_$;^ULIJ\"9K7OF&24I8C))U)>]BLGYTJN#3D[SJ995FO9Q
MO?ZC6IPIP5/!3D?Y$?3Q\$?]7.(\/XO</8/ER7BO$0P7%=*A3M3R_B94V\/F
M4HP25.AGV'I2]O/E45FN%K5:U65?-*47])4445_5A_G<%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]G+_ (3WX<6/QR\-6'F^*OA?;-:>*$MX]T^J?#ZYN&EEN'VAGD?PGJ4[ZDH
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MFWU#Q1+JTNGS,>ITP64:@E8XT0E:^FE5454151$4*B* JJJC"JJ@ *J@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTX)1A"*48Q2C%))(****DT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#WG]FCX'ZO^T-\9/"'PSTT3PV&HW@U#Q5JD";CHGA'3&C
MGUW4RQ5HTG^SE;'31-B*?6+[3K5V'V@&OZ^=!T/2?#&B:/X;T&Q@TO0] TRP
MT;1]-M5V6]AIFF6L5G8V<"DDB*WMH8HDR2VU 6).2?SF_P""9?[-_P#PJ/X/
M_P#"R_$EAY'COXNV]GJJK<1;;K1? T8,_AO30'!>"76!*WB*_",GFQ7>CVUU
M$MQI?'Z7U_HW]'OP_P#]3^$(9OCZ'L\]XIC0Q^(4XVJX3+%%RRS!-/WH3E3J
M3QF(BU&2JXF-"K'FPL6O\/?IH^,W_$3?$RIPWD^*]MPCX?SQ>3X&5*?-0S+/
M93C#/LU3B^2K3C7H4\KP4TYTWA\#+%8>2CCZB91117[Z?QR%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^?O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO'_CW\8-$^ _
MPE\9_%#7?+EC\-Z5(^EZ<\GEMK7B&\86>@:+&0?,_P")CJDUM#/)$KM:V?VJ
M]93%;2$<F/QV$RS XS,L?6AAL%@,-7QF+Q%1VA1PV&I2K5JLGO:%.$I-)-NU
MDFVD>CD^4YCG^;99D>486KCLUSC'X3+,MP=%)U<5CL=7IX;"X>FFTN:K6JP@
MG)J*O>323:_(?_@K!^TD;W4-*_9M\*ZA_HFF&P\3_$V2VE^6?49$2[\+^%YR
MA!*6-O)'XDU"W</%)<7?A^12D]A*H_$^N@\5^*-<\;^)M?\ &'B:_EU/Q!XG
MU?4-<UF_F/SW6HZG<R7=U+M^['&996$4* 101!(8E6-%4<_7^4WB#QEC./.+
M,UXCQ7/"EB:OL<NPTY7^I97AVX8+"I)N*E&G^]Q#A:-3%U<1623J,_Z)/!?P
MPRWP@\.>'N",O]E5KX'#+%9WCZ<>7^U>(,9&-7-<PDVE.5.==+#X-5+U*.78
M?!X9R:H)A1117Q9^IA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7XHS'#OZQB(73C.63916;E&24H8G-L!B:4E4P^F'1117\('^OH4444 %%%%
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M4YG#%86C14I5(9>\OJU+.O&Y1117Z\?S4%%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT:N)Q.(KU(TJ&'P]"$JM:O6JS<84Z5*G&52I4FU&$(N4FDFS]&?^"8W[-?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'%9;FF6XFM@L?E^-HU,/B\'BL/-TZV'Q%"K&-2E5ISBXRC))IKLTPHHHKI.
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MHX*LK*2&5E(!5E((((!!!!&:;7^:Y_NLFFKIW3U36S7<**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KT;X0_$;5/A'\3_
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M.5.M1K4JBC4I5:52,H5*<XQG"<91DE)-!1116AB%%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5^PG\R!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OPO\ ^"IO[5HN9O\
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M7\*'^NH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &IHFBZMXDUG2?#V@V%SJNMZ[J5EI&D:99QF6ZU#4]1N8[2QL[:,??FN
M;F:.&-<@%W&2!DU_7%^RA^S[I7[-OP:\.^ +<6UQXBF3^W?'.KP#(U?Q=J,,
M)U%XY2%:2PTR.*#1M*)2,MIVGV\\L2W4]RS_ )7_ /!*?]F+^U=4O/VD_&&G
M[M.T66]T+X86UU%F.\UG8]IX@\5QHX >+2(GET/2IAYD3:E<:Q*!%=Z/;25^
M\5?W;]&CPX_LC*:G'>:T.7,<\HNADE.K'WL+DSDG/&14E>-7-*D(NG*UU@:5
M*=.;IXVI$_R&^GAXX?ZR\1T?"+AW&<^1\)XF.+XJK4*EZ>8\3JFXT<ME*#:J
M4,@H59*O#F<7FV)KTJU)5LKHS11117]5G^> 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5*^\85<?CLIJR:ZX>*>FW[!4445_H6?XKA1110 4444 %%%% !1110 4444
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MMIPT;M#*HEAD"RPRAX9521'4;]?C9_P28_:!;7O"WB+]GOQ#>E]2\'+<>+/
MAGDR\WA?4+U%\0:/$6(XT;6[V+4K>,%Y9(->NU14M]-X_9.O]6^ >+L+QSPG
MD_$F&4(3QN'4<=AX-M83,J#]CC\+[S<U"GB(S=!SM*IAIT:UK5$?\[/C'X;9
MAX2^(W$W V/=6K3RK&RJ93C:D4GF61XQ+$Y1C[Q2INI6P52G'%QI7A0QU/%8
M:_-0DD4445]B?F(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B>)?
M$FA^#O#VM>*O$VI6VC^'O#NF7NL:SJEX^RVL=.T^![FZN92 S,(XHV*QQJ\L
MK[8HD>1T1MNOP0_X*C_M8_\ "0ZO)^S;X#U/=H?A^[@NOBCJ-G-F/5?$-JZ7
M%AX0$D9V26?AZ58[[6HRT@?7Q:V<BP7&@W"S?">(W'6 \/>%\=G^,Y*N)2^K
M93@92Y99AF=:,OJ^'5O>5&'++$8JHM:>%I591YJGLX3_ %[P/\(\Y\:?$#*N
M#\L]KA\"Y+'\1YM""E#)L@PU2FL;C'S)PEB:O/3P>7T9+EKX_$8>%3DH>VJT
M_P _OVL/VB];_:8^+NL>.+S[39^&+'?HG@/0)WXT7PO:S2-;--$C-$-6U:1G
MU3695:4_:[C[''/)96-DL?S/117^6>;YMC\]S/'YQFF(GB\PS+$U<7B\1/>I
M6K2<I<L5[L*<%:%*E!*G2I1A2IQC"$8K_H/X:X<R?A'(,HX8X?P5++LER/ 8
M?+<NP=)>[1PV&@H1YY/WJM:HU*KB*]1RJXC$5*M>M.=6I.3****\X]L****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOB7D/L_:U<9P;GM7!P:OS9CE^!JYEEFEF],PPF&=TFU:ZU2/Z[Z***_UB/\
MG-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:L@HHHK\O/W\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSN:GB,;P_/E7)2PM1*IC<D3Y+X)5\%",WEE2M5]"HHHK]]/XY"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "M30]6NM UK2-=L6V7NBZII^K6;9(VW6G7<-Y;MD<C;-
M"AR.1BLNBJA.=.<*D).,Z<HSA):.,XM2C)/HTTFO-&=6E3KTJE&M"-2E6ISI
M5:<E>,Z=2+A.$EUC*+<6NJ;/[>M,U"VU;3=/U6S?S+/4[&TU"U?CY[:]@CN8
M'XR/FBD4\$CGBKU>$_LO^(&\4?LX_ S7'D\V>\^%7@:.\DSG??V/AZPT_4&S
MDG)OK6X)!)(/!)()KW:O]A\JQL<RRO+<QC;EQ^ P>-C;;EQ6'IUU;RM45C_F
M2X@RJ>19_GF25+^TR?-\RRJIS?%SY?C:^$E?1:\U%WT6O0****[SR HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ>[]^AC.*JE*:V7[W!9(YK5_7,QC!6RS$LHHHK^,C_44**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]_O^"67[+9\*>')?
MVB_&FG&/Q#XNLIM.^'%G=Q8ETKPC,0E_XE$<B[XKSQ/)']FTV4*CIX>ADN(9
M9K3Q"RI^8G[$W[,]Y^TO\8M/T;4+>X3X>>$S:^(?B'J,?F1J=*2<_8O#L%PA
M7R]1\3W4+V,)21)[?3HM6U.#>^G>6_\ 5Y965GIMG::=I]K;V-A86MO96-E:
M0QV]K9V=K$D%M:VT$2K%!;V\,:10PQJL<<:*B*%4 ?UI]&CPU_M''2\0,XP]
M\#EE6IA^'J56/NXG,X>[B,Q49*TJ67)NCAII.+Q\ISA*%7 6?^<'T[_';^Q,
MHAX,\,XRV;9]AZ6,XUQ&'J6J8#(JCC5P61N<'>GB,Z<5B<=3<HSCE%.E1J0J
M8?-[QLT445_<A_DL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!PIP_E$XI6O6P&587#XB<N]2K7IU*E23UE4G*3NVPHHHKY\^S"BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7EB,''GQ.9<-<\G>53!+VN9Y7!\S>#>8892ITL%@Z,OS^HHHK^/#_34****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYP^T\QJ4H4LOYM:65T,-)4Z-?$XR,RBBBOVP_E0**** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!C<+4C5PV+P>+HPKX;$T*L6XU*->C4A4ISBVI0DFMPHHHKG.P**** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M_<G_ ((UZ2PA_:!UUXSMDE^&NDVTN."T*^-[R^C!]0)]/8CMD9SD8_;^ORH_
MX)%>'&TW]GOQEXAFB*2^)?BEJB0.5QYVFZ)X=\.6D#AOX@NHSZM%CH&1L')8
M#]5Z_P!/_ S!/ >%/!]&2:E5P6,QKNK-K,,TQV.@_3V>(A9]8I6T/\!?I;YK
M'./I$^)N*A)2AA\TRW*E9W499+P_E&45HKLU7P55R7\[EU"BBBOUD_G$****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M117J'SX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'YH?\%'_P!D[_A=WP]_X6=X*TSS
MOBC\-].N)FMK6$-=^+_!D)DO-1T,*@\RYU/1V:XU?0(UWR3,^J:5##-<:I:F
M#^::O[B*_F\_X*4?LE?\*>\<'XP>!M,\KX:?$/4Y6U6RLX=MKX/\;77FW5U9
M+&@V6VC^(@EQJ6DJN(+2\34],1+6VBTN*;^-?I*>%SDI>(F1X;6*IT>*,-1C
MJXKEI8;.8PCNXKDPN8./V5A\2XVCBZQ_J!]!/Z0"IRAX)<6XVT9RKXGP_P =
MBJFD9RY\3C^%YU)NR51^US#)HRM^\>.P$9N53+L,?EU1117\8G^I 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Z1_\$]/
MVPW^ /C0?#OQWJ+CX0^.=1B%Q<7$A,/@?Q-<>5:V_B6/<2L6D7RI!9^)8QM$
M=O':ZNC!M-GM[[\W**^AX6XGS;@_/<OXAR6O[''8"LIJ,N9T<30E[N(P>*A%
MQ]IAL32<J5:%U)*7/3E"K"%2/Q?B%P#P[XF\(9SP7Q3A/K64YQAG2E.'*L5@
M<5!\^#S/ 591DJ&.P&(4,1AZG+*#E%TJT*N'JUJ-3^X6.2.6-)8G26*5%DCD
MC97CDC=0R.CJ2KHZD,K*2K*002#3Z_%S_@F;^V7_ &Y9Z;^S?\3M5SK.G6Y@
M^%6OZA/EM4TRVC+GP/>7$IR;_2X$:3PT\C$76F1OHRF*;3],AOOVCK_4?@7C
M3*>/>'<'Q!E,[0K+V6-P<I1E7R[,*<8O$X+$6M[U-RC.E4Y8JOAYT<1"*A52
M7_/OXM^%G$?@]QOFG!?$=)RJ867UC*\SITY0PF>9/6G-8'-<&Y.2]G7C"5.O
M14YRP>,I8G!59RJX>;91117V!^9A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5_.3_P5TT<V7[1OA#543$6M?"+0B[XQOO-.\5>,;689[[+0V'N-V.F,_P!&
MU?A3_P %DM!\O6/@-XG2/(O--\?:#<R@<)_9MUX6U"RC<_\ 33^UK]HQS_JI
M#QW_  KZ1V#>*\*LXK)7>7X_)<9M=I2S*A@6UZ+&MMK:-V]+G]=?0=S19?\
M2(X8PSERK.LGXIRO5V3<,CQ>;1B^CYI96E%=9<J6MC\3:***_P W#_<X****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_NI!1117U9^=A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7A7[17Q\\(?LX_##6?B+XKD6XE@
M4V'AKP_',L5]XH\2W,4K:=HUF6#F-',;W.HW@CE73],M[N],4S0I!-ZKXK\5
M>'_ _AO6_%_BO5;71/#GAS3;K5M9U6]<I;V5C9QF6:5MH9Y'( C@MX4DN+F=
MX[>WBEGECC;^47]K[]J'Q#^U!\3KGQ%,;O3? V@-<Z7\/O#$T@ TS1VE4RZG
M?11NT#:_KS0Q7FJRHTGDHEGI44\]KIEO*_XYXR^*.&\..'W'"3I5N)\VIU:.
M2X27+-8=+W*N:XJF[KZOA'+]S"::Q6*Y**3I1Q,Z7]._1?\ H_8WQPXS4\RI
M8C#< \.5J&)XIS&'/2>-DW[3#\.X"LK/Z[F*B_K-6G)/+\O57$RE'$5,#2Q'
MB'Q1^)GB[XP^//$?Q&\<ZBVI>(_$U^]Y=R#>MK9P*!%9:7IT#O(;72]+LXX;
M'3[4._DVL$:N\DF^1^ HHK_-'%8K$8W$XC&8NO5Q.*Q5:KB,3B*\Y5*U>O6G
M*I6K5:DFY3J5*DI3G.3;E)MMW9_O!E^ P658'!99EN$H8'+LNPN'P. P6%I0
MHX;"8/"TH4,-AL/1@E"E1H480ITZ<4HPA%12L@HHHK ZPHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Z7P;X/\1>/_ !5X?\%>
M$M,GUCQ)XGU2TT?1M.MP-]S>WDHCCWN<)!;P@M/=W4S);VEK%-=7$D<$,DBZ
M4:-7$5J6'H4JE:O7J0HT:-*$JE6K5JR4*=*G"*<IU*DY1C"$4Y2DTDFVC#$X
MG#X+#8C&8RO1PN$PE"KB<5B<14A1H8?#T*<JM>O7JU'&G2HT:4)5*E2<HPA"
M,I2:2;/IS]BS]F#4?VF_BS::->175O\ #OPJ;76_B)J\.^(KI?G-]C\/6=PN
M!'JWB6:&6SMF5Q):6$6IZJBRG3A!+_5QI>EZ=HFF:=HVCV5MIFDZ18VFF:9I
MUE"EO9V&GV,$=K9V5I!&%CAMK6WBC@@B10D<:*B@  5X/^S!^SYX=_9K^$VA
M_#W1_(O-78#5O&?B&.(I)XC\57<,2ZA?995D6PMA'%IVCVS@-;Z7:6PFWW;W
M4\WT/7^F7@OX:4O#OAB$<73A+B3.(T<7GE=<LG0DHMX?*J4XW3HX",Y*I*,I
M1K8N>(JQDZ3HQA_@Q]*3QWQ'C;Q]5J9;6K0X&X9GB<MX3PDN>FL5!SC'&\08
MBE*S6*SBI2ISI1G&$\-EU+!8:<(UXXF=4HHHK]B/YE"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M92&4D$&GU_H$FFKIW3U36S7<_P 9VFFTTTTVFFK--:--/5-/=!1110(****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.Q5257$XS&8NK.OB<37JR;E.K6K3G4J2>KE)L****Z#B"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR/#2^L4*,+U<XRFES5*E!1BKU,;@;SKX.UZE:DZ^$4:M26%C3_N;Z&'TA_\
MB&O$J\/>+,=[/@7BS&P6"Q>)J\M#AGB.OR4:.,E.;Y:&5YKRTL)F3DXTL-7C
MA,PE*A1IX^=;^:ZB@@@D$8(X(/4'T-%?Y\'^T04444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^YO_!-+]M/[0FD_LW?
M%35OW\:I9?";Q)J,_P#KHU&(O &H74K?ZV)1CPC)*V)(@?#J.'CT.TE_;NOX
M?()Y[6>&YMII;>YMY8Y[>X@D>&>">%Q)%-#+&5DBEBD57CD1E='4,I# &OZ7
M?^"?O[:$'Q_\+)\.?B!J$4?QC\(Z<I>YG=(SX^\/VBI$OB"V4E0VNV2F./Q)
M9QC]ZS1ZU:K]GNKRVTO^W_H\^,']HT<-P#Q-BO\ ;\/35+AO,*\]<;AJ4?=R
MBO4D]<7AJ:?U";?^T8>/U9VKT:*Q/^3GTU/HS/),3C_&/@++_P#A&QM9XCCG
M)<'2TRK'5YKGXDP=&"LLNQU:=\XI12^HXV?U]*6$Q6)> _2:BBBOZY/\V@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M45#<W-O9V\]W=SPVMI:PRW-U=7,J06]M;P(TLT\\TK+'###&K22RR,J1HK.[
M!02$VDFVTDDVVW9)+5MMZ));L<8RE)1BG*4FHQC%-RE)NR22U;;T26K>B.;\
M;^-?#'PY\):_XX\9ZM;:'X8\,Z=-J>KZG=,1'!;P@!4CC4-+<W=U,T5I8V5N
MDEU?7L\%G:Q2W$\4;?RC_M:_M/\ B;]J'XEW/B>_%SI?@W1#<Z;X \*22AH]
M%T9I5+WEXD;-!+K^M-%#=ZS=(9,,EMIT$TECIMGCW?\ ;_\ VS;C]H7Q8W@#
MP)?S1?!SP=J,AM)(F>+_ (3K7[;S('\37<?RM_9-L&E@\-6<HW?9Y)M6NE2Y
MOHK33?SBK_/SQ\\7WQ?CJG"?#V);X7RS$?[9BJ,_<SW,*$M*BE%VJ9;@ZB?U
M2*_=XFNGC7[2,<'*G_LY]#OZ-"\-,HH^(O&V 2X^SW!_\)F7XFG^]X1R;%TU
M>C*G-7HY[F5*5\QFTJV!PDUE:]E4GF<*Y1117\UG]UA1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?8?[%O[+>J_M/?%.
MWTJ[CNK3X<>%&M-7^(>MP[HBNGO*YL_#MA< 836?$<D$UM;N#NLK&'4=4VRM
M8QVUQZV19)F7$F;Y?D>3X>6*S',\3##86C'1<TKN52K.S5*A0IJ=;$5I>Y1H
M4ZE6;48-GSG%W%>1<#<-9SQ;Q+C89?D>18*KCL?B9V<E3A:-.A0IW3KXO%5I
M4L+@\-!^TQ.*K4:%-.=2*?W!_P $P/V0_P"VK^U_:3^(FEYTC2;F5/A3I%]#
ME-2U>UD>"Z\;30R+M:TT>=)+/P\65C+K$=UJB"!M)TZ:Z_>6LW1M'TKP]I.F
M:#H>GVNE:+HMA::5I.F6,*6]EI^G6$$=K965K!& D-O;6\4<,4:@!$10.E:5
M?ZD^'G N6^'O#.#R# *-6NE]8S3'\BA4S',JD(K$8F2U<::Y8T<+2;;HX:E2
MIN4YJ=2?_/IXU>+F>^-''F9\8YPYX?"R;P7#^3^T=2ADF14*DW@\#3>D9UY<
M\\5F&(C&*Q6/KXBM&%.DZ5&D4445]R?DH4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% '\[W_  4N_9 _X5IXEN/CS\/-+\OP
M!XQU/'C32[*'%OX0\7ZA*3_:,<4:@6V@^*+AF=./L^GZ^\MFKPPZII-G'^3%
M?VT>+/"OA_QSX:USP?XKTNVUKPYXDTR[TC6=+O%+07EA>Q-%-&2I62*10PD@
MN(7CN+:=(KBWEBGBCD7^3?\ :T_9I\0_LQ?%34/"%[]IO_"6K>?J_@#Q++&-
MFM^'FFVBWN98U2$:WHCNFGZW;HL1$P@U"*".PU*P:3^!/I#>%/\ JSF4^,\A
MPW+D&<8A_P!IX:C#]WE&;5Y.3J*,5:E@<QFW*EI[/#XQU,.G3A6PE(_V/^A3
M](G_ %\R*EX7<7X[GXRX9P*_L''8JI>MQ)PYA(1C&E*I-WKYOD=)1IXB[]OC
M,L5'&-5JN%S/$'R_1117\Q']\A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %=+X-\8>)?A_XIT+QIX/U>ZT+Q-X;U&WU31]
M5LV"S6MW;MD95@T4]O,A>WO+2X26UO;26>TNX9K::6)^:HK2C6JX>K2KT*M2
MA7H5(5J-:E.5.K1JTI*=.K2J0:G3J4YQC.$XM2C)*46FDS#$X;#8W#8C!XRA
M1Q6$Q="KAL5A<32A7P^)PU>G*E7H5Z-2,J=:C6I3E3JTJD90J0E*$XN+:/ZU
MOV0OVI_#7[47PXAUR#[)I7CWP^EMI_C_ ,*12G=INIO&PAU;38Y7:>3P]K?E
M2W&FS.TC6TJ76EW$\US823S?65?QK? SXV^-OV?OB-HOQ'\#7GE:AIK_ &?4
M]+G>0:9XDT.>2-M1T#6(HR/.L;Y(D97 ,UE>16NHV;1WMG;RI_61\"OC=X)_
M:"^'.B_$?P-=^98ZBGV?5=*GDC.J>&M=@CC;4= U>)#^ZO;)Y$:.0*(;ZRFM
M=2M#)9WEO(_^C/@AXNT>/\J63YQ6IT^+LIP\?K47RP6<8.GRTUFF'@K)5HMQ
MAF-"FN6G6E&O3C"C7C2H_P"('TL/HV8GP;XA?$O#.&K5_#;B+&3_ +/FN>K+
MAG,ZO/5GD&-JOFD\-**J5,EQ=63G6PT*F$KRJ8K!SQ&*]AHHHK][/X]"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH X#XK>!++XH?#3Q[\.]0\M;;QIX3UWP[YTB[EM+C5-.
MN+:SOU !(ET^\>"]A8 E)K=& )&*_C$U/3;[1M2U'1]3MI+/4M*OKO3=0M)A
MB6UOK&XDM;NVE ) D@N(I(G&3AE(S7]O5?RR_P#!1SX5'X8_M2^-+JUMOL^A
M_$B*T^(^D,J8C:?7FFA\2+O V&4^*K'6KIHQAX[>[M2ZXD1W_DCZ5O#3Q.3\
M.\5T*=YY9C*V3XZ45=O"YA#ZQ@ZE1]*>'Q.&K4HO_GYCTG>ZM_I%^SMX[6"X
MGXV\.L564:6?99AN)LIA.5HK,,EJ+!9E1HQO[U?&8#'X;$35F_8Y1*5URM/X
M1HHHK^'C_68**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /T7_ ."7WPQ/CS]I[2O$=U;^=I'PNT#5
M_&-PTB;K=M6GB'A_P_;LV.+F.]U>36+49&6T61LD(5;^G&ORM_X)-?"H^$?@
M5K_Q*OK7RM3^*OB>1K&5EP\GA7P<;K1]-(W#>OF:]/XHDXPDL'V60;AM:OU2
MK_2OZ/O#3X=\-,IJ5:?)B^(*M;B#$75I>SQJITLOU>KA++,/@ZR6BC*M.RU;
M?^$GTS^.X\;>._$E##UE6RW@RAA>#,$XRO%5LJ=:OG-XKW54AGV-S/#2DKRE
M3PU+F:Y5&)1117[:?RD%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCU.+Y:V598Y5<+E7*Y4L34EB<R4ZU.M@?JY1117]&G\/A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OA_]MO]K_1?V8/ OV/1Y+/5/BWXMM+B/P9H,I2>/2[?+V\WB_78,Y72=.E#
M)86L@5M<U2/[%"#:6VK75CZK^T[^TAX._9E^&U[XV\2/'?ZU>>=I_@OPI'.L
M5_XHU_RM\=LG#O;:78AH[K6]4,;QV%F55%GU"[T^RN_Y0?BA\3?&/QB\<Z_\
M1/'FJR:MXD\17C7-U+ADM;.!1Y=GI>F6Q=ULM*TVV6.TL+1&80V\2[WEF:26
M3^=_'3QAAP/E\^'<@Q$)<6YEAVY58.,O[!P55-+&5%JECZ\6_J%&2O37^VUD
MJ<</3Q/]L?1'^C-6\6<YI\;<8X.I3\.,BQB4,/5C*F^+\UPTU)Y90>C>3X2:
M7]LXJ#M6E;*\-)UIXRM@.7U_7M9\4ZWJOB3Q%J=YK.O:YJ%UJFKZMJ$SW%[J
M&H7LSSW5W<S.2SRS2NSL> ,[5"J HR***_SQJ5)U9SJU9SJ5*DY5*E2I)SG4
MG-N4YSG)N4IRDW*4I-N3;;;;/]K*-&EAZ5*A0I4Z%"A3A1HT:,(TZ5&E3BH4
MZ5*G!1A3ITX14(0A%1A%*,4DD@HHHJ30**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K]B/^"9/['W_"8ZQ:?M%?$;2]WA3P
M[?O_ ,*UT>]AS%XA\26$Q27Q3-%*,2Z3X;NHVBTK"LEYXAA>?>B:(T5Y\=?L
M8?LK:Q^T_P#$V'3;I+NP^&_A62TU/X@Z_"&C9;%Y&:T\.Z9.04&M^(&@F@MW
M^;^S[&*^U1TF-I%:W7]5^@Z%H_A?1-)\.>'M-M-'T+0M.L])T?2K&)8+/3].
ML($MK.TMHEX2*""-(T&22%RQ9B2?ZF^COX3O/\?2XXS_  O-DF5XAO)<+6A[
MF:YI0G_O<HR5JF!RVK'33DQ&.BJ;<H87$TI_Y\?38^D8N#LHK^$O!N/Y>*\_
MP:7%6886I^]X>R#&4],NIU(.]'-L\H3][55<'E$Y5E&%7,,%B*6M1117]Y'^
M/P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHRN4445]>?F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ?SM_P#!6/X)-X0^+6@_&32;3R]#^*.G
M)I^NR11XBM_&OAJV@M6DE*@1Q'6O#PTV:!<;[FZTK6;EV9V<U^3=?UV_M@?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=:OE\O<IYSEL'=K&X*//3INF\?A<!5J1HGE=%%%?F!^_!1110 4444 %%%%
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MQW$>)I6CC*ZDE6H9?2?]G8":IN"Q>*HK'U"BBBOVH_E8**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS#XQ?%[P3\#/
MA_KOQ'\?:D+#0]%AQ%!%L?4=:U297&GZ%HUJ[Q_;-5U*5#';P[TBBC6:\O)K
M:PM;NZ@ZKQCXP\-?#_POKGC3QCJ]IH/AGPYI\^IZQJU\Y2"TM( ,X50TD]Q/
M(T=O9VENDMU>W<T%I:0S7,\43_RM_MB?M9>)?VH_B U__I>C_#CPW-<VO@/P
MI)( 8+9VV3:_K*1.T$WB+6$1'N2K2PZ9:B'2[269(;B]OOR'Q>\5,!X;9)>D
MZ.+XES*G4ADN72?-&%KPGF6-C%J4<#AI?#&\98RNEAZ3C%8BOA_Z4^C7]'K-
M_'3BM+$+$Y=P)D5>C5XISRG'DE43M4IY%E52<90GFV/A\53EG3RS"2EC<1&<
MY8/"XSSK]HW]H3QM^TG\2-2\?>+YC;6PWV/A;PU!.\NF>%/#Z2L]KI=EN"":
MX?/VC5=1:*.;4[]Y;AHX(!;6EMX+117^:>99EC\XS#&9IFF*K8W,,?7J8G%X
MJO+FJUJU67-*4GHDMHPA%1A3@HTZ<8PC&*_W>R+(LHX8R;+>'\@R_#95DV3X
M.C@,MR_"0]G0PN%H14*=."NY2D]9U*M24ZM:K*=:M.I5G.<BBBBN$]8****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8SIU(24X3A-*4)PE%N,HRBU*,HMJ2::;3"BBBD4%%%% !1110 4444 %%%%
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M%PQ&$Q,%RU:,XMJ,U*$2BBBO</DPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***^I/V._@#<_M%_'/POX)G@F;PG
MITG_  D_CV[CWH+?PGI$\#7EH)DP8;G7+J6TT&TD0F2&;4A=A&BM92OI9-E.
M.S[-<NR7+:+KX_-,90P6%I*Z3K8BI&G&4Y)/DI0NZE6HURTZ49U)6C%L\+BC
MB3*>#^'<[XISW$K"9/D&68O-<QKNSE'#8.C*M.%*#<?:XBKRJCAJ$7SU\14I
MT::<YQ3_ &X_X)A_ $_"KX'_ /"Q-<LO(\8?&)K/7\31[;C3_!5HDP\)V8W
ME/[3CN;OQ'(T;*)[;5=,BG02V(V_I94%M;6]E;6]G9P0VMI:016UK;6\:0P6
M]O!&L4$$$486.*&&)%CCC151$554  "IZ_UCX2X;P7"'#>3\-X!)X?*L'3P[
MJ\JC+$XAWJ8O%U(K15,7BIUL342T4ZK2]U)'_.7XD<=9KXE\<\3<<YRVL;Q%
MFE;&JASNI# X.*C0RW+:4VDY4,MR^CA<#1DUS2IX>,IWG*391117T9\0%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG&8B=I8K,<PKJ,7BLPQM6];%5Y1CS3:A3A2H4Z5*F4445X)]@%%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_*\)G?'52C/2ZY<3D605>5ZM7IYYC:4E9/\ L:4)75>"****_LL_R\"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MERQ]JYRIT,YP]&/L\-C9T\13A1PV/P]"CYA1117X2?UX%%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M45YI\7/BWX'^"'@/6OB)\0=632M T>+"HFR34=7U&57-CHFBV;/&U_J^HR(8
M[6V5D1%66[NYK:QMKJZ@YL9C,+E^%Q&.QV(HX3!X2C4Q&*Q.(J1I4*%"E%SJ
M5:M2;480A%.4I-I)([LMRW,,YS#!93E."Q.8YGF6*H8+ 8#!T9XC%XS%XFI&
ME0P^'H4HRJ5:U6I*,(0A%N4FDB;XJ_%?P+\%O!.K?$#XB:Y!H?AW24 ,CXEO
M=2OI%<VFD:/9*PFU'5KYD9+6S@&2%EN)W@M(+BXA_F*_:W_;/\?_ +4.OM:.
MUSX6^%VDWC2^&O MO<EEF:,LD.N>*)H2L>K:])&28E(;3]&BD>UTQ#))?:AJ
M/%_M0_M2>/OVH/'$GB+Q-,^E^%M+EN8/!?@FUN'DTKPWITK@>9)PBZAKM]&D
M3ZOK,L22W4BK!;1VFFV]G8VWS+7^>_C)XX8[CBOB,@X=JU\!PA2FX3:YJ.*S
M^4):5\8O=G2P"DE+#8!V<[1Q&-3K>RH83_:3Z,'T3<H\)L)@^,>-L/A,X\2L
M12C5HQE[/%9?P=3JPUPF6/WJ6(SGEDX8_.(\RIMSP>5RCAOK&+S$HHHK^>#^
MU@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3,,OQN58[%9;F.&K8/'X&O4PV+PM>#A6H5Z4G"I3G%[.,D[--QDK2BW%IO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)>^ _!VI0 MX+M9DW0^(-:M95^3Q9<Q,&T^QE7?X;MW$UPJZ]*(M$Q_V /\
M@G\?"9T7XY_'/1A_PE&(-3\ ^ -3@S_PC.0LUIXF\3VLHQ_PD>"LVD:-.G_%
M/G9?7Z?V[Y%OH?[,5_;/@1X'2P+P?&_&>#MC+0Q.09'B:>N#O:=+-,QI36F+
MM:>"PDU?"Z8FO%8KV4,-_E-]+WZ6<,VCF7A1X79GS96_:X'C'BS 5O=S.UZ>
M(X?R3$TW[V77YJ6:YC2ERYC[V!PLY9>\14QQ1117]?G^: 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG[U/%X[W,1F\;T:'L<K=269E%%%?UB?YSA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.-6K&EAZ>%PF'****_%S^I@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&K)\L(/)\-\57$MOZ%HHHK^MS_-P**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ IKJKJR.JNCJ5=' 965@0RLI!#*P)!!!!!
M((Q3J* 3:=T[-:IK=/N?C#^V=_P3/M/$3:K\3_V<=-M=,UUC-?\ B'X60&&S
MTK6'.Z6>^\%%S';:3J3-N>7P[(T.E7@)_LA].N(X]/U'\(M2TW4=&U"]TG5[
M"]TO5--NI['4=-U&UGLK^PO;:1H;FTO+.Y2*XM;FWE1HIH)XTEBD5D=58$#^
MWNOB+]J_]AKX9_M-64^MJL7@KXJ6UKY>F^.=-M$==3\F/9;:?XOT^,Q#6[$*
MJ0PWH>+6--C6(6MW+9Q2:;<_RGXM?1VPN>2Q/$/ E*AE^;S<ZV,R&\,/EV93
M=Y3JX"3Y:67XV;OS49.&!Q$FI7PD_:5*W^B/T</ILYAPG' <%>+U?&9SPU35
M/"Y9QA:KC,ZR*DK0IT,X@N?$9SE5*-N7$P53-L'3C*'+F5)T:.%_E4HKV3XV
M? /XH?L^^+)?"7Q,\.3Z3<,TSZ3K%OONO#OB2SB8+_:'A_5Q''!?0%7C::!E
M@U&P,J0:G965R3 /&Z_A['X#&Y7C,1E^983$8''82I*CB<)BZ,Z&(H58[PJT
MJD8S@[--76L6I*Z:;_UER?.<IX@RS!9UD>98+-\IS&A#$X#,LNQ-+%X+%T)_
M#5H8BC*=.I&Z<7RR;C.,H22E&211117(>D%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%?HQ^R1_P3S^(7Q_DT[QGXZ&H?#WX22-
M%<QZG/;B+Q-XPMB0_E^%-/O(V6"PGCX'B;48'T\"1'TRTUHI<1V_O\-<+Y]Q
M?FE')N'LNKYCCJVKC22C2P]*ZC+$8O$3<:.%PT&USUJTX0NXPBY5)PA+XWCO
MQ X0\-.'\5Q/QIG>$R3*<,G&,Z\G/$XW$.,I4\%EN#IJ6)S#'55&3IX;"TJE
M3EC.K-0HTZE2'RK\"?V>_B?^T5XOB\(_#?0WO#$89-<\07OF6OAOPQ8RN5%]
MKFJ"*1( P24VMC EQJ>HM%+'IUE=/'($_IG_ &6OV/\ X:?LO>'O*T&!?$/C
MW4[2.'Q/\0=2M8TU34,E))=.TB'=,-"\/K.BO'IEM-)+<M'!-JMYJ%Q!!+%[
ME\,/A7X!^#?A'3_ _P ./#=AX:\.Z<-RVUHA:YOKMD1)]2U:_E+WFJZI="-/
MM%_?337$BI'$'6"&&*/T&O\ 03PH\#\E\/J=+-<R='.N*Y4_>Q\J;>#RMSC:
MI1RFE42E&5FZ=3,*L8XFM#FC3AA*56K0G_C'](GZ67%7C/6Q'#V1K%<+>'5.
MJU#)X5E',N(%3FG1Q7$E>A-TYT^:,:U')L/.> PU3EE7J9AB*%#%4RBBBOW4
M_D4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:V#Q^ QM"IAL7@\7AYRI5\/B</5C"K1K4JD90J4YQC*,DTT%%%%=!Q!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1A1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 <'\2/ACX"^+OA6_\ !7Q&\,:9XJ\.:@,R6.HQ$R6UP$=(K_3;
MV)H[W2M2MP[_ &;4=.N+:]@WN(YE5W5OY_/VJ?\ @F;\0/A-_:7C/X-_VE\2
M_AY%YMW<Z,D*S^//"]JNYW-S8VD2)XGTZW4 MJ.CV\=_#&7>]T:*VMI=1D_H
M_HK\W\0/"SA3Q%PG)G&$^KYI2IN&"SS!1A3S'"VNX4YS:<,9A5)MO"XE3@E*
M<J$J%:7ME^Y>#/T@_$3P2S'VO#.8K&Y!B*\:N:\)9K*K7R3'WY8U*U*FI*IE
MF82A%*.8X"5*K)PI1Q<,9AJ?U:7\/!!4E6!5E)#*0000<$$'D$'@@\@TE?U(
M?M/?\$^?A!^T)]O\2Z1#%\-?B=.))V\5Z#8Q-IFNW1!8?\);X?C>VMM2DE8M
MYFKV<MAK6YDDNKO4(8([)OY]_CW^RU\9?V<=7-C\1/#,JZ+/<-!I'C31O-U+
MPAK>-Q06FK+#$;2[=59_[*U>#3M65%:4V)@*3/\ P1XA^#7%_A[4JXC%89YK
MD*G:CGV74YSPT8MV@LPH>_6RVJ[Q35?FPTJDO9X?%XAIV_V(\%?I0>&GC10P
M^"R_'+AWC"5-/$\'YU7I4L=.I&-ZDLFQ=J>&SS#*TY1>$4,="E!U<9EV#BXW
M^=Z***_)C^C@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&ZBN8T/BS5+<@?O;Z"+0[>5I%ATV_DAM=4K]75545410JJ JJH"JJJ,!5 P
M       ,"EHK^Z^$^#>'."<LCE7#F6T<!A_=EB*J_>8S&UHJWUC'8J=ZV)K.
M[Y7.7LZ47[.A3I4E&G'_ "*\1O$_C?Q6SZIQ%QQGF)S?&^_#!X=OV.6Y5AIR
MYOJ>4Y?3MAL#AE:/,J</;8B456Q=;$8B4ZTBBBBOJ#X **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5:=:C4J4:U&I"K2JTIRIU:56G)3IU*=2#4X5(32E"<6I1DE*+329^/7[1?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK\JOVZ/^"@FF_!V'5?A/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY;27+"&.IQ2GF^6TDHTI.6.P4%@IU:& ^?:***_ C^QPHHHH **** "BBB@
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M0KPUA-M22****]L^5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !5'4],TW6K"[TK6-/L=6TN_A>VOM-U.TM[^PO;=^'@N[
M.ZCEM[B%Q]^*:-T;NIJ]14RC&<90G&,X2BXRC)*491DK2C*+NG%IM----.ST
M+IU)TIPJTISIU*<XU*=2G)PG3G!J4)PG%J49QDE*,HM.+2:::/S>^-/_  3!
M_9Y^)OVO4_!=O??![Q+/OD6?PHB7GA66=R<-=^#KZ:.U@A4$!+;P[J'AV%<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BHIIH;:&:XN)HK>WMX
MI)IYYI$BAAAB0R2S32R%4CBC16>21V5$12S$ $U^"_[='_!1>7Q,-9^#G[/V
ML26_AIA/IGC'XE:?*T5SXA4[H;O1/!]RA62VT%AOAO\ Q!$RW&MJ7@TMH='W
M7FL_#\>^('#_ (>9-/-<[K\U6HIPRW+*,HO'9IB8Q3]CAZ<G[M*#E!XG%32H
MX:$HN;E4G1I5?UGP>\&>,O&KBBEP[PKA.3#T72K9YGV*A464Y!@)S<7B<;6B
MOWE>HHU(X'+Z3>*QU6$HTXPHTL1B*'J/[=G_  44B\-?VS\&OV?]92?Q(//T
MSQG\2M-F62W\/'YHKO0O"%U&62XUX?/#J'B"%F@T0[[?2WEUG?>:+^"\LLL\
MLD\\DDTTTCRS32NTDLLLC%Y)))')=Y'<EG=B69B68DDFHZ*_S7X]\0,_\0\Z
MGFV=U^6E3<Z>6Y91E+ZCE>%E)/V.'A)^]4FHQ>)Q4U[;$U(IS<:<*5*E_NMX
M/>#7!W@KPM2X<X5PO/B*RI5L\S[%0IO-<_Q\(.+Q6-JQ7[NA2<JD<#E])_5L
M#2G*--3K5<3B*Y1117PY^LA1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/R2BBBOQ$_JX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?RF_\%$M2.J?MC_&:7/R6MYX1TV->RC3? /A6R<#/]Z:&
M60_[3L1@<5\4U]9?MTS&?]K?XYN<_+XP$//'%OH^EVX_#$0QZC!YKY-K_)/C
MVK*OQSQG6D[RJ\5\15&WWGF^,E\M]%T6A_TA>#M".%\(_"W#07+'#^'7!-&*
M[*GPUED/F]-7NW=L****^3/T8**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ][_ &5]2.D_M+? *]!*@?&#X>6TC#M!?^*M+L+@^X\BZDR.XR*_L-K^,_X#
M3&W^.7P8G&<P?%CX=3#'7,?B_1W&,<YRO:O[,*_N3Z)M5O(.+J-_=IYQ@*J7
MG6P52$G\U0C]Q_DK^T;P\8\8^&V*2]^MPSG.'E+O'#9K1J07R>+F_P#MX***
M*_K0_P X0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K)UK0-"\26$NE>(
MM%TG7]+G_P!?INM:=9ZK83<%?WMG?0SV\G#$?/&>"1T)K6HJ)TX582IU(0J4
MYQ<9PG%3A.+T<91DG&46M&FFGU-*5:KAZM.O0JU*-:E.-2E6I3E3JTYQ=XSI
MU(.,X3B]8RBTT]4SXP\>_P#!/O\ 9,\?F:>Z^%&F^%]0EW%=0\"7NH>$/(+\
ML8M)TFXB\.,<X(\_19@N,(%!8-\<>-O^".W@6\:6;X=_&'Q3X?\ O/%9>,-
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ML=S',?PYU>U^4KB#Q]XX89.?G_TG7KD[AD8&=G RAYSF?\.O/V1?^A3\5?\
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ME4^$N%(.ZIU,GR#ZYB81>SE4XBQF=X><TMY+"TXMZJG'8_+/P/\ \$E?V>-
M\J?QCXA^('CZZ7;YUO-JEEX9T27')VV>B62ZS%O.0W_%1/A<!=K LWVCX _9
M;_9W^&'D/X)^#W@72;RVV^1JUSHL.NZ]%MQC9XA\0'5=<'(#-_Q,/F8!FRP!
M'O=%?JF2>'7 O#KA+)N%,CP=:G;DQ7U"CB,;&VUL=BHU\9ND]:[NU=W>I_/?
M%?C;XN<;JI3XG\1.+,SPU:_M,!_:^)P653YM[Y3E\L)EFVBMA%972LG8  !@
M# '  Z >E%%%?9GY:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!_)A^WE ;?]KOXXQD8W>*;.?!&.+KP]HMR#_P "$VX'N#GO7R-7W;_P
M4HTO^SOVQ_BG*%VQZK:>!=4C&, [_ /AJSF8>N^ZLIV)_O%AVKX2K_);Q"H2
MPW'O&U"6]+BSB**\XK-\7RR7E*-I+R9_T>>"V*CC?![PJQ<'=5_#C@F;Z\LW
MPWEJJ1=M+PJ*4';2Z=@HHHKY _3 HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#U_\ 9\@^U?'SX(6P!)N/B_\ #6  #)/F^,]%CP .I.[&!7]E-?R$_L>:
M7_:_[4OP#M-N_P KXH>%-4QC./[$U*+6BW_ /L&_/;;GM7]>U?W/]$ZC*/#?
M%>(:]VKG>$HI_P!ZA@%.2^2Q,?O/\D/VC6*C/CCPZP2?OX?A3,L5)7VCC,WE
M1@[=+O SUZV\@HHHK^L3_.8**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HK$\0>)?#GA/3I=8\4^(-$\-:1!_K]4\0:K8:-IT/!
M;][?:C/;6T?R@GYY1P">@-?%'Q(_X*2?LI?#S[1;VWC:]^(6J0;@=-^'FDS:
MU&[#(4QZ]?2:3X6FC9A@M;:Y<,JC=L(*;O!SOBGAOANE[7/\]RK*(\O-&./Q
MV'P]6HNU&A4J*M7D];1HTYR=G9.S/L.%/#[CGCFO]7X.X1XBXEFIJ%2>3Y3C
M<;AZ#=M<5BZ-&6%PD%=7J8FM2A&ZO)71]Y45^#GC[_@L3XHN'N+?X7_!_0M*
MB!9;;5/'6MW^N32J?NRRZ)H*Z!%:.!_RR&NWZ9 8R$$I7QAXZ_X*%_M:^._.
MAF^*=YX5L)=VVP\"Z;IGA7R W40ZO86W_"2# P%,FMR%<94ABS'\9SOZ3'AM
ME;G#+ZF;\058W47EV7RP^'<UTE7S6I@)\E]/:4J%=/>*E%IG]1<*_0-\=,_5
M*KG-#AK@W#SY936=YU#&XU4Y6=X83A^CG%/VMG?V.)Q6%<7>-25.2<3^J>^U
M"PTNUEO=3O;33K*$;IKN^N8;2UB7UEN+AXXHQ[NX%> >+?VN?V9/!'FKXA^.
M/PYCG@R)K/2?$5IXEU&%ER"DNF^&FU?4(Y./]6]LLAX(4Y&?Y(O$7BWQ7XOO
M&U#Q9XF\0^)[]F9FOO$6M:EK5XS-]YFN=2N;F8LW\1+Y/<USU?E6:_2SS&?-
M').#L%ADKJ%;-<SKXWF[2EA\)A\!R><5BI_X^W]#\/?LXLDI>SGQ7XG9KCF[
M.KAN'L@PF5<CTYH4\;F6-SCVG6U267TMU>EIK_39XB_X*G_LFZ(T@TW5O'7B
M\1DA6\.^"[NV6;'0Q_\ "677AA@&[>:L1]0*\/\ $'_!8KX;6V__ (17X-^.
M-9QGR_\ A(-?T'PUO_N[_P"SH_%GEY[[?-V]MU?@'17Y_C_I+^*.+YOJ^+R;
M*[[?4,GHU.3_  _VG4S&]O[W-YW/V7*/H(?1_P MY/KN7<4<0<MN;^U^)L31
M]I;?G_L&CDEK]?9\GE8_9K5/^"QWC>9G.B?!#PKIZD_(-4\7ZOK#*,GAVM-(
MT,.=N!D)'R"<8(4>=:G_ ,%=_P!HRZW)IO@OX/:6AZ.VA^+[ZY7@CB2;QM';
M$9.[YK,G(7G;N#?E517RN)\;O%7%7]KQGF,;WO\ 5J&78/?M]4P5"WE:UNA^
MB8'Z*'T>,NM]7\+LCJ<MK?7L7G6:;;<W]IYIB^;SYKWZW/TAG_X*I_M7S2;X
M[[P!:KC'E0>#(V3.2<YN=1N)<X(7_68PHXW;F;&F_P""H'[7DJ;4\8^&;<[@
M?,A\"^&F? S\N+BRG3:<\_)NX&&'.?SWHKR)^*GB3._-QSQ0KW?N9QC:>]MO
M9U8VVV5DM;;L^CI?1Y\"Z-N3PEX =K?Q>&<KK[;7]OAZE_.][];GW]_P\X_;
M"_Z'_0__  @_!O\ \IJOVW_!43]KF#9YOBKPI>; P;[3X'T%?-SG!?['!:X*
MY!'E^6/E&X,-P;\\J*B/BCXCQ=UQUQ6W_>SW,9KITGB)+IV[]V:S\ / ZI'E
MEX1^':7]SA')*<NWQ4\'"7X[Z[GZ9V7_  5A_:EM2IGM?A=J04+D7OA'4XP^
M%*DM_9WB6P(+$[VV%1N "A4RI[O3/^"P7QPB*_VQ\,_A3?@?>_LR+Q?I)/*_
M=-UXFUK;QN'(;DJ>BD-^2-%>C0\9/%##.]/C7.I6_P"?]:EBE]V*HUD_FM>I
MXF,^C!X 8Y-5O"OA:">G^QX;$9>_E++\3AFO5--=#]P-%_X+)S K'XB^ ,;C
MC?=:+\16C(/?;87W@Z7=GD@G4EVXQAMVY?9_#O\ P5Z^ M_LC\2> OBCX>E?
M :6RL_#6O6,1[EYE\0Z7>E1V,>FR,>ZBOYV**^DP7TBO%?"->US["YA&.T,;
MDV56:[.>#PF$K2]74<M=]K?"YK]"/Z.N9*?U?A',<EJ3O>KE7%'$-TWUA2S/
M,,SPT;=(QH*']T_JE\+?\%'/V0?%#1Q?\+1/AV[D( M?%/ACQ1I*KD=9-1_L
MBXT6, \'?J8.>0"O-?2WA'XU?!_Q\T4?@GXI?#WQ7//CR[30?&&@:G?9/1)+
M"TOY;V*7UBE@20=T%?QB45]SEGTKN+*#BLWX:R',8)KF>!JX_*ZLUUO.K6S2
MDI/76-!16GN::_DF?_LZO#K%J<N&N.N,,DJ2NXQS;#Y1Q!AZ<GLHT\-AL@KR
M@OY9XJ4WUJ=3^XBBOXV?!?[0GQS^'9A'@KXN?$+P];P;?+TZR\5ZP='.W&T2
MZ+<74VDSJN,*LUE(H&0!@D'['\"?\%4_VH?"OD0^)9O!7Q'M$VI*WB3PW'I6
MIM$N!B&^\(S^'[99\ +Y]WIM\6Y:5))"7K]0R7Z5'!>,<(9UDV>9+4E;FJTH
MX;-<)3[\U6E4PV+:73DP$VUT3T/P+BC]GIXI98JE7A;BCA+BFC"_+0Q,\=P]
MF57^7V=#$4<?ER;^U[7-Z:BVK.2NU_2_17X_?#S_ (*__##5O(MOB;\,_%O@
MVY?;')J/AB^T_P 8Z2K\!KB>*Z'AO5+6 \MY5M::M-'D(#-S)7WK\-/VM_V<
M?BX8(?!'Q;\)W>I7.U8M"U>\?POXADD. T4&A^)8M)U*\:-CM=[&WNH2<,DK
MHZ.W[)P_XG< <4.G#)>*LHQ%>K;V>#KXCZACYM](8',(X7%S:;2?)1DDVM=5
M?^8.,O /QCX 5:KQ3X><28+!T.;VV9X3!_VSE%.*O[U3-\EGF&6TE))N/M<5
M!M)Z:-+Z,HHHK[L_(0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_92QN$P-.IFU:%K<N*SG%?6,VQ:M_P!!.-J[M[MW****^6/T(**** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)G5I1SG^P,%4NE@^'X/ 247HE+,'.KF<FXZ3Y<9"G)MM4HII+^\N /H<>!7
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M<+Y^G>)?B#;F&^T?PA*-T5QIWAUB)+76/$L+;DN;\B;2M#D'D*M_J@GBTK\
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MP"Y\%@YO'.O6P*@!0%4 *       ,  #@ #@ < 4M%%?VN?Y4A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*<*5&A1IQI4:-*G%0ITJ5."C"G3A!*,(0BHQBE&*2204445!H%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 =U\/OB;\0/A3KT7B?X<^+]>\':Y%L#7NB7\MJ+J)&WBUU&U!:SU
M2Q+<R6&I6]U92_\ +2!Q7[!?L_?\%;+B-K+P]^T7X9$\9\N ?$3P39K'.G1/
MM'B#PEYBPR@DF6ZO?#DT!1%V6OAN9S7XAT5]QP=XC\8\"5U4X>SBO0PSGSUL
MKQ#>*RK$MOWO;8&JW2C.:]UXC#^PQ26D*\-S\E\3O [PR\7<'*AQKPS@\9CE
M2]EA>(,%%9?Q%@4E:G]6S;#Q6(G2I/WHX/&?6\OE))U<)46A_:?\/?B9X ^*
M_AZ#Q5\.?%NB>,-!N"%^W:->)<&VF*AS::C:MLO=+OT5@TNGZE;6E[""/-MT
MR*[FOXM_AM\5?B+\(/$4'BOX:^+]:\(:Y#L5[G2KDI!?0HV\6>K:=,LVFZQ8
M%_F>PU6TO+-V =H"RJ1^W7[-G_!5KPQXD^P>%/VB=-@\'ZV_EVT/Q"T&VN)O
M"=_(<1H^O:0AN=0\/3R';YM[9'4M(:5Y)IHM#LX\#^SO#_Z2/#'$KH9=Q3"G
MPMG$^6FL14JN>18NH[*]/&5/?R^4G=^RQ]Z$%:*Q]6;43_+GQF^@SQ]P+'%Y
MWX?5:WB#PU2YZLL%0H*GQ=EU%7=JN644Z6=0IKEC[?*/]KJRYIO)\/2BYK]C
MJ*SM(UC2?$&F6.MZ#JFGZUHVIV\=YINK:3>VVHZ;J%I*-T5S97UI)-;74$@Y
M2:&5XV'1C6C7](0G"I"-2G*,X3C&<)PDI0G"24HRC*+:E&2:<9)M---.S/X:
MJ4ZE&I4HUJ<Z56E.=.K2J0E"I3J0DXSIU(22E"<))QG"24HR332::"BBBJ("
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#X*_X*4^ _\ A-_V3/'%S##Y]_X%U+P]X[L%"[BHTS4%TK5Y@0"4
M$'AW6]9G9@,%8RI(5BP_ELK^V/QGX6TWQQX0\5>"]83?I/BWP[K7AK4UVAR;
M#7--N=,N]JM@%A!<N4R1A@""",C^+CQ-X>U+PEXD\0>%=9A^SZOX9UO5?#^J
MP'(\G4M&O[C3KZ+# ']W<VTJ<@'CD U_"WTK<A>&XBX<XCIPM2S7*JV65Y16
MGUK*L0ZT)U';2=7#9C"G"[]Z&%=E[C/]<?V=G&$,=P3QQP/6JWQ/#_$&%S_"
M0F_>_L_B'!1PE6G176GA\=DM2K5LO<J9A'F?[R*,.BBBOY0/]%PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBG*K.RHBL[LP554%F9F.%55&26)(  !))P.:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!117EOQ9^-7PP^!_AN3Q3\3_ !?I?A?3<2K90W4C3:MK%Q$H9K/0]&MEFU/5
M[OYD+Q6-M,+=&\^Z>"W5YDYL9C<'EV%KXW'XK#X+!X:FZN(Q>+K4\/AZ%..\
MZM:K*%.G!:7E.25VENSORS*\SSO,,)E.39?C<US3'UHX?!9=EV%KXW'8NO/X
M:.&PN&A4KUZDK.T*<)2LF[63/4J^<_CK^U9\$/V=[&23XB>+[9->:#S['P5H
M8CUCQEJ09=\)BT:&:/[!;S@'R=1UNXTK2G92@OO,PA_&C]H[_@JA\1O'AO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSC/&>SA'!824HQDLNRZGA<%>$*E2C5Q"E7F4445^?'[0%%%% !1110 4444
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M/XH^*]5\;>/O$.H>)_$^M3&:^U3490\A49$-K:PHJ6UCI]HA$-EIUE#;V-E
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMC1117]@'^9X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&<7<K<*F$PEU"MA.')--3C+DQ&<1TQ$:.!E/#8DHHHK^H3_/\**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:=#+<[JR<:>'SV3M3PN/DXT,XDXT:[I9HX2S/\BZ***_DX_T9"BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]_/,NH12<Y3D[U,SP<%_M2=ZF*PZ6,_>3AC)P_QF^F-]&A>&N;5/$;@G .'
M6>XSES3+L-3_ '7"6=8J;<:<*<%:CD6:56_J#25' 8R4LL_=4JN64ZGU/111
M7]+'\(A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQXCC7X7R"3C4_P!HI<N<XZD[2M@\#52>%A4CI'%XZ,$E*%6CA<7!L_BGQO\
MIK\ >'-/&9)P1/"<?\8T^>C;!8ASX7RBNKQ<LRS;#RMF%6C+667914J.4H5,
M/BLPRZK%7^&/V1?^";O@OX,-I7C[XMG3O'_Q0@,-[8:<(S<>#/!=VF)(I-/M
M[F-#K^MVK_.NLZC EI9SB.32=.ANK6+59_U!HHK^[>%N$>'^#,JI9/P[EU'
M82%I5917/B<96MRRQ.-Q,KU<5B)+1SJ2:A&U*E&G1A"G'_(?Q"\2.,_%+B&O
MQ-QMG6)SC,JO-3P\)OV6!RW"N;G# Y5@:=L/@,'3;NJ5""E5FY5\1.MB:E6M
M,HHHKZ0^&"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^OA92A@<TC'V6*]C7]AC\+_%-17Z#_ME?L&^,?V;[Z[\8^$O[0\8_!N[NO\
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MA]PQG/%V-2E&GF.;M<.Y(I/2%:G3E'%YQBXQ^*5"M@LKE)6BL1!MN/\ /_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&8BM4=;'TT_>****_JD_SS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^4S/B'/\Z=\YSS.,V=[WS/,\;CW>][_[57JZWUOO?4****[SQPHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKK8C$59))7>D:=*E",:5##THTZ&&H0IT,/2IT:<*<2BBBO1/%"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *XSXB>.] ^&'@7Q9\0O%%Q]FT'P?H6H:[J3@J)98K
M&!I([.U5V59;[4)_*L;"#(:XO;F"!,O(H/9U^*?_  5O^/+6.D^$_P!GK0;S
M$VM_9_''CT0R<C2K.YEA\*:+<!2RE;S4[>[UVZMY DT3:3H=RH,5T"WQ/B)Q
M?0X&X/SGB.KR2KX7#NCEU&>JQ.:8I^PP%%QWE#V\XU:_+=QPU*O4M:#/U;P3
M\-,7XM^)G"_!&'56&$S#'1Q.>8JEH\#P_@%]:S?%*=G&%7ZI3GA\&YVC/'XC
M"T6[U4?C'\5?B1X@^+WQ%\8?$KQ3+YFM^,-;N]7N8P[20V,$A$6G:5:L_P _
MV'1]-BM-*L%;YDL[.!6)8$GS^BBO\I,5BL1C<5B<;BZT\1BL77K8K$UZKYJE
M?$8BI*K6K5)?:G4J3E.;ZRDV?]$V7Y?@LJP&!RO+<-2P679;A,-@,!@Z$5"A
MA,%@Z,,/A<-1@M(4J%"G"E3BOAA%+H%%%%8'8%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116EH
M^CZMXAU73]#T'3+_ %G6=6NX+#2]*TNTGOM1U"]N9!%;VEE9VR27%S<32,J1
MPQ1N[L0%4U4(3J3C3IQE.<Y1A"$(N4YSDU&,8QBFY2DVE&*3;;22NR*E2G1I
MU*U:I"E2I0G4JU:DXPITZ<(N4ZE2<FHPA"*<ISDU&,4VVDFS-K]:?V*O^"<6
ML?$\Z3\4/CK8ZAX>^'+&"_T'P7)Y^G^(?'$/RRP7>I$>7=Z%X6N1M:-U,.L:
MU;EI+$Z?8RVFJ77U-^Q=_P $VM*^'W]D_%#X_P!C8:_XZ3R;_0/ $GD:AX?\
M(3#;+!>:\09;37_$<!VF*U4S:)H\RM*C:I?"UN]/_7FO[(\(/H[N3PO$WB%A
M;1]S$9?PM56LMITZ^>Q=K+:2RK=^[',&E[7!/_,'Z2_TV8Q68<!^"V8<TG[3
M!YSX@X:7NQWA7PG"4U\4MZ<^(=H^_+)HR;P^:QS-&T72/#FDZ=H.@:98:+HF
MD6D%AI>DZ7:06.G:?96R".WM+.TMDC@MX(8U"QQ1(J*!P*TZ**_LR$(4X0IT
MX1ITZ<8PA"$5&$(12C&$(Q2C&,8I*,4DDDDDDC_+NK5J5ZE2M6J3K5JTYU:M
M6K.52I5J5).=2I4J3;E.<Y-RG.3<I2;;;;;"BBBJ("BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK5,/BL+B:$XU*.(P]>C*%6C6HU(QJ4JM.<9TYQ4HR4DF?S-_MD_\$^?%_P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "OQ>_X+ ?%,V/A?X8?!NPN=L^OZG>^/
M?$4$;[773=$CDT;P]%.H.9+:_P!1O]9N C#8+G0H9.6C4K^T-?RE_P#!0?XD
M'XE?M6_$RX@N#/I?@V\M?AWI W;U@C\(PFRUB-&SM,<GBF3Q!<IL 7;<#[QR
M[?@7TD.)'D?AQBL!1J<F*XEQV%R>'*[3CA(N6.Q\TNM.=#"K!U=],8E;6Z_L
M;Z#7 \>+?'+ 9OB:/M<OX%RC,.)JG/&]*68R]GE.44Y/I6IXK,99EA]O>RR3
MO:+3^*Z***_SD/\ <(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *]N^!/[/?Q._:*\7Q>$?AOH;WC1&&3
M7/$%[YMKX;\,6,SE1?:[JBQ2I;JP24VME!'<:GJ#12QZ?973QR!/I;]D3]@/
MX@?M&W%CXN\4?;O ?P@699)/$<]N$UKQ7%&^)K3P;972%)8G*F"7Q'>1/I%I
M(7%K%K%U:W-A'_2#\+OA3X ^#/A#3_ WPX\.6/AOP]IXW>1:J7NK^[9$2?4]
M7OY2]YJNJ701/M%]>S33LJ1PJR6\,,4?]$>$_@)F_&KP^><1K$9+PLW"K23C
M[/,\ZIZ22P4*D7]6P<XZO,*T&JD6E@Z592E6H_Q/](SZ8G#?A7'&\)\$2P7%
M/B#%5,/B&I^WR'A:JDXREFM:C./U[-*4KJ.38:K%T9QD\SQ&%<(87%>"_LL_
ML:_#']E_15ET>!/$_P 1-0M%@\0_$+5+6--1G5PK3Z;H-L6F7P_H1D 8V5M-
M+=WI2)]6OK]H+46_U[117]]Y)D>4\.9;ALGR/ 8?+<MPD.2AA<-#E@OYJE23
M<JE:O4?O5L16G4K5IMSJU)S;D_\ ''BKBSB/CC/<?Q-Q9G&-SS/,RJ^UQ>/Q
MU3GJ2MI3HT814:.%PM"-J>&P>&IT<+A:2C1P]&G3C&*****]4^="BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MOEW]IC]DKX6?M/>'OL?BVQ&C^+]/M9(?#/Q TBWA&OZ*Y+21VMUN,::YH9F9
MGN-%OY!%B6>73KC3+Z47R?45%>;F^3Y7G^78G*<YP.'S++L9!T\1A,5352E-
M;QDMI4ZM.24Z5:E*%:C4C&I2G"I&,E[O#7$_$'!V=X#B/A?-\;D>=Y;55;!9
MCE]9T:]*6TH2WIUJ%:#=+$86O"KAL31E.AB*56C.<)?R ?M$_LP?%/\ 9H\4
M'0_'NDF;1KZ>9?#7C32TFG\,>);>/+#['>.BFTU**(!KW1;X0ZC:']Z(Y[&2
MVO;GYVK^UOQQX$\'_$KPQJG@WQYX=TSQ1X8UF$PZAI&JVXGMY,9,4\+@K/9W
MML^)K+4+.6WOK&X5+BTN()XTD7^>C]L#_@G!XP^#/]J>/_A"FI^._A=%YU[J
M&E",WGC#P1;+F25KV&WC5M>T"V3+?VS90B\L+=7;6+-+>UEU>X_@[Q7^CYFO
M"?UG/>$HXC.N'(\];$8.SJYMDU-7E)U(P5\?@::U^M4H^WH4[O%4G3I3QD_]
M?OH[?30X>\1?J'"/B1/!<+<<3]EA<'FCE'#<.\3UW:%.-*I4ERY/F^(E9?4*
M\_J>+KM++L1&M7I9;2_+NBBBOYJ/[M"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBNP_MOP9?73P^'?B%HUO,V@:J#N>&UOE8R2:#KAB5FET?4)"SM'</IEWJEG
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML+15EHK4Z459:+8****Y3T HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^%P\*6&PU*,:.'I4J4(P11117IG@A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 598>49U*6/Q>90=-4BBBBOZ#/XO"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>.(C4H4^=HHHKX(_80HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^17_!82;;
M\&/A;;Y_UOQ/DFQ_UP\*:XF<>WVG]?>OUUK\AO\ @L+'GX._"J7^Y\2[B/\
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MFK]\/V5?^"87@OX<'3?&WQW.F_$+QO%Y5Y9^#XU-SX$\.3C#H+^.>-#XNU&
M@!S>PQ:##(TL::;J316VIU]__!3X _"O]GWPPGA?X8^&;;1X)5A.K:S/MO/$
M?B*YA4@7FO:U(BW-]*&:1X;9?(TZQ\V2+3;&RMV\D>RU_<_AE]'7(N%OJ^;\
M6_5N(L_AR5:>$<'/),LJJS3I4:L8O,<1!ZK$8NG&A"7*Z.$A4IQQ$O\ )#QZ
M^FUQ=X@_7>&O#E8W@G@ZI[2A7S&-54N*\]H.\9>WQ6'J2CDF#JQLI8++JT\5
M4AS1Q.95*%:I@X,CCCBC2*)$BBB18XXXU5(XXT4*B(B@*B(H"JJ@*J@   4^
MBBOZ4225DK):)+9+L?PJVVVVVVW=MZMM[MOJV%%%% @HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K4T.U^
MVZUH]EC=]KU33[7&,Y^T7<,6,=\[\8K+KT#X3:<=8^*GPST@+N.J_$#P9IP7
M&2QOO$>FVNW'?/FXQWKJP-%XC&X.@E=U\5AZ*7=U*L()?/F.#-<2L'E>98R3
MY8X3 8S$REV5##U*K?R4+G]I%%%%?[''_,,%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7Y/?\%?K3?^S]\/;[&?LWQBTNUSZ"\\
M%>-Y>?8FQ'/J .]?K#7YF_\ !6'33??LLVUT%R-'^*'A'4B<'Y1+IOB72-WM
MSJH7)X^;'4BOS3QCHNOX8<;02ORY)7K?+#SI8AOY*DWY6/W;Z,>*6$\?O"JJ
MY<JGQ9@\+?SQU*O@HQ_[>EB%'YG\U-%%%?Y9'_0D%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M95IKVV)G6Q$IU9%%%%?3'P84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%2,HHHHHKA/6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>AEN A)_'C,9*+IT_=O*-&"J8JM&,O84*LDXGYCXG^,/A_X09/\ VQQQGM'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8'BCPIX:\
M;:%J/ACQ?H.D^)?#NK0&WU'1M;L;?4=.NXB0RB6VN8Y(R\;A98)5"RV\R)-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2H4D^2AAZ2IX?#TU&E0ITZ<8Q11117I'AA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 444$@ DG '))Z >IH **^0OC%^W3^S5\%?M5GK_C^T\2^(
M[7>K>$_ 0B\5:V)X\A[6[FM+B/0M'NE.-UOKFLZ9-A@RQL*_*;XQ_P#!6WXJ
M>)OM>F?!SPGH_P -],??'%X@UOR?%?BUUY"7%O;W$$7AK2W8'+VT^FZ^8V"F
M.^X.?RWBWQE\/>#O:4LPSVCCLPIW3RK)>7,\=SQWIU?8S6$PE1?R8[%85M--
M7NC^@O#CZ+_C3XG>PQ&2<(8K*LFK\LH\0\4<^0Y0Z4[<M?#O%4GF&94'_P _
M,IP&/2::=K.W[W>+_&W@[P!HT_B+QQXHT#PCH5MD3:KXBU:RTBQ#[2RPI/?3
M0I-<2!2(;:$R7$[X2&)W(4_F-\:/^"LGP@\(?:]*^$'A[5?BEK,>^)-;O1/X
M5\&Q2<H)8YKVV?Q#JWDN"7@CT?3+6Y0*;;5]KB1?P,\<_$;Q[\3=9D\0_$'Q
MAXB\9:R^\+?^(=5O-3DMXW8,;>R2YE>&PM%( CL[*.WM8E54BA154#BZ_E[B
M_P"E'Q-F?M<+PCEN&X=PLN:,<?BU3S+-I+93A"I!9?A&TWS4Y8?'2B[.&(31
M_?\ X:_L_. \B^KX_P 2<\QW&V81Y9SR?+G6R+AR$]'*E5J4:KSK,8PDO<K0
MQF4PJ1<HU<$T]/3_ (S?%CQ%\<?B7XH^*?BRST:P\0>*Y[&>_M/#]I/8Z3#_
M &=I=CHUHEK;W5W?7 VV.G6PFEGNYYKB<27$LC22L:\PHHK^8\9C,3F&,Q6/
MQM:>)QF.Q-?%XO$5&G4KXG$U95J]:HTDG.K5G.I-V5Y2;/[YRO+,!DN6Y?D^
M586E@<KRG X3+<MP5!.-#!X# T*>%PF%HQ;;C2P^'I4Z5.+;M"$5=V"BBBN8
M[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+4H5*<Y0G%IQDT[A1116)TA1110 4444 %%%% !1110 4444 %%%% !1110
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MMV*-Y<S@9K^.6I(9IK>6*XMY9()X9$EAFA=HI898V#QR12(5>.1& 9'1@RL
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M]OV"HKR?X:?'7X/?&*U%U\,_B-X5\7GRA-+8:;J<2:Y:1$!@^H>'KS[+KNG
M@_\ +_IUL>&&,JV/6*_<,'CL%F.'IXS+\9A<?A*RYJ6*P>(I8K#U8]Z=>A.=
M*:\XR:/Y-S3*<TR3&ULMSK+<PRC,<-+EQ&7YI@\3@,;0E_+6PN+ITJ]*7E.G
M%^04445U'GA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45'++%!%)//+'#!#
M&\LTTKK'%%%&I>2221RJ1QH@+.[$*J@LQ !-?''Q7_;Z_9>^$GVFUU'XB6GC
M#7+;>#X=^':)XNOVECR'MY-1LYXO#5C<1OB.2WU/7K*=')4QY23;Y&<\09'P
M]AGC,]S?+LHPUI6JYAC*&%C4<5=PI*M.,JU35)4Z2G4DVE&+;2?TO#'!G%O&
MN.66<(\-9WQ)CFXJ6'R7+,7F$Z,9NRJ8AX:E4AAJ*LW*OB)4J,(J4ISC&+:^
MRZ@NKJVLK>>\O;B"TM+:)YKFZNIH[>WMX8U+233SRLD442*"SR2,J*H)8@"O
MP(^*_P#P5Z\?ZQ]JT_X.?#W1?!MFV^*+Q#XON&\3Z^R')2ZMM*M?[/T/3+@<
M P7C>);? 8[F+#R_S4^)WQ^^,_QEN'G^)GQ(\4^+(FE\Y-+O=1>W\/VTN[<)
M++PWIXL] L7!Q\UGIL#?*H)(1<?@'%'TG^",I]I1X>P>8<48J-U&K"+RK+')
M:6>*QE*6,E9[.GELZ<TFXU;--_V3P!] +Q7XC]ABN-,RR7@# 5.64\/5J1XA
MS]0E9IQR_+*\,LA>.ZKYY2K4Y-1GA[J27](_Q=_X*'_LP?";[59CQK_PL/Q!
M;[U_L+X;Q0^),2KE=EQX@^TVOA:WV2?)<1_VW+>P8?\ T*1T\L_ES\7?^"M'
MQF\5_:M/^%'AK0/A=I<F^.+5KQ8_&'BTKRJRQSZC:P>';(R+EV@/A_4)8'($
M6H/L\Q_R?HK^<>*OI#^(W$GM*.$Q]'AG SYHK#Y%"5#%.#^'VF9UI5<<JB6C
MGA*N#A*_\):6_N'P\^A3X(<#>PQ699/B>/,WI<LWC.+JL,5@(U%9R5'(,-##
MY1*@VDXTLRP^9U8+3ZQ*[OV_CKXE?$'XG:LVN?$/QIXE\9ZH2_EW?B+6+W5#
M;)(06AL8KF9X-/MA@!+6RBM[:-0JQQ*H '$445^(XC$XC%UJF)Q=>MBL16DY
MU<1B*LZU:K-[SJ5:DI3G)]92DV^Y_5^"P."RW"T,#EV#PN P6&@J6&P>"P]+
M"X7#TX_#3H8>A"G1I072%.$8KH@HHHK$Z@HHHH **** "BBB@ HHHH ****
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MO4E9)SJ3E)I)7LD%%%%=)PA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1116!UA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[[,,WQN'P&%C)IN--5<14IQJ5JEFJ5"GSUJTK0I0G-J+^9:]Y^"W[,WQK_:
MU!;3X9^"-2U73DG$%]XHO5_LKPEI; CS/MOB"]$=BT\2'S&TZR>\U62,$V]A
M.1M/[C_ /_@EC\&_AU]BUSXL7DGQ>\4P^7-_9MU!)I?@.QG&&V)HD<SWFO>4
MQ:-I-=O'TV\C"O)H%N_RC].M,TO3-%T^TTG1M.L=)TK3X$MK#3-,M+>PT^RM
MHQB.WM+.UCBMK:",<)%#&D:CA5%?U%P/]%S-L=[''<<Y@LGPSY9O)\LG1Q6:
M3CHW#$XVU7 X-]U0CF$FKINC/;_/[Q9_:!<.93]9RGPDR67$V/CSTUQ/G]+$
MX#(*4U=*K@LJ3P^;YHET>+GDT(R2E&.*I.TORD^ ?_!*+X9>#/L6N_&_6I/B
M=XAC\N8^&M+:[T;P)93KAO+G96@UWQ((Y%5DDN9=%L)T+P7FB7$9R?U1T#P]
MH/A72++0/#&B:3X=T/38A!I^C:'I]II6EV,()(BM+"QB@M8$R2Q6*)06)8Y)
M).Q17]<\*\#\*\%87ZKPWDV$RY2A&%?$Q@ZN/Q5K.^*Q]9U,577,N90G5=*G
M)OV5.G&T5_FSXA^+/B'XJ9C_ &CQUQ1F6=RA4E4PF J5%ALGR_F35LNRC"QH
MY=@WR-0G5I8=8BM%)XBM6G>3****^L/SH**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG/M?.I'+:-NE-VU_KUHK^;KP;_P5F_:1T'RH?%.C_#OQW;+CSI[[0[W0=7D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)MML****\8^H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCPV:5%>\O[&Q>8PBK\TTTTOFVBBBOS0_=PHHHH **** "BBB@ HHHH ****
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M)X/&<=Y*W=QCE^?9?7IQ?1..;9'F5245U7M5)K[:>I_7YHO[7G[+VO[/[/\
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M+EA3IPC"G"*VC&$4HQ2[))!1114EA1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*TXRA*7B5%%%?"'Z\%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAN-/T*VNXV*G[2Q1"OV;'''%&D42)%%$BQQQQJJ1QQHH5$1% 5$10%55 55
M   I]%?T-DW#^1\.X58+(LHR[*,*E&]++\)1PRJ.*LIUI4H1G7J6^*K6E.I)
MMN4FVV?Q7Q1QGQ;QMF$LUXOXDSKB3,&Y<N)SG,<5CY48S:;I8:->I.GA:"LE
M&AAH4J,$E&%.,4DBBBBO8/F0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***ZSP?X#\;_$'5%T3P)X1\2>,=6?;_ ,2_PSHN
MHZU=(KG:)9HM/M[AH(!@EYY_+AC56>2145F&M"A6Q-6G0PU&KB*]62A2HT*<
MZM6I-[0ITZ:E.<GTC&+;Z(Y\5B\+@</6QF-Q.'P>$P\'5Q&*Q5:GA\/0IQ^*
MI6KUI0I4H+K.<HQ75G)T5^F?PK_X)6?M&>-_LU[XXF\-_"?2)=CR+KEZGB#Q
M+Y+D$20:!X?EGLQ(%RS6VJ:]I%PAPDD:L6"?I-\*_P#@E=^SCX&^S7OC9O$G
MQ8UB+8\G]OWSZ%X<$Z<B2WT#P_):W#1%N7M=7UO6;=P KHR;E;]AX9\ _$OB
M7V=7^Q/["P=2S^M\0U'EUD[._P!1Y*V:/W7>+^HJ#VYU<_F3CSZ8O@1P+[:@
MN*O];\SH\R_LW@NA'.^:2TM_:WM<-P^DI>[-+-I58V;]E*UG_./X8\(^*O&N
MJPZ%X.\-:]XKUJX_U&D^'-(O]:U*49"[DLM.M[FX* D;G\O:N<L0.:_0;X4?
M\$M?VD/'WV:^\8Q:#\)M%FV2,_B:\75?$;P/CY[;PWH4ET8YEYW6NMZIH4Z@
M'<H)4-_1OX1\"^"_ &EIHG@;PEX;\'Z0FS&F^&M%T[1+-F1=HDE@TZWMTFF(
M)+SS!YI&9G=V9F)ZJOZ&X8^BMPY@O9U^*L[QV>5E:4L%E\5E67WZTZE7FKX_
M$1[5*-; 2=_@5M?XKX^_:&<<9K[;">'G"N4<)X:7-"GFN=5'Q#G/+]FM0P_)
M@\HP=1_:HXC#9Q35K*H[W7YH?"C_ ()8?LY^!/LU]XW;Q#\6M9AV._\ ;]V^
MA^&A.F")+?P[H,T$[1DY+VNL:WK=LXPKQL 0?T*\*>#/"'@72HM"\%>%_#WA
M'18<&/2O#>CZ?HFGJP 7S/LFG6]O"TK ?/*R-(YRSNS$D]+17]#<.\&<*<)T
ME2X=R#+,I]WDE6PV&@\95CM:OCJOM,;B-MZ]>H_,_BOC7Q1\1/$7$/$<;<8Y
M]Q%[[J4\+CL=5_LW#S;NY8/*:#HY7@M>F$P=%>6B"BBBOICX(**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<&XSA*+3C*+:DFFFT%%%%26%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!8W$T(V3MBL'1K2Q>$FDTY4\31I5(W7-%71@T445X!]B%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***<JL[*B*SN[!41069F8X554 EF8D   DDX S1OL&VXVBOHCP!^R
M7^TE\3O(D\'?!OQO>6=SM\C5M4TH^&-#F5L'?%KGBB31](E0 @L8KU]H(SU
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.&LG]8RK,,)F%"SV?M<)6K4[/H^;7H1T445Q'J!1110 4444 %%%% !1110
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M&9EC<7F&+JN]7%8[$UL7B:C[U*]>=2K-ZO64F%%%%;G(%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1_$?P3^%NJ3RYWWLO@?P[#J1SUQJ=MI\&H+GJ=ERN2 3R 1X'XD_X)N_L?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ>H]:_KQ\-?LB?LP^$O+;1?@5\-!+#@Q7.K>%]/\1WD3+T>.]\11ZK=I(/\
MGJLPDP2-V":]UTC0=#\/V_V30=&TG1+08 M=(TZSTVWPHPH\FSAAC^4<#Y>!
MTK[G+OHEYM4Y7FW&67879RCEV58G'W[J-3$XK+;7V4G3=M^5['Y+G?[1WARC
MSKASPPSO,-U3J9WQ#@,GMVE.C@<!GM[;N$:\;[>T5[K^07PU^R[^T;XO\MO#
M_P #_BA>02X\N]F\&:[INFONZ;=3U2SLM/.,@G%S\H(9L @GZ%\+_P#!,O\
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M'@>7ZUG/#F<\N_\ :7#&7TN?_%_8_P#95K]>3E\K'\K6K?\ !.#]L?2MS?\
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M2\GA;Z[QGF6(77ZKE.%P=^]G5Q>.MUW3MY]?BLP_:/<35.;^R_"_(L&W\/\
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MX%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7F/BG_D+R?]<8/_0***\S
M-O\ =5_U]A^4CW.'_P#?I?\ 8/4_]+IFUX-_U5__ -=(/_09:[2BBMLN_P!R
MH>D__3DSFSG_ )&6)]:7_IFF%%%%=IY@4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>sldb-20250630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-08-12T15:25:36.7496+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.solidbio.com/20250630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:sldb="http://www.solidbio.com/20250630" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>75000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" id="Role_StatementCondensedConsolidatedBalanceSheets">
        <link:definition>75010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>75020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" id="Role_StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>75030 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>75040 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" id="Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>75050 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" id="Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
        <link:definition>75060 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" id="Role_StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>75070 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" id="StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>75080 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>995455 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisition" id="DisclosureFa212AssetAcquisition">
        <link:definition>995465 - Disclosure - FA212 Asset Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreements" id="DisclosureLicenseAndResearchAgreements">
        <link:definition>995475 - Disclosure - License and Research Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisition1" id="DisclosureAcquisition1">
        <link:definition>995485 - Disclosure - Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>995495 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecurities" id="Role_DisclosureAvailableForSaleSecurities">
        <link:definition>995505 - Disclosure - Available-for-Sale Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNet1" id="DisclosurePropertyAndEquipmentNet1">
        <link:definition>995515 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>995525 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>995535 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>995545 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensation" id="Role_DisclosureEquityBasedCompensation">
        <link:definition>995555 - Disclosure - Equity-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995565 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995575 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995585 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShare1" id="DisclosureNetLossPerShare1">
        <link:definition>995595 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReporting" id="DisclosureSegmentReporting">
        <link:definition>995605 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995615 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies" id="DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies">
        <link:definition>995625 - Disclosure - Nature of the Business and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureCollaborationsTables" id="Role_DisclosureCollaborationsTables">
        <link:definition>995635 - Disclosure - Collaborations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionTables" id="DisclosureAcquisitionTables">
        <link:definition>995645 - Disclosure - Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>995655 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables" id="Role_DisclosureAvailableForSaleSecuritiesTables">
        <link:definition>995665 - Disclosure - Available-for-Sale Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>995675 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>995685 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>995695 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables" id="Role_DisclosureEquityBasedCompensationTables">
        <link:definition>995705 - Disclosure - Equity-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>995715 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingTables" id="DisclosureSegmentReportingTables">
        <link:definition>995725 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringTables" id="DisclosureRestructuringTables">
        <link:definition>995735 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail">
        <link:definition>995745 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail" id="DisclosureFa212AssetAcquisitionAdditionalInformationDetail">
        <link:definition>995755 - Disclosure - FA212 Asset Acquisition - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail" id="DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail">
        <link:definition>995765 - Disclosure - License and Research Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail" id="DisclosureAcquisitionAdditionalInformationDetail">
        <link:definition>995775 - Disclosure - Acquisition - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail" id="DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail">
        <link:definition>995785 - Disclosure - Acquisition - Summary of Fair Values of Assets Acquired and Liabilities Assumed (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail" id="DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail">
        <link:definition>995795 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail" id="DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail">
        <link:definition>995805 - Disclosure - Fair Value Measurements - Summary of Significant Unobservable Inputs Used in Valuing Developmental Milestone Derivative Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfDerivativeLiabilitiesDetails" id="DisclosureFairValueMeasurementsSummaryOfFairValueOfDerivativeLiabilitiesDetails">
        <link:definition>995815 - Disclosure - Fair Value Measurements - Summary of Fair Value of Derivative Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" id="DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>995825 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail" id="DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail">
        <link:definition>995835 - Disclosure - Available-for-Sale Securities - Schedule of Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail" id="Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail">
        <link:definition>995845 - Disclosure - Available-for-Sale Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>995855 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
        <link:definition>995865 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>995875 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetail" id="DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetail">
        <link:definition>995885 - Disclosure - Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail" id="Role_DisclosureEquityBasedCompensationAdditionalInformationDetail">
        <link:definition>995895 - Disclosure - Equity-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail" id="DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail">
        <link:definition>995905 - Disclosure - Equity Based Compensation - Summary Of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail" id="DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail">
        <link:definition>995915 - Disclosure - Equity-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail" id="DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail">
        <link:definition>995925 - Disclosure - Equity-Based Compensation - Summary of Restricted Stock Unit Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails" id="DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails">
        <link:definition>995935 - Disclosure - Equity-Based Compensation - Summary of Performance Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>995945 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" id="DisclosureLeasesAdditionalInformationDetail">
        <link:definition>995955 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>995965 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail" id="DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail">
        <link:definition>995975 - Disclosure - Net Loss Per Share - Schedule Computation of Basic and Diluted Net Loss per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" id="DisclosureNetLossPerShareAdditionalInformationDetail">
        <link:definition>995985 - Disclosure - Net Loss Per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail" id="DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail">
        <link:definition>995995 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail" id="DisclosureSegmentReportingAdditionalInformationDetail">
        <link:definition>996005 - Disclosure - Segment Reporting - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail" id="DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail">
        <link:definition>996015 - Disclosure - Segment Reporting - Schedule of Segment Expenses, Other Segment Items, and Segment Net Loss (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail" id="DisclosureRestructuringAdditionInformationDetail">
        <link:definition>996025 - Disclosure - Restructuring - Addition Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetail" id="DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetail">
        <link:definition>996035 - Disclosure - Restructuring - Schedule of Accrued Restructuring Charges (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" xlink:href="sldb-20250630.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" xlink:href="sldb-20250630.xsd#Role_StatementCondensedConsolidatedStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="sldb-20250630.xsd#Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="sldb-20250630.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail" xlink:href="sldb-20250630.xsd#DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail" xlink:href="sldb-20250630.xsd#DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail" xlink:href="sldb-20250630.xsd#DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="sldb-20250630.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="sldb-20250630.xsd#Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:href="sldb-20250630.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail" xlink:href="sldb-20250630.xsd#DisclosureFa212AssetAcquisitionAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail" xlink:href="sldb-20250630.xsd#DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail" xlink:href="sldb-20250630.xsd#DisclosureAcquisitionAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail" xlink:href="sldb-20250630.xsd#DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="sldb-20250630.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:href="sldb-20250630.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="sldb-20250630.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetail" xlink:href="sldb-20250630.xsd#DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail" xlink:href="sldb-20250630.xsd#Role_DisclosureEquityBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail" xlink:href="sldb-20250630.xsd#DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail" xlink:href="sldb-20250630.xsd#DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails" xlink:href="sldb-20250630.xsd#DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="sldb-20250630.xsd#DisclosureLeasesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="sldb-20250630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:href="sldb-20250630.xsd#DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" xlink:href="sldb-20250630.xsd#DisclosureNetLossPerShareAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail" xlink:href="sldb-20250630.xsd#DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail" xlink:href="sldb-20250630.xsd#DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail" xlink:href="sldb-20250630.xsd#DisclosureRestructuringAdditionInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetail" xlink:href="sldb-20250630.xsd#DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="sldb-20250630.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="sldb-20250630.xsd#Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="sldb-20250630.xsd#Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="sldb-20250630.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:href="sldb-20250630.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisition" xlink:href="sldb-20250630.xsd#DisclosureFa212AssetAcquisition" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreements" xlink:href="sldb-20250630.xsd#DisclosureLicenseAndResearchAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisition1" xlink:href="sldb-20250630.xsd#DisclosureAcquisition1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="sldb-20250630.xsd#DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecurities" xlink:href="sldb-20250630.xsd#Role_DisclosureAvailableForSaleSecurities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNet1" xlink:href="sldb-20250630.xsd#DisclosurePropertyAndEquipmentNet1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:href="sldb-20250630.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="sldb-20250630.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:href="sldb-20250630.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensation" xlink:href="sldb-20250630.xsd#Role_DisclosureEquityBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="sldb-20250630.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeases" xlink:href="sldb-20250630.xsd#DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="sldb-20250630.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShare1" xlink:href="sldb-20250630.xsd#DisclosureNetLossPerShare1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReporting" xlink:href="sldb-20250630.xsd#DisclosureSegmentReporting" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureSubsequentEvents" xlink:href="sldb-20250630.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies" xlink:href="sldb-20250630.xsd#DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureCollaborationsTables" xlink:href="sldb-20250630.xsd#Role_DisclosureCollaborationsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionTables" xlink:href="sldb-20250630.xsd#DisclosureAcquisitionTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="sldb-20250630.xsd#DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables" xlink:href="sldb-20250630.xsd#Role_DisclosureAvailableForSaleSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="sldb-20250630.xsd#DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="sldb-20250630.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="sldb-20250630.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables" xlink:href="sldb-20250630.xsd#Role_DisclosureEquityBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="sldb-20250630.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingTables" xlink:href="sldb-20250630.xsd#DisclosureSegmentReportingTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringTables" xlink:href="sldb-20250630.xsd#DisclosureRestructuringTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfDerivativeLiabilitiesDetails" xlink:href="sldb-20250630.xsd#DisclosureFairValueMeasurementsSummaryOfFairValueOfDerivativeLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail" xlink:href="sldb-20250630.xsd#Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail" xlink:href="sldb-20250630.xsd#DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="sldb-20250630.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail" xlink:href="sldb-20250630.xsd#DisclosureSegmentReportingAdditionalInformationDetail" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_LicenseAndResearchAgreementsTextBlock" xlink:label="sldb_LicenseAndResearchAgreementsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans" xlink:label="us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_MaugeriLicenseAgreementMember" xlink:label="sldb_MaugeriLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ChangeInFairValueOfDerivativeLiabilities" xlink:label="sldb_ChangeInFairValueOfDerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PrepaidOtherAndOtherCurrentAssets" xlink:label="sldb_PrepaidOtherAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AmendmentAndRestatementOfEsppMember" xlink:label="sldb_AmendmentAndRestatementOfEsppMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_DepreciationImpairmentAndAmortizationExpense" xlink:label="sldb_DepreciationImpairmentAndAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember" xlink:label="sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_RestructuringChargesExpectedToBePaid" xlink:label="sldb_RestructuringChargesExpectedToBePaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="sldb_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_Fa212LlcMember" xlink:label="sldb_Fa212LlcMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_SaleMember" xlink:label="sldb_SaleMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_UltragenyxMember" xlink:label="sldb_UltragenyxMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AssetAcquisitionTransactionCosts" xlink:label="sldb_AssetAcquisitionTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:label="us-gaap_OneTimeTerminationBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts" xlink:label="sldb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AvailableForSaleSecuritiesWeightedAverageMaturityPeriod" xlink:label="sldb_AvailableForSaleSecuritiesWeightedAverageMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueAssetLevel1ToLevel2TransfersAmount" xlink:label="sldb_FairValueAssetLevel1ToLevel2TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions" xlink:label="sldb_AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommitmentAndContingenciesTable" xlink:label="sldb_CommitmentAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:label="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments" xlink:label="sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedRestructuringCosts" xlink:label="sldb_AccruedRestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedCompensationMember" xlink:label="sldb_AccruedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments" xlink:label="sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ExternalResearchAndDevelopmentOtherMember" xlink:label="sldb_ExternalResearchAndDevelopmentOtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_NonCashLeaseExpense" xlink:label="sldb_NonCashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" xlink:label="sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesAbstract" xlink:label="us-gaap_RestructuringChargesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_VestingOfRestrictedStockUnitsValue" xlink:label="sldb_VestingOfRestrictedStockUnitsValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_MilestonePaymentsUponAchievementOfRegulatoryMilestone" xlink:label="sldb_MilestonePaymentsUponAchievementOfRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AavantibioIncMember" xlink:label="sldb_AavantibioIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_GabrielBrooksMDMember" xlink:label="sldb_GabrielBrooksMDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedMilestonePaymentMember" xlink:label="sldb_AccruedMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement" xlink:label="sldb_IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration" xlink:label="sldb_CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PrepaidResearchAndDevelopmentExpensesCurrent" xlink:label="sldb_PrepaidResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_DevelopmentMilestonePayments" xlink:label="sldb_DevelopmentMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FirstDevelopmentMilestonePaymentInShares" xlink:label="sldb_FirstDevelopmentMilestonePaymentInShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ArkeaBioCorpMember" xlink:label="sldb_ArkeaBioCorpMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IncreaseDecreaseInPropertyPlantAndEquipmentDueToAssetExchange" xlink:label="sldb_IncreaseDecreaseInPropertyPlantAndEquipmentDueToAssetExchange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TimingOfAchievingCertainDevelopmentMilestonesMember" xlink:label="sldb_TimingOfAchievingCertainDevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostsAbstract" xlink:label="us-gaap_RestructuringCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BuildingInteriorMember" xlink:label="sldb_BuildingInteriorMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:label="sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember" xlink:label="sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AssetAcquisitionUpfrontPayment" xlink:label="sldb_AssetAcquisitionUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CumulativeSalesMilestonePayments" xlink:label="sldb_CumulativeSalesMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" xlink:label="sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_InternalGeneralAndAdministrativeExpenseMember" xlink:label="sldb_InternalGeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AssetAcquisitionPolicyTextBlock" xlink:label="sldb_AssetAcquisitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AlexanderCumboMember" xlink:label="sldb_AlexanderCumboMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember" xlink:label="sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommercialMilestonePayments" xlink:label="sldb_CommercialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_February2025OfferingMember" xlink:label="sldb_February2025OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ProbabilityOfAchievingCertainDevelopmentMilestonesMember" xlink:label="sldb_ProbabilityOfAchievingCertainDevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ClassOfWarrantOrRightsExercised" xlink:label="sldb_ClassOfWarrantOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="sldb_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PercentageOfOptionToFundOfDevelopmentCost" xlink:label="sldb_PercentageOfOptionToFundOfDevelopmentCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_SubleasedDescription" xlink:label="sldb_SubleasedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_NonCashAcquiredInProcessResearchAndDevelopment" xlink:label="sldb_NonCashAcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_RelatedPartyTransactionPolicyTextBlock" xlink:label="sldb_RelatedPartyTransactionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PaulHerzichMember" xlink:label="sldb_PaulHerzichMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice" xlink:label="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ExternalGeneralAndAdministrativeExpenseMember" xlink:label="sldb_ExternalGeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedResearchAndDevelopmentExpenseMember" xlink:label="sldb_AccruedResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement" xlink:label="sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueAssetLevel2ToLevel1TransfersAmount" xlink:label="sldb_FairValueAssetLevel2ToLevel1TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AtTheMarketPublicOfferingMember" xlink:label="sldb_AtTheMarketPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AmendedAndRestatedTwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="sldb_AmendedAndRestatedTwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="sldb_TwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="sldb_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TransactionPrice" xlink:label="sldb_TransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FirstDevelopmentMilestonePayable" xlink:label="sldb_FirstDevelopmentMilestonePayable"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_SGT003Member" xlink:label="sldb_SGT003Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_OfficeAndLaboratoryLeaseMember" xlink:label="sldb_OfficeAndLaboratoryLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_UpfrontLicenseFee" xlink:label="sldb_UpfrontLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_November2022PlanMember" xlink:label="sldb_November2022PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_GainLossOnAcquisitionOfBusiness" xlink:label="sldb_GainLossOnAcquisitionOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering" xlink:label="sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TransactionPriceDeterminedUnderASC606" xlink:label="sldb_TransactionPriceDeterminedUnderASC606"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_April2022PlanMember" xlink:label="sldb_April2022PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants" xlink:label="sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="sldb_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_UnvestedStockOptionsMember" xlink:label="sldb_UnvestedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TwoThousandAndEighteenOmnibusIncentivePlanMember" xlink:label="sldb_TwoThousandAndEighteenOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_JessieHanrahanPhDMember" xlink:label="sldb_JessieHanrahanPhDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ClassOfWarrantOrRightPricePerShare" xlink:label="sldb_ClassOfWarrantOrRightPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_GovernmentBondsMember" xlink:label="sldb_GovernmentBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable" xlink:label="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_April2022CorporateStrategyChangeMember" xlink:label="sldb_April2022CorporateStrategyChangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedExpensesAndOtherMember" xlink:label="sldb_AccruedExpensesAndOtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm" xlink:label="us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_KevinTanMember" xlink:label="sldb_KevinTanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PercentageOfNetIncomeAndNetLossesOnNetSales" xlink:label="sldb_PercentageOfNetIncomeAndNetLossesOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AgreementTerminationNoticePeriod" xlink:label="sldb_AgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments" xlink:label="sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_MilestoneLiabilityPayment" xlink:label="sldb_MilestoneLiabilityPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CumulativeDevelopmentalRegulatoryAndCommercialMilestonePayments" xlink:label="sldb_CumulativeDevelopmentalRegulatoryAndCommercialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AtTheMarketOfferingSalesAgreementMember" xlink:label="sldb_AtTheMarketOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PercentageOfOutstandingCommonStock" xlink:label="sldb_PercentageOfOutstandingCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_InducementAwardMember" xlink:label="sldb_InducementAwardMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_OperatingAndFinancingLeasesDisclosureTextBlock" xlink:label="sldb_OperatingAndFinancingLeasesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_VestingOfRestrictedStockUnits" xlink:label="sldb_VestingOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TreasuryBillMember" xlink:label="sldb_TreasuryBillMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PreFundedWarrantsOutstanding" xlink:label="sldb_PreFundedWarrantsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" xlink:label="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths" xlink:label="sldb_RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PreFundedWarrantsMember" xlink:label="sldb_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_MilestonePaymentsUponAchievementOfNetSalesMilestones" xlink:label="sldb_MilestonePaymentsUponAchievementOfNetSalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination" xlink:label="sldb_IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_November2022WorkforceReductionPlanMember" xlink:label="sldb_November2022WorkforceReductionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_SecuritiesPurchaseAgreementMember" xlink:label="sldb_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_SGT501Member" xlink:label="sldb_SGT501Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_WarrantsIssued" xlink:label="sldb_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IncentiveStockOptionsMember" xlink:label="sldb_IncentiveStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommitmentAndContingenciesLineItems" xlink:label="sldb_CommitmentAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_MilestonePaymentsUponAchievementOfDevelopmentMilestone" xlink:label="sldb_MilestonePaymentsUponAchievementOfDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_InternalResearchAndDevelopmentExpenseMember" xlink:label="sldb_InternalResearchAndDevelopmentExpenseMember"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_LicenseAndResearchAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and research agreements text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_LicenseAndResearchAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and Research Agreements [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_LicenseAndResearchAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Research Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining Contractual Life (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred, Transaction Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate acquisition cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Repayment of Loans by Employee Stock Ownership Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_MaugeriLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maugeri license agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_MaugeriLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maugeri License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_MaugeriLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maugeri License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ChangeInFairValueOfDerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Fair Value Of Derivative Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ChangeInFairValueOfDerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of derivative liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ChangeInFairValueOfDerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in fair value of derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ChangeInFairValueOfDerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Change in fair value of derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ChangeInFairValueOfDerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PrepaidOtherAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid other and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PrepaidOtherAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Other and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PrepaidOtherAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid other and other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AmendmentAndRestatementOfEsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amendment and restatement of ESPP member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AmendmentAndRestatementOfEsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment and Restatement of ESPP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AmendmentAndRestatementOfEsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment and Restatement of ESPP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Performance Stock Units Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition related costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Acquisition Related Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrual recorded as a result of restructuring charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restructuring charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Liabilities, Unobservable Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized equity-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_DepreciationImpairmentAndAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Depreciation, impairment, and amortization expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_DepreciationImpairmentAndAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, impairment, and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_DepreciationImpairmentAndAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation, impairment, and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, transfers into level 1, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level 1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated 2020 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended and Restated Two Thousand And Twenty Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated two thousand and twenty incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at June 30, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_RestructuringChargesExpectedToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring charges expected to be paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_RestructuringChargesExpectedToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring charges expected to be paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_RestructuringChargesExpectedToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restructuring charges expected to be paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of subleased agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total consideration paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total consideration paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Other Segment Item, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other segment items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_Fa212LlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">FA212 LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_Fa212LlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FA212 LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_Fa212LlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FA212 LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_SaleMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_SaleMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_SaleMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_UltragenyxMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ultragenyx</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_UltragenyxMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ultragenyx [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_UltragenyxMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ultragenyx [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, transfers into level 3, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Transaction Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition transaction costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Unobservable Inputs Used in Valuing Developmental Milestone Derivative Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Subject to Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Nonoperating, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-Time Employee Termination Benefits [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One-time Termination Benefits [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital, pre-funded warrants issued, issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Pre-funded Warrants Issued, Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock and pre-funded warrants in public offering, net of underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock And PreFunded Warrants In Public Offering, Net Of Underwriting Discounts And Commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock and pre-funded warrants in public offering, net of underwriting discounts and commissions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of the Business and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, liabilities, transfers out of level 1, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliation recurring basis liability transfers out of level 1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Out Of Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares of common stock reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares authorized for common stock for equity awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Estimated Fair Value and Amortized Cost of Available-for-Sale Securities by Contractual Maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, liabilities, transfers into level 3, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AvailableForSaleSecuritiesWeightedAverageMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Securities Weighted Average Maturity period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AvailableForSaleSecuritiesWeightedAverageMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Weighted Average Maturity Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AvailableForSaleSecuritiesWeightedAverageMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale securities average maturity period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueAssetLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value asset level 1 to level 2 transfers amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueAssetLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Asset Level 1 To Level 2 Transfers Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueAssetLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, level 1 to level 2 transfers, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Values of Assets Acquired and Liabilities Assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock units outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital, net of sales commissions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Net Of Sales Commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding at January 1, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding at June 30, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CommitmentAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment And Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CommitmentAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitment And Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CommitmentAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment And Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, transfers into level 2, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In to Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In to Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type of Restructuring [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options to Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized gain (loss) on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Deferred revenue, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Deferred revenue, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue - related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease, right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination, Recognized identifiable assets acquired and liabilities assumed, Operating lease, Right-of-use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Computation of Basic and Diluted Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss before taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-Sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition, assumed cumulative sales milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Assumed Cumulative Sales Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumed cumulative sales milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Nonvested RSUs/PSUs at January 1, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Nonvested RSUs/PSUs at June 30, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedRestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued restructuring costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedRestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accrued restructuring charges, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedRestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accrued restructuring charges, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedRestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued restructuring costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, excluding current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Segment Expenses, Other Segment Items, and Segment Net Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringPlanDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercises of common stock options, units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at June 30, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Pro Forma Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Compensation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Compensation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition, assumed contingent development milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Assumed Contingent Development Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumed contingent development milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ExternalResearchAndDevelopmentOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">External Research And Development Other [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ExternalResearchAndDevelopmentOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">External research and development other.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ExternalResearchAndDevelopmentOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">External Research and Development Other [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Condensed consolidated net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercises of common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of pre-funded warrants in public offering/private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan, units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted cash, non-current, as presented on balance sheet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Restricted cash, as presented on balance sheet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash, non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring charges related to severance payment and other employee-related costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_NonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_NonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non cash Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_NonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash lease expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock In Private Placement For Payment Of Developmental Milestone Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in private placement for payment of developmental milestone consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in private placement for payment of developmental milestone consideration, units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringChargesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, liabilities, transfers out of level 2, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliation recurring basis liability transfers out of level 2.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Out Of Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_VestingOfRestrictedStockUnitsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of restricted stock units value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_VestingOfRestrictedStockUnitsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Restricted Stock Units Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_VestingOfRestrictedStockUnitsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_MilestonePaymentsUponAchievementOfRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments upon achievement of regulatory milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_MilestonePaymentsUponAchievementOfRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Upon Achievement Of Regulatory Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_MilestonePaymentsUponAchievementOfRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments upon achievement of regulatory milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents, and restricted cash, as reported in the condensed consolidated statements of cash flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AavantibioIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AavantiBio, Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AavantibioIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AavantiBio, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized equity-based compensation cost, weighted average period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Company received net proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level 1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, transfers out of level 1, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_GabrielBrooksMDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gabriel Brooks, M.D [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_GabrielBrooksMDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gabriel Brooks, M.D.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_GabrielBrooksMDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gabriel Brooks, M.D [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Milestone Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Milestone Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One time transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of common stock and pre-funded warrants issuance costs in private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock,to a related party, in connectionwith the Stock Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Value To Related Party In Connection With Stock Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock value to related party in connection with stock purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock in connection with employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amounts paid during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amounts paid during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring charges were paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued As Payment For Developmental Milestone Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued as payment for developmental milestone consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued as payment for developmental milestone consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PrepaidResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid research and development expenses, current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PrepaidResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research And Development Expenses Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PrepaidResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost and Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of principal portion of finance lease obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_DevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_DevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_DevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized for common stock for equity awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FirstDevelopmentMilestonePaymentInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First development milestone payment in shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FirstDevelopmentMilestonePaymentInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First development milestone payment in shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ArkeaBioCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Arkea bio corp.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ArkeaBioCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arkea Bio Corp [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ArkeaBioCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arkea Bio Corp [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IncreaseDecreaseInPropertyPlantAndEquipmentDueToAssetExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase Decrease in property plant and equipment due to asset exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IncreaseDecreaseInPropertyPlantAndEquipmentDueToAssetExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease in property plant and equipment due to asset exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IncreaseDecreaseInPropertyPlantAndEquipmentDueToAssetExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in property plant and equipment due to asset exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercises of common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TimingOfAchievingCertainDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Timing of achieving certain development milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TimingOfAchievingCertainDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Timing Of Achieving Certain Development Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TimingOfAchievingCertainDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Timing of Achieving Certain Development Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Costs [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Other Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents as presented on balance sheet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_BuildingInteriorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Building Interior [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_BuildingInteriorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">building interior [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_BuildingInteriorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Building interior.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Expenses And Other Current Liabilities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses And Other Current Liabilities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty four inducement stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand and Twenty Four Inducement Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Inducement Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition, effective date of acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Effective Date of Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of number of shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in at-the-market public offering, net of sales commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock In At The Market Public Offering Net Of Sales Commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock in at the market public offering net of sales commissions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset Acquisition Upfront Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Upfront Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Segments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating segment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CumulativeSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative sales milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CumulativeSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Sales Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CumulativeSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative sales milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition, share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants exercise price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in private placement for payment of developmental milestone consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Value In Private Placement For Payment Of Developmental Milestone Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock value in private placement for payment of developmental milestone consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Basic [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_InternalGeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Internal General And Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_InternalGeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Internal general and administrative expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_InternalGeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock equivalents excluded from calculation of diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AlexanderCumboMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alexander Cumbo [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AlexanderCumboMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alexander Cumbo.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AlexanderCumboMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alexander Cumbo [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense, other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment reporting, CODM, profit (loss) measure, how used, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense (benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliation recurring basis liability transfers in to level 1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers In To Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, liabilities, transfers into level 1, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Other and Other Current Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses Other and Other Current Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued espenses other and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_February2025OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">February 2025 Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_February2025OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">February 2025 offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_February2025OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">February 2025 Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Nonvested Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ProbabilityOfAchievingCertainDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Probability of achieving certain development milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ProbabilityOfAchievingCertainDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Probability Of Achieving Certain Development Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ProbabilityOfAchievingCertainDevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Probability of Achieving Certain Development Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Equity-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Discount Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ClassOfWarrantOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ClassOfWarrantOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Rights Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ClassOfWarrantOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or rights exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting pronouncements not yet adopted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncements Not Yet Adopted Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PercentageOfOptionToFundOfDevelopmentCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of option to fund of development cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PercentageOfOptionToFundOfDevelopmentCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Option To Fund Of Development Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PercentageOfOptionToFundOfDevelopmentCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of option to fund of development cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Additional Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Price Volatility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Derivative Instruments, Net, Pretax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Balances of Company's Related Party Collaboration Receivables and Contract Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_SubleasedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subleased description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_SubleasedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subleased description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_NonCashAcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash acquired in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_NonCashAcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash acquired in process research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_NonCashAcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Acquired In Process Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award offering period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_RelatedPartyTransactionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_RelatedPartyTransactionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_RelatedPartyTransactionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value of stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PaulHerzichMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paul Herzich [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PaulHerzichMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Paul Herzich.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PaulHerzichMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paul Herzich [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions Common Stock Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, fair value assumptions common stock price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ExternalGeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">External General And Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ExternalGeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">External general and administrative expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ExternalGeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">External General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of headcount reduced, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Research and Development Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock to related party in connection with stock purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock To Related Party In Connection With Stock Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued and sold shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock in connection with employee stock purchase plan, units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueAssetLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value asset level 2 to level 1 transfers amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueAssetLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Asset Level 2 To Level 1 Transfers Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueAssetLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, level 2 to level 1 transfers, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forcast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued and sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs, units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AtTheMarketPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AtTheMarketPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AtTheMarketPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Market Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AmendedAndRestatedTwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated 2020 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AmendedAndRestatedTwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended and Restated Two Thousand And Twenty Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AmendedAndRestatedTwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated 2020 equity incentive plan member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock in public offering, net of sales commissions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock in Public Offering, Net of Sales Commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in public offering, net of sales commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination recognized identifiable assets acquired and liabilities assumed current liabilities operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FirstDevelopmentMilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First development milestone payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FirstDevelopmentMilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First development milestone payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_SGT003Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">S G T 003 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_SGT003Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">SGT-003.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_SGT003Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SGT-003 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_OfficeAndLaboratoryLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and laboratory lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_OfficeAndLaboratoryLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office And Laboratory Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_OfficeAndLaboratoryLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Laboratory Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares of common stock outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average shares of common stock outstanding used to compute basic net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liabilities, excluding current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition, Acquisition completion date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Date of Acquisition Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_UpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront license fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_UpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront License Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_UpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Earnings Per Share Basic By Common Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_November2022PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">November 2022 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_November2022PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">November 2022 Plan Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_November2022PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">November 2022 Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_GainLossOnAcquisitionOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain on acquisition of business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_GainLossOnAcquisitionOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_GainLossOnAcquisitionOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) On Acquisition Of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_GainLossOnAcquisitionOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain (loss) on acquisition of business.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at June 30, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Common Stock And Pre Funded Warrants Issuance Costs In Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of common stock and pre funded warrants issuance costs in public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of common stock and pre-funded warrants issuance costs in public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of share reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TransactionPriceDeterminedUnderASC606_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price determined under ASC 606</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TransactionPriceDeterminedUnderASC606_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Price Determined Under A S C 606</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TransactionPriceDeterminedUnderASC606_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction price determined under ASC 606.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total available-for-sale securities, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Data</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at June 30, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_April2022PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">April 2022 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_April2022PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">April 2022 Plan Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_April2022PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">April 2022 Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issuable upon exercise of prefunded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issuable Upon Exercise of Prefunded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuable upon exercise of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Recently issued accounting pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting pronouncements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncements [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash, cash equivalents, and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party collaboration receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_UnvestedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_UnvestedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_UnvestedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested stock options member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TwoThousandAndEighteenOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2018 Omnibus Incentive Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TwoThousandAndEighteenOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Eighteen Omnibus Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TwoThousandAndEighteenOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Omnibus Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at June 30, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Derivative Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FA212 Asset Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_JessieHanrahanPhDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jessie Hanrahan Ph. D. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_JessieHanrahanPhDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jessie Hanrahan Ph. D.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_JessieHanrahanPhDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jessie Hanrahan Ph. D. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ClassOfWarrantOrRightPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ClassOfWarrantOrRightPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ClassOfWarrantOrRightPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_GovernmentBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Bonds Maturing in One Year or Less [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_GovernmentBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Government Bonds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_GovernmentBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificates of Deposit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certificates of Deposit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value - 10,000,000 shares authorized; no shares issued or outstanding at June 30, 2025 and December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Expenses And Other Current Liabilities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses And Other Current Liabilities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Letter of credit amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit outstanding amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letters of Credit Outstanding, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gain (loss) recorded for a change in fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_April2022CorporateStrategyChangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">April 2022 Corporate Strategy Change [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_April2022CorporateStrategyChangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">April 2022 Corporate Strategy Change [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_April2022CorporateStrategyChangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">April 2022 Corporate Strategy Change.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedExpensesAndOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued other.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedExpensesAndOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AccruedExpensesAndOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Other [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Available-for-Sale Securities, Short-Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Proceeds from maturities of available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_KevinTanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Kevin Tan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_KevinTanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Kevin Tan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_KevinTanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Kevin Tan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PercentageOfNetIncomeAndNetLossesOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of net income and net losses on net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PercentageOfNetIncomeAndNetLossesOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Net Income And Net Losses On Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PercentageOfNetIncomeAndNetLossesOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net income and net losses on net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, transfers out of level 3, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement termination notice period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Termination Notice Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement termination notice period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition, assumed regulatory milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Assumed Regulatory Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumed regulatory milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_MilestoneLiabilityPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Liability Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_MilestoneLiabilityPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone liability payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_MilestoneLiabilityPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CumulativeDevelopmentalRegulatoryAndCommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative developmental, regulatory, and commercial milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CumulativeDevelopmentalRegulatoryAndCommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Developmental, Regulatory, and Commercial Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CumulativeDevelopmentalRegulatoryAndCommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative developmental, regulatory, and commercial milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, transfers out of level 2, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level 2.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Nonvested RSUs/PSUs at January 1, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Nonvested RSUs/PSUs at June 30, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AtTheMarketOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market offering sales agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AtTheMarketOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At-the-Market Offering Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_AtTheMarketOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Market Offering Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PercentageOfOutstandingCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of outstanding common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PercentageOfOutstandingCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Outstanding Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PercentageOfOutstandingCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, liabilities, transfers out of level 3, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Nonvested Performance Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_InducementAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inducement Award [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_InducementAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Award [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_InducementAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement award.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_OperatingAndFinancingLeasesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and financing leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_OperatingAndFinancingLeasesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating And Financing Leases Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_OperatingAndFinancingLeasesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_VestingOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_VestingOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_VestingOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock, units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TreasuryBillMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Treasury Bills Maturing in One Year or Less [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TreasuryBillMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Bills [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TreasuryBillMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury bill.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_TreasuryBillMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Bill [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PreFundedWarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PreFundedWarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PreFundedWarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value - 240,000,000 and 120,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively; 77,602,741 and 40,468,141 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Date of Acquisition Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets and Liabilities that are Measured at Fair Value on a Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining accrued restructuring charges to be paid in next three months.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Accrued Restructuring Charges To Be Paid In Next Three Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining accrued restructuring charges to be paid in next three months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available-for-Sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_MilestonePaymentsUponAchievementOfNetSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments upon achievement of net sales milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_MilestonePaymentsUponAchievementOfNetSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Upon Achievement Of Net Sales Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_MilestonePaymentsUponAchievementOfNetSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone Payments upon achievement of net sales milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares of common stock outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average shares of common stock outstanding, used to compute diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at June 30, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in right of use asset due to lease termination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Right Of Use Asset Due To Lease Termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in right-of-use assets due to lease termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_November2022WorkforceReductionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">November 2022 Workforce Reduction plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_November2022WorkforceReductionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">November 2022 Workforce Reduction plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_November2022WorkforceReductionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">November 2022 Workforce Reduction plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue - related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities Purchase Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liabilities, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Fair value of derivative liabilities as of January 1, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Fair value of derivative liabilities as of March 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net assets acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net assets acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_SGT501Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">S G T 501 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_SGT501Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">SGT-501.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_SGT501Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SGT-501 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of discount on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, excluding current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Operating lease liabilities, excluding current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination, Recognized identifiable asset acquired and liability assumed, Operating lease liabilities, excluding current portion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding at January 1, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding at June 30, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IncentiveStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_IncentiveStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incentive stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CommitmentAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CommitmentAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitment And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_CommitmentAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock and pre-funded warrants in private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock and Pre-funded Warrants in Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock and pre-funded warrants in private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use assets acquired through operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Recognized Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_MilestonePaymentsUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments upon achievement of development milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_MilestonePaymentsUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Upon Achievement Of Development Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_MilestonePaymentsUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments upon achievement of development milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of vesting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliation recurring basis liability transfers in to level 2.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers In to Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, liabilities, transfers into level 2, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_InternalResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Internal Research And Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_InternalResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Internal research and development expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sldb_InternalResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal Research and Development Expense [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_LicenseAndResearchAgreementsTextBlock" xlink:to="sldb_LicenseAndResearchAgreementsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans" xlink:to="us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_MaugeriLicenseAgreementMember" xlink:to="sldb_MaugeriLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_ChangeInFairValueOfDerivativeLiabilities" xlink:to="sldb_ChangeInFairValueOfDerivativeLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_PrepaidOtherAndOtherCurrentAssets" xlink:to="sldb_PrepaidOtherAndOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AmendmentAndRestatementOfEsppMember" xlink:to="sldb_AmendmentAndRestatementOfEsppMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_DepreciationImpairmentAndAmortizationExpense" xlink:to="sldb_DepreciationImpairmentAndAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember" xlink:to="sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_RestructuringChargesExpectedToBePaid" xlink:to="sldb_RestructuringChargesExpectedToBePaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="sldb_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_Fa212LlcMember" xlink:to="sldb_Fa212LlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_SaleMember" xlink:to="sldb_SaleMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_UltragenyxMember" xlink:to="sldb_UltragenyxMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AssetAcquisitionTransactionCosts" xlink:to="sldb_AssetAcquisitionTransactionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OneTimeTerminationBenefitsMember" xlink:to="us-gaap_OneTimeTerminationBenefitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts" xlink:to="sldb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions" xlink:to="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AvailableForSaleSecuritiesWeightedAverageMaturityPeriod" xlink:to="sldb_AvailableForSaleSecuritiesWeightedAverageMaturityPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_FairValueAssetLevel1ToLevel2TransfersAmount" xlink:to="sldb_FairValueAssetLevel1ToLevel2TransfersAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions" xlink:to="sldb_AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_CommitmentAndContingenciesTable" xlink:to="sldb_CommitmentAndContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset" xlink:to="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:to="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments" xlink:to="sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AccruedRestructuringCosts" xlink:to="sldb_AccruedRestructuringCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="us-gaap_RestructuringPlanDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AccruedCompensationMember" xlink:to="sldb_AccruedCompensationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments" xlink:to="sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_ExternalResearchAndDevelopmentOtherMember" xlink:to="sldb_ExternalResearchAndDevelopmentOtherMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_NonCashLeaseExpense" xlink:to="sldb_NonCashLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" xlink:to="sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringChargesAbstract" xlink:to="us-gaap_RestructuringChargesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_VestingOfRestrictedStockUnitsValue" xlink:to="sldb_VestingOfRestrictedStockUnitsValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_MilestonePaymentsUponAchievementOfRegulatoryMilestone" xlink:to="sldb_MilestonePaymentsUponAchievementOfRegulatoryMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AavantibioIncMember" xlink:to="sldb_AavantibioIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_GabrielBrooksMDMember" xlink:to="sldb_GabrielBrooksMDMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AccruedMilestonePaymentMember" xlink:to="sldb_AccruedMilestonePaymentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement" xlink:to="sldb_IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration" xlink:to="sldb_CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_PrepaidResearchAndDevelopmentExpensesCurrent" xlink:to="sldb_PrepaidResearchAndDevelopmentExpensesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_DevelopmentMilestonePayments" xlink:to="sldb_DevelopmentMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_FirstDevelopmentMilestonePaymentInShares" xlink:to="sldb_FirstDevelopmentMilestonePaymentInShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_ArkeaBioCorpMember" xlink:to="sldb_ArkeaBioCorpMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_IncreaseDecreaseInPropertyPlantAndEquipmentDueToAssetExchange" xlink:to="sldb_IncreaseDecreaseInPropertyPlantAndEquipmentDueToAssetExchange_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_TimingOfAchievingCertainDevelopmentMilestonesMember" xlink:to="sldb_TimingOfAchievingCertainDevelopmentMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostsAbstract" xlink:to="us-gaap_RestructuringCostsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_BuildingInteriorMember" xlink:to="sldb_BuildingInteriorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember" xlink:to="sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions" xlink:to="sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AssetAcquisitionUpfrontPayment" xlink:to="sldb_AssetAcquisitionUpfrontPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_CumulativeSalesMilestonePayments" xlink:to="sldb_CumulativeSalesMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" xlink:to="sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_InternalGeneralAndAdministrativeExpenseMember" xlink:to="sldb_InternalGeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AssetAcquisitionPolicyTextBlock" xlink:to="sldb_AssetAcquisitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AlexanderCumboMember" xlink:to="sldb_AlexanderCumboMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember" xlink:to="sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_CommercialMilestonePayments" xlink:to="sldb_CommercialMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_February2025OfferingMember" xlink:to="sldb_February2025OfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_ProbabilityOfAchievingCertainDevelopmentMilestonesMember" xlink:to="sldb_ProbabilityOfAchievingCertainDevelopmentMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_ClassOfWarrantOrRightsExercised" xlink:to="sldb_ClassOfWarrantOrRightsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="sldb_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_PercentageOfOptionToFundOfDevelopmentCost" xlink:to="sldb_PercentageOfOptionToFundOfDevelopmentCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_SubleasedDescription" xlink:to="sldb_SubleasedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_NonCashAcquiredInProcessResearchAndDevelopment" xlink:to="sldb_NonCashAcquiredInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_RelatedPartyTransactionPolicyTextBlock" xlink:to="sldb_RelatedPartyTransactionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_PaulHerzichMember" xlink:to="sldb_PaulHerzichMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice" xlink:to="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_ExternalGeneralAndAdministrativeExpenseMember" xlink:to="sldb_ExternalGeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AccruedResearchAndDevelopmentExpenseMember" xlink:to="sldb_AccruedResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement" xlink:to="sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_FairValueAssetLevel2ToLevel1TransfersAmount" xlink:to="sldb_FairValueAssetLevel2ToLevel1TransfersAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AtTheMarketPublicOfferingMember" xlink:to="sldb_AtTheMarketPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AmendedAndRestatedTwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="sldb_AmendedAndRestatedTwoThousandAndTwentyEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions" xlink:to="sldb_ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:to="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="sldb_TwoThousandAndTwentyEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:to="sldb_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_TransactionPrice" xlink:to="sldb_TransactionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_FirstDevelopmentMilestonePayable" xlink:to="sldb_FirstDevelopmentMilestonePayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_SGT003Member" xlink:to="sldb_SGT003Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_OfficeAndLaboratoryLeaseMember" xlink:to="sldb_OfficeAndLaboratoryLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_UpfrontLicenseFee" xlink:to="sldb_UpfrontLicenseFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_November2022PlanMember" xlink:to="sldb_November2022PlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_GainLossOnAcquisitionOfBusiness" xlink:to="sldb_GainLossOnAcquisitionOfBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering" xlink:to="sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_TransactionPriceDeterminedUnderASC606" xlink:to="sldb_TransactionPriceDeterminedUnderASC606_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_April2022PlanMember" xlink:to="sldb_April2022PlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants" xlink:to="sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="sldb_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_UnvestedStockOptionsMember" xlink:to="sldb_UnvestedStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_TwoThousandAndEighteenOmnibusIncentivePlanMember" xlink:to="sldb_TwoThousandAndEighteenOmnibusIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_JessieHanrahanPhDMember" xlink:to="sldb_JessieHanrahanPhDMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_ClassOfWarrantOrRightPricePerShare" xlink:to="sldb_ClassOfWarrantOrRightPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_GovernmentBondsMember" xlink:to="sldb_GovernmentBondsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable" xlink:to="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_April2022CorporateStrategyChangeMember" xlink:to="sldb_April2022CorporateStrategyChangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AccruedExpensesAndOtherMember" xlink:to="sldb_AccruedExpensesAndOtherMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm" xlink:to="us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_KevinTanMember" xlink:to="sldb_KevinTanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_PercentageOfNetIncomeAndNetLossesOnNetSales" xlink:to="sldb_PercentageOfNetIncomeAndNetLossesOnNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AgreementTerminationNoticePeriod" xlink:to="sldb_AgreementTerminationNoticePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments" xlink:to="sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_MilestoneLiabilityPayment" xlink:to="sldb_MilestoneLiabilityPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_CumulativeDevelopmentalRegulatoryAndCommercialMilestonePayments" xlink:to="sldb_CumulativeDevelopmentalRegulatoryAndCommercialMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_AtTheMarketOfferingSalesAgreementMember" xlink:to="sldb_AtTheMarketOfferingSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_PercentageOfOutstandingCommonStock" xlink:to="sldb_PercentageOfOutstandingCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_InducementAwardMember" xlink:to="sldb_InducementAwardMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_OperatingAndFinancingLeasesDisclosureTextBlock" xlink:to="sldb_OperatingAndFinancingLeasesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_VestingOfRestrictedStockUnits" xlink:to="sldb_VestingOfRestrictedStockUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_TreasuryBillMember" xlink:to="sldb_TreasuryBillMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_PreFundedWarrantsOutstanding" xlink:to="sldb_PreFundedWarrantsOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" xlink:to="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths" xlink:to="sldb_RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_PreFundedWarrantsMember" xlink:to="sldb_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_MilestonePaymentsUponAchievementOfNetSalesMilestones" xlink:to="sldb_MilestonePaymentsUponAchievementOfNetSalesMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination" xlink:to="sldb_IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_November2022WorkforceReductionPlanMember" xlink:to="sldb_November2022WorkforceReductionPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_SecuritiesPurchaseAgreementMember" xlink:to="sldb_SecuritiesPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_SGT501Member" xlink:to="sldb_SGT501Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion" xlink:to="sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_WarrantsIssued" xlink:to="sldb_WarrantsIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_IncentiveStockOptionsMember" xlink:to="sldb_IncentiveStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_CommitmentAndContingenciesLineItems" xlink:to="sldb_CommitmentAndContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:to="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_MilestonePaymentsUponAchievementOfDevelopmentMilestone" xlink:to="sldb_MilestonePaymentsUponAchievementOfDevelopmentMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sldb_InternalResearchAndDevelopmentExpenseMember" xlink:to="sldb_InternalResearchAndDevelopmentExpenseMember_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PreFundedWarrantsOutstanding" xlink:label="sldb_PreFundedWarrantsOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="sldb_PreFundedWarrantsOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AtTheMarketPublicOfferingMember" xlink:label="sldb_AtTheMarketPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" xlink:label="sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" xlink:label="sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_VestingOfRestrictedStockUnitsValue" xlink:label="sldb_VestingOfRestrictedStockUnitsValue"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_VestingOfRestrictedStockUnits" xlink:label="sldb_VestingOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement" xlink:label="sldb_IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement" xlink:label="sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_18"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_19"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sldb_AtTheMarketPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sldb_VestingOfRestrictedStockUnitsValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sldb_VestingOfRestrictedStockUnits" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sldb_IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_19" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts" xlink:label="sldb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions" xlink:label="sldb_AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="sldb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="sldb_AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration" xlink:label="sldb_CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm" xlink:label="us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering" xlink:label="sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination" xlink:label="sldb_IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IncreaseDecreaseInPropertyPlantAndEquipmentDueToAssetExchange" xlink:label="sldb_IncreaseDecreaseInPropertyPlantAndEquipmentDueToAssetExchange"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_DepreciationImpairmentAndAmortizationExpense" xlink:label="sldb_DepreciationImpairmentAndAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_NonCashLeaseExpense" xlink:label="sldb_NonCashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_NonCashAcquiredInProcessResearchAndDevelopment" xlink:label="sldb_NonCashAcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ChangeInFairValueOfDerivativeLiabilities" xlink:label="sldb_ChangeInFairValueOfDerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans" xlink:label="us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sldb_CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sldb_IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sldb_IncreaseDecreaseInPropertyPlantAndEquipmentDueToAssetExchange" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sldb_DepreciationImpairmentAndAmortizationExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sldb_NonCashLeaseExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sldb_NonCashAcquiredInProcessResearchAndDevelopment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sldb_ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sldb_ChangeInFairValueOfDerivativeLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="ecd_AllTradingArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_SaleMember" xlink:label="sldb_SaleMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_GabrielBrooksMDMember" xlink:label="sldb_GabrielBrooksMDMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AlexanderCumboMember" xlink:label="sldb_AlexanderCumboMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_JessieHanrahanPhDMember" xlink:label="sldb_JessieHanrahanPhDMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PaulHerzichMember" xlink:label="sldb_PaulHerzichMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_KevinTanMember" xlink:label="sldb_KevinTanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="sldb_SaleMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="sldb_GabrielBrooksMDMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="sldb_AlexanderCumboMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="sldb_JessieHanrahanPhDMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="sldb_PaulHerzichMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="sldb_KevinTanMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisition" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_LicenseAndResearchAgreementsTextBlock" xlink:label="sldb_LicenseAndResearchAgreementsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="sldb_LicenseAndResearchAgreementsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisition1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecurities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNet1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="sldb_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="sldb_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_OperatingAndFinancingLeasesDisclosureTextBlock" xlink:label="sldb_OperatingAndFinancingLeasesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="sldb_OperatingAndFinancingLeasesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShare1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReporting" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_RelatedPartyTransactionPolicyTextBlock" xlink:label="sldb_RelatedPartyTransactionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="sldb_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AssetAcquisitionPolicyTextBlock" xlink:label="sldb_AssetAcquisitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="sldb_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sldb_RelatedPartyTransactionPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sldb_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sldb_AssetAcquisitionPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sldb_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureCollaborationsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_SecuritiesPurchaseAgreementMember" xlink:label="sldb_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AtTheMarketOfferingSalesAgreementMember" xlink:label="sldb_AtTheMarketOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PreFundedWarrantsMember" xlink:label="sldb_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sldb_SecuritiesPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sldb_AtTheMarketOfferingSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sldb_PreFundedWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" xlink:label="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_Fa212LlcMember" xlink:label="sldb_Fa212LlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AssetAcquisitionUpfrontPayment" xlink:label="sldb_AssetAcquisitionUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_DevelopmentMilestonePayments" xlink:label="sldb_DevelopmentMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CumulativeSalesMilestonePayments" xlink:label="sldb_CumulativeSalesMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments" xlink:label="sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments" xlink:label="sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments" xlink:label="sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AssetAcquisitionTransactionCosts" xlink:label="sldb_AssetAcquisitionTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FirstDevelopmentMilestonePayable" xlink:label="sldb_FirstDevelopmentMilestonePayable"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_MilestoneLiabilityPayment" xlink:label="sldb_MilestoneLiabilityPayment"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FirstDevelopmentMilestonePaymentInShares" xlink:label="sldb_FirstDevelopmentMilestonePaymentInShares"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="sldb_Fa212LlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_AssetAcquisitionUpfrontPayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_DevelopmentMilestonePayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_CumulativeSalesMilestonePayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_AssetAcquisitionTransactionCosts" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_FirstDevelopmentMilestonePayable" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_MilestoneLiabilityPayment" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_FirstDevelopmentMilestonePaymentInShares" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_UltragenyxMember" xlink:label="sldb_UltragenyxMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_MilestonePaymentsUponAchievementOfDevelopmentMilestone" xlink:label="sldb_MilestonePaymentsUponAchievementOfDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_MaugeriLicenseAgreementMember" xlink:label="sldb_MaugeriLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_MilestonePaymentsUponAchievementOfRegulatoryMilestone" xlink:label="sldb_MilestonePaymentsUponAchievementOfRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_MilestonePaymentsUponAchievementOfNetSalesMilestones" xlink:label="sldb_MilestonePaymentsUponAchievementOfNetSalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PercentageOfOptionToFundOfDevelopmentCost" xlink:label="sldb_PercentageOfOptionToFundOfDevelopmentCost"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PercentageOfNetIncomeAndNetLossesOnNetSales" xlink:label="sldb_PercentageOfNetIncomeAndNetLossesOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AgreementTerminationNoticePeriod" xlink:label="sldb_AgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement" xlink:label="sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PercentageOfOutstandingCommonStock" xlink:label="sldb_PercentageOfOutstandingCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TransactionPriceDeterminedUnderASC606" xlink:label="sldb_TransactionPriceDeterminedUnderASC606"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TransactionPrice" xlink:label="sldb_TransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_UpfrontLicenseFee" xlink:label="sldb_UpfrontLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommercialMilestonePayments" xlink:label="sldb_CommercialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CumulativeDevelopmentalRegulatoryAndCommercialMilestonePayments" xlink:label="sldb_CumulativeDevelopmentalRegulatoryAndCommercialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CumulativeSalesMilestonePayments" xlink:label="sldb_CumulativeSalesMilestonePayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sldb_UltragenyxMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_MilestonePaymentsUponAchievementOfDevelopmentMilestone" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sldb_MaugeriLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_MilestonePaymentsUponAchievementOfRegulatoryMilestone" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_MilestonePaymentsUponAchievementOfNetSalesMilestones" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_PercentageOfOptionToFundOfDevelopmentCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_PercentageOfNetIncomeAndNetLossesOnNetSales" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_AgreementTerminationNoticePeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_PercentageOfOutstandingCommonStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_TransactionPriceDeterminedUnderASC606" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_TransactionPrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherReceivables" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_UpfrontLicenseFee" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_CommercialMilestonePayments" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_CumulativeDevelopmentalRegulatoryAndCommercialMilestonePayments" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_CumulativeSalesMilestonePayments" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AavantibioIncMember" xlink:label="sldb_AavantibioIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_GainLossOnAcquisitionOfBusiness" xlink:label="sldb_GainLossOnAcquisitionOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:label="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sldb_AavantibioIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sldb_GainLossOnAcquisitionOfBusiness" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AavantibioIncMember" xlink:label="sldb_AavantibioIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_GainLossOnAcquisitionOfBusiness" xlink:label="sldb_GainLossOnAcquisitionOfBusiness"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sldb_AavantibioIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="sldb_GainLossOnAcquisitionOfBusiness" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TreasuryBillMember" xlink:label="sldb_TreasuryBillMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_GovernmentBondsMember" xlink:label="sldb_GovernmentBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sldb_TreasuryBillMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sldb_GovernmentBondsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ProbabilityOfAchievingCertainDevelopmentMilestonesMember" xlink:label="sldb_ProbabilityOfAchievingCertainDevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TimingOfAchievingCertainDevelopmentMilestonesMember" xlink:label="sldb_TimingOfAchievingCertainDevelopmentMilestonesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="sldb_ProbabilityOfAchievingCertainDevelopmentMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="sldb_TimingOfAchievingCertainDevelopmentMilestonesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfDerivativeLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ChangeInFairValueOfDerivativeLiabilities" xlink:label="sldb_ChangeInFairValueOfDerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="sldb_ChangeInFairValueOfDerivativeLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueAssetLevel2ToLevel1TransfersAmount" xlink:label="sldb_FairValueAssetLevel2ToLevel1TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueAssetLevel1ToLevel2TransfersAmount" xlink:label="sldb_FairValueAssetLevel1ToLevel2TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueAssetLevel2ToLevel1TransfersAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueAssetLevel1ToLevel2TransfersAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TreasuryBillMember" xlink:label="sldb_TreasuryBillMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_GovernmentBondsMember" xlink:label="sldb_GovernmentBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sldb_TreasuryBillMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sldb_GovernmentBondsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AvailableForSaleSecuritiesWeightedAverageMaturityPeriod" xlink:label="sldb_AvailableForSaleSecuritiesWeightedAverageMaturityPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="sldb_AvailableForSaleSecuritiesWeightedAverageMaturityPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PrepaidResearchAndDevelopmentExpensesCurrent" xlink:label="sldb_PrepaidResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PrepaidOtherAndOtherCurrentAssets" xlink:label="sldb_PrepaidOtherAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="sldb_PrepaidResearchAndDevelopmentExpensesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="sldb_PrepaidOtherAndOtherCurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedResearchAndDevelopmentExpenseMember" xlink:label="sldb_AccruedResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:label="sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable" xlink:label="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedCompensationMember" xlink:label="sldb_AccruedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedMilestonePaymentMember" xlink:label="sldb_AccruedMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember" xlink:label="sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedExpensesAndOtherMember" xlink:label="sldb_AccruedExpensesAndOtherMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="sldb_AccruedResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="sldb_AccruedCompensationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable" xlink:to="sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="sldb_AccruedMilestonePaymentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="sldb_AccruedExpensesAndOtherMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_February2025OfferingMember" xlink:label="sldb_February2025OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PreFundedWarrantsMember" xlink:label="sldb_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AtTheMarketOfferingSalesAgreementMember" xlink:label="sldb_AtTheMarketOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ClassOfWarrantOrRightPricePerShare" xlink:label="sldb_ClassOfWarrantOrRightPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ClassOfWarrantOrRightsExercised" xlink:label="sldb_ClassOfWarrantOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sldb_February2025OfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sldb_PreFundedWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sldb_AtTheMarketOfferingSalesAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sldb_ClassOfWarrantOrRightPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sldb_ClassOfWarrantOrRightsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TwoThousandAndEighteenOmnibusIncentivePlanMember" xlink:label="sldb_TwoThousandAndEighteenOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="sldb_TwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="sldb_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember" xlink:label="sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AmendedAndRestatedTwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="sldb_AmendedAndRestatedTwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_InducementAwardMember" xlink:label="sldb_InducementAwardMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AmendmentAndRestatementOfEsppMember" xlink:label="sldb_AmendmentAndRestatementOfEsppMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IncentiveStockOptionsMember" xlink:label="sldb_IncentiveStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember" xlink:label="sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_UnvestedStockOptionsMember" xlink:label="sldb_UnvestedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sldb_TwoThousandAndEighteenOmnibusIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sldb_TwoThousandAndTwentyEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sldb_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sldb_AmendedAndRestatedTwoThousandAndTwentyEquityIncentivePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sldb_InducementAwardMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sldb_AmendmentAndRestatementOfEsppMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sldb_IncentiveStockOptionsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sldb_UnvestedStockOptionsMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="8.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice" xlink:label="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommitmentAndContingenciesTable" xlink:label="sldb_CommitmentAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ArkeaBioCorpMember" xlink:label="sldb_ArkeaBioCorpMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BuildingInteriorMember" xlink:label="sldb_BuildingInteriorMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommitmentAndContingenciesLineItems" xlink:label="sldb_CommitmentAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_SubleasedDescription" xlink:label="sldb_SubleasedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sldb_CommitmentAndContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="sldb_CommitmentAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sldb_ArkeaBioCorpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sldb_BuildingInteriorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sldb_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sldb_CommitmentAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sldb_CommitmentAndContingenciesLineItems" xlink:to="sldb_SubleasedDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sldb_CommitmentAndContingenciesTable" xlink:to="sldb_CommitmentAndContingenciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sldb_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_SubleaseIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommitmentAndContingenciesTable" xlink:label="sldb_CommitmentAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_OfficeAndLaboratoryLeaseMember" xlink:label="sldb_OfficeAndLaboratoryLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommitmentAndContingenciesLineItems" xlink:label="sldb_CommitmentAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sldb_CommitmentAndContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="sldb_OfficeAndLaboratoryLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sldb_CommitmentAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sldb_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sldb_CommitmentAndContingenciesTable" xlink:to="sldb_CommitmentAndContingenciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PreFundedWarrantsMember" xlink:label="sldb_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sldb_PreFundedWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PreFundedWarrantsMember" xlink:label="sldb_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants" xlink:label="sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_WarrantsIssued" xlink:label="sldb_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sldb_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="sldb_WarrantsIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_SGT003Member" xlink:label="sldb_SGT003Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_SGT501Member" xlink:label="sldb_SGT501Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ExternalResearchAndDevelopmentOtherMember" xlink:label="sldb_ExternalResearchAndDevelopmentOtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_InternalResearchAndDevelopmentExpenseMember" xlink:label="sldb_InternalResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ExternalGeneralAndAdministrativeExpenseMember" xlink:label="sldb_ExternalGeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_InternalGeneralAndAdministrativeExpenseMember" xlink:label="sldb_InternalGeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sldb_SGT003Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="srt_ConsolidationItemsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sldb_SGT501Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sldb_ExternalResearchAndDevelopmentOtherMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sldb_InternalResearchAndDevelopmentExpenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sldb_ExternalGeneralAndAdministrativeExpenseMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sldb_InternalGeneralAndAdministrativeExpenseMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ProfitLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_April2022PlanMember" xlink:label="sldb_April2022PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostsAbstract" xlink:label="us-gaap_RestructuringCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_November2022PlanMember" xlink:label="sldb_November2022PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths" xlink:label="sldb_RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_RestructuringChargesExpectedToBePaid" xlink:label="sldb_RestructuringChargesExpectedToBePaid"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringPlanAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="sldb_April2022PlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostsAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="srt_StatementScenarioAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="sldb_November2022PlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_SeveranceCosts1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="sldb_RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="sldb_RestructuringChargesExpectedToBePaid" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:label="us-gaap_OneTimeTerminationBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_April2022CorporateStrategyChangeMember" xlink:label="sldb_April2022CorporateStrategyChangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesAbstract" xlink:label="us-gaap_RestructuringChargesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_November2022WorkforceReductionPlanMember" xlink:label="sldb_November2022WorkforceReductionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedRestructuringCosts" xlink:label="sldb_AccruedRestructuringCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="sldb_April2022CorporateStrategyChangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringChargesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringPlanAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="sldb_November2022WorkforceReductionPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="sldb_AccruedRestructuringCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AtTheMarketPublicOfferingMember" xlink:label="sldb_AtTheMarketPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" xlink:label="sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" xlink:label="sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_VestingOfRestrictedStockUnitsValue" xlink:label="sldb_VestingOfRestrictedStockUnitsValue"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_VestingOfRestrictedStockUnits" xlink:label="sldb_VestingOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement" xlink:label="sldb_IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement" xlink:label="sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sldb_AtTheMarketPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sldb_VestingOfRestrictedStockUnitsValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sldb_VestingOfRestrictedStockUnits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sldb_IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="ecd_AllTradingArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_SaleMember" xlink:label="sldb_SaleMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="sldb_SaleMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_GabrielBrooksMDMember" xlink:label="sldb_GabrielBrooksMDMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AlexanderCumboMember" xlink:label="sldb_AlexanderCumboMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_JessieHanrahanPhDMember" xlink:label="sldb_JessieHanrahanPhDMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PaulHerzichMember" xlink:label="sldb_PaulHerzichMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_KevinTanMember" xlink:label="sldb_KevinTanMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="sldb_GabrielBrooksMDMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="sldb_AlexanderCumboMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="sldb_JessieHanrahanPhDMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="sldb_PaulHerzichMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="sldb_KevinTanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_SecuritiesPurchaseAgreementMember" xlink:label="sldb_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AtTheMarketOfferingSalesAgreementMember" xlink:label="sldb_AtTheMarketOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PreFundedWarrantsMember" xlink:label="sldb_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sldb_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sldb_AtTheMarketOfferingSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sldb_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" xlink:label="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_Fa212LlcMember" xlink:label="sldb_Fa212LlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AssetAcquisitionUpfrontPayment" xlink:label="sldb_AssetAcquisitionUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_DevelopmentMilestonePayments" xlink:label="sldb_DevelopmentMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CumulativeSalesMilestonePayments" xlink:label="sldb_CumulativeSalesMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments" xlink:label="sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments" xlink:label="sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments" xlink:label="sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AssetAcquisitionTransactionCosts" xlink:label="sldb_AssetAcquisitionTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FirstDevelopmentMilestonePayable" xlink:label="sldb_FirstDevelopmentMilestonePayable"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_MilestoneLiabilityPayment" xlink:label="sldb_MilestoneLiabilityPayment"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FirstDevelopmentMilestonePaymentInShares" xlink:label="sldb_FirstDevelopmentMilestonePaymentInShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="sldb_Fa212LlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_AssetAcquisitionUpfrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_DevelopmentMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_CumulativeSalesMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_AssetAcquisitionTransactionCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_FirstDevelopmentMilestonePayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_MilestoneLiabilityPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sldb_FirstDevelopmentMilestonePaymentInShares" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_UltragenyxMember" xlink:label="sldb_UltragenyxMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_MilestonePaymentsUponAchievementOfDevelopmentMilestone" xlink:label="sldb_MilestonePaymentsUponAchievementOfDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_MaugeriLicenseAgreementMember" xlink:label="sldb_MaugeriLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_MilestonePaymentsUponAchievementOfRegulatoryMilestone" xlink:label="sldb_MilestonePaymentsUponAchievementOfRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_MilestonePaymentsUponAchievementOfNetSalesMilestones" xlink:label="sldb_MilestonePaymentsUponAchievementOfNetSalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PercentageOfOptionToFundOfDevelopmentCost" xlink:label="sldb_PercentageOfOptionToFundOfDevelopmentCost"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PercentageOfNetIncomeAndNetLossesOnNetSales" xlink:label="sldb_PercentageOfNetIncomeAndNetLossesOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AgreementTerminationNoticePeriod" xlink:label="sldb_AgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement" xlink:label="sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PercentageOfOutstandingCommonStock" xlink:label="sldb_PercentageOfOutstandingCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TransactionPriceDeterminedUnderASC606" xlink:label="sldb_TransactionPriceDeterminedUnderASC606"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TransactionPrice" xlink:label="sldb_TransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_UpfrontLicenseFee" xlink:label="sldb_UpfrontLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommercialMilestonePayments" xlink:label="sldb_CommercialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CumulativeDevelopmentalRegulatoryAndCommercialMilestonePayments" xlink:label="sldb_CumulativeDevelopmentalRegulatoryAndCommercialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CumulativeSalesMilestonePayments" xlink:label="sldb_CumulativeSalesMilestonePayments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sldb_UltragenyxMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_MilestonePaymentsUponAchievementOfDevelopmentMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sldb_MaugeriLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_MilestonePaymentsUponAchievementOfRegulatoryMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_MilestonePaymentsUponAchievementOfNetSalesMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_PercentageOfOptionToFundOfDevelopmentCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_PercentageOfNetIncomeAndNetLossesOnNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_AgreementTerminationNoticePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_PercentageOfOutstandingCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_TransactionPriceDeterminedUnderASC606" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_TransactionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherReceivables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_UpfrontLicenseFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_CommercialMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_CumulativeDevelopmentalRegulatoryAndCommercialMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sldb_CumulativeSalesMilestonePayments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AavantibioIncMember" xlink:label="sldb_AavantibioIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_GainLossOnAcquisitionOfBusiness" xlink:label="sldb_GainLossOnAcquisitionOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:label="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sldb_AavantibioIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sldb_GainLossOnAcquisitionOfBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AavantibioIncMember" xlink:label="sldb_AavantibioIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_GainLossOnAcquisitionOfBusiness" xlink:label="sldb_GainLossOnAcquisitionOfBusiness"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sldb_AavantibioIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="sldb_GainLossOnAcquisitionOfBusiness" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TreasuryBillMember" xlink:label="sldb_TreasuryBillMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_GovernmentBondsMember" xlink:label="sldb_GovernmentBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sldb_TreasuryBillMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sldb_GovernmentBondsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ProbabilityOfAchievingCertainDevelopmentMilestonesMember" xlink:label="sldb_ProbabilityOfAchievingCertainDevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TimingOfAchievingCertainDevelopmentMilestonesMember" xlink:label="sldb_TimingOfAchievingCertainDevelopmentMilestonesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="sldb_ProbabilityOfAchievingCertainDevelopmentMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="sldb_TimingOfAchievingCertainDevelopmentMilestonesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueAssetLevel2ToLevel1TransfersAmount" xlink:label="sldb_FairValueAssetLevel2ToLevel1TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueAssetLevel1ToLevel2TransfersAmount" xlink:label="sldb_FairValueAssetLevel1ToLevel2TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1" xlink:label="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueAssetLevel2ToLevel1TransfersAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueAssetLevel1ToLevel2TransfersAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TreasuryBillMember" xlink:label="sldb_TreasuryBillMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_GovernmentBondsMember" xlink:label="sldb_GovernmentBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sldb_TreasuryBillMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sldb_GovernmentBondsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:label="sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable" xlink:label="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedResearchAndDevelopmentExpenseMember" xlink:label="sldb_AccruedResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedCompensationMember" xlink:label="sldb_AccruedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedMilestonePaymentMember" xlink:label="sldb_AccruedMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember" xlink:label="sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedExpensesAndOtherMember" xlink:label="sldb_AccruedExpensesAndOtherMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="sldb_AccruedResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="sldb_AccruedCompensationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="sldb_AccruedMilestonePaymentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="sldb_AccruedExpensesAndOtherMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_February2025OfferingMember" xlink:label="sldb_February2025OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PreFundedWarrantsMember" xlink:label="sldb_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AtTheMarketOfferingSalesAgreementMember" xlink:label="sldb_AtTheMarketOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ClassOfWarrantOrRightPricePerShare" xlink:label="sldb_ClassOfWarrantOrRightPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ClassOfWarrantOrRightsExercised" xlink:label="sldb_ClassOfWarrantOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sldb_February2025OfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sldb_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sldb_AtTheMarketOfferingSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sldb_ClassOfWarrantOrRightPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sldb_ClassOfWarrantOrRightsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TwoThousandAndEighteenOmnibusIncentivePlanMember" xlink:label="sldb_TwoThousandAndEighteenOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="sldb_TwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_InducementAwardMember" xlink:label="sldb_InducementAwardMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="sldb_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_IncentiveStockOptionsMember" xlink:label="sldb_IncentiveStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember" xlink:label="sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AmendedAndRestatedTwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="sldb_AmendedAndRestatedTwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_UnvestedStockOptionsMember" xlink:label="sldb_UnvestedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AmendmentAndRestatementOfEsppMember" xlink:label="sldb_AmendmentAndRestatementOfEsppMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember" xlink:label="sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sldb_TwoThousandAndEighteenOmnibusIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sldb_TwoThousandAndTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sldb_InducementAwardMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sldb_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sldb_IncentiveStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sldb_AmendedAndRestatedTwoThousandAndTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sldb_UnvestedStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sldb_AmendmentAndRestatementOfEsppMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice" xlink:label="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommitmentAndContingenciesLineItems" xlink:label="sldb_CommitmentAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommitmentAndContingenciesTable" xlink:label="sldb_CommitmentAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ArkeaBioCorpMember" xlink:label="sldb_ArkeaBioCorpMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BuildingInteriorMember" xlink:label="sldb_BuildingInteriorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_SubleasedDescription" xlink:label="sldb_SubleasedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sldb_CommitmentAndContingenciesLineItems" xlink:to="sldb_CommitmentAndContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sldb_CommitmentAndContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sldb_ArkeaBioCorpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sldb_BuildingInteriorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sldb_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sldb_CommitmentAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sldb_CommitmentAndContingenciesLineItems" xlink:to="sldb_SubleasedDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sldb_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_SubleaseIncome" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommitmentAndContingenciesLineItems" xlink:label="sldb_CommitmentAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommitmentAndContingenciesTable" xlink:label="sldb_CommitmentAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_OfficeAndLaboratoryLeaseMember" xlink:label="sldb_OfficeAndLaboratoryLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sldb_CommitmentAndContingenciesLineItems" xlink:to="sldb_CommitmentAndContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sldb_CommitmentAndContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="sldb_OfficeAndLaboratoryLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sldb_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PreFundedWarrantsMember" xlink:label="sldb_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sldb_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PreFundedWarrantsMember" xlink:label="sldb_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants" xlink:label="sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_WarrantsIssued" xlink:label="sldb_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sldb_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="sldb_WarrantsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_SGT003Member" xlink:label="sldb_SGT003Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_SGT501Member" xlink:label="sldb_SGT501Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ExternalResearchAndDevelopmentOtherMember" xlink:label="sldb_ExternalResearchAndDevelopmentOtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_InternalResearchAndDevelopmentExpenseMember" xlink:label="sldb_InternalResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ExternalGeneralAndAdministrativeExpenseMember" xlink:label="sldb_ExternalGeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_InternalGeneralAndAdministrativeExpenseMember" xlink:label="sldb_InternalGeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sldb_SGT003Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="srt_ConsolidationItemsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sldb_SGT501Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sldb_ExternalResearchAndDevelopmentOtherMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sldb_InternalResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sldb_ExternalGeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sldb_InternalGeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_April2022PlanMember" xlink:label="sldb_April2022PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_November2022PlanMember" xlink:label="sldb_November2022PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths" xlink:label="sldb_RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_RestructuringChargesExpectedToBePaid" xlink:label="sldb_RestructuringChargesExpectedToBePaid"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringPlanAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="sldb_April2022PlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="sldb_November2022PlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_SeveranceCosts1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="sldb_RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="sldb_RestructuringChargesExpectedToBePaid" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:label="us-gaap_OneTimeTerminationBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_April2022CorporateStrategyChangeMember" xlink:label="sldb_April2022CorporateStrategyChangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_November2022WorkforceReductionPlanMember" xlink:label="sldb_November2022WorkforceReductionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_AccruedRestructuringCosts" xlink:label="sldb_AccruedRestructuringCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="sldb_April2022CorporateStrategyChangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringPlanAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="sldb_November2022WorkforceReductionPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="sldb_AccruedRestructuringCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="7" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RestructuringCharges" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm" order="3" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sldb_NonCashAcquiredInProcessResearchAndDevelopment" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sldb_ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="5" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sldb_NonCashLeaseExpense" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sldb_DepreciationImpairmentAndAmortizationExpense" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sldb_ChangeInFairValueOfDerivativeLiabilities" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="21" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="23" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="24" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering" xlink:label="sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm" xlink:label="us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_NonCashAcquiredInProcessResearchAndDevelopment" xlink:label="sldb_NonCashAcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_NonCashLeaseExpense" xlink:label="sldb_NonCashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_DepreciationImpairmentAndAmortizationExpense" xlink:label="sldb_DepreciationImpairmentAndAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans" xlink:label="us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ChangeInFairValueOfDerivativeLiabilities" xlink:label="sldb_ChangeInFairValueOfDerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions" xlink:label="sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="sldb_GainLossOnAcquisitionOfBusiness" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_GainLossOnAcquisitionOfBusiness" xlink:label="sldb_GainLossOnAcquisitionOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset" xlink:label="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_DerivativeLiabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="sldb_PrepaidResearchAndDevelopmentExpensesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="sldb_PrepaidOtherAndOtherCurrentAssets" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PrepaidResearchAndDevelopmentExpensesCurrent" xlink:label="sldb_PrepaidResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sldb-20250630.xsd#sldb_PrepaidOtherAndOtherCurrentAssets" xlink:label="sldb_PrepaidOtherAndOtherCurrentAssets"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants" name="CommonStockIssuableUponExerciseOfPrefundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_AtTheMarketPublicOfferingMember" name="AtTheMarketPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_SaleMember" name="SaleMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_MilestoneLiabilityPayment" name="MilestoneLiabilityPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_OfficeAndLaboratoryLeaseMember" name="OfficeAndLaboratoryLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_AssetAcquisitionUpfrontPayment" name="AssetAcquisitionUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_CommitmentAndContingenciesTable" name="CommitmentAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_DevelopmentMilestonePayments" name="DevelopmentMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments" name="AssetAcquisitionAssumedRegulatoryMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_FirstDevelopmentMilestonePaymentInShares" name="FirstDevelopmentMilestonePaymentInShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_TransactionPriceDeterminedUnderASC606" name="TransactionPriceDeterminedUnderASC606" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember" name="TwoThousandAndTwentyFourInducementStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts" name="AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments" name="AssetAcquisitionAssumedCumulativeSalesMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_NonCashAcquiredInProcessResearchAndDevelopment" name="NonCashAcquiredInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_AccruedMilestonePaymentMember" name="AccruedMilestonePaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_InternalGeneralAndAdministrativeExpenseMember" name="InternalGeneralAndAdministrativeExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_AssetAcquisitionPolicyTextBlock" name="AssetAcquisitionPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_SubleasedDescription" name="SubleasedDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_SGT501Member" name="SGT501Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_IncreaseDecreaseInPropertyPlantAndEquipmentDueToAssetExchange" name="IncreaseDecreaseInPropertyPlantAndEquipmentDueToAssetExchange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_April2022PlanMember" name="April2022PlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_ClassOfWarrantOrRightPricePerShare" name="ClassOfWarrantOrRightPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sldb_Fa212LlcMember" name="Fa212LlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_InternalResearchAndDevelopmentExpenseMember" name="InternalResearchAndDevelopmentExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_April2022CorporateStrategyChangeMember" name="April2022CorporateStrategyChangeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_FairValueAssetLevel1ToLevel2TransfersAmount" name="FairValueAssetLevel1ToLevel2TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_OperatingAndFinancingLeasesDisclosureTextBlock" name="OperatingAndFinancingLeasesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_AmendedAndRestatedTwoThousandAndTwentyEquityIncentivePlanMember" name="AmendedAndRestatedTwoThousandAndTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_InducementAwardMember" name="InducementAwardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_November2022PlanMember" name="November2022PlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" name="IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_GainLossOnAcquisitionOfBusiness" name="GainLossOnAcquisitionOfBusiness" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_AssetAcquisitionTransactionCosts" name="AssetAcquisitionTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering" name="PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion" name="BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_JessieHanrahanPhDMember" name="JessieHanrahanPhDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_GovernmentBondsMember" name="GovernmentBondsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_IncentiveStockOptionsMember" name="IncentiveStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_PercentageOfOptionToFundOfDevelopmentCost" name="PercentageOfOptionToFundOfDevelopmentCost" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_AccruedExpensesAndOtherMember" name="AccruedExpensesAndOtherMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_WarrantsIssued" name="WarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sldb_AccruedResearchAndDevelopmentExpenseMember" name="AccruedResearchAndDevelopmentExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_ExternalGeneralAndAdministrativeExpenseMember" name="ExternalGeneralAndAdministrativeExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_TransactionPrice" name="TransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" name="ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_ChangeInFairValueOfDerivativeLiabilities" name="ChangeInFairValueOfDerivativeLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_VestingOfRestrictedStockUnits" name="VestingOfRestrictedStockUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_FirstDevelopmentMilestonePayable" name="FirstDevelopmentMilestonePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement" name="IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_PreFundedWarrantsOutstanding" name="PreFundedWarrantsOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sldb_NonCashLeaseExpense" name="NonCashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_PrepaidResearchAndDevelopmentExpensesCurrent" name="PrepaidResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_RelatedPartyTransactionPolicyTextBlock" name="RelatedPartyTransactionPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_SGT003Member" name="SGT003Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions" name="ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_TwoThousandAndEighteenOmnibusIncentivePlanMember" name="TwoThousandAndEighteenOmnibusIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_RestructuringChargesExpectedToBePaid" name="RestructuringChargesExpectedToBePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_February2025OfferingMember" name="February2025OfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement" name="IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths" name="RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_ArkeaBioCorpMember" name="ArkeaBioCorpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions" name="ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_CumulativeSalesMilestonePayments" name="CumulativeSalesMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_AccruedRestructuringCosts" name="AccruedRestructuringCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_TreasuryBillMember" name="TreasuryBillMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_AccruedCompensationMember" name="AccruedCompensationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable" name="AccruedExpensesAndOtherCurrentLiabilitiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_UnvestedStockOptionsMember" name="UnvestedStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_PrepaidOtherAndOtherCurrentAssets" name="PrepaidOtherAndOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_PercentageOfOutstandingCommonStock" name="PercentageOfOutstandingCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_KevinTanMember" name="KevinTanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_MilestonePaymentsUponAchievementOfRegulatoryMilestone" name="MilestonePaymentsUponAchievementOfRegulatoryMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_UltragenyxMember" name="UltragenyxMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_DepreciationImpairmentAndAmortizationExpense" name="DepreciationImpairmentAndAmortizationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_CumulativeDevelopmentalRegulatoryAndCommercialMilestonePayments" name="CumulativeDevelopmentalRegulatoryAndCommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_VestingOfRestrictedStockUnitsValue" name="VestingOfRestrictedStockUnitsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_ExternalResearchAndDevelopmentOtherMember" name="ExternalResearchAndDevelopmentOtherMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_GabrielBrooksMDMember" name="GabrielBrooksMDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_UpfrontLicenseFee" name="UpfrontLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_LicenseAndResearchAgreementsTextBlock" name="LicenseAndResearchAgreementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_CommercialMilestonePayments" name="CommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_FairValueAssetLevel2ToLevel1TransfersAmount" name="FairValueAssetLevel2ToLevel1TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_AavantibioIncMember" name="AavantibioIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" name="IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_BuildingInteriorMember" name="BuildingInteriorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember" name="AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_MilestonePaymentsUponAchievementOfDevelopmentMilestone" name="MilestonePaymentsUponAchievementOfDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_MilestonePaymentsUponAchievementOfNetSalesMilestones" name="MilestonePaymentsUponAchievementOfNetSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_AmendmentAndRestatementOfEsppMember" name="AmendmentAndRestatementOfEsppMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems" name="AccruedExpensesAndOtherCurrentLiabilitiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_AtTheMarketOfferingSalesAgreementMember" name="AtTheMarketOfferingSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_PercentageOfNetIncomeAndNetLossesOnNetSales" name="PercentageOfNetIncomeAndNetLossesOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination" name="IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments" name="AssetAcquisitionAssumedContingentDevelopmentMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_AgreementTerminationNoticePeriod" name="AgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_ClassOfWarrantOrRightsExercised" name="ClassOfWarrantOrRightsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions" name="AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_MaugeriLicenseAgreementMember" name="MaugeriLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_ProbabilityOfAchievingCertainDevelopmentMilestonesMember" name="ProbabilityOfAchievingCertainDevelopmentMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember" name="AccruedExpensesOtherAndOtherCurrentLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration" name="CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_CommitmentAndContingenciesLineItems" name="CommitmentAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_PaulHerzichMember" name="PaulHerzichMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions" name="ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sldb_AlexanderCumboMember" name="AlexanderCumboMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_AvailableForSaleSecuritiesWeightedAverageMaturityPeriod" name="AvailableForSaleSecuritiesWeightedAverageMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sldb_TwoThousandAndTwentyEquityIncentivePlanMember" name="TwoThousandAndTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_TimingOfAchievingCertainDevelopmentMilestonesMember" name="TimingOfAchievingCertainDevelopmentMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_November2022WorkforceReductionPlanMember" name="November2022WorkforceReductionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Aug. 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLDB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Solid Biosciences Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001707502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,869,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">90-0943402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 Rutherford Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Third FloorCharlestown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">337-4680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 138,933<span></span>
</td>
<td class="nump">$ 80,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available-for-sale securities</a></td>
<td class="nump">129,177<span></span>
</td>
<td class="nump">68,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,530<span></span>
</td>
<td class="nump">8,382<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">278,640<span></span>
</td>
<td class="nump">157,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use assets</a></td>
<td class="nump">23,133<span></span>
</td>
<td class="nump">24,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,317<span></span>
</td>
<td class="nump">4,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,924<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">29,652<span></span>
</td>
<td class="nump">31,360<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">308,292<span></span>
</td>
<td class="nump">188,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,704<span></span>
</td>
<td class="nump">4,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">16,546<span></span>
</td>
<td class="nump">19,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,943<span></span>
</td>
<td class="nump">1,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">953<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">3,150<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">29,846<span></span>
</td>
<td class="nump">30,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, excluding current portion</a></td>
<td class="nump">20,155<span></span>
</td>
<td class="nump">21,159<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">20,155<span></span>
</td>
<td class="nump">21,159<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">50,001<span></span>
</td>
<td class="nump">51,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value - 10,000,000 shares authorized; no shares issued or outstanding at June 30, 2025 and December 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value - 240,000,000 and 120,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively; 77,602,741 and 40,468,141 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,120,463<span></span>
</td>
<td class="nump">920,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(862,212)<span></span>
</td>
<td class="num">(783,450)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">258,291<span></span>
</td>
<td class="nump">137,246<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 308,292<span></span>
</td>
<td class="nump">$ 188,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">240,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">77,602,741<span></span>
</td>
<td class="nump">40,468,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">77,602,741<span></span>
</td>
<td class="nump">40,468,141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 32,415<span></span>
</td>
<td class="nump">$ 19,461<span></span>
</td>
<td class="nump">$ 63,329<span></span>
</td>
<td class="nump">$ 38,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,278<span></span>
</td>
<td class="nump">8,327<span></span>
</td>
<td class="nump">18,416<span></span>
</td>
<td class="nump">16,316<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">41,693<span></span>
</td>
<td class="nump">27,788<span></span>
</td>
<td class="nump">81,745<span></span>
</td>
<td class="nump">54,650<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(41,693)<span></span>
</td>
<td class="num">(27,788)<span></span>
</td>
<td class="num">(81,745)<span></span>
</td>
<td class="num">(54,650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2,966<span></span>
</td>
<td class="nump">2,565<span></span>
</td>
<td class="nump">5,266<span></span>
</td>
<td class="nump">5,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="num">(183)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">2,213<span></span>
</td>
<td class="nump">2,716<span></span>
</td>
<td class="nump">2,983<span></span>
</td>
<td class="nump">5,275<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (39,480)<span></span>
</td>
<td class="num">$ (25,072)<span></span>
</td>
<td class="num">$ (78,762)<span></span>
</td>
<td class="num">$ (49,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="num">$ (1.25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="num">$ (1.25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding used to compute basic net loss per share</a></td>
<td class="nump">94,140,286<span></span>
</td>
<td class="nump">40,934,361<span></span>
</td>
<td class="nump">80,317,588<span></span>
</td>
<td class="nump">39,544,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding, used to compute diluted net loss per share</a></td>
<td class="nump">94,140,286<span></span>
</td>
<td class="nump">40,934,361<span></span>
</td>
<td class="nump">80,317,588<span></span>
</td>
<td class="nump">39,544,867<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (39,480)<span></span>
</td>
<td class="num">$ (25,072)<span></span>
</td>
<td class="num">$ (78,762)<span></span>
</td>
<td class="num">$ (49,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (39,520)<span></span>
</td>
<td class="num">$ (25,083)<span></span>
</td>
<td class="num">$ (78,847)<span></span>
</td>
<td class="num">$ (49,405)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-the-Market Public Offering [Member]</div></th>
<th class="th"><div>Private Placement [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>At-the-Market Public Offering [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Private Placement [Member]</div>
</th>
<th class="th"><div>Additional Paid in Capital [Member]</div></th>
<th class="th">
<div>Additional Paid in Capital [Member] </div>
<div>At-the-Market Public Offering [Member]</div>
</th>
<th class="th">
<div>Additional Paid in Capital [Member] </div>
<div>Private Placement [Member]</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 126,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 785,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="num">$ (658,753)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, units at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,386,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,056<span></span>
</td>
<td class="nump">$ 89,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,055<span></span>
</td>
<td class="nump">$ 89,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,664<span></span>
</td>
<td class="nump">16,973,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants in public offering/private placement</a></td>
<td class="nump">14,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_VestingOfRestrictedStockUnits', window );">Vesting of restricted stock, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of common stock options</a></td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises of common stock options, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation expense</a></td>
<td class="nump">1,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(24,303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,303)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">210,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">893,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(683,056)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, units at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,833,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">126,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">785,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(658,753)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, units at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,386,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(49,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">193,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">901,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(708,128)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, units at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,551,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="nump">210,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">893,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(683,056)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, units at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,833,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_VestingOfRestrictedStockUnits', window );">Vesting of restricted stock, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of common stock options</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises of common stock options, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation expense</a></td>
<td class="nump">2,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(25,072)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,072)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">193,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">901,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(708,128)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, units at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,551,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">137,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">920,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="num">(783,450)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, units at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,468,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">135,367<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,331<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,739,810<span></span>
</td>
<td class="nump">61,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants in public offering/private placement</a></td>
<td class="nump">52,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration', window );">Issuance of common stock in private placement for payment of developmental milestone consideration</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration', window );">Issuance of common stock in private placement for payment of developmental milestone consideration, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">975,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_VestingOfRestrictedStockUnits', window );">Vesting of restricted stock, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation expense</a></td>
<td class="nump">3,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(39,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,282)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">294,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,117,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(822,732)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, units at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,492,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 137,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">920,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="num">(783,450)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, units at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,468,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises of common stock options, units</a></td>
<td class="nump">2,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">$ (85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(78,762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">258,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(862,212)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, units at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,602,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2025</a></td>
<td class="nump">294,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,117,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(822,732)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, units at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,492,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_VestingOfRestrictedStockUnits', window );">Vesting of restricted stock, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of common stock options</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises of common stock options, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation expense</a></td>
<td class="nump">3,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(39,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,480)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">$ 258,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,120,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (38)<span></span>
</td>
<td class="num">$ (862,212)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, units at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,602,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in private placement for payment of developmental milestone consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock value in private placement for payment of developmental milestone consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_VestingOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_VestingOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 8,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts', window );">Pre-funded warrants issuance costs</a></td>
<td class="nump">3,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions', window );">Sales commissions</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital, net of sales commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital, pre-funded warrants issued, issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (78,762)<span></span>
</td>
<td class="num">$ (49,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discount on available-for-sale securities</a></td>
<td class="num">(800)<span></span>
</td>
<td class="num">(1,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">6,486<span></span>
</td>
<td class="nump">3,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">793<span></span>
</td>
<td class="nump">1,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">1,162<span></span>
</td>
<td class="nump">1,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_ChangeInFairValueOfDerivativeLiabilities', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">2,550<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(2,060)<span></span>
</td>
<td class="num">(1,556)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">467<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(848)<span></span>
</td>
<td class="num">(864)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">1,695<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(69,262)<span></span>
</td>
<td class="num">(46,659)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(503)<span></span>
</td>
<td class="num">(435)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm', window );">Proceeds from maturities of available-for-sale securities</a></td>
<td class="nump">69,000<span></span>
</td>
<td class="nump">60,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of available-for-sale securities</a></td>
<td class="num">(128,777)<span></span>
</td>
<td class="num">(103,536)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(60,195)<span></span>
</td>
<td class="num">(43,666)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions', window );">Proceeds from issuance of common stock and pre-funded warrants in public offering, net of underwriting discounts and commissions</a></td>
<td class="nump">189,637<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering', window );">Payments of common stock and pre-funded warrants issuance costs in public offering</a></td>
<td class="num">(1,681)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement', window );">Proceeds from issuance of common stock and pre-funded warrants in private placement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">108,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of common stock and pre-funded warrants issuance costs in private placement</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions', window );">Proceeds from issuance of common stock in at-the-market public offering, net of sales commissions</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">8,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of common stock options</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans', window );">Employee stock purchase plan purchases</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities', window );">Payments of principal portion of finance lease obligations</a></td>
<td class="num">(277)<span></span>
</td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">188,127<span></span>
</td>
<td class="nump">112,241<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">58,670<span></span>
</td>
<td class="nump">21,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">82,187<span></span>
</td>
<td class="nump">75,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">140,857<span></span>
</td>
<td class="nump">97,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for Interest</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration', window );">Common stock issued as payment for developmental milestone consideration</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets acquired through operating leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination', window );">Decrease in right-of-use assets due to lease termination</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_ChangeInFairValueOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_ChangeInFairValueOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued as payment for developmental milestone consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in right of use asset due to lease termination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of common stock and pre funded warrants issuance costs in public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and pre-funded warrants in private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and pre-funded warrants in public offering, net of underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock in at the market public offering net of sales commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow (inflow) through acquisition (sale) of short-term available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the financed defined contribution plan to acquire shares of the entity. The plan initially holds the shares in a suspense account, which is collateral for the loan. As the plan makes payment on the debt, the shares are released from the suspense account and become available to be allocated to participant accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 138,933<span></span>
</td>
<td class="nump">$ 80,235<span></span>
</td>
<td class="nump">$ 95,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">1,924<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">1,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash, as reported in the condensed consolidated statements of cash flows</a></td>
<td class="nump">$ 140,857<span></span>
</td>
<td class="nump">$ 82,187<span></span>
</td>
<td class="nump">$ 97,764<span></span>
</td>
<td class="nump">$ 75,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Nature of the Business and Basis of Presentation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Solid Biosciences Inc. was organized in March 2013 under the name SOLID Ventures Management, LLC and operated as a Delaware limited liability company until immediately prior to the effectiveness of its registration statement on Form S-1 on January 25, 2018, at which time it completed a statutory corporate conversion into a Delaware corporation and changed its name to Solid Biosciences Inc. (the "Company").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates (collectively "Candidates"), including SGT-003 for the treatment of Duchenne muscular dystrophy ("Duchenne"), SGT-212 for the treatment of Friedreich&#8217;s ataxia ("FA"), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia ("CPVT"), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases, at different stages of development with varying levels of investment. The Company is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management and care. Patient-focused and founded by those directly impacted by Duchenne, the Company&#8217;s mission is to improve the daily lives of patients living with these devastating diseases.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on licenses, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting capabilities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Candidates are in development. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from, among others, other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, partners, and consultants.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based upon its current operating plan, the Company expects that its cash, cash equivalents and available-for-sale securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">268.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million excluding restricted cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, as of June 30, 2025, will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of issuance of these condensed consolidated financial statements. However, the Company has based this estimate on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to it. As a result, the Company could deplete its capital resources sooner than it currently expects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Through June 30, 2025, the Company has funded its operations primarily with the proceeds from the sale of redeemable preferred units and member units as well as the sale of common stock and pre-funded warrants to purchase shares of its common stock in private placements (including the January 2024 Private Placement (as defined below)) and the sale of common stock in its initial public offering, follow-on public offerings in March 2021 and February 2025 and under its at-the-market sales agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects to continue to generate operating losses for the foreseeable future and to finance its future cash needs through a combination of equity offerings, debt financings, collaborations, strategic partnerships and alliances or licensing arrangements. If the Company is unable to obtain funding, the Company would be forced to delay, reduce or eliminate some or all of its research and development programs, preclinical and clinical testing or commercialization efforts, which could adversely affect its business prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") along with the rules and regulations of the Securities and Exchange Commission for interim financial information and include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from the Company&#8217;s audited financial statements but does not include all disclosures required by GAAP to constitute a complete set of financial statements. These condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for a fair statement of the Company&#8217;s financial position at June 30, 2025 and its results of operations, changes in stockholders&#8217; equity, and cash flows for the interim periods ended June 30, 2025 and 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These unaudited condensed consolidated interim financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024. The results of operations for the three and six months ended June 30, 2025 are not necessarily indicative of the operating results to be expected for the year ending December 31, 2025, for any other interim period, or for any other future year.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant Judgments and Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, estimates related to the recognition of research and development expenses, equity-based compensation, and derivative liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from the Company&#8217;s estimates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no changes to the significant accounting policies disclosed in the Company's most recent Annual Report on Form 10&#8209;K.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This ASU updates income tax disclosure requirements primarily by requiring specific categories and greater disaggregation within the rate reconciliation and disaggregation of income taxes paid by jurisdiction. This ASU is effective for annual periods beginning after December 15, 2024 and is applicable to the Company&#8217;s fiscal year beginning January 1, 2025, with early application permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disaggregation of Income Statement Expenses (Topic 220)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The requirements in this ASU may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FA212 Asset Acquisition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">FA212 Asset Acquisition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. FA212 Asset Acquisition</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 19, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company entered into an asset purchase agreement with FA212 LLC ("FA212") for the purchase of certain intellectual property, including patents and assigned licenses related to a preclinical drug candidate, which the Company now refers to as SGT-212, assigned manufacturing contracts as well as research and development materials such as manufactured materials and samples.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid FA212 an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the third quarter of 2024. Additionally, the Company agreed to pay FA212 development milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, cumulative sales milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and tiered royalties on net sales in the low-single-digits. The Company also assumed from FA212 contingent development milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, regulatory milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, cumulative sales milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and tiered royalties on worldwide net sales in the mid-single digits payable to the University of Pennsylvania.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain development milestone payments to FA212 are payable in either cash, equity, or a combination of both, at the Company's discretion. Such contingent payments were determined to be derivative liabilities and were initially recorded at their fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined that the FA212 agreement represented an asset acquisition of in-process research and development assets with no alternative future use and recognized the aggregate acquisition cost of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as research and development expense in the third quarter of 2024, which included the upfront payment, initial recognition of the derivative liability and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in transaction costs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> submitted an investigational new drug application ("IND") for SGT-212 for the treatment of FA to the U.S. Food and Drug Administration ("FDA"), which was cleared in December 2024. Upon clearance of the IND, the first development milestone of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million became payable to FA212. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment is included in Accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheet as of December 31, 2024. On February 28, 2025, the Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">made the first development milestone payment in the form of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">975,496</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The derivative liabilities for the remaining contingent payments were recorded at a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2025 and December 31, 2024, respectively. See Note 3 -</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:32.48%;box-sizing:content-box;"></td>
         <td style="width:1.7%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.7%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.7%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.7%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,331</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,331</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,331</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,331</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities (Note 4):</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury bills</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,287</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,287</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,890</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,890</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total available-for-sale securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,177</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,177</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">259,508</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">259,508</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities (Note 2):</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:33.44%;box-sizing:content-box;"></td>
         <td style="width:1.68%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.96%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.68%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.96%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.68%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.96%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.68%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.96%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,088</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,088</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury bills</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,434</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,434</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,522</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,522</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities (Note 4):</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury bills</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,895</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,895</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,790</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,790</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total available-for-sale securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,685</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,685</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104,207</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104,207</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities (Note 2):</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025 and December 31, 2024, the fair values of the Company&#8217;s cash equivalents and available-for-sale securities were determined using Level 2 inputs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimated the fair value of the derivative liabilities by using a Monte Carlo simulation forecasting the timing and likelihood of certain development milestone events being achieved and discounting the probability adjusted payments using an appropriate discount rate based on market interest rates. The main assumptions when determining the fair value of the derivative liabilities are the timing and probability of achieving certain milestones, the estimated volatility of the Company&#8217;s common stock, and the discount rate. The estimated fair value presented is not necessarily indicative of an amount that could be realized in a current market exchange. The use of alternative inputs and estimation methodologies could have a material effect on these estimates of fair value.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant unobservable inputs used in valuing the developmental milestone derivative liabilities at each measurement date are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:27.267%;box-sizing:content-box;"></td>
         <td style="width:1.01%;box-sizing:content-box;"></td>
         <td style="width:17.168%;box-sizing:content-box;"></td>
         <td style="width:1.01%;box-sizing:content-box;"></td>
         <td style="width:17.168%;box-sizing:content-box;"></td>
         <td style="width:1.01%;box-sizing:content-box;"></td>
         <td style="width:17.047%;box-sizing:content-box;"></td>
         <td style="width:1.01%;box-sizing:content-box;"></td>
         <td style="width:17.31%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unobservable Input</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Range</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Range</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of achieving certain development milestones</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discount Rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Timing of achieving certain development milestones</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents a roll forward of activity associated with the Company&#8217;s derivative liabilities measured using Level 3 inputs:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:78.54%;box-sizing:content-box;"></td>
         <td style="width:2.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.28%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Developmental Milestone Derivative Liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of derivative liabilities as of January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of derivative liabilities</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,550</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of derivative liabilities as of June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized loss</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">es of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the change in fair value of the derivative liabilities during the three and six months ended June 30, 2025, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gain or loss was recognized during the three or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is the Company's policy to recognize transfers between levels of the fair value hierarchy, if any, at the end of the reporting period. During the six months ended June 30, 2025, and the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_48d73115-07e5-48ba-9dc8-452243c36a43;"><span style="-sec-ix-hidden:F_08ff9217-3602-4409-8438-1bc1896ee246;"><span style="-sec-ix-hidden:F_1be8fb40-e397-4eaf-b81b-88444ec1c2a6;"><span style="-sec-ix-hidden:F_f576a497-b1ba-43df-9267-28b759106728;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">between</span></span></span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7f2d05a5-0a5c-4f59-b707-ed7bd008cae6;"><span style="-sec-ix-hidden:F_0a9b999f-ba3c-4c75-85b3-624f3daa13ec;"><span style="-sec-ix-hidden:F_3c78939b-2f88-43de-94c1-2b2dca662653;"><span style="-sec-ix-hidden:F_5fe053a6-d452-4df1-bff8-51707a501d58;"><span style="-sec-ix-hidden:F_2eb056d4-25d3-4b79-9779-b2b71429c937;"><span style="-sec-ix-hidden:F_38c85a03-f1da-4bb9-bee4-e34e8e64f14b;"><span style="-sec-ix-hidden:F_981c76c5-7e07-41ab-a103-d0737a7932bd;"><span style="-sec-ix-hidden:F_81ea4290-b268-4d22-8def-51b3d1505ec7;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1</span></span></span></span></span></span></span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3a22dccf-9544-457d-a4be-457034ddacdf;"><span style="-sec-ix-hidden:F_cb4f10ce-e1bf-4e65-ab4b-c31784741e94;"><span style="-sec-ix-hidden:F_4ad198f7-47e2-4a32-bdfc-243a9a08f8d7;"><span style="-sec-ix-hidden:F_d2f01e79-37d9-4163-914f-7030affd467c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2</span></span></span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and Level 3.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company's accounts payable, accrued expenses, and other current liabilities approximated their estimated fair values due to the short-term nature of these financial instruments.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Available-for-Sale Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Available-for-Sale Securities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the Company's available-for-sale securities is presented below:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:49.39%;box-sizing:content-box;"></td>
         <td style="width:1.239%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.093%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.279%;box-sizing:content-box;"></td>
         <td style="width:1.239%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.093%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.239%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.093%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.239%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.093%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="15" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury bills maturing in one year or less</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,290</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,287</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds maturing in one year or less</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,925</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,890</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total available-for-sale securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,215</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,177</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.03%;box-sizing:content-box;"></td>
         <td style="width:1.259%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.232%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.259%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.232%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.259%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.232%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.259%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.232%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury bills maturing in one year or less</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,879</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,895</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds maturing in one year or less</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,759</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,790</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total available-for sale securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,638</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,685</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average contractual maturity of the Company&#8217;s available-for-sale securities was approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">0.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">0.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Prepaid Expenses and Other Current Assets</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66%;box-sizing:content-box;"></td>
         <td style="width:3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.899999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, <br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,235</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,731</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid other and other current assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,295</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,651</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,530</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,382</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.72%;box-sizing:content-box;"></td>
         <td style="width:1.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, <br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,944</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,268</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,618</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,221</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued milestone payment (Note 2)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,984</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,363</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,546</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,852</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Stockholders' Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 11, 2024, the Company issued and sold in a private placement </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,973,103</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock at a price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and, to one investor in lieu of shares of common stock, pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,712,478</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.529</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant, (the "January 2024 Private Placement"). The Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of net proceeds from the January 2024 Private Placement after deducting offering costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 19, 2025, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,739,810</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock at a price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.03</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and, to certain investors in lieu of shares of common stock, pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,888,340</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.029</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant (the "February 2025 Offering"). The Company received approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of net proceeds from the February 2025 Offering after deducting underwriting discounts and commissions and offering costs.<br/><br/>The Company determined the pre-funded warrants met the criteria for equity classification. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants were exercised during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Equity-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity-Based Compensation Expense</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has classified equity-based compensation expense in its condensed consolidated statements of operations as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:43.4%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,116</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">832</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,218</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,380</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,029</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,260</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,268</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,323</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,145</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,092</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,486</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,703</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Incentive Plans</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, the Company&#8217;s approved equity incentive plans include: the 2018 Omnibus Incentive Plan (the "2018 Plan"); Amended and Restated 2020 Equity Incentive Plan, as amended (the "2020 Plan"); the Amended and Restated 2021 Employee Stock Purchase Plan; and the 2024 Inducement Stock Incentive Plan (the "2024 Plan"). These plans are administered by the Board of Directors (the "Board") and permit the granting of stock options, stock appreciation rights, restricted stock, restricted stock units (the "RSUs"), performance awards, and other stock&#8209;based or cash-based awards. Upon the adoption of the 2020 Plan, the Company no longer grants new equity awards under its 2018 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated 2020 Equity Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 12, 2025 and June 11, 2024, the Company's stockholders approved amendments to the 2020 Plan to increase the number of shares of common stock reserved for issuance under the plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, there </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,450,074</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock options outstanding, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,433,589</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs outstanding, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,074,188</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> performance stock units outstanding, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,173,225</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remained available for future issuance under the 2020 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 Inducement Stock Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, the Board approved the 2024 Plan, which provides for the reservation of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock for equity granted as an inducement material to the individual&#8217;s entering into employment with the Company and in accordance with the requirements of Nasdaq Stock Market Rule 5635(c)(4). As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock options outstanding, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">492,256</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs outstanding, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">386,111</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remained available for future issuance under the 2024 Plan.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below summarizes the activity with respect to stock options for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.91%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:6.841%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining Contractual Life (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,927,937</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.22</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.01</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">193</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">642,148</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.56</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,733</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,165</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67.13</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeitures</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,882</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.09</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,324,305</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.93</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.14</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">467</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest at June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,324,305</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.93</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.14</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">467</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,668,986</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.64</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.41</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in the Black-Scholes option-pricing model for all stock options granted during each period presented are as follows:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:44.4%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:13.14%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:13.14%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:12.42%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:12.42%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.58</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.51</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.10</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.58</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.76</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.85</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112.1</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128.7</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividends</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.31</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.31</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.25</span></span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average grant date fair values of stock options granted during the three months ended June 30, 2025 and 2024 were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.84</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.52</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and the weighted average grant date fair values of stock options granted during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.83</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.91</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, resp</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognize</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion of equity-based compensation expense in connection with stock options during the three months ended June 30, 2025 and 2024, respectively. During the six months ended June 30, 2025 and 2024, the Company recognized equity-based compensation expense in connection with stock opt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, respectively. As of June 30, 2025, there was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion of total unrecognized equity-based compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes activity with respect to RSUs during the six months ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.58%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Units</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested RSUs at January 1, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,480,272</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.50</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,188,256</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.23</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">280,159</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.76</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeitures</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">286,245</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.73</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested RSUs at June 30, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,102,124</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.72</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of equity-based compensation expense in connection with RSUs during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended June 30, 2025 and 2024, respectively. During the six months ended June 30, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized equity-based compensation expense in connection with RSUs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of total unrecognized equity-based compensation expense related to nonvested RSUs, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.2</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Stock Units</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, the Board approved a grant of performance-based restricted stock unit awards ("PSUs" or "Performance Awards") to the Company&#8217;s executive team. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each PSU represents the contingent right to receive one share of the Company&#8217;s common stock.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> These Performance Awards provide for the vesting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee&#8217;s continued service with the Company (the "Approval Conditions").</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Performance Milestones are tied to the achievement of certain business objectives and are non-market and non-financial in nature. The Board will determine that all Approval Conditions have been satisfied and the number of units that will ultimately vest on the 2026 Evaluation Date, which will occur in the first quarter of 2026, and the 2027 Evaluation Date, which will occur in the first quarter of 2027. A maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the target number of RSUs may vest at the 2026 Evaluation Date and the percentage of the target number of RSUs allocable to any Performance Milestone that has not been achieved on or prior to the 2027 Evaluation Date shall be cancelled.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes activity with respect to PSUs during the six months ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67%;box-sizing:content-box;"></td>
         <td style="width:1.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.44%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.96%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Units</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested PSUs at January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,165,325</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.51</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeitures</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91,137</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.51</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested PSUs at June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,074,188</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.51</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">equity-based compensation expense in connection with PSUs during the three months ended June 30, 2025 and 2024, respectively. During the six months ended June 30, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized equity-based compensation expense in connection with PSUs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized equity-based compensation expense related to nonvested PSUs based on the achievement of all Performance Milestones, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Letter of Credit</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had an outstanding letter of credit in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at June 30, 2025 and December 31, 2024, respectively, which is required as a condition of the Company&#8217;s office and laboratory lease.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with its executive officers and members of its Board that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as executive officers or directors of the Company. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification arrangements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of June 30, 2025 and December 31, 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which the Company is focused. The Company is not aware of any material legal proceedings or claims as of June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Net Loss Per Share</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of the Company's basic and diluted net loss per share:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:42.4%;box-sizing:content-box;"></td>
         <td style="width:1.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,480</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,072</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78,762</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,375</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares used to compute net loss per share, basic and <br/>&#160;&#160;&#160;diluted</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average shares of common stock <br/>&#160;&#160;&#160;outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,539,468</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,221,883</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,476,597</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,981,426</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average shares of pre-funded warrants to <br/>&#160;&#160;&#160;purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,600,818</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,712,478</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,840,991</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,563,441</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average shares of common stock <br/>&#160;&#160;&#160;outstanding used to compute basic and diluted <br/>&#160;&#160;&#160;net loss per share</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,140,286</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,934,361</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,317,588</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,544,867</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.42</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.61</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.25</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included within weighted average shares of common stock outstanding for the three and six months ended June 30, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,600,818</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,712,478</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock issuable upon the exercise of the pre-funded warrants, respectively. The pre-funded warrants are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The outstanding securities presented below were excluded from the calculation of net loss per share because the inclusion of such securities would have been anti-dilutive due to the Company&#8217;s net loss per share during the periods presented.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.552%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.903%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.903%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three and Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,324,305</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,890,045</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested restricted stock units</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,102,124</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,397,063</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested performance stock units</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,074,188</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,165,325</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares subject to employee stock purchase plan</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216,802</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250,188</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,563</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,230</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,719,982</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,711,851</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Segment Reporting</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#2d2d2d;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable and </span><span style="font-size:10pt;font-family:Times New Roman;color:#2d2d2d;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment and manages its business activities primarily in North America and on a consolidated basis. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. All of the Company&#8217;s tangible assets are held in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting policies of the Company are the same as those described in the summary of significant accounting policies.</span><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s chief operating decision maker ("CODM") is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1cf5d347-81ef-4291-87b4-2b55905c5532;"><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief executive officer</span></span></span><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM assesses performance for the Company and decides how to allocate resources based on net loss as reported on the condensed consolidated statements of operations. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The annual budgeting process is the primary mechanism used to make these decisions.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The financial information also helps in making performance assessments using budgeted versus actual results.</span><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents segment expenses, other segment items, and segment net loss for the periods presented:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.05%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.402%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.402%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.402%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.742%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Segment expenses:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-003</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,219</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,434</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,385</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,340</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-501</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,223</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,422</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,689</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,229</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External R&amp;D other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,116</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,845</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,886</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,573</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal R&amp;D expense</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,765</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,921</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,608</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,298</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External G&amp;A expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,279</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,449</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,156</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,883</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal G&amp;A expense</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,360</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,037</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,003</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,731</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,680</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,198</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,324</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,213</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,716</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,983</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,275</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Condensed consolidated net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,480</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,072</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78,762</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,375</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:4.86%;box-sizing:content-box;"></td>
         <td style="width:95.14%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal expenses consisted primarily of payroll and related costs, temporary services, and travel and entertainment.</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items primarily included other program costs, equity-based compensation expense, and depreciation and amortization expense.</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The measure of segment assets is reported on the balance sheet as total condensed consolidated assets.</span><span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Subsequent Events<br/><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 4, 2025, the One Big Beautiful Bill Act (the "OBBBA") was enacted in the United States. The OBBBA includes significant changes to federal tax law and other regulatory provisions that may impact the Company. As this legislation was not signed into law until the third quarter of 2025, the impacts are not included in the Company's operating results for the three and six months ended June 30, 2025. The Company will evaluate the impact of the newly enacted tax law and its impact on the Company's forecasted annual effective tax rate in subsequent periods as required.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_RecentlyIssuedAccountingPronouncementsPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This ASU updates income tax disclosure requirements primarily by requiring specific categories and greater disaggregation within the rate reconciliation and disaggregation of income taxes paid by jurisdiction. This ASU is effective for annual periods beginning after December 15, 2024 and is applicable to the Company&#8217;s fiscal year beginning January 1, 2025, with early application permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disaggregation of Income Statement Expenses (Topic 220)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The requirements in this ASU may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_RecentlyIssuedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_RecentlyIssuedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets and Liabilities that are Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:32.48%;box-sizing:content-box;"></td>
         <td style="width:1.7%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.7%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.7%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.7%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,331</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,331</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,331</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,331</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities (Note 4):</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury bills</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,287</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,287</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,890</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,890</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total available-for-sale securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,177</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,177</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">259,508</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">259,508</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities (Note 2):</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:33.44%;box-sizing:content-box;"></td>
         <td style="width:1.68%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.96%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.68%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.96%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.68%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.96%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.68%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.96%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,088</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,088</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury bills</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,434</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,434</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,522</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,522</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Available-for-sale securities (Note 4):</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury bills</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,895</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,895</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,790</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,790</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total available-for-sale securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,685</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,685</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104,207</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104,207</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities (Note 2):</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Significant Unobservable Inputs Used in Valuing Developmental Milestone Derivative Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant unobservable inputs used in valuing the developmental milestone derivative liabilities at each measurement date are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:27.267%;box-sizing:content-box;"></td>
         <td style="width:1.01%;box-sizing:content-box;"></td>
         <td style="width:17.168%;box-sizing:content-box;"></td>
         <td style="width:1.01%;box-sizing:content-box;"></td>
         <td style="width:17.168%;box-sizing:content-box;"></td>
         <td style="width:1.01%;box-sizing:content-box;"></td>
         <td style="width:17.047%;box-sizing:content-box;"></td>
         <td style="width:1.01%;box-sizing:content-box;"></td>
         <td style="width:17.31%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unobservable Input</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Range</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Range</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Probability of achieving certain development milestones</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discount Rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Timing of achieving certain development milestones</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Summary of Fair Value of Derivative Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents a roll forward of activity associated with the Company&#8217;s derivative liabilities measured using Level 3 inputs:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:78.54%;box-sizing:content-box;"></td>
         <td style="width:2.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.28%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Developmental Milestone Derivative Liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of derivative liabilities as of January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of derivative liabilities</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,550</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of derivative liabilities as of June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available-for-Sale Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the Company's available-for-sale securities is presented below:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:49.39%;box-sizing:content-box;"></td>
         <td style="width:1.239%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.093%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.279%;box-sizing:content-box;"></td>
         <td style="width:1.239%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.093%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.239%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.093%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.239%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.093%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="15" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury bills maturing in one year or less</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,290</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,287</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds maturing in one year or less</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,925</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,890</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total available-for-sale securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,215</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,177</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.03%;box-sizing:content-box;"></td>
         <td style="width:1.259%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.232%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.259%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.232%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.259%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.232%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.259%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.232%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gain</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury bills maturing in one year or less</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,879</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,895</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government bonds maturing in one year or less</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,759</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,790</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total available-for sale securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,638</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,685</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66%;box-sizing:content-box;"></td>
         <td style="width:3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.899999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, <br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,235</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,731</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid other and other current assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,295</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,651</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,530</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,382</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.72%;box-sizing:content-box;"></td>
         <td style="width:1.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, <br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,944</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,268</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,618</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,221</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued milestone payment (Note 2)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,984</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,363</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,546</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,852</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below summarizes the activity with respect to stock options for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.91%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:6.841%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining Contractual Life (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,927,937</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.22</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.01</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">193</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">642,148</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.56</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,733</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,165</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67.13</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeitures</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,882</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.09</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,324,305</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.93</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.14</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">467</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest at June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,324,305</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.93</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.14</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">467</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,668,986</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.64</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.41</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in the Black-Scholes option-pricing model for all stock options granted during each period presented are as follows:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:44.4%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:13.14%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:13.14%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:12.42%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:12.42%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.58</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.51</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.10</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.58</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.76</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.85</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112.1</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128.7</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividends</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.31</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.31</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.25</span></span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Equity-based Compensation Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has classified equity-based compensation expense in its condensed consolidated statements of operations as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:43.4%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,116</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">832</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,218</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,380</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,029</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,260</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,268</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,323</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,145</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,092</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,486</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,703</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes activity with respect to RSUs during the six months ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.58%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Units</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested RSUs at January 1, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,480,272</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.50</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,188,256</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.23</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">280,159</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.76</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeitures</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">286,245</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.73</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested RSUs at June 30, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,102,124</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.72</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Summary of Performance Stock Units Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes activity with respect to PSUs during the six months ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67%;box-sizing:content-box;"></td>
         <td style="width:1.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.44%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.96%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Units</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested PSUs at January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,165,325</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.51</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeitures</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91,137</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.51</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested PSUs at June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,074,188</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.51</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of the Company's basic and diluted net loss per share:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:42.4%;box-sizing:content-box;"></td>
         <td style="width:1.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,480</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,072</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78,762</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,375</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares used to compute net loss per share, basic and <br/>&#160;&#160;&#160;diluted</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average shares of common stock <br/>&#160;&#160;&#160;outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,539,468</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,221,883</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,476,597</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,981,426</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average shares of pre-funded warrants to <br/>&#160;&#160;&#160;purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,600,818</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,712,478</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,840,991</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,563,441</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average shares of common stock <br/>&#160;&#160;&#160;outstanding used to compute basic and diluted <br/>&#160;&#160;&#160;net loss per share</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,140,286</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,934,361</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,317,588</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,544,867</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.42</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.61</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.25</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The outstanding securities presented below were excluded from the calculation of net loss per share because the inclusion of such securities would have been anti-dilutive due to the Company&#8217;s net loss per share during the periods presented.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.552%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.903%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.903%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three and Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,324,305</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,890,045</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested restricted stock units</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,102,124</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,397,063</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested performance stock units</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,074,188</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,165,325</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares subject to employee stock purchase plan</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216,802</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250,188</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,563</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,230</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,719,982</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,711,851</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Segment Expenses, Other Segment Items, and Segment Net Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents segment expenses, other segment items, and segment net loss for the periods presented:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.05%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.402%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.402%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.402%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.742%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Segment expenses:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-003</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,219</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,434</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,385</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,340</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SGT-501</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,223</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,422</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,689</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,229</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External R&amp;D other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,116</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,845</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,886</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,573</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal R&amp;D expense</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,765</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,921</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,608</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,298</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External G&amp;A expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,279</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,449</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,156</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,883</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal G&amp;A expense</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,360</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,037</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,003</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,731</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,680</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,198</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,324</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,213</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,716</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,983</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,275</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Condensed consolidated net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,480</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,072</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78,762</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,375</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:4.86%;box-sizing:content-box;"></td>
         <td style="width:95.14%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal expenses consisted primarily of payroll and related costs, temporary services, and travel and entertainment.</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items primarily included other program costs, equity-based compensation expense, and depreciation and amortization expense.</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and available-for-sale securities</a></td>
<td class="nump">$ 268.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FA212 Asset Acquisition - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Sep. 19, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="nump">$ 3,150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sldb_Fa212LlcMember', window );">FA212 LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionDateOfAcquisitionAgreement', window );">Agreement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 19,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_AssetAcquisitionUpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Aggregate acquisition cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_AssetAcquisitionTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_FirstDevelopmentMilestonePayable', window );">First development milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_MilestoneLiabilityPayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sldb_Fa212LlcMember', window );">FA212 LLC [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_FirstDevelopmentMilestonePaymentInShares', window );">First development milestone payment in shares</a></td>
<td class="nump">975,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sldb_Fa212LlcMember', window );">FA212 LLC [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_DevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_CumulativeSalesMilestonePayments', window );">Cumulative sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments', window );">Assumed contingent development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments', window );">Assumed regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments', window );">Assumed cumulative sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition, assumed contingent development milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition, assumed cumulative sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition, assumed regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_AssetAcquisitionTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_AssetAcquisitionTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_AssetAcquisitionUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_AssetAcquisitionUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_CumulativeSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_CumulativeSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_DevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_DevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_FirstDevelopmentMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>First development milestone payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_FirstDevelopmentMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_FirstDevelopmentMilestonePaymentInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>First development milestone payment in shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_FirstDevelopmentMilestonePaymentInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_MilestoneLiabilityPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone liability payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_MilestoneLiabilityPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionDateOfAcquisitionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when asset acquisition agreement is executed, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionDateOfAcquisitionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=sldb_Fa212LlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=sldb_Fa212LlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">$ 130,331<span></span>
</td>
<td class="nump">$ 35,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available-for-sale securities</a></td>
<td class="nump">129,177<span></span>
</td>
<td class="nump">68,685<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">259,508<span></span>
</td>
<td class="nump">104,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">3,150<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">3,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=sldb_TreasuryBillMember', window );">Treasury Bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available-for-sale securities</a></td>
<td class="nump">42,287<span></span>
</td>
<td class="nump">27,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=sldb_GovernmentBondsMember', window );">Government Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available-for-sale securities</a></td>
<td class="nump">86,890<span></span>
</td>
<td class="nump">40,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">130,331<span></span>
</td>
<td class="nump">18,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">130,331<span></span>
</td>
<td class="nump">35,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available-for-sale securities</a></td>
<td class="nump">129,177<span></span>
</td>
<td class="nump">68,685<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">259,508<span></span>
</td>
<td class="nump">104,207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Treasury Bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available-for-sale securities</a></td>
<td class="nump">42,287<span></span>
</td>
<td class="nump">27,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Government Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">86,890<span></span>
</td>
<td class="nump">40,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash equivalents</a></td>
<td class="nump">130,331<span></span>
</td>
<td class="nump">18,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">3,150<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="nump">$ 3,150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sldb_TreasuryBillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sldb_TreasuryBillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sldb_GovernmentBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sldb_GovernmentBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Significant Unobservable Inputs Used in Valuing Developmental Milestone Derivative Liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>yr</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>yr</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities, Fair Value | $</a></td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="nump">$ 3,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities, Fair Value | $</a></td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="nump">$ 3,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Probability of Achieving Certain Development Milestones [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative Liabilities, Unobservable Input</a></td>
<td class="nump">0.28<span></span>
</td>
<td class="nump">0.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Probability of Achieving Certain Development Milestones [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative Liabilities, Unobservable Input</a></td>
<td class="nump">0.70<span></span>
</td>
<td class="nump">0.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Probability of Achieving Certain Development Milestones [Member] | Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative Liabilities, Unobservable Input</a></td>
<td class="nump">0.49<span></span>
</td>
<td class="nump">0.49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative Liabilities, Unobservable Input</a></td>
<td class="nump">0.93<span></span>
</td>
<td class="nump">0.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Volatility [Member] | Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative Liabilities, Unobservable Input</a></td>
<td class="nump">0.93<span></span>
</td>
<td class="nump">0.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Discount Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative Liabilities, Unobservable Input</a></td>
<td class="nump">0.037<span></span>
</td>
<td class="nump">0.042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Discount Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative Liabilities, Unobservable Input</a></td>
<td class="nump">0.043<span></span>
</td>
<td class="nump">0.043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Discount Rate [Member] | Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative Liabilities, Unobservable Input</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="nump">0.043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Timing of Achieving Certain Development Milestones [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative Liabilities, Unobservable Input</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Timing of Achieving Certain Development Milestones [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative Liabilities, Unobservable Input</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Timing of Achieving Certain Development Milestones [Member] | Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative Liabilities, Unobservable Input</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sldb_ProbabilityOfAchievingCertainDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sldb_ProbabilityOfAchievingCertainDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sldb_TimingOfAchievingCertainDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sldb_TimingOfAchievingCertainDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Fair Value of Derivative Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liabilities as of January 1, 2025</a></td>
<td class="nump">$ 3,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_ChangeInFairValueOfDerivativeLiabilities', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">2,550<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liabilities as of March 31, 2025</a></td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_ChangeInFairValueOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_ChangeInFairValueOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities at fair value</a></td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Gain (loss) recorded for a change in fair value</a></td>
<td class="num">(900,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(2,600,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Fair value, assets, transfers into level 3, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Fair value, assets, transfers out of level 3, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2', window );">Fair value, assets, transfers into level 2, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2', window );">Fair value, assets, transfers out of level 2, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1', window );">Fair value, assets, transfers into level 1, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1', window );">Fair value, assets, transfers out of level 1, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Fair value, liabilities, transfers into level 3, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Fair value, liabilities, transfers out of level 3, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2', window );">Fair value, liabilities, transfers into level 2, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2', window );">Fair value, liabilities, transfers out of level 2, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1', window );">Fair value, liabilities, transfers into level 1, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1', window );">Fair value, liabilities, transfers out of level 1, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities at fair value</a></td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In to Level 2</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability transfers in to level 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability transfers in to level 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability transfers out of level 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability transfers out of level 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale Securities - Schedule of Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 129,215<span></span>
</td>
<td class="nump">$ 68,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">129,177<span></span>
</td>
<td class="nump">68,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=sldb_TreasuryBillMember', window );">Treasury Bills Maturing in One Year or Less [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">42,290<span></span>
</td>
<td class="nump">27,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">42,287<span></span>
</td>
<td class="nump">27,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=sldb_GovernmentBondsMember', window );">Government Bonds Maturing in One Year or Less [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">86,925<span></span>
</td>
<td class="nump">40,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 86,890<span></span>
</td>
<td class="nump">$ 40,790<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sldb_TreasuryBillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sldb_TreasuryBillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sldb_GovernmentBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sldb_GovernmentBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale Securities - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_AvailableForSaleSecuritiesWeightedAverageMaturityPeriod', window );">Available-for-sale securities average maturity period</a></td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_AvailableForSaleSecuritiesWeightedAverageMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities Weighted Average Maturity period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_AvailableForSaleSecuritiesWeightedAverageMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_PrepaidResearchAndDevelopmentExpensesCurrent', window );">Prepaid research and development expenses</a></td>
<td class="nump">$ 7,235<span></span>
</td>
<td class="nump">$ 6,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_PrepaidOtherAndOtherCurrentAssets', window );">Prepaid other and other current assets</a></td>
<td class="nump">3,295<span></span>
</td>
<td class="nump">1,651<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 10,530<span></span>
</td>
<td class="nump">$ 8,382<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_PrepaidOtherAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid other and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_PrepaidOtherAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_PrepaidResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development expenses, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_PrepaidResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems', window );"><strong>Accrued Expenses And Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 16,546<span></span>
</td>
<td class="nump">$ 19,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=sldb_AccruedResearchAndDevelopmentExpenseMember', window );">Accrued Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems', window );"><strong>Accrued Expenses And Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">9,944<span></span>
</td>
<td class="nump">7,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=sldb_AccruedCompensationMember', window );">Accrued Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems', window );"><strong>Accrued Expenses And Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">4,618<span></span>
</td>
<td class="nump">6,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=sldb_AccruedMilestonePaymentMember', window );">Accrued Milestone Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems', window );"><strong>Accrued Expenses And Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember', window );">Accrued Other and Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems', window );"><strong>Accrued Expenses And Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 1,984<span></span>
</td>
<td class="nump">$ 1,363<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses And Other Current Liabilities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=sldb_AccruedResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=sldb_AccruedResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=sldb_AccruedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=sldb_AccruedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=sldb_AccruedMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=sldb_AccruedMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 19, 2025</div></th>
<th class="th"><div>Jan. 11, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_ClassOfWarrantOrRightsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Company received net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sldb_February2025OfferingMember', window );">February 2025 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from offering</a></td>
<td class="nump">$ 188.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,739,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,973,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,973,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | February 2025 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued and sold</a></td>
<td class="nump">35,739,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock issued price per share</a></td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sldb_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,712,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrants exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sldb_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member] | February 2025 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">13,888,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_ClassOfWarrantOrRightPricePerShare', window );">Common stock warrants price per share</a></td>
<td class="nump">$ 4.029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_ClassOfWarrantOrRightPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_ClassOfWarrantOrRightPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_ClassOfWarrantOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_ClassOfWarrantOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sldb_February2025OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sldb_February2025OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sldb_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sldb_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,145<span></span>
</td>
<td class="nump">$ 2,092<span></span>
</td>
<td class="nump">$ 6,486<span></span>
</td>
<td class="nump">$ 3,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">832<span></span>
</td>
<td class="nump">2,218<span></span>
</td>
<td class="nump">1,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,029<span></span>
</td>
<td class="nump">$ 1,260<span></span>
</td>
<td class="nump">$ 4,268<span></span>
</td>
<td class="nump">$ 2,323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 12, 2025</div></th>
<th class="th"><div>Jun. 11, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,324,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,324,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,927,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Common stock purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">642,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.84<span></span>
</td>
<td class="nump">$ 6.52<span></span>
</td>
<td class="nump">$ 3.83<span></span>
</td>
<td class="nump">$ 6.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,145<span></span>
</td>
<td class="nump">$ 2,092<span></span>
</td>
<td class="nump">$ 6,486<span></span>
</td>
<td class="nump">$ 3,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,486<span></span>
</td>
<td class="nump">3,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,188,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized equity-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized equity-based compensation cost, weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized equity-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized equity-based compensation cost, weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Description of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each PSU represents the contingent right to receive one share of the Company&#8217;s common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sldb_UnvestedStockOptionsMember', window );">Unvested Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized equity-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized equity-based compensation cost, weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sldb_TwoThousandAndTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,450,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,450,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sldb_TwoThousandAndTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Stock units outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,433,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,433,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sldb_TwoThousandAndTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Stock units outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,074,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,074,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember', window );">Amended and Restated 2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of shares of common stock reserved for issuance</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember', window );">2024 Inducement Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for common stock for equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Stock units outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,173,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,173,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sldb_UnvestedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sldb_UnvestedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sldb_TwoThousandAndTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sldb_TwoThousandAndTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation - Summary Of Stock Option Activity (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at January 1, 2025 | shares</a></td>
<td class="nump">2,927,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">642,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised | shares</a></td>
<td class="num">(2,733)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired | shares</a></td>
<td class="num">(139,165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeitures | shares</a></td>
<td class="num">(103,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at June 30, 2025 | shares</a></td>
<td class="nump">3,324,305<span></span>
</td>
<td class="nump">2,927,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at June 30, 2025 | shares</a></td>
<td class="nump">3,324,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at June 30, 2025 | shares</a></td>
<td class="nump">1,668,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at January 1, 2025 | $ / shares</a></td>
<td class="nump">$ 18.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">4.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised | $ / shares</a></td>
<td class="nump">2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired | $ / shares</a></td>
<td class="nump">67.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeitures | $ / shares</a></td>
<td class="nump">6.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at June 30, 2025 | $ / shares</a></td>
<td class="nump">13.93<span></span>
</td>
<td class="nump">$ 18.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at June 30, 2025 | $ / shares</a></td>
<td class="nump">13.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at June 30, 2025 | $ / shares</a></td>
<td class="nump">$ 21.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Remaining Contractual Life (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">8 years 1 month 20 days<span></span>
</td>
<td class="text">8 years 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at June 30, 2025</a></td>
<td class="text">8 years 1 month 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at June 30, 2025</a></td>
<td class="text">7 years 4 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 467<span></span>
</td>
<td class="nump">$ 193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, Aggregate Intrinsic Value | $</a></td>
<td class="nump">467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice', window );">Common stock price</a></td>
<td class="nump">$ 4.58<span></span>
</td>
<td class="nump">$ 7.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">114.20%<span></span>
</td>
<td class="nump">122.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.10%<span></span>
</td>
<td class="nump">122.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114.20%<span></span>
</td>
<td class="nump">128.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free rate, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free rate, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice', window );">Common stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="nump">$ 5.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice', window );">Common stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.58<span></span>
</td>
<td class="nump">$ 7.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, fair value assumptions common stock price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Summary of Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested RSUs/PSUs at January 1, 2025 | shares</a></td>
<td class="nump">1,480,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">2,188,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(280,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeitures | shares</a></td>
<td class="num">(286,245)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested RSUs/PSUs at June 30, 2025 | shares</a></td>
<td class="nump">3,102,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested RSUs/PSUs at January 1, 2025 | $ / shares</a></td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">3.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">7.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeitures | $ / shares</a></td>
<td class="nump">4.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested RSUs/PSUs at June 30, 2025 | $ / shares</a></td>
<td class="nump">$ 4.72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Summary of Performance Stock Units Activity (Details) - Performance Stock Units [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested RSUs/PSUs at January 1, 2025 | shares</a></td>
<td class="nump">2,165,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeitures | shares</a></td>
<td class="num">(91,137)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested RSUs/PSUs at June 30, 2025 | shares</a></td>
<td class="nump">2,074,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested RSUs/PSUs at January 1, 2025 | $ / shares</a></td>
<td class="nump">$ 7.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeitures | $ / shares</a></td>
<td class="nump">7.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested RSUs/PSUs at June 30, 2025 | $ / shares</a></td>
<td class="nump">$ 7.51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=sldb_OfficeAndLaboratoryLeaseMember', window );">Office and Laboratory Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit outstanding amount</a></td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_CommitmentAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_CommitmentAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=sldb_OfficeAndLaboratoryLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=sldb_OfficeAndLaboratoryLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule Computation of Basic and Diluted Net Loss per Share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (39,480)<span></span>
</td>
<td class="num">$ (39,282)<span></span>
</td>
<td class="num">$ (25,072)<span></span>
</td>
<td class="num">$ (24,303)<span></span>
</td>
<td class="num">$ (78,762)<span></span>
</td>
<td class="num">$ (49,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding, basic</a></td>
<td class="nump">94,140,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,934,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,317,588<span></span>
</td>
<td class="nump">39,544,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding, diluted</a></td>
<td class="nump">94,140,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,934,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,317,588<span></span>
</td>
<td class="nump">39,544,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="num">$ (1.25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="num">$ (1.25)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding, basic</a></td>
<td class="nump">77,539,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,221,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,476,597<span></span>
</td>
<td class="nump">36,981,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding, diluted</a></td>
<td class="nump">77,539,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,221,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,476,597<span></span>
</td>
<td class="nump">36,981,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sldb_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding, basic</a></td>
<td class="nump">16,600,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,712,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,840,991<span></span>
</td>
<td class="nump">2,563,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding, diluted</a></td>
<td class="nump">16,600,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,712,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,840,991<span></span>
</td>
<td class="nump">2,563,441<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sldb_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sldb_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants', window );">Common stock issuable upon exercise of pre-funded warrants</a></td>
<td class="nump">16,600,818<span></span>
</td>
<td class="nump">2,712,478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issuable upon exercise of prefunded warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sldb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net loss per share</a></td>
<td class="nump">8,719,982<span></span>
</td>
<td class="nump">6,711,851<span></span>
</td>
<td class="nump">8,719,982<span></span>
</td>
<td class="nump">6,711,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net loss per share</a></td>
<td class="nump">3,324,305<span></span>
</td>
<td class="nump">2,890,045<span></span>
</td>
<td class="nump">3,324,305<span></span>
</td>
<td class="nump">2,890,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Nonvested Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net loss per share</a></td>
<td class="nump">3,102,124<span></span>
</td>
<td class="nump">1,397,063<span></span>
</td>
<td class="nump">3,102,124<span></span>
</td>
<td class="nump">1,397,063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">Nonvested Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net loss per share</a></td>
<td class="nump">2,074,188<span></span>
</td>
<td class="nump">2,165,325<span></span>
</td>
<td class="nump">2,074,188<span></span>
</td>
<td class="nump">2,165,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Shares Subject to Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net loss per share</a></td>
<td class="nump">216,802<span></span>
</td>
<td class="nump">250,188<span></span>
</td>
<td class="nump">216,802<span></span>
</td>
<td class="nump">250,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net loss per share</a></td>
<td class="nump">2,563<span></span>
</td>
<td class="nump">9,230<span></span>
</td>
<td class="nump">2,563<span></span>
</td>
<td class="nump">9,230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment reporting, CODM, profit (loss) measure, how used, description</a></td>
<td class="text">The CODM assesses performance for the Company and decides how to allocate resources based on net loss as reported on the condensed consolidated statements of operations. The annual budgeting process is the primary mechanism used to make these decisions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Schedule of Segment Expenses, Other Segment Items, and Segment Net Loss (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 32,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,329<span></span>
</td>
<td class="nump">$ 38,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">9,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,416<span></span>
</td>
<td class="nump">16,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Condensed consolidated net loss</a></td>
<td class="num">(39,480)<span></span>
</td>
<td class="num">$ (39,282)<span></span>
</td>
<td class="num">(25,072)<span></span>
</td>
<td class="num">$ (24,303)<span></span>
</td>
<td class="num">(78,762)<span></span>
</td>
<td class="num">(49,375)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="nump">8,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,198<span></span>
</td>
<td class="nump">11,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="num">(2,213)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,716)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,983)<span></span>
</td>
<td class="num">(5,275)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Condensed consolidated net loss</a></td>
<td class="num">(39,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,072)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,762)<span></span>
</td>
<td class="num">(49,375)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segment [Member] | SGT-003 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">12,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,385<span></span>
</td>
<td class="nump">4,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segment [Member] | SGT-501 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">2,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,689<span></span>
</td>
<td class="nump">7,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segment [Member] | External Research and Development Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense, other</a></td>
<td class="nump">3,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,886<span></span>
</td>
<td class="nump">4,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segment [Member] | Internal Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">6,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,608<span></span>
</td>
<td class="nump">10,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segment [Member] | External General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">5,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,156<span></span>
</td>
<td class="nump">10,883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segment [Member] | Internal General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">$ 3,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,823<span></span>
</td>
<td class="nump">$ 6,003<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sldb_SGT003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sldb_SGT003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sldb_SGT501Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sldb_SGT501Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sldb_ExternalResearchAndDevelopmentOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sldb_ExternalResearchAndDevelopmentOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sldb_InternalResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sldb_InternalResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sldb_ExternalGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sldb_ExternalGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sldb_InternalGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sldb_InternalGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>222</ContextCount>
  <ElementCount>259</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>75010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>75020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>75030 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>75040 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>75050 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>75060 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>75070 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>75080 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995465 - Disclosure - FA212 Asset Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisition</Role>
      <ShortName>FA212 Asset Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Available-for-Sale Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecurities</Role>
      <ShortName>Available-for-Sale Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Equity-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensation</Role>
      <ShortName>Equity-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShare1</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Nature of the Business and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies</Role>
      <ShortName>Nature of the Business and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Available-for-Sale Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables</Role>
      <ShortName>Available-for-Sale Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecurities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Equity-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables</Role>
      <ShortName>Equity-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShare1</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReporting</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995755 - Disclosure - FA212 Asset Acquisition - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail</Role>
      <ShortName>FA212 Asset Acquisition - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Fair Value Measurements - Summary of Significant Unobservable Inputs Used in Valuing Developmental Milestone Derivative Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Significant Unobservable Inputs Used in Valuing Developmental Milestone Derivative Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Fair Value Measurements - Summary of Fair Value of Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfDerivativeLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Fair Value of Derivative Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Available-for-Sale Securities - Schedule of Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail</Role>
      <ShortName>Available-for-Sale Securities - Schedule of Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Available-for-Sale Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Available-for-Sale Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetail</Role>
      <ShortName>Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Equity-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Equity-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Equity Based Compensation - Summary Of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail</Role>
      <ShortName>Equity Based Compensation - Summary Of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Equity-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail</Role>
      <ShortName>Equity-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Equity-Based Compensation - Summary of Restricted Stock Unit Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail</Role>
      <ShortName>Equity-Based Compensation - Summary of Restricted Stock Unit Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Equity-Based Compensation - Summary of Performance Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails</Role>
      <ShortName>Equity-Based Compensation - Summary of Performance Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Net Loss Per Share - Schedule Computation of Basic and Diluted Net Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Loss Per Share - Schedule Computation of Basic and Diluted Net Loss per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995985 - Disclosure - Net Loss Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Segment Reporting - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail</Role>
      <ShortName>Segment Reporting - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sldb-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Segment Reporting - Schedule of Segment Expenses, Other Segment Items, and Segment Net Loss (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail</Role>
      <ShortName>Segment Reporting - Schedule of Segment Expenses, Other Segment Items, and Segment Net Loss (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="sldb-20250630.htm">sldb-20250630.htm</File>
    <File>sldb-20250630.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img247595994_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="647">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sldb-20250630.htm": {
   "nsprefix": "sldb",
   "nsuri": "http://www.solidbio.com/20250630",
   "dts": {
    "inline": {
     "local": [
      "sldb-20250630.htm"
     ]
    },
    "schema": {
     "local": [
      "sldb-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 218,
   "keyCustom": 41,
   "axisStandard": 16,
   "axisCustom": 0,
   "memberStandard": 21,
   "memberCustom": 23,
   "hidden": {
    "total": 25,
    "http://www.solidbio.com/20250630": 12,
    "http://fasb.org/us-gaap/2024": 9,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 222,
   "entityCount": 1,
   "segmentCount": 47,
   "elementCount": 671,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 647,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "75000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
     "longName": "75010 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "75020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations",
     "longName": "75030 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_583bdf28-4c22-41d2-bf7a-5f216b481995",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_583bdf28-4c22-41d2-bf7a-5f216b481995",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss",
     "longName": "75040 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_583bdf28-4c22-41d2-bf7a-5f216b481995",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_583bdf28-4c22-41d2-bf7a-5f216b481995",
      "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "75050 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_72a44744-a858-4632-9155-e3c3f22a4ca6",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1e60639d-8283-41ae-8cd9-7b46f80766be",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical",
     "longName": "75060 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_0c822986-4362-4137-a232-16bb78f035a6",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c822986-4362-4137-a232-16bb78f035a6",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows",
     "longName": "75070 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical",
     "longName": "75080 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_11726ae9-e40d-4c5b-83b8-8005c97ded06",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_583bdf28-4c22-41d2-bf7a-5f216b481995",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_583bdf28-4c22-41d2-bf7a-5f216b481995",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation",
     "longName": "995455 - Disclosure - Nature of the Business and Basis of Presentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisition",
     "longName": "995465 - Disclosure - FA212 Asset Acquisition",
     "shortName": "FA212 Asset Acquisition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurements",
     "longName": "995495 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecurities",
     "longName": "995505 - Disclosure - Available-for-Sale Securities",
     "shortName": "Available-for-Sale Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "longName": "995525 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "sldb:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "sldb:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "995535 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquity",
     "longName": "995545 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensation",
     "longName": "995555 - Disclosure - Equity-Based Compensation",
     "shortName": "Equity-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995585 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShare1",
     "longName": "995595 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReporting",
     "longName": "995605 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSubsequentEvents",
     "longName": "995615 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies",
     "longName": "995625 - Disclosure - Nature of the Business and Basis of Presentation (Policies)",
     "shortName": "Nature of the Business and Basis of Presentation (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "sldb:RecentlyIssuedAccountingPronouncementsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "sldb:RecentlyIssuedAccountingPronouncementsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "longName": "995655 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables",
     "longName": "995665 - Disclosure - Available-for-Sale Securities (Tables)",
     "shortName": "Available-for-Sale Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "995685 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "sldb:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "sldb:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "995695 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "sldb:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "sldb:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables",
     "longName": "995705 - Disclosure - Equity-Based Compensation (Tables)",
     "shortName": "Equity-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareTables",
     "longName": "995715 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingTables",
     "longName": "995725 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
     "longName": "995745 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail)",
     "shortName": "Nature of the Business and Basis of Presentation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail",
     "longName": "995755 - Disclosure - FA212 Asset Acquisition - Additional Information (Detail)",
     "shortName": "FA212 Asset Acquisition - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "us-gaap:DerivativeLiabilities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_43934480-1ee4-495d-8199-c3e8feb3750c",
      "name": "us-gaap:AssetAcquisitionDateOfAcquisitionAgreement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail",
     "longName": "995795 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Detail)",
     "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail",
     "longName": "995805 - Disclosure - Fair Value Measurements - Summary of Significant Unobservable Inputs Used in Valuing Developmental Milestone Derivative Liabilities (Detail)",
     "shortName": "Fair Value Measurements - Summary of Significant Unobservable Inputs Used in Valuing Developmental Milestone Derivative Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "us-gaap:DerivativeLiabilities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b47160b-f65e-4831-8696-c2c52dd0bc33",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfDerivativeLiabilitiesDetails",
     "longName": "995815 - Disclosure - Fair Value Measurements - Summary of Fair Value of Derivative Liabilities (Details)",
     "shortName": "Fair Value Measurements - Summary of Fair Value of Derivative Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9",
      "name": "us-gaap:DerivativeLiabilities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
     "longName": "995825 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "us-gaap:DerivativeLiabilities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_583bdf28-4c22-41d2-bf7a-5f216b481995",
      "name": "us-gaap:LiabilitiesFairValueAdjustment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail",
     "longName": "995835 - Disclosure - Available-for-Sale Securities - Schedule of Available-for-Sale Securities (Detail)",
     "shortName": "Available-for-Sale Securities - Schedule of Available-for-Sale Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail",
     "longName": "995845 - Disclosure - Available-for-Sale Securities - Additional Information (Detail)",
     "shortName": "Available-for-Sale Securities - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "sldb:AvailableForSaleSecuritiesWeightedAverageMaturityPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "sldb:AvailableForSaleSecuritiesWeightedAverageMaturityPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
     "longName": "995855 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "sldb:PrepaidResearchAndDevelopmentExpensesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "sldb:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "sldb:PrepaidResearchAndDevelopmentExpensesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "sldb:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail",
     "longName": "995865 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be626f41-f068-4534-943f-caf740d9baca",
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sldb:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
     "longName": "995875 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "sldb:ClassOfWarrantOrRightsExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "sldb:ClassOfWarrantOrRightsExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetail",
     "longName": "995885 - Disclosure - Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Detail)",
     "shortName": "Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_583bdf28-4c22-41d2-bf7a-5f216b481995",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0a6c72f5-7161-423a-a27c-3a3a231889bb",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail",
     "longName": "995895 - Disclosure - Equity-Based Compensation - Additional Information (Detail)",
     "shortName": "Equity-Based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_e98d2034-0473-4580-b8ab-275ff9f46ae7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_583bdf28-4c22-41d2-bf7a-5f216b481995",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail",
     "longName": "995905 - Disclosure - Equity Based Compensation - Summary Of Stock Option Activity (Detail)",
     "shortName": "Equity Based Compensation - Summary Of Stock Option Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail",
     "longName": "995915 - Disclosure - Equity-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted (Detail)",
     "shortName": "Equity-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_583bdf28-4c22-41d2-bf7a-5f216b481995",
      "name": "sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_583bdf28-4c22-41d2-bf7a-5f216b481995",
      "name": "sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail",
     "longName": "995925 - Disclosure - Equity-Based Compensation - Summary of Restricted Stock Unit Activity (Detail)",
     "shortName": "Equity-Based Compensation - Summary of Restricted Stock Unit Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_583384bc-be95-42dd-89bf-a2fab8449504",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_583384bc-be95-42dd-89bf-a2fab8449504",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
     "longName": "995935 - Disclosure - Equity-Based Compensation - Summary of Performance Stock Units Activity (Details)",
     "shortName": "Equity-Based Compensation - Summary of Performance Stock Units Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_41f2e884-47b6-44f0-b8af-b6fb07efc6e9",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_41f2e884-47b6-44f0-b8af-b6fb07efc6e9",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "995965 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_fb4b367c-a294-43f5-af08-b0aea809fc01",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb4b367c-a294-43f5-af08-b0aea809fc01",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail",
     "longName": "995975 - Disclosure - Net Loss Per Share - Schedule Computation of Basic and Diluted Net Loss per Share (Detail)",
     "shortName": "Net Loss Per Share - Schedule Computation of Basic and Diluted Net Loss per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_583bdf28-4c22-41d2-bf7a-5f216b481995",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c822986-4362-4137-a232-16bb78f035a6",
      "name": "us-gaap:EarningsPerShareDiluted",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:EarningsPerShareBasic",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
     "longName": "995985 - Disclosure - Net Loss Per Share - Additional Information (Detail)",
     "shortName": "Net Loss Per Share - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_583bdf28-4c22-41d2-bf7a-5f216b481995",
      "name": "sldb:CommonStockIssuableUponExerciseOfPrefundedWarrants",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_583bdf28-4c22-41d2-bf7a-5f216b481995",
      "name": "sldb:CommonStockIssuableUponExerciseOfPrefundedWarrants",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail",
     "longName": "995995 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Detail)",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_583bdf28-4c22-41d2-bf7a-5f216b481995",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_583bdf28-4c22-41d2-bf7a-5f216b481995",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail",
     "longName": "996005 - Disclosure - Segment Reporting - Additional Information (Detail)",
     "shortName": "Segment Reporting - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_020b0edf-b857-4f10-ac8b-229a8c436b55",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail",
     "longName": "996015 - Disclosure - Segment Reporting - Schedule of Segment Expenses, Other Segment Items, and Segment Net Loss (Detail)",
     "shortName": "Segment Reporting - Schedule of Segment Expenses, Other Segment Items, and Segment Net Loss (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_583bdf28-4c22-41d2-bf7a-5f216b481995",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cd72c633-01e1-43fb-bc8c-26f766ba3391",
      "name": "us-gaap:SegmentReportingOtherItemAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sldb-20250630.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "sldb_AavantibioIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AavantibioIncMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AavantiBio, Inc [Member]",
        "documentation": "AavantiBio, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r722"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of discount on available-for-sale securities",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "sldb_AccruedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AccruedCompensationMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued compensation.",
        "label": "Accrued Compensation [Member]",
        "terseLabel": "Accrued Compensation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_AccruedExpensesAndOtherCurrentLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesLineItems",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Expenses And Other Current Liabilities [Line Items]",
        "label": "Accrued Expenses And Other Current Liabilities [Line Items]",
        "terseLabel": "Accrued Expenses And Other Current Liabilities [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_AccruedExpensesAndOtherCurrentLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesTable",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Expenses And Other Current Liabilities [Table]",
        "label": "Accrued Expenses And Other Current Liabilities [Table]",
        "terseLabel": "Accrued Expenses And Other Current Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities Table [Text Block]",
        "terseLabel": "Summary of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_AccruedExpensesAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AccruedExpensesAndOtherMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued other.",
        "label": "Accrued Expenses And Other [Member]",
        "terseLabel": "Accrued Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_AccruedExpensesOtherAndOtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AccruedExpensesOtherAndOtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Other and Other Current Liabilities [Member]",
        "label": "Accrued Expenses Other and Other Current Liabilities [Member]",
        "documentation": "Accrued espenses other and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued Liabilities, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "sldb_AccruedMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AccruedMilestonePaymentMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Milestone Payment [Member]",
        "documentation": "Accrued milestone payment.",
        "terseLabel": "Accrued Milestone Payment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_AccruedResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AccruedResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Research And Development Expense [Member]",
        "documentation": "Accrued research and development expense.",
        "terseLabel": "Accrued Research and Development Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_AccruedRestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AccruedRestructuringCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued restructuring costs.",
        "periodEndLabel": "Accrued restructuring charges, ending balance",
        "periodStartLabel": "Accrued restructuring charges, beginning balance",
        "label": "Accrued restructuring costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r85",
      "r151",
      "r546",
      "r573",
      "r574"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r12",
      "r23",
      "r445",
      "r448",
      "r492",
      "r569",
      "r570",
      "r843",
      "r844",
      "r845",
      "r857",
      "r858",
      "r859",
      "r861"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r584",
      "r857",
      "r858",
      "r859",
      "r861",
      "r931",
      "r989"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "sldb_AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital, net of sales commissions.",
        "label": "Adjustments to Additional Paid in Capital, Net Of Sales Commissions",
        "terseLabel": "Sales commissions"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital, pre-funded warrants issued, issuance costs.",
        "label": "Adjustments to Additional Paid in Capital, Pre-funded Warrants Issued, Issuance Costs",
        "terseLabel": "Pre-funded warrants issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "terseLabel": "Equity-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r369"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r107"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of pre-funded warrants in public offering/private placement",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r43",
      "r107"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r748",
      "r758",
      "r768",
      "r800"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r761",
      "r771",
      "r803"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "sldb_AgreementTerminationNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AgreementTerminationNoticePeriod",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination notice period.",
        "label": "Agreement Termination Notice Period",
        "terseLabel": "Agreement termination notice period"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_AlexanderCumboMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AlexanderCumboMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alexander Cumbo [Member]",
        "documentation": "Alexander Cumbo.",
        "terseLabel": "Alexander Cumbo [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r796",
      "r804",
      "r808",
      "r816"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r403"
     ]
    },
    "sldb_AmendedAndRestatedTwoThousandAndTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AmendedAndRestatedTwoThousandAndTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended and Restated 2020 Equity Incentive Plan [Member]",
        "label": "Amended and Restated Two Thousand And Twenty Equity Incentive Plan [Member]",
        "documentation": "Amended and restated 2020 equity incentive plan member."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended and Restated 2020 Plan [Member]",
        "label": "Amended and Restated Two Thousand And Twenty Incentive Plan [Member]",
        "documentation": "Amended and restated two thousand and twenty incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_AmendmentAndRestatementOfEsppMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AmendmentAndRestatementOfEsppMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment and restatement of ESPP member.",
        "label": "Amendment and Restatement of ESPP [Member]",
        "terseLabel": "Amendment and Restatement of ESPP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Common stock equivalents excluded from calculation of diluted net loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "sldb_April2022CorporateStrategyChangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "April2022CorporateStrategyChangeMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2022 Corporate Strategy Change [Member]",
        "label": "April 2022 Corporate Strategy Change [Member]",
        "documentation": "April 2022 Corporate Strategy Change."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_April2022PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "April2022PlanMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2022 Plan [Member]",
        "label": "April 2022 Plan Member",
        "documentation": "April 2022 Plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of subleased agreement",
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_ArkeaBioCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "ArkeaBioCorpMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arkea bio corp.",
        "terseLabel": "Arkea Bio Corp [Member]",
        "label": "Arkea Bio Corp [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_AssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_AssetAcquisitionAssumedContingentDevelopmentMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AssetAcquisitionAssumedContingentDevelopmentMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition, assumed contingent development milestone payments.",
        "label": "Asset Acquisition, Assumed Contingent Development Milestone Payments",
        "terseLabel": "Assumed contingent development milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_AssetAcquisitionAssumedCumulativeSalesMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AssetAcquisitionAssumedCumulativeSalesMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition, assumed cumulative sales milestone payments.",
        "label": "Asset Acquisition, Assumed Cumulative Sales Milestone Payments",
        "terseLabel": "Assumed cumulative sales milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_AssetAcquisitionAssumedRegulatoryMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AssetAcquisitionAssumedRegulatoryMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition, assumed regulatory milestone payments.",
        "label": "Asset Acquisition, Assumed Regulatory Milestone Payments",
        "terseLabel": "Assumed regulatory milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r926"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "terseLabel": "Aggregate acquisition cost",
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r708",
      "r927",
      "r928",
      "r929"
     ]
    },
    "us-gaap_AssetAcquisitionDateOfAcquisitionAgreement": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionDateOfAcquisitionAgreement",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement date",
        "label": "Asset Acquisition, Date of Acquisition Agreement",
        "documentation": "Date when asset acquisition agreement is executed, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r926"
     ]
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "sldb_AssetAcquisitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AssetAcquisitionPolicyTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition",
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "FA212 Asset Acquisition",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "sldb_AssetAcquisitionTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AssetAcquisitionTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Asset Acquisition Transaction Costs",
        "documentation": "Asset acquisition transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_AssetAcquisitionUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AssetAcquisitionUpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment",
        "documentation": "Asset Acquisition Upfront Payment",
        "label": "Asset Acquisition Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r128",
      "r146",
      "r176",
      "r214",
      "r222",
      "r240",
      "r244",
      "r288",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r438",
      "r442",
      "r475",
      "r541",
      "r616",
      "r680",
      "r681",
      "r722",
      "r739",
      "r892",
      "r893",
      "r942"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r152",
      "r176",
      "r288",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r438",
      "r442",
      "r475",
      "r722",
      "r892",
      "r893",
      "r942"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r711"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r288",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r438",
      "r442",
      "r475",
      "r892",
      "r893",
      "r942"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_AtTheMarketOfferingSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AtTheMarketOfferingSalesAgreementMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market offering sales agreement member.",
        "label": "At-the-Market Offering Sales Agreement [Member]",
        "terseLabel": "At-the-Market Offering Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_AtTheMarketPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AtTheMarketPublicOfferingMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At The Market Public Offering [Member]",
        "documentation": "At the market public offering.",
        "terseLabel": "At-the-Market Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gain",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Loss",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r296",
      "r540"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total available-for-sale securities",
        "verboseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Total available-for-sale securities, fair value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r296",
      "r456",
      "r534",
      "r711",
      "r714",
      "r869",
      "r935",
      "r936",
      "r937"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Available-for-sale securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r296"
     ]
    },
    "sldb_AvailableForSaleSecuritiesWeightedAverageMaturityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "AvailableForSaleSecuritiesWeightedAverageMaturityPeriod",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Securities Weighted Average Maturity period",
        "label": "Available For Sale Securities Weighted Average Maturity Period",
        "terseLabel": "Available-for-sale securities average maturity period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r956",
      "r957"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r67",
      "r307",
      "r956",
      "r957"
     ]
    },
    "sldb_BuildingInteriorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "BuildingInteriorMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building Interior [Member]",
        "label": "building interior [Member]",
        "documentation": "Building interior."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r431",
      "r701",
      "r702"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r431",
      "r701",
      "r702"
     ]
    },
    "us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionDateOfAcquisitionAgreement1",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition, Acquisition completion date",
        "label": "Business Acquisition, Date of Acquisition Agreement",
        "documentation": "Date when the business acquisition agreement was executed, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionEffectiveDateOfAcquisition1",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition, effective date of acquisition",
        "label": "Business Acquisition, Effective Date of Acquisition",
        "documentation": "Date when the acquirer obtains control of the acquiree, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r15"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of common stock",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition, share price",
        "label": "Business Acquisition, Share Price",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss before taxes",
        "label": "Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax",
        "documentation": "Amount after tax of pro forma income from continuing operations as if the business combination had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Business Acquisition, Pro Forma Revenue",
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition related costs",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail": {
       "parentTag": "sldb_GainLossOnAcquisitionOfBusiness",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total consideration paid",
        "totalLabel": "Total consideration paid",
        "verboseLabel": "Total purchase price",
        "terseLabel": "Cash",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r11"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisition1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r432"
     ]
    },
    "sldb_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseLiabilitiesExcludingCurrentPortion",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, excluding current portion",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Operating lease liabilities, excluding current portion",
        "documentation": "Business combination, Recognized identifiable asset acquired and liability assumed, Operating lease liabilities, excluding current portion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued expenses",
        "terseLabel": "Accrued expenses",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Operating lease liabilities",
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed current liabilities operating lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders' Equity",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net assets acquired",
        "terseLabel": "Net assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60"
     ]
    },
    "sldb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, right-of-use asset",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease, right-of-use asset",
        "documentation": "Business combination, Recognized identifiable assets acquired and liabilities assumed, Operating lease, Right-of-use asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60"
     ]
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One time transaction costs",
        "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Costs",
        "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, fair value",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value",
        "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of the Business and Basis of Presentation",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r96",
      "r97"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases included in accounts payable and accrued expenses",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
      "http://www.solidbio.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents as presented on balance sheet",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r144",
      "r667"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r119"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and available-for-sale securities",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.solidbio.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash, as reported in the condensed consolidated statements of cash flows",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r93",
      "r174"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r93"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r953"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash investing and operating activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r733",
      "r734",
      "r735",
      "r736"
     ]
    },
    "sldb_ChangeInFairValueOfDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "ChangeInFairValueOfDerivativeLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfDerivativeLiabilitiesDetails",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value Of Derivative Liabilities",
        "documentation": "Change in fair value of derivative liabilities.",
        "verboseLabel": "Change in fair value of derivative liabilities",
        "negatedTerseLabel": "Change in fair value of derivative liabilities",
        "negatedLabel": "Change in fair value of derivative liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r216",
      "r337",
      "r338",
      "r339",
      "r341",
      "r344",
      "r349",
      "r351",
      "r577",
      "r578",
      "r579",
      "r580",
      "r696",
      "r827",
      "r855"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Common stock warrants exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_ClassOfWarrantOrRightPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "ClassOfWarrantOrRightPricePerShare",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right price per share.",
        "label": "Class Of Warrant Or Right Price Per Share",
        "terseLabel": "Common stock warrants price per share"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_ClassOfWarrantOrRightsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "ClassOfWarrantOrRightsExercised",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised",
        "label": "Class Of Warrant Or Rights Exercised",
        "documentation": "Class of warrant or rights exercised."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "sldb_CommercialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "CommercialMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestone payments.",
        "label": "Commercial Milestone payments",
        "terseLabel": "Commercial milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_CommitmentAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "CommitmentAndContingenciesLineItems",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment And Contingencies [Line Items]",
        "label": "Commitment And Contingencies [Line Items]",
        "terseLabel": "Commitment And Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_CommitmentAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "CommitmentAndContingenciesTable",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment And Contingencies [Table]",
        "label": "Commitment And Contingencies [Table]",
        "terseLabel": "Commitment And Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r121",
      "r543",
      "r602"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r316",
      "r317",
      "r662",
      "r886",
      "r889"
     ]
    },
    "sldb_CommonStockIssuableUponExerciseOfPrefundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "CommonStockIssuableUponExerciseOfPrefundedWarrants",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issuable upon exercise of prefunded warrants",
        "label": "Common Stock Issuable Upon Exercise of Prefunded Warrants",
        "terseLabel": "Common stock issuable upon exercise of pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issued As Payment For Developmental Milestone Consideration",
        "documentation": "Common stock issued as payment for developmental milestone consideration.",
        "terseLabel": "Common stock issued as payment for developmental milestone consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "verboseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r730",
      "r731",
      "r733",
      "r734",
      "r735",
      "r736",
      "r857",
      "r858",
      "r861",
      "r931",
      "r987",
      "r989"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r603"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r79",
      "r603",
      "r622",
      "r989",
      "r990"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value - 240,000,000 and 120,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively; 77,602,741 and 40,468,141 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r545",
      "r722"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-based compensation",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r112"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r117",
      "r158",
      "r160",
      "r165",
      "r535",
      "r555"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r126",
      "r183",
      "r214",
      "r224",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r680",
      "r681",
      "r892",
      "r893"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r126",
      "r183",
      "r214",
      "r224",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r680",
      "r681",
      "r892",
      "r893"
     ]
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureCollaborationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of Changes in Balances of Company's Related Party Collaboration Receivables and Contract Liabilities",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Deferred revenue, Ending balance",
        "periodStartLabel": "Deferred revenue, Beginning balance",
        "terseLabel": "Deferred revenue - related party",
        "totalLabel": "Contract with Customer, Liability, Total",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355",
      "r356"
     ]
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate Bond Securities [Member]",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r333",
      "r339",
      "r496",
      "r516",
      "r539",
      "r668",
      "r670"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_CumulativeDevelopmentalRegulatoryAndCommercialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "CumulativeDevelopmentalRegulatoryAndCommercialMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative developmental, regulatory, and commercial milestone payments.",
        "label": "Cumulative Developmental, Regulatory, and Commercial Milestone Payments",
        "terseLabel": "Cumulative developmental, regulatory, and commercial milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_CumulativeSalesMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "CumulativeSalesMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative sales milestone payments.",
        "label": "Cumulative Sales Milestone Payments",
        "terseLabel": "Cumulative sales milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Available-for-Sale Securities",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share reserved for future issuance",
        "label": "Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance",
        "documentation": "Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "terseLabel": "Depreciation and amortization expense",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r41"
     ]
    },
    "sldb_DepreciationImpairmentAndAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "DepreciationImpairmentAndAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation, impairment, and amortization expense.",
        "label": "Depreciation, impairment, and amortization expense",
        "terseLabel": "Depreciation, impairment, and amortization expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail": {
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfDerivativeLiabilitiesDetails",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Derivative Liability, Total",
        "verboseLabel": "Derivative liabilities",
        "terseLabel": "Derivative liabilities at fair value",
        "label": "Derivative Liabilities, Fair Value",
        "periodStartLabel": "Fair value of derivative liabilities as of January 1, 2025",
        "periodEndLabel": "Fair value of derivative liabilities as of March 31, 2025",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r456",
      "r457",
      "r468",
      "r474",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r617",
      "r619",
      "r620",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r670",
      "r935",
      "r936",
      "r937",
      "r988"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Current",
        "terseLabel": "Derivative liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liabilities, Unobservable Input",
        "label": "Derivative Liability, Measurement Input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r460"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative liabilities",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r62",
      "r63",
      "r64",
      "r68",
      "r182",
      "r197"
     ]
    },
    "sldb_DevelopmentMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "DevelopmentMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestone payments",
        "documentation": "Development milestone payments.",
        "label": "Development Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r371",
      "r399",
      "r400",
      "r402",
      "r704"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r200",
      "r203",
      "r207",
      "r208",
      "r209",
      "r213",
      "r427",
      "r435",
      "r453",
      "r454",
      "r536",
      "r556",
      "r671"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share Basic [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r207"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r203",
      "r207",
      "r208",
      "r209",
      "r213",
      "r427",
      "r435",
      "r453",
      "r454",
      "r536",
      "r556",
      "r671"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShare1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r210",
      "r211",
      "r212"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Additional Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized equity-based compensation cost, weighted average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized equity-based compensation",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Subject to Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Options to Purchase Common Stock [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r140",
      "r161",
      "r162",
      "r163",
      "r184",
      "r185",
      "r186",
      "r188",
      "r193",
      "r195",
      "r197",
      "r215",
      "r289",
      "r290",
      "r305",
      "r353",
      "r417",
      "r418",
      "r424",
      "r425",
      "r426",
      "r428",
      "r434",
      "r435",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r452",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r483",
      "r484",
      "r492",
      "r553",
      "r569",
      "r570",
      "r571",
      "r584",
      "r642"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r748",
      "r758",
      "r768",
      "r800"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r755",
      "r765",
      "r797"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "sldb_ExternalGeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "ExternalGeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "External General And Administrative Expense [Member]",
        "documentation": "External general and administrative expense.",
        "terseLabel": "External General and Administrative Expense [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_ExternalResearchAndDevelopmentOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "ExternalResearchAndDevelopmentOtherMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "External Research And Development Other [Member]",
        "documentation": "External research and development other.",
        "terseLabel": "External Research and Development Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_Fa212LlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "Fa212LlcMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FA212 LLC.",
        "label": "FA212 LLC [Member]",
        "terseLabel": "FA212 LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_FairValueAssetLevel1ToLevel2TransfersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "FairValueAssetLevel1ToLevel2TransfersAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value asset level 1 to level 2 transfers amount.",
        "label": "Fair Value Asset Level 1 To Level 2 Transfers Amount",
        "terseLabel": "Fair value, assets, level 1 to level 2 transfers, amount"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_FairValueAssetLevel2ToLevel1TransfersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "FairValueAssetLevel2ToLevel1TransfersAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value asset level 2 to level 1 transfers amount.",
        "label": "Fair Value Asset Level 2 To Level 1 Transfers Amount",
        "terseLabel": "Fair value, assets, level 2 to level 1 transfers, amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r468",
      "r711"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r468",
      "r711"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r714"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r714"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Assets and Liabilities that are Measured at Fair Value on a Recurring Basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Level 3 [Member]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r467",
      "r468",
      "r470",
      "r503",
      "r504",
      "r505",
      "r694",
      "r695",
      "r698",
      "r699",
      "r700",
      "r711",
      "r714"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r358",
      "r363",
      "r457",
      "r468",
      "r503",
      "r698",
      "r699",
      "r700",
      "r711"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r358",
      "r363",
      "r457",
      "r458",
      "r468",
      "r504",
      "r694",
      "r695",
      "r698",
      "r699",
      "r700",
      "r711"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r457",
      "r458",
      "r459",
      "r460",
      "r468",
      "r505",
      "r694",
      "r695",
      "r698",
      "r699",
      "r700",
      "r711",
      "r714"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Derivative Liabilities",
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Significant Unobservable Inputs Used in Valuing Developmental Milestone Derivative Liabilities",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r466",
      "r469"
     ]
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3",
        "terseLabel": "Fair value, liabilities, transfers into level 3, amount",
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r469"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "terseLabel": "Fair value, liabilities, transfers out of level 3, amount",
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r469"
     ]
    },
    "sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value, assets, transfers into level 1, amount",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level 1",
        "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level 1."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value, assets, transfers into level 2, amount",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In to Level 2",
        "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In to Level 2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "terseLabel": "Fair value, assets, transfers into level 3, amount",
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r469",
      "r712"
     ]
    },
    "sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level 1",
        "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level 1.",
        "terseLabel": "Fair value, assets, transfers out of level 1, amount"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value, assets, transfers out of level 2, amount",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level 2",
        "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level 2."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "terseLabel": "Fair value, assets, transfers out of level 3, amount",
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r469",
      "r712"
     ]
    },
    "sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability transfers in to level 1.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers In To Level 1",
        "terseLabel": "Fair value, liabilities, transfers into level 1, amount"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability transfers in to level 2.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers In to Level 2",
        "terseLabel": "Fair value, liabilities, transfers into level 2, amount"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value, liabilities, transfers out of level 1, amount",
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability transfers out of level 1.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Out Of Level 1"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value, liabilities, transfers out of level 2, amount",
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability transfers out of level 2.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Out Of Level 2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r467",
      "r468",
      "r470",
      "r503",
      "r504",
      "r505",
      "r694",
      "r695",
      "r698",
      "r699",
      "r700",
      "r711",
      "r714"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462",
      "r464",
      "r465",
      "r466",
      "r469"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r469"
     ]
    },
    "sldb_February2025OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "February2025OfferingMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 2025 Offering [Member]",
        "documentation": "February 2025 offering.",
        "terseLabel": "February 2025 Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities, excluding current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r335",
      "r349",
      "r450",
      "r471",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r554",
      "r689",
      "r711",
      "r712",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r723",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r881",
      "r882",
      "r883",
      "r884",
      "r932",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial liabilities",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r938"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Liabilities Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_FirstDevelopmentMilestonePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "FirstDevelopmentMilestonePayable",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First development milestone payable",
        "documentation": "First development milestone payable."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_FirstDevelopmentMilestonePaymentInShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "FirstDevelopmentMilestonePaymentInShares",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First development milestone payment in shares",
        "documentation": "First development milestone payment in shares."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r804"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r804"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r804"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r804"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r804"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "sldb_GabrielBrooksMDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "GabrielBrooksMDMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gabriel Brooks, M.D [Member]",
        "documentation": "Gabriel Brooks, M.D.",
        "terseLabel": "Gabriel Brooks, M.D [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_GainLossOnAcquisitionOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "GainLossOnAcquisitionOfBusiness",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gain on acquisition of business",
        "terseLabel": "Gain on acquisition",
        "label": "Gain (Loss) On Acquisition Of Business",
        "documentation": "Gain (loss) on acquisition of business."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "totalLabel": "Gain (Loss) on Derivative Instruments, Net, Pretax, Total",
        "terseLabel": "Change in fair value of derivative liabilities",
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "General and administrative expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r626"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "sldb_GovernmentBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "GovernmentBondsMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Bonds Maturing in One Year or Less [Member]",
        "documentation": "Government Bonds.",
        "label": "Government Bonds [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "verboseLabel": "Public Offering [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_IncentiveStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "IncentiveStockOptionsMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Stock Options [Member]",
        "documentation": "Incentive stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r310",
      "r462",
      "r466",
      "r469",
      "r566",
      "r568",
      "r627",
      "r665",
      "r713",
      "r958"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r310",
      "r462",
      "r466",
      "r469",
      "r566",
      "r568",
      "r627",
      "r665",
      "r713",
      "r958"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r407",
      "r410",
      "r411",
      "r412",
      "r413",
      "r415",
      "r416",
      "r419",
      "r421",
      "r422",
      "r423",
      "r582",
      "r707"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r138",
      "r196",
      "r197",
      "r214",
      "r227",
      "r244",
      "r409",
      "r410",
      "r420",
      "r557",
      "r707"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r852"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "sldb_IncreaseDecreaseInPropertyPlantAndEquipmentDueToAssetExchange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "IncreaseDecreaseInPropertyPlantAndEquipmentDueToAssetExchange",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease in property plant and equipment due to asset exchange",
        "label": "Increase Decrease in property plant and equipment due to asset exchange",
        "terseLabel": "Decrease in property plant and equipment due to asset exchange"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in right of use asset due to lease termination.",
        "label": "Increase Decrease In Right Of Use Asset Due To Lease Termination",
        "terseLabel": "Decrease in right-of-use assets due to lease termination"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r796",
      "r804",
      "r808",
      "r816"
     ]
    },
    "sldb_InducementAwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "InducementAwardMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement Award [Member]",
        "label": "Inducement Award [Member]",
        "documentation": "Inducement award."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r820"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r820"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r820"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Nonoperating, Total",
        "label": "Interest Expense, Nonoperating",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r847"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for Interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "negatedLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r172",
      "r173"
     ]
    },
    "sldb_InternalGeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "InternalGeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Internal General And Administrative Expense [Member]",
        "documentation": "Internal general and administrative expense.",
        "terseLabel": "Internal General and Administrative Expense [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_InternalResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "InternalResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Internal Research And Development Expense [Member]",
        "documentation": "Internal research and development expense.",
        "terseLabel": "Internal Research and Development Expense [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r225",
      "r244",
      "r680",
      "r846"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary Estimated Fair Value and Amortized Cost of Available-for-Sale Securities by Contractual Maturity",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureAvailableForSaleSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Available-for-Sale Securities",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r139",
      "r253",
      "r256",
      "r472",
      "r473",
      "r951"
     ]
    },
    "sldb_IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock In Private Placement For Payment Of Developmental Milestone Consideration",
        "documentation": "Issuance of common stock in private placement for payment of developmental milestone consideration.",
        "terseLabel": "Issuance of common stock in private placement for payment of developmental milestone consideration, units"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "IssuanceOfCommonStockToRelatedPartyInConnectionWithStockPurchaseAgreement",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock to related party in connection with stock purchase agreement.",
        "label": "Issuance Of Common Stock To Related Party In Connection With Stock Purchase Agreement",
        "terseLabel": "Issued and sold shares of common stock",
        "verboseLabel": "Issuance of common stock in connection with employee stock purchase plan, units"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in private placement for payment of developmental milestone consideration",
        "label": "Issuance Of Common Stock Value In Private Placement For Payment Of Developmental Milestone Consideration",
        "documentation": "Issuance of common stock value in private placement for payment of developmental milestone consideration."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "IssuanceOfCommonStockValueToRelatedPartyInConnectionWithStockPurchaseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock,to a related party, in connectionwith the Stock Purchase Agreement",
        "label": "Issuance Of Common Stock Value To Related Party In Connection With Stock Purchase Agreement",
        "documentation": "Issuance of common stock value to related party in connection with stock purchase agreement.",
        "verboseLabel": "Issuance of common stock in connection with employee stock purchase plan"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_JessieHanrahanPhDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "JessieHanrahanPhDMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jessie Hanrahan Ph. D. [Member]",
        "documentation": "Jessie Hanrahan Ph. D.",
        "terseLabel": "Jessie Hanrahan Ph. D. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_KevinTanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "KevinTanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kevin Tan [Member]",
        "documentation": "Kevin Tan.",
        "terseLabel": "Kevin Tan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r831"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r831"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Letter of credit amount",
        "terseLabel": "Letter of credit outstanding amount",
        "label": "Letters of Credit Outstanding, Amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r176",
      "r288",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r439",
      "r442",
      "r443",
      "r475",
      "r601",
      "r672",
      "r739",
      "r892",
      "r942",
      "r943"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r122",
      "r548",
      "r722",
      "r856",
      "r885",
      "r940"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r143",
      "r176",
      "r288",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r439",
      "r442",
      "r443",
      "r475",
      "r722",
      "r892",
      "r942",
      "r943"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of derivative liabilities",
        "label": "Liabilities, Fair Value Adjustment",
        "verboseLabel": "Gain (loss) recorded for a change in fair value",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial liabilities",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r74",
      "r75",
      "r76",
      "r77",
      "r176",
      "r288",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r439",
      "r442",
      "r443",
      "r475",
      "r892",
      "r942",
      "r943"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_LicenseAndResearchAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "LicenseAndResearchAgreementsTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and research agreements text block.",
        "label": "License and Research Agreements [Text Block]",
        "terseLabel": "License and Research Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_MaugeriLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "MaugeriLicenseAgreementMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maugeri license agreement member.",
        "label": "Maugeri License Agreement [Member]",
        "terseLabel": "Maugeri License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r365",
      "r404",
      "r460",
      "r532",
      "r565",
      "r567",
      "r575",
      "r593",
      "r594",
      "r648",
      "r649",
      "r650",
      "r651",
      "r659",
      "r663",
      "r664",
      "r688",
      "r696",
      "r703",
      "r714",
      "r715",
      "r719",
      "r720",
      "r725",
      "r894",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount Rate [Member]",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r936",
      "r937"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility [Member]",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r714",
      "r935",
      "r936",
      "r937"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r714"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r714"
     ]
    },
    "sldb_MilestoneLiabilityPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "MilestoneLiabilityPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Liability Payment",
        "documentation": "Milestone liability payment.",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_MilestonePaymentsUponAchievementOfDevelopmentMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "MilestonePaymentsUponAchievementOfDevelopmentMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments upon achievement of development milestone.",
        "label": "Milestone Payments Upon Achievement Of Development Milestone",
        "terseLabel": "Milestone payments upon achievement of development milestone"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_MilestonePaymentsUponAchievementOfNetSalesMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "MilestonePaymentsUponAchievementOfNetSalesMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments upon achievement of net sales milestones.",
        "label": "Milestone Payments Upon Achievement Of Net Sales Milestones",
        "terseLabel": "Milestone Payments upon achievement of net sales milestones"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_MilestonePaymentsUponAchievementOfRegulatoryMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "MilestonePaymentsUponAchievementOfRegulatoryMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments upon achievement of regulatory milestone.",
        "label": "Milestone Payments Upon Achievement Of Regulatory Milestone",
        "terseLabel": "Milestone payments upon achievement of regulatory milestone"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r365",
      "r404",
      "r460",
      "r532",
      "r565",
      "r567",
      "r575",
      "r593",
      "r594",
      "r648",
      "r649",
      "r650",
      "r651",
      "r659",
      "r663",
      "r664",
      "r688",
      "r696",
      "r703",
      "r714",
      "r715",
      "r719",
      "r725",
      "r894",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r95",
      "r123",
      "r141",
      "r157",
      "r159",
      "r163",
      "r176",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197",
      "r205",
      "r288",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r427",
      "r435",
      "r454",
      "r475",
      "r552",
      "r624",
      "r640",
      "r641",
      "r737",
      "r892"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common stockholders",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r189",
      "r190",
      "r191",
      "r192",
      "r200",
      "r201",
      "r206",
      "r209",
      "r435"
     ]
    },
    "sldb_NonCashAcquiredInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "NonCashAcquiredInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash acquired in-process research and development",
        "documentation": "Non cash acquired in process research and development.",
        "label": "Non Cash Acquired In Process Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_NonCashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "NonCashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Non cash Lease Expense",
        "documentation": "Non-cash lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r796",
      "r804"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_November2022PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "November2022PlanMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "November 2022 Plan [Member]",
        "label": "November 2022 Plan Member",
        "documentation": "November 2022 Plan."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_November2022WorkforceReductionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "November2022WorkforceReductionPlanMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "November 2022 Workforce Reduction plan [Member]",
        "label": "November 2022 Workforce Reduction plan [Member]",
        "documentation": "November 2022 Workforce Reduction plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r681",
      "r864"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segment",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r674",
      "r686",
      "r864"
     ]
    },
    "sldb_OfficeAndLaboratoryLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "OfficeAndLaboratoryLeaseMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and laboratory lease.",
        "label": "Office And Laboratory Lease [Member]",
        "terseLabel": "Office and Laboratory Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OneTimeTerminationBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OneTimeTerminationBenefitsMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One-Time Employee Termination Benefits [Member]",
        "label": "One-time Termination Benefits [Member]",
        "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r691",
      "r692",
      "r693"
     ]
    },
    "sldb_OperatingAndFinancingLeasesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "OperatingAndFinancingLeasesDisclosureTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and financing leases.",
        "label": "Operating And Financing Leases Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r673",
      "r863",
      "r865",
      "r866",
      "r867",
      "r868"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, excluding current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Right of use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease, right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating segment [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r245",
      "r680",
      "r681"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized gain (loss) on available-for-sale securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on available-for-sale securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r287"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r722"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Income (Expense)",
        "totalLabel": "Other Noncash Income (Expense), Total",
        "negatedLabel": "Other",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "terseLabel": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables",
        "terseLabel": "Related party collaboration receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r611",
      "r681",
      "r954"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense, other",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r760",
      "r770",
      "r802"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r763",
      "r773",
      "r805"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r763",
      "r773",
      "r805"
     ]
    },
    "sldb_PaulHerzichMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "PaulHerzichMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paul Herzich [Member]",
        "documentation": "Paul Herzich.",
        "terseLabel": "Paul Herzich [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Available-for-Sale Securities, Short-Term",
        "negatedLabel": "Proceeds from maturities of available-for-sale securities",
        "documentation": "Amount of cash outflow (inflow) through acquisition (sale) of short-term available-for-sale securities."
       }
      }
     },
     "auth_ref": [
      "r848",
      "r850",
      "r853"
     ]
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "terseLabel": "Other",
        "negatedLabel": "Other",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r849"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amounts paid during the period",
        "verboseLabel": "Amounts paid during the period",
        "terseLabel": "Restructuring charges were paid",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r851"
     ]
    },
    "sldb_PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments Of Common Stock And Pre Funded Warrants Issuance Costs In Public Offering",
        "documentation": "Payments of common stock and pre funded warrants issuance costs in public offering.",
        "negatedLabel": "Payments of common stock and pre-funded warrants issuance costs in public offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payments of common stock and pre-funded warrants issuance costs in private placement",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of available-for-sale securities",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r168",
      "r254"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payment",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r433"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "sldb_PercentageOfNetIncomeAndNetLossesOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "PercentageOfNetIncomeAndNetLossesOnNetSales",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net income and net losses on net sales.",
        "label": "Percentage Of Net Income And Net Losses On Net Sales",
        "terseLabel": "Percentage of net income and net losses on net sales"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_PercentageOfOptionToFundOfDevelopmentCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "PercentageOfOptionToFundOfDevelopmentCost",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of option to fund of development cost.",
        "label": "Percentage Of Option To Fund Of Development Cost",
        "terseLabel": "Percentage of option to fund of development cost"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_PercentageOfOutstandingCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "PercentageOfOutstandingCommonStock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding common stock.",
        "label": "Percentage Of Outstanding Common Stock",
        "terseLabel": "Percentage of outstanding common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Nonvested Performance Stock Units [Member]",
        "terseLabel": "Performance Stock Units [Member]",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "sldb_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded warrants.",
        "label": "Pre Funded Warrants [Member]",
        "terseLabel": "Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_PreFundedWarrantsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "PreFundedWarrantsOutstanding",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded warrants outstanding.",
        "label": "Pre Funded Warrants Outstanding",
        "terseLabel": "Pre-funded warrants outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r337"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r603"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r337"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r603",
      "r622",
      "r989",
      "r990"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value - 10,000,000 shares authorized; no shares issued or outstanding at June 30, 2025 and December 31, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r544",
      "r722"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "sldb_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_PrepaidOtherAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "PrepaidOtherAndOtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid other and other current assets",
        "label": "Prepaid Other and Other Current Assets",
        "documentation": "Prepaid other and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_PrepaidResearchAndDevelopmentExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "PrepaidResearchAndDevelopmentExpensesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid research and development expenses, current.",
        "label": "Prepaid Research And Development Expenses Current",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_ProbabilityOfAchievingCertainDevelopmentMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "ProbabilityOfAchievingCertainDevelopmentMilestonesMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probability of achieving certain development milestones.",
        "label": "Probability Of Achieving Certain Development Milestones [Member]",
        "terseLabel": "Probability of Achieving Certain Development Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from offering",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and pre-funded warrants in private placement.",
        "label": "Proceeds from Issuance of Common Stock and Pre-funded Warrants in Private Placement",
        "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants in private placement"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants in public offering, net of underwriting discounts and commissions",
        "label": "Proceeds From Issuance Of Common Stock And PreFunded Warrants In Public Offering, Net Of Underwriting Discounts And Commissions",
        "documentation": "Proceeds from issuance of common stock and pre-funded warrants in public offering, net of underwriting discounts and commissions."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock in at-the-market public offering, net of sales commissions",
        "label": "Proceeds From Issuance Of Common Stock In At The Market Public Offering Net Of Sales Commissions",
        "documentation": "Proceeds from issuance of common stock in at the market public offering net of sales commissions."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock in public offering, net of sales commissions.",
        "label": "Proceeds from Issuance of Common Stock in Public Offering, Net of Sales Commissions",
        "terseLabel": "Proceeds from issuance of common stock in public offering, net of sales commissions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from private placement",
        "verboseLabel": "Company received net proceeds",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan purchases",
        "label": "Proceeds from Repayment of Loans by Employee Stock Ownership Plans",
        "documentation": "The cash inflow from the financed defined contribution plan to acquire shares of the entity. The plan initially holds the shares in a suspense account, which is collateral for the loan. As the plan makes payment on the debt, the shares are released from the suspense account and become available to be allocated to participant accounts."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercises of common stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r19"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r533",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r666",
      "r697",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r890",
      "r891",
      "r896",
      "r955",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r533",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r666",
      "r697",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r890",
      "r891",
      "r896",
      "r955",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "negatedLabel": "Net loss",
        "verboseLabel": "Condensed consolidated net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r157",
      "r159",
      "r170",
      "r176",
      "r187",
      "r193",
      "r196",
      "r197",
      "r288",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r427",
      "r435",
      "r437",
      "r440",
      "r441",
      "r454",
      "r475",
      "r537",
      "r551",
      "r583",
      "r624",
      "r640",
      "r641",
      "r709",
      "r710",
      "r738",
      "r845",
      "r892"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r490"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNet1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r133",
      "r136",
      "r137"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r490",
      "r538",
      "r550",
      "r722"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r490"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r357",
      "r365",
      "r394",
      "r395",
      "r396",
      "r404",
      "r460",
      "r506",
      "r515",
      "r532",
      "r565",
      "r567",
      "r575",
      "r593",
      "r594",
      "r648",
      "r649",
      "r650",
      "r651",
      "r659",
      "r663",
      "r664",
      "r688",
      "r696",
      "r703",
      "r714",
      "r715",
      "r719",
      "r720",
      "r725",
      "r731",
      "r887",
      "r894",
      "r936",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r357",
      "r365",
      "r394",
      "r395",
      "r396",
      "r404",
      "r460",
      "r506",
      "r515",
      "r532",
      "r565",
      "r567",
      "r575",
      "r593",
      "r594",
      "r648",
      "r649",
      "r650",
      "r651",
      "r659",
      "r663",
      "r664",
      "r688",
      "r696",
      "r703",
      "r714",
      "r715",
      "r719",
      "r720",
      "r725",
      "r731",
      "r887",
      "r894",
      "r936",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949"
     ]
    },
    "sldb_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently issued accounting pronouncements not yet adopted.",
        "label": "Recently Issued Accounting Pronouncements Not Yet Adopted Policy [Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_RecentlyIssuedAccountingPronouncementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "RecentlyIssuedAccountingPronouncementsPolicyTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Recently issued accounting pronouncements",
        "documentation": "Recently issued accounting pronouncements.",
        "label": "Recently Issued Accounting Pronouncements [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Segment Expenses, Other Segment Items, and Segment Net Loss",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r755",
      "r765",
      "r797"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r364",
      "r493",
      "r494",
      "r542",
      "r549",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r621",
      "r623",
      "r647"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r493",
      "r494",
      "r495",
      "r496",
      "r542",
      "r549",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r621",
      "r623",
      "r647"
     ]
    },
    "sldb_RelatedPartyTransactionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "RelatedPartyTransactionPolicyTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction.",
        "label": "Related Party Transaction Policy [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r364",
      "r493",
      "r494",
      "r542",
      "r549",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r621",
      "r623",
      "r647",
      "r941"
     ]
    },
    "sldb_RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining accrued restructuring charges to be paid in next three months.",
        "label": "Remaining Accrued Restructuring Charges To Be Paid In Next Three Months",
        "terseLabel": "Remaining accrued restructuring charges to be paid in next three months"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of principal portion of finance lease obligations",
        "label": "Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security",
        "totalLabel": "Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security, Total",
        "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r333",
      "r339",
      "r496",
      "r516",
      "r539",
      "r669",
      "r670"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r665",
      "r680",
      "r950"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r756",
      "r766",
      "r798"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r757",
      "r767",
      "r799"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r764",
      "r774",
      "r806"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "totalLabel": "Restricted Cash, Total",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r854",
      "r952",
      "r953"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
      "http://www.solidbio.com/20250630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash, non-current, as presented on balance sheet",
        "terseLabel": "Restricted cash",
        "netLabel": "Restricted cash, as presented on balance sheet",
        "verboseLabel": "Restricted cash, non-current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r841",
      "r854"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units [Member]",
        "verboseLabel": "Nonvested Restricted Stock Units [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Number of headcount reduced, percentage",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrual recorded as a result of restructuring charges",
        "verboseLabel": "Restructuring charges",
        "label": "Restructuring Charges",
        "totalLabel": "Restructuring Charges, Total",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r312",
      "r313",
      "r888"
     ]
    },
    "us-gaap_RestructuringChargesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringChargesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_RestructuringChargesExpectedToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "RestructuringChargesExpectedToBePaid",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges expected to be paid",
        "label": "Restructuring charges expected to be paid",
        "documentation": "Restructuring charges expected to be paid."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309",
      "r313",
      "r314"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315"
     ]
    },
    "us-gaap_RestructuringCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Costs [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r107",
      "r547",
      "r572",
      "r574",
      "r581",
      "r604",
      "r722"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r184",
      "r185",
      "r186",
      "r188",
      "r193",
      "r195",
      "r197",
      "r289",
      "r290",
      "r305",
      "r417",
      "r418",
      "r424",
      "r425",
      "r426",
      "r428",
      "r434",
      "r435",
      "r444",
      "r446",
      "r447",
      "r449",
      "r452",
      "r483",
      "r484",
      "r569",
      "r571",
      "r584",
      "r989"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Revenues, Total",
        "label": "Revenues",
        "terseLabel": "Collaboration revenue - related party",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r164",
      "r176",
      "r214",
      "r223",
      "r224",
      "r238",
      "r244",
      "r248",
      "r250",
      "r251",
      "r288",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r475",
      "r537",
      "r680",
      "r892"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Right-of-use assets acquired through operating leases",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r721"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "sldb_SGT003Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "SGT003Member",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "S G T 003 [Member]",
        "documentation": "SGT-003.",
        "terseLabel": "SGT-003 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_SGT501Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "SGT501Member",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "S G T 501 [Member]",
        "documentation": "SGT-501.",
        "terseLabel": "SGT-501 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_SaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "SaleMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale [Member]",
        "documentation": "Sale.",
        "terseLabel": "Sale [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forcast [Member]",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r366",
      "r860"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r366",
      "r828",
      "r860"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58",
      "r431"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Values of Assets Acquired and Liabilities Assumed",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "terseLabel": "Schedule Of Earnings Per Share Basic By Common Class [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r35",
      "r203",
      "r204",
      "r207"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Equity-based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Restructuring Charges",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r101"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restricted Stock Unit Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r109"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r103",
      "r105",
      "r106",
      "r107",
      "r147",
      "r148",
      "r149",
      "r216",
      "r337",
      "r338",
      "r339",
      "r341",
      "r344",
      "r349",
      "r351",
      "r577",
      "r578",
      "r579",
      "r580",
      "r696",
      "r827",
      "r855"
     ]
    },
    "sldb_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement.",
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r679",
      "r687"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "terseLabel": "Segment reporting, CODM, profit (loss) measure, how used, description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r676",
      "r684"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r214",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r228",
      "r229",
      "r230",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r251",
      "r674",
      "r677",
      "r678",
      "r680",
      "r682",
      "r685",
      "r686"
     ]
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "terseLabel": "Other segment items",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r229",
      "r230",
      "r244",
      "r680"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Data",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r247",
      "r250",
      "r675",
      "r676",
      "r683"
     ]
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentExpensesOtherSegmentItemsAndSegmentNetLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Costs",
        "terseLabel": "Restructuring charges related to severance payment and other employee-related costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Recognized Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of vesting rights",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights",
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeitures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeitures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average grant date fair value",
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodStartLabel": "Nonvested RSUs/PSUs at January 1, 2025",
        "periodEndLabel": "Nonvested RSUs/PSUs at June 30, 2025",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Nonvested RSUs/PSUs at January 1, 2025",
        "periodEndLabel": "Nonvested RSUs/PSUs at June 30, 2025",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested",
        "terseLabel": "Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions Common Stock Price",
        "documentation": "Share-based compensation arrangement by share-based payment award, fair value assumptions common stock price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividends",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock units outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Beginning Balance",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares of common stock reserved for issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized for common stock for equity awards",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for common stock for equity awards",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "sldb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award offering period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining Contractual Life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at June 30, 2025",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at June 30, 2025",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeitures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Common stock purchased",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value of stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodStartLabel": "Outstanding at January 1, 2025",
        "periodEndLabel": "Outstanding at June 30, 2025",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Outstanding at January 1, 2025",
        "periodEndLabel": "Outstanding at June 30, 2025",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at June 30, 2025",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at June 30, 2025",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of number of shares outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfPerformanceStockUnitsActivityDetails",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfRestrictedStockUnitActivityDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeitures",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "terseLabel": "Summary of Performance Stock Units Activity",
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of vesting",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at June 30, 2025",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest at June 30, 2025",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Common stock issued price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, units",
        "periodStartLabel": "Beginning balance, units",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFa212AssetAcquisitionAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r79",
      "r82",
      "r83",
      "r140",
      "r161",
      "r162",
      "r163",
      "r184",
      "r185",
      "r186",
      "r188",
      "r193",
      "r195",
      "r197",
      "r215",
      "r289",
      "r290",
      "r305",
      "r353",
      "r417",
      "r418",
      "r424",
      "r425",
      "r426",
      "r428",
      "r434",
      "r435",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r452",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r483",
      "r484",
      "r492",
      "r553",
      "r569",
      "r570",
      "r571",
      "r584",
      "r642"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r215",
      "r484",
      "r533",
      "r576",
      "r585",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r603",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r612",
      "r613",
      "r614",
      "r615",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r623",
      "r625",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r642",
      "r732"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringAdditionInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r366",
      "r828",
      "r829",
      "r860"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r215",
      "r252",
      "r484",
      "r533",
      "r576",
      "r585",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r603",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r612",
      "r613",
      "r614",
      "r615",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r623",
      "r625",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r642",
      "r732"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r759",
      "r769",
      "r801"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan, units",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r78",
      "r79",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock issued and sold",
        "label": "Common stock shares issued",
        "terseLabel": "Issuance of common stock, net of issuance costs, units",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r78",
      "r79",
      "r107",
      "r577",
      "r642",
      "r660"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercises of common stock options, units",
        "negatedLabel": "Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r78",
      "r79",
      "r107",
      "r380"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r78",
      "r79",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r78",
      "r79",
      "r107",
      "r584",
      "r642",
      "r660",
      "r738"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercises of common stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r79",
      "r82",
      "r83",
      "r107"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r82",
      "r83",
      "r98",
      "r605",
      "r622",
      "r643",
      "r644",
      "r722",
      "r739",
      "r856",
      "r885",
      "r940",
      "r989"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r175",
      "r336",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r350",
      "r353",
      "r451",
      "r645",
      "r646",
      "r661"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r721"
     ]
    },
    "sldb_SubleasedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "SubleasedDescription",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subleased description",
        "documentation": "Subleased description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r498"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r498"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r498"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r499"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "sldb_TimingOfAchievingCertainDevelopmentMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "TimingOfAchievingCertainDevelopmentMilestonesMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Timing of achieving certain development milestones.",
        "label": "Timing Of Achieving Certain Development Milestones [Member]",
        "terseLabel": "Timing of Achieving Certain Development Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_TransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "TransactionPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction price.",
        "label": "Transaction Price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_TransactionPriceDeterminedUnderASC606": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "TransactionPriceDeterminedUnderASC606",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction price determined under ASC 606",
        "label": "Transaction Price Determined Under A S C 606",
        "documentation": "Transaction price determined under ASC 606."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r335",
      "r349",
      "r450",
      "r471",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r554",
      "r711",
      "r712",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r723",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r881",
      "r882",
      "r883",
      "r884",
      "r932",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "sldb_TreasuryBillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "TreasuryBillMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureAvailableforsaleSecuritiesScheduleOfAvailableforsaleSecuritiesDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Treasury Bills Maturing in One Year or Less [Member]",
        "terseLabel": "Treasury Bills [Member]",
        "documentation": "Treasury bill.",
        "label": "Treasury Bill [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_TwoThousandAndEighteenOmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "TwoThousandAndEighteenOmnibusIncentivePlanMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Omnibus Incentive Plan.",
        "label": "Two Thousand And Eighteen Omnibus Incentive Plan [Member]",
        "terseLabel": "2018 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_TwoThousandAndTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "TwoThousandAndTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 equity incentive plan.",
        "label": "Two Thousand And Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_TwoThousandAndTwentyFourInducementStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "TwoThousandAndTwentyFourInducementStockIncentivePlanMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty four inducement stock incentive plan.",
        "label": "Two Thousand and Twenty Four Inducement Stock Incentive Plan [Member]",
        "terseLabel": "2024 Inducement Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty one employee stock purchase plan.",
        "label": "Two Thousand And Twenty One Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309",
      "r313",
      "r314"
     ]
    },
    "sldb_UltragenyxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "UltragenyxMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ultragenyx",
        "label": "Ultragenyx [Member]",
        "terseLabel": "Ultragenyx [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r414",
      "r706"
     ]
    },
    "sldb_UnvestedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "UnvestedStockOptionsMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested Stock Options [Member]",
        "label": "Unvested Stock Options [Member]",
        "documentation": "Unvested stock options member."
       }
      }
     },
     "auth_ref": []
    },
    "sldb_UpfrontLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "UpfrontLicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront license fee.",
        "label": "Upfront License Fee",
        "terseLabel": "Upfront license fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r131",
      "r132",
      "r134",
      "r135"
     ]
    },
    "sldb_VestingOfRestrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "VestingOfRestrictedStockUnits",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting of restricted stock units.",
        "label": "Vesting Of Restricted Stock Units",
        "terseLabel": "Vesting of restricted stock, units"
       }
      }
     },
     "auth_ref": []
    },
    "sldb_VestingOfRestrictedStockUnitsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "VestingOfRestrictedStockUnitsValue",
     "crdr": "credit",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting of restricted stock units value.",
        "label": "Vesting Of Restricted Stock Units Value",
        "terseLabel": "Vesting of restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r730",
      "r733",
      "r734",
      "r735",
      "r736"
     ]
    },
    "sldb_WarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.solidbio.com/20250630",
     "localname": "WarrantsIssued",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued",
        "label": "Warrants Issued",
        "documentation": "Warrants issued."
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedInValuingDevelopmentalMilestoneDerivativeLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r460",
      "r515",
      "r663",
      "r664",
      "r714",
      "r944",
      "r946",
      "r949"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares of common stock outstanding, diluted",
        "verboseLabel": "Weighted average shares of common stock outstanding, used to compute diluted net loss per share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r209"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.solidbio.com/20250630/taxonomy/role/DisclosureNetLossPerShareScheduleComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.solidbio.com/20250630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares of common stock outstanding, basic",
        "verboseLabel": "Weighted average shares of common stock outstanding used to compute basic net loss per share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r209"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-6"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "7",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/820/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-9"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0000950170-25-107279-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-107279-xbrl.zip
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M; 6^J<EK>$OMO'#L$;:#GV!D.$G7-OO2F_B",615Z<5(&Y67J(5:WIP_"HE
M)S8H"=,$K;DUJF:(T3/G])$:(WR]G+X0I332=3F-(U656AS<A5"Q"!N6*XF@
M&2-?[\=)-3^;%(G,L6S\C 3IZRZ_BKRLZ[495[@B..!3 82Z>]6.3.6^6<_3
MRW7<PU":4#UP/O7*$0%HL"MP)MLQ,?9"GY4N9)@8,I&<VYSY_;ONK1UO$C1F
M"D=N!VSR!!T-MI\UCY:8:"7[YP3OUJ2+?\,>Z^-A+.M0T:Y#ZR=[)=YT+O=U
M)<*Y6CXL^)!/ ;+$[;8L5*8L/M.R)_8 D3XO)Q&D@$EOYA5H"_%[P7YL/S!7
M]1*D,?A-*ZS['I3_A6S#M9KUE7JT=NH.R LB)"QKE?3%J%6GQ.K;E.'A>"S5
M04W_K#70H)3MGP+NNJ%%"(APXZ<).5P$\P2E]+)6RT6B,3C'?WX>F.D$:DH6
M!V!7D->@XW/5$W'DC@GU>Y"GX(*9Y:G5'+'1ION.(EY%DE%1A<,;WY*&E=Y\
M5;ZE=0'"Y+A7/ \!ROO^R8C>%2TK,$^DI8G*\#!-5V*Q"]YU</3* #[O!KID
MQ"G/ZJQDF;0<W1"UR<QF,/#YLN!6)MVOE6,2WEJ+S(MT$)P*<K/"K ^< HQ'
MJDM<FL:D-ZJGGU I8Y11CL#N5J#:(:LV*^'R4A0@9PR/%J1\A[E(7SJ*0Y)]
M2'8N:E:[$GG$\O#O:SJ)C=7]L@>[SVY<XO\[)W/!0I %]).II,SCWF9WT_B^
MIZ%EHTK_> DLX+MM=I>PW$RO/$+PG.^?CRE6:83ZJ.$1&;AL3YWTA:@9K4*'
M+Q.=<U5IO(KT-+TK[/8@/-"N&^/"I*>7;*N!3W=+:,[655%BP,D.V!,CA6]D
M+I.I)ND<_/O;^K B$,M9LZ0'?,E(VZ<'BVY(BG%)NO65L!(.L5!_,L@RZQYB
MD%;8F_5ZR+[!5Q:;!=:.AIWI$=I73>V$02P\EGLOY@.R6!.7Q&RMJ_7:,5TR
MU*Z!)4?=[=6+#[S4]3<V1[@\M #_7C91FK/OQ]P:U1S>1K R7>NYG[TK8:\N
M>51GA:E,CUI7 ?[B:8'4/%PX!4RHWTRN@A\@K@YC'WF7Y7]<JG^\P'&@FY]L
MK=)]TK5I>#9^)9_ ES[#*Q#Z(?F-EYK :(AW6)G77K"D_!RSJ^K]!9O)^P4K
M28Q$.C)[TL'7L::.X5+H=9(5TV//;R0+X^9LS@HW-0W\#>?+@C=^6^==&[[#
M:[&LR4ZT/ 7PJ)GT>6^2!N6^9>^UF+0ZI1OF!0=R7AEK4)T;6%D+UAXR_+N?
M[$LQ:2-'75WP] N9+ _K&ZM)'I1C:)-M+A])DEKK=@U+0Y[=T(? LSZ7)3@N
MB)AO^2-FAT.25H, CX(4 +$W.N.^6MG[3"[6)QL>#%Q4TP-1OJJK@DO 1/Y.
M[]B045^7 '3^PC;;GRE 2&F@KWODN*"P<&\LV]/DP,7,'3'Q!9\_=AW!V:>
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M*R^8!PL&7HJ.IE=ME+E27$PO)T/S0/##!9@"YBIFO@18C8KM.Z!>C6N%,VR
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MJ-2H# F#M>!4M/=[SJZOUY9,2IZY.3A3C[&[?XX\(J'V]F#BG;H868Z4X7F
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M]$#2^N1<$9EK*1:9(=7[O9@L.WNTTH%,P5/J\,KKO_KU^^O81;6;C9)MLBX
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MSPE$C7_=>[B6NBX7:<\HOY9OHH2)9P\U?X775A,'SZ\QD1 DK@M <"IY_ )
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M\0.:#,I\-R]7^S68TV@<78XK[8$:\D7T8GA^G><PF:I> *X04\Z4'M4#:[Y
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MFAK"%9:!+GZY#%^"QG*42F&[2%HY=0H2<HZ5M"'1!)\J6U-:%C7X[3P.6\D
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MB9C%7X9E6?/)!X$E7:V,9Y_>&1VX<GC%#WA1%+U>A%(1>0/:<+D404R+>U?
M.# ME!=X9,%$O;Y%VRP ^.!UXX:"<9F>A:%$5E7E>95YVB2"/$$1GGWN5]J6
M4\3U)^:V- *>LR$ETE0S1*BO=#%;2,&ZI2ZFV7;N@>R0L\47 ,^6\USR[=3
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MYR];N]&F08XQ'@!?*C8WW=F=E7MMM03?.%P#C'$NPF E@>(F5!7S4>&/H.%
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M]HGZWD5/*E5UKX>_W3HWOJ*BWXFNRLXL>$*?2%SC*R6'>]"& ;D@UA]/(_[
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MUL4P)TW@0E'#HMM]0.;XT6^CC$H6W;VYUST:9=G2RA"#=+E8XV-?6FOVE+(
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M(X26MG_&WI8@:3#Q7JW4/W[GX?\#B4 M+/:"FI?=S<SR8S+WVT-U]I]Y';I
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MZ<#1ZM ^F PM8AE.'?<[F$U"N\!H61WC@OMH@UAC)9+Z4W\V,>\]7'OVG<?
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M#L19H]C#GLSSK<RIUKHCT<7 $*9K,DK0V ATS5W6+4P/@86D#U W*E@@X_'
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MC^ 0N#<FKBV5G#5?MC"G)S.G5UGTT5"-.?;?NK[F)_*=]\H<+NY@/P1($KT
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M&([+L3KRD1JI9NTU## ^E?FDI6)LY.5=!3]0TF:S.O& O?FWI_"_'[3[)E0
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M<H\CV%7U@O2EE;YWQXHA%/^QSWIV\2P5MOP!S@IS#QPGB^/O!Q)9<8K>[ZB
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MZ3' 'DW R8WA>D:16/FF$88$_W3^OY=*ZFJ+_OV,X^]T>N"76^T__._AOP_
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M5FD(LT"X6>F:$50[-1!N%.ACG+?.MR8XJ#MHE.:CVS!WI?(-GH^5Q)3HT,1
M]:(H&+'J410/DX2DGX_'1RF8P#O5&3<G(IUNJ](91AHE&FG=+XX7NO/K7S+]
M>RC-9.5R\G<+<F%SNJ\@Y;;6W[[-SI7H^(>$ADA:SUFKT$>,ZP+'>0P?1(SL
M55SC,3\6/E,$\]43N?#FV*5N#N>$725V_%'M=F!W/?1''(HYS+BGL6+9!=<\
M(^Z[^*W9-7EB!Q\M3#]S<'8)N-%/Y P7#/]JUB$]Y?7E@HGXV)LL0:Q \Z>U
M/FXHCK<1[Y) KV3Y5WOT08_?^T^^U+%+<:]]-ZO13>$)=^_BL\W\^[ZUF%7E
MFH0J&0L*RV0M;_65*;7=0\'B^KLRN5[!U^K,ZM.4!PHQ3+B@0+$'6"1%P(Z&
M+$>,0#4O3EXU)&&D#@B$.Q.U:]"MUM?239")4S(*EFM\^<M?KU+W<Q](;M&O
M3@S^X3^$K >--U".6,)?"3E7-*L*#!,&ZU6Z9D^T"&?=GPCKJ0.%+V)1[0JT
M)<,9*/$[PP@57X_(A"3=H&F!'U3/($(RY]VU" 1W18MDALLS-DL+AXST5:;[
M[U1NT/J!D*LAQT-$SB6 \G,N#I#8^%15FWBY+0TSZ.ZN,"5(OX=^--#%_=HS
MRK(84-;%O1#@@.Q[GC8$@@NW!-4GDS<? *V3Z\Q7,;UWHX_ 5,D8TV7@7#.K
M)J%';:+:M;7Q16^A+]89T9,_9M=Q01X.($27S1#=V1?IM=YY*8K4:8N7(]&4
ML0^E\W)J2^S/%!\6Q<"&!=O,W&/=U?-6+ZR*XX6)JY< O8A_ 5_Q[^C(.,]5
M]DB)YZKCBE=N +*40YZ#? V;HMJ,EVV-W'.[%Q^\D2W1'(.[3LA\*.+P"A[B
M87FQ9B2<WC&!6=%O.JF(/PS(6Y+Z7$<EYIFV4L/VPNEM>06V!F25G&\58"43
MO#>2AYL7&B^':J,>:>=;Z.5!67#^+'=6@;:I*\20N-I*YI!4UW1.KGN9*QM]
M#9SMLI/%.[M"P7!=]6HN.G43 JO'5YA=E%4PO,O_XA/:S1[CBTW9%<?R$EA>
M'RGSF]7$WR0HOPT6_#VE)YRE+9V6N[U!_<&V7O[?9XXHA+)DUPG3.R#+QT4+
MS/D=^UY(-S*.4XZHBUL0[^>B :M!L(4,[O2^J$D1'H .)9/4MR7,9Z1G^6:C
M1['BL,(IV\Y>"0=_U"?6BU1E)_3<2B=7?7!5UMLVZV.:&R2GZ'F1'(:GCF-
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MK\CLC8AJB_:670(V1N^/!G3P?]Y/YAZ0,.A;8_MN^W8X8-Y$B9TH$GS;T>_
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M-7_,NJ_!9E8*07;$VBFCR8ACJT"UA'2@\LI==2Z:7.W2I9K/@9 7T==C2UA
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M$!'I79$BO?<(RT(+34+OTIMTD(!(EDB'@ (!Z8L:6NBA%R$$EE3ITDD0D)X
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M8)O!D'[*7>(=\U/!EQ)^/&*YI$[,E$UAM=6Q2EA0Z=Y6(+XZ+U;E)$]TW4S
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M_C"02=E4XN4WZ!OF*O7+1*:E>/Y2/J_K=NJ^2Q[*4_-\QI(U@#:X.Q80L&K
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M+I]9_;G-0@WEI5'@ZV#C,B-\3E7SPR!:,5D,MQ@CBN,LK4%]VH"XS99FVT[
MGBU*L5INBY7A).%8(SI;H<:*B0R1-"_!"P PYTT/VT$,IWV^KQG]%R);T^.D
M\G?5N))=/V-+F#6W?51:2AH^).EVR2WON_Z&:;4_MH[Z&38B00\+.]>^_;OM
M1T?-FD)/S94S")X9B3_",:>U)<'*);(]@YC_1ME0FL0K,0_9?#FP5:)-*G>8
M4(JW27GL=ROUZ\KC(,22C>7(=IJ9N,+UR&'?CSDWU&@UV2+Z#<MC,/9^C&NF
M4:%,#E@PW#) 7R82-^]>TW<P>*0[Q#=<J]1OD(1QSBRUB"^"#1W=8G+'$B!
M6VZ/$DX-;I0"VV2EOA\XL7"F8G2K$7K?KG%S%[UV 9B+&0"37#'/58NP2QHZ
M"<DW(#,S2VL30(/29VOP(5 3^W3*9\;0_@39L4>)HZE/^9>S@^S+;,[F[.9^
M8FHB\RA(2ZMOK+ _^_28Q5S_F#;RST\7>ZH]]4";><QR7*()F/6JYL6$BI6-
M!IL%MZ=56?5+;V^D*]GF N!Q,$>'H]QMQ17Y5 PHQ*KR>+($"$8"0SQ??G8.
M_Q-87N(I57H\ =3T\2XIK84/*]1AQ)8SY*8[@J\NG!T3,GI$?:XZB+BV7E<F
M[=^I,<OL#FT2O%\.-DWBX!!S-KHNI/V4*AG^PP_M\*VRS<0/NF<P#MVR@D,Z
M(]"^,:RSO<[<_"_PVU)ZD^@7D"[835O(607WGK)2E3V+F=1GK&<)\)45VXN9
M![098:F7R_,(>_[7/UU;YG^:SUR'/;BSD\<P*]M]E^1JVOT%=7Z72*NI/2/;
MGOGRX/ATP96.%H,:%JW7Y*5_]PXU5:_HY&*4K&ZC#!<RCK(TRA5N1+"G;1NE
M%8!SM;1!#)&XJ0)%;2$-0P_#%#W9\5P/63]&#RR!L7P6/8L _Q:<_4CV*0],
M+U*XL;2$.FW["3@*%)"0B/M]V,$S<0'853M][9;?2 O/0-?$,7R%0-?D8&4Z
MP=PFZ:F$V\OSO!/;[+)0/M/P>TD/Y]]8H0E8/O54\+CQ',T0+<]Q:7>L",WI
MGCAQS&A20KQQ3].@+8*(?E[7DC5![#^<,<F;WY_87EK+F]]8=M+^*X_MKGF)
M>HJ"V7/-8Y732QO1\[@J7$RS).P!:;QLWCV?\8%659@<KGS8--2G3^Q/35KX
M\K571&ZI%P!S8TU7'.7G.BTY%BN._'WHM;.0Z) ?^O1KUL9"KK8;/$)C(B#)
MDNS.^SJ4R=F-[AO)6N-]*D;#7.4C YPX0OXWZ$3-]S=FD=V-85KX2HERNRCH
M:QA.E:&WU\2/4Q:5&S8D6,+M 3^\?F",>8$KL>*'[8!-I$ODX.3:W[46K:&Y
M]O_TB<1_*S!MK#"'BT$85C/>_O")5:.7*POTH=L20H7OMD57EFDES83*)SAV
M\DT%O2;"9F8F> '&Z=L;5J]%/"O+E B0#G$*FM_=21E]/P+YV3\FZ@O2@V7+
MGA> Q(.$IROE"ZA]_ZUIES97J[?51U>V:!KAP5KSJ@&983]97\BM&]11NOH2
M; E]^K)E]OCC2^TH/%,)-HR\?[,5I,<'HXN] -P%LN S>N;'DL.@U?.0UVAE
MKM:LPY.MN!#GE\C.J*CZ&RU3<BI;?M>3\MTYFQ6,Z@<875/4/O(L4!"'"(@]
M39RC1[XG?K:W\_;A[T185(YWWK,CWN0^6T$W3C041Q-K$VDHHN-8L##$GY0U
M\5F\H-PC;'//YM2"=$ L)GR80D5G/,6+)_@IDR0^S?P4XT]/]?Z5?*IC%'0S
M*S_VP'Y@08XED>]F_Y!!TO(7Z:%#&#3?5A:R$K\6.DT*CA&>Z<'#V7-0%=6A
MBGGWRO7-3.KHPQJ*,C0,C7I7B].V49SZTL(U]6@L=.Z@<'9<11Q?1!NYYJV$
MQ@:HW94R9M*5YVJ#Y-#=&*_1GT"_*&TM=PAH[=7/4Y,K7=>/".AQ3@U4K4L<
MIGY8V)U+M_?E7PW&0P@WU!>*J+1??_;<(O,CUL3XJL7']P! BCY@)##O-MXU
MONL>*4,;#XUHY-+IZQ*8%3>=U!D_KGS5TMZ:%C':=TOS>B-]Y5APB"]^WL)R
M0&QZ$;^ X2L_9P[O[\;K7P"HPVCU9' L&*WC%;8S:QJF]:CJZ0[\P)^EGR"S
MVDE.<Y60Z!OWAG!4.'H+_8HL1LF/'";=YSSHFEN*R7V)0]N_;"0JUB&A'RSR
M0N(0:N4O"O<$]9G7(1TO_SK0H=0 ^7>X6D)";YNLD7Q@RVIXM;>MO/V$VP].
MGZKUC^?4BS-\,D6<([-&%&[.5 8IKK<:"PMR:KC'O4-P@]+PC74M+0-4:N^A
MCG8D@5<%N/S=FKCN1I?\D"+(RU\*)W2]OW1G+&<Z8NZB@]>8GW+-Q!6WS'\N
M>/9EQVQ.\'DJJ#EY]R0)NH>X%+1S4V=WY[LQ$G-'>NTS'>RWYF-BPSD7X@Z"
MQJ@'CG3\7F/_U&VVW(S!<61YR6:B<N\#(/HEB%]CI= _TLR(QUW)X=Q=]!<
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M3_-'5_S#FOVBL\3_4(34.M!G%4IUJ3&:ZE9K.-WDN?GP_9T>,UFEJ668C<=
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M0Q*ZW%%*"0/)JBS;9!%2*DXE.7I9;D:6M ^DP*HD,+7*T\&S5))CZ>$*KRC
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M.=^J%&QPP_/G!-;?;_U[U[V6FS+WFV:9U)MR[?IL!<XY H"Y.)DD"I.C'&2
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MOB'1[*4L]*Q-^:+G< OE -#Q1I'BZ;@N&7L_BR/6H:4Y76DU3S:+K2 H1:@
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MFD;EX'= /ZC(D%H$#3U34UR-_GIQ=J^2"!/L*#T#_>#EW8PO5[D8+BWXIPL
M-S?-=AA'/ZD?'[[!P8>[I:?3P?VE*,,%5?JC5^Q^U(!Q<._K1C_IDQI^:XE?
M!<<-)_>J)D\-,'14AQC.L9\M^R*KB]=%-&662P65L;MRBO-*&1@KJ4$WC.C
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MOD^G0J"@>61[O+-* A7.^>@C[B""#W0$M%_?&M_<LM3/*'!/9Q>/0YAOL6O
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MQ6X Q' F]%5%7$,PH8+XR<0V/JWRQ>3Q[\H/C4Z^$T3_E3P0NK/="\W 3OD
M*H+?)]5N=L97;0Q0]6;QQ8'*K0\Z[>%U%ST#R3B9,+2_OY^P,)>@P_3[-$$I
MF73#YDG*2AVAA1/^2"PD+O2(4FB@U,Y<.0GE_?KA 4:;FF3_J;Y3[X*UYP,/
MI+5 _KP!=LK)0*WQV*L^9]9#E0,7%\ZTQ/YX-?O1H&R@5(%C?SUIZ:EL,[^Z
M.UFJ56E/(9589[^:NO%K'U*\GYI*P$BV6#Q1L4V!.' %8 ITT#3?O@)0$X2
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MK)R@K2+819O!T"2R2,0E?,"3SYC@=9E^!5C-#F1N4[P,1LJWEA'$\)[>Z\-
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M-_:JH^H\_GKWM.7KJ\X,OZ,MW.>U2&_TI0!K[2'K;.S,-\<KIY)H.V+X0:O
MY%B_1.2C=V*& ]:7&J=*C0MP BN@,X^ET.0+U 1SA$ROC=ALRNV%F*?Z2"VW
M)%+HD"YB?.V'BN(ZOT?0-7#5L?R.^B\O"/!_J-T;+"X_Z/]::I+VU<! )]G>
M]O-#@!K79T ?NCW*/;)-) %-@CS\&B"7K)($!V/<'T*^6_3]BC*9AOG<HW[>
M,XL.@J C &2LCL7_\'\&55X!XMHXW>]!*?#=Z*_KHB/_$$1QTR5.3[+*12J
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MDG&K A&97/(J%<"0&HBT$Z-0Z\ U'KPW&'.<L\=CF_]7"Y$6$]6_3!74.,
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M1H)#G))*4Y 8:;T _VM A"NEL+1M1<.9EX?&NZFS&XK7T8/K^<]L8<3MW!#
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M$6;1N>D:X#0>2/!]Q(OP4SLUY_*C;PY/YRZJRM>%(X]ZWF<[)H7X2O:[L&1
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M)I M3]YL#C8\T.M$E7(#J1W"==9O?JF!BKEKN79:N=6VO(,)66"5Y?YF>(>
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M*IKNB:P ;R$J51'\9*R)SSG.E+5%S/#NXY8OX4#]/,]@I]=2B-V^#LL$L./
M9."4EUA *CBRSVK]O52%V(+95/D+;1WM;&GG%Q1)O9B#J'86I ,I$F23X*TN
MX)=F+<CC54E#8D!(,8@B>6>< !F*&<+4IV9&LC[4R5YB_#U]FLJC#Y;?$T1
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M$%-FB!4J)7I%A7OC]#65IR$92)?QKJ'M5JX"F(]\\C]+:4@WK@%X8@A:&D>
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M$K@U-X0>&RWW7O]H>ZJX[*W(1:P>^G.J\'DXD[259_-<!W,@$.W?#27\W4&
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MRQ]T:L;KS9^-HMY,BYMK;C/PRVO5-"2 6]K:VYI!:TU-H>P.R<;FVGKD&B%
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MS$:%C">WQ"Q,1SZ6 U7CWP1B')K;ZUOC730737@;VT-<G.!1OS*%-*3+K??
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M!M2DLR7/Z!DWUXH*/K3DU+0#V. 6#Z3_LPX?,N?#E*6K0UW&XVGV)^+LSVH
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M22+(PQ'_CT]UMA-N=#!6#\B505604LYHO!JIR0\]Z,^R+7RT1$/-UT!1DR=
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M6L*NVODE#R;4X\>&=1/T");5Z/$BSECO42%,"U483LLNW3FQ$&D21W9)\GF
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MK>\5"Y]#ULRF;MJTIU_Y%#RX<:_W;C@':_ET-3B;86:]*N$]9EEY-?YZ+RB
MQ<OR21\D6$T.YK(),>>%/C8Z]4S72&$48M.=_S'9JUMI:.@LYN_0T[C3?2>8
M$@K&CU;$D:(3WAY?DC!;E:/2@,4F'XIW"O0B-V:ERU/?J4U\M.T=+[,R?3RP
M823\IW(G[%;W:K+5#2C=B98>)K>V FHZBYD7VAFSPS:_LTFV[HT#:K4GF4R#
M,I3 <PO8N@X53L=)FGOHZBG..WBC/B6*B4J0(IJ*:KN+Z8LKG5UJW$>GU-?:
M&:XM).FN%=8A2RPG[[@C3S^O2,6.J%=O']X]$\'=L@885TF.;+^24W/2$1F&
M:XJ-%C=T*J2'C::N+NHLE6H'QFC)#<6Z9Q >8@(.;JZ.9#+'=O?NQS#U_XK>
M# ,=*2(B!UN\L[M&G>7DWX".)**=2K]4:O)H20O8P"MT!E;F]XADDOE.(M88
MG05^) 5&<5W</"$BE[:MM>&+C74$X]DE2=3C1>=,!*E=?VX4QX<[>JI/7W?!
M7==E]SG#H4!T]RW'U[#P#MY\)R56+#'E=O-4@QMM[^+S*5<,*>_+AH9X@1?M
M=#S5S2.9AH%V#A_FXX\9+@)Z"'_T0BE"(99L0XXOM\ TX?R<8'SL,(N+(J9V
M)K!<6U0SY\4[1!B"[R*.W.GK)8DTX3DN#>G!Y,.0L);+W;^I7S*=\_R6KNI7
M4(SPIK;,)SOC8',10#35_#"3H73M\<>"6KFVT=^Z;*M7P9;_=$//_PQ(3_"H
MQJL8J1FJJ;WXO/VI7$CH&HLQ+<NS^R&/F*4)Q[">Q\K6I'@'OS*H!UZQ2!(J
MWY5S2'!"/U2B7<&^7?XVF"$=)+HLS0OE#)3<?/.*#2KKC;:E*-"B=;+ZTOG(
MS\4ER,7'-LC-(] NT$.Z<B-G6OR;Z9+I-]4OW\S,%T>JZ4^.D-_IOPS%L=?^
M2TT:3(K4H?*VHJECS5!U8E!C4LMMTLN<"K6+&A:/%P2\;X\I#Z\<9K852TRV
MCBQ* B,L<\A_PFRP.JA<0:Q:K( 7WR.P<44W[8YU2T)$N6$*Z%90JJH[.-]P
MR#E<D6H47&62CLK>72T?4D<UT78!R:*(G"754RN+IR>LK7BFLB6H =X:,>Z'
M?6/610J>NF\BRH?W*;<<8E04_/K] T$$YG4_1F6:EV?GE(HC"L:?>68W!O\5
M9K6IP^A9[-,3N"EY?]QSG"JN5UUN3#:5DR4\*[B/[5W9&H,9A:5@BQ:O@+IV
MG*->M4:E *RSBQT?U4L4Q.::H,RYXXU'JL4C1#3T-L)EA0?T8BV!@!$L+GN9
M2:QGS"O.V7P2 ::%1_495(<BK7$,&@(%7:[G[PO^7G7/]1-%(EGYN1.L]T&)
M4W?]0+^(F4>8WYMQ;C0BLI$,F\LVZV$O#.(- E5&_GQHOZOJQFK_4FK4QK\^
M:%8A60=.O##"8LEN4#^[OT[3<\/W_@E7=Z$.GE_VH$ )N,VX<K.+=S>?*("W
MTN;NR^PGS+?@3L,KN 9I1[G=VW#:[]PXI$60WW87S%TJ.!N^+>P%D%W ?_KC
M8(MJ%.COM)CN-S=*/;NL(_-P+]/:/\R5\A.> 7\Q#.FLA$!N-PJ\W-&_)!%6
MRE)6S2O7$<,5OI6X)#EQKH/$*P]Z^E;N"VE;GC):"^@9GD@7S9WUD'MIIQC6
M1ZF^*,^8*SQ#_"X-%2?:_N,D[)\&3.G*HP#G+2H3Z2H-K]8O"&]=[H&U? ?E
MPD=5?]5)[S"J_OJ<&>(]YIA%!X']V1XK3<C/?&AD]M90_$0$P!:GM@?$"WP_
MR RF@02OK2+Z+(R&\3F83D4BP,VFU]4<0M?'A*.F%2QTF^WBQ]UL_X!(X=I3
MG[0X]F.<D\WDG8+)=[Z>PPU,"O6O.+#K1'1(1U^L)\'[Y<[H\/<G/;@+P4!,
M9L H^[W"6S6T[F#49,19X$^>,^GSP)<@I[4*TD.G02/L)0D_"DP4>=8=$..E
M#U##^Q9EHO&C;X[IZR-[5'.-(DM^SU4VAY7^F[7N_QT65F\)-)CJ* [A+QU4
MJY6LWZUPRI'?"Z=^YHB._I$:N'XS5_V53:WI_$)OXM**Y;<.PU09S_&  "E#
M["#7^K8I8STFR$$3^SVB87C)P6+V^X'O*+?ZU,?$W?,7TT!>8Q$W$3?,G1^C
M4E4ET:1ZB8]#U'Z>G]\EHEAE]T?1XAA.NB=VY=!7.*U06^3KAF"+$0Z6J0U!
M.6S\6Z^0KJ<2PAZ5SF(T%]4EC[/N_3Q7)%'6Q5;WW9E"5N"LG=Z8\ZF\S5'(
M6';-AZ"W!Y?EG@LE>I:FVR0F.SXZ4DVFQTG; GQ_ 6!*%P\Z@C^#R-#RMGOG
M=X9CZE_[E7@B[BK$:;)$A>CFVJ8#O T<7\U#$628LOY>2&9\+BFEW&S%WHM#
M9=M+DGE@;W?=RE^S_4J#E00U'#WC%'ZO?X=F=+3W#Y[7=Z,G"\;=T*, 5;MF
M56/$].&3W;0)%9[4$W]E*UT56+$\AUH*=MD@Y(IE\8+NFJ5-Q-V1X4B<4+$8
M@ZNWCU6^GO(NM^Q4 S26:_LY:^@E>1#8,&-"F+MR&.&YZ)9"B>HLAXPQ@'&%
MORSUS(9,LN!$H;:@7A_:<]I6ARJT=R)6P-ISNO1%_FTP@OGJB*LV_O7E;YZ*
M_PZ@H1XX9?1XGR;P@#-220&;%W) +O5!'6,!>SZQO"[([9;-U"PV_D;P?MD3
M)_JI9WW.W+(,X=QTX3T3I5']F*MO_+-PU+"+JU*!WFG@5YE!N4 OS5%RHD*-
M,;N_730\9+@&4M''%IG&^U_(>\^HIM=O730N"TI5>D>E]UY%L@0!"0)20X^
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MO!]T K<DW-?P\>7_W'/#5]#-P3E-V-F%LU/FK7N[TQ]Y8CFQHV4$ 9+M!Y<
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M:.,:#=-Q+4(L)FQ;:C>,G24X4$AV3*W?!4LAP/ V\:?"7H@#2H7!7VG_T8*
M Z^,A\7"!0S2/?T5%KTH<9&EQ/T:0NU'YQ$Y**-3Y3C[?*S189%[1.15U$8
MQZ3A==?JUABIU_G?][]#5.P+38.;JCY.GXX3Q/%![6UL 6Q0&!;\L2Q@,M<)
M3L@<,XIR5&!' 0PGJMFL;\]TU2+SM1<->A/H.H5O'J4G?+>8G=<B1A-8L(-*
MP-ZKET3RW4@L_8^)^Q4.]>VK!#[/<63J:$2E=V*Z@YW4<H/#=)("_@4B(E@
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MA83DSM3!?HN-=T,5/L+;1_.#'V3[!=GBGGZTJJT+4W=S<F-]>SRJ>D.WNVV
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MC&D+?N<]G53DIS_=U5W,ZG9P">C@7/Y5,U&*^RS"+EH+#<&A.WBLJ;%DC]4
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MEZQD+ZM8%W-5+V=1 =>DFD1Z[FTU_?0?5SFQ/$@O 20>I>>JE^# E>!2'=]
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M\)7 WU$>^_R]RGW/*C%6Y=5'C9,\?'+SMH^-91@?UFF@;C]9VISP^7X5OW)
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M7?+WQS>&R.(,QS'O5%J/!5.)HD<!N"=$\PGX[#T,U>A[W"T>%<,:4U-HIDN
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M<QUZ-DVM'H%6 7&WB>V]23SWZ4YLBV7$U"6 2@J>$X4+X_[:4'Q1K;J\ CH
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M4R3"@G()I2&"!M'<=L8#OG"#2<RW-UQ<?B?1%C$>ZEIHZ?Q0$ 0-L.J?Z76
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MQ'=R%63.'*8D1!N4K%ZRO''F@_><4ZR?4XP#T*.'=K*A]FGV+1"H<L_0]H$
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M0,,5NLL?>,,L,YS9^ 0&1>7K<\'%BI-@!T$3#$[0"/6@0V$,J5'/8YKI:N*
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M4E,.,OX9RG7F]"]WX$YTX5'MP7(?4EA<N>PBR+RNU&J1GF+P'G9 RAQO4_P
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M88<Y5%UO?/S$]_5)EQO!Z;JU7&G !)O96%[( EO3E(#-J>"!.^GVJ2E!P[W
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MQ"S5P2C^9U;8C+;L]ICR^=M_=^,_;\/1+ZZ6+L;8O60Q4A8;T+E8Q,&?] >
M/OG+7P_G-.NLK9'%"S/P3,O4!30&-J<"MRG\;J[M%Q#@Z[[%S%J;EO:#_Y?\
M[:?]W ]P7+WG]%Q4ZF(K^10%6<I&\@8_Y!)WZF2EP4/>NM)[YB"[6>5IRQU9
MRT+7', W)9TP\[MJ&B\:)]#?#IH^P :QXQ(QOUU.VD] U![4Y3. W980F@B+
MC, 0?M7M^3 "R>]?C <:>+_23K]E:N$G->OP\/9%O5)9\P"AM2@UR96V7 A6
M_J?%A25!#E)^D8T45A!G2O_;;I][*&PYIG/4?U&BG__'2RGN$<?G%99X]^30
M]<*HXJEJ9*^5=)!4H#BQBKVY6J3;8+E5,F]84_&^<DPAJ.U25/Q$=>GQK8J0
MC@!%S)-R-AING%2A/GBHE9&1(\"$:DKM6R1J/?;J9"Q +!^]E^?E^18=LS>,
M#P_'J1*TC66B^6 LFZ\KS@#,.]DEU4.CV-^OIO(3-.XV-!)/YP2 OZ X*P[B
MKU!O<1D<+_.(]_ -<H!:K=9C2;61[:7/8Z4N[Y+XZFKJ_HR6?R2;U#K&/P9*
MUAP62]AI4$7Z$"4CN<7Q/R_@I>D9*N4^LB]7.QO$.P\#A::I9X!;_2QT(EJ9
M[!8@(;RUZ)!L2WZA(O*]E00"3V",5VSVXI4>;/BL8):<:X!K\,>$?Y5&#/TX
MU;V\:>CC(1VZ6O+!QI'@<6CCZ-D9<$T_[]FG&-&?PU__R]**_R_">)_\@YCW
ME+Q(3.^!7:])YG9'5*O48ZN:W\O'2YK7O6K])N?S_+K4Z&&).=>::GNF N_%
MUYI?S@ \5GS$HPJ\Y,VM7%;2E93&UTWX%IC>MYHLV@B!J@G9K(92M[+\GBM_
M-828] N+S/H*BRA7[#2VY2:217Y]822K4.]MM/'(7I>4Q)T!F$(<%D3W^&89
MTA.\LQZ(E^?/L"J< ? "WUS"BF)*]Q8WS+I6<1EN;+Y[=:.A(;SP=TL*4Y?4
MLSAP.R^J=9XN^$@'6MIN._;U-HA=!1=$\^=I :-*Y/NU= _D-RX1.A'(V'TD
MW;ZS;G6_PI#T( (YHS.^X0&VC*@59;A>P]ZOV">T)?QP/:KO@8F_GH\4*_+]
M^+D\O0;<^OY/UP?^;P"8W*]J+%T81VD"3NG. "'.@31G@'#<B3)\06"BE#JR
MM!NF 5_6MNCG/7&JN"F.JPB53>>73D\WKDLW=\@WCB$,XW[5CMH,/4<6;I)[
MCAC) # @\ +Q9T;Q=%!Z#Z_<+?)4S]6G1_-FFTIHK+KV-[LYT-=S"_".LHYV
M! 3MTCFN0^LC+^Y4'_D@"\'7W!\M)5SNWWA9="*VK%CKE851FX ;=QE$3K@;
MM+6PO6TOEBTV:(KS<&,YM^*M.BI-D!C(Q$H,T9)-V*/H3BK8A(_A@SG=47)T
M9(O6&MV*M93MW_>K+880I:J<FR(^TANK!YNP[]U=S'JP"M3@/WT2X?]DT! D
M*2RZ1V8G?TH%CU)IQZKEJKZ?RPL6Y[)[_5JNH!(>FF[G*&FSV5/@'Y,K5Q*G
MAZ*]^9[NU(@FDVU@LP5UGWZ ^4=J8(Q.DZPSY='E\*E&M8H"*S4![+CLO-J"
MEM:6Z(=AQBN#V"J5>RM,">[*[14KJ*.ZTYQ#V'3),F_3DI_QVGI'W6K-[@4G
MF9#%F5R6UEP])_JQ<,-D@Y$"#>\@DROQ^8W8$T<5'O3A1R2>,;\PHNW[="EB
M5^BC<_6C<HR]-T9]OGU=1KN'?=SHH[ILG*U(DN-(3T=^H3S(14CR<'=#>+F:
M$ Q$A8&TXM:'ZZ%72=S"49V&+<^&(X0UI3!IPMIU!K=Q^]E\3^@L1GLWOQ5J
M)J%3H454F[_G1YN<LXQ_.>)7_# KR/NXF>E:E[<P!V^L343:%\/]X_/C&28B
M\@KGU'UM_5Q$\)_J:QIBA/'O_31NF7B*A+/HI7P4&F)*^?L$X=^'#C^-Q>7Q
MC\5]&H479,)E?ZIJ>F^.Y8A\#C<SLA;Q$1Z/L]=!*W9UNV?S9]O3=M7W2>M(
MQ\(+,D[]@WO;@ >[,Y"EBHA Y.W9+H("'_4+:3+CZ@2G?>Q!_0O.=T^5P=II
M&.[:F84/6:C^L1I1!_[WY7=RH#\TJ9:0I5P@%D41THTW;A2,\F&L#E0@YQZ!
M.4F*N99I_N"*=26$?1=C?:G'?52 CP0*H_/SO4J>8_I4,BUO]SST.+;B8+\=
M==.&0$-C[8'(K$P+2-FSS=AYA%8DP,>L< ]61TY ?2%&<RDVVB_S8C]J*WQK
MH%X^%:)P8):&HW]'6+[!#7'S=0;/@O&<M<EHK0M6U<<+VD,_<YP3V03#GJ>L
MFYG0KGXO'M1B???W4+(1RM(_K5C^WX#=HBXL8A&GN<$TFYX;=1VS!,'$KL5P
M$'VE@GD)K5T=<#97*.Z5=$6D[(])+?@;'VW/7ZH)A@YVR;SR-]<;D/0K&07(
M3*,C$_H26BA;5%(=:)P%\RT_2].()(?698P,G\*6&6>S5H'S0NK5%9<71+\J
M/(K<"+*1)W#W,Z8M$<9;<@2-H66QG9HB.KFW+T7&.]M)EV7FA7\T*S$.A7"W
M+:$AV$2*A%M<%8(1ETY%GF?DL.1%!^/XRTUE/A7LLK&,,7*?G__VPL'EFOUO
M9-S=M]GS/NG?4@S,L5*%9#.7#@R81MN]-/W[ZAT=#?X]#5"2GV"R!FR5AH5T
MW[IK3B63Q&LOX6P%C\WQO2(H9+U18M"!%Y:WWW;_X*"/TV]K_C$:F[JRLGC*
MBO#],BT?T<R":[[U;FRUOQXI@0Z-AU[K*)=GGBNQV1?3C/4XGK1-*(GJ>:D(
MNU=FY1$2K]!]KO)%UX>Q_W)3]NG=\_SI2NT_ Q";6D49HWA%QUI'B%-XV]7<
M/%^> ?-MBL;RK=HM9>)O4YI4+_A+([E!3VYMX/3'L8.M^L!X%^Y CB7@)40R
M 18/DEL"7C,!HPFZK(Y'F0^3'1H,Y=ET(^H;4D2O!W )_5G7&#Z;*#+4O4#8
M?%GY9!M2@7R#O J2)]+@H>'![ A;8Q/91U+WRXK]GHC&(SNA'U#F4ZX1II3^
MD]&U!;8D ]O"'MM"U;MUU6&,&\"\W8@SP!;J=NFN#&Z?N,M@E!==QOF^10PG
M9USR]HN95AI:1$>4(SZ^$&A+I^#_^7EWMQ9Y^$?.,HKRY.>%0.%WRX\3N3P6
M@+=#.H;B?GMPR#.:?ANLCNW:'^E\R2>?9FLDJ8,T*8GIMMX,>%;E$=QSKH>.
M)9!1UO\%DM!_AJMJ3?C3ZUU*VFNA!!<V#=*-R*+.%^.R05XZV GOIN\:E[M\
MK8/HC^INK5RJ,LE1!KQ]QQ!L%^AX;GT#RBW2\L+YM^N'EE \;POX-U2W1HT$
M#$'G5&U#*MU^?IR0;9=%"5$')I?'MI=MCH)X)I@X3S4_M<*BZR7#$3WTG^>T
MWB]YF:A)R)88%^#C<!BKK>L)'T5,YN1FFPQ%Q_3]>Q\!D5^"A<GA^#2Y93);
MK$PP+T;? Q.%LW8J;K![J%<5V[/*7D^0;O:*T91"- O E2V5N]?WZDA.5-KY
MD^<48:>F?*(B.?(O<S;;J6#N9U0^^RC;T'[\"$-=#-XV<;W>^F,_G/;&E96B
M5FMRTM[0KFYC;C=U<JW[:!(:LCFT1^M27E80MY/$L;-FF,:A]Y:1.ZH\W_J-
MW&G;5";Y#+"TV)$8DS;H0N+"+X927M%;/?-5.@HM7-A\B F!?/.!OG'T#WCS
MU-39=6?U^5,HX!TR"Y&U@4XE".BWT7KP"DHFN^I]L3>T2<#-[] AMD5P!"&#
MA/X9?&4-)[E@H>(D[\T9P %U<PFO3DN0O_Q"IEY5[?:0 HP%E,?3SR5H7&N0
M<+Q&PV;EWR &EA?^"X73%%6EO!B!C58D(I=2VJKE8^A_\3)G]0!O2,Q5M]^(
MK(AW4X^?I?I_)Q?/FHR_BF+2['(KF]Y9HKEV$=K3*GEN424R]=L ]2*Y!\_@
MYSE(SRO^30Y%5\]C+"SA'1WX(N&+;>"(&U/#A>:BT)MMT?80=3?FJ@R-D5YB
MPP3[PN%>8/]U(]G:59R-[=L>S5/F!U6U0S.PXZ8(<!9$?8$O7H& 0$GAG8VT
MS&D[IWFM(SW<?$"OH;H/^^!%=:7%=C=UO6=T%N-3H!N,46U+'\X -3\C7CVT
MHOD&,F)6K9:/#'3!I]XH0>4J@)21?UE^O<9A:&XC]?6B&,E*KIC:#:RQ2ABH
M0UYHY7OV?"E'5#G+TJ 7*.H07R0:%]K'RHZSI\^G^L43SP )56N3\J'UJ!NI
MI[]7_-*K7B^F8=U'T;)-W2Y^*.QJL#19/:=;NJ]99XG;*;7-1RO64R J_L@
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MBTL4N44J[_!N2]*07)4T%218"6(6N3$*%LDRY8N?T!%9]LF))'E<8+%T+IS
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MF]FH/"37>)MRN#Q$Z-W,XA]54:XVQLA[1R/],S"S:@YQR3NY,\_YH[^< 53
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MLZ@.S+<*\LAWM/E :Q&.-L.7M'[(4)2QKD2Y_37G 36ZIYL@=F+4_934&L1
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M%I5[(0]\">+%C.P)?J#8_5Z%0@EMIP"AX@"0+^K-Y,LUY .C(IH'3<+RKJ<
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MO#>?RRI/7<\AK"C&I&7D)O$\2">]*4W/P3H !Z0#!?[J<B$QXSK@+WD%OW:
M[T]5I _ 9V!&6>/!(2G75MQ!%AN0:"(ROGL@GV<0D/>NX.[E!\RIQ2JU661'
MC5"?7O5H.R&*"%D*M_1?=TG!F+;*)H=U1^A6HY>*AG6^B'4=0Z:"2F^N?'61
M)T>V0/+RPSLZQ SVH8IC=*^]M'*$%.N+WL^HF-ZGM:PU+97W+'Y.%L5A\1E
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M5"!:>0G+R^';79QS=V[.,E "=%GG5J[6^(XX\N?<DV9GBN+CB<"K+J")7^'
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MZ$FQ,3D+JR_#EOKM_M&$[6;$M88X]I;/U./IQ1LOK,*YUPIUDKUN-F:F4+K
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M-7*SJC<DZ9IG?<P&T-(]S\>0N0!?BJ2I0'**HQF4B%;C3W .=^2?G@*"!>&
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M9G7*!_',:R[$;/\:0!QA[+-*OJ<75><3ZV%B+A[[V$N(+FL\+7AX74^ZVCY
MC[N0J6CY&E"P^T<*9PHG_U^N\!T)QUX#;BLQX(+0L?A[V$SD8I##U_.&G:S8
M0#?8*@7PVX>[I<@K<_T:B;W>A;!I8H%#?8+F8N= ATE+Y9H)J]9]<E+Q'EL1
MAG@ZBOBOJ!VM>![BZ&(2[+OC4LQ_*/H3]VT?<.Y/NHQROY/5]<AZ+9M&*CLH
MSNQNF&T_@XS^ZB +X:ZA9@KM-?0/>Z/T*+3 )&6V I/4:1G3::EW;G]5"7T%
MCV9K]!T]C#S>_J40B,X9&75;%Q2;Z)K_A.! ,0$9=CZ>QQ5KA5;Q5SVQ_WYH
MU0.9L OP;K<"$LV=$7IY$"Q1+RRKW!N%C8A9+BU:J2>K>-WY-C%Z!_VMFKEN
MF$G"6^-1@YPX/Z^!&N0)?@:(ULXG XU?:O=? QJ[Z]".T:_%EE=P"NU>;FO+
M[H:9G*QLK0_A2&IX9@M1E9DFLHVE()P3?=6N[7D-Z,OCN6+$F$E'CN$4C45;
M]=Y50Q@K]<>9(H T\ 8O6A9,T^?:X9!>O;U$??U"4R8#KV**$_FO;*4.P,P!
M@IXN2=UXTTS(X;W0]4Y)6CV^ >UGJE=VW=\3A$RC4JK',]=VK@'VHZ/CU.%#
M.P:Y[^#C,-I9[/I7:W&L*TK[AKJ!SA 6\# %S1*EQ2\\YDU)LQOZ,40UKQSN
M,@TSO2\^D"25=1?P>-0[VT+]=&@KJ?9GUC$_TM488>LT@T ]-DKE.^:?RF6<
M=NEN'<NU,*9QU"WBS+F9.BU!B4FG:\ SSXQ.;F72B(%77F9@=U(Z]3P.TM@>
MD]*H'I3GR>=2K2XV2G7#8HLX,TW=7 N?%)X'Q0P24S?1U2#WKZV[\._6SB-.
M%; #E]J[^LJA33Z?L7Q,^1RFV# 442D,O?PQKM[K;DZWVD"DK]E[/HEE+H<C
M!R?U4M\2RR&A]*G!(ZO%2'$2!A/-=%2C H):R$+F.1>O<267[ZBLY7*Q>A9X
MQG4FY?%$V):)9["W-06UEQXYVD$G%L7*-^:-B^#ZJII/G;%I%FFSK=)TSJLR
M^'NN=]8901&&Z*GAH=:O,'MGS*<E A7?OI"J1;&8(%2_O_VB:C$+LRRK>CO*
MH]78.BTI^.3(C_A>=6IJE?>2U9+63P$O5:8.UK^RKOJN$N%KZ6D7@<[Y]^'.
M@4["'C2(P"(P=_#;O/[Y?LYP(/.JI3RB3(N)'"Q=^OP4P,==&Q3$W/). ?B)
MK=%TWP,=<FH_90 DW2GM995M@UTJ-6(H@,$,OI?UCQ*:+';TA2ZAY,Y44AJG
M?EG@>929J3%\QB%8_L-)'-0=]/+8<_A(.GQ<9L?F-WB!G+;NG)FQ.N45=_7C
MSC=9&Z.B(GZZR<#YXY\E;5Z5\[,)YZK''RZ\MJS,F?V)L6H"'O<\-]0,[\6A
MABK,K#G'>.5[O(;6\I4IUEPJ6^<,\/.UA+I6YY:G/RQ2]_</)"ZU74E)+0.9
MF/A!;@+[56O1"Y.3LRN2T2L+"RNTSUZU!',^NUE0SU!QQI3&1K=LH_DO"KAH
M"FD*Z8L*:9(TN5XG67"F10E2*8^;:QFFE,IJ^:3D%/-*WVPR_BG%/'X_%_\(
MW2_OTNBKB3WYKP761L*B-NHXGT#9X3"*5;B^_9(GTJ.I'BE,\JS& *F@BBK%
M#S9W-+W2N-"-<Y0\A=/S$+Q-_^;1NN+@FVWC+5 H,58_N=&](4-F;1/ELC06
M3Q6Z-R;2=<)=,*@K/^0=:^!6%+@DB&B+H/,24NEI>T[[?#RR,;:#ZVM?R5J]
M;)I0&E7*KB1ZHIBOHMBY0SWWL:ZWBZ@;5![>(MV_HR0'F8!(SKWYA9]" DFM
MX!\4Z*ET3@\*0-Z;F\0P)F_RN827LZ]G)%N+^!J"TO"SQ.*GO@/?:/2!/R&!
M.>LR$;*CXB,][J"E19:H 5N6Q5C'R$J^O#$ZK+-^C%%9M_F3E(<W.V\1?(<C
M%&0GL%9#A\13#997F /)-^B9"PE9C1G&TD@I2)16JKL$U+F]TCBH]5OX8+O3
MY3R\_W')?8/MZ3\MD'?Q1]1B$KMT#2!1=JKF[[F(6TU&ZL5,J*SEZLIR+MY1
M>N1L[4&P*R]V>^F>M:8$T?#]^D5L_"\#AD31\PV3JEKWX\5%'?4>E*O\)6EE
MX")_A[]3*:P#ELKSYP;1P\(LXD)-.]^'B3-FS-%G6--(43!_;X TY:N<KOH4
MNVW;:0XAH(<ZU4:?S>L+PSZDO26IZ1>Y*<WJ\3@,18C8(:4,6[0,CZ3^13[5
M:VPG;"9%%E\>54X.OJM$.3\[7'^,_G%!UVY<-[VH.ZO<LLL_ '5<C9:Z!C J
MD8*EL;G$,>,88+B .\SITT"R*XK_[PO'J#>?;Q?Y65RE%;NR/DEFUNHSRBW\
M47GE_M6N;C[O-D'FJUV^5@4$<?B #5]U!;+^K4UD@;[+<2[?QZ29P[9K@'1
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M&%\8[1@4ZQ(_R97SC+4A4GO<SZO.R_GQ!JKO_F-(37O,MM^!%C>X^JPD"=)
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MV+_$Y2(HK[STI;H/RVA\@1O+<G$/ZXYDY\2WTLLJ_B==?-> X,";28A<;8A
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MKZ>#1\RIE3"*Z[F4^>7\0OCM:-XVU4?]0H[#NC+G,^7)MK(T0=7/K?^"!52
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M"BF>K0HL]#;H'^]> ._QT3CWI,I<9:@)?5"C,2$T^\<@*LCWD@HR?GBIB@M
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M WK<%DH/*T#772DL"N9!(U :D2QBE"=MG=+([(!GVX-<)>4HU["X!/6D"4[
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M>P>EA"-618+%S"R:B5LV>+D>R>*@*V?D%#EX=AVH4C+1,XC[RS*FV)$OT&A
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MCH)5VJ$]G_.*'3: _LZIQ:K'\E(%Q)C8XQN>DQ,O5E)Y"AHZ)X>=R<N_%UL
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M!@=QOBO0VVRN?(*2[FCP/GF)JW?9[TGL;0NZ96KF;':I__<?G_[+(:?SJ@O
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M\ )PHZ$HS_('\8/2@O?$KZQ7^IS!5(>,(!1([1E;*5;6/S:A<4H^YYN\,\X
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MC>&^@T##G)^JLL5YCFY*B\ZC*^]>M']8M.>^'D,CA3+%41=NL;2_+[5TF66
ME?YNJ<SZ8*FBI]G>/%9/KJFA*0)_O1JV=I/,,>K)RRV0'X3G<LM)P6,7 (K8
M^IQ*3*!>E"*%$G4=*L)OU.7MIX@73U_B=+(F5;D"4YXK-_M:GMO<F/>03;"?
MN  $HN.+;+2CWOSV<J3"[)?%C:0 ^<MJV=@7#P5?"@6!&,.+ZX^=ACD-7?G\
M/9:'5,ZS"<:I9=,=E. !$0R+Q%J69#!WGG"BE+YI/0MS'/VR][R;P_8X3KKF
MK:R;;+-AZB&C6K UA.-R>16$&[CAF3=[D1;NC=AXRU0[#]^W-> "!)702R.-
MR@U9K\V45E2JFS9R,L7D1[_]N+GQ"FA4CQS?BFB7&]GYVT.4QLE&Z%=5[ZEL
M-7K!I-=\S.'NU1^I&9#C.\RTGC1/K#19V6L$&]2@ZE@4"[:$<>2(()=K?U*F
M;YA]B[Y9HN[5CF/$=U.CZFF[.4U%_%OG;_3;T#M>4Z$V]_'.4:<E;-@P7^20
M,;N@?)L-_40_SIA^+HY<'J%-G6QKH;7S4B(YRZ3FZ6^G_*C3CP?8?S:X_6^C
M*PD:;"-]%".%U5KQ;-5/HW!]K##3N"<OC$?&D]^\,$[Z]/!:%%$+Z$;U+B%X
M&,A!,$63"YF&(UA^YF)3\+<,F+H@8I5Z2L@2KJP4*!6J.^B+@I]D?\8;4_>K
M"^J6I[/P(3&\0.IW*KQE[M427$^X[5$\"X13KIVO3OQ_A"1HNCD)O"PO9N7D
M&^H:&G!T=W=?O-'<J9SZV>Z)"@NZ*\]X[K4$49<CTYAUM)+8\8&0"0>432'4
M,X@3G>I3B4?3%EY=B#NZOE[RPBK\<]FYDQ> QR"&"P"&&5S[H?] 6*\:':QZ
MVGA[C3@*J1-O3MH"'@;*P/R9-#:G3T>_FY0;Z)<\)LFP=1TB]LL2[2_EVN4=
MCS]^\B]CIN,SXDT^W/ 9M)-#$'^[TL9CG'!;N5T8^\:[+YT'F],(9K3ZVO@(
M.N'4SM6LO<ZW9HMY%[UOB88"7!>@#KDQJ1U7@F7!Y!C[VI^OI:UME#QH9A\W
M->2A=8QULS%"$G?N.62>26(",TD_26K YLRMW%!7J4^!(01[4=+EK$Q%F#Y2
M%&9Z)J>@V6YN;[;Q*.>^M[9YD(%+G.J=EK7RD!*&[1D\=%0,@0<WHL7H/.M9
M),JS]9$5!V'<HS[A=U;OP$"D6EDYGP*2!5YYOZUG"1ZF2IO,L!K1@;YZ8ZRC
M2APP_EH](3U7ZE&WHS4T2T0<S70U'/N9?BKJKARG$35YZGXW0>&5+[>BXM>E
MB98+@!$7_Y!$%G<1,\^E):@E&9,\GC\QIB,]IE.</7(!4)$*V1@RVE1_GL7#
MKTL;'8.6;V16UT_0_=M+1N2O5?DE/TH@X=\9RJ GM%\ .C7;%: (U'F^#(AJ
MPS37"1N/>%JE3%40L8)R\ZI">G+C4DK?,8!DK1UD1B#3,_E--=CSD(UXB=JS
MO3-3@G/X$N-W#P["8\V">.O&,58U+$3R->]Z]^GN#O"Q$"W.BR-;.K[2IK,S
M2$G[6^<UAXY/ >L9:\Y5[@XI& S&G"\GH-#9(<?9JD]X3&LU1]/.SS%!X]70
MMGDD=P;QX:DA+G<"JZ!!\F++HEA5?Z@V#6%1P<%1"%M-<XFTEI_J1K0+>D%J
M8K[*.Y?WY!%3B,,@\O;F3"^QZ( <EC^28+W0IE>^7 4_<77.4\/5XYF:/<54
M(N4A QOCT4F"CV5[1_VR&9U*\Z.(/,")K_^JB(!OU!)O9F/)B/2<WZ.AK*XF
M($=<;@]##4YG/9-C+I/SIAI=0>?LRWG)?,S0YE:7@:WK[I1M8[;_#"\*<6G-
MD"Q9H>KX>G.OXVG /(E(V2F^KD6%#)7.%]BP4&&IS>=MD0>/3G_NF^/?3MI?
M0P:4S_4;%;IK' Y?NS/W^'9]G;[EW%PWVYV'%*YTXDB:&Y@H_D^"&G1.99][
MHNCI'Y4"KH"F.M2JR,RR_!Q[TS;EBE+/GA5P^<3%L]HDV:?;W@M40F.3!98V
M!GT>0:VZ-31'Q@ACYU_:A=LH#3^#'R9AW"*&@N)I<*^*5&R3T1(T<6HI$[7.
M%0ZVCQH<+9*27 R)/P?*A$:[MD3H]$%SCB?J__9@VS]!ICV<=7([<UC.H[>,
M&>HE59PL^/UY9=OO[909<\_'W41-[VI@V)_UG:>BNS5FUB\Y=8N</'+G36 7
M$QR9&X_"ZG/.DBP'VFPH^GT-9@3?7_\9 ;;M9/27;3Q.@2?OU^_1QW.93Y#W
M#-,/?DL?^1/8E/GZ]#%U$U&I-U@>"R11G-9JFLI>?]/\91^28[0U7F#LW!??
MHQ!D2-*_76:8K97V@V^0C7OD7 [-."+7G<N0PBB)7'4-E3>E[M/WDJ-!--#$
M\894G!?KIY1> )S6YK&M!3;)+ KVFFJ(2S'%V=K!#G3;F]E:HFX=:]-;OG&)
MD[>>;T*HEHH^=G'<CWOS0_8T/0[#SO<@B;TH;\I717$C_Z7(M_KO2T1%B-LE
MPBB#>.(.;)Q!Y!5O]D)LV%(AF@%.KW!DL>XO7N<Y^PZ<&8W5(07=WEAS:C1V
MU'Q.?S7)-ULSM3K#_3?]\*_/.H [L8][7W-+$]1+</P3NKPKZ.LY36$%MA3*
M3+(-[7/19=H8"Q36]1"ULBM.]$KL/'\4@]E1I*D?_M.+V,MS_-C.4:$J)S^P
MCF&\8Z"?5<LA4*!59:Q54[_Z'MVDL%JWT5# +SRXAL\PU!GK[E82@=\!)W:I
MBDQ4'>[1;;7T1LH,'!^(U<<&&K1-'&HW*YSL>NRM-;6DA^E2)#20D5RM=LKO
MH( 9%+DDEIL4;D[ !'2+M!*2-HVR,O_''&C-AE4!V3FW1I_3Q5@6>1?IK_BW
MTJ7/\W3I2G\57'Z,%.D*BI=H)=&]U,VZG_3RAIJZQ.6VO_[K8['^5R)KA'"=
M%Q!E(12MFD0FPN.I-A7']8 I%A+=EMS0/:L&.]?AVRZ1 ?D#PN7-MV=GBOZX
M[+KMYGFS!3=#J"Z/JL4I]0)@.Q(,! OJW%IM>$24P[+YH#:N90DT32@+!2C/
MUL>XT/4IGZH75/8)QS>@GC;&>@+)?L-_-3WN5E58BC2,T\AYI5IP/;-?8F>Y
M!M9SG,05 N?].G_J,_Y]F-RZ,+6^&@^/A&K ;T+,2FQ*&#QSR,]LZD!B-/;4
M<?I=1NNNZH4'PMSW<<1!N>W?#N.U%,*6'IN[%KFS(&1'%(B2*/Q;'Y^*;HRI
MXV1V&KJCZ9N/TO 2R4H0/6P8W[:T)R8&UKF[LNM.CN+(Q*Y.!8*Z^3ZT!2R#
MPEEV&B/;2#'9_@B6\ZIK%B7AAT*5LK][F\UWUEV=J=TKU@1)NY-'!YV]+_F8
MF8M';ZMW^_P"0.HR)3UFBT;-<B$?@VHYK,@P5!\KW;;K2U-#S]1;T2\F3VT*
M4CPD,5N/,C7 +V(BI"U/YFZ?>WR_ &@.,0]ELU$QHD$4:[2KX5,;BFEM"76+
M6:,9,=4!4.F,.E<D=7@)W:HI.UW\@4]W[A<-#L^RKK5%EC7JY?F,7!70=A2N
M(-7+AB'AN-EYQ"?..CM0GG=5F=V*0;9N_F58OXMF;ML;TVR"-+X6BUIF#,_'
MZ2&!3'^G-X)>#:BF^F26WRPTV'(NWTBL4,R)#?KJ(:M8F9T]_0R86)T<GV_Z
MIYV1,;3WY>]E<;,,II^\]V]5<=*'5NI1A\-U0;>U9&!:;S8?6?/<U!(K (9(
M4;2*]WLU937*?%^6_-E+:F(DD4:!O&U)%HLP#>_5H WM>I3]EM[V"#91PMQ;
M]C=G]F'/?SKO5QS:::M\UQW"B;7LK48\&"%H8J W%H;*CSO0W&/",K&J I;$
M]$L *P*3OKN<7J*\'M_I0BR#+N6WDZ@JGR<0>2KN,!]2D?%^7AX$DK?V<;".
M?TFTR'WWE!K_:MUZ@,*-3-CO.MF)"?P OB&1J"V"$ZU2>31>2\@5^4F74&?]
M6D9A5>9E4-8R6WNR9M%H'??A9^)<$ DX1V']/1,DPUBA' NE=6P6*A&P\4+:
MEAMBE%6T/;9+#!6[1HH7LZ;??K)X>/?2AC_9)H[^8_Y1VXZE."*U7"YUNSAX
M!\,# 2Y]HT)\_3FP'PDQKVPO%^SI>O&C&J\@EWSRF>?YM/D##U09H>OR(C\'
M4^ =CUS;<;Y=I*)$+O"6U83;NMWLZ.\<SK@Y)(/^577K>Q-UPW>>QF8YK+YC
MHX'J;ITK885X4[31'N0&, Z+:8(,!%->WYSB&E49C>B#GUV!A<:>[J,</A-)
M@T2;<I0-_WS$D5.KE]0A5O#;G!3H44A_5E.@*&*U"<_72(@M7:-UAHBZ*];]
MG2!W_H;X^K_:U?Q/D *<!>R-ZE&EQ#F&N!^=)W;;L$Q!%'S;W/5JMS*L)]-E
M<1^3]W<S/3M__.B$8PJ>?VT=W=NK&\#;S)[IMC5__=;XZ>52:VWZSNY+KQE,
MAIPZ1YGK&02^4G"T@@^^ -R^ +C$QUA(=JZ8;1+Y,WLRS(WG*%)49</$:+\V
M, $>.P?";)P[C4CCM 7N@Y))H?>#A+W-C?N;]")>DKUF '(FO>)-WJUEH:L&
MV_B[<=VTGTYFS%^K&&OU H[FS@QT2R!QC!'SC";Y[:Z)JVS:'TH$+$;[O)+W
MYZ&U.E7.QF'^[Y)&=:W2['F<>EZ?*$;QPS%<YZ!_ZLDIQ8?94&?V7@"H"21+
MKF\">'#A,6U2Z&2C'R]DOCD,Z_H+JV+4V)&:W"&A4=+.3&4PKC.=.'ETG'R^
M6AS_9]LXZ><P-J<\?6KUJV6EM\H    9/>$;M%,JF+,C#NAR ;BQ:6!Y<NJ!
M'&3M4E48EQ/;G=1VI<US^FF&Y8FVF:H;^)'$/GBD<==-0^C\B>DQ=$2;!VQ#
MCQ$^\O1*\<@:Z31P<U66U0M=BWW:ZDH6^;/:J!'_>U FWX/P\3S?RIBMMTOU
M%IK%F Z-5):(&I2@CJF"V39E<N0I2L7^*?VJP $"&1.4=61S*BYYG0@##HO_
MIYT#,!>+E.P",QN7EF_G*<E%&T?[UJA-B^1Q!ED&V:^P@"H/,='"J,7916[2
MP@QG&NGGYFE7,@CP\[R.I3(0A3+  Z*$-=2-QL"C[AW<]:"VTO1ZB;T Z#99
M5>&K;/?K]>C2%CQ'-A[KC>YRV:=,=4DNY9VX"RS;,"ZU,4XUI<HC5NM6"G_K
M9V4_<Q?I!;_ &AGAS%*RD[(%#4*52DS>H /$?D%4L+7Q;8:#T!IYQK!:BOTV
M'M+H;H,0)_N UPY_8.EK3>D&WU^\6 YX)(.[4PY*1E)IU6L_)):XM#2DYFU,
M9;0WPIQ/51-+OA_+G1:7!WB4;$S*CNP?,Z8V>C]V<[M*:6->]'2J]19A$+]Q
MJ8!U\3S8#;@T*/3('\2DK$.53C7W9F-. ZM2N)7$JW=GWG+0M^+&=$6IM(CD
MEFY;C"1OHWN7/$$$/W*F!7'"7P!@K'N1[;+C]='\ZU(;1)8ZC^WAFQM\GW)G
MB)PU$F;"(ST0^ YYZ6Z]>0' &C0O+@P1[/B$G]O0S%RV?LU(8O^K#SO83STD
MI?7&*R!;;;28D^1M$P7K?M4!(X]#LH!3QVC'+: CZK:]/M(A1\315SZ3(TE0
M.PP<W, G^H-_0/WWLI3K\R$I^6/PTY7/,7 &W)VZHL.]GHZYS*,X_(J'</T%
M@'4>;(N8"OR%E_O>#@VKXVV$A#5TI"QBK%TMWZ>ZXWT'+?4;1?,P'T0_K@CR
MP]?8EE6&P.',RDCE08F9!DG_=B[.R/)(&%,CU%%O5DLKF9O(8I0D\-#\$;4F
MU]E6F+Q&*%Y,N"31,Y5JE4TAQ7#5E2QQ21S/(I5E*M8 WQ9 F&4]2:F7D(\T
MAIOH]!=I:C;T\^>W%?S^\)_)CVI%A:/HVN\3!"9-07BO93UJL)0QJ?)<+)EA
M4TT<CHLGX;;6(-N,2\J[!)V<(C=?E]Z]1Q.=^I;H:ODL]K=F%1SWVQEI'[D4
ML:FS5&K1_QYT4S2&:=$+#+Y)XL[X/?3,CX0DXP6..=CQ \)!GL):3H/^?>_+
M4@P6G&& A[T2GXXP*K#(JH#?^I0$,@K^^=^Q;!,>_O2,(Q9WT/D+7-,':2K$
ME7PHJ!]5?A(ASK*LCQW??_C%I5:"NWI,M$V&SND+3^%NP'D$'GCV&,*&QQ5#
MG2%BN,EXC(!MJ$/[B/+D5YQL4HE+XU%)N"]IXT3E?7,F1&/81-U9)'ULT4(7
MV(?@,9D36^FJRCZ^7=]!M3F;$EJQ,28RE%ON=#QEX5!BZYD^HY)]GO1UP?)9
MLY)]F)%78MA:QQ>\T 9?3YOB;S3X_>-HR1_>W6VO)SGEBTCMWP9DR^MMB0CU
M@V;I)(Q=6C6VI O*B*(XP]\B:!!+A>[+SKC&<.9#W;=1"O9\L>@L-=/*\A69
M<L/3&$O]$&!U-9A"YD:SSI(731WH:$L-J@2L/2;0@S#0][%Q[W&-VA> T")T
M&J&)*F*[?: (?Z;7:"66SIWV41T'3&9Y5^URLVC3E(8Q8P^4'C=V%H!U/ K'
M/\2=J1.G\:!E%3GK!"8#:[U'R;'AD7\>K1I5P;]8G[R-K7AE\%)[(LQ:<O.)
MQU>4M3I)[K8N&<[Q0Q/Q3DGBFBM5AKR/49^4Z#->9W*AX1D#GVSAUW?KDZUN
MOWYVMW+'6D'5F&B'K_WCC3/L[*\7\E)]+.SPH,S[.:8M<OQGS:TR@]7B:J:(
MT9*(_LWQ1/U0BKG;[V$F+MJ4Y9T^'2Z7J.M/ ?;3_P>NW?^02DO"6-,<&INB
M%'9V[R<P+Z4SF#F$&4D,T%4WV24H4*=S:QA451B_OQ:5$J7#F^$L/9'QMCAG
MHPH6*\=0Q#">J",]ZUSR9LRB. =6:0C\#)HC6WJ&JIWJS67",Y 'V&*[%[[C
M@.\=/5<=L6'-P@?.6&[XP;-3D2[_=H[F]*\.K:-\:?R:SW/37$__]C8L()!<
M<D$RUH0SBH4]-1O3\7'8I\PZS7;!*VC)^@$BA_M]PSL[%NYJ<WPHAXG$S+3Y
ME@//@1@K<+ (FIHCZ?EX25?QY_XF7;9RB3AT]D1(OUY^22)94"[TX]SY1UH6
MO S#_(*@M,O0X@2(^"XXFB@$9U3F^B&5Y7#/%/,L12BL":9E6JF,$B[0$O\I
MR+N[Z/4.%O)S789IU"Q+EX]*]P)@FJ!&IP]*SOWUK[9](?O3<0&XUH''!/-!
M2$!77(YSH%'!E-8/T<4TFBV8]<ZI/IGA$-%I6F)5/[\,%>63B*:HN4=USDQM
M)\ B&4(1\7LN&Q"M01QII_TV#E<=0'.RBV/)HB%]LI8/'>%6<U6)Y<_,3O1%
M8^'=Q396UI*IX=K$L5AF!LPC:+G6!4 + E@&'C:^$S>#Z("<,[#C!9^7FXO>
M)HO_$>@QMQ$T;<LH_[""["_,3+92IZ65/00BXHM-0U$X2F6[0:\F-KEJ]*Y2
MK*YP?\"] ?4X.7H+?0S%-1:M6V:0J=GE>^I9MK>8A =(=(7^MN0\.CB1_W?5
MT?+G-\5'VJB,J#*"27HXJ975> =9.]LYQ@_/)BAA//T;1Z,ZMT.;7W\,*)V/
M>"U<T"FY,(]D^3!TI9<V(B\$.=7]=YXG*[EZ%1>U14$=_Z^"FT;E)AZ%?^=D
M\XWP#E50DC.F7XI"/Q(J0_JX7LQ7O# #0TQ ^2LO<-G7O'#D:/PLS*+^J6'(
MVWY-7^ MX%(E\/),^/"QZ/CWIS)KYUSHB7QP=+=$-Z]M9H_-O3J3L1W'!^86
M.E1(P\?"-%<KXC&6>&[K$8K@1U/&R[E,6] [;?:87'9PPO*.Q7%T_8YAEV(%
MTF^XP:4Q85&;[59W6[D91;M:!6#[PZQ\7HR@^A?O>J*NUQZ]Z;*-Z+!\0J-B
MV,O8S,[1S"FJU.?:5*GH6;P1[,6&OK&5@6'ECJ!EQNL+0 &0K$T9 39%PV]Z
MRM(;)EME"A76/E/CV5WV:;,KBAVJCM(1T,J&#%!'@GWE! P1972BRUJREX_Z
MA.3/O^@0/O:8*5D:O #THF*#2?'V+K658=5E15.1\!?79#/1*OSLC[ODVMUO
M/98[>D,S.RT=:F!ML-DSI[3^(-![OI4Q<TV>K?R*YE2O@UF;*ME-=:6)+DP9
M(I0)E)^LV:V@<A_.E^^8G+,>X'%[I;GCSCI3VM)^5KQ(S]I,BB#T-@4#*!P6
MU371$*<K[:S30[Z857FC1( [>/T"T"FB>A6*:,)+^.(,K6KV(<:X8#.Q"N7?
M1\.V2SHB:_$/(OT_C%P W*TU ^$_<.)Q![I-OS+44"Z%P7D3(E(Z7T?J%H :
MHY5WOX[^*6?5D=.I;GA(7Y\<&D,].S-KV=.F05K?IH^DH:21-F:[U0K:$KN.
M':+]V&3+BVYC%"I*7H*-P$PD5D^'1/W+8[O[W(NBNL<KK4NP9VJDA0:@@\\8
M*,>:#9_7,9W7I.L@F\8=A^1J(\_17,7O]N/CGC,FEC?=^.U/W-A$*25-CG*Z
MQU._*<CJJ]'_Z>W\IXKL_RU$GUJYE2$75I?]V 9'65GB9,&1Z,:S6U*^>=QP
MZI=9,OM(2F1P=6?^L^7<HX^LA2E/GC]E[@,0!8GCN5ACM=!Z,=+@P3O<5>UN
M1>O=;BZ];[3F"SH^*@.#&'AFO5:W;.XUBB?P,)S2C=0WY <+Q4(>HMVO? \*
MC*AE^I7]M&]I?_.FZ<^#FQI@M'B4?E)^D=,PM8619U(AIMRT9)"5"$.#/JK>
MQ?=F0>VPNIJ&C%HA&[U20SAWLV?AO"';$\\&))/X;N@@#DH^()&T:9A[S /D
M'ROR5$'C5'&HNJE.U,R8&G$<GXA)$_$5BO;/U<#&I:YNJHI--:3HGV?F%U:W
M6$I'C<C"8-HO"Y#\U%8NU$]_Q.+OG3V%=FH2I0A.9]!P")4PZJ8JY_#:]TD6
M4D(L9L%EHO$>RWK4*\O :+!CO*I#:IY&B66 ]X!SD$]Y%X/AR04  Z0!AW>?
M+A9@].A=WY9$M#TLMY*9+*G8,IU23"D*\OQ.PC.X.I\P+'"+_HY4<IS,TV5R
M%L$8+2(CCFKC2O>\P];JB=$ZD@VHZ@(U^CZ5>A0GFSA&I)-B$O15<&0]>.D9
M317NF5EDC1DWUB VX87^2&'G$'BT5,[] HWXIOY4'ONT-;P9])4].-09BI#5
M,# N]1G)T,VQ35=VD# J85.GMA_RSD].3X^6$/ZI+27!DQ[9QYVCR9>@Q[WO
MS)_?<0WX]6CZGQ+].VU7<)R]4')E-5?,<'BPT&3;/0RKY+6W<;'@HV%ARX\R
M18?-*&>8F99Q\$B)B[BUV7SIG)?'?1RH 53K2*#W5YNTU,.6[+ 7(=$+:H16
MIV!NO/=H@#0KC)*:&R<6_L5\3]H?<CW78*1]H:1ME,&-3Z,FM@C4^59H#\S7
M526Z1&%0^<G!)X[2F YGKBZ629N$.5H[:M+4%4PVYT[L0CN&=_,7T8-2<-!X
M<.621EB[Y N>\&7AL*0#Q3?6PF0TJVUI'%P#_BM&4DR&N9/\#YNUY-EZ4N3$
MO!,S$6>ZYKUGWK_J=ZBZ6=3"(Y3E*IPSB*%E<T6+Z15.4Y.S*>E0-UX_/<<@
M1^')*6J):QY1ZL\[DSY]?U\)^L&W?7YF1'AUGNG[.0A[UB5Z>GL0,5P)YK*4
M<N&@F21NM@X7GXRHA)[=OR\*+]1["0M]$J8-<X,,. /SJ6:@1]MXM3/-3M=\
M#<]V4GS&J\'A=X=;T^:'S-1R W(A]7[:KE#JN;)PO_JG;C+E8$R&9:R ")=E
M'[2E318W%PH^F+9O:M8(;TK(CV$PCZED#.LUGKD V-L6PA!MQ=O+'RM9Y <:
M68QPXB6"PX08W/#O< QC"*?EL.2T7JP\2W2VN>., X-7[ZHT_>P%P,P[3:O>
MBEW193,@A06<53,2@Z/_:BSTF*)][N]4-MH3X?\,V_3B&$)+P"7(T[TPWPBU
MGL\8%5;#7_7:/C%Z)2Y'AAO'O[+"F%)F,48KU ?>-S =T;EL>&T#+%6LLN52
MD/TME_8[.-Y&=.4#.GZ6O2?C[F\V5M1>YXJ:-DIV?:]I<X^KZ.^,/_H&&@01
MZ+714F#&HXCPWA238G9:#"I\QQ<N0VO'B4T"!RL%4769C+R33;<852$S;?;T
MX1FJ%?HZKRVWWSM:$%84CX:D1OXV7(-]<J#MQ*S2EWUWO)7$95"8@BN*1[X4
M>*A2%).IXR-] ?@%G]GH]>PC/,#D7.F>?)[7HR B/"P2LUI8F\.2_+8F3UW,
M&>,=XV<;6<Y3D9=B:*"7(A)L/Z)&3V"#PO_E]H3_$1E:S@W[>Y$654A:62WH
MT'^K;^,?U5$^4.RED%#_4MLG'%,:\:56BA20^'QJ%H75@X<,XAR/\K&DWR9@
MS;\@Y,JYU(0'6AZ1=[&UG:K1;/T:J=S^P0*Y#^LRF"EGW(J;^G^4_@C*8>_S
M4M;(M3NAI 96.)RD4(F5<%?!SAW:!'3K$F:S;V@9E\D5.B,,WO)">EF]=,D^
MR#^.;.J0]#I-O;T2D.)C0ZE%V3$N7N\ZAACS>#O=\K4D-(\^0+?>Q3/*.T'O
M] 6>"WO$&<IY(YB5H!#*98H-_U@GPG%2T*D=:T/.E&O91AILX%$?( 9G@O?;
M^''%F,+TU:!5T\(\%!UD(=]?OH"A/<U<F)[)R-0K,KD\+U G=[NG2QVW0'52
M.2@E[."3OJ;0_M)XJG>MB6!C'U>U]W;ZI]_]8B%:XX7&M\EE0^X[K=\L;_'G
MM^C^EUM[_P3!$7IX83XD8^.4*CW$MK;A J Q7G=V 0A_>X@0'8\[T,E8[E)E
MH;DC?F!C@0)_)FD<NC>Z_*Q&\-KY'#SI N 6'R*&*S]ZC8]':[."ZL'A.F.,
M/1STL8:0'3A>/ZZ<OBA_Z0)0Y,H"L8A[3RW/B9-]71-T2)CK7F1*9< '=#7K
ML+A7R3+QI=N/Q 24:;,G]]F6CA967  "HF)9TGA6(Q-:ODWMYJJWJX:'$64\
MQ:A?N0HR6UM-V)G/KXM:B/?[G'KW>\E'[6X=*T!P1CZR*6W3_$I:\_ 3KK]S
MEK\"?S__9Y17A?FLM0NC7P.#[/["XN+\0V='UZO2M?,+5OU?Y^8N[9-1;>FJ
MSSU1Y$HUI=<^Z_#Q%M"M"D@7T&6Z-=HE6#0L1HI8TA4QJ1MF%=Q0%S5(RHBQ
M92KO-TBLT=>4G7/FKOH## (N?0)2@#2Q9%T=T::3<[RXL(Z7:/9;YJ94YY_1
M9MQM$Z)NF=_JB?"*7F>!/M[U!T*A^_L7@.KD96#M,&):]1:!%N^&[9<.=8>(
MH*/Y95(_.H<M=Z5V'X)HK;L&D&J^<)2+89>F[>K3=[6V?#/EYR#L7!AT@O(Z
MNN*#YTK7TOZLKP2NIN6G5TV.DGAT8)]ASRM7PX]OS^0?.B5H$]] ?)>[,:!H
MB&^/45E+$]NP,OPQ?_9"CD;RHQS#1!T-)\49=[+;-H6V)0WE!J:)B8F7#^WL
MX_Z+_W.&O-Q3-(BYG85 B:TCBN,S,=E I,638#L_KZ$U-T/SMB>+TCODFN\T
MH>6@IKMIPNA/#YGEY#P\G-D:J0]L)=*>M9*#V..[7V+-E$443+HP.&,8&OM'
MX*&-L9!).?]8R8W#I)74](44^X 4W[27DEFY5V(&I9XAVL2GV5K%D"8]MEYI
M47&_\L(0:+1!O4L-E$( 8>#G/OGL\!:>]2CM O A%,*,OW*>AQ[DP  C<VDJ
MVZ99$>WL[2'.;T4P]GY@>)=3JFS&ZT\M-8-%T]TP5_T?T?0+L3'>E:-$_>!Q
M*-8 'HEBUBU BX6N/\=;8A=M1>IJ+*QO$'PPKK+]<D=#U8[WK!GZUY0#,F1#
MQ7DX7*T?FTU4VN^G'DC_S5/(T531/)0AA&* H][9?" ![&Z2JXZ/ :RK:?/V
M:/2$@KUYD!/<96Q2O@)Q*WD\R5,FC]\$.#I,TOZ>WHNZ$\<9"XY$P[1G,/R>
MO(91VK3RK9J/(VICI%$3X\D3SSKXRK:*^)O7IM]6EX>J)N//SRP@K\\+ZLF@
MG."<I\IR[+VYQ7A&)-$O&7U;NMP]M*/6),!^PAW-G78HXKUN.'X?=?^A%P7%
M/5!&:7Y'?*T52GI88J)6>5F\>PU,>-)<_@I7O_E*:&AJ-5Y%4[,GBW:U1$NY
M;J.;WS#F50)H(Y?*<_$APER7\3XZ)E/TAS>$3D%\QL\TI. C8K3%:NSHC2V]
MXH3%6J5-B<K;0U:81>&F9E^2OEI ;\,_DD/6C.Z@Q<=WSBZ$1RKS56TNLN*N
MIXHWC=5G4SUO&9,1$@AGW=D37HT"'PL(W ^?X7X]\J,BIM_S=WF)01%+TI8^
M3-'865=&P+A$X5&1XJ>$)#[=_W5,6O^W6TQE,E^G,Z2KF2!J"B/P<+@N?>ED
M@8DHO8!)D;Y6MI;OW?G+'R4Y,BQSCSF=EYUG="R5SQ;G3'+0G1?634YL WW=
MJ+I0MZ<U."I?RS^4BU*6<?@\YZ)/D9*KC_UCDOJYFXGDT82H74#YT5AGL (6
MVN5!.0VN_9[#/4(P10]JRIEOGO)LRS7$?1=(6#2)C)ZSL4RYZ6_[YM.BA7::
M^Y<P8SO.[MN!P$[0+!FF8_L<(X/C0W+2+?P>?8:#NCK5KATC;>Y]X.IN:,Y_
MAK+[9AVZ'+9SC24[:H!K8VK21RX#6-RF<*JY?D*2E^*5Y>K%H<=AX?73,'KX
MZ_,1'ZU*3?4<5UT!V>6H;&6K3&_P1FE/-)$<U_I;I'/>ELTA"/T&VT;556-8
MJ1RGGX&F&"V?2LB^)0ZS#"\;W&!>_;-E7ZT?PV"L.01./O\T LH!U700Z!ZC
M/7IQ)6"][IXQ=$FW J$<_$=%"PM%*& "&Q D:!7WE9[B3<PS)H)*&9/O@_VB
MAFS9YE6=-\#'KF?^X?*Y]S#S-2D>R)D<5JGO$S4^>4)&>0;]NF%B5#(L^&=/
M#'6-).@VQC5[K*IH8G)/'O:RD?1PL*Y/Q[$N6T6S?UJ;#NS3[^Y49&IA&Y+H
M7L7WZQ;3BG<:)5F$B9%9U)/Q]V=FP&XB>.CT;7"X_Y_[PI+J/$(,&'_]-GHH
M9"96MZ,UNH8@]J_)I,SN]^\S-K;4-T5VFK]H^J!Y/T66U$;._NX'UQ.2\]+V
MFXO$X0Y6@@=VUBZ[+O/V@\U@FF^Y/K(%Z-LOZM<^^JPU7#N8FU,8/;QINL)2
ME0MEN@"8@J95@K4O )VF1)(+ ,(>V_$8/Y,W$]!R 4#>[$G'R(:IC%GC6:U:
MGTXZRX8EZ*-W@ET#(SX;\7R+JZU<?#; QAV_CBITO";*MQ25/D03K^J&\"Y/
M-_2*W33N+V'JE<LKF2G1RA9&[.X(4Z!)WU9= &8Z'G'2HP!@N$;H@;!>#1I%
M71#^H[PL<;4@',-B"!-E[9%>2"K'"+V2=!7B/7#Q%52U4G8C[%W";.*;W)WI
M?[4SS)L-T&3\]F,<DL@XO+VWU$$+6C@O[P[F#,'S]?S<:T<3U-#3(NC_1MQ;
M![6]M6O#5"G24EP++2[!'0+LEN)6'(*54B1XT% D>^-%BQ??2*!(2'&'XALO
M+J5 $J1828!""B%\])QWYIMOOO.^LY_S/L]Y,KEG\L\O,UE9]UK7=<MU$Z=:
M^#)S;:>=IG_L6/ G.L^619%^U^08]@\KNUX306596"\9KLH8;UJU&F3+CF\M
M!X!\1O#1:X.K['&[%YJ.SHI/B'/3A18S;(_-.[L5 +=KXWB07XG)P-=XJV1L
M"Z6:K2XRSH$RBPXN](QI9WR2OU^ZV-=B&$CC$_(1GHS@JS0C/CMWQ=M=D5"3
M]HSUR7U"=3;!4 ?:'899+:HYC;IE^3P&;[TA 3XF\,P>I]1(XPS03V66G&9)
ME9(V_N+N:5J"U+^LXH'@^RN-%N)![,5J1!!O?SO+E:9B_<H73["A,X@QH'"1
MU6./<O3)WKKOT)^B%<IZ(R.KMX4;\-YK,3@^5OAQP>ZN"^( 492*1J.#&/A?
MAM.!>7+ UI4:=(95P%3%.\^-QGZ[O8"[(KDP#G$LQ"P,><5R4!-V[#1FI0-G
M@'R4N>D@O,9SCJ4"#D,*A_TCFR6KFHI@\H3[VL0?1^-<XL0WYYJXY//63W7#
MWG.=!8X#&?#, 76S"LK*\"CKY<I#EH\%'*)YH+,*3-E\;1MQ^OP^U('8CF]_
M(#"$NJS10 VR% 3)ROD:5?7+59CT8;?8]9=-BLP*).7AW)?+2VK\PW*S]3^/
MXOB1QQ^O@?3?3HEV_[F&YY[\E(Q7(W) DS%-K8Z;>RK4O&E]731!)?U-JQ13
MHIJS-:A7]%/ IVA%IZ3G+U5[4)W*6[SB7WWQ0=A 5&8C+@T-"U=FPH>(S78X
M($%@.S!UMKG^1YX:_U!;EP7*TV69E#NG53Y5QTR #8K,QQS[OKWLUU]W'V7W
M "K9%Q!O_R?4_/D,4*5D680L0G_:'5W7:.[-./Z^C[SA6&P-.,X]3?.]_XK$
M.)01SW=A'EN[XIA8,AZ.6@3R@K99>VM\$TMG=]5W!@UN_)X'YV^ D[?L\[A(
M"SK_Q)T0<>:7MNMYY;T$).UP#J318LL27:YH4M3[TY93 JX.EI8#8&3A^G3;
M#!ACJ@PGN3<IW@BDFAJ=^5D*4>7?'CW]/UG(\(4F<5Z%[(K$28_$#KI@K) 5
M)WI0<+VB%.J99!U:B(\B*2M:M+)9)=]Z7[\N!,V&M-MOCM.GOXDZYTGH?A2V
MN(8U\GI  "@@^Y+_J-]9%<8G4Q?TF>/ U'9XXQYS+C]?59<;P3 :?-)<LY"5
M0"BM3ML-:69IBMS@<698(8S^&IMVR>'N5J"1C'LYA6^!&@CKQM6*ZMTSG]6U
M5?U/_&"G[/>Q&#5-CW6]=U9/V0).<0.W(8/=8V%"ET_J5AFA>1$1\)@)N7"V
M$XAEFFN3<;J)>0*&D7'T/69'L5R=YKR,'9')"7=-WUV?/(25(#]7 3'X=;F^
M_F^8%N<(UPN V2VNN$S&V);,B(:=V0_E["%I_/WJXZ]<52\T6)^VOOR ^C#?
MMZ4QQ=%0?@##^9[FSC,3+"NN2%Y!1:8WQHM"E#YO%XA2@8NT'EJO;92N/IXW
MDPC<7<ZI?;N1!\YLLRD=' \S+XXC,DQ(YBW$2K*I>^0[X.0S'>(+E4)L!4LJ
MS+SV>V4;P--EG<LF8'4ZEQY!OZ)[:FJPFA#)7H)23ZL(10S4BN_3:TM>&SWC
M7L<E_WN?B_3 DT8!G=KXN&G;&>JX?OT:/EK3D2;.1E!=^M+UCGL?_$^)Q_Q_
M8S,KUB#KIX%@X'RSV8P&Q,/72Z@/X@44J5,%TJJ/<ANK<5:G#+,*E536?7QY
M7U5-:AE<]JL7HU[/-<?-9&8ISC"A&,,-9^9C5M>2&Q&V+"M(E"XQ4&]PWG?>
MS[XBN:.Z$,+O-WDC;*IN#5K8YVI?/T/D?4J["BUY'K\9)XZNTDP?17LHTR]/
MNS;MKG)%T5B*<.)N'S^..(OI"^/!7I$D2"E)]J_2SS=,/L0'6S;J?!6RG#I\
MW#V#/"C]R]*C!O$5_>[N?;8XUA"CD@'!T@_?NOLS0DTO),(6"NE5G!Z%.F,'
M]MRZR+K:M#HTL&?FK;D7%*;&C;SM,RMD=K\MA&10/*BUIPU*9".K!+EF>B.R
MB<58Y YC-O:B[W4(!*@.2171E@O!K")R-[VGQ<]' PO $>4E68K0<[$MO]U7
M)>06IL2PRR=AD994S!J/!@IH#7N\)^E'E]&U>9+?[>6\5*J<Y4/5!03E[SJ;
M?M58^K"!S^F(ZV2[71X[U+WW)@Y+M71XFH&WN]"&ZD*S4*<(8J'3.]&W0)X*
M)@1!!Q4_G'X08U2KQ4VSK#N"'C*K"TZ4P7._O?^I-7QW>6UM[Z(0,'9$V+X1
M/2Y1[<0A-HI+SW 7$:4PDW8Q*_N.9!YHUY;0IW\BI)^O.9*O.0A)-__)5?B:
M>8%B"T^(B*WK\-3+V\S8C![:;(TB0^$L7*>TCB;RICTE(Q*U3>W'M3N9>QN9
M)])1\M=T)9#]MW](%?;3->\4#9_$>9UZ+/RP$1G["BU'>7S"$9,X]18DP0$/
MM4CCW1_^;MU_?KM9H3F%I7YE]5L3-?\P_=FFAI38BJIP9[_AY&W<,"56-Y[;
M6%4P/57 P7N8VX=+0D%.<%?[X^,46T;:#29] =0^)J9VV;X^Y"[7'?FC"NV$
MW9X+2EW._7QK87\=:NWS8.T77JI[+10)DAQ4^)EHZ(R !Z;%3;['*7W'MT6#
M7H?*--3KEAE8YH,3DY;Y)S2@YMLK09XJE9@VH9W"Y>-UF\G],QQF,.RV#I@3
M.S?P!9KV::8+G67[8(&W(%1$*H,(+IWFT4%2K6H_RQ9MR,VF#VE6]\JN(F1,
M2%1[JN5LR<LX:$T-.4+'U$GI]5:G$-%5@L80#Q%7'\@V7*K5U3C=F750J_ $
MUF>MFH'SHGJ=9Y#ZBD&(?_*H@\$C:\&L ]NR#Q2GR] <&%V:+V>^4#BQVBX!
MT0OH"?1JT?U3F"C])2.LAX](T1U.?."VQN ?+/F@$6=E9N$7D"T."*/ =F3)
M!!@-LI$]86EJEZF'</[.U5Y?/_7]CQ1@IEVO03B,O'$RL9L>2(_M[AM!7PSD
MS'5F#"P/OM83THR57FU%Z'=2LJBG> 5_T.QT9$ S]>EP"L$<V!FQ\XGK:_>A
ML%YE]@:=^Z1]+#+9?[K,:YUY^(US3K!2\/O^T5G2'"X=R.67Q/P%T+_PPV[*
M-X+G/>ZN_>#[-KWU(Q;CT:,E;>4#W;5':D/41GDYX X&&R/OBD<LF0[/(&%[
M&C]1%[\1C*)U>EI%H[(#G@!&$\3IZO/.\_@./Z,Z2FC*PTM 9&4E.<Y^X-D2
MH094*GIG0J:"P?/79(UEV+M_^AG[;S32([L+[Q#JM'6# WJ,UX-E4&AN[RIW
MFQ<;5.AUF$T;/K@_2U:6U*"9J7?HS]VIW3>4KI;Y13/V^5@^:T*RW70S@>Z*
MY!0&BX/=QN!3_ES*)MA@O=?<?$K%O[?, JG??$RF!^7_+IG_Q,,#J$&K/2"\
M?W)@*_=B/,27,+OP$X8QN*,3+G<LW6M8O+,I7[V9MS%MV"@=.3B;5XFR_R4#
MZ=I%(^8Q_J+\6?7!00GL[/A;+;H4:(Z%Q=0#S'C,T,KL\ >,:.A(R-QFMJ,)
MV+AOB][S9^EQ2),%<-#?Q%0V'A%?I']()15W31KX5$K^%I;]/^+<IU<DZSEK
MMU_CZR_475:Y9H6!A^0A7$D<;+M'6NS?>!;LLXNQ3OGME%7>Y],PCV*%],R9
MOH6IU.H1MV-T=Z4=GF_[$RF>"GM+C64NNQ$WV:\1,T@4UG)8\G\I>N!@1X4/
M\_BD&:,^1<AL:WKG] 4T*YUN7743YHIE#(</LH7^7A5;O.O()K>S'90.9YW.
MUU5Z?K3"C80.HR%3Y?+3J:XUM%3Q9G7.1\TSI ,64.?U[Y"8'K0I.S<&.H_2
M3:+.KYHN22S&%&R]T*H8E*,L\Z\P[G]:KBH^N#FQ,V[W7>$7M<(0'O_#E$E(
MUG+>+_G!#BBZ';D;P"(27[JL!ZMT78:O,"@$%#JZ1VM]1XJ*V,H)'Z!^ VDY
MIAC^MK&P#CM(_#4G9![HXF\7O5;?>7!%$M/!.>CVR!FM379R14(#357)$7B)
M;1.+.^S+ 91 %/+".1[:E3Q^ZV=AY'+8194<HHY"/CB:1&Z_KW'7<YF\4!3H
MDS,0'W/54/]@Y*.=?T^FLTND/IH]SE7$"*%@XAK6O7X6SN:/<0J]3.FU>*![
ME\&O(+ ?^FT6GKKA)ZA8\:J6.B'?W4:S BAB$Y5H[<0S:&R"BBZWH]7X#EM>
M(Y)S7*.-=9+9$/IUZ1GB$P(H5L=#N9!^.*V7^*"5I.R0;FWI+Z3_AQX^852^
MS.NNN_)<<Z(-1O-;F)_+^ I<()IO$,E@@Y]!V[W]047KUFQ5\O9[GH9#F>6A
M<[+>E-_B[0 %_5P*<9?]_9?1O"FE+>DZOH 9K6W V/[$_L3W@?S%3"<G[GI)
M&IU?DG&I6MQY,VX$'(YQ((D?Q\&PZFBS[N-J:HV5O_N@=)X\JJ;(G%9(W8+P
M*@F?]]R#3!MF5A)=+JMY1>(60G.N (6MAUG1IZ 8/ ;D$A3@N9 D9_7<<4B2
MEL)B""5MA0'?*(\T=%W,UZ>":?J<R,<!2G>+HC.T>U_8]:]@(>1DMQ]J/@Z_
M)_<XZ>EMGWO < 7SW>[]K.N](8XK[)V!XQDQP;MA*OA@YNB1H?Z+Y<-!(DT3
M4Y**3-"*;%R#F_WO'J*.-D[3E)<Q+]JBEQ<T8"-OA';PQ@G0^'!?3:<5^??S
MG]#F +=I@V5[\08'$>?H(7O'BVH],C='Z4E]@^47^8)3B9H$JM@N)JQ!W(J*
M>8S<&G??UB*S[R19K-OBEJ69H.&FQ4JY6/CY("D]J_H17-31EOJ4J<TB0:K2
ML/"T=3WY$50%;1#M-\D,I>U7<(X#2E8_XYOY$<J[;N#%ST2C*OBN?MG62MF^
MXV-'',6>4%1P<#O4.1%C6]?]CFKIRVDAOOQ""OJG6]?-N81EZ?TI#AJ\J$DJ
MN$,2;>776]@$XJIHF"U.\*B=K]952"RZG$H-9A:IKH&5B2Z5G'Z\AH8&4)==
M6ZI.!?.XAB_0P@'VFW/ED6[GE(A&%O3C=EJ+SQO9X2"W3/%8;BHZV<_@M@BM
M\@%B.-02XZ2*YA$,"A!:>MUA2AY8E6%2<9$ X_8RZC($E71"+172>F9A5GT#
M>E^HU=-K10FOSI^%TN&'>K1_''=T+J +J5S-FCAB75XTB?*9.I5HD/6W@ 2&
MR(QS#$MT)(N[ZR$9CZ1#& 0[Q*C/ ^+XD5\,-A__N].*_SNK-J#!!VK@8#'^
M:^30Z!$EC:<XD>0*%X7QR.[=0ZE.T(0;ZYXS5P:ME0&GI[4$#;/FRWM?BHOA
M"OX5LW"SAQ7:U3SZ<(44XRAMWU^]YL-R([3QD'30+Q8D":+?LZ\R[$?MSA;%
M]LV5VT:],<Y0:' SRJG01@BFN+ZHT(=</]+(/RS FZ.!R\<-H?1KL1KHR:0P
MQCU;AQ6\@75+?7U'"K#[0(_!.ZOMP<<X$E,]<_76VN[%5FKIOF=AT$4J?N0J
M!UXHYA/LX#YMKUT#;Y1C+N(.@D"-&8Q6MM/H:LWT(M]C9'U6B8A&0 *+K:TU
M;<%)C<5?$E1=_@RC,O]IBHZY.[NN+SWA0\]<3>D6&LA?(=3MEHZQKEP_$' S
MLO"?#$<HT=4R@>;-:J](5+M(H(4: VOD+0X)C[1]QLNC+,UIIF($S[NI-R'1
M')*=<COJ3,/!@!D*[8.^.\F]9=\7#=7H?_Z\$/L[M,!L(9KPM JJTZ_ &.='
MT0J0GKR_Q^+96;*F1JR;-)GV>M+]L55?'<1:!2TEP0:L8_5>39GKP[6EGYBE
M;^HC! ;A"N_2$G9F(].+Y+1_Z0*DIK_. 9?.M$D@U)-X$]V5.3,43H2F*]0[
M63Y>4Y@/<Q%1(-,GW!@%_R<"S[Q3(>E6>E)+E_DA3/C<4H(CWGS=[NVY2'\=
M+CFFNE'+HP0F!EXNF/% @!_\5(1/_8@/OA1Q&KXO7/).\W&A/K)_$L^M,=C=
ML+.JB">MMMFRD9[LI[HS))7-.[BK8R,[D./.^A=YY@*B9+?I=,K3.53'LDVP
MBBT!YKYW:85=B+<?)-"G0*BD;(6H(Q,I)ZCK3BUK[G?(* /C5B>DA68R.1-8
MNN?V#%/;4KV( 4!_["HRBET0$GCGR"3)[H\QQX2_7">S+\(XQM"U2\_GM& ,
M?MX911']LWK(&A1$;/H%^!K,AT[]9/H7B)'?P(H2Z"(PY@1!E:7V?A:SW,!3
M&!W!)*/C1G'LFD>_@FV1%W>7\*SI4W-J5=1)ZW0_KJZQD=A8KDGV#9;%<LE\
M11*>%^)Z11)5<O%\%:^JVWY,$,>&31B0@@ ^7LU9_<=:C]82D/0^ =9J'WC*
M8SPU2)JCIW[_&2^[+0W+85?"Q9POH=D=*97LP)G>1\2>3SXC)]M 'JV.(6K6
MX#K_>C+T$Y9:KV74!_O\92W1LYAO@:A"@FKR'1_!EC&5VDGH7(W8A#S&=79G
MRP0,R"*5Y:Y\:E_G"E5H%#O6^CSTJG8T0]O'O3A.".=PGO?W\O)M5&1X!Q"N
M^2U!:?V*Y %(FMB-SG?3_2SE)O67+$LF(NA^8I[:[XK4Y?G 80OW.+%I^7L)
MZND5)DBS?'*I;;-&UW=P[0RYUMD*H])T@9G(5[GIV[PE3*5?/+AKQB!,<4RZ
M2B%F@HU 9=;[ORJ.;1LP^HGD=/:"&56F%;PEY'X5@\9Y&[,.3*TRJ<X'' 0:
MR74S@X0K$A<EG\GR_'6.FU*XLRL2C0Y<0+TG6P#'4AL/?$6YZW&]$UH-N0(Z
M-H@HI&RPB["C(%!CAWXC]SLD=6%X8]EJT:]A..N]H#!1"WCY+HME @D)K5SA
M5S0+'K[Y^Y\W=OR)U5!PSTD+:_B1+8=A^,!4'T#?S4@F[(O,((_=(Q%_@J91
ME6CEYX+#^S'%;1S'K9CNMQD$*YQ!7,OX1,DHQ&+A=]2NM'PQ=D4Q<XTLO6]I
M%"\M3O?D!\%&NGC(0=S(?,O]5_:^[^C??E?\U[9!\,4@R4*DL67U&!C;7I,R
M&[;K#Y>%G+(JV!.+HH2'*7V4+DBEKP>S8YGS,@PI!D&A@0"9IG=Z$ "DR71O
MJG<*\;9_'A[3A]K1;WSS8_=9!HL46&T"#FITPI#[[?1*Y&W+\_<*C.AQ+TU%
M]KZJQ5?+D-Z*[G<0;QDY\6[196=(U%47HG_;;Y(HR!2B1&Z8#YK;,\T#3\/U
M:2J,?!*>,/*F-%?MGIO] =]E66VML/AVKIP&5BZJV&W+GV50""MT<&/5\PT,
M#O+!]7AXW-:>UI&:YG:)LWQ_PVYR\N"7^O'C>66N+B2V>UVD*!1U#=/'MW?.
MSY+LCZN!3S$682XUPE*AO4*=I'V,MWS^VE"MWA.C?C1YZA^9!0K=C@A;*FR6
MC;\B 2>"8!1XOS6\P?IJ;E"W+G8I7>T#OM@-+.F%P/<<;$#+TA40@X5% X V
MS]15J_JU76J1(KM;"]CF!)@FI7XPP)S26YFWAHJKXYL3\R:?@MS8J@KEMW7X
M][E>Q[IYR8KOKR ?S^QJ^[3A (WSS9-7Y\SKT&?,@>SXVO"^+6M+5XNQW,B]
M2FAU?30<KBU7/:]\23FJ5'8@Z"=J?"-CUAIWOJH@Y;;^BRAF&)S\"SL-_M.^
M$UD)NKBA7A5&<)@"/@@M='@?FJ45\F7-4DY J;V.^>12??K%:4YF=@"UT;%^
M5W2P3H;I\2NGYX[$#!6'PB_U/78-385>**^'\52D(:_J&H5#46F2&F708D67
MYI7=U0<Y6QJ9?O>0D* _)P%M9=E,F6JAZKVK>L]A(O3!NG/2PK2&M?-2'L_.
MM.<:VMN#+V6-9VJ<ZKIG#A$\E@=>@.\'J_('-1Y;SS.942G<<6KFZI0WD+,=
MDCB[6*#,&-W'M$P5SOZYA'I@7*<E0"GX:- BCWLY:[86%ZXM%P?QKBRY]PIL
M%BGP ::,/S[Q7Y]\).%,.9(G$2;R";5MP(G>YV6G&42!MO+$Y#.D=JY(7!UI
M*_@$UO=,$G6!Y49--[L8$-H3R-,?:F$&Q#X8]L57%?3"J4&O5Z+Y_!N-_J-:
M"[SO0&J0#$@C^:L)MTQ@7+&BA^C \<O;X=+Q!@ME/'XGC;/<,7JMER^1)\&1
M<D-/, DYT4%]^,:WO7,-0H:% '$HI79<ABZ[0GAZ/J6:B*-_D'$%*<NLH&F1
M4;[E]?9FYX$Z#A!I<>JBD?A1X4Q2L;[5&D9:@YP:F]QU1_EGT<[IZ)4G;+;D
MW4+:UA\1SZI=[2%^WO@VZ0_&_+\4N=;_D9 "U7@A7B!F?Y-O4#1"=8C(4GMA
MD-1%S4-LI7NAUG9HB7T]55K /_WN,17P/"3@,S2\A^FO$:E+]8EI6DAEWA6)
M9.-E7UU5%5=EFT2&XTMF2PO[C/0-^L?OGMY^Z U%;B:?GE^^Y[G,#Q-=6?W&
M(,K81Q7K:^=&I$CE_ZMQZKON*&\SZN8G^P<Q$%^V'-<FG6_F.=X2D[Y>;X8)
MEB<%V.\O$*K]P)H(ORI!9AB->AXLQDR03F)E(J!]L^H.93NUK,N@'Y:,3W#&
M[=+@_"9T2;^&D7D=^?#5K!L*'C_1P@ /^O+%OE(>73\6GB6I-=LWY^_;0<]?
MH0\77&I/+S&@4*=":5_[6U+RR<;_G3]U95^F7I$XA]J=9N 'BO L*];+^%=_
MU;1CQCWO#)T:1+F7Q=J42M*_UC,PST!/2T4)/;$:K0WB%G5V#)@ZEU<W3I[T
MU;VKEX':C!N3!)BRL=-$!N:[SKQ(EFJ*DK.90%B"Z"K4_7EGN7@[]'G0P,)(
M'TK,6WP$L\&-U W+,#Z),8B_##RZ=\:?MX@C#O$F4=#B#=VA.75LO@)=B6#C
M$\;SJ2N2V\67>:78YLC&Y&6J_E-EVWI,;I ?U8T!" -O'384L:C05%>)\?-
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M'#V=^<^E0MQ=R !S#9_").3',=L0HXAK2]Q1-\ X)-UE)LX$BW^C=335-Y7
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MF=H:\IZSLT_V3MPVYQTRC62#NXW #(<4I!\C1O63A%C-]-0!Q"N2:Y!>3D1
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MCO[)MP7D>-7U3K>A*Y*'TNT>I'V@1ZV9N[N^;6[9:T)N93M-E2$'JB;=Z?<
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MNL86;\58UP:84E7J_T7IZ$K2J8 P0(.U\9Y_:LIN'\7"B@A96N,'W/9]X*9
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MF:5T8A:IH'&!_$S^/& 7D;[53X &V;/*.XCP#O#J_*8Y!V#O$/@Z4SHPI/K
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M^2+'5RQ67,SLYW^K7.RO&]5O;WRZ%7Z)0H'T&-:NUN;J3RIJ919\C4U\X$1
MXK +_=IXK<);9V8Q!^%1W*Q=&VR9.5;3&$75[=N^/'6> O-(]VN5=O3DZ5,%
M: '>V"PZ>^$.(4%"-8/@0&\9F/%20G[+WB=0Y&X?](D(]I-,X#G T3R.LJ.
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MQ\Y%&J!.J'C./317LP8FF<&Z=LK2H5X1C7#;"7+:^P[#!I9:=K]-[H+%\-(
M0W'EG:P\+(1XC(1O^^EA*_:E0KF(1.L(PV=PG<NQ^KT"I/VOZ_%/QSPD*TJ[
M[1J]!V&NS.B0!P3'"]C&UK^1B@KC@SYZ@$^*ONUL)>'3(5;C)B>)]D?8T#7D
MV.P5B6:=NG=5KCQ+X=I.@PSFA1ZX89+N9(3T1(H]BJRQS!O+9)#/MXYG--CV
M+.N8\)D2<AP,]T$_%/OY#:37>P[PAZH<;"\O4$8Q"N 9:8PZ>7B*>T'L&2!\
M41>!0T3XIQ.S9_0P$X./\;X)M;]+,U@Y@H]-"ML11UHF8"Z82?P/?Z$ODV$
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M&/<;#;FZP4,S>C]YZ(W&IR2J^,T[ADCOLBVI-5?+KFE#LYTO\)^K<U)]8W0
MU$82S:F,MX>WJ'F5:.</3,+EU;Q/(W[[U-@*;GC?QY&/.*@^=',8PJ@Z_IQ$
M9,KQ5H]M 9^&$#S1TIW/@,!^?%YHGE9!GLQ^8DANE+"Q63+PLWF9F-Q :-[A
MD;GN52Y%0:ICBQ*FXJ=$""G_'+"4ICKYX8A'@%2L,%(TO78WF6"FQM@2M6W1
M:,OY:^$V_K%:0'XITG'&VP6#+].39W#B]M5K@F0=U7SCO1E"A:M!9Q;0$X(P
M-IP=:MS5 '3IQF2L1VI_G<'N;V>!W4.)AXX:9_K%'X?]87Y]/%BLV4EYW8>V
M3XUB:%NZ)2[U:@RQBJYKZ 9;WAS+I)A"EX1D&7:=:=,H#02FB8CBI1IHRK@J
M=L&XLL-$H=M82 )T I*H'%[Y\DN&F=EE=+:?8Q9NUT8BR)97 J$B>K@$%^[A
M?C?1X\25ZK<@,59K<,&B%WC?_L=B@*8!G\LW<ZZE(;>_3!S69Q=O? E=*R]W
M-4L55\P)RT7,]0:&!OO+A7RVFIU[)+[_9)[_Q< KXR$O!+N^3\+MZWV^>2O%
M; ]%FD"&[L+=(DHBBJG:];]L5/W%C!&@#)6)<E/OBV?E/G]1X[QT._V\.WD(
ME=Z/W3+ZAFG:@K-:@Y"Z]1V1XK"!0DH%=5:0.PKH6'%RRHO>N1;PDX3 BCP3
ME_*P,V503'S?B3::F&>;?*SC+N,<]=NH1H*80W@#F6PQJ]KF$<3SP/TKW&;)
M\*#R;8[*7U%67Q\9C@L%Y_8WQ]Z4XQ_[OMO^\,.ZJ^A[$U[ML&E(;2;R3)?X
M;"+$DF=MKOV54/[[D'LC" G>Z1 5S[O2XQ[N^]7W()V,;\I<H]=3>66G=/9+
M&T9WS$/*(6M9B0N"QGB*V'6=2Y;@*!^5R8[G!V.N;'UY?<H5L]X!+9]3PY,X
MLX5TKMX02\VW?)<$.P[>*%JZQWM-^5JFD%)'N_<ZBR':":AG"9(MSS18]9<E
M<\(5_#F"7HKV0<\!3JL<)W!KG:.,3P?2M@/_H6X\_Q^E/QTVD"GCSRP*HPO$
MDI=8DP[E>,.!WDA/W#W2K\5&W'"BI\U3E]LKR@VC(58B3PP5U/0:8EH'1378
M)A7NPHFI"+X6CU3-':Z4ZB^J,F9:ANPV[$\<'9_]2Z%>H8<8M8?8Y'BITZ_.
M:V6 CPFB]:CH=#B',I%9LSCN&U8B>+33Z(L>4E7!1%Q#OFP$(7!R'&?+N<(C
M[J49V,ZEH1=J)%\4(JC(M S4-\AYJA\4YO[&QRV+/ASEHHQ\J)P'+%_:5HKN
MG(QH:W056X(1A(YW0&VU6AW0 Q@CI**-B<S5[E!,J!EZ&XKHY'#3''E1(*TA
M)-L*9Z)UJ91U[I_<\9#DN>L6"NI0/,.V3:AQ8KD:XO: #3&R<0MSE[(Q13$?
M?GZ%B]SMJ.=HL9^-XJ.R59 FQ B.BQGE&9>DIIT#"O15EUJ.T:T2PU"Y6.E%
MTR%9:G]='@&M[)%.HUI7C/>T19],AC6+7012B_--V3*K$8UM.IRMM_%#G##*
MZT3ZGP2-_POM,BZ+?&,'!_Z5T_ Z3.W%T;LW9HDAEY:U[^@*CU=\:!H/$4&"
M:QGV%EQZRS:-YI^8\"4_&95HEQ*-(QJ@?OD>)1"TG/'#2XA.J2@E,=K9%JWW
M\S [:W"M0'+LP:0>&&U6>9NS.([&=:A_Q_&&?*:>KX<Y_Q M?B[4(:C4=L'E
M2V3M9.!IZ$17XF%^!]NNA*>$8'!PKLOR,PZ5]SE*<<;/;JA6IZ1 UK-&S=ZT
M?5)>8"=S9 E"NM(%$K+$W:\[38.='\F&-UB.%+!RBR@%37:95=?2'I5O"& ]
M3U<Q]_1O]F#O5?ECAF39GS.M#IJB:-;TZZ7NE,VYU$4BP3)]=M=[,I-8I=H7
M]$T81$<TF(D;,,]_A*VV8PIB.YR&8X>ADEM6W&!0:^UX[?8TY_.CP$FY'G\7
M?RK?>JO@F.),Q?;9#42=P8<\1V&07 2<LAMDD&Z54"S<W&V06F.H)YCC4EI5
M)^@5::Z?_T03KIJ2+GKA9!AE/>4AQH2TB_<UL&MJ(P7'].3.) GT>,V>97#[
M.2"ZC?$7M2C0!M,LMO-PX?(7,>X P"3/G3&Z5&T;.=O:\9>7'#)9,#&<GVWK
M(/$7V@^<('@.0"_2JUW;"M2HDN?\2+X%-63G]<WG,PX.%>H\^H3DZZ\?.S09
M01DJT+0N0[Z^W2%+S5J> \Q"%+ ?\8@K7N< .I5N:(7^#28Y_HHF7UU&J&XH
MMO6J$:.F_Z;&.: _KK8$Q7[Q)>M&/1!:(8QG'-&Y_3-"-"CLL@(R[OM\FFOI
M@QQ-E4RP2W-9=='KSM$.>R&6J<E/A)B[((:X"S@Z*]Z[_Y_ARBNT<S788Z((
M:B87R]+DXG_D20<M^ ZEZ!A K0Z2/F._KU<W-M5[/;#*%WNHYVSY^F]^G=+W
M/2J\O75A;>> =FNR%,PS!(0#MU<J;H=&_^WGA%>**4HD&V%AS/RPF:,I@Q7R
MF0YNM:YNM>:9O13#@-K+Q+:WS&1O$A^TG&2'IV7.>HH<?HT) <JZ@B1QF:KG
M /-!42OX$ZRK.(T>ZO"ZR\0YH+'P(2VM^CCJJC3[@F1T]2#Q?O<$-N0Q@M,D
MR:COD[7Z@[[^G B<O&/NTX7%V4.%R>\7NP5.[HSNGR%[:P,INI7J'-"!)Q43
M*3#E<^ Z@C/Z6*N'1\8,+'L-=PZ($FSX<L8\NKS6,%D7*Y__EUV&'<_'W1*F
MP5=-/. $+/6ZV'<<_7JWTS11\O+-' \99%SE#5#)#FZTI&3+I. '@G*P]L/,
M_KQ59Y/G-:\>.F\G;Z.9U;R[Z0[["6YZ(GU1EVF,Z$7E427E4U[&T@<3JX9?
M07[8O)(T\@5_M*?]<ZQ0#'/FO41P.AK[U2HXM4.;!+2O*K#>QO(R=ET=J?YB
M>,DJD?%)LO8/07;1YZ/9XV]/U*T,-&"5,SS@-QAB[I_1K;2O*E/_&1W($!%9
M_&=T>),R[,7H]I$J@_4K,^< )2Z+SJ8L=F\U6%=V%]@MQYO%,WE(IEJO4;-5
MG?%B?,8HW(_W9:)LKUQ'X _S5;U ,G_ZC;]"#/__ZQ373!W;QO0B[#INJ&V9
MEA'2!2<$HSDTBZK<5"-Z5NK&:OM=)'?ALVHN_/2/.]@<:,3WTJ,$@IYK7) S
M_4C1C'+C2%%YEZ%*RSK^(OU\56]?I&')RKC==0T5T)\*(?6CFM,A]T)L[T2Q
M4FE6\3'&5NK01J-_1)1-HO[5DX]#_CU<-<-U_(+<T>D;Y:7;Y[KP BY6R1-U
MU\LX=8PVCC?2_[(G7@P+AQ]E.TC4-GL0E3!<H5D0_/7G:NYUJ[-]?C8WK-&W
MOA2< PQK<X=&N#E/,E >I ]ABMN+M4)=PRPA^E/ :;Z)77(_9D=0&]CY RCQ
MS):;2C/>18:BH99$(KXMTPHJM]YB/6/>G3>+F3H)QA[',+<\PA)M'4 EYX#/
MLL? MEM%8EU:ET&>N:RB'O-U^QQ(;%E]QA,C/^DQ'_,7<J1SP*D"5"8*9X;6
M;1;H-"@AE*L8UU1)=S_*]"EPMTT/DIWUSSC!!4ER]UR*-D@K-FSQ?K?E%?%Y
MXNF?MI\NI&O_)?75_I\*]NVJUR!Z>.G(P[PL+3)XI?O['G?&/-2ZL/>X!?:*
M\:R1G@ORDP<6L6JV)TL:36.K&<^3ALUJQU #'I-Q"/3'JOD&F>Y5]B@J^?[/
MC!W+>T0]+B=&>KU9/V^V5RGE(#>_$V=F:*]RKZVLO@1B=3U;TJPS6\WEK3-4
M527*(&])QL+),;P*I<,<WFV03ZW!/H.\T&,KQ<K*0WF5JCX)R^Q2.\GMK9(7
ML)+<(H+YS4$P>QIOC%N/\XOG]M1LBW]]+ZGH+S!M-OO)4F."2M36[-,:R_D>
MB=J-M,<;7R7"6"^\25C=Q31\VY"40[2 G<6C=F@90Z1SUFSO?+E_W"J,*^&,
M/?&P9R3DZD7^=4>/(B;[YVIS?4+8AMDI'#/,@5$^!T14#]U&^QAUFD1/U.CR
M<Y/A.9AEMF7ITP8!O3Z#3KN\0GE<QH:^-DA/ZF05W]S1TM\^3%^S>Z-'M>X3
MU+6<&WV2:/[Q'."*.U(T$<IT\"AF4QV)$'V&[\LY\MOG$I1-X"K2ETVY4%_S
MA:G_86Q0&!'02GILP9=BP9\XKJJJ++JQ]:U<3$2T[UO4E?#K\EO"B]ZE8WJ*
M.8%Z+\:LY$_E0Q+QCXY82%FMXMJ^0:@0R5'Y>Z[KP8IM2X&Y[;/)^8(Z/\'7
MXB9/%>%^*[LNAZ%B!@&>V=5!J.%S0 P$I^7&SA-<& EAJZIT.&D=_$"\_^/#
M5P\?8STLY&:O0^U-IDA<2<2;Y@ SM[#Y$4B>-VU$&!<>B#"3QUC7V;LJB3C(
M$HS[/OODG@.R,MQ6:SKZZ146&7?21N1'/Y_!KI+X0SR6V R+T NWUU&7-329
M]EK6*B7O]+N,)F9]*HH8=G&B:Q]UL9SF+>M3\F!(R'7>PR^#"8+@'7>,T+M-
M\LT?(?[.-W4@4*6NG,=E&W)1\6 \5ROG9*G097ITJ;:@><B[*\GO@'IG0"(4
MY];7*DQ0PBMI/&GP^-*" \=$%;2'[6L@M1"]B*$WS>V^=VA_FQWI:81IY(0R
M$>XRBH!%AO>)E;WU2*PIE5S1S3[Z(S918CFYP-Y5^QP@0Q)!GP-J'W7^HKX-
MCB'<?5-#:.???F;K]G99="[(!'DX,$4Q+'G@Q?2L;7T1AMD+#MIQ2EU88W=?
MCZW7N8)OD7N\7-;[IUV)K)KITZ!- [.C=>2&I6!MD4(B+VCBK<C]G()"E[ B
MRM[[#4_[_DKK?2H-5A[T4EK\BTSIFO1\O/4F46S\N=/"<"CNN,/, [)VTF_M
MPB#CF4^V]]UO4)<9[K8/BS4G])*,$G$9Q8&>%2LFG_9TX*1,YSB]8]>IA;XC
M"/(9S.6:@7+/F4Y'2#_-74GGU]A?DHH2FX',,=]EC](F2N;<-((\8.S&9D?*
MBS7@7RMCH46M@!!&%[08Y1S&[+5N>]HES@%5RM#OS _S9ZRIZ5];9A9>"KOF
MLA=4SWM-C7%&YVU(/SC:EK8^[98T18BJJN)])\#Z+;F;$5/\:K'9VUEM72>Z
M#J&8+ <AL<!5?V3YB6_(L"9BAPO#S#F*&XY95[/:&Q^6[3-8&].'8MS4;$B[
M.CN[VPC\AY@]U1X.^=2[5Q]KB.\.>)65O:^1X0< ^ L *$/<XK?A1#49:%9'
M&Z4:/R%"][YV;>$50NK1'$T",,O+!>5&;1T^VB_[N#C32P7URTT'-Q4M#X39
M;W (IOQ]G]P_6N%'_.NOMVJ]5Y2OWK_B=PL 9:ZSW:78R(A*2*^15$*9JOH:
M?ELQQNTU6)EU.D$S4)JX4T_GSWLJ#3NW>O1EHS0PFHRT=]4L3QI8)KN[6I/,
M=7D>_.TBB72PRNSMGH+U"[UI6\J%U4W%YU#D8B80$>((L<1'W6J"/_PF8I2,
MU+(=@LN@X;?>7'WS8JZIHUSZF5HOCH)(/V48V-!(@.-3NV=87;Z,$"^]'WZU
M=_DX@H</SY1)=<GV86T!2^-B?I>1QR1I]$.;1F]8HBW[JD\$_EW(G#J2!7X.
MN-&4CAQ9,WUET(=T+'O:1FRN%.VM%!I*[H0B-N>6A^D>PKEJN-%YW)JN3\\!
M"<%\""O&7PN9T*K;J )]YB __T\_T-KJKU)+=CQC6]DN /:>NB,DBM8]R!.W
MJ\[IQM(,VN:E1_%V^3SI#:]6BY4/6&"P,.EY5XW&3,.UVLTN/96:90D(>.5?
M^36IT,W=P=&%X8&;L_,5T\GZ']V*)8I'N ^/J)\H/UG6T. "7+7XT.;4"_6]
MA>GC-?GN\[)&Z/VH491-.!H36FX%JMT82]@>_@H:S9N;Z*TY\8U37DR +K)]
M)MIUL1\SVF-7-DV&]JV=''XQ-42Q% C6@<PM;9BYY$4,XT:E_Y7@.:MF_>\,
MD?R[3?40E:_&']:K7A/=E09<4"0\PE -:J[4Z%5NLDAA8'0ZMU=TU)HPL7Z)
MACLIK8Y6_>4Q-4V6BEK^GA\V4.JR?3XMRS=QV:U6?P]*5W_%S231TB:^_UWL
MD2F8#PK<7VWZM1*BT<DEEYCDB Y:\T:?1$CT)_7ZBGN8)22+?=%A?%WYL"YM
M<OYH3YV_)? <<"62(%-Q,@:]C&5-:J'UO6V?>=JB:I8H'^Q;F&%7]QRW6_'4
M3_W%5!77X4V5X=X%B7- ^ .BYQAU*O0NEA==R/PM6XSEH__O&UM&M!CZ.1HE
MVS%T(9;1%2]Z%+ )^7'(?*+ON401F=V<#S[T/9.M_?VJ2?,N9[A!VYZ=B>N[
MZW,(2?J 0%.M S,:DFSKVSPE#C_8E'^AW<6&$R;0)]LR:527]5N.(K(HS_B+
MY;Z35+EIFOLY0*SUUL4P/,G3EI0!D,B4[?J-)V?@:")D:6YI(5=\=<K=7_.*
M#^VTM"H7CUB?@OKT.>"H9%0I%+7$VJ42<$@>P$555JZ'AT%^N063YB\?^PZQ
M(B_X+T3>K!U+C@MA-&@('R844L%J;*O,XB-"BONS[)P]1?3!9SW;,YX[#'C3
M" >NJ3>-5-*KU?[2M7+$^I+1;2'@;UYM[4,O^/6C</7$"Z'B?+'<IJOGB12$
M08_OS?G.!,@R-$Y2R<-., INYCF8]CK)-\X<YDP[R[-:;T6\2AB^Z[Y8SQNY
MH)Q1[[WOKD>9M* UF."CLF)V]$@CJ! ODDVK1,PX:9,X(@^W^UH1;2>G]E=/
M>(Z)QIX)*A=_"=U45-,.'N;NE-<P^CMMVG9N<WC"=0>UQPPG]T#J%#\W_"J\
MI":$;O-0KP-*?'P!G:?D;*LO'COR.VG8F?7BO/)WJ#-Z$:=7.$=A.[U'E*W#
MD5K>S7EC>=D(:F. 0UD+B^W TY+@5RD"X6DCC^CNDQ'"*".* Z.E.#T=SD)O
M-<E)#WG7U7=/M(]2@SP$$6(['"E9Q\F% VTODN,(,7WLD.M>-VT&/R!CT<X7
MO$P2YP9L-UBS6=?T)J\;G6SADHGTYX!E2?BJ]C(DMI 6*$:=J]/SX0&*4$^^
MRN_!T'XO*TI<MTSV(;I,CWTI""WD.=EZY<(#-(A4/XC9Q,!E" _T:/=>JV-=
M28[GFX.[":&_98>&:,PL[S_I.%'C3RA+I0Q 2VU?93YNTOK;EL61(5(#[3U0
M_G#QZR"^<>!51ELAE>K(-]#O8(S"G#MM#R%K,_$@ OO"N%A2%9EBYPHA%495
MM]0(Y4F= ]3V.90MUNFJ1ZQD]R<M"ZAP<T<VI$(U>E(!!! BB M(A+DW?)_<
ME1^I(B3)OKN%B 7>/RW]DOV,.T/AJJ97A9EHXW&9,&JBFE@CT>>%[W"T"*,0
M[T!CT(X$$!L0^+)R=P0]AM!S*4V9)@<,^?[:C\'7##1&JPS6S'?#2:7J*@/>
MV06*\#G/0N;$2MN6JKE7@UN[%VHBD.?)_T[3$3/L;R(SY*C G1-42\H-X?[X
M<KQN+OB>+]9_HJ(Q=?B19)8E:R3WLD!QKD6J\F&EZ1W[MRY/79XVY#M76FM!
M/BYRMTH18$M:'85LQ*=X>FV)$*528$Y8GB.]3N5V@ZZ$_#V&GY\&^,</5=QW
M5C(8P-66N?&;=.UN(KP]QTDA+EBIF 5IO% 2T2+L-"N&:%9AN_WJZ_)SL9\+
M Z.U3S4M(K_FES'5?:Y]M&HQ@[Y:<=L^D@DF&\K?HA%R]ZW1TJ^J-D'/SEK!
M?<JQC+)G>SPNAI6L3GG..>,)N+>O$)'P)#U-0SC?V=R&U%("="ZA')K;R:9@
M%M7(RJJO<D\4MU:<C8_FEV%SX1]+V/0B48X.E$GY]TAW.LK&Y]VVI1"Y4 8X
M>G+OOS]48'"?!W^F2/2?NL 42'PK.R'K0]"48J9<_MTN57'#(!<L+^5B+\.V
MZJ/=.^HJ'Y+N_I2U:-!PJ[!P.4Y*JE_E/,7A"N/\I+B@#O?QR5$*U_TAM-#"
M)Y^FY-T?7CYKKKQK6)^T-?L0L18'EKQ?\^"61>6:Q:UL!O.?K(0LU#R,P'\.
MV!$>4@#/H+I>1874C0/!N%:K[*!IJ@4"HN.M!S!R8$%X[)G&=PA!FS]5K]R=
MCEQ\*D^(V]/=0UQQRMC)\+[JZ9;>5_)U@ ?Z_L-'C?ITE[7:(@[%2<*L\I.Q
M.&A<-6Q]?:RAG0T/H1S%0VZU([UIK]E]C:;OB%1?6 L1W )Y,BLP_03-WXLI
M!QIEI%G8"DGG6R8IB]]3.'MS,47'2/*]?_?T_ \&DSX'X(RDPA=QY>HO?H([
M3]T1*9CD^'K4<O"U1,6Y+BR?=!T^([4>$!P]D1!V*^]2'6-GP :EZ'UR@=C^
M,OF&&<Z*S-+V"U-!>*-7>Z85I\8PKY1TT)UT;XIAPQ3'"6.;C@)4SYT#[-.J
M0'%P>"..E/?L;VU4=TL@AO:P&3TP\12^(P>,)K-6[YJ\2H6R@;?'^1P'I3RS
MP Q%(/7.3C1ML7<LZ='! [P4^79;HC40#TUV2/&.)MJ=3 &;7HQ9U+FJSRCW
M[JL[TY8Y&W^Z674GX$B9HW%BD&T\_T)$;@E_:!M D];_:5*,6BHI)4RJ\/5B
MK10:QF-MG>M^XY['/8JN!,A+H8Y6/@JM2>?\5T]RK)5T*M'LMSB_RDYG<OJH
MHYX^ (1?OT7WX/NMO>M\X==7Z"?;HN/(U>IVZ@F\N*9S@%-R].GJZM1LBP8F
M7A-'&Y==./!NFX<ICNIN<'D6?U;31"V[O(TK)H8]U_#MI<A><O>I"!XBX'%K
MJ44/$E#AT,ENS?_K*US=,7Q0I/NLSV\!8LFT[%2LQ6@XZ*M MB./\-[\6LK[
M!FCT#?-;'+CEY0$SI&_V<VW1=$$?;OF@ IC*Q==I3&MW\_#*'*+:>YJ09P8:
MS*026*;=_V[[B_]N%CD+-:6$0,T)XH.*GUH.)2\L'<DU90M]WLP%N:66_<&A
M_K>Y8G9VGF6:W<N@<9E:!Q.9MK''1#'/F1I#7%WD5!J6-MXR3XVJSCBT@1)#
M&'<-$_]B\IW673+?\^9K?S0=\!$/:_[F?HM5)UL8$R9O/^8SL*K (,O>VQLA
MY BAOZZ,D>[]:6E>8?P1@RD[WJHT79\E>+>_&Z8C[$<0A"X/<Q"U"Y[YS$P@
M>%SLO/Q=D6O*:Q6_J:]!J$T52Y./H4$OCF!#J&[:F-FLKN$X-2 AJ^PD-G!9
MG7'KRZS5][G9[@XL)@LT.E$]$P\:'1W6BUYS6)GMII(Y2<X=T8"E*K>8\G''
M=RY_]G>T8D[H-.VR=P-;3';:BX+J7*M#'0U+5E6"ZF&CBE99S_82FB^EKX[?
MCNS?&V!AE?R&098;H9=PQB*83[6W"LJ87AA&*J-6X_X#&1T;R61*!1R$3"\5
M$<9':"^;#7K5TT5CO'G*E"KT^P[.,[)*\N6D>3P 3V/5"2Z7W[C6'Q\J!&HR
M]1=I^%-D/5RA,-96%9>,/@?0:JUMV\K@;V9@?JJ+#G+)N6:E6.8V)[; X>D^
M]U972B*C)BGA <::=J1, F?[K!)Z\1K4[%LK]YM?I[P1\C1"Z"_6SX5]G4LL
M'CE2US #M'U5T>L_=35/JO@SG<5W.\\!AJ&LRH_.P+'[/!)=AFL=N%UVC!=#
M>NB,TTR&RECZTL_Q D8I\TA#Q1:!1/2@_&C;R>'9_180N7U)/!D=<HTO2WHY
MQ&= #OHPC*3&];W<$'7#Q#XGG<4A'\CTL6]70605.FL8KU<W\<>I-V#)K__?
M.O5_MD'B"G&FX%F)6I+<(U)>B RL?MTB:;BKD(%G 9QS3Y2=N$A%\/")^-OS
MM_MPC-3.O):\E_D+6:1;\ ESFXV: /0<<)]@ML3+&J*!?TS6C%PBW3@'6+6)
M]E7/4SV);?A4=_/AUR-$P ^72;JT;)3'^P@?;%M28>PB'?$1W@%+$=_*1RCS
M56M>IO'8M_B*KNERK6F=NZ<X%B1>SV$29^62$_*8O-8]NB 9"QE4U[:]%W*O
MXZ#12 K5FX/7==5BP8@9HY\;/R^.]QC"!R7:6C-)YKEBBM]I* @+P@)#KQ!Y
MDCF@KV/PC"H=9[:\N",_5\>1\INNRKN2G>W#D@9KUC46@MPZ"LB^\0T'1)H>
MXD:J%N6?O)-36,V#?_>\_/>\ED<8*6:W5@J\>C31 1-_XG>!'@YF%ZS#C1!&
MJB\JG>_Q=[]MM-=/GRI]03I>(")+HDQ>E/BK3PM]XTVP%.I!1811$XJ*3@RD
M8FIK55MSN0H<7A3<J18<AHR4S(<,F+MZS6NY\Y<E!]J[2V5<,3-(([J;;7L2
M&=*.7GM>(SZ9(%^#AI_UX]8[/YVB_@_VWC.LR6U;&\Y:%A9=>@>5WI5>DR4(
M" A([T1$>F\2-!)%>E6J=.F=@/0:" $4!)0JG03I+:$&".'#?5W?N=ZSW[V_
M;YWS%O>/_>/^ES^9SYQCW/<8<]XC]/[>$W)J3N=G:2G3HCUV$9 ,U0;70)9H
MI>FXZ#SSSC#MHKESF@/?I4DDP:;I!0<XD0_3;- U[5.O)./+N)3RA.$@?J)0
MWO[0R. H$1Z:I>F#3@!%$C,YJ?OB"9*IK/9RQH:1!(4P;LEV 9L.Q= -@0'E
MKH%D0;TS(/WZJA'[,J]Z-O6=0G7.43;A"X"JG[X:+(\$G_VKVP__QO\?P*"@
M,1!;!<@1$6PCA4]4_/.T/C;^"!SBYMAEK=?+VO3"FFRR7TZRR],+;#3VQ!!Q
MQJ\[QF-C5T4Q*M'U8\H#)//%58/Z]8#7^YAG8G4-Q>'=!LDN'[4#M1.H4\CG
M,RN9B_G>;6*):FDX8& B=D4[+$52=MA7A-$P!6W;[N8!HM&C#'^3G!ZB7/B@
M)9EWQZ"HT,!=713>DX,7BM^FG[_,JW984'<JT3$4R/3%HTW+?7G.LY3P9UNC
MH)2$.R\OF&P],4L"U,K#6I4+GWE8T$7#E3C^PG ,?IBE_6A"VK+YD-+0N*-U
MK%[XK)35LGSF;/U'2UMK<_+'D6%?;Y%$'6[:8>Y:3AU]^!XL%E+.UMNFEX'C
MD^^7EF0W*E9YDRKE!1'2-.AZO'BTW&V;JYM92-]>J:8P8G7(LW#.A#=&KQBC
MP0"OR2OV9'3Y"8]OZ;%$Q\CSICG4SZ <FK.,<;YV-8>N$R$\/];TDT6DP+7Y
M5Z,$\CK,SO_XU;6YOUVA*L::QD#O8<]ZYMEP?:&>.3HXIE#I#$I?C;:'[QAV
M<KQ2:42^!>>],&]@%A=]RB=<;N[0D&8A:*UW5\U9O=Y*VL4L1EGS&URE4F',
MU2 Q5,O864<W2\LWVB $+=?[*,G".T%'ZEN8,'E8+[J&6<2>S*R"3RS434R8
MTH:F7)4F#&68+'0@;)#N5:I5+]B?]4!3;HC6.\&Y#N8 O@H460.Q!S'@)3'A
MX5J%J5%^$54>%?>#S?U>.LRECUI]$V,&/)S6+;\V]^YM670$.F[CCFVVC*<)
M?'672"I_]F<.!7[!!G\-PX9)%X^_.L^-?93]4,UYB4/L"X>E;K@W60[V[9I,
M\*)]\'EM-_8>&<OA];GSWTU/<]&.;(9+.^3]M9,","=U:O&A4I6![RO?'R#E
M4C]S"'8SL!CT/0I&\%(8"\@LLW#MCQ^$8(L0;[(%O:G_Z&6 U3CJ.[*+1I0M
M\T>BO_3[.[[6+6C?J/<Y?8NRERNKY#=E2ITLR<N5D[GD&J>W\.__;TU<_2LP
M?C&@:*TRLH$\G6=K%=YTWMH5]:"Q#UZ96.$+P\Q#,AD26/("XNX_-OZ6]N!F
M>HT:7U)B3(*W<U&ZCM1XNO/:J(74@5-)_Z,D1U(MNIBDOUW[T0^(R>=U*+C\
MQ:B.M0N,?:$N'*F=\QK!UG$;*I'&RVC#.;G#]F>Z^Y?C;*9Q&FDPI;54^&WS
MI]\\W5*VWV7R;EAU6GZ)[,21G7^Y  2W$UCW18F<4,A()?#%,\]PFSLI/)_O
M]'L<YI""'][PJM$Y1Q1;66MGUO?&N[8]H0>%^1.-((5(O>"F3="G7)WN:Q26
MO?860'-[R.%A!;LMOP>L7"6_:RQ=4^&[2UG_!&CMS=H91@EJA(U_T]10Z30^
MZ++\K1\?:NW;'2$1?D@QY'\;$7XX76>7]JUHQANY5+W=^'/:!C@GI_8O*>6@
MC@M %S=0'/88JHUK[&K7VK0/CS\PQO&'Y[TCZF-@9#RQ,'=W+J[V,8*L;T"@
M#V%%G/+/?(X+P,WR$2 U07TLB(:@C^5"M0L\. ZBP &3*]O;W&C@6Z([#/[6
MHN_?1=1;B^Y*3<4MGP^.O;=7BJ_%[D>N=LTZ=\_>+Q3XVNE GR*OOCTLBBJU
ME606@$?I7;-H+4IW-GZ48!KENK?+VG0])Y+(B(-?DU.!5"SPPD6*#)>U4EZ\
M\OKBHU7E,?O6O(B)G'7$(!H2:/P&6IL F[[&D):WR1H0X?>2'_QM)[]C1'I0
MHMML9/>)?-2^[MCVD_::EHCC.,PTI%!USLHD"U;AE2FDPB#8+UDLU^N5R9K$
M3\HKT"^A4ZJN[]Q3-*HCM04;LK8P%A@K5:^7'ZE4]RTT27[09%1LD)G)K^N5
M<!E/>)8$/O.S\*7K7"ZGT9__*SO==!]T ;CV -]^ 2 G/XI.[#)ALGGV!ANM
M'MY]-P^(YT*=EH2;X73&H(3:^R/.%I0CB^XY?WI)'L<?F./8>D]-N\$ _#"&
MJJ'3V88".U2+T4;-T^QPC[CQMUG*:9+(RGZ\GY)2<D4JE:Z'55CR&J@7%$E0
M*\,C4!TW<0ZM7AZ'"+K-Y_ (_Q?YF;,NSP</3F,)"W>?*,V4IUG]CGKEG1A%
M-#@U\M;N\CK21IH]3ZG,MN-]O[3$!#\*,EG:$C2*)5*H R_C[5P.(G7 U948
M21S6HTYQ[6TSQ  EPF780O8^/4U3UNR;"YP(*C[L/^#UQ"Q^A"J[2=O[G[5M
M4,\C6L-_%OQRB2U_]2X 5R4(JPE^@\ F$:QP&CWGNI-!R=@!=06;<)'(/5!T
MFR7E8%HZXV,3U2*\AZBMF'X0Y.F$U'JCF)'L 0C,3NQ"D(#0#X,&.:^,B+L#
M!S!Z3):-*"X&8?Y4N7&H(67[8'(ADJ9%,5:X^^M:B\X7-]V9<I;O[O-&+V/!
M&_QOV/F)Q?C =X^%1HX"PX#Q1_-.Z<OIO2O>H?9:>0W)=]Y+AW3IP5Y03+M+
M$F' I&SN"P!*!U<>71NC#/-,?(I/1K:!! :R$_L_LHQW:].HF$Z$V:5IWQUT
M5N3_'*=9\-,HZ327</#K*=C_"+,.'AS5.[0XM6N'T.0N]^B!..7::4IK!5B;
M6#6L/>*V@NAH#OJAZG[UHSM[PUP^SVM]@T(%J563BB7=9 &M0JW$A!C!T1"K
M8OE^'?6[,89)!=.:?#,?I7-5&OCJV64X_S9OW<)/0+^0U*C<HMZ\S*_4L)A^
M62&97P!Y(\HG*5U3YMM/NX9K7O@]]ZTV[C.E-=D"3=@1C -R\OAMC'F72#5$
M^W[S=ZV/PX$,.^T!KF*3L150T+,/!?WC>$N;?%PY)@R.R\<TQG7P;SJHM>'"
M(\2E!42?PNZLMV@QU'T]"(%F?7,Z%:T/2Z-[FA+WS2SAB^;>Q@5 D*"SQ-KF
MWYLV$;0L^Z;4&BV1[M-R)*]+V2(G4*+LW%]'7^./_HC"N-;G@];"._4HG" :
M:#"YET^QKGPA.^N7IH0Z>4L4CM.1^8FON<*[D;H[]>P2L[S6[-5R[$(N.+)+
MVO7'><2OIES_0;TL[TU*@RE<TT&14FQ3=7.>?XZ+2%=RZ3>Z-S(J9*?Z,VR'
M_A"Y][NE:\GM-(D_9M_<C(GZG%>6I3F2*32:63I6+#=6;$#KG<E_O9 4J>^B
MG_0T*9]G5(<OW>EO?F_&N399_\#O30JMX!N2Z4C*SZ+6]%EJ&O31\Q47DQ\\
M#D%"(,=I:.T]N0"$9*B%65OT,HFTZ$54I&TIJ1804)\_=ILUM 7/+9,=,P;/
MKXE]_IKS!-X%P_-X]G%M#=-"AA>IZ@,;AE'5 TOQ5_M$WAM-^@TX5;;I%UF6
M\M2U9$=3IE2R.]'*Y6./\H7I>/M [0S$,HAY[Z.EJC\^UT[I2O2=<94XTL0F
MAKD'ZQ=&>P@_$-';P8U]@ ^H,FC*OLC9_WSP!HLL#@D2QNG]85AL(*_2([(0
M5J:75C:KF-[\Q&>MU^>X7!LPYU9,8UY0]F2/<#]!J^LRR*UI8+K^!2H$_\8_
M 7BHD<#@N=1'X+L ,!S WBCP[F:@%T*?70!<)T,D/(+W^RR6ZPR&$MSYY./#
MZS3J:B)K5RPV6%/:G6^7<Y.=?\=/X50U\>+8XCX8O31<=%OI%OJL79W<G&N
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MFTS:+6WW"=237EZ)HV=Z0H:E H;14Y,#&Y@R8Y<=[6N:TD_3+P#*"">]\ O
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M/.8"X(F(YD<S;2%PY/IU36? UB4V)R(')#"9T!PTA_F^(^HO^.$M!V[6#._
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M^(FK$:\993%^<-RO]9S.:*S.VF1:6]3P :)MY%!8/FRJ4OS@+%)47+20'?-
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M?[ZA2P_ZAH/PC2P-CG0P0, Z7Z=YW+'Q-)#7=*CGLVN=R?O GL /ZXUD;7W
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M\7W8$7-E-*?$MY#-"\"5D)8<.YO_A[WWC&IR:[>&8T5 1$%Z"4J3(BB]9UL
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MV7;/_FC:\!EP.V1>^#R($6XTWW\I4EB3(=9+R$Y'XK4N: UNHE_ZHQ*ZMN+
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M7Q%T"L,UPC,/A[(2?NQD[1E'VB./15^5&&^YFHPGY=*E50G\YHU< PBV-'2
ME,HLJ?-7!@<5\.#XHU*20*];_P'"_G]!,^RH2(V=,0)86=N./*WN04S7.VRM
M3<D-P1E/\\/B,&[ MU47,OD7(TMV=:4FNS4?EM?6)]/5*_,',JI[.GYVYU+H
MWN;.Y>"%"T%?MB^0WD^HN;!WL]S:-6Q.(OH*NNZ6KWEN!$1ATZ@ ?MS#"L3
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M?];!8,\$P4X%M/ @^-::2)WXDD7X/K&>K8V!<\I/+E4+@FD6>'_M<,:V$5_
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M5[TN'B;J0UP;;VL^>(OP#EQ&D.FD?[7\W<(G"+OZ7\ O^#NX_8OWZFOK[6L
MT=99&;8OOX<LR:X,FXUS*-ZW_%(/C]MWPQFP+E0!R.>M=]*: \K>5K=E]H8Y
M$_T2[;!56/T2<AL_@DU!EZ/^)-^/ZK$BGP+R!+(*??? /2F+4R3D>@R6ZTF+
M&:<=9.PGS:Z'O*O&'EIO*,1\I4>N4$BU\,+DLGG]1[AH(B,J\L*'?GD#V=D:
M6W3(8"5W+E7;1B]8+X!@ZXO=U;3(UN<R[0L4H BT]&N9<K^4%WV/M[Z+T==.
MU<LT+=:TF7)-^YF)W_"DD)"0H;]#IT(*H9T<..]KP/WS?>HJB(Q_PSSN.9JT
MTL7CWGZ[>R.RO%PK9!@S-B0CSLS&\&SQ3M$[H@J&BV?PM=TS74P'C@\^K[K:
M&&OE4;M@"KD&*$Z<\IR[D?]<9FVZT98>YA^R8&5.]&V[HHFW/W.KD;A<WH6?
MW/Y9GW45^$Z,,=][L_SC5OV4E/5JYVM#;E2ITT0F'6/G64BC0F_"/''7-6!.
M7NA5EJ9&K@ I/Y*1L=RPOJW*Z:,M1OH-EV51?^H@I]GEP%F UXU4L9X@0'O^
M1WW6L+^N 7?#,8UGOWN=1RB0H3)?M?-@&DI0@=%C[0XUZ#<PUSM>[ZX!_*]:
M,;ZM PRW-NN,+3YIKVSM=.A#5ROEG^)7KO)/6.YW"NY:WPJ2&Q>H>K*4RV>*
M83K(JUIJO]65[O.^55Y896TCDKV<FR5U"F\'P61!7;$E/92PKY\WIM!S<M2!
M1]#72&XD1N0:T+41FV3)F!%0#&U7^).4]AI@A$_(NJU1)/_"V"^\#RS/,[\\
M<^DGTKTF3"W0@7N_D3JAU3A46LK'^3MS"/<6G_9W+'HY^)DGFN9WB4F" B'P
M/OHJ?Z*;61:-DZDS]SOXX7I8,-GZ;$'M26L;Z:!NTH.C[%P1XD2%ZGF\:\=J
M$I[@9MP2SE+:,:]^'-1C_5<% HU"O5K"S7H[.$HB]ED)6/B&BYPSCLM?,34<
M"6% )YG6*U!E6-*.!66F@T&4@,4QL)3(J[$O=."S09[R"EQ0M-V.P;5RJ:ZC
M]QHP3]GC\11C'04Q2[$*DB3T+**O=SJVGGO=JA1;#NL1M$R3-PWO=PAF:&Z/
M$4C64X9JYW[[;\.25*WJ])ZQ#$;AJ/C.'!0 \F(6N\Q,7RX5$-;O$ZTA"5WY
M]QOF?C;G9B6@%(@$?SQDGQ \L&T;1QJ9K(WY\C&8S)NZNJ>'W(/O49[]A;V;
M'S)V#2# J:*W#"[EJBK9H?/X!].;BGW/,6]RJ?K4._C+CHAE$R3<A(S5I@K3
MU#K:U107:5\E_*+%*$36C][#QEJ@<]_7[<:Q=<LS3@GYN#F\:+9,FG.6"48L
M6#Y;?5A98[+PZF.M,K^]_?ME256%S<.$$$;Y^ZBOFZ:^I-J,*(V4ZB8R!V+]
M;VON)0F#3(EQ4EV%^-JP4+V$*3Z5.'F'B+*9R_0364RO/#_$3Y-MI#IG)@Y+
M'T_#-[SDG#6;M<*CZU,#NUQV]RTS*E)?]9:)&RDYBZ0W*3O(&!+&I/Y6*>&Y
M,^_^Z1%3IKZX>PVX<W*5EKEV#>AI"E)&!4N-HCN013TY]:CGX$>N.*7*J.,Z
M%L(_5OO U),_LE7-8UVCQ5W4^:M('CI/ZTNV(("RZ>#7P:F>9P::\VNUP!?"
M)P>YM04/'*RI+7LD&>4?A3O;\O5SKFEDS6L;ZZQ#CN-J%$B;E.37M-FZ TE*
M'G\SZ@7I@8VJC8Q*D:(X]M=K=&O>)!8_7WY)7BR@0_%-Z"?;#'/COT [GW:\
MAF(-6.[W=2M0;E\#'+!1&-OI0:,,V>B&I9_,Q+?WY9G&[H,WS2UV^+C.\'!:
M$>G$K1=?6L,M'+_-;#_]]Z@/8 00/"-XR0T_=8F0<A%$DC(/-'GS10E2\G=U
MA7Y&%1A06C8:4,(J!PO@L=W:5:R5;5,R\<(:%# 0;A_ROL]_Y7V04S?0HYM:
M^OAF:V$QH.8522Y1O1T1$\=XSSS"ZSR51J#3("\4<1QX5*0H]GG#V" YYH9A
MA6/_^B\0V_^%_WO<HC.:^CAE2:=1\X6DHD)X8,"+Z,/O7AU20-!1RV5PR+#0
MI2S.L2WM>;6C/#U.T67T(98#!:LL3F/3KJS":IG?,JHC7HB>'WAL4A4!+?1(
MU'SG!;HH@&=V.*_,':M>%>))(6'?:&SG%[J%2V> #RJU.X[N8=QS25;FCM0?
M@WPF3KDW<E6GN@KCKK*A8'&]S":!'(7OK8[H _DGGG%!\H^RK*!)EQ9]K)_W
MBO1;7[;7IDFWF.78JQ E:NN%@WW0*66:B; D?-*% ';&H-/CX9=/BUUMRIV+
M&I]?95D^E]:@\JPM#R+UHP=W/ U*H-0W6E\CG,JQ-!=%Z"74=_? UUEC9C%D
M4:>Y1"[SHY% Y1*+;?KSJ%/9)1;3\4/*P>8ODW6[[P6$!+@L/K"'0G)$C=(9
M&#ZF$U7WP8^9?]>)R!C9R/@ZC1CN&)32W$B\>VM2V@\U]+)>9=G3L:,FM#@3
MSGOCG*5BQ*MI ^IV?\"UJ3^#"J0FB\SB3$HGRC4*&?/TL]4TQ,)7%QT>%3V:
M^%TQ$O;L'YX0?PQG9R\7^+N4S)KK! 8'>]_-3LFNT)&;6EJ:++U;7U]'P:<I
M?CRT326B4G&DMA-=].GVE3V^YQI0FU*R-X<&*:-[ULE9&+%1@QC);C[LF=HX
M)/+H#F%!CV=1ZR#9@[GHNDQK024/N2'0118/PXZW0(C1-:#S9E^Q[\5$Q:Q?
MY>$<2AZA^T(][*NQ@6Y^- ?UN72]+>[U)^JW3"M:>:@R^3?OVWE06"@_;=WV
M15Y&[U[<AQ_H%$A&D0E\,UK#+9 -Q@WSZ! C3LIZQQ$;\<;=F[RBH+@779Z&
MGA,:HB:\OKR*!@4)JK_X3HXQO=*;X"BT1Y1(UB]K,EN>UXP.5A&:$[T.F"@)
M @[OL+J?ZW5E0&V)S.358XV3SY,10&W=@]\FCB,TZ\E_/NBD5[B824;Y++0Y
M=-,WI.<YGE'0P>LM;?$S+R9<\QCIJ@[A]J'3\X_5AI(THL7Z2[.0V@]+]<$1
M4LHCWEG)-O>5)7DT])U%8/IN_76)6HVVV_JE5D4RXDXC]<ZU<3*&I8I&O$:E
MTMQ=V5+/I;6]D_1@K%E%G(E:=7$R?,=AJ',<-?&9)]:;8SH3R9=MAUIN\6@7
M80E_HFG]@*/+@6(14FYT)%#R+I)H"1O2UTW.].T>NY3UT#7@_0K:*'=>K%?(
MVVW5W)HXB'>\</&+1$I)#\J#HE!;C0=<"8EGB'NZXD14.POQ?I%.:B4!FN_'
MGE-B,4@XB481W19TP63 K?0E-B!CJ,BW&=*C'P^B4[ZL":_>*;2<B)AH/)D!
M7)$#?==^ZO7H(75.07Q5!=ROLQRL3*D8N1SH^OA]P-*G:AID.=1.&P_SI.9Z
MX6T,UP!U@]&[=:*+%L/4;:W<X\/ (W;='OH_1MEKOANQ*0-2_5Z6W6)_9RV+
M'3QKN4H'_G&LC/*(6R%#?FU8%.3WB7,7HG+6%=T2&2Z&6/IF*_) 4'0"J08?
MPV4CH<E01IPYM@ CL7'0_ABGB$F %?H#IQ*ZY9],/9558Y!]6_?EZ]= !NX?
MQXP2J6@E%C3K3 X(^75F?)"&1YM1MDO*643KR-:[(MCBS^)FZ=4OXNBR3$O;
M6J+&]D3CF8N9B X'3O/[!N6]R^QKU6*)L>7OD*ZY9*$1DB6B)1F;4]X$EG*&
M]OR9I%-)8+\:_">@YHV(,;E*\9%,$2\-885\?\(J'22'O%,;:2MZFP?C7HE\
M/T9V)UU@JBOKEWWD/(;)#D_,L"K%U/L.K=,SG_42OW^:0.TXS]"TE18_J(4A
MZ@WPK.F?//XVNNI&_6M$=IL/E2K0&-5G3V?K-B_%F/M 3^6*YBQIB,-^(D/K
MW/4*P7-!>,7B-=LK-53P7NR<*BG'K1M[(9IIW)+X/57SSHJ5FK+S7FKJ577S
M-2!TP$6(1\*Z]BS=@U1*$_X>!$K<FAPD"^4W8%[682YIU[UY2Q]VQI-K%1HQ
MX'[G,R:^@K;*_]9(S#-;*1+=M_[SJM38/F6(*.:PYVM+NW!5]N'!ABD)C4XM
M29E(0Z;9PG9YQ\S$!7,PP[9JJCP=DEY=Y50J%L:G,7AY"HGT]FC-^IIK/+H@
MJX#EKZI(W-*]RJW;C=:6-U=X#Y)(C/\JNX66VY$@O"/8,T)TP! FE.^X@C89
MC:IMM>M6N(MS*.H%;S;$H2PI+7U6'0;C+R80L9RD>^Z)_&\)>U$T:-:8743P
MDR S1+\T6 [XPJ"CMGO]*U72D7=1ZEBYPX:>>5&"+-,)_X64'>ND%%'#'V[F
M"R\AY;$%W&?..6S ;N1!2S/I-<!YZV08"<?RYNX55+6JEZW<J.;.=YAVZX<0
M"<VF/"ZZE1LI'IF'2C<A,T%Y/=O.X=L^O!<RS5+KT$T0R4(<Y((-]/<#O_,H
ML<:&SB NZO;Z;CT9#_K3IU(;=!HG0#?YLN:M,I3%!S1G#]6(E^X:$!D6C6<>
M=N+,RI:16NR@YB@:K]2DL7[ )'$-L'63]/-]%6+9S5([T671)99+AA&B1Y^Q
MJA^I-/#QC=1@%6J6Z=LMP_NT1WV.E7T2+:J.H(O\7JKB3OS:B3VL_!_[&?CZ
M6*5(XN,+RPMX2"H*(^^0JXE?X(5Q=S&YJ)FN[;5<Y%8WE ZK,!B\.:.$N5?D
M4#SDY\[G5UC4.2%4(' L+IF:U#U\+/KP%KQ#GA;::0)U9"&4JX=WR[%UY5*+
M-YW%OC]PG>ABYOQ( [A?;_G'RB4%Z>*!2P*QI<8>->ROPY6+0[)@GB9)X109
MB^?)FXMRQEH\H)+^+/N3,ZV1*F;:H."D*5Y_-]57IVU)>-<UG;E#5*0F45,\
M"4J><<V,:C)+..4*3N) G8.)XY>7J)+D;C&3-AYUY."LR'#KNWB6WP$,(8=V
M:D%?P]_7F&VW/YFJ%PJ_P%VR70K%YT4*W%-?8$A=Z,D(2C-[(;&=B_TU<PU
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MH_;KI*^<]M&"SD3=)?>KKZWM'6WI I7\^P(H4&I@9N9[MLC[ML:)II9Z5+4
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M=5%OEWTVZJO&JW=S.789X":=B LH@C]<$K4(*3)JN0N6\V[&?R-/21(#P)M
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M^89WUA=HC\=:S@$Z1"WZM95IV6-\UX["&+WMJ++]G'@.W%V[:ZHL*[@E99;
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M"\&$;)\ 7._>S&S8XCD@3#.6I$=NB.!KY9RJ/)"U90GTY>[UAGJ<9>9BUU[
MEIYNL#8L\<U.+M5=4"WB^-F??V>6D07G@&[A</#9RU/#%:*O[;/N-7A<)/]$
MR8OF*[F%R<'EQ*SY!Z"$^T$'PC;:O&FA]LW>)T;P=7F"*CX4IWR@C5-'7P4+
MW<)?UOGB6[&$<*G'!PY@Q'\)J'+$2R &EIW:DE2ZMZ%PM7/ GYJ)MO!9%1JY
M(6'QJ4&5*.9B;I**0R0[37SYSDB"S>R"P>%S:#*P"1@';=1X^/G[2="OQWCE
MJP_=K,IK#^1YBH!O'XI7[_^281!SG-Z?KIG39K$^[B;Q_+\F8PGM=NBP/7MS
MJ@G1[?DRU+#6>PY@;IHIO/WU>U 1P^./TV=?%J:;O=*W?48M0GXEY)(#Q0D>
M9!I.[%@3<6L5^3+-$.H",4=W210R1OXD"7)U5KSQ%HCJ&B/>\YWACSS,D0%"
M9M<4H;G(^^&3IP:]AB?Y;B,&XJB-4$?AY^7[=2RRBFL; XF]+@]G(2WMH"5X
ML0G#.< Y@@^BTX39W\-?E0=A:>\B\DY& Q(^8826,L\J[+,?5A0=#0C,6_^&
M;B90]=^!;H9&Y&J1$^T_NA&U$'5]!)S<BN(01@9](:DM_E%D)B.N<X#UI)OS
M@MH^EZ'8HD]H9MP-:O*'ZE\7.O65)E'W5 N[U2O-W6&_AFMY(1$.XLX<1(6N
MT871?"XS)\GEF5"!T;#*!-NXN]XG]/!C]>W>C#,M5*@[<S*LT*,M14[>:]1"
M)B'6VIA]C\/Z$_91NW[9&3NQ_/@$JYP/V:#-E>^4NHZ12!7/%/A6G#CLECBV
M9^%=MNL<Z$ KB,#HY+58_2X&R )E_H^WV_@7#9B*;&$G72^<[:^M)CD0*<OG
M=Y:5 Y5*L<BXF1+NV\J]1[P3B[O+/%H;"YY=PG]]2_MN+,0+ C^=95*L:' G
MSY&N(.NZ)@[]%):,1_>,IX).<_;A^]*UFTV=#1V(S.*VIG9$Z_VMYK:6'#[1
MU5R%+%&F-&TK,TK"*;@(VBR]S[H*G]>9..SC8_4&4H2[MC2CN8@QZ3IX_Y;7
M@LT%:S3/'\_K9/ +(F"O#TJRS>JC=5FGU&HS$;49P$%-V3.@IT=:;X#NY0NZ
M-2HX!I;[[#R@19-K@BV\)8V4E)!R5@ZU+!:F59(SFC(KCM^"P(_-MWN/1]&X
M_*=D -Z;\W4_#LTJP:?;^^/V!W%9S*[^U/9J8R:KVJ]8 WVE9%H'5H=(6XI]
M-QXGRCE=:;+3]H<MK#(*S!,NB/>%K4)?1_).:<AB'86,6MC8\2\:_QS>HR 7
M!7,^=S0P;+\VYE%I,Q+@%O2B25Z3FT<12H?U_YK$Q]]\G?UN,SMK;+6:2I(2
M?\;V;+%=?KZ86:U^F:M9P7T]E='K"1F/<CT5H+4V/,]HY+LQ@3PMG+'#<J1@
M:IL:-G4*IRQQJD24]:M*7:98M.G%^%*K_-+?94@?Y-ME//I'%5'T[G]K*]"?
M\+GOA !BYJD>9%2:"G+9\!R@W?Q8""^<X#=ATZ&.<52S%B>,6.&96AP,F4UA
M.U8]CEIF::H4'9KWV$.4EF=/^<DH*"/4L]9XQ:F+/9*6J.<1W&B)+Q]IE@I.
MOY+G&U1T=7Y1Q,B8U-#!SE66,*^9,B3NT+FT+[NC#)Y8Z2F*[KI$%%T=4?X$
MI=< >;^#0(TIYOCY? BP"'[^Q=WYD=.HP,K=EDB[T)_94L-,_,TO'S:VM+3$
MG7#W2/\1:*Q2"+R-Y<#*%5XW2];W@1D "T6:S@JOREF7OLJLM9;)\%'X)1-0
MK6S6#"3"=X2/VS]K")4F8Z1H*J.PTDSE5*8U&5FWA#&JQDJ$N8[*H6S6W![2
ME)Q=H'%^K;U\ ;5^%COWUDHC='\$MT9PP]E!P-U*4._IP[1E/S;(()DCMA-;
MH,-RPR"8WX\MS*U1H[K\<=8$]VTU4=Y$1_ BV(N]Z-ZX-O1=J)-E]J.<2':Q
M0?\@&<YG5S,>._N_?2P6]'XR]1[B:4;9XJY%7J8^0E LTT,M/:.(.(#FT2K
M.P6^Q3,P;4(ZMM1'ZN5[-SFSU*JK7Z-G"C(WA!_W%*B(3!3?S7#68KC+LOT
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MXI^6&8@!F!%0C^85W&8Z!DSG&;#?,*'@??] TE4R52GT#P:YW2-,7$Y(1+#
M;'8Z6^%N:(5[X/0X>'&1#@.G(D9$$3BO.F5)U2K2NOLE;L!SUWS<IY^8"%B*
M29F:7<Q3Q-DBK:@^6!4F?632"^<-U\&7RMN,RHX^.IIG+;>6P-0@++IQ!,M@
MD4KG.KZ)4GC\@XQB"130FOVM/G-0H:#I@_(+#0GO!/']M\:^_8_]1TTS\.P=
MU T:A6S*2B8 7SOQ:<_Z^,S3L??-2Z?#B.WW1C?OM4QUY%B==#LN+=R??H><
MF%O:-+#YUNR@2R)&3IP#?C]?)9T#&B?!Q%>CX^1;X8HM<L,:;IAVT>29-X_+
M_B)+X$X0(YOQ]9?D=AD-WF_?IXUTKZ8]2K0D5^Q<HZ6NH[C_.YV6Z=4U#4;=
M*WS7X ,:6CB/:(V[,8968E&#@5LT9F-/=_U3^)_J?[%-X3T:'_84UP9Y81*2
M^"N_](XG3Y+?7*"[-M;ZU86.D.'H1>?S505:8WB^==JN[MPUVZR4R.;JK!"^
MA=;_GG;24)T]6K-ASYJ%K7J*(&F8@B?]#H 7Y_@K419?>K#,C]/P)PG@S_IS
MU%>VV9B0T8B\BJ'T6J*=<'-+2VZH_*97&,M'G_X<B>P0PGQ'L2LH&LD'?326
M?#'[VOU$/&5/(#+.#BK4W\\'E-OCHY^B4?K\Y[3K*^5)*8\;O]2>M7N7>YG%
M>"2,8__0(LGV=]'A80#C#[=X7X86&EQ=E%_\H"B^NF9,WNN;W"#\"MK'EO]X
MKQ/U_I>(B_?"!?&N76:($"9)X%,*@909FT,WL55O$JI[-.Z8I3 H%-@_'Q*K
MV?JA\2W=RQ?XH%KCD:?N/!:G8NQV>7-0I 0I"BKY][B6EG"S,22]-4FO?E0D
M\Y=@*//>27X)'4CG2]-IK;EYQU]'5C3J*A6%?R9FO^EYDB S<7\P81CDA/0P
M(0K\C ]NKL,K'URO:8D)*MU8A*-6:)<6'(E9!RK!<4[X*RY;^N.WGERZ79&F
M^'S'^5GJP;SVO%MD?[0*90)QB_V',?>@+,?G'B^._*#9NB'_D$8_UI3JH;OY
M&6"U8DZ3ZU:BIURL;M^*WA*SUX!Q3LQNR'F> /1;C89R?;/*EX.B!GNAWQZO
M!95F;[#PU <7B\6;98GYE[\H5M7=L_G(&#YTU())[0&_7N$,-Z",CN0D&ECA
MW=N4^K)XU1@E%?9"(HI\9Q358^.,QIM^0-_ $>KM]@\V7)AS')F0(2!W!J+@
MV,M(("_H@D;Q"4UV"4!ZI,5V%WK8=FX1*;7RG:?]UEI3Q%/9E]!_TDJO(KZ\
M]'2.$#:EHO@1F4%2(=KC?F+8XR1)PKB%'COE: 7NB)HGQWG./"WI5=?(<U7@
MP8E=KJYWVU4-7ESETTO[554-QH-5E!'@!4W>"%X5[Q@GH#S6TQ0;?G1!",VJ
M]6K2+UO:PIVCJ]KJIT4'2:U)01%Y35[FW<Z[O8;G -$.WQ-?_,KK@+Y'/)2T
M)@#_3#]/G8I;#*]-$N6?:,#9ZG,*^1QRC+CJ&PMI1(J:]:9*[17['KS?>6._
MT.U]1:FYKM?'QX?E&8% P)?)W+DB4H^BE>FKYC'5YJK2Y1(KX:^JB@%8-)F"
MQRL%TGZ_CP@^2AL7R(H7; #%+3SU-?,U2_<U\VE>"/%IJ?;979BN*TD0??W/
M,A;1#SM<"FER)?R-[>T4][0I<G+>OJAZQSQ\'_"'WB>8]3"P.03]C&A[*DL"
MXRT[-E?,LGM:^#C'RW06-,*021Y1/3/62HNOW"=7K'P,76^:#:P_-.4 *JL.
MXWX)F>9ZJ,">*%EFNP9*Z#1']E/$5L:_3X]P$&WJF+?R:._Y=54^H34[CN@J
M;=V/9PO)7(?<YDE#;[;N<G QIUG]=#7K<),T,S5J3FLCH<@312QEQ''\+#8$
M7:2X68]G2)#6B7;([\<4B.B60ESX83%!7X+.0*/4K(:;U@ V1<R4*7A=R2T5
MO=D6"U+H,YE?D^=Q%P8FO#\\Q,H&PU[7WK:/_*&?]KQS[,3Z\U$X _UZF\Z=
MS D+N<54\4]NG!&L?DL/&Q8E)?C8"N.EG\9P!?@(/H,_NE A 7SO_@U5VBX=
M;^T'X"V[Z,@3()H.5\7NEO$-_!5-3KRH9#.0J!MN11]5Z>! FXSW=#F1=#/7
M6/2LJQMX('ZR#\<L,M/?Z>9YI1:U!_[:LC^.YR'9$2EP15C:QHB24S#./4,Q
MI\7WNX9V6=^\</PU56'@PKQO"<"U%7 Y_-,L(74<]'I#S,&T)[C*T2R+&_3)
MW/= ++\MTGWZAZE9K-6$7:!%GJ>JXSD@JZ@)_.JF"1/F'/#ZJY>H 9,);W=;
MYZ.:<C6>7Z-:;#-I^<7F(+.,SF_Z"B5Y26:I;;_S35*@;__E4I/@!"C.9N5:
MZ#*0*+CVM:2?$%F/';L&-F0_\R",9&77[)BJ/SN"UB&RDY__FBC"P.<'2=_/
M :_>$4W(S"9SPKU<:;V;0ZNIK!#EW@! >X'&B W$#&O!JYOM@<W+_BNUG7JP
M?^,J4@9?)$;^BD,FU55I3)1FC,G'9%6N3V]OCO37_O(W,U[H;=W-TSTLTEZ^
M&2Z_=@Z(^155)"#KH&=PHS+D\2"/20P:MVN^C87EWM4_$>V3&^]5)'7_KI%J
M#SS^6SW-64]D+Z[*)CR8= N)R$HLRPEOPO>_(KEAGEW!//+VY@AWYN+!MR)C
MK@X?@:G;)"Z1MN#%R$=C+- >[E/#<+K97+ 01Y<@T=ZH_6U!B20(S96A"9QZ
MY'J&KIN6LNT/HE6?G<5=]3A+[N>YE=/V%$6%MM76'R6< ]RSU)(US)#&3S1V
M>SL1TXK%O^!);0PG8QCE>%7JN*;J''\3YO&>OL65@R^# 99US"W6M#YBU_6\
M%H,\YXJ^LK*8@O?TS@$J-__W8F5>D!9KANOG@$?DT64VW+J93U$O]'I34);&
MVO"D@A$#>.J#L5I!;OSXJ.S+=N$K4E +<5P>F0:(A2H[$+E7/Z_W?PV"<T$*
MCQ@CSP&$VLV8<L\).<(1LAYAF;16I'9G'BF GY4C#^.J$[TJ[2 U0NR2%>F-
M180LU^CNZ81CU$RMJE1]4M8)< )T[TGJZ?,=!DP7WX/-TA?#@;1'3;7!)J<,
M@L.-&AH;>\DH9\_>XX+[G<K@A(LE@+[5/?WV]Y9*^O=2X5I( B!$5GS56U(O
M3O<5R0,;*^#FJJS$2+S-0[@"2IBZJ1%[,T[L&FD;/I]*O)4:$W[('.Z';WJS
M=JJLA8N+\1$2'SH'^*SL<347\_BD_G([!UPCOYWXH!.^;4RO<@;J#F\\M>[E
MHT4]_2ZFVA$H7#Y![D?-CE@4>1M0<BL3:EH>DRAW#(J@U4C=0Y: P?"T7O_U
M!I$]3SV\E#(5:B(ZK'EG,_"C_1U]DWOS9ZLE">)G>J"MJ?],TX;_7D/CV6,[
M;F//N$Y176)?CE.9'ZOEZ]!IZ<PJ[!E9&W9&?V_8[".(UE8 7@QUR9E^"K[Y
MXM91U-I/$G/()TT)[R7HJF97)*_WT]!T:,]-^,#S:HC0-_>A:_N(2P0X(R3
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MK]:Q+5;I)A%%JG10QS9^Q,U2L'Z>P23OI(MC]X[]_B7C@/$BUO^5T[LK.Q>
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M\WV)47./SI4NX@J,Y(''OOU_L3[^'_VC?_3_($1G'(%?>&N3JRAOS:+:-E1
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MYG<K#1*&_F8:):P#"]-X)V;:WMZ;;)+RPE6_@GJ=;[01%OQ]VA-/'6P2PFD
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M)Z<6Y1TUN#%6I*9"NO'O'.?,[-I_1\T8Z_3J)\]LPBLB^2+R_NZ^0ETS)V;
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M*#-!QN:*L..;K3B3X0E#(\%F59AR_Y&[2"P_ 3@@=/0*D\:?KK41UA;P#%>
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MOKZ$U\RGX^E0@PDD\*ZV &D9-<SA^G0]AJR1VL%XS\,F[5R-XH=@)6A+*X!
MC6J]@0L!9@,*5YC44U^$LD<28D:6$6E6&-J)1W=76F!WLP&K.LEFP<<>2:_U
M(<WF7,U_+CW,2='9O]0VX5_J@F$ ;9<YA&['_5[%7&O:2?_[E/R7*)FI\\PE
M)/7S#ZF;%P 6UO<?7&-^,P&T9I).<B\ UW]<^OMJI+57Y5P3Z<$%(")+>$0D
M8VM_ZX#"U^F9[9ES@,+TD,^Y$.+0JX-H..DGL^ASW'0!T-\#47DUN7<L\F#L
M)<\:AA,"O!16#;N)36?"71< VJ>1P*\7@/#/G=+%KE/*R9;IV"HR$8LYO8HW
MVJ3M0&0\8@:A+SNT[8H?W*J] '!WKL-L9=I^53OR*Y)?  ",+G\]N]%M3ZIQ
M("R=PR2TMA'3[$MEA8_<S/TL"'$"MV0N ,HL0N-+-:;'Y!^^\K 'Q4HC4*W)
M]%F:-!@_Y@M ')JF MA"*DIYQVL^;V%6=]ZR C4.&(R^58VGCMN7-SG7"L01
M[CDXGN=FO:U@JEL?.$_Q]5S> VI&\B P8N>0?VN&K25R,0U9ZPL1UA]%VB(B
M3EN!K&7FWJP4A^<O/G"''&ZN1U&2SPWQHGUH6[QX94VCVSU:G-RO7;,N%F]T
M/KAA@6KCN/_\<>#MQXN!,M<?_'Q\(''.>0%HEX%^8"6895%:!%\ [DMH26$1
MGSW&SN[E^$IN(I@(:I-]@<P:L*]ULYNGC^T^U QTE@G#IX>,A=V!TR6@2W[R
M9R*:0,(Q1#DL4']3-RB.?*ED< ?.Y]K4PS>6T)3)PPVLZ#D;RP52Q7O@/ I(
M!N=2K3&X=BV&):WK;Q^ZU&P4X4G:P3 [#)XF/X>%'S6<7UKTSEY-O&JM7>CU
MZR*;RN@DO]X6X=%>GA_("LI]CO_TKN,_^D?_D\67GU/PV[Y6*LV\R!I<!&Z,
M*3V2#<V&.E/,Q1PFC6G<&( MPSM4;PS4H(7P6M>'FW6ZMN+Y^>\[#JMI1^?R
M]/)IQ[LFOD^(_C&>\3YS5$,RS7[ KC=X5=.U2%,G^&^,#\ZPO=-9I*R="')-
M!&F*:HB/@.=8AQ:VX9?Q96;<CT8(CE<_\ALI.T3<9%5X@Z=#E6A+[-1AE$Y@
M6<<HD6S131!N@V) *.WN:6OL=R#[F]'FR9'+4/7S\1?EVXM!8ZR*%K-* 9:D
M22A.XP)PP\_>W[![@>Q>YB)EI.%-AYDS=H8ZG%>,T((P_\;'B>$F.]#<*'$7
MOOY+U=G[F3H7O.#2&[06W<*O1D%5)"*RN,.)<CF:F>"&R6Z71E>86E[FLDZM
M*J_T:"[7+G>RGFO>+F=@D>98N=L%0",@YO)C]3/LTV(<HZMGB6515S(ES]*)
M<C[[ V6RL34,H>R^+CRB@'[ZP5"1<OX3$-4 V& %;:-W 4B7Y6\D1.&&NK/O
M^&G[+BZ$M]*-^W%C^:^^3F;,>T2+O;KU=7Y]TC55H$9#\J/*F22LP-3,:/:&
MU=W=FHJ.27PL-T5X.Y;?TA7B\]O4@"6O$/OT=Z1NCGF(D13#"%PYSTHG\Y6J
M!(^F2"*H2C5[0_X6<V _#O*A6[#+TOTN\I%R%O>MV/9WO._*OS7+&16-($+1
MOS+5)-;&HG1"0+J)W+09[__>/XD8^Y<*Q_^H)(U(#^?%*^O%BNOL[/SA8^,+
M[.]'\Q4'&GT!<$SF^@D25/!T2RJ1CG[,N-&.Z91(B;[ ./&/KM<K1P6-T8Z%
MFZ",KF<4[)HQX88M8T*/@QN,K,#<\=+9I^SG7Y&+62Q7" "/H4<$_%; 8Z))
MB%5#'1+"J$4.D=V\4DLP[]B0\!U0NR7-PCF6H][)$P_^*"O&,-"]/L\,T>YD
M8;=BJ]R@O!8_4IP3.X1/7"DW\D@[2BSOFTM6H,\M[L LV_6@-B7*QU89"Q8#
MI/S9"-?:B)5N@WC7@?J"!R_T1;,H^QQ&DQVB$Q..)/ C-:_>G[POP%OAOSCE
ML>N_??K[] #V%^'XB.>231W,-BK7%6B@=N<,6P?!>Q*L=XE\2.788STGSKHQ
MH)=3NWF?IG:ED9\ H;G5C<["1%TZ?Z1&>*[$%R+X.'!BXK8C')X3.S\]/2\>
M2@YYHA1+_SA4P@@;RC-N%2L]KOW@$EH^\8'XSZD7M2@)7JC9'S(&2J%^AS+<
MWVR,0NZL,&2Q\<(,:4 B,3GD/6]0NF]RPJ)A6Y@AV1H^:(2Y$*&O:UX<ST$(
MBZKH&<G9!K^?HJ48*TAX+RT;KX'9(XJO2FZ,+P=U+I7TYHLQ2#^?*%[7R5&+
MN*2-F>S$?QWZ#9RJ2M?-F4<D-*!F8X(><#JET9U#,Q/=UE3!K8-SV8X[0@AG
MH0(W*GY?!TA>FC$]1OM.409&DZI(1SOX"8.F>T:BY6TE&36=Q#3M:!TG'4>.
M!,<I.K4DM7'>X5Q-3P?]#%X=F-KEU7"U>.T069?_=8+5W[_0X$@'LQCB]Y?B
M@BY-5*C/+CJ;0:-Q1C,:M#8-U%6AS<$ZWY_M?C)R0"$N[7P0U</N+<3]H#<M
M(/O&#DSVD:^,P\GE".&A7=G, 4\N33"5GQ?TJ,7!)/O^-/J]V;.7(SD"C4Y!
MN3,_=X_,A#4^-Q>RSXX,\6OY>PMVGL^-]\]OGMF1QD'=VW)X6=\S5:'25D:"
MCDF+&.8HB!<24>E-X]2L7M2F.0R'?$(]W'_"BA<JC^U6-_BZ;=O81%A!#BHP
M-1L5=4^-]HI&[L?=^3.^RL08Y1KK&!,F(9L*MUOW,7"#I>BF.64Q#S:]*8HL
MTLP^"SM0/975QGF%I%"Y"E%E-"MCHSEY5X3RK&0SI)+T_R!4PESV)U.HEADA
MT3MPKEQ#!C*C5[WPNZTQ/IW_^BG]_W(6S '-Y3KN/4[<#<ZF]6">(@T08JQ*
MMH;F2#.X@9"LK8\+%X#;)+$%VYH I"&F@/@ H3_C?O;76NS4_EN"0W%;ZOH?
MU25?]=IKYXCJJ:N^CH!#^O,^Q,%JFZGA!)$+PU#GK9.3:FD]KZ W6"4 I+X
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MF ^".QYW'\EO0:NRQL\%)T]%#NS09U!R7#4"6F1KW,4XU[ QTF5R 1#:W5=
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M_#85,R^N,1*;[9.VBG"OSM) 3:TXI5=ZV^C&=>>?<8>@QC6R+@!*?G'N9Y"
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M&8BV24VGPQIH*,C-\Q=7EVB%VSD@\/3^X?K0:JC)A<.R\Z>M(P^'WJ@VZ]H
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MX_':IURRKJV"7H,1/VI2[D;_G,7W+]1U@\NPFK*O^0,9VYZG$.C282$A,#?
M Z:&QZFWO"4J?"',>T3-/(1&-56I:O5/M&D'44GW@3CF=,.TQ@^^\(:TEIT#
MOK:9$=SNXJ?%'C>H]L9(312)5@D:N]Q=Z'#8OW%O_]L7XZSD6'VYFC1[8;9
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MYW_>Q_N\=XSGPQPC'Y*17UE[K3GG7GMO'"%C'[&"1L*0\U%Z+S&\'3TP$J
MZQG(TTGP'*S@ZE<D]N$6)I'N)[+@I'98%&AO[U):ZW:WFP?HL/68=PVI.>G+
M+E/YADAEWY+@*]J6[,Q* BR9P0:Z1">'7,K]ADD X)SL%-:S\]L*L:%>]:O9
M F:W%&<T8+ -+)_.A4^J'KZ+/_M.QT!8 +Q6P;VD(+KY'@/JX%B5#CSIQGM]
M9"Y#H2^/!'AGA:4E@%=+SN=M0IG\5TF @1(Z5#<<=QG\/GKU=U^0[=B??8+/
M@-_!H2"4,"%9Z9*C"EC*$&>-TA)9?KK8Y8,BB &IY]0Z,])V)&HF[T_T4%!8
M(J-/B)G(^626*8>Y[V1OMS@><D)]GF([0M1E7QAB+?*+E6\HNL8XWBVX<&3U
M*^LJO=$!V: >QRJVT2NIRLZJVJ'X-0)KV+1L B\S/),',D4/D9I>93BRPY 7
MV':H3HO)B&7:TZPH#$YEJ\BUIE(U5:Z?0->VA..KR/0$;V;MK)\-VT9J[,C?
MSV+_FUD/E"B.GZPM#K-QJ(OM93RZ/*>/>^^>@Y<;5G/.&;9(-"OV%LNBZ)(.
M?-W@/?/M'J78R^ZTXB-GO]_KBBWQGLL;D,N--^Y+*;7FX(([38NKG4*I"CU=
M/MO1B9$ Y %V1"YE2RJ4Z[R5_< 247QE"#5'@4.P:\,^1JA "'%!]I-^XS*%
M8.'X_,8$OI]M8VW*Q5:;3Q/S@4@"DXP2F_-"9["7EK?%^*5W_48T"R-9?9KK
MT^+!Q>DJ:7:;J^A28S:IJV[V'7"3)[%+<2"ZU=_31,(#)^1_53Y3) $.C7&Q
M?C3$GW/D,"_NYHKA?02S_9CIXE1E =0=(HK:H9$__^!;N/*H:*[!*_HN%EK]
MMSV$@'',#N37W.;4 A)G@@00::"HY5/EV89Y46KU@KXZOZTW'1V*XA#6[^H3
MQ1.07+/E8S\G*66XK2]=V9H,UI9"/Z/NQK.]37;YS65DV=Z-J;Z'@D;F:2?
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M;V0IOTN_I%(AZZ6=NL2TV#]==:?#^D;4!<F>#4W*Z)Z[U4];+X0$=SZ\X8\
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M#0L;'=.MW45EE_Z"0@/CGD]C95CT,?7J*O&B K]8_):9))?"ZG/\#5NMN'=
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M6S 6K5JZ_@K3R[((=-!U_4T4P\3S_B_VWC.H":UM&XT5Z8+TEJWTWCN2#6Y
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MTP9F<FYB:2!]%C)]H'Q=A2V)5,31IN8>K6;^([G9>&?D]1:M)@%O)$0I!6!
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M^RHMNQ!!7X?/;UU(A'0#2:X #AD6;H;/:JX [_LP\F_Z@G'DW0Q5&7BPV5#
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M6"_/WOPW"#7\QVJ@.H%XP8AOJ'Q\41<06&>A*@0SIE,FPY5VYPB%/!QWX\I
M@9/W;@CS(+XL+#FY[IG():%2GTIRCX+:I];@==1=E()KR,XK !M!9.J9.)#V
MU5'A1[@$ XM>Y)Z5*.%QZ<TOWVG[3!OJ4K<?"?R6@3C7":\ORH&RH46=U6L5
M]T:\^50E^BZX$_HW!44=,UXDEZ -DNM"NXL,;YFX$^K$C<'3??MP#22= %0-
M@R3'^6G5/TQJT^['IV?*YS2@AZ:O"3EMBER%<\TWS>?#52>&UA.,:3:8>9V<
MWB7Z\LHM<&.X]+ C"OPK>=Z]&7UI^GQ,.DYAU2V[SVC\8+T:6??IYI^)RSND
M-C!:V8>=G'=K7 AE"%W?(@7CAP)^_"-&.X:9EHZDG4TC#V(3D^V9>9G5\B=T
MI-)!6PYQSF;11J4_2G7KR4[0X#AGP[\#N$;160IU.RI-(UE/-;4>Q'@E@Q/=
M_IXW@I#ZEWA!XDP;N<UEVFH"B=.GA<LL-(3:S&V[<2]=+:L#1"U*3S#9/DV
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M\< P+8/I9$0IU]^ST_3Q_](!K/]JKT,XOKXW)M>;/(I_$O+("<C>]MAN'1^
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M)&)'99/YU\0_IU%/9^4-9JP?^P:NZ)6MUP[Q=;&7V++?6S#WW@LAZ4&J)'!
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M!JT<4<0_)MQ/XARUVA.&ZI$3E5^#@DJ=TAZ&]C^HHHI-[%UX&37^EZE5B8"
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M9"K.5>=%I0@[&P#PFRWA]/>Z<<_+=G92SM0R>R%@?-]RWA]+='(CT3PJ"(+
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M+!;5IXM(6LU1N>+&2NT@+ZY4+R9/ZS _;]D%8PH5AJ8V!X8WB5E>\['@I<G
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M$PPB*H4PPHOZ!%/&#$.&5&$3XPN92'Q&SO^73"JI_1P09DH>/^#[J5ZK'1=
M\ZV_);(=6[.UY>"4>B4SZBT1R.[DEU0ZUZ9;U .@;WM%].9E__0$A!)9P"*B
MZT>N09(U<-Z1]3?JX#<A'A:?IV4]M;Z_%L\M+K'K#00KAU$VZ19HX'0JF?I:
MA(U77IJ>=/#@2A3^:(*+8<1XLS<??_SH"M'1&P"F6J98*%P?=Y?P"S>W4RF%
MC'6/YEN7[NQ S5>,(IHMXQQXW-J8,T3,JME:)%G?N<K='A(K?'OWS^R:P2Y:
MX2'3>&M]FOB(>X8=]M$]CLD.<]L$CX(VRY,@_$ A,12OOHR(X=")9)<C23':
MCSOZG0-F.@0^"XR@.!Y<<TUUKILHR)Y503]M&7>IZ9CC;=$(+4=,AB" X4,^
M;&(CEVP4XV@=(_+CNRRCD+8TT<4<$^Y:)V##[!51V<SV3 -9V# Y('G-3C7;
M-8/6-Z+L]5"-'9(]=<U*N7SR[LS.M3LEG,P:+UN\<MQ-$V5MXY),8GW!-3%"
M5<C!_SB?^AM_XW\RB ND!M@3&!WT6UH@XJ8:=W<IQ&U%KKCC].F3M%<*B>C&
M.#$;V%MV5I>JIG<%R&)\7)E8!4_.I],&4;>@(N@[8Y!J-Y=XDF^"4?370R*3
MU'LNO1:C!7@DG&E2S(&VQA 28LXJL#D9N=F?HS-1:%*L1"H%0-YT0]EP\A2Q
M$ 79BM0U/+M? ]ST1D*7H7$:K\3@Y\IRR'<$4SZS+9TE6"OGE4QA=*%6NSH&
MU UEP@F^;M.L@.AWGPD4HI<8GEGZ66W-R5=XG30V6$HM[R9=$)T?6KJ5>W?
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MN_O=WO(-X.U[-N 0[<)-"WKUI8<=[V\C6]2WU:[[BC4YHZJX4'JE JRRJ'/
M$^>J4V<1]M8$GMCLACBA%7)Q=#)TRTP.[([(AJ:I4-&J8@7CL8\+=_UY@)T2
M=_MM$E5UG/"^1IPQ9LYMY9@:V.ZCJXJ]BW[=<R*&H^G'[)I,EF=0V!_Y_^E(
MTK_Q-_[&/T Q!*M3V"G$!I^DCG:7)KZ0K(7$#,\N?R/ZYY_*JXF.=AQJ,RR^
M+XHU';?0#O3DM8@\04KKB[=9-,8U^IX#5!!UO3NW<5DG?ID_;=(ZB8'8*<'
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MGMF?]]F1GD>?R4(0_VBPR4HNL\%.A5L&E+UQ5DSSE0%"U.',"P)9 JCX?!'
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M(_O#AFH7%R0J.<_3@0[6+2MNG9HS+LB)OR]T3)UD]V\G]=]F)ZL3^H@S 5A
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M19;BG1)@SU?/*E=<\*6QL$<81 *.;F/3LF$Y4Y[P)O)0W,K[:^<H\Z#9W 4
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M8=^,^K@5PA8,9XJX/C>/MTG=KMMLM4, \(,5-M W3C$$^4P7H7NA3R]1+9=
MC:UJ$HPF\T('N[FEIR%0W?9 @[QC#][D)KG&7-==L:,O#[\RU4Y4[GGP]OU<
M-8 ,+SH=Y6" Z5-=WE4,34QV']?H*EO 5U*-LL8)2,.<&NB(MMN@.HU^A'G1
M%DYL,O.79,3*'U[TT.+G=9)WZK@D 0YR3")MK5*E.3X:KI[C:QD,$<YK<T[U
M;[7!K(G(./1P T1T/>[M^2&Q__+"[(ARJ^M?QLF,1+@%$8'HZ>";VI F@CO[
MA0:\$O>?U6=#)ML^7'&,O4LU,KYU-=O#RC[,@80@MES^E.*\E"R>C=!N"Y1\
M30+YVFA%=7!I24;>O]-A4I!O%8O%]2C$\$$3H9X!,W5I7CU%;KSWB5FQ9 LL
MBH.D@=TPS9!1K<SX2\0&[FAO/>?(F+RO7ZPC ]TUD:^$VDF]C[:QT>#9!$5!
M-"#7V^2-1=?:>"-'#V.IZ,Y>Q;7GP=^?F5MEM%.QQ4H-^)[V+_56666L;B/J
M-_C==(&'2WKBPT/CB]9@WF'@X;=#/=E:J2#^# MJ8,J3[KHO=3)28MTI>AJ7
M0*;NT;C@T?1RN;+IBQ?"Z<A01UA36%-*6U.8+T6GGZ]>6YS!DN]2Q%S[SSB_
M"N0:[ GQ#7[4Q,8+LQ]/TET=?L8D;4/TL^@8SUJS4S+WLJO/4O2J3'SRRFIV
MHS%95RQ9NH;BJ'3U%XDY&Z<0GM"82W!"M_+TJ-ZGTA*H=*TFJO=L\=RR=TN0
M'X?007X_N59!]W%VT;KYN7Q)"5@*).2,K,3D 7&T= B.'*5N]D2K&Q)!S^];
M+3@<.[QJLI+H+I_E&-X;-J(3YELJJAH=)AYVT=TF/?VD#/3J_"#PRM3X/$>&
MH]FK?,/X7GHAEWS@FPQ.>72G\WDNE[UP?R\0GZ+-,[71"5]8.'$GSGJXRZ(X
M^E9'F:QW-?#YW?1>F$H=[16J:G-7AL51S)ZMA?UBM95+UO#PV6<:_C3^*?#<
MZ[ KU^]H/N(*HWM,Y^U&#$0BR!3D^95ZA:_J+@X8$*>UFQIS@U!A)[<T(S0.
M_>!ZK_CN_>;F),.Q@M64#N[)^F(G_F(+WT?D[-7]8I,_MYXKXOCB<3^[+'H?
MMS@VQN;QBG9/K>4?3I5%]$S4@N?^*II_0Z+'>NT>%/)'#\$$L"U&^>V&7#(]
M^WDY3:G%8=C;-#>47S;5H<?ZUAJ"LI.F913Y19).YPI0DJ&72-=II$9%TCQC
MB2'H3,/?DH6R!\-77!D;$:M6<R.,_K;W(F]5^1OPWDR?L*UNG-C%B7+N9$I0
MYT_8*!A.-&13ZYD]F11KL)$@W_I9$2 NOTV]0[W@HKE9)2XI;I^QO$[)%)GH
M; ]=]*W0@)MXC[)[][%AU+Z@@T:H98O9>DU<OG_&Q*']8%(]JP@1:!M?OD9T
M(3AK)DEZ\@( ;#Y$TZKA^Z3)@[@JUF'%5_1*^HJNL^4B)39)QF3AM98J#I/:
MQ2YZ4]\,.F:KE"WC'^GC7S28S"9X;OY7Z___MO^OS.3GSSUW<4])KRJ/W=V]
M^RG8[9\_G??V/"HQZGP3B]9/^YD>=L>.\M4J%]P3&P((I+H*#^@)%2UX%*7H
M[#4>:8M;!?,I]AJE/;_U_VQS]$TK%G1@*W[YM\#Q:+(W+^(#:-\#4/+E "CX
M4J  6FU5T4,0;I_$?&TUJFNZ?:R#BY?T@N#/;2^@1TMP;Z-[[MUBO00M^]3"
MT=AE:@RFM=A^&2C"33%5X? [D^"$R]^K/'M$"GWU19*9.()3Q^=^#^"^B7?)
M1Y/9Y7^"3]4^,2DP;%N>^K\ /OJ\'5U+,Z8%Z*+K(BYLW?B:\V#G^4/S&!]-
M+W 6R*A_VRB#-EWCQ">H;J/+2+N4O>]6S=26GN_4IYMP:ZC1T4/"J^YH3)W8
MS U: *9UFYG%I?M(5%VF>RP]7\T&_<[_D&.XRZ!,)RB^-H?[0?;&I_BR CAJ
MA>,2\#Y"ZKPZ3;],>,)L+@"4^[%[@;W+K,1@\>/?F.:G95&&TQ'=W%P3W,+>
MF2\GMH?+K1+6_.=R;SL=Z.)X2,Q6N-'$A.5L_#1:DZCQ<<!6\:<[ X@!VO6$
M4Z3+(]"TP49^K/5Y<GWEU=Z3J;FV2LW'9?=([06HU&;4%@66E4FY_N%[(G[$
M2LVY0N#/#75&(54&9-:(89^.BWP1?NJAOU.(L[@X.0'J=B2)-T,?1_6L*ZGJ
MJXX*"^E8)+&*F+==%T$H 07IC.)]HPU\=8QQ284?L"YRSKB[2Z<\C,2F'EOY
MJ9]R%P V8JH-P;3%W\\'08PS[9@.$&X18]X/H/PI025L5P,<CJ:E-_:Q/F8R
MP\JY3B$- Q"3998-%DJ3"%/?,L.B'_O"(WZ>1FEY588>30BGXU >NJBN9\41
M76.%D>AGI1S&#XG!SPH?)PA)F!L5Z^38Z><J\EWZ5Z_497*]]%E']_^LDX=8
MX%^=S)P7J5%R6D&H8'].-D#HK-Q-\)GQ@T0$.N_Q'8W*"H[XRL_.TS_B:XEP
MP_&[M7.IZ^[D:A++)1DVP10([/7CH?)$W6?$H+*.;VL$4-2-T9@V?MX<K^;6
MB109K >WM#[#\OQ*=_<-2?[YJTQP-6.S+1(OCC6:BVW+:%!FGMC6D9XRX!<E
M-BAYXCI=K,-<4L.F'&P[>UN?ONE5^Z6?7"7P;O:OCL92TT/4,%P"5CE8I2)B
M4J0),$[Y9+R=P+R-<0&R.%F.#%CT4DAI6PA5F3><(X@\6-8W'?R;WL342VJ,
M\Z=C<_;;H_Y,A!LU3'Z,-?R4T##6E/RCMNT/'[ET[*/ :PX"$5S,=Q/@S&HW
MB3$X9&3P#S4^8@AV_PY4Q3K*-4$+?9H[G2W[7=3S3 Z[\*T&8M&"=1.=_2DN
M:&CH;*\I K?LN ;OM(+I%66+4Y^$X<NA)3VP9DB?[>VPB:>$VVY=V0E6:(F3
M>>[//8E;#N,20-"/[OPO$T@!1:_M#JI3?7RC[]9?Q#I*LTBIB;6H&9?6][M9
M%4N9LN6/>:R_'O9O<4RZC15S#E3)\<V1 Z%E1S<)%!'3@C+X#>E/?7-Z:L'Y
M<R9VNL+8+*;TM4$J9M>V)OD3;STEC(_Y4]L'L!KTFF%:B]F^ _,:B$I-$29,
M7"F@@6/@"?5>S',%FC.-C:GU'",IXR&S 954!/'C$ %3I5N2NQ\MODIZ'G2;
MC"+,CDJH[X8-5=?[S(5*TB1VOKA7_IP 53ZJ470]6IXHMHTOU2^R71Q+-6L%
M1<@\1<CV2Q$K$$J#-7/Z+F'EFSCIW5%*R+7$KNF$[.+HKA=EXTC- CTUG32<
MJ.R>XR5C5A6^_B?. OB_RUK =XD9DC>A/+VV#W,^1W7E,1%88QPE$\+$J9^T
M3?%)IMQ<RBA]^81M5"X]>!)_Y/9"5/MQ.I6)J$GVO.S6HQ'?4(-XJ]]WV9Z*
MNWN*TH2A'TUVOR P>3<'NP6GUS#SZJ2QYI3K2]FZD_^$NW@Q7P"ZO"YCOPOA
M<?^&U3:*$?ABFL'II3]"S_< _81]O^EI0[UUHIHM@(T9R\PWH>LCV\3X;7P4
MF*(G6Z4+3!GH^9$\>S#TL^=]GC;?9  9N&X^_R'#+FG(#<[*D]!CY[JT=/;4
M)#A](W!F^?,Q: OY8.#S#PL!O61,Y3$L6V3PH$(U/;-FL#K-.ZVB5=))4][F
MCH$&<W?PI__7C8;,XU 5] 2TJ8?,C"]NW*^'9G=G\415GMQ&Y5:ZOFQUM[I)
M:S748E-(D>/MIB-;;H;0B1!JF:HT9"KK]!))Y_MT"ZFD7=3^U$<Q5O&I/"]K
M=%9I5-<8(AIIL*>?P.&+,/4:>!A?1$H^#R8/J[%> ,)E3EX113$92?W-XV0V
MHKA7X4*39UG QSG;[5(O@R^&+:V>01OK_?U(K\\>>YCZIK#I>;G(Y7FVRM68
MFPQ"SS42A<9>&FN8&,Q>,3([H\M8+5MK>7E-HMC+X1*LO8UW*]KS6"*4[]1N
MMK@@>,GV=8O3C:]R-]B7'Y!7%(?];D^W+ZTT#DD%U 1(G'8$CW_9[KIT_8F!
M_Z <HAN92A4#)VI? .QY8FFX0AU6HGBZR$+U;".CNR@F%ZEM!G_^E\Y-P1^^
MG3(PU?#XSJ23_/"E)$'0#;(84>G%H2-!$IW/OCG]^>8ZZ\PR]^2]ZN2;M/:1
MQQ^S)&CY-!1513<4^\3(<Q@)@0'CH+4/]NP=5#D>@7L^;%1'G^M167(.E)H+
MVKP_@=*CJ"DX?3-U].)YCK2:%*9BNAYICR=RX2BBNQ^#P;[%5 'W#6QL&5*V
MX>S^!AKP9*USH7^I-3#DQID0L8Y\)VG>:#4J>AXB0.T5H\9:W9']\CO+!Z2K
ME#-'1?@OXXD E1('OIO/C-_1P,Y,W9$2LF>#NF=*EIQ?.-]+BCM"VIE[ZLMD
M&9!G!@.QN$6J(^F<D*<(N4$9';.3%L_G87T3C4GS?Q%D"7?J]H?UK(8(S4F"
MA=U U;P?;'&O;A\*#$L'DP8()TIY-SNH2J6G=U+:JBI^)NV18S?:>+'4<!8B
M&,TM4K]P F:$OM(@W*A"MZB-5FPUSJ=Q6@F*KEE73:0FO\W:=#L/+S;-#39&
MC*?DBDQB3'.F)TH-1;Q3#M(LW?KS#\6C/UE11R,CNA\;(S (DT^V:?7IRI-.
M(@'W^4EC.0ZLZY<AK_+VXW]SX0]=%P]1#(2.;")0=('C3*M3N4N+ME%T#1_2
M7U;X;;$:0J/0F-G;P";O;?(#0-,0[T2Z[P"3(+82;OIW?9$G0H]@=V)%C'!P
M\?240]WHI.L.N6$2V-R*3[&V=BUCLMM(>86D7G0[,27T';;W##TR&?VY\OL)
M\C!SBQ==VP][TN/XL'0P'/N4EE&NF*]2[X6+D?GM -G3R0#OFAX3RYWXN'E3
MR-X%8,PN ==C2_&7M,Y4^M.^-W[N?5&(+L-VI]?=)D&]1I:ZQ<Q10R(.1W?3
MIZT4YYJ5_EYE_16\^X\TWB++4"_RHV@(6B<?B8\P+?=D7*;5A)L(GK7L@>KG
MJ:O??A!4NQ6 =ZM=&5R\M_XDM.H2<3<LT'09;B>CY%MG^+*2*34ADFM'DYI>
M0F4I&D[[=+"%>_MX#ZB!S7R\R#>=,4UFB^%[6A-GV!I?*^R0>@2F4GQI;81E
MI7;0SZ]'5XPD@KBRVM0^I:\\['E<>":%!-/B^]NW3</-VOF2NLG),"\>NC86
MPK7H0@N#WK8H^M0U!OTI4,,AV3I;LDQ'H6TCHC+!?$O#0Y?:U/?7?0%4P']L
MRS>A^XW[WZL?EG-4(8HW@P-^UE1NFW*H)9<LZ 9]WLXJ7FN/S'WN<C4S:_OD
MY.>3RDH/S!^V%J7IO F/'/^ZZ>HDU"6=L\;VF-XW9WW2CJU'05A'KYBM1^ 2
M85(]9EO]MTW*J(P_*3>XCLAN392RZQ?KI*;$W[^EH:3OEVH0_R*G6"!%K_8\
MJ+1',AYRFTP-]04SP_0)D<D8U?NPGD:%0YEMCB*"T,NZ[_YQ]OG&TUZ/W_7.
M/*UO_7#G@[UQA*T&J?&\!+Y:3N;&$R9AO&=*LPO$4@NP_#0.J];B(4)\T67P
M?HFD4*C[8PD:!EWPB3*8C,A(K.WCJI[;F3:ZB41? 'A@FH29'DGZ)6(3EB>V
M(9\5&GF4+%%<L:PZE*S1DBLN]O&WA__.+=VFN:,]-6HK3@=^\3TL. .515(_
M?8+?H&G][43Y.(EQX\YZJ=B+,OYWJ]NBR%?TVN4?<@IVEX"W,5$I\'U"CL-3
M\@[>:%.JE^3')1""574' _##$"?+/"N1AYFLZ_[\3LY_(7J-?3D">/T1Z_7;
MN.=\^2>J.D8)=L=F)U&70KJ:B.Z./$/#Z]9CEV]]?]_ON:Q,N-N>>ZE<D;S]
MZA+)A35MWV$@KKAFL9DHJTD.^41G_53_"+,#<'>>($$P/B![A1[:9#L-U$-N
M&[(CCW,##;Y,!:BTJ,C^:JH=]KEG<%!0'V'W!SWSLQMLQF8$+Q;"/C.A5W+'
M6COGA<_W^$4\46APUJ%998D_XJOA&GH\)>Y'0 M_-(*IO<&UMBW_-!>#>DN^
M"]7+%$.]:7:ZEC;BCP.S9XV K$9E1"U:'-D[!.?M?.ZDS=0GLIM$4H6O\5\"
MR]MG&DP&$.[0]_\NAS,?T772S4?AG'9_?>;O0WMQ0"Q<Q!7S+C4/1YD'I//T
MDQ@'I&%3P3"(Y7#D9K_<7>&C/6O!099/=Y#YGZM(3;)#M>X.7&CA/NS!8@#%
ML!;KFVX3] OACG(YYP'&M?1*17F<XK*TOGCAMU$HG!<+JV-,(7 ;9&RT:$H#
MWU<TR7<^)Q!%!FW-@&H"N3J>WEY9N1K,AFGCN4J:+MIP;5 =DL1,@6'M8:G&
M;_0XOR!JX)2&7NZ$A/A[ J^4+S;>D>M "6G#@./5+C1-T86Q77-4?[:>[PY=
M.5<.@TI\C%R?=J[RJ'J0^.I5-)_VQSS*9]I,8X.<LKX](M)MOKS2R@\=^.ZX
M$6%(),@)M&"'\]K%^+D]QYR[$PN_N@FYH:(ZA/*POQ[3RZP[COU4R%ZYO=2X
M===AO$B7W=/":;)^^,F]Z N *3'D*+\78\/5U'U;M ]S/N^#O=T8+XQS$><=
M?>]P]%OH10%R6'F6/ZJ23>NI@$A1%3S75B8$4-L&\PG:?ZL4-N"3468)8\U[
M43X]0&"8MAT4&$$H-[=U>"[65[=4U#2[ICNVU'%UA#- IAV8"?N[<V<>)+;S
M8O'5B7K5IT0P%A 5LH]>85BTZD1\><"2!Z%;%M8%,<[V-6H=RIYGI<EOG23H
M:D\8C/%4(\XX^49]0WD'-]=;6!S"AZ5)C\^7!2E-C*.DM0?2GVP91@0'ZE1Q
MMPG/%$N^+%;4V;P 2#4CPJ'9;PXKS&@)+[7>X\D!;^&HKX[F0<\0WQ;31,?R
MZGW,+1<KQWJ?NYIV8>^U;)J6W2RZ=*O@OI'_ZK&S_[;_@W97>68TGP?D<@%X
M>P&HBXPZ+R-P=B?WE"]9M<T+OJU_P_()NP<K<^"9.WV2)?E@[%L"Y_9\T33'
MG]*2J?SXW,)(\,;HR?O+R!Q.<B"2 ^AH-W])PV2(+KX.KXEFZ*;Q"X#+CJF[
MSAX!$OW=H^J8[P.UV+Q-6O#+:$)M7X!=B)BN_THJ- HG> L:1/7>W?'^>LLO
M03FQ*(DR2NR+'TA*NYT.5R4/85OI]E#WIUN#\\_Q[Z-+O397;H3&<_-#ITP3
M%<0[);@Q=&[],5C2=H(EE+*780UQ.Y^J14II78 EQ]@[YSU'P,=-G P7UZ+7
MV;4SK0M IQ:9BG1'X3)9YA!(YL2W7NM?YT&1^Q@(S>:,6YHHEHY9,],T3HSA
MID7],(>XV;-$Y[SI<_]&AUSXK5"UT)E\+I3SEY;4OE"1C(FN=1^Y_-<DA0UG
M\IVZV3.,]-86L&Y'X:&\I>A>Z+YQ>\2'GK:Q/__4/;S+3)+IZY#Q*>71:>1A
M30@RU9:?E 96!0@]%]0_%0MPJ]"T4Q%J$?N37%$N$:QHR5I#;H*J'EGCZSIG
MG]>T>!HW1\5N:4J7];0]TDF4E"JU',RRT&3O6:W5<=5WS:F6S0#-#G_O<62K
M;_F@P63VH^_(^9_8%?0=:M:S+(R7;W' >MTD1EG@4=&R<\#!NTZ/)CWKAS47
M?W@:M]1G"-\V?%,+O9O%&3VH\?=2P](3BI._=]#5N@5;F4.=3N*_TZ)*DR26
M0GFAIB/4'KZ+WF%P>J@C#Z_^U!W&CE?#U&<2ZVQV:K8)Y=8M@@3?V#,U.L*U
M.$56UN,\KF$$1GC$%9K347C::Q'?D&I>0:.Y.:(OFFP65AI;RG*>$.QE=+#/
M"&3'XWH66U85<9'X#PG!_L6ZUW+&="GRUW)F7%9E7*D4R_UQ"GNV#/6(55%]
M*6@./[3*Z.P9,80@^A7"W*;DAEV)LA7]W@;!G+6)N'*HSH_<RW;]8NG*4L';
M/GY\*SUMM-35]"1S^NQUWK+T'U585+QD1#Y;*#^,B2"F)D9TP.Z9=;5V!;GY
MG0BK;YU6MGE:6[A9ZG4-E^RP\,<\=_L\OZC!%:YW*S% V^Q7TLE?E_?F(PE$
M3+N\2;=@7E'Z1 ><!0SAYL505"N(/@_&5'\<#@CDJR-J;IN"MAO<XBJY=IW(
MBTT9YNYN9VYH9)'9;8+=IPP?/A?OCE<&O3G\EI4'U@%F]AF<G":E;Q&&9FMH
MNZQ83Z8M.RDY^P)X6H=""*7B(?H]]O#GS0S!)*)F;*YK&K[9S<?4("JI;5E%
M%%W*-1XA5%^:., KW,"13F!WI*"CD#EVC4T4?I$GM!'V9#W2>=S<,6;Z27&L
M!AU7\K?PHDN35DZI*)).N27'#]<HR6H-!!M/#P>"HN==ZB?TY+-<A^4*]52-
MP/Z7&>3J?_DZA'_*?E\[^47P(MU'U6KUQAUG#N:;XM>0X1^?>1_"N^PJMCHX
MOL2H^I2Z!M9^4T$SM?N\/3X/-8!WVK19G:?B&3O5&")M,KDEB*DN?LI.YR_3
M,95T9BTM>BW7(Z;D:!BL#Y@^7G=(2PHCZ,J2>_$[\81MZ]0HNG4V5YGV'"GV
M"-9,3!&JG8-8[BE:D6(#G@U-6@21ZZ$+F%!]S)ZP,0Z8>3>FU-/!Z$;JB\(<
MW"=^4EWGVC%.<%R\(^JP[#(H_'X"_Z[XKSSY9E.0Z@M Q 4 (WE>$7K311,D
MYP'T\, Z6MO?P-ND[\<K-+G?'T/[]?YQ]PDRW>WHD$RI@ 'OC<X[&1"N)Z_S
MW( I$+C+F+KMM3Z[SLPK1(EC*8BV5C1F)@Y A_OO CO/X#2^*WOP.XH*DCX;
M$9Z\ ^6F"<CAR"[L%K9&]P) N6DRX_!EC%38Y_[;>_2MK>"&2.A(%6>88F0B
M2V"3A I/IME@[:\0^5XL_E0@>TYV'E0T(%2 FF8D^X7]3^Q/;'<N> V*RX\+
M_;L;EA6+[$;>^!UJ2-3MZY#$_W")OT(;A]SF\.=789OG](?.PBHY185%'B%5
MD8V@U0)N)C7&<Z2:6'=RT,NL\^FWV"_RO2N*;F3.<2\Y=I]X^#>O,T/I1RKQ
M#C&WG_ PSORFZ_D .1%D\N$&#WZK;3N4^_I8OO8$^C0@F&D1_D7$.[Y@.E%<
MSG_TU 2_ ;H 6+:!5D/Y-TY21HE:47ZQ*>TKC4.^\0(B]0[MI50-3E0Q.^R]
M!L$EEX\-[/?)\W_EJ)-CQ!DUM!DZ<?*4R%O.#IOSW[^%#%^_44M0"&O@W*?4
MX'J=8GR>K1GV)TW86#]G4OID?L7.02J9DA7'LY?T.E0&#QO?;\$[=;OUKR:]
MA.7R=)^J?0AR_A*<<-J0V"[PD[GISDV3F',KY'$@^O;"F1=ZA&;(NF7#Z-X@
M_GCCU>&+:B:[USW:O]OT61!NA:W3?:1MXCD:&0%T):CP/3OQ_^R3$1#?9=30
M\I"]0\2B%W*]HCZ1@B=*NR@MQ5#[[Q;4D+G?M_[=1,7<T\;Z#.SF=SN09>9A
MOY?/]6^UZD!&7BTQZ=[5BN1^SDL\$!GH>7(O&=*7M">)C\6M.O5)1J-HN)7,
MP&,-O]?Q/VHS'%OQ515E"*BKGZB]GN2)ZEH1:V)%IR2F-;R1F$.WJX]B1:U6
M@:Y> .I)JJL7@/EK?]8M!6):[N-!"<M\@_(1939Z/I@04U^ 29+^=)6D;$RQ
M[\&P8+1LL^:#1DYX;D=*#H_$_57GC?>6MA,/,<J'?1WFR[X#/B),?D^T!I($
M6'D,]>9EO4W<LU- C:%A'0+HL#;+3,IUMB2[5&C"V]+4JB#?\=)N*/M4-_[<
M0IXL!FX8DHY]&!]4_L+OJ=Q\/#M1ZN^'?!7>@/D'SL^Y6E[WT.3&AV@3D^MU
M4HJ *_U\>,"/O!MP6U M:^<HT0!>MX)&7;6Q.L^'<.@0HWHZ,QEYF*'Q%P#7
M[>G#=S=/QBVA]4)%\\65_E]\-7=32;\N59=:Z(W\!%0])!)5OTN>N+R%4;:0
MI#9#>[WI&9XYUF>7F HJ'&QF*R)/S<SW[;&D..TI:Y0@(QQB".=&9B?([U9O
MUW3I<@F]$NEYHN0[M4$Z\IX1PA/=CN^C;2RZBJ'/'TYN:PZ#:>)*EK*U?EN=
MJ</T(GDYN_(8UV83G==VSCVQYD;IX[TOA$T[O<FT2%%].:'5;4?STTG'K'1@
MJ(T%'^[O"6_X\_SU)_]I%WQF8V,YNV!MN[S8Z>3D='W&+##02,O+P\W#BU-7
MM:?[H%;C^IWN)+X)G1TN'X1*;7D*B 7EAB**,%=E!("B\NOTICH*/TOF.B!(
MYAEL/_T7!#D+LWBNS5GS=I;K<XH M>&,6W$-^=JUDX9N'J8\B3A](*;JRL"R
M2[?BYIB1D3F0AMNR)='.E%)!ZT;$>GRY[!JS8?T:F$8]3[K;M)A=X *@CZ_K
MHE4FQ($2'W5:_$GPS"X5&Y7O/L0</$VE,]03TW=[_TKY74%6_)H6C0XS81;E
M9*@(E'C@G6:VDE_?M)>$CSJQG^  ,;D*=G,KMC;(;*[0R;*O9D+::$MW?UE6
MQ-M>ROX#-9G/V^K#>7(?ZA$TIFY!XGV'^6=:Y%D(&\HE1-\ N_?7YC)UY,;(
M=S+W)B/8 X.@YV3T4OL8T4V^-V7'(S5Y[/BA('V=/-0X(5Y\]H T5;%CV1?=
M8*-N,W.LIVXUW6!5YA6@:F7:UCPI)_[XX.62W-3>WF3*HO4H+U=;W9.??645
M Q< $$F'T!0+>Y3K3J.<^HWHTE\>)$];WU)C/-'FE/VBX!/0?3GEM#4!R"S_
M$1>5:_XJZ )0NWS]G D&PK](9)6OU,QG\9D/=["*E0'*JN9!+'HG2M$?8$N6
M02:*.W152C/#;IHF3#5I^./0LJ<%L:*$MZ?O_NDW8C4N@0'/ SQ"[/Q\'%XY
M <U,,S-2M3T"W/RN551;6UD_[A=C1#^H2-9EK$AN113>!"3-(.<@9*ID+)PB
M5Z434O\$1<B/9.IQ<R(PC(/JH7T:<6L)=-$>9EXD_I=WJJ8SR"#)[N2"8=E*
M+'7,@S<@'F=D!896 >MY<ZCP W[=P8S"4%^4,2)]>U7J"'O)A(F=_6<B^+J4
M^#V.HZ!BH*JKG+C<[]&84$8\3UP05ZV$XK?JW[ELO85?'9G&T1OLJL$QDA5K
M2CD/"&PZ.=_#RPW;GPJ(IC 1FMWUF+9 >U&='7+X_&Y)6I<\";Q6M#^*">IF
M'@XN=>-0G0Q\Z8?4YG54[Z!&! XIO P4IEG*[;J\\NLRO00D&-(WLWM^ID<R
M/\^&/9%#167MT$C\A!81*-XVJ,NM1,"TF: VK8E9_$G?VLW[,CT06P>6KHV(
M]X5?Y,?!7@I''\XDR7,0JDL:W;O_8JPJ*K+CGH5ES/%^5%;/I)9IXZUR"<DC
ME7?5?5AQ>GO%LY <@R5+A,9Y9>D64K55[_P7!IX(5,%>=UY[O^*4[*,E8C@H
M.@4Q'7)BWI\<D))Q6U @M-%8V0E+.-R(+=:!OB5Y$RX FYF]';='&?/60E?B
MVD GB0:CU<TO:WZ+*PU,;A($;F9*H_GFB[EFZ(8SL'P?M]MN!!]5:\W(&FB$
M8N$"_^55@?^V?]C,WL%<B3OXB1,X'D:6(69B;_EGTZ]K%&^]N]XZ0](*C;[K
M/TJW]?C)^J0DIV]0HB6G*-NB];99AJGK+\K^Q+[5VB%NWH=#/E 8+06ECDF-
M>9N)^3/T6#%/;(#KI$_X@WHS+]-)DP7M4R5-@RRGWWG4 OW2NXX>V8[FT<^]
MV3TA48BX7IP4\]U/6G11A>R390J.\_$0,>-B44UQI&E;6_U$I03RF!KAQDDM
M&E2U[^4E^/?)K=/+\AG8]>WUET\\]E9CN"U*TL<5"TT#'4SX0F7)4RMXXTJ9
M1QZZ7_/KGM?-!/@?NA_3Q09.[_A]<AF/[[N'#_W@'2G^<EU^-+-RVR#WCNRK
MW5VY+Q:X+TF'"R=5YZUJ@N3Q7TW*7-+@U:0([T7/"1)=B:U2B,F+5'_6Y8>3
M+^XT-@6U&#K7GR=OMOK'4#;69QVP3E:I\2"Q<*;0%/.A'JPTF*[43/+KJ\D:
M+BU%98M$<3=VL:JT\0S(8QU2<WF-^>]2=L/(F][MX&/(Y@7@B'50^LDJM*XW
M& K;4&P ZM.]*3-.@&6*YZ6^Q=[6$%8.&I&@'0@*H&S+RX['1)=E&WTNU'W5
M318B\"3(+>EVD\5GY, ,T"CS9K=*L,6TE].D'.?<[ TZU:G!?EZ1!Q7/>MDT
MK@MS/2SRT8QNEC6 ]#>X3E8:%KM."9I66@P46S8XB:2+&.?DE!H6_5@L5>IO
MT3'T-$SU:)PC)XRAQ[K&"B.ZOA='HI]O&7V*0H^54LD*&10S4QD[CY>R313K
MY/"R&97>ZKT3:Q"K_7<#TZ//__1BZ%]:NTUGP23+\QS^6OSQY#CQ$@!=GY0I
MA 5\F;M^*GM[+@5"L<,@WCW/628N>&*?O.3L5_>T#]STI5GA,MAIK%Q%.2,C
M(/5F$3/=*!J8.O/1.S[00AYGQ\$NR0"#^/"FI[&I**A6FZJN(L;KLY5V0-%*
MO6$V]=DGI@A08M8NZ0J!KA=%#3,J(4Y@+@ Q<B J8K9.:DA)6?'HVA,[1R/Q
MXD5:[IEG$S_#1&Q=FO"+L[8:[ZLJU^+3D<LP*<)&-)'%'(:42_>\AX$V3YB+
M''LE#;HXM]16F)C.E^HK]TEV:V/L"SX]ABHH3<'[R&HA=$3>GF]V,N2[B:QO
M%<D%91;KS=8@"7 >EL/W!Y:K(]PP *&S;3%"13]T;WT;N[6>7*I+BVJP%#UD
M/?GC A"60%3 N8Q?_FNK,X6O<&;^.W.SMD$H1WQ4PL_$69R-R*L/;)M9>X.D
MPL<=N9BVG(+-7S.,BQ*9'J<!D!68>$\+!?N:<5W>W2%A.WR .%6LVCHOI>V
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M;DKO!@E.5#>4L7%IZ=F<AQ>F7;)382G1_W]](0E7A>/-Z2CA3C [H@/N"?8
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MC0@/.D/M6CJ7T?MN1(L?5>6A;C2+K+!%<%E8 []_[,DLMYW634KGI1O; $X
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MWI"=_S;/"K]E?.KN9'2F;^917BFU10=INWV6T!!RS;+[B%#<&Z]RJ)V\>>R
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M%"C#Q)KI/%VOP)*Q_/F2%+^ASBWNV'(>U:?LKQO2]%/B/&?BS)?5="1Z@TX
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MXZOGTT5Z0YKD5<*<>U2ZY,@(I(2:%,9AK2]>*=34R*>"]DK)G VA00$2RXK
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M3%RW>!VVS 0V[A5-X_+ZMK7'U:;];N0XWT(P;NU] T=D.D^ZT&G3;?@1RYK
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M%P7YXSO_FX9D@#%J3M//\:2X,0<4].X&T KG@=4U!))NYGB*3:W-/=PW )-
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M4B9!@$0<_U+FXRL#I4M]:=*]_\<W\5_X3P[X-RA&VRFJ&#.X4 DD.>"9Y^B
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MTC%H_(!61 &2*#+SUA*=(GO<F)0^Z/%DC8*2%Y.)640$G'U*GEH/373X/ZJ
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MI5MK/\(:VH;2H4E/^;%N6+(2$KXOQ9C1S*=T&Y'\VTA:97>EG O F.G4#.K
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M1A4&NM $PCWU]LL_VKM[)O3Z2_7OBZ1]/\_TJ%<B9 S)TYP?0"/E_K0>_R]
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M<@B?/JJHQB!.+9YFD_)@B(#HEX+Z %_OF$Y&BH**]C_8KEA]ZX(6YJF6!?1
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M_UK-*XGL2L!E+4'Y"?#30L,6<'<*B^2:8;E:TX,< 0^O$CF9&FNF!K4#M>I
M:996"=J(#FNP5BLOO64J*_6#S-42TQ;_MX4J*;)G)>,E?!V"99FJ^^=!X9K<
M140FOW+T?NJE@EF"PF.<]7NP$DG-C>-7<*YX3:].B:M7PQIB#":Y1T6,_QH\
M2[B57>;HO-_7"&3 I>EABZ.;-="43E8*QEC+MC)(@D$:5Y04N]O3^G&8.0-W
M+7QP(,S3\_HUKPF""M8GR"@*EZ>$(JLP&JPVMY?.MFL1NF<Z>E).Z;H=@1#0
MOY/EHI*I64U(Q$LCR=BN?&$#MJ=[4UFR(K=@@N6Z>8C([F\=8X1O75MITA)
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M[^[6?JMXKI"BM;@@3Y 'V;=%)^+I<.N88911%I>A$@=6*GTJ-"!& QFGKU8
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M.%"G([=*SB&?7TORJ$U;G FN@B6.U(;>L UX$M?Q8D!<W&;NNUME&V<8:/&
M8U7K2Q+'RR\^6Q#MO9U.D/B0J6 9D:WT!- >HOA"_WB2PQRF5PT?2Y5]Z^0'
M8D0>&AQI--DE6F>O\#.N*%?8" >+S=YMERH[Q@4,<C"TUCYK]#3 '.=G.*PN
M<P:Z):>*+;V=:$ M&F<L*YQRZPZ1PXY_6L3\G\G\??0&"_$<E6.[^P3 ..TZ
MH;W^9>["3I/'(D1.;J+./-.I'S'-?;XS*D.$(L3=AL'4UTI4]15HE1DP6'U;
M))12/YX %O):JULIMZ1?<9MFCB=-AUR#:Q^)Q .=5G2JMMJD)(<H@BW<6=Z6
M+$=T^GG!XS4OLX)]C2?2+ N>=&_D7B0*+B8JMY69"4"3GTCE>F7[=F>F/1WY
MF$MS1JW",CB(C;.K2,D%R"?A&-<D@9 )EH3;V;' 0._ZI#N#&,0)>Y#(>B>3
M/"E!1J !>[4[(2</R&Z4,>A;8"=::IDK(A$_*6F=]^Q/^3538.'3/YTL^&_\
M/T30P58,Y,N,!HYGP3^^A0_H3?_,#;39>M$.A-'.6^3CNED_XK2;%P>3?H<<
M4: E6LJ7FY\ [.?  EI&=B%NZ?;59=4"J<[R9O"++F$=]C[/;9L/.3.-BXQ$
M7/H4N)1HT8$L1ME6J29W<OF&=@W9AJH\;_;(RK4['S"XA Y4;3ST/$Z_?28:
M&?-^B:?(."M'@;NF:,NL2'0TTSL[A7H-O2']_//Z]]O&F-QNH[&*+7?IC8H/
M3SW=M]V7@X)0UM$V-+%! 8O)7!^\N568WIRZI1)(:2O1=&AZO(4?;HPAC^#[
M&,7;!=B0;_RVJ[MKY_7)$6ZT&8]V%5^^26*=NN]7'R-Y<[#$@R":Y1K=1BE%
M[R#BR=9\;7"#+.+<'26P9*=>#O>6E&SGPMI-\(7XXMH?G0XN>F@QK^E>XR*1
M(=J;)P!M?@Y86"JYZ(N-0K>*6KSWP3+$L%;D<G$I2++_9UW4@%SOD,ZF#.>A
M&9&R$Q^,43;IN*MJEB]LI,6VLS+_KU&P NO@&6G7Y]1(H*@F+GP0K8(&$ZS
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M1;IHBG+FN@FMW1PP3QF0ZY75VY/E2KOTW6J(./IGC/?K"<"U_>].EDQODX5
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M6G.)-5-V7HBY[UQ#BA^;X/-X^N"&_'WP%Z+H]4\J3ISR8G-S(]6_?\)8;(W
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ME7#;.9ZBBT%F\/&!"GE'SS.>TR]F)XR%CWVQC8%LB;Y'GNB"AA?^V35;#6;
MTSGTG,B2L*^:0?3Y992V3DZ=*/GZ+_;YGA/2[SZ%@9%AQG-L.?I^8AVX\V#Q
MM/OV"BCM<N$:B=O43TML6RS]74;"EG,M:YP*#'+X:Y[F+**8ZSP%:*'B]*\Z
M"+[UO6.D[WH\U-]+H?REJ6(/<?B5WK+GXTX[\:JF!6*#A@^Z)5L2?S&=4"F1
M D\8Z%_SWJ!4%%GN/V_KTO=H1X/Y[>^3$.'HQM$RWML+ZK ISJ/&G<J(<U*>
MI3L-V_RE6@CH6C*)[;4\(LKV*BGCY1&(+^T]!81K//L'W\R@8$G_6'8)5'V^
M-YV?WV)V=A%86J&_LG=]<+VG#+N;_PKNE'&%E' 7EYH:5-G?&J]NBB=-] /G
M&=Y.&NZ[.Y38 [LW:JBTE5RM3P$YAFS*VPP$[QAUAQ[V*),4C4%?ED_,J_/Y
M="GX!A\+*4;PAH24263[M]QDXR*JH305>68CK1"[_2__1Z:M8D.'050;H4I'
MS)184C>>7TE#B+0QXI*B7ZWC3/"\G6)*&EAK6.*OG?0H%6P ?AER$PFOM^!L
M*402^WW8K2?/)?3)C*5YL#J$=R[X^MN.^WQOE"NPS9Z;V5F%*-5F-*PL-K2"
MHK;C2C1Z2_IHLIXTI%]1[*N0H7QTJ%S7E[!EK*PR]U\;QJC9V$Z HFGZU,HT
MME8[#N:L=*>Y,M<W)9VU$UZXE[A:<L4&H1YSJMAE\JHPO'0,<!3@+S&?;R,9
M&[Y&D(H1KMX,;@<AV"1\&S)]C7P%\D3O+F_1QR')ME@/W,OK@^KW+LV5DH&)
M_*.6%28YD=XO2X[>$.*B6#J.M')(>S*@4D>.2)%+8C6])29HHT-:/?.CPZZ'
M_A7,AZ,E;&.G@ ]> "+ME6ANIHXCUW3E4C[&Q7KN"7F45& $-AK%%O=Y+'EX
MHH^,;*5N*4_SN'T_NZ;C#,&N'I#^R2[!_MH\H3(B-YTP#85-Y7?DVFX/D.D[
M]._:CT+-^_]H4)%I)\T;=<7\EO7_%JZQZ/H[PS\>(>SO0*CX+4]\Q=<2O[\F
M!AZ))DZ)MVL(M38=BD0$WU,AZ<1;+&YMC.+F!/+FZ#=H4G*NRDO:2DK;IH55
MO97_87\W\P&HF"+3#5LUYUND'.R&I%N\'3ID4_*<8OB\S"+6H8Q,=*1EE6*W
M]IC-:<FE3DKL'OJ9B!:)Y".S!',3K/.IHO;V3\#ZOH9THCU9U57666EN:;?\
MC<W3]$8EBQ)[5[17->;9M#]@UY..78S^FM[F;Q_]V\]R_Z>C10R(]H>@)W+H
M.9N3D;9K.U7'N46&C,&/1B3LU#P"5&9O5)/[;W4W0:=-T]Y7DF_>R;,MW,MJ
M*ATJ<JM3/ 4@TXZ;5[-LL\M=LQ+B2Q]-K3XW*',(*%S-\MQAF/GAQAFR0^\9
MY!CH#:PVF;:QZA.4P_%7@KDJ;]U(@O7Q;;0?"JTBJD0ZG;.UZQJ;*49$KNR2
MH0MNF\L&_CT7!P(7CJ%+=;?&J@,0.QP_GTZU)BW:EB;;X(KO.1^)[<22<A<I
M4S,O<!0K1Y7X)Y37-)J\OZW>3B3KWHJS+^/F=8!"RZ>,4(EI^SF^J7C=XX #
MAF,!@<Y]6Z[VW[(]\]%;>@*)EY?9BUM/ I/P8K5;EBG9+7I#@KCV9G[](9:4
MT:6')GWB9IW!6EK,YEM))S'_VE2@?^AU4D9T<Q AGJ:]E7'D=P"6$9YA4C,B
M[RDU?$\_\$7@C00%B4X=6IFP41L;/?+TE)6.PGA_A15.,'8P8 4VW';$]'I/
MR?OU"5<L$=09(MY+R2?2R=/3NRI](ZQ];F5NC8=Y?/JB9 G/Z+Q5^;7H\ODU
MO9%^U7LA682?5C6(8759TA\9,E>,S[X&V]3#OH]/[:N:>V6:;W$\SS)>\E36
M98MQ'6XW"O0K7H(:[3&+#_+%4':)!N %Q'D'Y0R^==^@.;FI!643@5P=SLQN
M7V!@E/KC\0>.]9=$"55Z>M9F$JH1U'X'R])4$.PDHC)_'8_?_)&!-\A8R%5;
MGSP1:MNJ0?!0DD6_A+SHK-(L 27_+I']=6",Z&RZ7QN0V%<=4XZ.\=[$+F6O
MN(EB=^E%>Y\>Q4I\7MR'<N;12_5]&B/5Z]U6^#V*ABB:>VWE@IO&2J!>9L#Q
MU-6QU&(#8\3V<6>.5@[Y64BVK])U8HF3Q5Q0 O;M\J.I#;^)3H+PDM2C$LTT
M3M\E=!1N)$X4_VEGQ>Z7)K-K!\,9"=@QO/[/'^BU&A]_/%,W;9'YE9M1K#\[
M_1#>E'FSFG08#?R"7D.,@J>)JTO*P[%"<>"O4+Z$ )F!XME[ OW#0]<RG(ML
M[LHS[ <-!J3Y[%DA![9+G_%)]?F8'A<*L,7D2RJ+3\D@P8-EELENN9S,*-7Q
M8HC\BDDN6%MZ'I_ 2N"5'WIZPHGWP'#D_LQ$.]Z[E/'8]1 R[N@L-I:3'2^A
MP1NA /R>8\N/EE!D#1>!,5BFL1OX_D%$(QB.Z$F8CL;$^-";E!1]4EUD=?7
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M)1.6MW"$<2F&NL@VP,VG'-@\@S=R5TBV7X4P->/3":[U^,JOIP#PF+G"PBF
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M7LH5:$O$U-WC?-=GAE&=.3JI/GGZ\4-5_=8^0<\NY]\&MSU'6WS=&L'9K=A
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M7]9D8?$BART_:[J%9JE_?X7_,I:[HT4%43F<;-S^,*7$*,2KU"'\%"#8FHF
ML/O>]@@,S^-=!@:KA)?^\DU'A)4\#]J3HS=22G+<76DR%&Z?B#H2M;<3X1YE
MT[?[59=A]U/]RWND^,&74X#*_[+MX=^(MCP815RI&T\80FIP4211<T%92C@U
MAE)X$G]P%RA>'>Q.2YKN9ZY\,,47Q3GTY<UUTHS[5%DIDE< UH1@">5W::,*
MY8:/$@RC']&)M+?RC2DT$+8O/K4=\J1BY;1I^@24VO6\N^'?=POG;C/;@0&D
MP+KGXYHMRN#;7:U"Y+H8J?CE%L* GRGY&M;OBX4"G>66^W2^&$=V[RO!3%1=
M.,^;.TD=+_E%^?I $"G9DSY\<]MK4IIG+ '8Q_%6M'<$D^JXZZ"LZ6K1Y>!W
M=60Q;2I-_1HP)\48] WQXQC_8HCR4X6L)(/;7LIABDBW2N[]($T]HYN#_VE0
M9NF)X6C&"N<)3+6C@0%5'I?@8$CF@)$6RQ$GXM,_K?9<&4%42K=W4]8.[P:K
MD5BZ*NJ_\9G;(+KVC8>EPX]4+Y>4WE4#!*/''<)N7Z-ZX&@U !V[?A>[-FQF
M9,9@QF *+'Y97(RB+D8!1 %GKW.OND*5$.W\H70(!XI<#XB[QDH_HU6Z]4R-
MBW<D][X-("V_E@^T/%YJ(OZL'0^^N^=^A:-W!FY[Y\Y%UN-D[([YK]D.T.H?
M $ZITWBQ7QG+<(Q1$G+MD7R'B>HMTB#E@DH=5M2:<+Q8I]*V3@1&*0:TAHTS
M@SM?B=YK4(IZ!%KG- IO*#*\W=4('^3OU(+-EAA4MB_N$D9J]')K_'^?Z=2V
M=T.$?]3/^D\#VSY/$>]I3_SD?G*.LOEARK-VLFSH93!, AQNXZ"?0#0FM>QT
MGK<-N0?FK,T53#!S>'UWE& S<*-GD^4LC:B10N>)=9^'HF%TEJ+9)A/R8*\C
M.?DF9DM*E8[C>+"*4L[W6UI21:Z7<M>C>P<P-K::8+"-U78;2[V6;]UYYP8A
M5;="T.H\K->_.=WU9:L S54U#7/D4M[EIU5NZ4!TVGKHCYU LA#%A+!YU=?&
M;3#A(;E/A  **G[Z12[[<15UC7%5SM.3YQ8URC9B]K('8DW6)^HN1;\]RR5^
M>TG\7DB?6IT(\BSWQ,2_SYLC4'&*O<L2.4=,%V- )2N=2QHK =QEN81(BY>?
M<BW,UE=PRAHNS"O"H P=3B*)HKTRJ4_0'$*BO9+*O9(V$$D;^5%]^?6)C__4
MB4&^VM/!F+17@78_4%B<"JTH6(6JMJ8AO*:=*\:JIS]B/;SP]E<M/,L+D"Y?
M+UZY\T#A.#;X/*6F,/@I!;0 0G+"DE]W<?(T'Z!S)!O\AZ[_J%HYX1]I</)I
M#*UQ#_&D 4=E_;A9W_TU-9]HV^:*6$B:YP%5U6RRAPY-S2Y+!M])@1,_?Y7/
MD:K!3..\";G",S(20Q]=KUNX7[_SBC]"_K:E7Z:7 0(5&A_L>H+U_4!YP6:5
M(DGH?=AQ%SS%O)VC=%NO]OG<$!,'P4>]PKS(BB%B.;AZ^ BTLTZJ.O8GU69P
M+GU'N.;!_6S+'<Q&XU<)R@ZW]N3]>O6U1(1>Y4JP>@^I*'_K6*BZ]F#;//"8
M>(; QS2@+I__^EK;/]@!L2"/^>^'.%@-7UAG+<+^6RN0XC3BL##$TL?QX+=#
MW^ )&YDY26! XQ5"3@YW"USN+[YO9521\*AP;.?8<$-5O&=HB[LD9BO.2R<7
M+T9\.A,BHLN@61CO]M?:$QN:P!^AQ5DM/NI;!"D54 9#1 ^\KA&O\2]("?;6
M5T7X 7] @U((#C'MA(]-&%2\AZ)P*M:0Z767<2J)TBSITIL@0F^,!B;YINB0
M;Q-!E^$H_"92 7N),JK50OH3<W0[1#B_9(4SW%XMUBJ:U'M/S*5<LIS?Y;?'
MIN2'])&]$1>I#>&L*1=TJ'U;,6CZWIX4J6?C+AZ[$2+X QY(^!-5^B01IR$"
M/VJRL9^ZO2T2J?[P&TI7(TV^=+GCV-BJA7K5N:$6O"'<-KJ)>&O("9?N ET[
M,BJ#2W<W"OV)"C;$'_Z04/ 4>9C85U^;"W!T=)1D&2CKU.<92-NH3K&8M]2E
MF_VP;:7/C#UQ@Q?A;;WQY5XKXV8R,Z#X$M!Z,%YSN(0YYP03OV2=*D=]O4W]
M]G=[UR["K;6,*1/4R<8Q;^N;&04BEJYXC(<6$[=5S)S!Y(,K"?J6[8LY+DH[
MU-F0"9("EM@.HG^:7X"Z7XD/'?Z&12[]>H\\^G@2]5_GCH*M13@@O@]US=>P
M(2_MSD^KJY#R[[3$JYL3R-<ML.@[*4J1S=(_4?>"RJT[OWAY60A7?O-TTEW;
MR0JJWE RWI.E?:U$")Z^DOP$#JP_ZN,Q,BG0S*H$NQO7N"5\*XA"75PUQT*-
MT) <1Y6O@L$][.0,.A+]-:=@\Z[,0C[1+UM9UVK%V6QJET1^#^/L/G:IUI=Z
M 5'QW,*,_ZV7UA<#84P1.HX]!3AX,X6.\4JQ'23/_8)=/5(*N4X.1#*H%]6(
M?1,\!9"0%-<E[800M]^L]X*>,5IY7NY^TM)D(>4\*G^L<Q!#R@\_4EF T?UJ
MO4Y*2'1\!W?'35QWS=)(PG0M6?ZP^%Q__XZN>O*7KL*&ALS%AJ:&9/>2HL+Z
M+ O;_%?!-'A09"O3L#K]0@CC$&Z.C;21_&C%TB:9)8$]-2/9]</349NYV?XM
M&QC,!BPYN[LX:C.K+]DY\F#6$X&V98%;I,'=4UZ(JL+G;O2,8B1^*BU6%0FY
M2ERCR10;Z2-M4_CWW>S=I$LGC5+0VE$4_9WH@[OD*PDSAKO(XE:S]H;;;M_P
MH=P!3*:N?3/I[EDO5%0?Q?WDT)=V5VX8_CR,,.Z /#0CLU<B1;'CB3__ X!:
M; XBYM,>R9,"HX^"B)(020&<!NO(;P5/VP-KQG02@)$&OL6Y?+ 5B.PSK(J5
MFYNWMIJZ@Y4?+NIM>:YLR5*AG%7]RXZT4VR.M2TE&J1QRML!T]S&BX11U/YX
M#H._I1J3%%<!%%5XEP,9[G'M"KT56WPW011_"ZZGH#+1:5_Q*"L)%87[AM+_
M6[8I'F1>,0EW5$U)=6!>'%$7V:L^QJ@K'$H?R322;2BUX^IVI=GQTI\U6-*-
ML65K[HQ5LS8?]*IZWOTJDC#/&A]A/]&I&7V?)[YAT!>XE4ALXZ:4$,QC:S9Y
MX)/F#9/!A@2K_0 >*^-&NU:+#]1).%K(16@M](T@-)T5NL)3%I]ZW=*RB_EZ
M#^=!_H;TX5TX9B^9@BD+ODNF&7 OS A1ZN#E=HVKG6,GM32/*.87:B7.MBPV
M3?TQ;S:#U:YFL,GQ=WGON<,U$-AMPVYO9K(&_\\15%@1-(/&4<'-Y"L)F\5G
M]1%K4.B-+%R?#88TXC1=U849NI/CQ$V[(-C#AAWK@]L+Z@P+%/LJ"'NP8;0U
M.!(%B_&[6&"V5.W89YE(Y[B;-N8#YWC:QP--S?'C[I;%BHWA[+8H?RO_;>R@
MHO\MXE[M'P\S_:9@HV0]K$ S(&(QO%D6<%O<9/2W8$WKZ"Z-6#)A9&MDF17\
MN*$V3SZ=P\'1/XDE-4Q<%?G1P/\G1X=Q.%YTD"D\QYFJ"\.A#<9P:'T@"H[J
M"^=^*3+(=0L0,\-05Q=WF*Z.%+$/YD+\8N-6QL+_%I#KSC[<;>0I/^IR@@'9
M(:8.<'O9)*Z5/(&LP3["YFM)3SSY6?;UA%F%-;[DN<EN2_WB#;/JUM12SJZR
MRGU+@W("2&JNY^%(.JQ)G/*9HD6VZCH%7#RY"?<C&+[:'$AOPD^/Y]Q?&D@O
ML1/YO<O#9!;!$3J*7JV-U-6MKY- EE=-@R_-L&YW'3\-OD;YB@<E(FB/%,A*
M[:.O,6OI!=X[/X3 TLV@<JM+^C#<P9L[3=+^T^\=YHP8M\8W K@>3P36CH!/
M8BATA)Z#W51=_L$U3)>%T%75&J>1/+_TKNXT]2Y)KJZ'J47?^HWU(1]^$5).
M :ZYJB""X>B%7[^:!0B/? .I'R_QT2N7<!@]+(#(^E,<U'.<;6O!(L4)%UBN
M3G0]2?94-D+'?(: UN5+[%N\SO;U+SG*YW^_C/M_/C3O7$P& )+!GP%/P2(O
M :ON^]VG@+"8DZF48'ORI<WV_,@L[)%E/JT;_VT$]-/;?=CU8"W,0,J-/+E:
M8D>CY Q\!*4Y,55;0#7)4?XX5BMY>CV?(E:W\>P40*^N)O*9+ZJQZ'4/K_1H
M>)[:N(13UU#$T<T0#BJ4CH1GX[0%V90V>";I=D:4)3BXQM/=L"EJ_Q>6< KX
MX!QKDJ:G$Y6C%N.+H;F']!T3*0-7?ZA4->/?"6<R&>"V^:G$38MFH?7D. 44
MP33I41&BP^WPR>[O5\=*S!KS^!R5&\WC.7U38@DS6IRQEC6":,.H_?&B43.Y
MY[ZIQ4OPK+_/;[I_'OQO'T(?TG=X/73RH&>]AU@SNMOP>Y<^W%:ZM2ZVVQ*X
MGU(;_W1:LH"<'N.EQ#)6_2M,&.-.?0KHW(3$KB<+S%FZ*K'"QO*22ERS3M(*
MU[*$C@M+4&NLBEEY:47?#7D&T@LP\W<R% -K,QCD=&[7##17#-!^[+)5@AK?
MQ1)XVYP1"V_Y:J9_J:*QZ[-D>C.1>Q/E3[PCGI?MS NGE%M_V;:FR"RE;NCR
M/'-.7KNK^>7&Q!31(-XIQ&U$S7MU"-46:_*UHC[T H';)$C#P2KE1M=D7J:3
M@ZVEXW9J?E-8/[!WC&7?A[*"#?Q!6!U,W)_>^7Z@-$((+N$XNR^7%@1XA;[Z
MM$[&/5V7%-<%??6I'@D:4+[[8K]<-RJ"K-^3SY4ZFN*W]R. ^E'^7.,9+C;1
M;PG^)\MQ'[>7<YRE3G]H<*21W\$KJC5:,P ::B$YQTENC'@:=AST)T5L/V2-
MQ\J?D1$I4846GN4$'LTYY0]@R1JNVQHG0_M0"H[TH@=V_BBH-%B=$O&A-;/<
MU7#YKOJ+Q5&%%BGS)(^ @6MD5+QW=>Y=AV=A/C$2LA_VS#]-K;+6/7N#<&;9
M!FW</92BT.R](\GG<9'5==&4;%W=V,1+E(F)6:'Q8(4BR&O@YVK/CRX90]S@
MDE\CO4DVG3'JC%-NBA/F$_,OX:,+W6R)I)3!K0=&';ZAU^(+A(F0R* H-)_?
MI;CL:CLDAJ7O5?< FN?6]\P0F]&2B),O!Q+'HN03.B=3B@ERE5#%1R>G9Y)K
MZ6O2:4\QX8K.VLLLMP KJ6:&6+2Y9COZIP3P*8(NT)<7[\C1+VH@=[WCYB\=
M(4A</9;YN%- =);:2E;+:X[2WX1YJ13LBJ%@C&NYB_D MSL"/1<]W?=&T&]:
M+^71_/24&^LD]-.^/B*/?8956K*+X,-^I.#!JW3%LI"/):)S- VX(VZ<$@\Q
M<QT0T_1-=BULGDAW/G1(<VKP"DI?\(O+YXGHWRKMH]/AREAF!XZ1V?6<6)M9
M( JDW17(PR*##YQN1MY55?K\2-%RD^;_*C 3WSL%G%"M'5YH:HTB_R$^BX,*
M'6J4D:8_/T>W#8@'5SVB]'36^DGW,1YE:'"/B.B/U*65VKZ+\;#/S?^D=,3T
M ^/)143TS-*64GON&IX+5AS?($U>],P:ZIR3J<A]6KNPGJ]#VNCUJK\I'0"/
MJ(_L_OE'MJWRB(8D9?U=0Y%HS86,Q2"_/.4V4P-_55!5*736=EL1<7LKP:(5
MI&%MP \$YJJ< C+:=//1G2IR(.IF\?ZQ)06K<]WJL)>E.0Z7<R7,Z1?9BXVK
MT=+/$]RSC#(D!(9>M1N8I#W?09YMI2K#K<5_.UO\SZ,J(!>F3SI)*EZ;&EA4
M#4U\[UHWU5J"\)F67/>?59RRZEO[.GW%0W'B4Y]\_.MP;>6B'+P!8Y&Q4?C-
M,XZ:\]^[C/].P\09>QE["J9X_F"#I$'&Q891!@%NXSEBQF@#V5Q(&A"LS;S2
M(=;KEY,5Y\"\)":?[)D?GT\R!R7P_3B@#SL!_*I[VSBYE-ACJYC H>$X7+T6
M4Z8NB9ZY)&1Y^YXY\A1@GL5&)6CL8FFZ]O;W.=#KM/7\:K:N 4,BIEN:-_CA
M6-PP)B:@87%XO="C-@/?QZ(/PC5:G(NS6Z]VMU(NMY0LNKU0WR#>&BC2O794
M0M:-<^Q1]\YU_I2#?AEP@DK5-H=P0"_O^,1KK5V)J2;7/-[L@[&8B;CS[:CM
M!)-Z\\/SF$C8JV-HZJ#&#H2[KP2Q=]:6?R!51B7547D%JLRZXOCH>9%4L# L
MRE/D3$"(;X_NO?PG&J)LGA;N9TY.C%$'X27/CV-KYIG6+&%1.R_D!]=R#1^U
M1!E6O+Q^;5AHH-/-ZJ*H4")@@B7TPRF@':A!@^@()..,*:CBJ:#&*QVWQ3<4
MI8%>D0@.2K)XF9KVG7)%W>-<=$_9:D1JU8]YW <]S>JDVR$ZEWP&!>*42P3P
MS2#5H$*--,[=&U@)#6JVLL1.M%/^^"?3DDGPKUD%MH;]4P R)^@UJ0\W*$G,
M\:Y*A2-$.NT_50,U'CG(09KK]?(!4Z[HA $9=G6!Y,!P=Y7I65#H"6.PRH@&
MPY$<"833IQ4;;>; #RC=MYB086AKJ@M7Q!3WOHZH']]5D590*_7Q\EJZ ?"U
MC=%B.:FVNU4??(V-+JS#.)Y6BIY>AR82=<G%"(=?Z4[C?&@C8) C<+4\1N#$
M9YL;QY'MQ+X^*=-IVK7,D2?'\M:APLQFE>#[MG>[DU#!PIM19-D"'LNN;/[P
MW4B+Y9OO_^G&;+X^[!%SXD+=$1 VI6,[(3]M6$6!$4HEB<<WNK,?1T%;Z^'!
M-H_9 7E/W5<TRNWC-:=_N*<SQ.V" ),[Q+,<K$@1#A4[&9R<DQS94/_KJ\37
ME-$-]>3TJL_&,=Y/;Y6K-'E=>W5GL8;,TH[//F&H)YILIWDOJ[;U8WGJ0<=&
M9'J%>&K;(8DAV-Z>56^9@4R/Z4=R/7QZ-@RW?+U+DQEUI"[_Z?=7 Y'#\9W[
M9+D3?O.P9C43MNB]_3]7L;L@]9\9"JYCO:+#%E!95,I>&J^24-'+(G,&^7$/
M?YDBB!]:\2]8<8,P8?]$_S1A(T'7%88B8->;><A<N*=!SX=>!QRKV51I;G";
MNSNKUDSD/OV:KFB)SJP?Q;ZYL&PQ:\A'-J?1\H[LG&PG^%#Z)2V^==FYCW3B
M2T:#:T0G"XP57,;#&_]Z.?F&"*:H^'[G%G9^U>W8$,F;+GWNK9TO.[<78W70
M+X+/VT8Y',%GMV"O"(HR]E_5V=#4#P#5#)VCC-ZCQ"^TT<"W<>9\;M^"8>]6
M\FZ,+ D%M[L636GYOYD!IC/83'-P3FV=#YR>O2?/>$[0XXH%+&&>! 8EY)/>
MP 6Z8.=J2@8.\E]A,KKRKB58R FV,DULGE]+9_UE>%#&U!DH]GQQ:YZ44BRZ
MM7$"^YYUADR4"[&BOG57G^3H:+6;]M@)< >PW[[U(YVGD2.2=Y[9@=9,-2%1
MU@ >9%SB9='5MC]$3L&5.D=H"/G"+MBG@8UZY<3ZQ#K'+(F5ZAX.<5\K$L"B
M!FCKUI9+,7M>1NBX2/Z(_2+P62K&5H)D_E4#X/^OH/3MM1['-[,<&L,=ADX!
M6J3)+IYK@P^.A(A/7B;QBP69X.:$'SP<^ A_3@ATB@_[^N*]M:[0WEL>H3'Y
M#</U*?$O0T^Y,3&5I;:ZN0L?ESF\5+,Q,'J+8#PTE3 .4?C5.RYJCA8U0QG+
MY*IT@^56X#JQE,17RE&2A'*F 5\5Q: T<[-/;V?DTW:M:WPH2!-C%+*=X-I@
MU&4G<[THJO-;S@H4HPQ&46HIN:2V'M"58.<2. V!]W4@?I/19<O>W>HE[]S6
M^(^(6@QZ3B?;4Q?28NHJL;DAF$SUTG^F2D?"E\1R'!PZDE_Y!X>8"FSOP;7*
M52MR[N5R;\%UNZ?\&7@"<6R5'P4[!Q^Z<6J-Q;"/RZMELDX<R%OP)_<]C!PR
MJCYYC' !_>@CP-:GB2K!0N0+NOQ32YAL7*C8)[ C:1-9_?\P]YY137=;]VA\
MK'1!>E7IO7<D"M(%I'<0E!(ZTH($\HCTJE3I#T* T"*]"$0@@#21WDM"KR:
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MIV=V'TPH1>D?@'Q]?8)]?8*"E*;, GT'?/W]?3B'?'Q]E!*$#H>E(HK20;"
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MO$<246A&'=OMX#I6$-EEO]EI(OB[4EV@G<!LO"+POXT"8-RT,\-S<_,V\T]
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MOBQ)5,5&JG=7>?(R)Y-M#DZJY!) VE17'Y?F[L[.+OUPWA7]&6Q1 B?NA%!
M!*(B%ZD<@Q)ER4MQO.QEK$;9WPWJWYB3Z[)@]VUD1G/L(_JW-9@4[L7F<7!D
MKFSUN?QVQ6.'6ORW!1=03216QVOV&I&;P-J"-T$L,K6:8"&SYJ"?2MDEXTJW
M2S.1: [_>55-/Y+EEA]<YAD#=6/V/^C5)>8/"0N_&]NKDWIFE/\(_9%W"Q<Q
M--* _0X'M]_%?7;FOPXV0OG.S2XNS+](&-D,C+''<#]_$N07O<+K]AE8!I;N
MJ5D.5>SW^56N$&3Z4CIE0^N+D3FKAZ:*7.;"C- M_N<]S5P;NZ43)6P"?<"-
M?!A5Q'.<<R?[PWZQ:4>[Z!IM0XPM?>K+-S]E^N$F<"4*GK2Y(2Q-]]J'=\DE
MO^+UV%OWL5BW,_2G/Y\ PNYPWD]\<KO@=I.4V5DT='CS'W4.2*G:M!2-.0K1
MZ5KD'*V[\%69%.;Y/.&78#K*LJ?XO*;),,7*9M::Z_TP>6R0UMWX/[O(KW'\
MB6R0)=Q3M<9>FPCE"AUN>!,50[B;YW]<B[UX-IL4JR1():&C'-8[^ 4G\PXP
M3U'.U/JD1(43!&QXP6 VF?\C@@ZK!$4C*<!QZ2$ZBEVO'3;5H3,S/<QBB2\S
MC-.1+:5C)MZ':;D0-D]7.K/6-(41F&7^KBTE>*TWE,1Y:;:5/^FXV5,$)KKW
MG;E7&_8L0[% =W8ZECH9#/&0DQ<2<8[PPX&=YEG+T,YV9%9X\'VXP-?(&V%W
M[H=1WKE_<$?I;M"M9&0QU>P*D61L&9BX88CK[8H<"V6'F&4/M;2D"<]RD("_
M;[T-N 2$Q_9_EPV1-<G3SVS5*+8:4/I^T%Y9LEW3Q]:-..S"*:+U41SO0@7;
ML&:H?')790;<S0^BQV[3$Y6(2IT:C=(MA7 *X2OZI/<-PW*AC,%,+'#%#=Y3
M$P(1P?@8M#XMV#?>9Q#[DREEH@S]=OBSWX80);=BDU%5V]8+GT3^0WL?JL54
M5R5I:UT^!<1%)59_BQI]"4AD>N7\?H7>##7]AK3*J^,TS=5G""LB(% )X=2^
M.W3P[;N6JEA'YX_X+:$ CNO1I9]WAJ]R(F'PXM\D'T0:7@)>(?$\)8G*PKFB
MO4 F,R-\$'91E6(M+WJ$Q8X%WSZ^!QZD;Q2OQDXF^94$'N<57G>5?>[A(?OL
M_-$X<QU0I[/U 4H)E&74+^<K4IG4K9-N4D+7%]$Q\GH-G./)8PJ++& +V4XV
MA'/!1Q*T:R+D(;S1H=Q8NX@<H%6,W))BUZM3B#PZ$B:[YTL^1L=X*$1I]&?Q
M(B]'7!:HQ>\%6IUB"C5>$!FA_0,_=@RYR KE#QT-%;2CA"B/#!_[%[W/I\8C
M#2TJ">+H. M]FFVS'9;3QN2_G&I&A9)7C-H%?E(T-41NKR^=.5Q\1+Y*BN2H
MN01$4>1'5$(;"([P.0V&6"5HV9R*])#C6POV[WVT_5GL82EE?5Z%%MK;/7(\
MXU7UBM-JZ!.[:Q @UJZ+BFPKCPQ[.TIJF SLK)DT4#-:UZ14^DZ,W6-B\/NH
M]=+2?$V,J#3+5I4HPFEPRNR>=O?P2[M-CHC0.ZO*[$:PS)<V0CNQ,/V3S%QM
MZ.Z,;XZ'8:2!^J<V;J>M838#(1MP<VF%-'-M%\<*QRC#EETW4=H4]<K"$N6-
MB'I??IX3EN#_:W?+,"N-U8S&H;3=6G4]WLVPOU1K;5H[-CN[%^-]5#UX!4A.
MKI_*_>=EI?]UX(%$4F[<')$6L?NS:@9DEN^$RT"M -\JR:YIU6Q/?B?.#,?Z
MEX:EI=W*+9":]%Y0&> NKBP'T;S+(EKL_,S'\PWWOL45'D=,2E4^/-E3)L>;
M-K+?PEX"TGC.K=H,)U<;X_P__BG,PK+@*C-FWQ0S*]@F^G1T_V[">OLMQ*%B
M;ZC,)<"ZZ83]<WU;E4$788;'8D!PM!0[P?V+\$IHWO%7A5L9?"+AHHHFD7IQ
MQ/02$*0<;4L'18EB WG3@12[<BGQ%_ET&XNCK/6;0OZDT.E31[U79:K;3(9=
M_0WL 7Z2K*8.R7JOF]5HS59N__H['4 "\\F('#MV=*$/P9+HWJC47+L>VP=C
M?BP6VE(?9F![G=R+,.]8U9 4G1H&YH25/V0L+0=/3]T@,LSMDO>B.M @O79>
M.MMT%BIUTL-*VS;-T4)MLHIMXQQ[NHFZQ&>ABB3I+WR:T^VC2\*_.DX_4U=D
MB:T4L31WYZ&)QS'FJ%F$9/FYC.5J#10YS)P/7 )N9/_V?;J3U F]2W@UL:?4
MYH:)_.2W<&WMF<[M,(*D[R-$+O4+Q-W)5M6+0JZML SZ%N4/?O'?=I(FWZRW
M,J&%&;Z&4F.'PR#R[L)2'"2;EG91=7'0#+\ 9K54&9D>4Q,[B<!$NF2,@^R0
M8I]D\C[JJ)Y8@Q4E^['\G>9;DV<49Y#GK1QQDQ=M\^KV%JWJ]M&6OY4FIFV:
M_#8]V>$BXP:7 'EE$?#;.)P&*E%X)<>N+MYW?K;^67N$6="+ XC0R["^S[H\
MF)*(?BS>TL1:F#EMQ;0RI;0SE@]1 93[]]SYY,<M4=1YQ7.0MWIAAVU)I9:8
MP&_.-4"SXH*@DQJ-]2W+.CZP6RZ'2>2 <?WMM7/='+6W3+='2JL@M@Q4B9T8
M;_,6 T1$C_V.O8\4#X)T&J(F;U"I[5;A:I13P#TA$[ V$RG+-RC&5&45#0\?
M?#WHR2#VU6&SW;+)VI.T55S.6HW?S375;;3$D*KH4R9!!XSH4N@-(^AC..Z
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M1\">=''RYB3=\>C:$27-#W\YD=P?D7ZH]"783=<0'=>X.ARMI(BA(MEA6.3
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M_2"/0H*$J;WOI>?')Q?7.^S4]V4PLAIT^7S>>6;*%D!$Q^30=L<,<4<P'"U
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MAEC1NBHHU>>=0!WI?CL756FS)OA[-7$K%5?5#2#R5&3;FYOTK; QMANE KX
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M*FXIV'A*5.F Q:N$;)QTFZM-$Q[<RXX[.A6$_\!!J&EMU>WWB<P,UV*3)QY
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M$P3IMM.6G#,Y$ FMFF^\>>9OHSIE%9L3D"N*;QKU;O=N/69;$M&K4$W)*WY
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MTQH:0C\T86XOG/QW,'Q+X)@PBK8Y?QLN-Z-1X/@8,RQE(9)XB:BP^>2@=Q>
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M*6,MDXCE[#PW%ORPO=CHIL9D)-]N<S^O^%6WP^?9B9DSXR6ZZ^L@FG8&# A
M<$9OS])%2=^1^VN<YQYTNFG<L[B9A47T<Y'U8)]FV]>\I!,6_V&EU/V'CP(9
MS4^_J$9SBE'*>SP2-.S&;!A_4$V2_S1>JI'(I&A2WN/&:ASE>+/'M2C5FOL
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M$)F4I,);SK'N5FX=3#BO?!_-T[X)K\8[WE;1ULUOI;^2_6);VZ$OQ, 7W"\
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MLS@N2\Y,4OXPNG+98%WO7?X/YP[)PQ2B= DIC"B)@T<I]ES?"<R5_A6J6&:
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MR,K'1CX,Y5,?B:\R#-L+V*PL;I7[+J26#J>M,XI/,@J*=75JA<B;2+[^;2^
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MFV6HW:/TV?0FPAU)L=_T@QQ2_7_5?]HLO\&#G-OT)M%-'3X_ T0F$+QVL&>
M&+'0G1NA?#"!22#Q'#] MR2+G"<9%:GKS@ ]BB[K6W6I]OPEQ>3;J:]3;H7E
MA\.@[/VAX!3\\A5Y"]F^GC3($'"8,N)UH&_+8%6.3PLDL$*IJ76)4>ED*A9^
M"1O-M1;&C&>F]YWUPHDI/$B?1AOV*I?I28V4MV#J.II2F\UDJ7J:V"F*4PZ-
M*D2F='.5&T\\3\1(-+6G>5W7B;(8M/ E#X4FZ )9JBO<@UJOGZUGP+_:)J3\
M6OZ5XBZ[=Z6Z'Y4G X8O>[^G?D'YI^;&*<291F#8AU735L/PXUH+4.W:#0WX
M<(<:6ZKK9%R0S>2WU_[9OTL5A0=;=>K)_K!PM5&E(M4QI92[Z&'6[.^MZ;(*
M([6RG5N.TL38S*S=>*]IX1/=9%/DP!)"7S.'+L+AG+$M0G#_J;9*KC%O$N.#
M?XS>"X+Y $XQ^F=H#07),H39=I=WT;LT]-Z'E_)'?G_Q0?$I&Y^RT/=2Q&=+
MW;"B44H4HKLEJ%JN!>O5DO<G]T-9"*6]HH3+%@O5>=ZATF5CK6R@N(#.N6=7
MBSI$=3@N$J[D%7W#6C5DCZK/:#-30S]=K2_:S+L]*V][R;HN7W\V0%7W1'NF
M80LQ[V^/W&B6F5^Q6A(PF*_R*DAGM>"[I@G(:R0'O."!T9^:XI2_6XH WRLR
MMLTG2&@OY'')QQ>=5D1-0$00D%3"_M2:OL.F<4FKSV[S2? ^/^$YF4<P<IIH
M+=_WW$X0OVWO9Z/5F"\?ZGUS.F*.QG%%=CV[0#WR:5Z[S218HLBNH97PKLOS
MCU[[P.'?59N]\)FHUP?9>=5AA#D#L,(<R+:2:#66F9_RHVQD+I1GF5NS]%=K
M;5-2'?I)O!A>FTTT!J(M8!&K97(*)X_#V>0DD\X UTG<!)#Z;@%YZ8-E8Z<X
MWQZ7.D$^4;QQF\DF7XKR[OZ[RF_O'9^/*GBPXU^+MNR1O.<V:4CTE(?)YP-G
M08" (_($SN<]&H+[K]DY@^=O@A9^H&[1,BT^;+-%5QH1D^_DW>[XTE[:I<:5
M;,7;7/=V;I]YXCM:\D KSO'=.N-IGD:?;%%X^:;N](>0.B]6+YGMW:E(-P-+
MCD>=7W;GBB"5K5)ON/JY]*%74%@^HJ^$V*!/WEQ<AQHB=N2'9KQDS*B2GY&9
M[$C=A,U!.08YF>CY*OPPV4RJI5*",[]QY,G*?M+Y0WXL!H_I_C=7F/VO-.C8
M.(GQTB$$=#/4#W6[@[V4A<1(8#>&D:P]/6AW@2#<QJS>FQU60P=V+N9B?W>*
M[WXE[3?+ZW3H5C9FOQ\+5,MB!5\"Q0G@;C4^X@N<OK(\E(I8\2C_/()@=Q]"
M"G!2#BO'MC9.!YR4K:*FO&D?I0<?SOXV"MOEKQDC&:YR",;D",</BK0%^%.
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MZ[-,?7TZN\4MT[_G#2K);9*Z+KG_\_ ))+Y9C1V)DF)QYPY)[6;^;OW@PTB
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M*X+*3M_L1 !?:)R"J0PH*>YVRS*B;$PC,U*D8B"1U/S;*_$##:(,A@VFOM_
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M9;:H,1K+IQ@Z,827.RLDDRP5JBY^C7;X=6"[;]M\21S#KA#^??_7_PG@\B\
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M.&^KH'!L9:S&\V)GW+MII3I\HG?%_I<&_KMW<5155\1[_W:?4YV;7P!\4N?
M%P W1%*.GQOKB"):/;;V)7;I&K^W?EVU4'YB':11TG<$L3#_J%GR85JQ!5@5
ME["Z&WFNN:(>]P;_)\H#=Z_)L8&T,K<ZRRQ6KA*T2OX[?Z!G\7!_3M;4V"]3
M(+$RJA3D;^8%TSEC(3%5KVC'6P"YU:)6>W[(;\O622+ 6@6>_*+(RN=^E9Q6
MW:%Q<'%54+XH6JKTG6.EWIQ#*3O4ML[C14M\4ZU]K]7O,TQUG<=<UM&G&O<0
MGS5;=XY">(# ZN]5]+)W[MH:6/#-J^OK2H!G-%7"B ..@ *=4;C.(%PW/7/3
M)#]_77FD33<@,R\3+J*P*CCOU3SO>0& @HW@#[-4F$0F2K62E8Q*M3+Y#+)$
M37#%!@4JOKI,&Q,1H*B[F4Y,I4SICX5+$C+^K0 YV2+,)?7U"7*'EI"!XJ$Y
M_ 94X$A>G@2:5OV3EQ*/O2U=6F0[.<3L-@YKR/HT\>A[0ICCJ4%3,(_;=22B
M@$)C'"I=XG;.^=7SV?CA?;(G'[\UABE,!5M_!^<ZUY@%*_C^'^R]9U33Z]<M
MBMM*$T4Z"!9ZE=X"V:* = F]1CH$Z2"A1ND=Z4C=E!!ZJ(((1 A%0$%Z%4@B
M72"A1@CAXOM^N..,\9[[[O\9=]S]'^?<#_,3@R]YGO6L.=>:O[4$N&-JMHOB
MN =$FB_9ZFJ05B_RAP/Y@K7AR\ET%Z_-$($G.@6'BG]_%%A9TV/AW@2^K$9#
M9A__T].:TN^-$#2.]) OEW$QV<V/?L$E.#1K^D3V( A_3G&FA[GA2#SA'%'"
M9G_KQS+@(*W:]:I#PEU29^NZAIMZK#'Q^JE5L8E4]:O=O4C\\48)3I;T=.F.
MH.>B7MS1PD,,B1"@?,T0\?6)Q(B#'%KYJT'\CRI=Z76#0;R!KN\BUV5A8TY-
MN9/8='W5T!,8QS^UZ.B_1&CH!9U1A3F>4Q"M45=VVA]C3NF:2$^)IEF+?/CU
M,)'CP,[8'R5$!/H9@U2:1H"=*U-%61>;AM3<^S0GA^N98CO4H6_TK9GO>!Z!
M>P.NN:(_E,KCS6KIR]A*-.1'<YO6;<N75,&4,9'".M=V,LR?NTG[DC^^;AV7
MQ^\F0(,2O:DZAZ0P/P>3E",LX6RFE?H= ,?+=X9V ;QVX14QG[ X=DW3EZI&
M3*7C8'0'XS&*Q"!YY'%.$4E):-LW_B:L_!6_A?59@I9T%]]X;[9AGI+/WD-F
M2894>XEFP?SN[A1ZL%4_=VZKS75C3=EV$L*KPM(YM-"_HJG69A%TCNEG!8J"
MO1/=DPT01CMVS2C>C)_?::PH03W?TC0&$TTU2K]GG3%[\K'^6+SO&4U'0-!-
M'<V:W%II$B?ZKK :H2=R/'M?> %J^N3:4<Q41 [+.Q"6/"73LC&=BW.&.DW]
MW2/@A.,ML$NQY&LD'3RB9Y=2*]$ K1"G)YWV>71N2T%[>7[SA)'\K6=V<RXX
M;7:PRUSK5:KBQY L8_RSPNDE-%?,(@NQ99F+BJ2.]UONP!_'^V9+:S'S $Z=
M0D:M-UK*$[9NEL#!JCYEFX^N>3PX&</>^W)+G"Q<==A"IO0Z?0[KOHISZ;Q$
M1.OOD1X2Z)XS*U-_:,NZM5X 2'D8X1(S_&?<2"]>E;':F=)H>KMI9CD6;-R1
M?4ZA$<)!>G9.842,Q)>YQOSXW)IU6Y?%92*C8N77CW07F\KO'U4R[1AIF.[/
M$X>N@D"1@D869.83#RCK.<7MRV$X+!_=BS,DLR?OS69M/T&&7U5K !Y6O=M)
MZ#FAG-J'W'F5JZW206?F9C4W5&J"U3C%R5'KO\?'/$XF!/_3WS7]_VB'X9;Z
M:.\L [O!K*3GT\$?[/"+&0\W GT&5MXW8]G[F *OQ;->_W).$9M4(=TD.4#_
MT7SVK/(PO=?M/D<VZ=4=X4\X2>$09YLZ4QKI8$>QV_IS#)XS$%"->77!4:2<
MI@[W?'.J6VF@O+)!]MJO]V8I*RSFK3^GY?HQ$E]:KJORF3 F]9L@HKHQ&V5C
MJU7FU??R<N(Z?HSI(#_#B$+7M[D]_&B%CMSPM47DV#)VNCLDG=0Y<&:(VE,M
M%#71VCN"/E-F3QVKH_(=W<O3NQ3] Y0VHUE"4&ZC8R266!)0L<WG%"S0'+*5
M7@\GW^0AK8\9*IMT;)Z$\.'Y/O$Q]*?7.P<;!OXKSY_2LV38J>J/3/_2P=*Q
MVLGMQTM:/^SUZ<[D1=8/U8UGD.$9F/DH:JI4=T%]Q.G"D\@2 V:3VV;<FY+D
M6  S'BV"#T<7<"XGH&:-D&_0PL;^R0A.\+;UO3XU:1_+;AVXO$&^;QU1&G3(
MOS(3S,DZ4$EYD3; 3*%E_[1MYC>LQOW8S[CTZR8/JH82@89CNVY^=V7(8R9A
M.WWD/NC.RUT1IX0JM)>;%X//$\%;A,]QFX\II@]1IP_(WYB 3; N,5KH^H![
M@4"C'E$]. CQN%X9C=T695$]J/B]):_QRONYU7RV'=.7ARS;VHE*U1A8BL+9
MC8MD[Q4Z>GTYJU\12.O:<D[AB*?KC:K'UWY8TW@_KDVXE#_=;7ZZ(\2A=:W(
M1S0Y")#,\<BE[>OD=I='76_+L1Y%^Y_!S'V&GBQSY)'[6)?G0SY7Y<TSF5E6
M<9F.HD<)1FR'/-%(>;EN%DLC2".J/A*50LY>I.GO!5(3Y#N-(HX6;#YY]JY]
MD&V(EGG(E=F7YU1H7]_@4TZ0T[S5;R.@(E%A(CZ$;PVTK+IC-'3RNCA.Z(P;
MV(W_%ZM7_V9(<BENB3-;RY2[%R:;XU+FE\1OFZ@U(-P@;Y@D-ZKU\>-5U:O9
MKRF+FM+<9D4L@GB^)_+.:<C,:W#7S@=RITZ^/]!PUU -ODTH(5,IG4J3'KI^
ME=0E,)Q3, #T(?8QZRBZ*5HMW:@5[R(QD@F@CAC(W_.FI)7-;149 AGLU@&\
M9T0)A@I?\!,CE+,>>_-D,OI4[R:)9]1!M%X#;J&.!3/\HGMKUSK=/.\_GG'T
M0O@$'.W[L3R[L=^3W8[O!\ ,EQ5MR2/8),XZ."Q)90(::KB!EJAA[5>G:LV>
M0&0]KV -:H2#V76;K'8UFL;(&?BU]32<?^RMHO@N?'NK$V]M";^3I9W"!TXV
MWS4GMM9@FG6388(OXOJ(9B>S4%54>0UD0U/DG$)=8?A#,=%'K]"$<+,>OFYN
M5/[=IV)+(;(L"S&/Y/,];AE_[';C$Y^$9DGX!O@>=)],=>>4AT@]$@6+R^04
MG+B_P*R'YRVL@#9N7Y6X$6XR7I,<E?3LDG;;#\U?5ZGY';F&1A)"[T%WL9S%
M?AZ<T*%>3HF)>$61W=CF[WH6!2)KPF^52WR\CJ"O+X%8KGCVQ56P"0J6_Q#Z
MM:]\8K)F!%<(ED2SOOJCH#Z*3[['Y(OK@&\.VH8G:[1$T8W2N+=+R2+U6.\G
M^>99/D L,E%P(:!_=LK+XGN^-AW-B[IWO/3TQAVL=HW\:W)Y1KS'%32B5OJ]
M<^)ETY)GQP1_$A,?9KLPI^ *41YW-SAQB(8L-'W@05FD="7Q6AI=@E4Z5^[0
M?HF3I0 TEB?4D\!,8CS&Y6^D "3QNYC0-W=^"&UZ0@M[9%,$AL<Y1K=.>(K>
M>F5FZ:70 =M8V6$\Z\A!'S%.DM&7%5%W@:JPLEV(O/MUT2XU9K+Y1%VA>:@E
M,;9Y;/B8'/.Y,[I0/2'JT0\\.<K56F:U9^U#IW_.8)6%/*9J%3@[]-&PSA G
M-%M6G;6N7'%.<57Y#.E'NV1/*(QJ4IJO/\M:!M/H-'+?8CZ%H$V'%VS\=^7X
MO.S"Y'*3B?S^VRE^'[\0)\MKUT1#1S!BT5/9MAK=9VG=GC]U=1_JU+]YS4QA
MA]T4^K%%3,,R/= U@J[%6^WNH&-\S)]/P[Z/]:I0K]PY>,GW)I1JN;@D&I^%
MCIF;RM>EQBRH6LETO%0#&U?]^KI5NS8K?G')'P-?RN7;@Q/;!ASD_]"C@_(:
M F[OJXM%6<MP'#C<X[C]^5H;K2R92N?4WN4G8"0.#_$*+^0#X?G0L\R=CS.G
MNZ>RGG(D*8^^:7*;HW;"0(040N\3SE@%#'"AHN%6K6ERC?/0=KN$S'BUG-%7
MLLAE1#@TN]4$GXLVCZT*6J!%"VJ1),UL\ZQKAR5TK&8W0W/7@7ACX%RXI@-Y
MHHYH@X42;TJ#J2&OO#,HKHD/_ 6-5T_D6'X[<J6<I?![1G=R,!Y!8@*:)*:*
M<033C=>.QNR+!0O@V//EBRF\#;0F#ZR>ZVJLUU1;;-\UJR)(Q)T 4'U+#'O3
MS$\2? 0'Q3!?!)8;I7DF-599++5S7+4J!$1PW(?*7 HG_&><^S.Z<B@:;X!P
M67ZE_62C=IAG",_55!Q>:ES/B%7E>9 F??R%EM<JN'Z1(:K(0XO\T+\(#Z%K
MF(F?1O:Y/:%L"K79W"]AE1_QD6LQ2+9[NN,BP^^<PC/M#=FWMCVBE^XJTY*,
MC2Y$A1]!LBM4M-5>U'?[H75=EEGD'SO??8H&I,Q[_YJCO*"\]?'WQ+E\<<2O
M%0\R37F2G.U368M\,P5L7R69EJK1I*H_N/7;^*3P=O#3K8MTM_&!:ZPDH4[W
MUHCWRRS%$G:?D9OUK+HRKC5;!IEBU]K3O8E;'R%3)/9XF!,BBK44,HGAY,<6
M,/3J )VT6/#!&AD@F.,,9&)O85CS1&-$OB"S04?QG,(SW60/C$<>K9TA.F\W
MM[,Q]VR#>Q2DV)G)MT<X):']SYP-V-W^2C,)\$L4G;&+:=(QT?[$?3GL\1F0
M*'MQ]U_AC1NFVL#]='\L064(@^I\<>U,X\1P-'Q8=L':658;\!ANP7>/)W(D
MSIUC^Q<#O<EQ$M.).C&@AQX>_:4*2P2SZY?OK3'@A*^4;9=* H2J5/*EIVH5
M6%C6=]W$2# LW3>?OEJ:R&!']?"AUG,*P6*XM$%4U3!KCXO0Z:0W1[ GL:TY
MU]@TN*S635%J//18[&<BX]K2S4XADBSQ0[%83"<;<1Q-EA@+?2QU(D+R63 =
M>)"I%6*@!Q/3'Q,=#%NRFQ01$0TC]=VZ(;TN?=K'S!C9A]FPQ9OFL+2+0 73
MQ>7,)P@L@1.+XW#S=(1N*9>&BJY8"?!M_:]0H&"?K<3/\<L)0SXT=S7T>Y?%
MB9 9@"-34ZB@:8+H X:M;Q7LM1 _&U:AS; X_IKA1_]\\OV?87\W#D5/$L<'
M87;C.KF)?5L_VZY''%0TL_\5>;7WYR]3J3/!7JL,APF_$!4+-UF]V'?Z.SM%
M] KJ'=,TQD)T86A;\>RV"?R,-@]5:Y[N@Z9T@>?H;PC!YBK#W#&IC?$$A+P2
M@X&3(_AUWVHKB<DD$^-JY\,QQ!SUZ<4C4V>%U@1K269SEF!1MDBY12,ADQH0
M0T67T*!W@G$UZ?@B /-")[CPE9T<8EVH&YO*>LF=_!OC_=5ZKJ+SR)LD8,J/
MI@EW2F-:VJ4XAR3<DWI%/9(6=AIA'(9E%^#Z]0FI3>PEF/2<4[ K<Q,;L1[Q
MB'WI9 :(MU6\?<J/YC'?]>[Y#7.>*)+$C/.)K_$4T_SKU*?A(WD=/8W/R$[@
M%51<.RR&<"?>ZUWOYA-!-/ARB@V?WT^).<DL'C.T,]:KT;L7ZY_N!)*27]&-
M%()] XXN=7UA#BM@7\F3'E)#WL+]\@D5_2)@#K88$9?ZJQ*S8;0(Y:A-M\EZ
MX39$];8(X-08^=(AU#:.'_DU^;O*WW7(=7XYBSRG<)(]*R;+;;!9USCN!P/Q
M3BG8$2[-P= 1G[(Y2_[Q8+F1UV7@.Q#^3(FGG/+G% T/ICQ$!H(X3/I&^[G'
MU!GTVQL&MSCTU:KW-![6&29)/3?[/A-I]-PL^_4E;BHR$FA3.#L,G!U??I58
MNOG>A2Z99/<#VMB_+Y'<9+&9E;EU5HB9"C5]@LF7+ZF#9FK<4VC<8G[_@X?
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MWV>8=L(.WH)1KAW((:*\E>^C]\H=?SDRLPMZ^1NZ3L"Y:FSF/[;7S628T(F
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M3+!9C<Y1"!>:C;,&>]<X%.A3MOZ>F2WC "5^^?C5U%C=P.6D9TCL:;^UZ"0
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M AJ]P_^)<.UZ3@T+L,HQFT?4=)75P:4+6]?P<<6(/L'5IE)S,U,P@RT5%.%
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M3+IL8U:",]W$YL0-#A_#>?@O4!5@E0=P<@Y^(#K[1G+U:@(HJ6C=1)=D#4O
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M7="K@N\.!\Z1XS:W/7*+&QH?K.?Q/%TC(V@*^7+N]6>V@[E0U_.'117DX"?
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M7ONS*7>2."+<7\3A)FCT1'/,!*KA\B% $=5LOA7_Q G&CCI:G8-P_6+5_#/
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M\#K2"]-? T2:B<_](JQ8U5XX^DOG)%%V)41TI5H&XC2WZ#YW('@.Z%L[!WB
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M;7I1:QBS0?JX67 2N\^HBO@*Z1[Z4]G^6E"(F9V3X@O4"+\<YL4FRML5-6"
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MRS3>0B"] /)L<454!6U[A^ BAEFB'N5?RU*QH^2Y5AC3;>_ U*YN_0&=$_#
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MK/JTB%W"BS;I3+]?<=3&OV-ZES2S/=_XQHT?C>CW.=)O9T\%],<1ZT[&TY&
M6OAE+12%M.,X?Q1DE_!-)_\2.1M_UTP5T2:%LBC_T*QSB_2N3O(W@RW$&Y-L
M1_8WJ0)B(P*E?>@Z4E?SV3[C9+M1Z7QMZE)]F$;&S;4=^O;=/\L8!D.O =W*
MG78MG:_<F4)Z/-<"B8Q7#]Z?W#,W,#5<2^CO>!"F[NV.4@ KZ2T$/?OV Y<)
MB8;LVC=-V8I9.,/]G XPG62.2]:Y#I?*B:@?06]L3/5C_ P\CNT.C/O0CLGM
MJ4QD((U*\'P#_6&/!)SWL373P*4?,I?1(]6[/T@_UD2QD!LI/T/M[Q#=;^MX
ME4LEW#697+B'_7[Y-#^R9W(CUA)T-)/#3UYNQ&9Q\Z+BUP [G;J!XN#)/*IZ
MQ'&T_AX;49!RZ1-\,9U>)R9OV5RCY<A1;P('<GC!$3:,II_(=+U_*+)8!KWW
MH"&4R>65;5-C$U16:&\U[F'HO8<JS"^0U#9V4-Y"PV=KJ@9/7Y3]]8[?[!J@
MVPP,%<\%H$;8@.NZ^J>:BW;8VM#PH&%1.'V%FGA#EDM.O^2FWD8B$@6?R&<
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M;.X%,B"[RF-_Y&+^&J 93'%SUE[\(7"+0KB40%K73'&@JO%:\5RA]R)!DF?
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M^7DY1R%!YL+V@D/BPNG0AFS5KOO#W,E]>C>;5,YM@:M[A6;QW'&":JR5\KB
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M=KCF.M&GHZI-Y(DL&[/+C!%&6GI(&]'I0D4U$3JK%_GAR"FX63U*FS+QUS7
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MY,FQTKI;H2('5UHC3\)0L \PA[;+]54(SK>0GH#OBO>@G.T0M=Y#R^DI>Y>
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M4)^0T(M#_\ \.=@,UP3]P3G%!N2'?G'/N.<B/\G]'5P[3M@P5TC]J\>W6)5
ML%:RE*H-8S8H1"DQF:_,),[[CWQUTK-GN6+'W@4U/QYX:Q,EXTN@X9C9G#A4
M_I:)PNP_[D_:^A_W)SXY]3KM7FV7'-/CS?7USIL>'@^O@-I:;)6,0B[6U,40
MP3:4\T0'P!0RFNQ$I=G8)Q,-D-$OR72N&R;N5HC6B8[GV^3HRI>.YXC^&QL'
M"0 PBXS#Y>#4?V5Z9O,G%_+C^3-_1ZK"_XW$WJDH& $4WY.^T1O^R=43J^J
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M0J/2K[;[:T[=7-.?>Y4WTQNRICM"!Q3 [SH,K":JS>8=H+:?&@,,3HS%IA"
M9%9S'3ZB!IFZ_^01S V:]^=9;J#RV^:GA(1ZHFE\+!KN,!SI7D%%($>J=7.F
M:8[LYADW1J*_OFB:W(X6M7:V=\?K^[3*$-T:\$LLI+3N1?XFQ:9SBFCY06 G
M1TOO5W-Y.HM]R%R>"(UBBEOB4_N&]X"OMY]@8_Z(_7,5>9J/)TMV>?:PK'%I
M1WK'2*=G:%QZY'9.8=1_[YSB\Q?;Q#9Q!UI56]$A*JT205^D9691U3F%9BX=
MU/4=(0T3Q+X<2 U7F7&\)N\=8WUA2WQ<)^SDL6S[[$S#9%&\J!$\U)BK6/N*
M'DW8JF?^1901PP/'+_\'M;OHQ\ D0?H=JG,*ZEJ\1J#,U%Z,&AWIRV3F8Y[
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MMO'\5!""#:UUUP >-0@9B^-CXC!RQMXS^SW%JH=^8_GO9YK'BD=V9YFGSB>
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M;PF<@@3A<M1L3^P@[K&/'B4[ "DC5K'963>K6 Z>SM$+5D^L#^/[91#CB$%
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M".(-5I15732-VK^/BW;+U!IT.LKG<]DHS*=;25Z_*$OV[8__"7&*YK:P/+I
M!Z)?]RP]9N_2RP.(C2"1;G;.?+8G.7A1X.HNBEOK^P?NN#2X97E:0.CV]$4(
M%?+^7%_H'H:QDTZ/8GLJ0-V8;2**4E7CI'^4739995,WH6+D;!CL_6^#"Q@
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MW'^=X.'!!\O;^FXBV')5>$=CWU075@0NXD$6K1M]YFQ]83Q3" $N"5/?,(1
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MH_@+ )U@6@%>&V):".[N5GB52A]WW'(<?Q)QYVG<BL_-!9W["?>'(%Q7)UJ
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MM6/>@Q)+,]:$*)W__,\'?JLKKE@^+=).T>%V3E*<:ONYKU%T7UA\=%BC_*M
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MEL7"RM))M]23@EW%"ZX8R51PAA%D489"/2NK(]%1/H^OBYUTL@Y8RQ=LNUP
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M4%3S3H*,;DI;@O\K=>,>MI#7;X4G$8ZUU(?A9&M4B<),J2DAI@B>6'"=_*N
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M'-3GH35$X+6URHT:?YKJ 8'. A]H&,NO"X T+U>8"E&+5*CJ%80NB%D8 JW
MLVY\*EX,_NCFP#$Q'(F:D.56*T[WDN [TZ]M&WD+E58(29Q>GFP?P0/C.^77
M'7B?5:2Y2$9Y]DZ[$SX;>D,$C3D^=:@:NB'YERW913]#.F42/6K\RFS,A W3
M=J @$@<YSNX16EV*OJ==JP:BAFSD@!_X,].[?,:*_QGI:Z2XFVBE6,Z0YJ+-
MGCL5J2_/XQ$@_:L7M35;&G4,7$C%U>!C"<;@)H)1C[]\_-J((,H927]E;FE
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M1/P%I"QX>_@ MQL2<:'HTOB#0^639(;<:-_NVI9)1L2'*X"/OG?%E@4J2YO
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MSS,$])=SR#PPMW+N/A<0"],)4^.ZKDG/OOX'=) ;"P@%0AK^)D:KE?$SD8V
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MBGKK;5_6342C9S355A%K7G[#UR4)-\FH/-CZ8\,9[M8)*LG(R]:%H*&A4M0
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MLH/2<-W_!4=V':0K459\GGQAZ,\QS?W4R][NP<\Z7J'8\AB/RM[")R<35X"
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MK!I8A-E""1@:9Y1$(J&"+4L#=.C\DLCAVI<[&#^3A( 3.EYX?R#;0['A5+P
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M7=-4P["TH\A^2:BP;'8=>$JO]2FDC/K[P0D+UFAW&-J-5G'?=1##=Y=;9\Z
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M(JN,Z>-Z,"[Z"B(8F:-O0RPNL\5&L@B=*I5^_TT6D4%M(>@M:*,!B6FS[QP
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ML'\D,RN&\TJKD[.% H\4@9\07)H54#-:7>0@3ZCS\+=4^[3^@#SIWDT&DL>
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M4:8=I7;.@NDAB3Y>EW!SUU00LR-R;;?[M3W.BJ,ZZ.5TAY1)ZC<TD6+F6N>
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M@+*#HUN1,K\$$CV@"FM^%DM7$^3USL6HY1Q _=(E[,:#.Q8VG7IM9-&YE7,
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M!7LTDG[^Y=[5<K;6:2\:?CW$#F=$WWZ A_X:/S4269KC&\M]>="+5F;@F^$
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M:60O5+>7&YQK=TP1'O/G)CX8T"]@_;0)R?Y4I:L-3LG.TY37BN(_%;;=$85
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MUP/+![>KXWHFDR0SY1K#%B]Q&A7.*=R%BTBMC3.JO.T4]1EO[O=1MTV'O,M
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MTK:$9@U2O5O(X(BNM;HEB1MT5I$]:_=?N8B^\N"AI=>FC4)/):/UHGG>BTS
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M7.)_*[SHH]GL\&4E5F)Q7SGN-!*K<9!'E":)$9^KB! Z,&:_Q?P&!6,Q\5E
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M9?3KPE7+HQ]R?7CIC+_1S;?VO<AANJS>7S6_U,$WI+S0\N%I^I.7S?6C4F7
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M9@(M(LSK!/4E?.> =';3EX%9'95QY0?ISXT\?]4G"!D-YPN>)2JY54&.*W'
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MJZ@;MV\]NOJ6\>_;^[>/KK=@Z"+;K45.+03%&")R#@M#2G6;Y?V;3PP2/ _
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M)"J;#>S^Q+[3TD&']]0*>0O._',2B8@J^'<KSG\A-D-AH R N5J4%R30'4#
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MQ_EZ0#6/(!6=-DUH?O7LNZ&@V[EB0B+N>YH;@O/YA#R?S-4TO:]O9#+X!V1
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M3MDX;FV6D\R2]Y>*!C,Z75N97TL=E/$.NHZ/G5D+_Q*>\D:,,'#SGK%&V^/
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M=:(+2XUH_9',L#PQL^[S/+]O[>Q[) :Y-(OY\]7N-__/YU12XX7$).\^QW.
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M) ;BS/@>$\?F*8">Y[/.'F!=W,;'U/9@%!@R"N--RQOVGQLGO[L$J"G+GH5
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M!#01%"X^Y=U_H1-!TF<3*;H*I0A\KCP//+%1Z9-(B#%].4BE6:*;X*V#*S0
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MO>X,[LE2^"R</YBZG2HQ;Q$11)>AJ9"1.]>Z7/99_Q/[,.G3E<FN]U!R5!?
MU;4 PMIKQXH-_9 M48)WTYBNUY5]85N@_6RZ:F_*-8JG_8@D2],IX+63?5 Y
M,0*=6-!$^:PC-U1H'+>P[NBJ>RNCW]$RY&RZS#RK$T3-,2LPUZV]@C*;Q\,3
MNUR<V9PZ%TG1FV3K;/P1&=*"&RVS6GT*$\"%*G6JH;!A<7].9&$4PIENMK)<
MZ6>H"_3*Z;^S"!T/O7DN\R=^L0_$T)#Y6ND2X/FS,Q+]6?%9M"A!Z=/8S3UF
M!:!;I5O0S[HXX8'N>["'[8*HB3L01IW8AUCS<((*FIV!C>D8?O?766AT:06
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MK+4<:M2A6$F8;TX]URR'7Q;.S]M'5PA[+5V0M4Y4_@5?Z8I>P3[F!+S,=^G
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MX4D#WOE>"+.R^G!'\9,22W.:YZL!M\+Z*REE^CTVPT<[X6HZR"^& QA>T<)
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MIS($YZ_Z+ V*ENWZLMV6NV9MNEO3;(6WRK"NUCG>&M%O=0F=2'/^R!>LOJ/
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M"JHMA*Y0N',/M='J=="KJ29-T/F%VT1(<OU(SL:7"27.F[EH)I_:YZZL$7=
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M[TAEM%N[<+0 :)]%IOKZ33K@)?C@$)B9ZA]'!V!+Z8"'!Z#]EJ?H:/A/,!V
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M&-78Z^2I75SI7/I/E_H&GC0*+^!8>[NE_NU+P'[16-_I#--EJAB,#(ZB2&-
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M=&0AIXQJ(+#<"LT);Y&7"E,;9*"IV-J-31@,OPY"BR9(Z71N.L 0-X1G/V<
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MN+CDA+*[T-!5%#-U'VQD:3;A+-<K1!09%PCL1(Z,XAXI;9)CQ#LCBQT54]K
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MN2C6I7WW\N[;H-O*TL@OZ^7JYGJY619O#B1@H@62%E@>MSSD>+I&S"=AI N
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M#-Y'42IZ;<RAP/! I<*&J#VS!%1,'@25"DPNN4+@@D9J;+"RE99"VY>*+FY
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MGWM.!$OE_UO4C7^XR77ZO&QL'C=S'"08NK>B:/3:F$.!X:&*AF=&2,;!Y>Q
M:$7 $1E 9.&RYD5 _-H8C"&6\N@D4%/D1206P5K.(--L'94D1;-7T: EY> <
MEW$-W651.7IMS*' \*'*T98MGU0V\T![&T89 G5@0$6^[+4QAP)#Y$L$:B^
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M=?PNS<.X+N=SOQ1K=M4X#;;GP1"BLQS4 1@>: C!G54TB0C9JPA"EDC 6QG
M^\ RY<PRSK=>;[5\\VQ%4[<\%I_<MJ=I!8NM_8;NMR@?O3;F4&"((W8(U%X
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M,*$PH3"A,*$P#4F8LN1>$&**M(@,PCH!EB4'S#%"2P)E;#/K^*DPN:RT]T*
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M)N648S69U755",*]=>.)\Y,$Q<.@V:"MJE,HSKL8)RQ,PFBBLY34 1AB]H5
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M,--MUG,''87PBOBJLGF_3T>TB8'$R,ND*\NY"-M(A+R=^";7XK^*_;]O)PN
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MILVK=33\VQ(,7ZYCX;9V/!F!&#%8]?3!*J0QI#&D,:2Q[=$8LTY1HRTI50A
M8Y4#&I.&>&^<$-S3I,5]<BA/2&.I_AH#^7=LIAD$-&?\%^2PI^<PW%AE+]SU
MO^>7)=-$YFT$/[V-L[:P_E_SN@&_?78, _CY>"T),\X[([4#((B!3"4T:M"H
M0:/F@8P:96BLJ%;$EQH\<A,$<;Q2)+%26*.HEV%C8Y6[U"MV&/@^_=[&%QD
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M>XYJ8W-6^[CR"2-HW_0\=I1AF]FD>XH._0"<Y^/\W+=&"_:C1OO[$R3YK09
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M#8W-VG@A@@[Z#K7P=XV]!C54[=SUY>#][K^Y#6W=U_,"!N3=#;H*D?4"\I_
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MEHC@QA(;*TDT2\))&P13Z:J3$85FCH-K4>DHB !7A#AF*V*\C3ZJ4@JAT<E
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MQ>RE;9IS>.BN;]Z6NN4Q/:):#[-=WD#F+E()4LF !'K05((V^0YK+@(I NF
M!'K00+IG-KG40H48$K%4)")<K(C51I/D2V&%8-Y7\JI-GI00U(B24,/!CD_"
M$>U](LE)X4IFA>4EVN3#G+L#J7?%G,G <B:?8!C:>7->N'H\QGS)P>1+=F9+
M^1VU@1]X)WETZP;04@35?JC6#N(T*NP@<'K/O,84HA6!1N(B#41(*HFVT9/
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MH\LHP(72$-=XP;QVUH=>$[+,<G)>69"Y:[YG))@8 J12G8AZ21F]+@]MKU:
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MEBFXLI$Y2I:%$L:8?$UKM5E(*;8_SF?O"Z6Z:='&M2@_2_*F (FZ$B"1M_8
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MA-J!]@P9R)Q_XC6_30[](]?\NI<LQ?FGB]5$/N@BX/:&)3HRDG]SY8'(JZ>
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M#D"[<RY#+(^,\%-NSZBJ09(:XZ]$=VP"K3'^TXGQ:T59IDX#\UF!4%Z =5:
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MS8,Z:L.=#VID]U!;=N>\.:0GVG#X:-L'?5ZN9%%_-[W H0FSWZ=X@R&-SW%
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M3'Q6Y*.,Y:R,E\ ??)>V?BE"9##-[&;X^.S;G@%;G.#:4YN3RF"5ID =8(O
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M^Q5%K=U/O$HFTP&3,IE,!VPR64V]Y38GAOD2LYVQMKB0A)?P-74^UZ&X:BZ
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M:>HE)OV6DB4.+2S1M??-VH7YI[=S/,GASZ?CYM(/L8GEP8[I6$_V$[V2 77
MI$P&U $;4$7@DC)9D++$TIX!G'3MRP#&4%5RD9M"E5O[.C;80GFKB*M4#L8#
MMG+GH2(2/'6IBX)S=U Q"J=DF9=>DR* V<1S6V$=.D^8H52#?:ADOG6@PWA>
M@-7HB2^!$%Q4ABBPFXAV' PKZ4V1;U6:W@\:,"I&,G^2=IQ)N^VK=DL >\"D
M/ X6?*4 Z[W@ !$<<+(P "ZX'5 %342>5X)1IXMR*T(12IX'3#00%;;&M@K
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MARVULKG^E(WUQPBI'3[/_.D"#*D&#&N :G2G0=/!R_0\.]> YN= IWE\^7>
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MXL.:;5)LP/WH6NM@7/_OHH;/E_UF*Q#" ;W&S30&U'M] [,%KWF&DI'!D@,
M?O3]X_WGZ'K#1+?AX48A/>GB8N?]:CI082#@2/^9[S[K=A@Q6B?#WYW =9_@
M'2NA7TG@A^\Z3.@4#1(_6D9C%/;%%&D5GXP+O1;3P9><Q !E5G=&V/-3'^<^
M;+;#+<LI/1[98PCO,BYS3QB0=.#^&.V"(2[G/%L??(L/7_$LQKZB(*!XC75]
M'FG9&- SD4@CP!3KIW%K!@$[ACC'<4!=L"PSE\O07!37Q=@O5QO6;X0(/UW
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MI=UWCE].RK#,L,RP?/:,RK"<][RQG1[[,.H?-= U"%7;_9A0 D<-\OWZ(WQ
MQ.!J'YEAS7HW_L-VXD=_?N&\>#XJU@+4CV:R,#'K2TR6;V;)FK$D$Y/EF^6[
MN2S)Q&3Y9OEN+DLVG)C<<K@1O1T^BSB)PE $5BP"\L=PHF9M$(D;R]0BA%%?
M>#\H% QMH#>S:;/8E-'RI(G9%#9L'EKV[6&?T;)A;,IH>=+$; H;-@\M.P.[
MPW#9-#YEN#QI8C:%#1L(EQU[U+ED/JU%'B#[JVODKW[_ ^0[= -V4S=4-W(N
M/N?B/T,#GU&?"U>;S>PUH1RC,C,JH_+.;=6./]J/49E1F5'Y[!F543EO\C+H
M<POB9C-[32C'J,R,RJB\(RIW+H\?(#@W5.86Q#4,"<@6Q-E#6@K4 ,EJLA.L
M<D\/A5CE'B<HW[4[W.ZRX=Q>$\HQ+#.C,BSO!LMMN]?CL$&SN;TFE&-89D9E
M6-YM<F'?'K8Y;M!L;J\)Y1B6F5$9EG>#Y8[='O7JS.N-A&6N/FA$]8$,-7!X
MX:PUL]-R$*Z\*!L'HFZZN<SNNU/Z90UX=F\R-T]-=QV[5[M8P]J.-%)1,THS
M2C-*,TKO.I:V-ZB;CXM1FE&:49I1FE%:;<>@:W>=4;T9GU&:49I1FE'Z?%&Z
M.[2[W;H%)LX!I?/0!/S@PFM6O@6%#XS7&,"O1W#2%VNYZ^&[D^4?PIJX81C!
M%@L0(OB:L&[]=&Y-@%]</TQ75CH7EI?%;NI'H6U-HB1-;'+\ISY\?69%4RL*
M9Q'^B']=!G _X5F3P ^1X:PT]MT@P:]]_>W;1;O=M>D'I^/('_KMCA7%5I3!
M_^%9L?46;N-[;BK@.?"!/[6MV[D(Z9<T@I]=##3@"UBWN-H@L&8B%+!"8<7B
M1H29L*9QM*"53Z+%0L036(+_'WH%6F3B C?#BMQP1>O/S*=:4W@0;,%DCO>/
MQD@'"_;SNTCI)9?+.+J!%RLM^MZ02,L"6B_<E17"A[&59).) #+!K>43\-85
M#\&U5*ZR97V[?V/6-V%]<9OO3N3T!*S9LY!8UHT;^R*E!4S=21K%\! _G 09
MRG]I,J7GW\ #W23Y\PM@W\5%X"?IA0@$/HE8>"GB?):+&1SKM?K=RU=O/#\!
MYEE=30/Q8UW4_I4EJ3]=:<ZE[UPDJ1NG;TBH+O")R=78302\LM@0OX+_NZWN
M:/BJ/O+8;?7[H]ZHY_1[W<ZPYP AC)#G=R&6L,P@)XX?XOM=$(WN( H"WM!Q
M!CGBX>:H=RO?JBY(A,*:3**EL"V29. W$($9R!4PG!(BR=[PIRQ($RV_%4"S
MQM-XT3U2"ISMW_BI#]].$5]NI:S"\KQLDA9Z \A8^B^H#9.T_Z'@[H\KYPWM
MA>?'8H+B>054S19AF<77E6^K#SH4R:/"XO(/E9L,TOEF&24^W9OFEO@W E3W
M#]P6)'6NQ7]LT<H'U&?*_C(ENJU_4_9!79C,<4H6@-[!>;P&2TK*2):NW"R-
MWI0_ /K+/R_=F9"B>N%.@0I7;G#KKI(W+WY>9XVRW88[6S#+QJ8?=F\?9W(]
M9%_OVTGG8#M98<^9\JCTT (4J[Z(_H7?#26D=Z!?0? 7K-!8H3U6H?D+S5BH
MEF(QRX"[HGB%B@C4%>F&!.VL-25FF%C6- .+C"QKH -\6'QW'@6>U&[X++#Z
M!/UBZ+)8_#L#'>2AW1SXTY04)IB><WEMI5YCKF>NWY_KLU"?')'__'7.!J,K
M@<TJ^'GBPZ+AE!3&41#(,TEL>7&T!"-._NPG>'<_S.3Q#8U#9EQFW$,S+K*E
M/P5.Q=, <.=D[H8SQ-]9!.?UD%A3 ;CV(AAX/LO@K &LSXS)C'E@QEQ&^ -B
M)YX@D/G@QR0%XP!N" "Y?OY%G0_6!2C]\<ID43BIA!.?L9-9]$E,7>5TE+@X
M$?XRU0Z:3:]F\@:_QWS(?'AX/E2N0O)7^["XF8U^Q$1,LI1^\<14A)YF51%.
MHW@B?UN!14I1!6! ?V&Z#<&:%4$@)FD&, MW R9, 5O1!Y*TJMAX!Z?,O;Z0
M)XH@W4H_TQC.?P_>!'K4E9_"*B8/V);?*#HC#['7'GP+A#HF+XOU?JU@Y$3>
MR#(=3^<3+30WTBUOI YSH<L\@3^#F/CP5O \E,3$#3",5';%RVG;*FY5^#O0
M99&N+A"&\=,%WE?%N# 8MLSG=6/H+(OAR23;-P(^]T,TPFUKG"4 2TE2]O%O
MKGH*QU7RP;2L7=X--%>D5BJL0,PP/B?(S8*G EA[&FD,H2-$%"\C"F8LW#05
M&#D#\)C"NJ011]=2@&\RB;)0XI.;H9&'/Z7N#W6;$ ,>>/]$Q#?^1!"]DBS&
ME]4$A,7"J^9KE:&2J3L!# 1JKL\V;YTG _]#;N8DE5$>9)_9#OM.05'8=U"G
MH%F [U#13+,TBX7E)A@L2K(E;+6\XRY!I@T_G=P>X!^\PX>/7S]_^/+>>O?'
MV[^^__CQO33M;?I,Q]<_SW$MG?&V0+O3<>@I*L0N^8$BR21^^C; ?>I%UN\C
M(\^>59P_-F/IFU'I!_)59W@V6O 3T?U#"%0$A/HH4M9YIP 9GY0%*+<M%*G6
M<$E9Q:&-B%Y]]=46['3I#\5E]&7Z$\ $R:!49!,WD9A!/Z :A*,2+ *Q_,;U
M \Q-N@"IO*#L%;1H8T*//"I.$04AKS\'0=QI_]XBD1#6KG,E:WV.@/4U#/\A
M#POOX1RT0 @[4S8'!H0KW!D=M?]O0G[WC"P5I3G<8 7\JR%?FEI2*X32+;6>
MG('')%=&N. Z:<]I5H^P!EX:>"&U/2#U5]P43J IK22Q52K6',P;:RQ$"&(G
MEFXL<Z?0<HK)\RK3UI0V!Y&$3\02;UH85RBP</ME(",3J,3_"'W\SM>T2*F2
MMR_IMP<L5Q%!JG.D81"!H5:$XA(K2U#-+]SO(/^:YR2)DR1;+"7!R#QQIU-I
MJF!>&YH7^#8+?!F9_)(D0CTP\-TQ&GJ$!F00RM-M;KBJ&&&Q(,H.H[C*C$R3
MRGMI$_L![T]I;KC7TC;/7Q"(.0?TBV*215P8G ?(5O\>1K>P&3&<RM6J;W)"
M8O)9! 23-HO*/\LS=,8B\.'+%C"#A:89&-68I9K!8F.9_.?'DVP!BPO)9I:$
MS/E3\A4 JLP4A$7[TNJ!O4%N^5?FS=2>CC$817=TXWB%'P(T9^*.;5 [""O#
MY$I8G8=ZPETBYP*]*3]1OE4"A)JH_$"!MZ7LIQ+QUKF#9"W/NJ2%MRR48%>Z
M*/1+8@J3YP,7X3N!-O)),G1N9&(PX)F>!]Z!"L5C&^:>^3^L!7PP3RS@1.#N
MOV6AL+IMVW+:3I^8!S;S5M".YN2482*1:,M]HK6-B3I*V\@MNNL;Q"^>2. [
M8UA!P<ASY!_X(CGDVF]^SX$:_]"Y?)-8[\IP?6W ]:^YF+XM0?670A0^Y5!-
M-W3>/%AKTLHZ;S1B7(<A,N(7(4]%H?4KBEFG??'?)&'X3BNP?A2IWXF)6(SA
M7;L=(G<O!RP0'DE<_"4+Z7 L86AG0%;G=5(7GUU8S0?;^@ ?6O L1<^"0E^+
MZU[GC_O)UF\';YP"C%G_D\&-1 S"M/F&_R,A4&&3/&=.[V4.B4[3* BB6W)'
M5G"'']Y$ =U3 *N"9:D12KD)%J#9?L!I_V!9N<[PN3SJRGU?&YCHM2[[(%C#
M06_D="][ET[_3%WJP(=QMLM$@8.'%9GYSI[YMKJ"GR1^R QW]@P']I9_(YV_
MABV_;XBO(4;R-9VQX6O!RC:/76B&Y+8)G('0LH,C.!R6U)DLMW? ?L,LUI6T
M:/$\5@1@Y8F'ZI4>ZE9H61^FZT<>,"[5^7'[P:<X]MCF(6_MD)4E,H4FHV,P
M($>P4F>%1!AFF_3XJ]/YP[PB8.$%\ AAKE&>^877VIK:SJ4FIU%JTN52$RXU
MV;74Y)P]])5^B-/P1QTA#/<6S& W]A/IG49M]FT>"V']+GU7[S=]5Z2!T*MR
M&C0]-'M]*_E5J,+? BV/D;O_H =71NPKU+-V5*&K.O+0"O!\.5[O-44/HBP!
MRE)U*H8:\'NHGP"FDY^NCDOKYZ/N!CA2(P5%Y<UC%FDRI55P>7A_>!L*;8*U
M$F7J*_)1G7:[U7ZEOP\,%+C+1%PE,D CRAJ"KGNQT6/ZQD]\,N175_H&;RJZ
M1ZN#4/^5J?XTG)/^^WG;19WGNN;9'O1<U[3KO#C>H2=[H;N:P0_OG");A6N/
MZ1!_X&Y;%;!< ?[# ]G,1>.CW;#_B?MO/4OGLD/1[@B=RX"5\:,_OQB\>!(J
M/G[$Q]%X=F][>T<+<-U _M,X_ODOVDA^7E[?>_!''?:)L:7NV.(\#;8P1S(M
M3X:6+-W,D?7BR&;3LK''N<8!"5.NKA#,A[=M<=2VL]<8*#ZA,8 P@#" _&4]
M\LD P@#" ,( LO/&O+3>4I$/@PB#"(,(@\A>(/**0:0^(++_,/KG=ECM.WN^
MV*.3&2VO<C^Q Y0J*;NJK08XX?EIQXXE'&]:5U.,$B8FRS?+=W-9DHG)\LWR
MW5R69&*R?-=7ON\X[A^*JLWV&3:;E@]WG>A<GT=X2>A]L7XV3&7MVEY3J/?U
MI9CU:YW6L-]]55I0^\WSX,Y!G2U?MK3SJ<%(\/. ^=W(^>AIWC4AYBF/J*^O
M#7?8\?..W>OLE6G51(9];D%GW&3<9-P\1=SLC.S>H,,,R[C)N%D;8C)NUA\W
M'7O4WRLQMXD,R[C)N%D#8C:%#9L'EX-!:\!<^CCM_NK R8#LT:Z11WO[_,:Z
M@A3KROV(N6>..6O39\G?;XB^'=G.Y;#.K'YW_CXS.Z-R;5B549E1^3"H/+2[
MSF6=69U1F5&94?D\&)516=O*_>/'/QF3&9,9D\^>41F3=7BUTSI^</6$0/G8
M,84#9\D[1XTI=%N7[<L&Q!2^1:D;Z)% 1F."&@!=3<2&-3)K9-;(.^U(KV,/
M1MTZ\WK==/()<GM-*,>PS(S*L+Q;>]A+^W+(D=YF<WM-*,>PS(S*L+R;_ZIK
MC]K'+T=E6&989E@^>T9E6%8[TH<WJS.GUPV4CQU6.$"IPK-&$4XP2/#W*$FL
M:1PM=* @"CE P+J5=2OKUH?Q^FN.$#R7>OVI!GQ?$Q(R0#- ,T#O!M <*V"
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MX35J*C+9<.]9!G>/XA7=)_!!=2=XUZD02>N!V--Q[D& X\,/W?G*3^&ADP<
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M[+MK(Q)N?-W-TGDD(P/,H\RCAX?';+SP4Y/CICZL;Z9<)>2.E0/E[]?Q!+7
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M\K"#1Q[8]*C=S%0F1<ES_AT+EK/4%YMK75L4KG.&9;<A.3''D70?/V2EF+N
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M]4O15T6LAIV,5_@E;,$HKRX78]*]52EDWMF*8ICPNI0A09M-?7\62\S=+O?
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M,,@:]4V3F.8-,O,S\Q\:GA,<6X,MHUPYEL,VV1=]PCZV*1QGJC>TZ6K=['1
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MSB/IV2,3P'R6\O#!UHD;%TL-BIXN<.MU^5+,;T91T#I$+:/$ BU3/Z'9!4A
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MW#H*>K+V4"@D/*4_SG8YV^5M<\PSO#X7?'=Q47<&.@!0?;C0$UP[@8'K?0=
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M7V?;O6W;U?/4?1"]C4U),AZ:^9H-;C:X6^;^*G!8GC..I-,<Y 8IA;)T9'P
MO7@K\B<?%02)R-V$2D=@BW-G^1?867XZ=Y;/G>5S9_E\\?P[@,G^/&CZ?=29
M810(UV% 9D:UG:VK"<W*-/U,,9UQ&8YJRGG3GDPZ17>G$$%E\1>_+)YI//..
MXYDWH6"Z^/JK9^_>?/6-UJWREO'#7'<_VS=%N7AP__010G1HDI1<O)YXZG.^
ML2]<!CSF+BE4U1'7^/ 4<,D'7+7W/[_(BQU@/RV!WKP12T+ &_T.U/8H>G&
M]:\\J:H(A7->^=EL7+6:Z,)MM6SWHB='Q2_*+Q4@A+^*TEQ=H<*WXL);ZU:
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MGOS9\8K(H/'B7-4<5V4IF0/S=A_<;J\-%_Z__&)R3 !?0XX]?]56H"3-24!
MKW0M2L!1]<O85.P2:P,^:L?D&&;RQCL0@DK>Q#+?A!-4/ !.%Y'G3.FAZ"X=
M6VBL"TW"MJ;*)6L:QIX S!?V%9MH%NPSU-;"Y+ +$\:F3PJ]DH/((CR 6&GP
M._(*F3;_40%+G09)"_"4M<)ZGTQ&]" 44^'/7&'-2>^5T;08E-[@6M%^4!D$
M$]6V*>E0F/F?!\:" Y3/2ZD0(!%31])?_L=,LC(4^H2SCAP.C,6(!26=C^*#
M?58(U1E_^(7C#Q_/^,,9?WB+^,/_$L^8^RN1_@D20%)SI&O;%JA3JA,$D7[R
MN-X&QX!]3CKF#U$[B'C/;*,\B,Z8,4P^,KB)I )W@3;4Z%-H/.Z4Z@'X>1N=
MHT8XJ'123_^A\I.T$L@_4SGZ.25$E$9FN118K7<F?6LJ%Q=C@^ \C/T$;996
M]RN5FH^2HSDG\LB707JB;I+JQ"!K?.3'YMC\BG#O.J@=^>H(!O/]P3A:C1.D
MFY &]GM6&3ONX:02@W<VO/Y]\VW=2.^+4]$E%$:1(Q6=LFNG??'*NXSUA2@9
M-&#8,042=E')M^[PCOY JJ&JD2. H2^6^3X"OH9( D,8Y+?MY+N,*3DG\JV*
MK*78UU$:5 I37<*I\ Z/1EV!J*>4\QM,1"AKP.O"P+XKB.#"'VZ+%Q=YV<?<
M)S$VY8T_9+_^ZMEW+]XPS)!:D6H6SI-X$"7*X2MQN!&ZK4131B/?9]YCIW1M
MMGB'8@'^@1@79-SDX9^M+XJ6K '%QJYSCE/<5*-:T'A0:D"=C49PPM_7WQ_"
M#9CQ=R2]*:-'9$U9MT)Z6'-.)A#Y+T="RZ(6O9Z5#H>PH66MZ>CXT54<+V?5
MZ2?:^!N4/5[FK5\8W$DZT$9G.^+#<L7<A<=+JIO*;P%=Z 8O2S P;X+]-@KH
M<9-H&[I$3;/GT!"[VA\ /%]"!939=;8T/MIA%TDHE >7/HK,<PT0KF@9N;6+
M^ A^L4+2$ PK3]\C6SC!LEN3YX>+O7>1%"6H+B+ZU.?.C)__^==^9U8/NSV2
MK@2B7I7NM436QC('U$X#EE_[Y9)+*"F;\?VDQW-U[G:4PCQ,8>-%W*=-B'7I
ME$SVR<N?GOL!I0/D0YYN?Q^FNURK-E,?HN(:22G3^;9VS$HT>*<BZD'Z%WB
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MX"E%+G*;(2/*2+"4.T>+3>)^VF[[%!@6A)]"-G%3-"UZS2*6C/Y,#$5-QCB
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M#]QOXM7[<S3G^"MM*4(O*DVI:4?KI].^CAD4*BIYVRZ.7&-S \87V(#Q8&[
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M1_FQ540:20%H1[0$@:QF=6U?K3 :Q8"V.[=EQQO0^T1M*?CEWA*1>!NR;Z#
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MQRU+SYIDW^ X,?U1(!':-E:;^&=C8C4^_:9ICZ,<K @_X5J,B%A?1M\@\G6
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MOZ8NHJZ4/X_"#40=30\0T:V<YBZ9HUC/FN3X3PA0YW0L.\HL#]7#36N4Y&9
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M(4P^&X=&!DRAF1_I41(3RL(:KHBV&]3\?;-Y3;3810N\#I'O<'M<N [(Z=;
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MEL1*.'F;3D7M"[1=0,U&#'(5CK1A&XTO&F0:-@F\"!+></N[<8_:UU]>)PH
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M8+_"!I5W*9]'Y'UWL'&E8^4)G*?@,E8M^H\+"@WS_7N2TJ 3]@9M!]Q/YD[
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M8.Z5&D5243$09.22R!4_I9/&$H5-^3>5;"U7MX>>"XN 78?M"WMZ N3H*,W
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MOLF<P)I=%[>DI(L&[X9:](A%_'A#;;AN$/$F'6C>C(]$#IHD56^L,XS5("+
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M;@V]=OZ)I,TK>2O5TV$4'*52>!H9^4#[#O4XL%;,2/!.B-:L9GA_YB5<R&%
MT_R /2E+?X0?%O2 S/JW]L\M>P'D0"DLD&XBSAK8"$=_>W -)O9#S72<FQ!R
M)!]_]OD;3 NA#<@.97Z$8I+T@_G9#_EK3D&X6F);A%VMUC0$DV<"LK6*.W.1
MRA[J XMNDG?&.Z<A#_UX4=1$<PDUAZ:(LB,EAGHWG#[/E>Z0LIX1".2'XLQ
M"/<K;$K+#,-#S9G\J M4XQ-APZ4)"2,6OLS![2;?4CL:@:K#N V246B ZZI8
M%4<HJ&V!*<*48\VXV#BM<-<2T*6>2R7@T(FWT9TBN3733#.<6U)N9+7-4?$T
M=;%O>EAOLO=+#,ET#'8]XXSE;\)X8TW*N0XS,/5$GF?,@@B[YX?R&=2XH.<>
MDUY&_(E8T0HSO&O)J.E89I6>N(RQXL),''N][I!0'L?[;9M5UV3C]^>U"'PG
M?W*Y&";@#UYU62(LM*Z:S6N%J;N$I1PO@OU$H>%A+KBY24EZ[&7'Y-%F?O2D
M!5\5V=BV]&MBVC_O=,[;D=\[+H]<A&M$;RF+[M(;/P!W([L7"P<BX2VWCE#7
M+YEI[\1]18?X6U\7W@#4\PM?= &A_RR[%E/F>$MY,CA[Z+2E->#R]D1P)MZE
M1<?&I[C]C_D6E#OM5DQ_"[F] ABN==ODVQ2YQ/ED\BO.YQE-?T#1:_0T $\!
M:P8TB^N\<;O<!;*,4=92+',F#?DPM\5O!]OGI/J/9OA5&/Y]@:,FLS*8C+NE
MN14OZ2>B*%YG8AS93/H[IMU'D()9278/CS>A5/(XI)RG"*=QU7VP.E)9U\TM
M;RIMBHI*E8RCJ\'UZ)C*EQT-05%';=%QEV.,\#BRY2'H&UTMU@FNN#\#\(5X
M7:I3<]64<R."Z0F'2!4VU)[53S<YO/N&4P\(... G==A'HW(7&X_5O3E2['H
M\5?-$4SUL!32ZK:.M$I33(V),QN,1*PD+&9-&"KDDTX!D46X<HB_B:0F!)2,
M;\<B$:XP\5GGX]L'N@O$<#)WS?^P>>C:_TP3#3L"GP#G3:-QDF5C3<]XTVEM
M+X)U:9;')4;8K>FCL-(QUN!\"8NLB"Z:_D(:3!DNHSTV=J* (L3#<8W.XVO&
M[:2%55/ ,/#;: CY^"R"291R>DM72%ZGAKPB38TJH\944U>F>&7/[MJ.8/JY
MQH\7[JEASI.GQ%;;WYC6ANQ%8.<.?\);7+Z4ACI2RZ=8J3K]C"<A=UMV<EJZ
M]]S-O%(42GE7+1L@NK<6/[N3@0NLEY] N[-F')Q:0K);;D#J%-G-]>(WN/C5
MRGHGXDGAQ^C^$1H1X?!!<NG[EY8<'EG.Q=E=.5U?>/OW;(T]S-TYR8"JX+;O
MJG#:-4@JL?X/YV:MY<*89<CFZ_ 8XR;E-751Y^0+TT<Y^N[91ME8-$\(X:&D
M7O+5#V-Y\JK8EUTEJ[QSYSI2*/L&F[N)6A$[>QF>"*Q576>M_AB"GPS$]3*]
MAY3]3PAD6*4O_+"DK Z2F54^U)N;B#@S(3\GC!1N],]P\*&<__3QT\=<&ICY
MIF6JR),#!],.O2B\&+EEE//]]NJWG.II!\ZR.6^+:!TW8")2R_8Q->,U.%0>
M6HN(W82C%<7M54RR8[-#J=NRV3)O5-.&J:E7VW;82^R$A^;K\['#WOL.,WH,
MC];SF7-S)TT\:GPQ!25J4-0X&D9DT#I"^,IUV).KU=-/@8QX%IQI_=.3QPR6
MR-*Y>)FW59ES+F#;')&'B!ZR;,(VYNBP9%B9#C?]=FM"JNQQ;EZ3*X>IY)\6
M6YLJFH@#4$5<+Z T**-A]/YC<_&/2/I:T3B"?965E?7T*7DU]0IJ$N2FMN"C
M-$430' 8?([[\OD&&Q"7@+[.8N3VS>+_;^]-F]LXMFS1[^]75"BNX\HW0(J#
MJ,$^W1&T9)^C;MO2E>SG]\U10!6(LH JG!H(H7_]RSWFSAI 4B)MTJB(CCX6
M"-20N3-S#VNOY9YD"Z/XC%[.OY.[X\17[;B"8ZFQO' 5/FJXDK(\:9RA;KN-
M:KP0EP7&2.6-DX=[E(CI)]:$@W[BX6@],?%$U8),Q\1R&9ZWB'FU@.J16O$_
M?PD24PI.Y$,$EI'2GD[0[SK 7L^5P$'I]/FDX7PW)+W5^?33AW69*J,V^:O0
MH[O85\6;).CB"$-[X#"TYT<C#&V$H8TPM$[\4R/.!AD@3"#Q,2\VD$**:Z-G
MAY EQBYATI#ZV/OR2<PCD4B?>I"0/HS.%>8&Y&.M[@;;;(E"HF$V>PDT!Z!,
MFE;K@FXM<=M5@&[V)MEW- K G?+.=2HZME,E2+,AUH6_OO/ XYLAFF:PE+0[
M*;^G_LDKELP%E>:LG0\7K5H*TA$BZ)ZFUKS8]8HA*)X'D'X7?W4J_Z;\X+-8
MW>(,18_2GM#L;LDE^\0*@U(73T0PEYJFX,DOXV63^K6R"Q8%LNUE66S"HJ,W
M2Y/(]T1K;N'[SQ\T%<'?Q-;-%NT.JXI2V5;"7#IBJ)X[EXPKZ9+COJ%]-8I?
MHF*A:1IMZG532S"<X2WKHHB6K#LPM"^&E,;H#X)1%IC<,GP=%!0$C$4=F)1
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MA>W7/(S>]98\0Z>Q1Z4ZO+2X5+ZP(L?9-$7Z.*KQ$9S9'-D6E7,;M1.EW-A
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MGW,G@ICL#B%LQ.!F%,LE875D/R/N[PT/&#.4=5>11'',H<]U@I20I<)#QK!
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M[3Q W,[)B-L9<3NWB-O9L[IP?\>B2GMQXV0/L-**7V>581? &HT2&X1-P&&
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M_AMS;2HJT,GMF31:BX ZG%5BO^)>XCC/P1@P+Y?FV)DQ3R6)3?@Q,RF49K\
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MC[]P+LS6MK@%^W*[YH,)%L5X7"JE)>,(9NE:K-S&,H.,O=CD ]#M($'CO W
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MUG4PRD4P!:K8B%F,*NA8397ZQ:29Z1VF)0*8D;%/=$&*"F04MU"*$YP?NVU
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M!$5]9N"RYD:R^[(@Q]H%"=A[.Y(RC.B'V[*XQ+F<VPF2JI?$'D3TYC'K*1
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M^1J<*.+0V:2D;NNF(T8JV<'OM^7&>7U?QLMF@$ZI7P$ -F28+Q0-_E\G9T=
MZ+Q$N%<:@WWH3NV\F]I(U\:Z^590#DFBN3,IMX5SY*W-.W&>-PAY<%MYDY(<
M.E)KT1V/C_P=DT9);5?.S5&%<<,DS#=!)O465]#GO+IYD.='M_7JA]&''>L&
M[8#7%V!'LP2!'6[9(=.[]T\#3CRS7I4.4CU;3&[UK.QBNF2'TZ*A)J3WSC^K
M%\!N!HJ@[-%[ 4AYNB('%J=-@:-.PA -$1=[1(MG>)L0+]RL*(%/LD!9#O=[
M>3S>L'[J^J>OW8,WJ,2-KWB.>:$,[_>#WN>5U-:$_UPZ<-ZNF:U8$G?[N]/
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M6,>MY1%M&#T4XY;;+O[=<WSW&.>I%\%O[Y[)]$&I(_\AQS(X"CI,H;V(3<Q
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MIG@9\3S#+U[R.Z;]V"H9AY%_AA/(.[E+/+"E=PV&6AO.,DRS#%O3D =\0)!
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M( 4#A276/@U3=88</PR.@C9DL0E4'"HSG2$Q5\0G*_Y*MB-,]QN5NA8 +H9
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MS.0$WGZK[]MG1$Y1@1X@DP0UWW)+%^42C->8-DJGZNA@%PZ <4MR#EPU19[
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MP,:3%\+\]9(><HCKOU">W#<(1DMZX/^10DSSE;%'X(PN_5)]XU7)II+)3"5
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MQS"&M':D):[L^@O4%MDT^'07?\HC7VN* !;;4,>1UNTZIB.!3W>50[:1UMT
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M]V99'NUV(3F!^,I9%UL4RZ<HCCX0E/8@KRU/#)]YQ1$_G]/)L8A;E8!\&+>
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M&_5&_0^4I@'ZFQ\E_JL?W;]>#=(::&\>[\Z[?_V]=_7[:70#0Y14]#PY1<=
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M)V<I$9Y !<N\SJ!*52Z%<U(D#VQ"C@?T"/E1[ZO6!F4B'\M[>'Q*_W"/_X_
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M9>^8Z^,JWOI!U-<$Q'L#PIB@XQV?<9!&[[_H&*.++Z,4B@O(*"NHY5V/#N\
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MCO+$'K@L;>A0KMC27AWJT[L3S*I4I2M#D4AJU-'RDTFY9!V0)>.5L<X=$64
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MZ54,Y",F>5KCIU2QO,%ZVZ8+Z^O#;!"'3Y^?B=987:/J[TZLDR+8++OTD^2
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M"R?(IE-:^C^*F".MGJEK[P1!$)LLP&17Z@<H2XJT^,P1\O!V6E%4$:A;MX7
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M4 50!EYD?(5&^(^D/D]M[W;XUHD5EE>[.>A@8K5?.$&4K&@IH!L\1?$S0!G
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M)L@TYUAHX)X2TE7YL$<"C[ODIML+/PU6BNG+VSHS]:L@W&=*5Z^JM;7I_X(
M8@VMS]_PCGAAA5 7FYJ%3K<BW?IPC52V!&T=W5U[<<SR6#,QE<.@N4UG%O[B
M!@M1.7JW;(T9@S^A0ZQI-.A4LL]TII-9["6US:7,J;J18Q;L:6TH$;FE-D7,
M@F?=#1FJK<8WY*E++;G-7,65)I[.AEM:G4!S$\PB+JK33=AHEIL%RWH*>XT)
MT"C;_DK9%J$7./ N,:Y9?LG.[!A[ZHCEE&A[G07L2%==76+K'8-/^'W\')^
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M6=>187& AUXAM$YO\&-7ZL>EO*]8 :)R:C!YP3[A%LEW\#U&+^+*-1BVIIV
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MW[;M8?HM/=X^'G/SJMR 1/&YC6ZP<D&R5"!/G[RPH)2[\JW2[5N;$2HYS[M
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M4T1,N]?CZ,#O?'[R +:/_&7W-T$4%:7KQGB@\WE[ 4RU#L^F5[1]#+WHP3N
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MI-Z0-YJ-!]XLQ4C ;[U1X5A^E(X&F>G62&9,'4C<,=,+>;,T<0,'_WR.$%O
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MYWNL;$\$M-%1E4YN2TS4C9AHFQ-$HZ.$6<:.LX%K=^#-C)32QYLKC(W )CB
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MA^6O1%[E*<1(FDH\%,F<8D$?#<+^TJN3X#.2TLLLSP0NSP0NSP1:7:,ZQ98
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M4YDU(^E><A0F/.NE[8RR.:O#.C[J&$PVPTX[TY"\@XX"A,,Q%'>BXZ^B2%P
M![DPIY,1M=IN@V+G]]$N3@Y82MB2R/0 LK.]A,5?UVAJ"CXLZ7K97*@'=>3#
M.5X)8[%D)IV?-A\85'\ZH:0F79\U#] EL8ESQB6Q:0GVRW;O7FW_-T^S9O1-
MH&MW8Y+B8&?;$"^JD3=Q4=EQ+K$Y(+N1%.24F:Y_YQ_*3W\<MG/J=/-\T) T
M7X-LWT_O;FN0MKK!)ZS/=!]EQ3%_D1!O"C\Z*6"N\VR]&QV:S:_JXBJER*\8
MB\F(>K[H 'S.Z!P-0,U/.@"A&I\?1J>@#R[ YXS.T0#4_*1S(KV^H>G7BLQ/
M30!P^C0@^UM6<B4)V?IU'_.KCL!I%!W(_JPCD!I#%S*_Z@B<1M&)[,^ZG\X[
M@K.:F)BAS9=K=>K+DM:K(Q%F9!J>16JOYEC+#--[EZ0V"WF9Y\!W-'W"%%CE
M(PZ.IVS8 F!Z8$0'@/\R70"/%9C1@99?%[1<'.+1@9>_3A<OHX24=.#D;PM.
M+@MCZ4#*WQ>D7!0YTX&3?RPXN2Q:I^5F-@,WBY[0GQ9LS."BK"F>J 4=L[E@
M:PQE:D',;"[F.F.G6C SX1O]:+%:+8B9\)U^O."PDX5/]4,/NSA)6P\]//M[
ML,U#L-[1QQ@NAB)LL?=>18\H.FE%<FL8K,)H/KO1W2JKPDADIC5OGW<V>XB3
M+/@#;*_C-,,L2#FC]#+&#JSCO9$.,)1^0G53/,)3?OVD&L(H<RF.[*? NDF*
ME-&V,ICOYX<\]#*P_93$*52P$/(A8I5/$/E72.!#"?%C&-<)KFT,--=Q<HP3
MN#_T.,]YW\SZ,/8<Y[#\&?Y+%Y;;:RN6(Y27E?JBA#S0&D31W]42P@5UNK,I
M@X-,NG;>E("AY'B2S\5 DC>['(?8\C[QD#P]B4N'L8>UED=U7<B\TRVQ1.U8
MQ\&H2XP)FL2.YRD:(\*.F>TX&*?R9.J(<2+EE'?I>[Q6>*&?X/_\WG!%^SZ\
M:FQO?QRA(@:(NM;9'B37>9) <FCD4-<O%0K/N,Q/3;F#"G^=YH(>NHKBN[3P
M#DA>YB$K&+M]7WDAE$/@>0] ]AE] 4D(NC./.MRJ S!]P8P)4SC$Q>])L5GB
M":0 E<M @FZT/"S)G.YSDIAMSA%5[+'!FR6WTCQ/U/%Z0'\='Q"<,*ZYD"8,
MUK.KNMOEHW?"W2]Y.Z-,T"O!L?"E"V'NIN76&4<;"6^Z,\$Y1^B%ID5M2,MJ
M=?=],SSMWK2G63K($4BP7GI0 XK)O/3 MSBZ;".D^1V%B@()(V!%V P<K@/\
M@GL1C[4F\>R"/$.1[#G'_6#R0*"9CXY[M^0!(6FI.EY=/!P^7>O77>?><Q;[
MW_9Q"&&?WOX[AV>PL;O^=>BEZ7J'-TOSVK''&KO0GUW,>$=7)[P_5F(H:X:Y
M8V1>AJ]4!9$@M0'E)7J,@>ZG8\\Q=Q2OANV#=X#_B0,GGL_U=PE,-':H1YRQ
M#QY#SP=4#PAGL+'-=^B#B03R6(/)BH=#'&&:X"0H=L>9H__\-0VV@9><&@3-
M8F/J>(/2"&[A/DVA2K[)41W((X :>/N\]Q*0/H#O^">Z6!*:K+H/(GA-<@A#
M],MZMP/HPW3G&6.TXGT])N N1U;%5R^!XBQCN"%I0\V1 499@4K\9AS$)/X;
M#?/4\<:.</^X9LJ-\^_F1%QA4)5(7R=/Z/6M=9ZEF1=M(5VR[3#Z--4.ZFRS
M!U^\Y!O(*HY!\BI=O26 KA*EIBK>,1%"+#H6G647J=S^ (D?I #OL?XQ+7]-
MN^U;+UO+H $6^P!LTSMXQ402!MTL[]%%S@L?\]<P\"O*HMIDHO/'H,*T O16
MF 0;4ZQ"PGK7-7<E,$"8[%SD2N@2W72/,J^L3ON/)2[E+8"P+[\V@T0D"4[X
M/MR$">W":34PA.*50JZ.)B@HUU>K(<$G"^:EO)V<W+L"6WUT,2+@79);\D&
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MA%I/9],A1O7@. IY\WU^G,\(&=-=-/4Z,FL1H#/A;!K)'WK=3%.OXA@WZ4;
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MWQQ?7=0S5RPYH*/':",[+539*SBMZ(;J0@J[ WS9=1@OJ'*7+Z5]TW.M;'"
M+PE.[ 5;[K*FG+-\DAFYS7>F:@=;.R<W79)R"0LO2;E+4J[II"\W<KJ6I%PR
MX*A/_!'/3AMM+]Z71-PE$=>T'6EADJ<;0GM)Q)T:8I9$7-L<L$LB[I*(.VD
MV\<#2R+NDHB[).(NB;A+(NZ<\U>61%SY1%RJMVKJ\',X7+FDX"XIN$L*KJ52
MP=ZP^)*":[\)LZ3@3D1'+RFXTQ&<2PKN=/AR2<&=#E\N*;C3X<LE!7=2K#F#
M%-S/ $(E76VW0;'5^P@[TM _+FMZ2WFS&+W^$V08!1'$5X2>'0>1'X"T=VEI
MOCPL,DWQZ\KT3Y(25(6FC/J*ZW6<H];-1R_)3LA;1'FZESALW(>%P3%/_#VD
MP]5; C#'=C=%3+R4FVLNDS*)CP#N!7GM$%T@J7,LQ!(G>TYDIGW'0EMC)LJ*
MS)SFL7Z'<MW+PTRUJ%HEWX!W%<37<7(DO]I,&:5X'U=Y$&ZAS,,]XZ$RI.^%
M,M)<,FL"/-0!W@MOTPRJ]0J9M+Q6VG#% 'W.H=I 9LL-2/TDP.8$"9S$<>;R
M%LK=W$?0!*'F#[0'.1?'E[5FZL<4N7:%S=$);CA'QG2J7B\C6RHV@X'_8"++
M^JH?!!0W?-P%Q@ SJ!79%]''CD"G5/XC@Z<V.NP&$^?M0]D[0BUN2;:1HX 8
M8*/68*"99HZ"8HCVY=MZ-H>WE&M>*<EC,V04DPG#\'8TS'()LW1M>2>=G.>S
MI]W#+YY/!SV?$G=1[-]&&TH\/\N]$#V;R7"Y48=;=0"F'XHQ80J'T.5#6^]V
M@8^R*S][KW&"IIWP)N@^+,X,@\#.H(V7KG?7"8#";9UGT,R)D/&W.B";F0IR
MSK3%13-/%PU?E-H,#C'O!$]-\. P(4^$&E X[W405UVUV."I$$<A<<GU@:^+
MG+Q0/(#L<YRFCR#!F255[0+*/\DS?(58[ZZ\-/ AL&Z",$=5+NTIAE\4OO62
M""*AW@[>+.T>(CC)@J9CQ!U>G1#QQM%UZ*7$&\SP=<P=&3FN$#<6.4R(\.((
MWV_I=QOV'&-'Z>R&>2T@CS6V]8(><&M"9GNL_CB3^0V[ $LB>AI#-4#Q#>LQ
M 7<Y$L)?O03GHM.O5K2AQL &I7?A 4. 6;U#T8WX?Q,W,+N/0ZB14RPJ*+"5
M7<78<3O9CD6%9EF9ES:4..NP<FO8=M12:_=V*W=8ZBKFI"U)L\GH>WNV7@)7
M<//5:.>\&'(F&[D9A+!=9/451>@F+V09-:%$L3^LA@3_VLJTJIK')]@PKA]=
MFE&:1I'-AQ]03"]Y(VJ)#S8G.1H2%F80MLWJ^NFE>43: G8T6#X<0I)&L^.%
M8<K@0[>T=4#H+S9#B&*<ZX##KR[!H;;TI^ LUI!QLKB#%W?PX@Z^U!ULG]N2
MD9]5FESW:9HCTGN!$+C] 2\'00KI%>YCU]H'+65+<A7%YZC619_O^7%((\PY
M^A&/KW?E=M;)$[)D^%Y![K3%&;4XHQ9GE(F[MI7^J,'2W68(+4XK8Z345;"S
M<\GP]?84;I1GQEE%6;!%E^7@'3P#/X<G"T!Z^\,/<_CU.PC-:R_T\[!,4;(K
M)TE@\\W\JBXU\*ZKRI:WX&)[X5G$;KU*/F*NHP-Q]]Q7_+C3S%V,#\<P/H'B
M)=2B014SZ8@^WC*<"%/4U8F\ .L!.HU?M R,%Y/VQ94UINF#6=ZB9FUCH'D"
M:98$/@J4U"\A/SV_,"4 >\[RM*@".2PN@4UON[2!F1MNCW'6.:7:D"2[L=38
M8#;?W 6N9**JJ.7CHALR5D-#[ D0_29.JY<%%_Z.@)15D6893"=3VJ933BHR
MY6R&\ #'ILI[NT)HLSG$<9_I$!7%L;8=]Z,.@<BH+ZR-F,9VL0&C$PXC)JL-
M@4/G2N&D*_VYN'P\@6.<H)KFQC-DQ2^W/U!+>5#TAB__AK7>*MJ6_RS=Z(;=
MY]V3/ %XT?*#$#5]@_N]BY,UU%<>^NF<[XY40SD1I?)&&'@>E'L\;[JNKQET
ML)0'*'4D>_MI>_\LA[J"A4=MQPZWM<W]; V)/7E'_0S(?>.)PTQLM&!$O(>4
MVB>>/M:]+6ORTW*?$ZBH$E(QYE7JSJE#C3%WS7,5ES'=8+31JIM[?]K\_/,O
M]&S"UN^&<4U]/((XT#7"-!_Y@!<. *VU/>H7 MY!&!\;M@?=O<^8HYY8?_WY
M Y-8S[^;XW-DI V!I<!$Q0"]A79L FUC\D?Q?NC0%I]L#!6?0 2E: AWMMH>
MH#$/+]0>NERP\<";I1@)N!LR%8[E1^EHD)EN+FND8ZECZD#"CQDNY<W2Q T<
M_/,Y0FP!LP+J =Y$*Q.CJ*D4$$[T29IX8C JY!9PM1..&Z%0S4Z!ML_T\@NT
MS>Y^_IL?K)MS]>8'XP;HR.%)D;J+3^]\3$WD)M+D%NJ-U.'S<[T;Y_;ZK:NO
MU4<6>.F'=5D^OW%$HPU'3D]C^\N.[P;?"T=ZU3F1Z8!SH.6RP+/"8]HE3'>
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M>O>"$.F1NSAYAAKT_.+7#7C-SO_JJAFW$,M6I\@;Q;"5'#BJ&,-6#56\L,A
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M]#@A4LNXR00N 3ZKZQHD_W"4D 3OSU7^AP^7H-0F_.PH! ;(W4*ZXK.EMS]
MX@<IBB,2(.$2( 1)H>^=HE0QGP%B>_Z_:H"4A>HW92,L8L'ZV??F<*1F,(0Z
MC6[.P'"AL$ ]+#H],RI*.3,6P73Y*-^)<Z1Z!&GX= L4Q!=8\GX&8(+AM1##
M!&D!<YB02,H@8TI\ :,-TL:/*A$ZK8VX":--CX9D7A"!-G QVV0&PTH6DQFD
M!88>$EUO?ZHR\HK7.0WDA+1.;V #YAK84O(9B.1 &:P:]8JR# @X5;.RP>8S
MC,@W$6.L&<:U_)#P-5/K#UC0.!#(X6GF,8E3C!]$.,8L@T+J*HIECFQ0N"];
M)%<86UT*AG 'Z$&QE8V3IW"\5NQ>P5E%#WFVHZM4&FP-L\0NZP4\U5E<W:45
MGU@N;MD_EM1\DSZ0H:%(FLMDX'J*T2<>1NRC3GCN^-)<-MHW2+!+?L1@.;I,
ME(](KU)+&*_W)H3NB*>BC[="T%!B;UR!0IYGL*V&<!2->#3Q^18=42PN)GA>
MH<4L.GPOY"5XSNX\NXXD%;D2/[',LO95!2./71BG.33YD>6?XC;RSRBTF)S6
MN]HR@&JC(-/J @B/V3PT5+ 'U+XX@]<&&PJ&K_(TB.#U%.KOUR#"HY^ '[]%
MJ*3[?@L58; +$(T*G*IL!DQYX1H;&WH_5Q)9KY6?[<D;*J'">5]<-[YG"/$2
M#&U5IQGFQ4C6XPG6HP++@W.WB(947>\JB E"$[5F"+9E ^]- F^/A?WPP7H@
MZ""1<0BQOE*TJ7^&\&Z\XJ<+V!P1:V=NYJ1,"_)-C%;R/G5TJ,,#X3.G2L+0
M0'[[HTPP*=%4-I6:)2;&-3Z*?*!&!M L83X.L/E]B.8$\Q&4;,>$F1-TV>IU
MG"]2T\=GA(>^9%%NVG">'UV /L;%?6A_DG&<PN-(EH[+6/-'%4=F1_9C]J.V
MXVY@$J0X+@U:\7"\]IN&?B8V'?0SY+P=%[S,O2@6G8(NWZ:PXTVQB3@8OFA1
MG-*7L.F@BNPMC20^)=%!<;=KAR'YNY, :<.EH!& Z"M.&9\,3_?89BA]*T8A
MJM1G?2E,56YF$FQ-<E+KMZ;Z'YT$,&7KKL?Y]B1 *^ !-> H4969.(+JXG@R
M]2HK]L=M3E^L4Q6_P)W#?^-D]W,B8U'2[84E#%IGW^R];)54$[>K[%P0$:V>
M4%X\*@JX\M(@M2?#L3A(O=,S($@>WTZ#@U5V[27)"1X*SW7IH8H:D0W\"0*!
MW5[/]M0>*7RSR_<(/>%L?>*+>^IN"POJ>*/]4%B\1SP'9Y*QPTBR7^=4HK,-
M=B#@E\ZQQYKC%&&6)S..Z'2;;0!&1P1_#[9Y"-8[^AB+='L'&6T4E(6UJ$M)
MFF&K1$0%=-;P_?R S@2VGY(X3<_OW2&G]!4"#F@^ >G"VV FH8;<^'VH.?!<
MD Z@<:T-^3=<S,A046!P9"EW&5L/+"HDAD!!<&WG0-.1!$I!TU[;&M#,Q]3
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MYW ><E_=@-1/@F.Y8.'^(OXVX&:F^PR?-K_^_*'CS6[]S4KN)W67IA24W.0
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MNSI6H8Y""H&/NN.%TOOVL]8KCYV-CLX@_Z\_(XBG_AX<O/_S_P%02P,$%
M  @ :H ,6Y7VXFT#"0  8$    \   !S;&1B+65X,S%?,2YH=&WM7%MSV[82
M?L^O0)U)QYX1;4FVZE12/9,F.3-Y.6W3/IQ7D%A*J$&"!4!=^NO/+@!)U,6.
M&]NMY*HSM4UB 2QV]]L+0&0X=H6Z><6&8^ "?[.ADT[!S<?_)9>=\\[P(CPB
MP46D&*9:S)EU<P4_G%1<"%F.^F^KV:#@9B3+/J^=_D86E3:.EV[P9R)+ ;-^
M>Y!,(;V5+G$P<XF5?T+"Q>^U=?U.N_UF4&DKG=1EWX#B3DY@<.+9$7*R,5GB
M=-5OG_=DN1R\.RADF8Q!CL8N-FV/E^H934OLIMH(, F^P5F&U6*"7)>!,V2I
M<G%!8;J!;\MY(=6\_YLLP++_PI1]U@4O%X2I=DX72.M7R)4<E7T%^7(@^AM;
MXY,)S!(#-/:"A^E8.DALQ3/H5P:2J>'5H,%8%QF[CQ??=@NFI'66N@0OFJD4
M;MS/4?H9M@/JY>3FV]>=[]J#X07UN!E>5/@_"GLI]$QQ:W\X*3AVCYW\;WP&
M<[)@=Z&!WDX%/JMHO0 WQ9=II4W_==O_-[A;F--@*ZE68K#!V]-(]^-L+%/I
M6$!1D/%>,LJ:%O  ?7W1 N]16893@ME;G;T'XV0N,TYVS'3.?C:RS&3%%?LX
M@ZPFJV8_Y4@!AE6UL35Z..8TMF9C7HZ O<L<^UPKG+]SR9/.U2D_>U'*_VJP
M[KGF>2E8IR>"QEJ,6\:%KAR(-37_"IFWC,MVEZSC5VY27H)-?IHIF'O=X]MN
MN]U]43I_#.!]^#MA4F @F5=\!%]I $\M@T\M]D[!#-6.2'Y?%ZENL<RC?\[<
MF+O^8S3XK IKA&:<OTB4M"X!!07%9^*A:D1G(6VE^+R?XUJW5$JY%ZYW,9$G
M2JSCQ@V\\A(:W_93;D%)8F]#S2MVK\Y[E]=OMO7^3XDO\C/%+"])#?#;_BU
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M>%\?0(J'VQ6F8\'^)+S -*K/Y93/K3<VPPOZ$P WKX87_H\'_ 502P,$%
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M2BH@"ZL"B&'8/K4;M=6235F"*&HV=15^;ZAK-UL/'-IR[/;)O<;"-W%+PZ(
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M).$, '-L9&(M,C R-3 V,S N:'1M4$L! A0#%     @ :H ,6TZ8[FDU6@$
MTXL5 !$              ( !&TH0 '-L9&(M,C R-3 V,S N>'-D4$L! A0#
M%     @ :H ,6Y7VXFT#"0  8$    \              ( !?Z01 '-L9&(M
M97@S,5\Q+FAT;5!+ 0(4 Q0    ( &J #%LH'B!]ZP@  $-    /
M      "  :^M$0!S;&1B+65X,S%?,BYH=&U02P$"% ,4    " !J@ Q;L7<:
M-N %  #B)P  #P              @ ''MA$ <VQD8BUE>#,R7S$N:'1M4$L!
M A0#%     @ :H ,6W9=.5#>!0  T2<   \              ( !U+P1 '-L
C9&(M97@S,E\R+FAT;5!+!08     !P ' +(!  #?PA$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>sldb-20250630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sldb="http://www.solidbio.com/20250630"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sldb-20250630.xsd" xlink:type="simple"/>
    <context id="C_80913da5-18e0-4e2d-9932-f1f9a150ed8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_81638abc-ed31-43b9-98ef-a8496af60b08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_8254bb6c-0764-44d8-a999-479ae11715b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8353f2de-6a98-4421-bb84-ff19b77babb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sldb:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_83ce3b1a-e318-4538-962e-ec2695fed38c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:ProbabilityOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_84148e2b-261e-4a0d-b76f-daecd9f88a20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_8466f2d9-6b68-47d7-ba93-53848911d53e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_852de8fa-b9b7-41ee-aac7-7d5c2c175c8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sldb:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:February2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-19</instant>
        </period>
    </context>
    <context id="C_86fa028f-2418-4cf6-b959-b70470ee2aa9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_888d7863-e043-4b8e-9a9c-902e9e4efb65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_889a20b7-df33-41ee-923b-1fa83b319dc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8930ba8b-d153-4438-8796-eeb7f6030e7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8b6d4398-1614-4734-94af-3cd9579e2b1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:InternalResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8bdf85e3-0c40-4066-9f25-f31d21aef5df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:TimingOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_8bf9e100-f231-4586-b5dd-838b0884dd87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sldb:OfficeAndLaboratoryLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8d226a90-397f-41ab-935f-5aab9dd4c71c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_8db1bca0-aca7-44cf-ac19-c26a69173dfc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sldb:UnvestedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_8e05825b-3564-43f0-9df6-8e98b1d7be91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8e9b54e8-5db3-4a2c-8d9c-a1cdfcf765d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8ebf87b6-992f-494c-8560-27ee2a653d27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_8fe8d85b-2d6f-43f1-b624-cffb99addfa2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sldb:AccruedMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9123b419-0bc2-4374-94a6-007cd47c652a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_9357a2d9-9713-42be-ad31-6036ccaefd7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sldb:Fa212LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_944b7695-ad9e-4285-960c-d72aec8f998b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:SGT003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_9611295f-24d3-4b23-a0ec-62392a8b5c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_96ed23d1-a1e6-4659-bc21-14e675a602f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_96fa1fb9-5125-47c5-9d54-82197981893e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sldb:GovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_98efec03-6261-4884-8666-bf6095a4bb0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sldb:Fa212LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_99ed3715-c191-4bd1-af0a-a1b55b1bcf04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sldb:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_9a0af20a-6059-403f-91cf-5541fbb0763d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_9a594a20-a7ac-4b49-ae92-d855f2517334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_9a88d8b1-f41f-4be3-91c2-23b45a6dd969">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_9afdb802-6737-49db-88fa-ef76a745ff30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sldb:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_9b1b1aff-b775-4fdd-b8ca-07668edaa8ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_9b696383-da9c-41fe-9065-748e255e49a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sldb:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_9bea4674-820e-4575-bad5-37c016a585cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sldb:GovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9d8cd037-690b-4ca0-a376-cbffcf5bfa7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9e42e73a-a6c9-4461-a752-a23c4b0480e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sldb:Fa212LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a1407b45-da9f-427b-a243-aed2688829bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:SGT003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_a14e5cf5-aed7-466a-9751-7832ebbdde1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_a4cf9151-2ea2-4600-8153-d60667cae2dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sldb:Fa212LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_a537fa02-a1f1-49bd-84cb-8936826a3d3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_a698c408-5f01-47f3-97e9-aa9f2ef0cb86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_a77281d0-83e9-4ceb-b6cd-ee4c4377550d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sldb:Fa212LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_a81e0a2f-1838-4bd5-b00c-b952678b1b8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:SGT501Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_a91acc16-ec5d-42f1-ae23-d52f464888f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-11</startDate>
            <endDate>2024-01-11</endDate>
        </period>
    </context>
    <context id="C_a99a7b4d-7291-4c75-bfcd-d11cbca34f46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_aa5bd7ea-c156-4475-926c-e8eddecefd5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_abb48ec4-81de-4bdb-9fa1-14513edb7132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_ac9669fb-6c3b-47fb-90e4-6286c0192e44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_ad417689-b70e-4fdd-8ee9-88aa9781e90b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sldb:TreasuryBillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_af5ce639-0ee4-4ebc-b2dc-3c8e938ebf5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_af67bb44-76aa-4851-ada3-634e88aa092e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_b0005526-5d37-401c-9d72-c06da6f9106f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_b09c9e6d-7e59-4302-a92f-007cfefb2664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:TimingOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_b1b96c09-b829-40e0-9943-61aa3ed9067c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_b1d34379-d268-419a-8067-a8edfa178a20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:ExternalGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_b1dca8da-6809-47a8-bc34-ba283cb61a5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:TimingOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b4ad5fd9-ef1a-4596-931b-e54dc3cf2c0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:ExternalResearchAndDevelopmentOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_b5119432-e3f6-4b09-b1da-c2228aab8045">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b83fb99f-5542-4814-ad4c-4ef8642b65e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:ExternalGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_b8a19bcd-ecaa-4d90-ba75-094d33c6ca5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:February2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-19</startDate>
            <endDate>2025-02-19</endDate>
        </period>
    </context>
    <context id="C_b9aed1ea-13eb-4016-bc97-d2029636fac4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bdad8e63-34f9-4989-b0b3-c9137d6a4917">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_be22b5d9-efe2-482f-aa0b-2ae151a5a94d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_be43a57e-e5c9-467b-9ef0-ad48c48eb300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_be626f41-f068-4534-943f-caf740d9baca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sldb:AccruedResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_bef71313-6e23-4dd9-8241-70fe0eb1517e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sldb:AccruedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c267e437-1d14-4b97-ac07-f8b08257fa7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c465dc2b-b8fb-4093-a52c-31899dca9507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_c599352c-a66b-417c-85ef-0627fd3a2f3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sldb:TreasuryBillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c96a2be2-695f-4030-9b68-3a5f63eb3737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:InternalResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_cb1343da-e01f-4ce0-adcf-425c15f992be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sldb:UnvestedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_cbf823b0-60bc-410a-aeb8-2f8b923dc7c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_cc190b1a-b3c2-4730-8745-e9776ccd432e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:TimingOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cc99c4e5-1df8-4c44-830a-6d130cb72576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_cd72c633-01e1-43fb-bc8c-26f766ba3391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_cfc39ec9-d790-474a-94f7-86f38a3344d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_cfc4b4a2-204b-43b5-a661-f05441902b21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_cff1f316-69c3-4b3f-a8d5-620b81ea7de8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d3cfa6b7-1a5b-468f-8cdb-18aa29db656f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sldb:AccruedResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d565f4e4-dbfe-4ca6-945a-b8666899b153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_d8ff73cd-5ef2-4164-872f-1f12e3c684c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:ExternalGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_d9216090-1e30-4279-8a28-35be3c27b884">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_d97c1211-c3a9-4ea5-91b7-040fde3392b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_d9af6823-a26b-4885-a9fb-907deb94d20c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_dc97493b-5647-4a4b-aaa6-bd066ad9125f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:TimingOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dca2999e-bb17-4181-8e87-86f8da45617b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_dd44ede6-4ec4-41dd-9ad2-bab26319cb0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sldb:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_ddbae127-0489-4e1a-9f96-5243dd079a21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_de18e3d4-4b86-42dc-b5ca-c6702ad6d2fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_de9d66b8-e543-4914-8cdd-a9d5b58ab10c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_df55ee2b-223d-4c46-ab63-80dcac637cef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_e13de2f2-ceab-4e18-9846-718dd592da8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_e1fc1533-e5f3-4a29-a6a7-15d22fa44a9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e39737d4-96a5-4208-8dd7-4b8993b23f93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_e445144a-7061-4fa5-ae92-64b3821a428b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_e481b2b4-78e4-493a-b1a7-9caece635448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_e604e914-7ff0-4f04-b45a-8f2f9ce0c9bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e6208aaa-c289-4498-b410-b580516620c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_e6263d79-32c5-4715-9a16-d2aa12863296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_e87fa31e-fdf3-4012-9418-bb7b976dcee5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_e98d2034-0473-4580-b8ab-275ff9f46ae7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_ea7a5a80-b49b-47e8-a532-b9e2fbc30677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sldb:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-11</instant>
        </period>
    </context>
    <context id="C_f1fd8b2d-e76f-4251-951c-312c4df54169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_f2a02817-6c5e-449e-a477-05d0a714df5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sldb:TwoThousandAndTwentyFourInducementStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_f2feab69-5f72-4f85-8dcc-ead4e1b51215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sldb:AccruedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_f540fe1f-6760-4c9b-902f-500441ab7298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_f578dfc8-5ea5-41f0-905c-c47b2fe1a24b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:ProbabilityOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_f6440943-092c-4f4b-8ccf-fb54b31a4a23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f72bf3d9-6c7b-4a2b-a09e-4c623d761a64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f86d33b7-2665-4a04-943a-c562c8410bd5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_fb4b367c-a294-43f5-af08-b0aea809fc01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sldb:OfficeAndLaboratoryLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_fbba6851-1a6e-4905-b021-c0bc7d5f40f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sldb:AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-11</startDate>
            <endDate>2024-06-11</endDate>
        </period>
    </context>
    <context id="C_fbce7cd5-1b2d-4126-b546-1df19016fd56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_fde676d0-416a-44d0-990b-c79ab2d42ba2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_fe6f9f56-6572-4eb9-ab24-7440ff654b29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_004daa09-8340-480a-b520-e166a80e5304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_00a86f62-54eb-4a64-af3c-51b16552e396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_020b0edf-b857-4f10-ac8b-229a8c436b55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_04579f4c-0d92-4807-b526-47e70d33525d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_067da7b3-96d4-4d90-9b0a-89c4f29d4125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sldb:AccruedExpensesOtherAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_07264e86-c26a-42ce-a8e5-89f7da5029a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_0a6c72f5-7161-423a-a27c-3a3a231889bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_0afad434-c6ec-493a-ad86-7a15c47c34be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_0b47160b-f65e-4831-8696-c2c52dd0bc33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:ProbabilityOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_0ba68b2f-2dd1-4b87-be43-3f478cee6225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:SGT501Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_0bea57c3-1523-47ea-b446-8474ebbcbd5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:ExternalResearchAndDevelopmentOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_0c822986-4362-4137-a232-16bb78f035a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_0dbb79eb-088e-4b58-8b14-1c279ad90bd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:InternalGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_0dfd0d13-a826-4ebd-b93f-49699f6c04b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_0e4f4078-c836-4440-84d7-12e84fc594a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_0f922a3e-5746-46b4-a40a-2a645e0ec579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_0fbb6db9-57f0-4f7f-b13e-14af89636f51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:SGT003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_1159e041-c22c-4bf8-b89b-c533c983f202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:InternalGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_11726ae9-e40d-4c5b-83b8-8005c97ded06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_11a10128-fba6-447d-a976-5fa084bf9295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_121327c9-aee0-4ee4-85a3-a872dfee9989">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sldb:AmendedAndRestatedTwoThousandAndTwentyIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-12</startDate>
            <endDate>2025-06-12</endDate>
        </period>
    </context>
    <context id="C_1289e95b-8da8-4d52-8d1f-4b8964a89bb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_12e60ca8-b4cb-4f88-953a-ab24ae966a5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sldb:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_14340f1e-e345-45e4-974c-789fb31cb960">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_15fd7743-86bb-49ec-b84d-abc109f772fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-11</startDate>
            <endDate>2024-01-11</endDate>
        </period>
    </context>
    <context id="C_1679319c-e556-4669-b19c-516102e53d80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_176c63c3-fc59-41a1-a932-f7bf7ba8d013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_18030d3f-b395-4cc3-997d-b26bfd8329d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_1a3c625c-1186-436d-91aa-d8d2544b7b4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_1e06cedf-6a5d-4473-b93f-a7e7df103a67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_1e60639d-8283-41ae-8cd9-7b46f80766be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_201319f1-99d0-4366-bfc4-d818dfd528d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2161a6b4-6f9c-4f31-a82d-4f7221bf0362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:February2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-19</startDate>
            <endDate>2025-02-19</endDate>
        </period>
    </context>
    <context id="C_232dc221-d840-420d-bab1-6b1e75c2fc36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_253f834d-9848-47a4-80e2-b6033edab9fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_27139884-7a96-4e34-a577-e29115f6dc2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_2724230e-7cdb-46f3-a217-d029bcdf1d1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_28011c1d-5f4c-4932-ad90-695a175099ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_2ab7d9ae-f3fe-411e-aa31-941b38ba994f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:ProbabilityOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2ad125fb-5eec-4263-bb8f-8a0e750525f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_2e4a7c1b-d7cd-41ff-9b20-980516f53df2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_2f3b7b59-d24f-40f5-8461-a913f95f8f17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_2fba1c08-32ae-4049-8fbf-3094c4c366bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:February2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-19</instant>
        </period>
    </context>
    <context id="C_3189d97a-043c-49ab-94df-6b80295ced76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:ExternalGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_32a641e0-2697-41b7-a866-ce0eb5498572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_360e00c1-d83f-408a-8983-fda0502e6613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_3a78b22e-0dc9-4c13-a887-682de9fd6013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:SGT501Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_3b99cdb3-b726-4538-afce-a3801788fd13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_3bc4e127-2055-433c-a159-d00bb0f66d84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:InternalGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_3bd6d252-5e42-42c5-8ae2-0186828da84b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sldb:TwoThousandAndTwentyFourInducementStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3c01f597-7579-48d0-bd5e-4b0f4f5104a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_3d8b7096-5d1f-45b8-b514-de72cd28a61a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sldb:TreasuryBillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_40de0e1b-6102-4d68-a514-295bf97cabb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_41f2e884-47b6-44f0-b8af-b6fb07efc6e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_43201d5f-3fb8-4b8f-bcc4-042087291ecb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_43934480-1ee4-495d-8199-c3e8feb3750c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sldb:Fa212LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-19</startDate>
            <endDate>2024-09-19</endDate>
        </period>
    </context>
    <context id="C_467782df-d0fd-4099-acab-ff5bc1e9ec7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_47b90c1a-3b38-4665-b877-e9472f8c44fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_486f1e6a-12ec-4d97-ab93-1669ee41521b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_491fb316-de76-4866-ae64-7e0adfba538c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_4a834eb1-0754-4f74-8286-ff19658ed3c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_4f06942d-922b-469e-b680-72ee9ddfb246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:ExternalResearchAndDevelopmentOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_4fd6bf31-bc0e-49ed-9f27-784e94385c06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_509be445-ad50-4826-9d85-bc19b599ef83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:TimingOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_50c05ebc-0ef9-47a4-a21f-7d16f9e48827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:InternalResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_5102f076-6976-4786-8570-ddc9fcaa4fda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sldb:AtTheMarketPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_51655aef-3697-4608-9eff-6b7264ab13cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:ExternalResearchAndDevelopmentOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_53878ad7-f60d-4fe9-9496-c94de89a86d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:ProbabilityOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_55f5bc14-0f86-46cb-af50-0c8b568c21fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_56e1e286-3df8-4b2c-bde0-b81555ab2370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sldb:TreasuryBillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_583384bc-be95-42dd-89bf-a2fab8449504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_583bdf28-4c22-41d2-bf7a-5f216b481995">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_5a01998c-63bd-4627-945b-11d0879cf70c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_5a879064-7c82-4954-9b22-68f6cb214734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sldb:AccruedExpensesOtherAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5b2c2df1-3cdd-4a8f-b2dd-15e41f28a290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sldb:GovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_5dadfd3e-8058-4606-b32d-a0cfe60eb067">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_60238495-82b4-4a9e-8f0c-dec2e85bad33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_60a0c528-a68d-432e-aab7-f31907efd67f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6402365a-b943-488b-9bd3-756393cdd6c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sldb:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_64acb9d0-11e7-4835-9467-65098353bd5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:SGT003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_6573f6ee-fbf9-4133-87fb-c760c893c038">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_674b0646-86dc-4ece-b574-7ef26e78d9f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_67fc3ae3-0a38-4bcf-a5f8-68d2ff13b334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_69be95bd-262a-441d-b2bd-98d19efe9bd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6b0dcf24-e56b-4005-a22c-bc5fb3b0c9b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_6b51695d-2c24-4616-9d6b-cb74e1484c1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
        </entity>
        <period>
            <instant>2025-08-07</instant>
        </period>
    </context>
    <context id="C_6b940487-af87-4229-a014-aac844c38125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_6cd19d05-d8a7-4151-a703-c33e74dfa457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sldb:Fa212LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_6d1d0185-6a08-4a4d-bf78-3cf596bda452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_6d7a65a2-794d-4455-9e96-273e3ca49062">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:InternalGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_6da01f39-bdb4-4e8f-b42c-7df09d145c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6fc1a0fa-31ae-4532-816a-741e0211781d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sldb:GovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_6ff04018-2bea-4ce0-9148-099fbf986bc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_71f48d56-146a-435b-9b14-f7e66b80f25a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-11</instant>
        </period>
    </context>
    <context id="C_72a44744-a858-4632-9155-e3c3f22a4ca6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_75db7873-c2fc-46ea-9e70-df62f468e4fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_7621a0fc-5398-41ee-bdd0-b6ec3eec8693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_77693677-27d9-4472-b43c-7dbe442a2eb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:InternalResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_78d04ead-7986-4a8d-8aac-14a63c569702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_7aca4bd1-bcd1-48cc-9174-dd70c602d117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sldb:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_7ad823ef-64bf-4820-ae9b-3a36a9790d50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sldb:SGT501Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_7b3b5780-a030-4090-8d67-27c854d7392e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_7d4b4b58-8e68-4c67-aaf1-47f818c7a79f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sldb:Fa212LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-28</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="C_7ff2cf9c-d175-4659-8c95-55b9ec8a0868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001707502</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sldb:ProbabilityOfAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Y">
        <measure>utr:Y</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Segment">
        <measure>sldb:Segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_f5ded806-230b-4664-8011-753569c38b74">0001707502</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_13f7ae0a-ea3f-46eb-a941-70f57ddc3a47">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_8a6adb43-91a2-481d-877d-ef5fce7f1ff4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_baff5ccb-e6a8-4cf7-a384-1b3280c8fc2a">Q2</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      id="F_7ed96db2-e2ed-4040-b7b9-483f0b1967e0"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      id="F_29f36a27-1849-4abf-89d8-42fbc895f4a4"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      id="F_fd6a424f-9e78-46d4-9165-086964b4e16b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      id="F_3f4e1821-c913-4d84-8c0a-80ca54685688"
      unitRef="U_USD"
      xsi:nil="true"/>
    <sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1
      contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c"
      decimals="INF"
      id="F_48d73115-07e5-48ba-9dc8-452243c36a43"
      unitRef="U_USD">0</sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1>
    <sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="INF"
      id="F_08ff9217-3602-4409-8438-1bc1896ee246"
      unitRef="U_USD">0</sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1>
    <sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1
      contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c"
      decimals="INF"
      id="F_1be8fb40-e397-4eaf-b81b-88444ec1c2a6"
      unitRef="U_USD">0</sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1>
    <sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="INF"
      id="F_f576a497-b1ba-43df-9267-28b759106728"
      unitRef="U_USD">0</sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="INF"
      id="F_7f2d05a5-0a5c-4f59-b707-ed7bd008cae6"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c"
      decimals="INF"
      id="F_0a9b999f-ba3c-4c75-85b3-624f3daa13ec"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="INF"
      id="F_3c78939b-2f88-43de-94c1-2b2dca662653"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c"
      decimals="INF"
      id="F_5fe053a6-d452-4df1-bff8-51707a501d58"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="INF"
      id="F_2eb056d4-25d3-4b79-9779-b2b71429c937"
      unitRef="U_USD">0</sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2>
    <sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2
      contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c"
      decimals="INF"
      id="F_38c85a03-f1da-4bb9-bee4-e34e8e64f14b"
      unitRef="U_USD">0</sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel2>
    <sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="INF"
      id="F_981c76c5-7e07-41ab-a103-d0737a7932bd"
      unitRef="U_USD">0</sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2>
    <sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2
      contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c"
      decimals="INF"
      id="F_81ea4290-b268-4d22-8def-51b3d1505ec7"
      unitRef="U_USD">0</sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel2>
    <sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="INF"
      id="F_3a22dccf-9544-457d-a4be-457034ddacdf"
      unitRef="U_USD">0</sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1>
    <sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1
      contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c"
      decimals="INF"
      id="F_cb4f10ce-e1bf-4e65-ab4b-c31784741e94"
      unitRef="U_USD">0</sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersInToLevel1>
    <sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="INF"
      id="F_4ad198f7-47e2-4a32-bdfc-243a9a08f8d7"
      unitRef="U_USD">0</sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1>
    <sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1
      contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c"
      decimals="INF"
      id="F_d2f01e79-37d9-4163-914f-7030affd467c"
      unitRef="U_USD">0</sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersOutOfLevel1>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_1cf5d347-81ef-4291-87b4-2b55905c5532">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_8e15066a-70da-4663-9669-32cfbe205d12">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_de0fbd29-bb7c-4fff-b496-61c9ac711a0e">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_a1882ff9-f1bb-4740-a162-637230c0b28e">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_32929bba-e059-4bf6-9e8e-569dbd587654">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_50169f3f-0f42-47be-88d8-59be20e7aad1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_afec392a-2f00-4bc3-a74d-d31c078f0dd8">001-38360</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_e3cc7a5d-6a8b-465b-ba16-73f52ae50368">Solid Biosciences Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_7f03510d-3476-4716-ab2f-e45d242a94d8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_367eff5f-14cd-4794-8537-d0b6e8e3b250">90-0943402</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_6d014bc0-1bc9-4565-a9dc-13cdf577f204">500 Rutherford Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_822bc2e0-bba9-4980-9841-a83d306739a0">Third FloorCharlestown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_36ddcffc-8224-4e75-9bd6-0b3136d70a5c">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_3084a607-7c50-4016-8b8f-b82f49c3b412">02129</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_69a05166-7e07-475a-9442-5fb65986f577">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_f6c2feb1-ef77-48c0-ba04-ae6e949ca771">337-4680</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_ed4bd3c9-d068-4721-b3b6-4952a5c1c2f5">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_31d26746-9a2e-44b5-8a65-76cedad3737c">SLDB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_62031173-5122-4d86-96c6-999ae561c509">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_3f41a032-89c5-4c3e-b9e2-9ea40cfe445f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_2ea3c317-6fe9-418d-9566-590b0ab2020a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_35307faa-5ec5-47fd-a7e2-b841990cf334">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_8de1dabd-b5af-4cd8-9639-496067ef6a5d">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_c3c817e6-b800-42b1-9af8-91de2e44798d">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_5ee34f28-4e27-4fc7-bc6a-bf52cf30f11c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_6b51695d-2c24-4616-9d6b-cb74e1484c1c"
      decimals="INF"
      id="F_bf03a9aa-1737-48e8-9bb7-249be2bc21d6"
      unitRef="U_shares">77869071</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_fc137035-7d99-435a-a38a-dbaaf0e59c0b"
      unitRef="U_USD">138933000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_eefbf9f1-d469-4629-abca-d66fffc4af6c"
      unitRef="U_USD">80235000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_ffa49c0a-0a0a-4822-97f8-45bb0de2f69a"
      unitRef="U_USD">129177000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_28aac1e0-fa62-4dbd-a8e6-e601bc409fc2"
      unitRef="U_USD">68685000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_1852fa52-0738-4876-bd93-834e249d35e1"
      unitRef="U_USD">10530000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_387ca047-3663-4ad7-95e1-1e3d9cc784fa"
      unitRef="U_USD">8382000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_d77fc629-dfc9-4304-aa55-54bb6302592a"
      unitRef="U_USD">278640000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_1a14e2b4-3029-49f1-b2c5-dd7a38f8aea2"
      unitRef="U_USD">157302000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_ee5378a4-c79c-4cb6-8b92-ed23242a01bf"
      unitRef="U_USD">23133000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_b2d8fccb-b22a-4def-9444-e61fa9035bca"
      unitRef="U_USD">24295000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_72fd1024-ddf7-4c26-b0aa-7f49fbc285b8"
      unitRef="U_USD">4317000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_b83d3796-7ec1-4b6a-b691-097b0676abda"
      unitRef="U_USD">4747000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_20055164-7f9d-4774-8a74-f9a8c9010984"
      unitRef="U_USD">278000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_1e81bb6a-8beb-4a14-b048-b6420eba9d5c"
      unitRef="U_USD">366000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_ed73422e-a8e8-439d-beff-3e2abf6f2de6"
      unitRef="U_USD">1924000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_dbd6c758-bf02-451b-bbc0-26a6c7b4e289"
      unitRef="U_USD">1952000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_6872eeea-8832-42e1-b91e-15050a2b6308"
      unitRef="U_USD">29652000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_c1c3c8ee-e795-4f43-a12e-cab86aacaa38"
      unitRef="U_USD">31360000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_74985eae-459b-45d7-b0d6-135639c29600"
      unitRef="U_USD">308292000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_b5640f9d-2777-46e0-a3b3-cc77329a3935"
      unitRef="U_USD">188662000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_d06bd60d-bf9c-4a82-860d-ff765e101fcd"
      unitRef="U_USD">4704000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_2cfdc32c-f343-400f-b02f-571403cba4d8"
      unitRef="U_USD">4237000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_2a9d4822-8a46-4eb6-aaaa-5d1befafb5b4"
      unitRef="U_USD">16546000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_6436dc68-c83a-4e9c-bba4-b58587bae3cd"
      unitRef="U_USD">19852000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_e889e131-96bf-482b-91c6-9407021b5cee"
      unitRef="U_USD">1943000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_73aeffe7-7fe7-4892-a983-8fda45e1bfde"
      unitRef="U_USD">1787000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_261c4b4d-c903-4ade-8567-b05547ad105f"
      unitRef="U_USD">953000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_674a0ec5-ffc8-4b91-8015-eab86c5c80c6"
      unitRef="U_USD">1231000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_c0affe51-c35b-4c38-bc4c-81c9986e440f"
      unitRef="U_USD">5700000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_9fc99fbe-bc42-40bd-a0e3-cc0cd9194207"
      unitRef="U_USD">3150000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_8a05c06b-0e53-4556-bf15-8b57e51ce47d"
      unitRef="U_USD">29846000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_8c696cc4-50f9-4293-910f-a737d647d61d"
      unitRef="U_USD">30257000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_11cc434d-6429-490c-b3f4-e4a743c65bf6"
      unitRef="U_USD">20155000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_f72a0eee-7906-4c33-b740-b64ea615b7a1"
      unitRef="U_USD">21159000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_76b8d1e3-0a14-4ffa-947f-9aae8628b243"
      unitRef="U_USD">20155000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_e8e471b7-495e-4d28-bcb0-9e9c09383de8"
      unitRef="U_USD">21159000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_b731415e-61b4-4838-9155-827916608689"
      unitRef="U_USD">50001000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_1c0901fb-234e-4401-8dbb-b9903389d250"
      unitRef="U_USD">51416000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="INF"
      id="F_51f67fbf-9993-49ff-8cdf-722be1c0ca75"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="INF"
      id="F_c82094c2-94e6-44db-b17c-17d09b1b2c00"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="INF"
      id="F_6344a8f5-f36c-45b0-b376-bbecd54c919e"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="INF"
      id="F_b58fb8fe-47ad-4153-baf1-8d4941de9f46"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="INF"
      id="F_0d347513-81a4-4242-98b4-31321ea05cc8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="INF"
      id="F_5cdfcde9-6495-497d-aed4-0f21cac0e0dc"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="INF"
      id="F_d995a80b-2b5c-426e-83ea-05de2dbd2f07"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="INF"
      id="F_3b771784-dd53-4128-94be-a01242dae4b2"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="INF"
      id="F_aa3e691c-6867-492c-a0ed-876ba3cb82be"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="INF"
      id="F_9425cc57-b673-435d-a4bf-c47d8176591b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="INF"
      id="F_19908f63-bac3-4727-bdeb-451e6d85d6f2"
      unitRef="U_shares">240000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="INF"
      id="F_8af4f9f9-e9de-442e-86ea-e1f69be9db24"
      unitRef="U_shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="INF"
      id="F_e79b779e-6e79-4442-8e40-cff5000445b7"
      unitRef="U_shares">77602741</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="INF"
      id="F_63484ed9-d240-4d40-955a-5cc73ff8f7bb"
      unitRef="U_shares">77602741</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="INF"
      id="F_037759d2-b4e5-4a37-b181-443f47e741a2"
      unitRef="U_shares">40468141</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="INF"
      id="F_ec1a7021-a4f3-4a5c-8dbb-697708d1a34d"
      unitRef="U_shares">40468141</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_6b896f63-61b9-4196-99f9-c2c9f2cb5a1d"
      unitRef="U_USD">78000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_abce63ab-22f7-46a7-9f37-e2dac9bf6e72"
      unitRef="U_USD">40000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_4bc9a2bc-9331-4a91-8ae8-e84b77aa9dfa"
      unitRef="U_USD">1120463000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_815baf88-27c4-4033-8c41-7b9324fccc2f"
      unitRef="U_USD">920609000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_8186a5c9-a550-42b4-a931-983140defc4e"
      unitRef="U_USD">-38000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_c28470ba-8fb8-466a-92ef-2a07751c5f1b"
      unitRef="U_USD">47000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_0cd01681-e6eb-414a-809a-326acb49aa8a"
      unitRef="U_USD">-862212000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_5a267f88-8b63-4c95-bf90-8ac43adb3ee8"
      unitRef="U_USD">-783450000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_ccddce9e-e6b3-4e14-8cfd-d751db9dcea5"
      unitRef="U_USD">258291000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_fd47a363-28d7-4e78-bd67-13785e21ca8f"
      unitRef="U_USD">137246000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_8e4a53a3-404f-4549-b2ec-1d1f8e985ba4"
      unitRef="U_USD">308292000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_cd37ea1c-1721-4b77-81ee-2b09edc2cec0"
      unitRef="U_USD">188662000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_c1673457-524c-4e11-b85b-b2fe15a43459"
      unitRef="U_USD">32415000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_015e77c3-be4d-4b69-ba23-b3d331e2a40a"
      unitRef="U_USD">19461000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_e06014cc-5c91-451a-82c1-589fb9d9719d"
      unitRef="U_USD">63329000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_6a1c9ec1-fb00-46b1-82f8-f6d238202233"
      unitRef="U_USD">38334000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_ee46a6ba-eb33-48e3-a40a-7c3488aa655b"
      unitRef="U_USD">9278000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_635bac91-facd-4d36-a04b-67bff6a32575"
      unitRef="U_USD">8327000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_2b3d65be-398f-4e9f-962a-a41ac7c6ce80"
      unitRef="U_USD">18416000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_5cbefc35-d72b-4348-8c54-baf067e90c1d"
      unitRef="U_USD">16316000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_3c98e8f5-0793-4c78-a8b4-7b66762331b9"
      unitRef="U_USD">41693000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_d503c23e-9929-4fe5-b352-feff387358d2"
      unitRef="U_USD">27788000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_bda55a0a-dbde-49fa-9320-2f7e6a791345"
      unitRef="U_USD">81745000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_d792b26c-e4df-4daf-bf30-147c650311b0"
      unitRef="U_USD">54650000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_9e8518f5-38bc-4db6-89f6-660947b6ecab"
      unitRef="U_USD">-41693000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_946c41a9-f619-42c6-bf5f-1492a33b89f3"
      unitRef="U_USD">-27788000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_f7419d01-f03c-497d-b559-7dba2d84d601"
      unitRef="U_USD">-81745000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_71b6f884-1177-45b3-affa-a5ef6eb5e9cd"
      unitRef="U_USD">-54650000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_c6bc8e1d-564e-4fff-92e2-954331ed2085"
      unitRef="U_USD">2966000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_4e404325-92b3-4354-a161-d68c7292ba7c"
      unitRef="U_USD">2565000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_f1f60782-28e2-45f3-b86c-28134c9a2058"
      unitRef="U_USD">5266000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_9cd7b290-6deb-4156-8fac-c341d189c950"
      unitRef="U_USD">5216000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_ada6d0c9-6eec-43d3-a436-e454bce91992"
      unitRef="U_USD">60000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_f7528715-c380-43a6-968c-b1a5fc0f9706"
      unitRef="U_USD">88000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_7caf4138-2f67-4e4b-ba0e-5b0d2200f0e9"
      unitRef="U_USD">128000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_798845da-15a0-4061-8f25-6f77a25a399b"
      unitRef="U_USD">183000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_124c15d4-1903-4bc3-9673-ca8cd5bb39ff"
      unitRef="U_USD">-900000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_865897ef-5488-416f-a3ad-3e5fbb852bd6"
      unitRef="U_USD">-2550000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_c075f8b9-c71e-428e-9d0b-17e925773c0f"
      unitRef="U_USD">207000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_cb92755b-df27-4497-8432-9b75e6218f11"
      unitRef="U_USD">239000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_568b55ee-3f25-4cdc-ad74-49346252a321"
      unitRef="U_USD">395000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_6cb3acf5-66f4-40ed-998c-6d33a9e10caf"
      unitRef="U_USD">242000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_f90e3bd9-8834-48b1-99c5-621eec5744bd"
      unitRef="U_USD">2213000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_f7f62bbe-4f5b-472e-9cd2-ac41cc8779d3"
      unitRef="U_USD">2716000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_d5f6304e-d26e-47d7-a41e-3892ce3a8db3"
      unitRef="U_USD">2983000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_d5a19c9e-db46-486f-8621-c34f6b69bf78"
      unitRef="U_USD">5275000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_6f9cfdbc-f898-444e-aa01-e933776afa35"
      unitRef="U_USD">-39480000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_6d03f2c4-f300-42ca-990d-59eb18de297f"
      unitRef="U_USD">-25072000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_653993c8-03a0-43e0-ba1c-bfca1a969b95"
      unitRef="U_USD">-78762000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_64ef396d-ac8f-4689-ab8e-8ff68b99ad65"
      unitRef="U_USD">-49375000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="2"
      id="F_1b3d9672-3fd8-4d96-acd5-8e76ded05503"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="2"
      id="F_c0440a03-3bca-4cd3-a442-2a2ffc17ade9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="2"
      id="F_22bcb14d-8938-4dd3-a083-127d265c2512"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="2"
      id="F_3c3e88ac-d667-49db-89dc-fe71799513dd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="2"
      id="F_5b25c427-f8f8-438c-940f-7c7e94dc0264"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="2"
      id="F_2bb9a5f2-60a1-4b35-8830-ab80372f91dd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="2"
      id="F_b8c2893e-edd4-4c9a-a40f-164235c17bf6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="2"
      id="F_13fd5eef-063b-4246-9551-6bc3f3392fb2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="0"
      id="F_d61751ce-7ddf-4177-bfaa-30c6b8ba52b1"
      unitRef="U_shares">94140286</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="0"
      id="F_860015b8-9da5-404a-801c-548ee0fc0c48"
      unitRef="U_shares">94140286</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="0"
      id="F_aec6f4f7-89de-4d8c-9b4c-eafce7c4d279"
      unitRef="U_shares">40934361</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="0"
      id="F_8c0e2d39-8350-42ea-9a5c-eb7d4a283edf"
      unitRef="U_shares">40934361</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="0"
      id="F_0eec50fc-d9ab-4fd4-8419-0b375aae0849"
      unitRef="U_shares">80317588</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="0"
      id="F_4e42f12b-e3d0-4839-987f-8c474b56e703"
      unitRef="U_shares">80317588</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="0"
      id="F_fd662e65-28ae-4541-8ae8-1c268274d06c"
      unitRef="U_shares">39544867</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="0"
      id="F_bde22ef9-0ab4-47de-aec4-d8c80302c9db"
      unitRef="U_shares">39544867</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_fb9e43df-f54c-4243-8a6c-d05d4d4e3ac0"
      unitRef="U_USD">-39480000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_43a90bd1-3bdc-457a-aef3-9e8e913dcea2"
      unitRef="U_USD">-25072000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_00c8fb4f-5d97-4667-96e9-453180d440ca"
      unitRef="U_USD">-78762000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_cac23818-f2fc-4a39-98d4-b17cef1d8a7c"
      unitRef="U_USD">-49375000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_3213a7bb-84fd-47e1-9b4f-2719892b3e19"
      unitRef="U_USD">-40000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_05e617a0-c67b-4e0f-bccc-9a35a38aa73a"
      unitRef="U_USD">-11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_bc6e1215-cc99-4897-bd66-0568f0f82505"
      unitRef="U_USD">-85000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_8943b831-9a3e-4f8a-9b01-20ab95001d0e"
      unitRef="U_USD">-30000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_ddeb7f51-b1bd-44c2-a6a7-a5594c3f99bb"
      unitRef="U_USD">-39520000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_21ae2302-26b2-438b-9cc3-b3ba213b5832"
      unitRef="U_USD">-25083000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_45bb94d7-a4be-44df-98c0-35c4fdad6eb9"
      unitRef="U_USD">-78847000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_81276fd3-2070-4d0d-a868-18957c489972"
      unitRef="U_USD">-49405000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="C_69be95bd-262a-441d-b2bd-98d19efe9bd0"
      decimals="INF"
      id="F_abb170d3-a7a4-4aa7-88d9-3c6a27a88517"
      unitRef="U_shares">40468141</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_69be95bd-262a-441d-b2bd-98d19efe9bd0"
      decimals="-3"
      id="F_e6e3adea-e500-4ae0-8f54-40d555d7cc2a"
      unitRef="U_USD">40000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b9aed1ea-13eb-4016-bc97-d2029636fac4"
      decimals="-3"
      id="F_bab68d28-f007-4bce-831a-3ff94a21c911"
      unitRef="U_USD">920609000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cff1f316-69c3-4b3f-a8d5-620b81ea7de8"
      decimals="-3"
      id="F_447fa5f6-10ca-452d-b230-cb935986b9e9"
      unitRef="U_USD">47000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e1fc1533-e5f3-4a29-a6a7-15d22fa44a9a"
      decimals="-3"
      id="F_21a37dc2-f4fc-4b5c-9f61-aeb27a583b35"
      unitRef="U_USD">-783450000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_420a5bea-299a-43b5-a7dd-b2268675fa8d"
      unitRef="U_USD">137246000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0c822986-4362-4137-a232-16bb78f035a6"
      decimals="-3"
      id="F_e0386487-aa4a-4500-9c8e-b0213f2c3a62"
      unitRef="U_USD">8665000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9123b419-0bc2-4374-94a6-007cd47c652a"
      decimals="INF"
      id="F_b3c84ead-bcc3-4e87-ac58-e1903a88334a"
      unitRef="U_shares">35739810</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_9123b419-0bc2-4374-94a6-007cd47c652a"
      decimals="-3"
      id="F_7a211662-e070-4d82-a4e0-f83b3042e42e"
      unitRef="U_USD">36000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_80913da5-18e0-4e2d-9932-f1f9a150ed8a"
      decimals="-3"
      id="F_7b284523-affa-4760-a05c-4f4af73a4eb2"
      unitRef="U_USD">135331000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0c822986-4362-4137-a232-16bb78f035a6"
      decimals="-3"
      id="F_5f70cff0-33b0-4d90-bfe9-8df31d226d73"
      unitRef="U_USD">135367000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <sldb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts
      contextRef="C_0c822986-4362-4137-a232-16bb78f035a6"
      decimals="-3"
      id="F_086c2c4c-211e-49e9-b460-2008d157e8be"
      unitRef="U_USD">3366000</sldb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_80913da5-18e0-4e2d-9932-f1f9a150ed8a"
      decimals="-3"
      id="F_79b9a69c-527e-4edb-8a4b-dd67338bb48c"
      unitRef="U_USD">52590000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_0c822986-4362-4137-a232-16bb78f035a6"
      decimals="-3"
      id="F_948ff807-e1d2-4b4a-9562-d781965c7a3a"
      unitRef="U_USD">52590000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <sldb:IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration
      contextRef="C_9123b419-0bc2-4374-94a6-007cd47c652a"
      decimals="INF"
      id="F_39f30175-342b-4023-b131-8027ade10a0f"
      unitRef="U_shares">975496</sldb:IssuanceOfCommonStockInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration>
    <sldb:IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration
      contextRef="C_9123b419-0bc2-4374-94a6-007cd47c652a"
      decimals="-3"
      id="F_62609475-550c-48e7-acbd-82d1194ba5ab"
      unitRef="U_USD">1000</sldb:IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration>
    <sldb:IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration
      contextRef="C_80913da5-18e0-4e2d-9932-f1f9a150ed8a"
      decimals="-3"
      id="F_f91837a7-36ab-4619-80f8-5608cb132a8e"
      unitRef="U_USD">4999000</sldb:IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration>
    <sldb:IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration
      contextRef="C_0c822986-4362-4137-a232-16bb78f035a6"
      decimals="-3"
      id="F_54cd9b93-ae79-47f3-9d3f-51619612d58e"
      unitRef="U_USD">5000000</sldb:IssuanceOfCommonStockValueInPrivatePlacementForPaymentOfDevelopmentalMilestoneConsideration>
    <sldb:AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions
      contextRef="C_0c822986-4362-4137-a232-16bb78f035a6"
      decimals="-3"
      id="F_0e8f9594-11f5-4c68-a77d-9ad42d3045bf"
      unitRef="U_USD">6000</sldb:AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_d97c1211-c3a9-4ea5-91b7-040fde3392b0"
      decimals="INF"
      id="F_e3b09dae-7f3d-4cb9-a431-467db17a8316"
      unitRef="U_shares">61542</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_cfc4b4a2-204b-43b5-a661-f05441902b21"
      decimals="-3"
      id="F_4d9b6120-50c9-43b0-b945-be4bb40f5214"
      unitRef="U_USD">246000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_11a10128-fba6-447d-a976-5fa084bf9295"
      decimals="-3"
      id="F_596500ea-217d-4901-97da-fcc82cc80d72"
      unitRef="U_USD">246000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <sldb:VestingOfRestrictedStockUnits
      contextRef="C_9123b419-0bc2-4374-94a6-007cd47c652a"
      decimals="INF"
      id="F_a888fdf1-614b-48ec-ab18-ec3ffdbab577"
      unitRef="U_shares">247970</sldb:VestingOfRestrictedStockUnits>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_8d226a90-397f-41ab-935f-5aab9dd4c71c"
      decimals="-3"
      id="F_872fbe4a-d612-450d-a604-6b6890c4194a"
      unitRef="U_USD">-45000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0c822986-4362-4137-a232-16bb78f035a6"
      decimals="-3"
      id="F_93d48180-4813-4dea-a68f-f8dc7a4e61a2"
      unitRef="U_USD">-45000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_80913da5-18e0-4e2d-9932-f1f9a150ed8a"
      decimals="-3"
      id="F_3159eb15-a9e6-4f8a-a2e1-46d391bf0351"
      unitRef="U_USD">3341000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0c822986-4362-4137-a232-16bb78f035a6"
      decimals="-3"
      id="F_00afc5c3-7ae5-4fed-808c-e49467fed75e"
      unitRef="U_USD">3341000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="C_fde676d0-416a-44d0-990b-c79ab2d42ba2"
      decimals="-3"
      id="F_ecaf500b-79e9-46cb-bf87-0c9bd7ffff1a"
      unitRef="U_USD">-39282000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0c822986-4362-4137-a232-16bb78f035a6"
      decimals="-3"
      id="F_01c5a599-91e0-482e-a8eb-e8de1f9f509f"
      unitRef="U_USD">-39282000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_e6263d79-32c5-4715-9a16-d2aa12863296"
      decimals="INF"
      id="F_d7001778-b8c4-43a9-aee6-60c1756311c2"
      unitRef="U_shares">77492959</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e6263d79-32c5-4715-9a16-d2aa12863296"
      decimals="-3"
      id="F_405119df-2ea1-430e-b2ae-15a069709efe"
      unitRef="U_USD">77000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9a0af20a-6059-403f-91cf-5541fbb0763d"
      decimals="-3"
      id="F_728453f5-c5fa-42d8-a04b-5a48c6f0ce89"
      unitRef="U_USD">1117116000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e445144a-7061-4fa5-ae92-64b3821a428b"
      decimals="-3"
      id="F_c18a84f9-8d3b-4258-9dd1-1743297dba45"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_360e00c1-d83f-408a-8983-fda0502e6613"
      decimals="-3"
      id="F_716d0ca2-ad8a-4366-9071-ddb58d1fd345"
      unitRef="U_USD">-822732000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1289e95b-8da8-4d52-8d1f-4b8964a89bb2"
      decimals="-3"
      id="F_a8fedf1f-50ab-4c3f-aa86-23bce8fd3e7b"
      unitRef="U_USD">294463000</us-gaap:StockholdersEquity>
    <sldb:VestingOfRestrictedStockUnits
      contextRef="C_aa5bd7ea-c156-4475-926c-e8eddecefd5c"
      decimals="INF"
      id="F_26e2ab69-9aac-498e-909c-5cafc68f7f41"
      unitRef="U_shares">32189</sldb:VestingOfRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_aa5bd7ea-c156-4475-926c-e8eddecefd5c"
      decimals="0"
      id="F_a0c9b481-2de0-4a38-80d6-f59378c10f35"
      unitRef="U_shares">74860</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_aa5bd7ea-c156-4475-926c-e8eddecefd5c"
      decimals="-3"
      id="F_718ead90-ad4e-4199-96a3-c9e9e1f42805"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_cbf823b0-60bc-410a-aeb8-2f8b923dc7c7"
      decimals="-3"
      id="F_ad1fa47c-5a74-4af9-b833-c3b0df3259ba"
      unitRef="U_USD">196000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_e19f3ca4-59e8-4cd8-b474-c9ae70b05b7d"
      unitRef="U_USD">197000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_aa5bd7ea-c156-4475-926c-e8eddecefd5c"
      decimals="INF"
      id="F_3a961e4d-fb6d-457a-b95c-bbc2f1329233"
      unitRef="U_shares">2733</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_cbf823b0-60bc-410a-aeb8-2f8b923dc7c7"
      decimals="-3"
      id="F_09556609-581a-4fa1-9e8e-c95ffc935315"
      unitRef="U_USD">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_2db018d3-b313-4631-80e6-5566b36760f3"
      unitRef="U_USD">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_df55ee2b-223d-4c46-ab63-80dcac637cef"
      decimals="-3"
      id="F_aa7561cb-231a-431b-96a4-6eea6ac8edb9"
      unitRef="U_USD">-40000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_85041128-b935-48a4-afe1-31290bf543f8"
      unitRef="U_USD">-40000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cbf823b0-60bc-410a-aeb8-2f8b923dc7c7"
      decimals="-3"
      id="F_fcbd4864-7c84-4bfd-9a9d-816858674c6c"
      unitRef="U_USD">3145000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_3026e75a-afc3-4e50-80ac-94d856a600b4"
      unitRef="U_USD">3145000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="C_f86d33b7-2665-4a04-943a-c562c8410bd5"
      decimals="-3"
      id="F_27391452-aaa0-408f-a465-e474789f0500"
      unitRef="U_USD">-39480000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_f0fc0507-17db-45b9-8e45-ac035a71453d"
      unitRef="U_USD">-39480000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_8466f2d9-6b68-47d7-ba93-53848911d53e"
      decimals="INF"
      id="F_cf17f70b-5c5c-4281-93dd-00b61927f884"
      unitRef="U_shares">77602741</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_8466f2d9-6b68-47d7-ba93-53848911d53e"
      decimals="-3"
      id="F_9285f8b6-4c53-4772-ad4a-fe0a3b896a32"
      unitRef="U_USD">78000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_af67bb44-76aa-4851-ada3-634e88aa092e"
      decimals="-3"
      id="F_f53b4008-ba4f-49a4-92ea-2a20128189d5"
      unitRef="U_USD">1120463000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8ebf87b6-992f-494c-8560-27ee2a653d27"
      decimals="-3"
      id="F_5bf6b6bd-c2fb-4084-a4d7-a13d54e182d6"
      unitRef="U_USD">-38000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ac9669fb-6c3b-47fb-90e4-6286c0192e44"
      decimals="-3"
      id="F_7c5d57d1-39d1-4029-8dd3-01040cc5118f"
      unitRef="U_USD">-862212000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_1802014e-9373-42b7-8fc0-778d43814456"
      unitRef="U_USD">258291000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_f72bf3d9-6c7b-4a2b-a09e-4c623d761a64"
      decimals="INF"
      id="F_e1265827-268a-448d-aa2f-43ae3b5823c7"
      unitRef="U_shares">20386606</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_f72bf3d9-6c7b-4a2b-a09e-4c623d761a64"
      decimals="-3"
      id="F_95a64ba1-3e09-4271-9eea-bd58aa2a5579"
      unitRef="U_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_32a641e0-2697-41b7-a866-ce0eb5498572"
      decimals="-3"
      id="F_a26f9860-ede9-4946-8836-49cae154e4f4"
      unitRef="U_USD">785199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_60238495-82b4-4a9e-8f0c-dec2e85bad33"
      decimals="-3"
      id="F_8bfe00c0-6ede-4754-a274-50c24c9bb561"
      unitRef="U_USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5dadfd3e-8058-4606-b32d-a0cfe60eb067"
      decimals="-3"
      id="F_6909b3bb-fdb0-4159-8a4f-e81adf88a4a8"
      unitRef="U_USD">-658753000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_72a44744-a858-4632-9155-e3c3f22a4ca6"
      decimals="-3"
      id="F_b451f7d6-e660-4c6f-a786-ee2f49932548"
      unitRef="U_USD">126481000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_8e05825b-3564-43f0-9df6-8e98b1d7be91"
      decimals="-3"
      id="F_58f2848d-c84d-4167-8200-c0feb8d087d4"
      unitRef="U_USD">4407000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e13de2f2-ceab-4e18-9846-718dd592da8e"
      decimals="INF"
      id="F_1406d483-8b9d-4194-a9d7-53233b565560"
      unitRef="U_shares">16973103</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e13de2f2-ceab-4e18-9846-718dd592da8e"
      decimals="-3"
      id="F_52dad432-c442-4d7a-b608-a830179e5094"
      unitRef="U_USD">17000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_674b0646-86dc-4ece-b574-7ef26e78d9f8"
      decimals="-3"
      id="F_2142b5e1-4511-46d4-919f-d4e03a4d3875"
      unitRef="U_USD">89437000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_889a20b7-df33-41ee-923b-1fa83b319dc5"
      decimals="-3"
      id="F_6659c3e5-87d9-4bc6-b5e3-050108e5f7c7"
      unitRef="U_USD">89454000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <sldb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts
      contextRef="C_8e05825b-3564-43f0-9df6-8e98b1d7be91"
      decimals="-3"
      id="F_390914c9-621f-486c-8708-e0f8e9c57b94"
      unitRef="U_USD">704000</sldb:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_28011c1d-5f4c-4932-ad90-695a175099ce"
      decimals="-3"
      id="F_fa8821d0-219f-4df7-ab98-4fc48f9486bb"
      unitRef="U_USD">14293000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_8e05825b-3564-43f0-9df6-8e98b1d7be91"
      decimals="-3"
      id="F_c701b104-abd2-45cd-b730-c3d105d64a76"
      unitRef="U_USD">14293000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <sldb:AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions
      contextRef="C_8e05825b-3564-43f0-9df6-8e98b1d7be91"
      decimals="-3"
      id="F_eaac730c-f788-49c2-8fa8-b557fa97bd9c"
      unitRef="U_USD">78000</sldb:AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_5102f076-6976-4786-8570-ddc9fcaa4fda"
      decimals="INF"
      id="F_f75277d4-2bc1-4c6d-8522-dca3b88c551f"
      unitRef="U_shares">350664</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_5102f076-6976-4786-8570-ddc9fcaa4fda"
      decimals="-3"
      id="F_cdb1602a-c379-4a23-96e9-fe8a8c46aead"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0dfd0d13-a826-4ebd-b93f-49699f6c04b8"
      decimals="-3"
      id="F_c684042f-7a0c-4e64-9432-7e3bb5280ba4"
      unitRef="U_USD">3055000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_1e60639d-8283-41ae-8cd9-7b46f80766be"
      decimals="-3"
      id="F_95a5e72b-d1b3-4036-8ff6-67cb87f9e38b"
      unitRef="U_USD">3056000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <sldb:VestingOfRestrictedStockUnits
      contextRef="C_d9216090-1e30-4279-8a28-35be3c27b884"
      decimals="INF"
      id="F_90ac8cad-41fd-4e7b-b6c3-3734159f3b68"
      unitRef="U_shares">98677</sldb:VestingOfRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_d9216090-1e30-4279-8a28-35be3c27b884"
      decimals="INF"
      id="F_b3b5b796-8658-4f7b-b98c-f32d83b17c0e"
      unitRef="U_shares">24639</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_28011c1d-5f4c-4932-ad90-695a175099ce"
      decimals="-3"
      id="F_c7665ecc-4377-4da8-86a2-f133b25590ad"
      unitRef="U_USD">151000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_8e05825b-3564-43f0-9df6-8e98b1d7be91"
      decimals="-3"
      id="F_4e916482-3345-4f23-8eb6-386ea924c3ff"
      unitRef="U_USD">151000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_8254bb6c-0764-44d8-a999-479ae11715b9"
      decimals="-3"
      id="F_201d83bc-f35e-4fee-b56a-98244a5db99f"
      unitRef="U_USD">-19000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_8e05825b-3564-43f0-9df6-8e98b1d7be91"
      decimals="-3"
      id="F_9cdf95dc-44ec-45ea-aae6-a8c95fc98176"
      unitRef="U_USD">-19000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_28011c1d-5f4c-4932-ad90-695a175099ce"
      decimals="-3"
      id="F_3dd8962f-ced3-4d31-b70d-060709019f80"
      unitRef="U_USD">1611000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_8e05825b-3564-43f0-9df6-8e98b1d7be91"
      decimals="-3"
      id="F_a2276179-9aaa-4646-887a-a7aeee70acf2"
      unitRef="U_USD">1611000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="C_18030d3f-b395-4cc3-997d-b26bfd8329d0"
      decimals="-3"
      id="F_5850f591-0bdc-4e53-a536-4a4b1678dfc4"
      unitRef="U_USD">-24303000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_8e05825b-3564-43f0-9df6-8e98b1d7be91"
      decimals="-3"
      id="F_2d250068-fa24-4753-b899-9469498dd39e"
      unitRef="U_USD">-24303000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_ddbae127-0489-4e1a-9f96-5243dd079a21"
      decimals="INF"
      id="F_a543ded3-ed1a-4dd1-82a5-cd0fc2996302"
      unitRef="U_shares">37833689</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_ddbae127-0489-4e1a-9f96-5243dd079a21"
      decimals="-3"
      id="F_ff2acd5c-25f7-4ee4-a017-9305e656a0be"
      unitRef="U_USD">38000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2e4a7c1b-d7cd-41ff-9b20-980516f53df2"
      decimals="-3"
      id="F_e859c34e-ddd5-4669-8259-3ee0f0ad0929"
      unitRef="U_USD">893746000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_af5ce639-0ee4-4ebc-b2dc-3c8e938ebf5d"
      decimals="-3"
      id="F_9b9a1260-0d19-4e8a-973d-b9cd0e7fe726"
      unitRef="U_USD">-4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_86fa028f-2418-4cf6-b959-b70470ee2aa9"
      decimals="-3"
      id="F_0f046481-8303-4ce4-8daf-10cdb6effa55"
      unitRef="U_USD">-683056000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_004daa09-8340-480a-b520-e166a80e5304"
      decimals="-3"
      id="F_5af20fd1-bb1c-4a6d-a117-534a5de336b2"
      unitRef="U_USD">210724000</us-gaap:StockholdersEquity>
    <sldb:AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_cedd105e-b66e-4da3-8b9d-63a623643dc8"
      unitRef="U_USD">138000</sldb:AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_be22b5d9-efe2-482f-aa0b-2ae151a5a94d"
      decimals="INF"
      id="F_a81f8081-342d-4388-a132-f983f2739be1"
      unitRef="U_shares">526953</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_be22b5d9-efe2-482f-aa0b-2ae151a5a94d"
      decimals="-3"
      id="F_b94ce68a-1664-493e-a0be-49561a0be7c0"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_1679319c-e556-4669-b19c-516102e53d80"
      decimals="-3"
      id="F_3e598aaf-c937-43b1-b266-778914ad683a"
      unitRef="U_USD">5356000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_04579f4c-0d92-4807-b526-47e70d33525d"
      decimals="-3"
      id="F_236f0240-73db-4feb-8192-cfa46eb9f245"
      unitRef="U_USD">5357000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <sldb:VestingOfRestrictedStockUnits
      contextRef="C_07264e86-c26a-42ce-a8e5-89f7da5029a5"
      decimals="INF"
      id="F_1f0a1dda-e8ba-4c24-95ef-418fa1df516f"
      unitRef="U_shares">131859</sldb:VestingOfRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_07264e86-c26a-42ce-a8e5-89f7da5029a5"
      decimals="INF"
      id="F_f1173f76-d27c-444a-b23c-c3d14745f48b"
      unitRef="U_shares">56855</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_dca2999e-bb17-4181-8e87-86f8da45617b"
      decimals="-3"
      id="F_670640e8-f93b-41b1-9c1a-bb55fdeeaae0"
      unitRef="U_USD">145000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_24dc3ada-9efa-49f4-9bf6-18dba328b1b1"
      unitRef="U_USD">145000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_07264e86-c26a-42ce-a8e5-89f7da5029a5"
      decimals="INF"
      id="F_a637c0b3-24b3-4f22-96cd-a69b771a3915"
      unitRef="U_shares">1703</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_dca2999e-bb17-4181-8e87-86f8da45617b"
      decimals="-3"
      id="F_900efdd6-d00b-4da4-8aa4-b634d4fa4003"
      unitRef="U_USD">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_183e993d-2da7-4d0e-9151-6a97cdb03df2"
      unitRef="U_USD">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_1a3c625c-1186-436d-91aa-d8d2544b7b4a"
      decimals="-3"
      id="F_601be6d4-faef-43c5-809f-33615b8c6c27"
      unitRef="U_USD">-11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_d77c37e1-a699-4e4b-9661-ec0e98393951"
      unitRef="U_USD">-11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_dca2999e-bb17-4181-8e87-86f8da45617b"
      decimals="-3"
      id="F_28f4770d-45a3-4122-909f-1f4177e4d93e"
      unitRef="U_USD">2092000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_4c411364-cd84-4b85-b8b6-d929030c454c"
      unitRef="U_USD">2092000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="C_b1b96c09-b829-40e0-9943-61aa3ed9067c"
      decimals="-3"
      id="F_74bbd04c-2c0a-469e-945c-e373f2fa5b38"
      unitRef="U_USD">-25072000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_b15f4b04-0fdc-4daa-9117-0ec061a55ac0"
      unitRef="U_USD">-25072000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_6d1d0185-6a08-4a4d-bf78-3cf596bda452"
      decimals="INF"
      id="F_6cc47fd5-e036-442e-be6a-1329bb7f594f"
      unitRef="U_shares">38551059</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_6d1d0185-6a08-4a4d-bf78-3cf596bda452"
      decimals="-3"
      id="F_7816a6db-2965-46cd-9d63-feccfe9c4b43"
      unitRef="U_USD">39000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d9af6823-a26b-4885-a9fb-907deb94d20c"
      decimals="-3"
      id="F_8f61b84d-db5d-4a42-b4d7-fe3ee0df0fac"
      unitRef="U_USD">901349000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7621a0fc-5398-41ee-bdd0-b6ec3eec8693"
      decimals="-3"
      id="F_470f4420-c1de-4683-b5ef-dbe510dea15b"
      unitRef="U_USD">-15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_888d7863-e043-4b8e-9a9c-902e9e4efb65"
      decimals="-3"
      id="F_93475c55-63bd-4811-8ecd-5ff7b15a23dd"
      unitRef="U_USD">-708128000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_11726ae9-e40d-4c5b-83b8-8005c97ded06"
      decimals="-3"
      id="F_958f1384-aef6-4d84-a94d-5ef5a27db9c5"
      unitRef="U_USD">193245000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_44758709-26ef-49af-b61d-d632743851d0"
      unitRef="U_USD">-78762000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_e268c6db-04fc-4b14-8502-4b465bf742a5"
      unitRef="U_USD">-49375000</us-gaap:ProfitLoss>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_a85ec5b8-6ecf-47f5-9601-f003e700ed7a"
      unitRef="U_USD">800000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_30448f7e-8201-4c70-a26e-58892d9ef085"
      unitRef="U_USD">1581000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_cb350e9c-0f3e-45e8-aaf5-102025aeaf43"
      unitRef="U_USD">6486000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_39ae56a6-7c3b-4bff-bfc7-b8740f5fd11c"
      unitRef="U_USD">3703000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_8b0faaa0-ddde-4703-a214-07e28cdaff97"
      unitRef="U_USD">793000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_46502047-4b51-4dde-81e6-c8ea94c8bb38"
      unitRef="U_USD">1562000</us-gaap:DepreciationAndAmortization>
    <sldb:NonCashLeaseExpense
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_ae0c3435-5ada-4fe3-8b18-e5894be01ff9"
      unitRef="U_USD">1162000</sldb:NonCashLeaseExpense>
    <sldb:NonCashLeaseExpense
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_e66fbbb6-0358-485e-bd07-8298d260f2ff"
      unitRef="U_USD">1241000</sldb:NonCashLeaseExpense>
    <sldb:ChangeInFairValueOfDerivativeLiabilities
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_adc93b1b-0a16-4b67-8baa-e705a6cbcce5"
      unitRef="U_USD">-2550000</sldb:ChangeInFairValueOfDerivativeLiabilities>
    <sldb:ChangeInFairValueOfDerivativeLiabilities
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_cf7bfd9d-3f9d-4562-ae49-691cc96e92aa"
      unitRef="U_USD">0</sldb:ChangeInFairValueOfDerivativeLiabilities>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_b7a7860f-3c1b-465e-b62c-08a419fd9a4a"
      unitRef="U_USD">-55000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_28562620-118f-41f5-a84e-903707a8e809"
      unitRef="U_USD">94000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_4d8e44c6-c77a-4b4b-89ed-ee23f87a224d"
      unitRef="U_USD">2060000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_ebf5f78d-381e-4c67-95f7-9b29d8e6f5e4"
      unitRef="U_USD">1556000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_48e8ee1e-e858-4374-b863-a8ae3f5edccc"
      unitRef="U_USD">467000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_57b04278-7567-4804-882c-498c14ece90d"
      unitRef="U_USD">472000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_479327cf-e08c-4c84-9f5b-5dedfc859902"
      unitRef="U_USD">-848000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_7ef33a4c-70d8-4edb-a40b-1a1c4d57eb5b"
      unitRef="U_USD">-864000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_e6c4f6de-05ae-4994-b9dc-9a0d2cc4ebef"
      unitRef="U_USD">1695000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_6c424c8b-d778-4ed2-bdb6-134bb3594db9"
      unitRef="U_USD">-167000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_5e1a3b43-37b3-4376-b82d-2c4eb4836dbb"
      unitRef="U_USD">-69262000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_fd4ae9a5-63c9-4ccf-8d8f-a7ce306ba70f"
      unitRef="U_USD">-46659000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_5c6e8f9a-4c31-4777-85b3-303392f982aa"
      unitRef="U_USD">503000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_e478161c-64ba-404a-b879-694391a1cd91"
      unitRef="U_USD">435000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_be2ac74d-4c08-44e0-9351-0686310e423a"
      unitRef="U_USD">-69000000</us-gaap:PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm>
    <us-gaap:PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_a46cc4ef-e83f-4418-b6b2-67045d3330c6"
      unitRef="U_USD">-60300000</us-gaap:PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_79b83879-68da-4ef4-81ff-d7a9e264659e"
      unitRef="U_USD">128777000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_f54aa0eb-f8f1-45ae-a3ae-c41fa7c70d52"
      unitRef="U_USD">103536000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_b0dde2bb-20ae-4180-a5f5-5d6311b94241"
      unitRef="U_USD">-85000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_6eb0ef95-656b-4086-a60a-2f07fc48b369"
      unitRef="U_USD">-5000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_3c985bb5-5268-41a2-95d3-0ae239e8cc91"
      unitRef="U_USD">-60195000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_f739e8a0-e7a2-4851-a868-ff49a4f8a8cd"
      unitRef="U_USD">-43666000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <sldb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_3c3978f2-86bd-4553-89be-6588a199072a"
      unitRef="U_USD">189637000</sldb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions>
    <sldb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_a532fbc0-18b7-43bf-ab95-49499ffec96e"
      unitRef="U_USD">0</sldb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions>
    <sldb:PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_b622c692-1a07-46b7-b8a6-e07e0e4278c7"
      unitRef="U_USD">1681000</sldb:PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering>
    <sldb:PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_8d9389f2-b513-45d0-ae05-a27d142395b8"
      unitRef="U_USD">0</sldb:PaymentsOfCommonStockAndPreFundedWarrantsIssuanceCostsInPublicOffering>
    <sldb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_14649455-3ce7-4686-a76d-c3dc98d0eecb"
      unitRef="U_USD">0</sldb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement>
    <sldb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_44a82ea7-ceee-4ef6-82df-dd6d4ab2b065"
      unitRef="U_USD">108858000</sldb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_3aae34ab-985c-46db-ba1f-a053595037f7"
      unitRef="U_USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_e3b998ea-df33-4d7d-a0f4-3b145a969c07"
      unitRef="U_USD">5111000</us-gaap:PaymentsOfStockIssuanceCosts>
    <sldb:ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_31a2e7be-5fd4-478f-a98b-4c5fad678451"
      unitRef="U_USD">246000</sldb:ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions>
    <sldb:ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_f635c565-e137-4634-a8e2-f9d5a2784418"
      unitRef="U_USD">8414000</sldb:ProceedsFromIssuanceOfCommonStockInAtTheMarketPublicOfferingNetOfSalesCommissions>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_5c7be9fc-448c-4800-8c9b-0f8026c7ebfd"
      unitRef="U_USD">6000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_bdd27d54-06d2-4a40-90e8-84f354b29310"
      unitRef="U_USD">160000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_bfcf9175-cfba-4e96-8c16-197672ce29c2"
      unitRef="U_USD">196000</us-gaap:ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans>
    <us-gaap:ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_9e464993-9522-4d1e-9877-e35e70e5a8e2"
      unitRef="U_USD">145000</us-gaap:ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_d920269b-56fd-45be-981d-fb3fcdb45023"
      unitRef="U_USD">277000</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_e80f7591-27de-4694-a763-5bb8803180e8"
      unitRef="U_USD">225000</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_464ec563-995c-4e32-ab33-ef6bd2ccee8f"
      unitRef="U_USD">188127000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_21e501a4-f9d9-4f07-980a-5b3a160aa650"
      unitRef="U_USD">112241000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_36a93ede-2d2c-4e12-9f41-b5af3ce9de7e"
      unitRef="U_USD">58670000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_e5bfdc61-6f60-4e87-9363-b88c5adbf4a3"
      unitRef="U_USD">21916000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_bdae07c5-7090-4370-be9d-31027b3b97bd"
      unitRef="U_USD">82187000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_72a44744-a858-4632-9155-e3c3f22a4ca6"
      decimals="-3"
      id="F_5ed1e7db-7b9b-4d7c-8edf-1ad1926f212a"
      unitRef="U_USD">75848000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_b79f99c7-5c43-4c2d-90dd-3f388dad0d5e"
      unitRef="U_USD">140857000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_11726ae9-e40d-4c5b-83b8-8005c97ded06"
      decimals="-3"
      id="F_2f5a0ce1-89c2-4c4f-a87f-f17e6f088621"
      unitRef="U_USD">97764000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_b7a94b15-bae2-43b0-8d70-dfa0d4e537df"
      unitRef="U_USD">128000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_b121b1d8-3cc9-4137-b3ce-9efce09ce388"
      unitRef="U_USD">183000</us-gaap:InterestPaidNet>
    <sldb:CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_dc4df418-07b3-45fe-a620-4cf0f7fa7cb5"
      unitRef="U_USD">5000000</sldb:CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration>
    <sldb:CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_1ab6098a-36dd-457b-a659-cc9b442c0f84"
      unitRef="U_USD">0</sldb:CommonStockIssuedAsPaymentForDevelopmentalMilestoneConsideration>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_690e7086-c380-49d4-b276-f134a960c5dd"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_51688c29-636b-4ba5-9494-2ccac2459b07"
      unitRef="U_USD">407000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <sldb:IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_6dd444fe-bd94-4e88-b36e-817507435070"
      unitRef="U_USD">0</sldb:IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination>
    <sldb:IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_5c024dc2-1ece-4b43-a7af-0540efe3e9ce"
      unitRef="U_USD">-197000</sldb:IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_625a291c-edc8-4cbd-a06d-417ba6912bb7"
      unitRef="U_USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_764cc880-993b-4236-8e3d-6f9b46aa41cf"
      unitRef="U_USD">20000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_c271aa81-89fe-477f-8948-b54e6b89c092"
      unitRef="U_USD">138933000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_11726ae9-e40d-4c5b-83b8-8005c97ded06"
      decimals="-3"
      id="F_89064947-5a14-4a39-a034-4c31b7a6e0cf"
      unitRef="U_USD">95854000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_bab2deb3-2739-4ba5-937a-84fbc6bbbf91"
      unitRef="U_USD">1924000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_11726ae9-e40d-4c5b-83b8-8005c97ded06"
      decimals="-3"
      id="F_30c2fa49-b96b-4251-8b7d-093f4d6c5273"
      unitRef="U_USD">1910000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_f0b0760a-ee9a-40d0-a95b-f5c296614a75"
      unitRef="U_USD">140857000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_11726ae9-e40d-4c5b-83b8-8005c97ded06"
      decimals="-3"
      id="F_0d358abf-c55c-4542-9d64-272369c88ef2"
      unitRef="U_USD">97764000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_9161644a-60c0-4b9e-bc1c-5210040d5700">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Nature of the Business and Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Nature of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Solid Biosciences Inc. was organized in March 2013 under the name SOLID Ventures Management, LLC and operated as a Delaware limited liability company until immediately prior to the effectiveness of its registration statement on Form S-1 on January 25, 2018, at which time it completed a statutory corporate conversion into a Delaware corporation and changed its name to Solid Biosciences Inc. (the "Company").&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates (collectively "Candidates"), including SGT-003 for the treatment of Duchenne muscular dystrophy ("Duchenne"), SGT-212 for the treatment of Friedreich&#x2019;s ataxia ("FA"), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia ("CPVT"), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases, at different stages of development with varying levels of investment. The Company is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management and care. Patient-focused and founded by those directly impacted by Duchenne, the Company&#x2019;s mission is to improve the daily lives of patients living with these devastating diseases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on licenses, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting capabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s Candidates are in development. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from, among others, other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, partners, and consultants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Based upon its current operating plan, the Company expects that its cash, cash equivalents and available-for-sale securities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;268.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million excluding restricted cash of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, as of June 30, 2025, will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of issuance of these condensed consolidated financial statements. However, the Company has based this estimate on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to it. As a result, the Company could deplete its capital resources sooner than it currently expects.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Through June 30, 2025, the Company has funded its operations primarily with the proceeds from the sale of redeemable preferred units and member units as well as the sale of common stock and pre-funded warrants to purchase shares of its common stock in private placements (including the January 2024 Private Placement (as defined below)) and the sale of common stock in its initial public offering, follow-on public offerings in March 2021 and February 2025 and under its at-the-market sales agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company expects to continue to generate operating losses for the foreseeable future and to finance its future cash needs through a combination of equity offerings, debt financings, collaborations, strategic partnerships and alliances or licensing arrangements. If the Company is unable to obtain funding, the Company would be forced to delay, reduce or eliminate some or all of its research and development programs, preclinical and clinical testing or commercialization efforts, which could adversely affect its business prospects.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") along with the rules and regulations of the Securities and Exchange Commission for interim financial information and include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from the Company&#x2019;s audited financial statements but does not include all disclosures required by GAAP to constitute a complete set of financial statements. These condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for a fair statement of the Company&#x2019;s financial position at June 30, 2025 and its results of operations, changes in stockholders&#x2019; equity, and cash flows for the interim periods ended June 30, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These unaudited condensed consolidated interim financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024. The results of operations for the three and six months ended June 30, 2025 are not necessarily indicative of the operating results to be expected for the year ending December 31, 2025, for any other interim period, or for any other future year.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Significant Judgments and Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, estimates related to the recognition of research and development expenses, equity-based compensation, and derivative liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There have been no changes to the significant accounting policies disclosed in the Company's most recent Annual Report on Form 10&#x2011;K.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. This ASU updates income tax disclosure requirements primarily by requiring specific categories and greater disaggregation within the rate reconciliation and disaggregation of income taxes paid by jurisdiction. This ASU is effective for annual periods beginning after December 15, 2024 and is applicable to the Company&#x2019;s fiscal year beginning January 1, 2025, with early application permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Disaggregation of Income Statement Expenses (Topic 220)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The requirements in this ASU may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-5"
      id="F_59938593-a977-4a7d-991c-abad97147d24"
      unitRef="U_USD">268100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RestrictedCash
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-5"
      id="F_a307bbf1-f3ab-4012-b779-799dcc535f90"
      unitRef="U_USD">1900000</us-gaap:RestrictedCash>
    <sldb:RecentlyIssuedAccountingPronouncementsPolicyTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_448a6369-a0e5-410e-966b-75e12564ccba">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. This ASU updates income tax disclosure requirements primarily by requiring specific categories and greater disaggregation within the rate reconciliation and disaggregation of income taxes paid by jurisdiction. This ASU is effective for annual periods beginning after December 15, 2024 and is applicable to the Company&#x2019;s fiscal year beginning January 1, 2025, with early application permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Disaggregation of Income Statement Expenses (Topic 220)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The requirements in this ASU may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;</sldb:RecentlyIssuedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:AssetAcquisitionTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_a6a06271-7b10-49aa-883f-773ed53bc3b4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. FA212 Asset Acquisition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;September 19, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company entered into an asset purchase agreement with FA212 LLC ("FA212") for the purchase of certain intellectual property, including patents and assigned licenses related to a preclinical drug candidate, which the Company now refers to as SGT-212, assigned manufacturing contracts as well as research and development materials such as manufactured materials and samples.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company paid FA212 an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in the third quarter of 2024. Additionally, the Company agreed to pay FA212 development milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, cumulative sales milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and tiered royalties on net sales in the low-single-digits. The Company also assumed from FA212 contingent development milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, regulatory milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, cumulative sales milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and tiered royalties on worldwide net sales in the mid-single digits payable to the University of Pennsylvania.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain development milestone payments to FA212 are payable in either cash, equity, or a combination of both, at the Company's discretion. Such contingent payments were determined to be derivative liabilities and were initially recorded at their fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determined that the FA212 agreement represented an asset acquisition of in-process research and development assets with no alternative future use and recognized the aggregate acquisition cost of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as research and development expense in the third quarter of 2024, which included the upfront payment, initial recognition of the derivative liability and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in transaction costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; submitted an investigational new drug application ("IND") for SGT-212 for the treatment of FA to the U.S. Food and Drug Administration ("FDA"), which was cleared in December 2024. Upon clearance of the IND, the first development milestone of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million became payable to FA212. The $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone payment is included in Accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheet as of December 31, 2024. On February 28, 2025, the Company &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;made the first development milestone payment in the form of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;975,496&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The derivative liabilities for the remaining contingent payments were recorded at a fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of June 30, 2025 and December 31, 2024, respectively. See Note 3 -&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:AssetAcquisitionDateOfAcquisitionAgreement
      contextRef="C_43934480-1ee4-495d-8199-c3e8feb3750c"
      id="F_977a4ee1-93db-40cf-b1db-9d71286c7372">2024-09-19</us-gaap:AssetAcquisitionDateOfAcquisitionAgreement>
    <sldb:AssetAcquisitionUpfrontPayment
      contextRef="C_98efec03-6261-4884-8666-bf6095a4bb0d"
      decimals="-5"
      id="F_61e8cca3-f573-43de-9b4a-62cc85a8b58a"
      unitRef="U_USD">1000000</sldb:AssetAcquisitionUpfrontPayment>
    <sldb:DevelopmentMilestonePayments
      contextRef="C_6cd19d05-d8a7-4151-a703-c33e74dfa457"
      decimals="INF"
      id="F_0ebf0aed-dade-403a-9b46-cfc3f4489480"
      unitRef="U_USD">34000000</sldb:DevelopmentMilestonePayments>
    <sldb:CumulativeSalesMilestonePayments
      contextRef="C_6cd19d05-d8a7-4151-a703-c33e74dfa457"
      decimals="INF"
      id="F_bbe8e722-5b8e-4687-9070-008949991760"
      unitRef="U_USD">21000000</sldb:CumulativeSalesMilestonePayments>
    <sldb:AssetAcquisitionAssumedContingentDevelopmentMilestonePayments
      contextRef="C_a77281d0-83e9-4ceb-b6cd-ee4c4377550d"
      decimals="INF"
      id="F_619ac4b7-7d99-4104-a7e8-592f4fd50bb7"
      unitRef="U_USD">4200000</sldb:AssetAcquisitionAssumedContingentDevelopmentMilestonePayments>
    <sldb:AssetAcquisitionAssumedRegulatoryMilestonePayments
      contextRef="C_a77281d0-83e9-4ceb-b6cd-ee4c4377550d"
      decimals="INF"
      id="F_3498c045-f732-4302-8e48-1c5e36ee8336"
      unitRef="U_USD">13000000</sldb:AssetAcquisitionAssumedRegulatoryMilestonePayments>
    <sldb:AssetAcquisitionAssumedCumulativeSalesMilestonePayments
      contextRef="C_a77281d0-83e9-4ceb-b6cd-ee4c4377550d"
      decimals="INF"
      id="F_a727363b-00c7-4278-9f3f-a35038797f83"
      unitRef="U_USD">27500000</sldb:AssetAcquisitionAssumedCumulativeSalesMilestonePayments>
    <us-gaap:DerivativeLiabilities
      contextRef="C_a4cf9151-2ea2-4600-8153-d60667cae2dc"
      decimals="-5"
      id="F_02cee115-e8e5-4e45-a75f-f41817a97a1d"
      unitRef="U_USD">3400000</us-gaap:DerivativeLiabilities>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="C_98efec03-6261-4884-8666-bf6095a4bb0d"
      decimals="-5"
      id="F_17a0abb8-f164-482e-b780-5028b3b9cd21"
      unitRef="U_USD">5100000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <sldb:AssetAcquisitionTransactionCosts
      contextRef="C_98efec03-6261-4884-8666-bf6095a4bb0d"
      decimals="-5"
      id="F_b7514b33-a560-41e6-82c4-07dec80845de"
      unitRef="U_USD">700000</sldb:AssetAcquisitionTransactionCosts>
    <sldb:FirstDevelopmentMilestonePayable
      contextRef="C_9e42e73a-a6c9-4461-a752-a23c4b0480e5"
      decimals="-5"
      id="F_91901942-feaa-4307-80c8-68b30c0f0af3"
      unitRef="U_USD">5000000</sldb:FirstDevelopmentMilestonePayable>
    <sldb:MilestoneLiabilityPayment
      contextRef="C_9e42e73a-a6c9-4461-a752-a23c4b0480e5"
      decimals="-5"
      id="F_a4757028-6bac-425f-84f6-faba5d4e1f72"
      unitRef="U_USD">5000000</sldb:MilestoneLiabilityPayment>
    <sldb:FirstDevelopmentMilestonePaymentInShares
      contextRef="C_7d4b4b58-8e68-4c67-aaf1-47f818c7a79f"
      decimals="INF"
      id="F_23e7ae13-767b-4940-a56f-a6f39a7255e5"
      unitRef="U_shares">975496</sldb:FirstDevelopmentMilestonePaymentInShares>
    <us-gaap:DerivativeLiabilities
      contextRef="C_9357a2d9-9713-42be-ad31-6036ccaefd7e"
      decimals="-5"
      id="F_41721cec-7452-4baa-9c33-72844314e97c"
      unitRef="U_USD">5700000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_9e42e73a-a6c9-4461-a752-a23c4b0480e5"
      decimals="-5"
      id="F_7c34c8a4-5216-4eb2-9bfd-9d4015d8ef11"
      unitRef="U_USD">3200000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_f687c476-b2f0-4131-ac4a-96ef7b8f46a9">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:32.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale securities (Note 4):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;259,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;259,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities (Note 2):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:33.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale securities (Note 4):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;104,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;104,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities (Note 2):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2025 and December 31, 2024, the fair values of the Company&#x2019;s cash equivalents and available-for-sale securities were determined using Level 2 inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company estimated the fair value of the derivative liabilities by using a Monte Carlo simulation forecasting the timing and likelihood of certain development milestone events being achieved and discounting the probability adjusted payments using an appropriate discount rate based on market interest rates. The main assumptions when determining the fair value of the derivative liabilities are the timing and probability of achieving certain milestones, the estimated volatility of the Company&#x2019;s common stock, and the discount rate. The estimated fair value presented is not necessarily indicative of an amount that could be realized in a current market exchange. The use of alternative inputs and estimation methodologies could have a material effect on these estimates of fair value.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The significant unobservable inputs used in valuing the developmental milestone derivative liabilities at each measurement date are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:27.267%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.168%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.168%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.047%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.31%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unobservable Input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Probability of achieving certain development milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Discount Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Timing of achieving certain development milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents a roll forward of activity associated with the Company&#x2019;s derivative liabilities measured using Level 3 inputs:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:78.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Developmental Milestone Derivative Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value of derivative liabilities as of January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value of derivative liabilities as of June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;es of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the change in fair value of the derivative liabilities during the three and six months ended June 30, 2025, respectively. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; gain or loss was recognized during the three or &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;It is the Company's policy to recognize transfers between levels of the fair value hierarchy, if any, at the end of the reporting period. During the six months ended June 30, 2025, and the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; transfers &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_48d73115-07e5-48ba-9dc8-452243c36a43;"&gt;&lt;span style="-sec-ix-hidden:F_08ff9217-3602-4409-8438-1bc1896ee246;"&gt;&lt;span style="-sec-ix-hidden:F_1be8fb40-e397-4eaf-b81b-88444ec1c2a6;"&gt;&lt;span style="-sec-ix-hidden:F_f576a497-b1ba-43df-9267-28b759106728;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;between&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_7f2d05a5-0a5c-4f59-b707-ed7bd008cae6;"&gt;&lt;span style="-sec-ix-hidden:F_0a9b999f-ba3c-4c75-85b3-624f3daa13ec;"&gt;&lt;span style="-sec-ix-hidden:F_3c78939b-2f88-43de-94c1-2b2dca662653;"&gt;&lt;span style="-sec-ix-hidden:F_5fe053a6-d452-4df1-bff8-51707a501d58;"&gt;&lt;span style="-sec-ix-hidden:F_2eb056d4-25d3-4b79-9779-b2b71429c937;"&gt;&lt;span style="-sec-ix-hidden:F_38c85a03-f1da-4bb9-bee4-e34e8e64f14b;"&gt;&lt;span style="-sec-ix-hidden:F_981c76c5-7e07-41ab-a103-d0737a7932bd;"&gt;&lt;span style="-sec-ix-hidden:F_81ea4290-b268-4d22-8def-51b3d1505ec7;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_3a22dccf-9544-457d-a4be-457034ddacdf;"&gt;&lt;span style="-sec-ix-hidden:F_cb4f10ce-e1bf-4e65-ab4b-c31784741e94;"&gt;&lt;span style="-sec-ix-hidden:F_4ad198f7-47e2-4a32-bdfc-243a9a08f8d7;"&gt;&lt;span style="-sec-ix-hidden:F_d2f01e79-37d9-4163-914f-7030affd467c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and Level 3.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2025, and December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company's accounts payable, accrued expenses, and other current liabilities approximated their estimated fair values due to the short-term nature of these financial instruments.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_580b497f-ea45-4c89-9e24-47d2a3d11430">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:32.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale securities (Note 4):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;259,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;259,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities (Note 2):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:33.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale securities (Note 4):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;104,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;104,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities (Note 2):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_0f922a3e-5746-46b4-a40a-2a645e0ec579"
      decimals="-3"
      id="F_93c43fec-4fe8-4d1a-9b0b-08c0393aa439"
      unitRef="U_USD">130331000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_e481b2b4-78e4-493a-b1a7-9caece635448"
      decimals="-3"
      id="F_8ab12053-1f1f-429a-ae75-81f4b5ad416f"
      unitRef="U_USD">130331000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_3c01f597-7579-48d0-bd5e-4b0f4f5104a5"
      decimals="-3"
      id="F_48bb5fe2-18c8-48a6-a39d-ec88d94a60a3"
      unitRef="U_USD">130331000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_72c75212-5fee-4f4c-8313-8a58ec31bf84"
      unitRef="U_USD">130331000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_56e1e286-3df8-4b2c-bde0-b81555ab2370"
      decimals="-3"
      id="F_8940870b-9413-4c2d-bc56-60013ca18e87"
      unitRef="U_USD">42287000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3d8b7096-5d1f-45b8-b514-de72cd28a61a"
      decimals="-3"
      id="F_30a86583-2a28-475e-99eb-115988eea4c5"
      unitRef="U_USD">42287000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_6fc1a0fa-31ae-4532-816a-741e0211781d"
      decimals="-3"
      id="F_52c21f62-1b26-439b-8948-fcd56226ece6"
      unitRef="U_USD">86890000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_5b2c2df1-3cdd-4a8f-b2dd-15e41f28a290"
      decimals="-3"
      id="F_c6e4b5b4-8ae0-4247-b65c-41d78fdfc7c8"
      unitRef="U_USD">86890000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3c01f597-7579-48d0-bd5e-4b0f4f5104a5"
      decimals="-3"
      id="F_a492eceb-a38f-4694-905f-8bfbe0ca87c5"
      unitRef="U_USD">129177000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_8d28de46-6274-4642-b1b3-548b5188948d"
      unitRef="U_USD">129177000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3c01f597-7579-48d0-bd5e-4b0f4f5104a5"
      decimals="-3"
      id="F_e5d42f37-cb4c-4c86-a7aa-d17f925c55f9"
      unitRef="U_USD">259508000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_89331459-909c-47bc-a021-ddb5569d5213"
      unitRef="U_USD">259508000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="C_40de0e1b-6102-4d68-a514-295bf97cabb8"
      decimals="-3"
      id="F_184a3021-5188-48d6-bff6-411ea42df5dd"
      unitRef="U_USD">5700000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_20d1dd10-a9b0-484e-9f5d-b2369d41add6"
      unitRef="U_USD">5700000</us-gaap:DerivativeLiabilities>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_40de0e1b-6102-4d68-a514-295bf97cabb8"
      decimals="-3"
      id="F_9f47802d-f921-4612-a457-2e8fe2c2b118"
      unitRef="U_USD">5700000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_5b359e37-fbb6-482a-a7da-141b4cea234b"
      unitRef="U_USD">5700000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_e604e914-7ff0-4f04-b45a-8f2f9ce0c9bd"
      decimals="-3"
      id="F_61eebad7-c14c-41ba-9f5b-a29bab7c10da"
      unitRef="U_USD">18088000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_f6440943-092c-4f4b-8ccf-fb54b31a4a23"
      decimals="-3"
      id="F_5846dedf-a04f-4be7-a898-fc34a441cc75"
      unitRef="U_USD">18088000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_c599352c-a66b-417c-85ef-0627fd3a2f3e"
      decimals="-3"
      id="F_fdea4d0e-be0d-4505-8aec-d23e4bf3f4c8"
      unitRef="U_USD">17434000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_ad417689-b70e-4fdd-8ee9-88aa9781e90b"
      decimals="-3"
      id="F_900b6a14-98d2-4510-bba2-6ecf7b797f85"
      unitRef="U_USD">17434000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_9d8cd037-690b-4ca0-a376-cbffcf5bfa7e"
      decimals="-3"
      id="F_612c872f-5305-4a4a-8859-0f16aa96af91"
      unitRef="U_USD">35522000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_14f81a41-6dec-42e9-ab78-bf13a8f7b984"
      unitRef="U_USD">35522000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c599352c-a66b-417c-85ef-0627fd3a2f3e"
      decimals="-3"
      id="F_cbc6f6ba-06c6-45a6-b8dd-ab23203b7920"
      unitRef="U_USD">27895000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ad417689-b70e-4fdd-8ee9-88aa9781e90b"
      decimals="-3"
      id="F_3b8d0258-3068-4d7e-bf19-7df2b868666f"
      unitRef="U_USD">27895000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_9bea4674-820e-4575-bad5-37c016a585cb"
      decimals="-3"
      id="F_8837ef66-3cbb-4375-8db8-d206b33be958"
      unitRef="U_USD">40790000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_96fa1fb9-5125-47c5-9d54-82197981893e"
      decimals="-3"
      id="F_9e3d55d2-61e4-43a7-ae7b-a4e663a68381"
      unitRef="U_USD">40790000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9d8cd037-690b-4ca0-a376-cbffcf5bfa7e"
      decimals="-3"
      id="F_83ed8e69-d146-4749-b66c-15f258e42a01"
      unitRef="U_USD">68685000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_334e769d-0e13-4c63-a9da-70dddff6f0b4"
      unitRef="U_USD">68685000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9d8cd037-690b-4ca0-a376-cbffcf5bfa7e"
      decimals="-3"
      id="F_fcac6d21-8466-4f7a-b1ff-1e6bb8185c92"
      unitRef="U_USD">104207000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_01df38fc-10f4-4498-b05c-271861bd9bb2"
      unitRef="U_USD">104207000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="C_de9d66b8-e543-4914-8cdd-a9d5b58ab10c"
      decimals="-3"
      id="F_b358ecec-3df3-4389-b2a1-f6454710fde4"
      unitRef="U_USD">3150000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_919466e6-681d-467a-baa3-fc8df98e2380"
      unitRef="U_USD">3150000</us-gaap:DerivativeLiabilities>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_de9d66b8-e543-4914-8cdd-a9d5b58ab10c"
      decimals="-3"
      id="F_c0caadd7-6413-4c22-ba05-c2eca456367a"
      unitRef="U_USD">3150000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_69bce532-787d-4289-a541-e10be74bbe3c"
      unitRef="U_USD">3150000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_4e9d17f6-a563-49ea-8c8a-ebf30d5e3167">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The significant unobservable inputs used in valuing the developmental milestone derivative liabilities at each measurement date are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:27.267%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.168%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.168%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.047%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.31%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unobservable Input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Probability of achieving certain development milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Discount Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Timing of achieving certain development milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_0b47160b-f65e-4831-8696-c2c52dd0bc33"
      decimals="INF"
      id="F_e4daaa50-ea22-4abb-be21-daf556726b99"
      unitRef="U_pure">0.28</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_7ff2cf9c-d175-4659-8c95-55b9ec8a0868"
      decimals="INF"
      id="F_78c618c8-3fef-4e64-b4df-920ed0b07576"
      unitRef="U_pure">0.70</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_f578dfc8-5ea5-41f0-905c-c47b2fe1a24b"
      decimals="3"
      id="F_665c1328-0890-4c62-af15-5bbdf7659027"
      unitRef="U_pure">0.49</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_2ab7d9ae-f3fe-411e-aa31-941b38ba994f"
      decimals="INF"
      id="F_47d5b89d-2b05-45f6-b396-b18f16b20918"
      unitRef="U_pure">0.28</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_83ce3b1a-e318-4538-962e-ec2695fed38c"
      decimals="INF"
      id="F_5b10531f-12c5-4f5d-ad11-76153d76603d"
      unitRef="U_pure">0.70</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_53878ad7-f60d-4fe9-9496-c94de89a86d4"
      decimals="3"
      id="F_6627e314-ecc8-4bbc-a4da-9befc56c2702"
      unitRef="U_pure">0.49</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_81638abc-ed31-43b9-98ef-a8496af60b08"
      decimals="3"
      id="F_aa6bd80c-20aa-4400-8829-0e74d78fde89"
      unitRef="U_pure">0.93</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_f1fd8b2d-e76f-4251-951c-312c4df54169"
      decimals="3"
      id="F_7c55606d-2e46-452d-8fd8-c30d1c31ad8c"
      unitRef="U_pure">0.93</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_60a0c528-a68d-432e-aab7-f31907efd67f"
      decimals="3"
      id="F_4a535531-e89a-41a2-920d-041d30f5b2a3"
      unitRef="U_pure">0.85</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_201319f1-99d0-4366-bfc4-d818dfd528d0"
      decimals="3"
      id="F_d3297411-8abd-4aa1-911b-10de5f6c107e"
      unitRef="U_pure">0.85</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_9a88d8b1-f41f-4be3-91c2-23b45a6dd969"
      decimals="INF"
      id="F_cba8cd2c-b373-42ab-8c64-342356dee76d"
      unitRef="U_pure">0.037</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_9b1b1aff-b775-4fdd-b8ca-07668edaa8ff"
      decimals="INF"
      id="F_e3cb5ff2-7525-461d-ad74-08258854182e"
      unitRef="U_pure">0.043</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_6b940487-af87-4229-a014-aac844c38125"
      decimals="3"
      id="F_0881df4c-9870-44b9-afd5-e77e1dcc8569"
      unitRef="U_pure">0.04</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_b5119432-e3f6-4b09-b1da-c2228aab8045"
      decimals="INF"
      id="F_314fdeab-d8d6-44f2-b959-2c5a5a10f3a2"
      unitRef="U_pure">0.042</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_6da01f39-bdb4-4e8f-b42c-7df09d145c96"
      decimals="INF"
      id="F_b1a2e673-f91a-463f-81c2-85f6156e1db8"
      unitRef="U_pure">0.043</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_67fc3ae3-0a38-4bcf-a5f8-68d2ff13b334"
      decimals="3"
      id="F_2606a329-d0af-4031-8198-d13767e0d441"
      unitRef="U_pure">0.043</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_b09c9e6d-7e59-4302-a92f-007cfefb2664"
      decimals="INF"
      id="F_25c853ae-a865-4ca8-a447-fe1853ffe0e3"
      unitRef="U_Y">0.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_509be445-ad50-4826-9d85-bc19b599ef83"
      decimals="INF"
      id="F_6e448aaa-34f3-4667-9458-a65e415163bf"
      unitRef="U_Y">3.2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_8bdf85e3-0c40-4066-9f25-f31d21aef5df"
      decimals="1"
      id="F_b7b15bb3-318a-41bc-bf98-9133e0ce0e92"
      unitRef="U_Y">1.8</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_b1dca8da-6809-47a8-bc34-ba283cb61a5e"
      decimals="INF"
      id="F_7b799ff7-e9e4-48e7-b2f5-23d1031274aa"
      unitRef="U_Y">1</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_dc97493b-5647-4a4b-aaa6-bd066ad9125f"
      decimals="INF"
      id="F_2e141e16-e3a7-4531-8dc8-8a90945178ce"
      unitRef="U_Y">3.7</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_cc190b1a-b3c2-4730-8745-e9776ccd432e"
      decimals="1"
      id="F_af8c77a3-7d64-4b37-a7d6-5bdf089d9543"
      unitRef="U_Y">2.3</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_d2e8e70a-c63d-4f36-a868-212ae28dff2b">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents a roll forward of activity associated with the Company&#x2019;s derivative liabilities measured using Level 3 inputs:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:78.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Developmental Milestone Derivative Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value of derivative liabilities as of January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value of derivative liabilities as of June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_e11bb2b4-270a-4e59-b527-8bed2f265e5e"
      unitRef="U_USD">3150000</us-gaap:DerivativeLiabilities>
    <sldb:ChangeInFairValueOfDerivativeLiabilities
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_39a01517-633b-4fba-be48-777494dd63d8"
      unitRef="U_USD">-2550000</sldb:ChangeInFairValueOfDerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_372140de-2112-4a9f-866a-879f358d184b"
      unitRef="U_USD">5700000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-5"
      id="F_4540bf90-f8a3-4f3a-95d7-8091063bd027"
      unitRef="U_USD">-900000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-5"
      id="F_b4904a5d-fb8f-4f9a-9715-db487b696816"
      unitRef="U_USD">-2600000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="INF"
      id="F_c3d6d6b0-9534-41d3-b4b1-bca30a335ee5"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="INF"
      id="F_9a18399c-006a-4f92-8c1f-a83caaf346f3"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="INF"
      id="F_01cdfaeb-103a-46fe-ba5a-7b76e0a7f1eb"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c"
      decimals="INF"
      id="F_be148fb4-4cbc-47e4-b8d2-3e80a0f0dea9"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="INF"
      id="F_0c3cc998-3928-40ee-942b-46b5ef43316f"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c"
      decimals="INF"
      id="F_10af4575-5cdf-4c8e-8e13-1adcb308dcb8"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2
      contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c"
      decimals="INF"
      id="F_3e7525bc-a221-45d3-b627-8b430af58d43"
      unitRef="U_USD">0</sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2>
    <sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="INF"
      id="F_32da3084-c042-4b88-9e95-d043945bbcc3"
      unitRef="U_USD">0</sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2>
    <sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="INF"
      id="F_e765419d-8bdd-4dbf-b497-cfebe69c35bb"
      unitRef="U_USD">0</sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2>
    <sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2
      contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c"
      decimals="INF"
      id="F_8712b1f8-d71e-43af-876f-73d9afd038df"
      unitRef="U_USD">0</sldb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_d092a821-f972-4f0d-a349-38048bb5656f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. Available-for-Sale Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the Company's available-for-sale securities is presented below:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:49.39%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.239%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.093%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.239%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.093%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.239%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.093%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.239%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.093%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="15" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Treasury bills maturing in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government bonds maturing in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.03%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.232%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.232%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.232%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.232%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Treasury bills maturing in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government bonds maturing in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total available-for sale securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average contractual maturity of the Company&#x2019;s available-for-sale securities was approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025, and December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_21117239-cecd-49c9-a9ff-ab38b46c74a8">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the Company's available-for-sale securities is presented below:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:49.39%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.239%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.093%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.239%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.093%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.239%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.093%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.239%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.093%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="15" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Treasury bills maturing in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government bonds maturing in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.03%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.232%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.232%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.232%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.232%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Treasury bills maturing in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government bonds maturing in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total available-for sale securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3d8b7096-5d1f-45b8-b514-de72cd28a61a"
      decimals="-3"
      id="F_55cbc64c-c79e-4a81-96c0-0f524688ca46"
      unitRef="U_USD">42290000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_3d8b7096-5d1f-45b8-b514-de72cd28a61a"
      decimals="-3"
      id="F_2675e865-5e7f-4484-9afa-481cc8b437b9"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3d8b7096-5d1f-45b8-b514-de72cd28a61a"
      decimals="-3"
      id="F_fa37df58-9173-42f1-a9ab-dde8df79c38f"
      unitRef="U_USD">42287000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_5b2c2df1-3cdd-4a8f-b2dd-15e41f28a290"
      decimals="-3"
      id="F_7e9d3d95-5fc5-4844-b29d-8abc4c247ea6"
      unitRef="U_USD">86925000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_5b2c2df1-3cdd-4a8f-b2dd-15e41f28a290"
      decimals="-3"
      id="F_7768a0ee-2094-4ff3-a3a2-5fd816f2d17c"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_5b2c2df1-3cdd-4a8f-b2dd-15e41f28a290"
      decimals="-3"
      id="F_b8a611e4-c06a-4c4a-9a9e-136660e6cc17"
      unitRef="U_USD">38000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_5b2c2df1-3cdd-4a8f-b2dd-15e41f28a290"
      decimals="-3"
      id="F_befcd9c3-d7b0-408e-bcb4-4979c40a5cc0"
      unitRef="U_USD">86890000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_e5a6d730-1fc8-44b9-be91-1015abe121d1"
      unitRef="U_USD">129215000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_3481dd95-70f7-40f8-af26-c1989022029c"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_ab3f612c-13e3-4eaf-94f9-7022a96d864d"
      unitRef="U_USD">41000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_51055e9a-cce2-48e3-83d9-fcd8a02bad65"
      unitRef="U_USD">129177000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ad417689-b70e-4fdd-8ee9-88aa9781e90b"
      decimals="-3"
      id="F_37c36b2d-27bb-48ca-8a93-208711dcde74"
      unitRef="U_USD">27879000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ad417689-b70e-4fdd-8ee9-88aa9781e90b"
      decimals="-3"
      id="F_99f8d656-f55f-4b02-9b22-b1261baaf781"
      unitRef="U_USD">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ad417689-b70e-4fdd-8ee9-88aa9781e90b"
      decimals="-3"
      id="F_0efe2f9d-9c11-4cf0-8d9e-13142d8d2fb4"
      unitRef="U_USD">27895000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_96fa1fb9-5125-47c5-9d54-82197981893e"
      decimals="-3"
      id="F_cc9983ce-fdf5-4607-8170-17f2ef0373b0"
      unitRef="U_USD">40759000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_96fa1fb9-5125-47c5-9d54-82197981893e"
      decimals="-3"
      id="F_fc982fc2-eeaa-46bc-86db-2b40f0fc0a34"
      unitRef="U_USD">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_96fa1fb9-5125-47c5-9d54-82197981893e"
      decimals="-3"
      id="F_06a766b2-092b-4de8-9d45-64c607c28578"
      unitRef="U_USD">40790000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_5a551901-55cc-46f8-85c3-630dfaa9c601"
      unitRef="U_USD">68638000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_8ed5609f-0a3a-4384-8f4f-e84c9c514a01"
      unitRef="U_USD">47000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_8074b2f4-d5f6-473e-a940-f4f73db9937d"
      unitRef="U_USD">68685000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <sldb:AvailableForSaleSecuritiesWeightedAverageMaturityPeriod
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_35dcdc6d-c7fd-494d-b422-4049550fb15b">P0Y7M6D</sldb:AvailableForSaleSecuritiesWeightedAverageMaturityPeriod>
    <sldb:AvailableForSaleSecuritiesWeightedAverageMaturityPeriod
      contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c"
      id="F_b8c15ef8-d2fe-4701-8ad6-1b7d8b41a069">P0Y6M</sldb:AvailableForSaleSecuritiesWeightedAverageMaturityPeriod>
    <sldb:PrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_d6edc11c-a2a9-4e50-876c-e3a84cfc2e26">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.899999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, &lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid other and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</sldb:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_839dcbd8-9252-41f3-9d24-32ccc7543d88">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.899999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, &lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid other and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <sldb:PrepaidResearchAndDevelopmentExpensesCurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_70ef1c0a-46ae-4154-a8f6-83444128a02f"
      unitRef="U_USD">7235000</sldb:PrepaidResearchAndDevelopmentExpensesCurrent>
    <sldb:PrepaidResearchAndDevelopmentExpensesCurrent
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_57ea9529-b60b-4a71-8c16-bad4ec88cee0"
      unitRef="U_USD">6731000</sldb:PrepaidResearchAndDevelopmentExpensesCurrent>
    <sldb:PrepaidOtherAndOtherCurrentAssets
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_dadd220b-b03e-4f69-bc3d-605286d2f5f6"
      unitRef="U_USD">3295000</sldb:PrepaidOtherAndOtherCurrentAssets>
    <sldb:PrepaidOtherAndOtherCurrentAssets
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_50857f5e-11f3-4062-b402-d1ef4ba41ee9"
      unitRef="U_USD">1651000</sldb:PrepaidOtherAndOtherCurrentAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_377b95e2-e6bc-4d9f-b97b-714b11df1036"
      unitRef="U_USD">10530000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_6c29032e-324a-40ad-b7d2-c796cbe6183a"
      unitRef="U_USD">8382000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_b890e920-9a30-4437-a750-6cf23b80dcd2">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, &lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued milestone payment (Note 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <sldb:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_62a5ffee-d989-4fda-89da-c2ca16f58e29">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, &lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued milestone payment (Note 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</sldb:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_be626f41-f068-4534-943f-caf740d9baca"
      decimals="-3"
      id="F_726faf82-6990-4b5f-82f6-0cde43a6e3e5"
      unitRef="U_USD">9944000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_d3cfa6b7-1a5b-468f-8cdb-18aa29db656f"
      decimals="-3"
      id="F_c7de5e0f-63de-4e74-b013-1e049152e676"
      unitRef="U_USD">7268000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_f2feab69-5f72-4f85-8dcc-ead4e1b51215"
      decimals="-3"
      id="F_cddd90d0-25bb-45d4-ac40-f8b42b7a9bcb"
      unitRef="U_USD">4618000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_bef71313-6e23-4dd9-8241-70fe0eb1517e"
      decimals="-3"
      id="F_bf91d6ac-5dd7-46ae-b5ce-322af6982350"
      unitRef="U_USD">6221000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_8fe8d85b-2d6f-43f1-b624-cffb99addfa2"
      decimals="-3"
      id="F_0e6af3be-3598-482b-a901-3fc3fca39029"
      unitRef="U_USD">5000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_067da7b3-96d4-4d90-9b0a-89c4f29d4125"
      decimals="-3"
      id="F_fdd72b60-4c0c-4b08-b6a0-a6e573d32825"
      unitRef="U_USD">1984000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_5a879064-7c82-4954-9b22-68f6cb214734"
      decimals="-3"
      id="F_34316ac8-76fc-4fa8-b40d-547d71385b6c"
      unitRef="U_USD">1363000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_412b40a4-53e1-40df-9cbf-fde9f48bca13"
      unitRef="U_USD">16546000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_7090c17f-8e68-4f25-8058-b4cf47ff5f55"
      unitRef="U_USD">19852000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_4e6cc974-2767-4a03-b818-3e05eb15ad36">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. Stockholders' Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 11, 2024, the Company issued and sold in a private placement &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,973,103&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock at a price per share of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.53&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and, to one investor in lieu of shares of common stock, pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,712,478&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.529&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per pre-funded warrant, (the "January 2024 Private Placement"). The Company received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of net proceeds from the January 2024 Private Placement after deducting offering costs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 19, 2025, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,739,810&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock at a price per share of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.03&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and, to certain investors in lieu of shares of common stock, pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,888,340&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.029&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per pre-funded warrant (the "February 2025 Offering"). The Company received approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of net proceeds from the February 2025 Offering after deducting underwriting discounts and commissions and offering costs.&lt;br/&gt;&lt;br/&gt;The Company determined the pre-funded warrants met the criteria for equity classification. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; warrants were exercised during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_15fd7743-86bb-49ec-b84d-abc109f772fc"
      decimals="INF"
      id="F_9474361a-6e76-4eca-8127-ba2e762a595d"
      unitRef="U_shares">16973103</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_71f48d56-146a-435b-9b14-f7e66b80f25a"
      decimals="INF"
      id="F_40899468-77da-492a-a00b-24df62220a10"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.53</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_ea7a5a80-b49b-47e8-a532-b9e2fbc30677"
      decimals="INF"
      id="F_8185fa8e-0f59-4e2d-be4b-c93cf8569394"
      unitRef="U_shares">2712478</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_ea7a5a80-b49b-47e8-a532-b9e2fbc30677"
      decimals="3"
      id="F_6c32435c-b06e-4e2b-b805-4ad913fb7932"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.529</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_a91acc16-ec5d-42f1-ae23-d52f464888f9"
      decimals="-5"
      id="F_07651602-9d6b-4d4a-a70c-68c3b0333942"
      unitRef="U_USD">103700000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b8a19bcd-ecaa-4d90-ba75-094d33c6ca5e"
      decimals="INF"
      id="F_727a2822-3a1d-4e70-818a-64fa9954345d"
      unitRef="U_shares">35739810</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_2fba1c08-32ae-4049-8fbf-3094c4c366bc"
      decimals="INF"
      id="F_de0f1f0f-d9b2-4c9d-9511-cfce19af884c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.03</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_852de8fa-b9b7-41ee-aac7-7d5c2c175c8c"
      decimals="INF"
      id="F_24d92b83-b0d9-4aee-98bb-68bca9ccac08"
      unitRef="U_shares">13888340</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sldb:ClassOfWarrantOrRightPricePerShare
      contextRef="C_852de8fa-b9b7-41ee-aac7-7d5c2c175c8c"
      decimals="3"
      id="F_a409e44b-f3b8-4aaa-b8cf-4c8e074d4851"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.029</sldb:ClassOfWarrantOrRightPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_2161a6b4-6f9c-4f31-a82d-4f7221bf0362"
      decimals="-5"
      id="F_cd872122-e65f-4231-b46c-1eddb426b7f5"
      unitRef="U_USD">188000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <sldb:ClassOfWarrantOrRightsExercised
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="INF"
      id="F_6b7d9c74-b4bb-4509-878a-b36b18635ac8"
      unitRef="U_shares">0</sldb:ClassOfWarrantOrRightsExercised>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_a23cc27a-3132-4af2-8396-e14a18d74490">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Equity-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has classified equity-based compensation expense in its condensed consolidated statements of operations as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:43.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2025, the Company&#x2019;s approved equity incentive plans include: the 2018 Omnibus Incentive Plan (the "2018 Plan"); Amended and Restated 2020 Equity Incentive Plan, as amended (the "2020 Plan"); the Amended and Restated 2021 Employee Stock Purchase Plan; and the 2024 Inducement Stock Incentive Plan (the "2024 Plan"). These plans are administered by the Board of Directors (the "Board") and permit the granting of stock options, stock appreciation rights, restricted stock, restricted stock units (the "RSUs"), performance awards, and other stock&#x2011;based or cash-based awards. Upon the adoption of the 2020 Plan, the Company no longer grants new equity awards under its 2018 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Amended and Restated 2020 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 12, 2025 and June 11, 2024, the Company's stockholders approved amendments to the 2020 Plan to increase the number of shares of common stock reserved for issuance under the plan by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025, there &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,450,074&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; stock options outstanding, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,433,589&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; RSUs outstanding, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,074,188&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; performance stock units outstanding, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,173,225&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares remained available for future issuance under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2024 Inducement Stock Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2024, the Board approved the 2024 Plan, which provides for the reservation of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock for equity granted as an inducement material to the individual&#x2019;s entering into employment with the Company and in accordance with the requirements of Nasdaq Stock Market Rule 5635(c)(4). As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; stock options outstanding, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;492,256&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; RSUs outstanding, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;386,111&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares remained available for future issuance under the 2024 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below summarizes the activity with respect to stock options for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2025:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.91%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:6.841%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining Contractual Life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,927,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.01&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;642,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeitures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,324,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.14&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,324,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.14&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,668,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.41&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The assumptions used in the Black-Scholes option-pricing model for all stock options granted during each period presented are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:44.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;128.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividends&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.31&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.31&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average grant date fair values of stock options granted during the three months ended June 30, 2025 and 2024 were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.84&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.52&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, and the weighted average grant date fair values of stock options granted during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.83&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; an&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;d $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, resp&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognize&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;d $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; m&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;illion of equity-based compensation expense in connection with stock options during the three months ended June 30, 2025 and 2024, respectively. During the six months ended June 30, 2025 and 2024, the Company recognized equity-based compensation expense in connection with stock opt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million an&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;d $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million, respectively. As of June 30, 2025, there was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; m&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;illion of total unrecognized equity-based compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes activity with respect to RSUs during the six months ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested RSUs at January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,480,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,188,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;280,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeitures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;286,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested RSUs at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,102,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of equity-based compensation expense in connection with RSUs during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended June 30, 2025 and 2024, respectively. During the six months ended June 30, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recognized equity-based compensation expense in connection with RSUs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of total unrecognized equity-based compensation expense related to nonvested RSUs, which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Performance Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2024, the Board approved a grant of performance-based restricted stock unit awards ("PSUs" or "Performance Awards") to the Company&#x2019;s executive team. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Each PSU represents the contingent right to receive one share of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; These Performance Awards provide for the vesting of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee&#x2019;s continued service with the Company (the "Approval Conditions").&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Performance Milestones are tied to the achievement of certain business objectives and are non-market and non-financial in nature. The Board will determine that all Approval Conditions have been satisfied and the number of units that will ultimately vest on the 2026 Evaluation Date, which will occur in the first quarter of 2026, and the 2027 Evaluation Date, which will occur in the first quarter of 2027. A maximum of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the target number of RSUs may vest at the 2026 Evaluation Date and the percentage of the target number of RSUs allocable to any Performance Milestone that has not been achieved on or prior to the 2027 Evaluation Date shall be cancelled.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes activity with respect to PSUs during the six months ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested PSUs at January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,165,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeitures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested PSUs at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,074,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;equity-based compensation expense in connection with PSUs during the three months ended June 30, 2025 and 2024, respectively. During the six months ended June 30, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recognized equity-based compensation expense in connection with PSUs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of unrecognized equity-based compensation expense related to nonvested PSUs based on the achievement of all Performance Milestones, which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_22c70847-7870-4282-9908-c9f4dcc27a38">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has classified equity-based compensation expense in its condensed consolidated statements of operations as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:43.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0a6c72f5-7161-423a-a27c-3a3a231889bb"
      decimals="-3"
      id="F_2837cc85-269d-4249-963b-bba923152a2c"
      unitRef="U_USD">1116000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9611295f-24d3-4b23-a0ec-62392a8b5c79"
      decimals="-3"
      id="F_39d92011-b27f-4052-a6be-5782c217701d"
      unitRef="U_USD">832000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_43201d5f-3fb8-4b8f-bcc4-042087291ecb"
      decimals="-3"
      id="F_6a84f5de-a20b-4f6d-b851-6edeefdda9e1"
      unitRef="U_USD">2218000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_de18e3d4-4b86-42dc-b5ca-c6702ad6d2fd"
      decimals="-3"
      id="F_d90ab604-8ce5-4cfd-8beb-d67a64816dd8"
      unitRef="U_USD">1380000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_232dc221-d840-420d-bab1-6b1e75c2fc36"
      decimals="-3"
      id="F_99f72d5d-21b8-4aa4-86b9-4b8fc87ef0d4"
      unitRef="U_USD">2029000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_fbce7cd5-1b2d-4126-b546-1df19016fd56"
      decimals="-3"
      id="F_156c270e-b81b-4e96-9402-a0220e718a4e"
      unitRef="U_USD">1260000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6b0dcf24-e56b-4005-a22c-bc5fb3b0c9b1"
      decimals="-3"
      id="F_12632dc6-e6f0-4adf-b676-c3155298c4d9"
      unitRef="U_USD">4268000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b0005526-5d37-401c-9d72-c06da6f9106f"
      decimals="-3"
      id="F_8712d9d3-d292-4d52-b5ee-e250dc550397"
      unitRef="U_USD">2323000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_3031335f-15a8-4732-a40f-0719dc04f94c"
      unitRef="U_USD">3145000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_9d3eaee8-69ad-47e2-8b42-c7c5faf88ed0"
      unitRef="U_USD">2092000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_2439ddb3-0e71-448f-997d-15fb0980f98b"
      unitRef="U_USD">6486000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_c183a77b-7e69-4125-8427-4cffe9f94f1c"
      unitRef="U_USD">3703000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_121327c9-aee0-4ee4-85a3-a872dfee9989"
      decimals="INF"
      id="F_16f50379-1f0b-4c04-94d1-eaab2868a495"
      unitRef="U_shares">9000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_fbba6851-1a6e-4905-b021-c0bc7d5f40f1"
      decimals="INF"
      id="F_68a26beb-160a-4d6d-b787-ac06426f69a4"
      unitRef="U_shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_6402365a-b943-488b-9bd3-756393cdd6c8"
      decimals="INF"
      id="F_a040b587-9c5d-4134-a69f-a18f7ce4c540"
      unitRef="U_shares">2450074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_9b696383-da9c-41fe-9065-748e255e49a0"
      decimals="INF"
      id="F_0bf27b1f-3b36-4593-8c77-0f884fb9bd26"
      unitRef="U_shares">2433589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_12e60ca8-b4cb-4f88-953a-ab24ae966a5e"
      decimals="INF"
      id="F_e3d433f7-ed7d-4ee6-889f-22285b4608d4"
      unitRef="U_shares">2074188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_f2a02817-6c5e-449e-a477-05d0a714df5a"
      decimals="INF"
      id="F_6946bb10-bac4-4150-80ca-6b2acf044b95"
      unitRef="U_shares">9173225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_3bd6d252-5e42-42c5-8ae2-0186828da84b"
      decimals="INF"
      id="F_ad34b0ac-2718-49b8-b2c5-d83b37db2973"
      unitRef="U_shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_f2a02817-6c5e-449e-a477-05d0a714df5a"
      decimals="INF"
      id="F_fb8cb85d-2717-4ab2-a0bc-f64e488422b3"
      unitRef="U_shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_f2a02817-6c5e-449e-a477-05d0a714df5a"
      decimals="INF"
      id="F_e7e92b38-4ba4-48d7-b3e8-7e94d474ca94"
      unitRef="U_shares">492256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_99ed3715-c191-4bd1-af0a-a1b55b1bcf04"
      decimals="INF"
      id="F_ba056263-c65b-4e35-9e99-b4f319cd3fc5"
      unitRef="U_shares">386111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_fcb7ce95-713a-4460-8fd9-3857466c0948">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below summarizes the activity with respect to stock options for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2025:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.91%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:6.841%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining Contractual Life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,927,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.01&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;642,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeitures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,324,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.14&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,324,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.14&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,668,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.41&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="0"
      id="F_56bee5c9-6f40-471b-815f-d236a4c18ec5"
      unitRef="U_shares">2927937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="2"
      id="F_0a26701a-ffd8-4b06-b37b-fd4265cb0efe"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_c267e437-1d14-4b97-ac07-f8b08257fa7c"
      id="F_e7437aaa-59a4-4817-a1f4-a2125b65bed2">P8Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_26b5acbd-5ff3-48a2-8fca-f885dfc4adb9"
      decimals="-3"
      id="F_044bacf3-18ce-480e-b41a-50204f766053"
      unitRef="U_USD">193000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="0"
      id="F_09f842b3-f962-432b-ba8d-6bd002d04ac5"
      unitRef="U_shares">642148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="2"
      id="F_d3fff342-c67a-41b6-aebe-40c0c7b8471b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="0"
      id="F_5caf50cf-1775-43e3-99e9-92ddf070ef6b"
      unitRef="U_shares">2733</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="2"
      id="F_17106c48-1f3c-425e-9154-1113c80dfa66"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="0"
      id="F_76aa5d34-88c7-4e74-b031-55153e271acf"
      unitRef="U_shares">139165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="2"
      id="F_7612f1a7-2bf6-46b4-9a94-797116c0dcdc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">67.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="0"
      id="F_ae2d121c-548f-41fc-8475-0f8606dd78c9"
      unitRef="U_shares">103882</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="2"
      id="F_7d062735-cb33-4042-a54c-04d8b5059eb5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="0"
      id="F_b3355c3b-e197-4170-8e7c-63a9f463dc59"
      unitRef="U_shares">3324305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="2"
      id="F_ce88f8eb-a8f6-471c-9c28-1b6b2c000480"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_c48e0f62-bc6a-4c1a-b954-d15ac500d7c3">P8Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_cf6fc7a1-1590-4d64-8bbe-b91fd7765675"
      unitRef="U_USD">467000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="0"
      id="F_238d0eb2-77ea-4b6f-850c-4f3a69a31f23"
      unitRef="U_shares">3324305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="2"
      id="F_d3b87de6-87e2-45bf-8d2d-8b9f94979936"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_858c7314-3d86-4d33-9653-7a2025b6ea56">P8Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_18505c20-c077-4829-a704-367510d1ced9"
      unitRef="U_USD">467000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="0"
      id="F_bad18198-5a2b-4554-969e-0c850a801472"
      unitRef="U_shares">1668986</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="2"
      id="F_815eb63b-dd25-451e-b4d8-425100dafe2f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_bf5287b5-36a5-4c19-95c0-bf98b5119faa">P7Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_e98d2034-0473-4580-b8ab-275ff9f46ae7"
      decimals="-3"
      id="F_c80a1859-4c1a-40f0-b858-aa6835261717"
      unitRef="U_USD">107000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_0cbda973-ba65-4162-bff6-31f5d64da29c">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The assumptions used in the Black-Scholes option-pricing model for all stock options granted during each period presented are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:44.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;128.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividends&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.31&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.31&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="2"
      id="F_a0a2e61c-e5d7-4c44-a11f-805f811a98a3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.58</sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice>
    <sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="2"
      id="F_f367e450-6dfa-4e25-b129-c1e2d5b4694e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.51</sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice>
    <sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice
      contextRef="C_e6208aaa-c289-4498-b410-b580516620c2"
      decimals="2"
      id="F_d3eef135-1fc5-4245-8f37-35ca0ee3b7fe"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.1</sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice>
    <sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice
      contextRef="C_6ff04018-2bea-4ce0-9148-099fbf986bc0"
      decimals="2"
      id="F_dce78b4e-dbbe-4369-8899-9d139f81e3ef"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.58</sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice>
    <sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice
      contextRef="C_4fd6bf31-bc0e-49ed-9f27-784e94385c06"
      decimals="2"
      id="F_9c382993-3efa-44d7-8469-039179b5d7d0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.76</sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice>
    <sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice
      contextRef="C_a537fa02-a1f1-49bd-84cb-8936826a3d3b"
      decimals="2"
      id="F_85835563-4eb3-48b0-9de7-6610dca44722"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.85</sldb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="3"
      id="F_01fd11b9-33d1-4b31-8cc7-54b266b88995"
      unitRef="U_pure">1.142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="3"
      id="F_9584163f-b856-440b-bde4-dd4d9233b6ae"
      unitRef="U_pure">1.229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="3"
      id="F_c4ef685c-4889-4610-85ee-722cce83f2d6"
      unitRef="U_pure">1.121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="3"
      id="F_9e28d381-166e-4376-bfea-6ae92279eda0"
      unitRef="U_pure">1.142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="3"
      id="F_f3bec24d-714c-488d-a6d7-dce305523f90"
      unitRef="U_pure">1.229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="3"
      id="F_6a45647d-2714-43f8-ad1e-a1b3cfcf5248"
      unitRef="U_pure">1.287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="2"
      id="F_4bb6775b-d42f-47f3-8931-880066c045f0"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="2"
      id="F_9be38802-6592-4cf5-8ca8-467e98e8f36b"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="2"
      id="F_ed27de38-b230-42ac-bce6-ca2a1ca66d1e"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="2"
      id="F_d8032eb1-f543-4df9-a827-c9457a030fd8"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      id="F_5e1ab501-bb80-4f48-bec4-ec2ec792d8f1">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      id="F_d025f403-1182-462f-a7a7-012b98ed6f7b">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e6208aaa-c289-4498-b410-b580516620c2"
      id="F_d934ba21-f70f-4d88-83c7-73875340c64b">P5Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_6ff04018-2bea-4ce0-9148-099fbf986bc0"
      id="F_8284f44e-5eb4-45c1-b20f-77952a48b9c6">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_4fd6bf31-bc0e-49ed-9f27-784e94385c06"
      id="F_b78a5e4f-deb0-40e5-befc-96a579ee8ea8">P5Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_a537fa02-a1f1-49bd-84cb-8936826a3d3b"
      id="F_2338e74f-bea7-48dd-b78c-6e2aecb8af8a">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="3"
      id="F_da6d0952-25bd-4f7e-80c2-453e766661ae"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="3"
      id="F_b2909fd3-e92e-4ec7-a23d-f3b0dd6d6479"
      unitRef="U_pure">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="3"
      id="F_d23889b0-03eb-480e-9a8d-1ba5445735cc"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="3"
      id="F_20f2e557-4e67-4e67-8ba0-6988910b4e67"
      unitRef="U_pure">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="3"
      id="F_6604bb0f-0fa3-4f82-b303-a6e8bfc8c51d"
      unitRef="U_pure">0.038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="3"
      id="F_df27fe7e-8151-43d5-ba80-b7f6ffead346"
      unitRef="U_pure">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="2"
      id="F_79c5cb56-e927-46af-8a06-04f8dc28035f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="2"
      id="F_d0470835-cf70-49d7-bb48-d5ff5c230e52"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="2"
      id="F_dadc3720-2e31-4c48-9d8b-803390d5160b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="2"
      id="F_7b5d8922-3ba6-4275-93fc-f12af3541362"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="C_a99a7b4d-7291-4c75-bfcd-d11cbca34f46"
      decimals="-5"
      id="F_7c14a6c8-522f-418e-b1c6-91f27fc5a577"
      unitRef="U_USD">1200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0e4f4078-c836-4440-84d7-12e84fc594a9"
      decimals="-5"
      id="F_c2822216-5324-4765-be49-c4ce720e585d"
      unitRef="U_USD">1100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_8e9b54e8-5db3-4a2c-8d9c-a1cdfcf765d7"
      decimals="-5"
      id="F_033af1b2-0680-491e-b94e-9a5f94f50cdd"
      unitRef="U_USD">2600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_e87fa31e-fdf3-4012-9418-bb7b976dcee5"
      decimals="-5"
      id="F_19db7b38-ce6d-47d4-8fbe-ea57acd6576a"
      unitRef="U_USD">2000000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_8db1bca0-aca7-44cf-ac19-c26a69173dfc"
      decimals="-5"
      id="F_3e6ec7a0-dc43-4df4-b2b6-378eb2e09dcf"
      unitRef="U_USD">8300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_cb1343da-e01f-4ce0-adcf-425c15f992be"
      id="F_f34e3a42-aa76-415b-8e1e-f74cd139af05">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_4fcd5acc-34df-44bb-806f-e67cea6a3c17">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes activity with respect to RSUs during the six months ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested RSUs at January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,480,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,188,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;280,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeitures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;286,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested RSUs at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,102,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_583384bc-be95-42dd-89bf-a2fab8449504"
      decimals="INF"
      id="F_0f2e69d1-0776-4512-8025-ea4d91063284"
      unitRef="U_shares">1480272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_583384bc-be95-42dd-89bf-a2fab8449504"
      decimals="2"
      id="F_fcd82b0a-0016-449c-a6d7-e71e9c1f2a08"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_14340f1e-e345-45e4-974c-789fb31cb960"
      decimals="INF"
      id="F_03ddc33e-f486-4614-87d0-6dce0403acb0"
      unitRef="U_shares">2188256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_14340f1e-e345-45e4-974c-789fb31cb960"
      decimals="2"
      id="F_0e198101-81f3-44c5-a27b-523b6dc3f781"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_14340f1e-e345-45e4-974c-789fb31cb960"
      decimals="INF"
      id="F_3c2ffef2-25d9-4889-9dc7-119ecec030f4"
      unitRef="U_shares">280159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_14340f1e-e345-45e4-974c-789fb31cb960"
      decimals="2"
      id="F_42e50e08-4c30-491d-97c8-80701a6cb73e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_14340f1e-e345-45e4-974c-789fb31cb960"
      decimals="INF"
      id="F_6a30b2a0-30ff-4258-9b9f-307186d76edf"
      unitRef="U_shares">286245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_14340f1e-e345-45e4-974c-789fb31cb960"
      decimals="2"
      id="F_f5b3eb25-57b5-4074-b915-9fcd9f3520c5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_75db7873-c2fc-46ea-9e70-df62f468e4fd"
      decimals="INF"
      id="F_31b3a0fc-d4b1-4747-9fe9-ed980eb8c150"
      unitRef="U_shares">3102124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_75db7873-c2fc-46ea-9e70-df62f468e4fd"
      decimals="2"
      id="F_1e3d81f9-7ed2-4680-b8b4-c9a55ed7c7a6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="C_d565f4e4-dbfe-4ca6-945a-b8666899b153"
      decimals="-5"
      id="F_e26019a1-0381-49fa-b146-5dafc34c4c7f"
      unitRef="U_USD">1100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_486f1e6a-12ec-4d97-ab93-1669ee41521b"
      decimals="-5"
      id="F_7e4beb6f-b7ec-47d9-9454-51fd3ac80998"
      unitRef="U_USD">800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_14340f1e-e345-45e4-974c-789fb31cb960"
      decimals="-5"
      id="F_3d9b8044-3bd1-47fb-ba42-b2aad380eca5"
      unitRef="U_USD">2100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_abb48ec4-81de-4bdb-9fa1-14513edb7132"
      decimals="-5"
      id="F_48189a59-36ca-416b-866f-b919675c53fa"
      unitRef="U_USD">1400000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_75db7873-c2fc-46ea-9e70-df62f468e4fd"
      decimals="-5"
      id="F_3b4b42a0-1316-4d04-b206-22bcee181fd6"
      unitRef="U_USD">12600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_14340f1e-e345-45e4-974c-789fb31cb960"
      id="F_54450cb7-e36c-4232-8391-b26cc869b180">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="C_c465dc2b-b8fb-4093-a52c-31899dca9507"
      id="F_0ac1b0f7-86ce-4ef1-bc7c-9ddec8303ded">Each PSU represents the contingent right to receive one share of the Company&#x2019;s common stock.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_491fb316-de76-4866-ae64-7e0adfba538c"
      decimals="2"
      id="F_c3da6f3e-4bbe-4083-913e-0570de154717"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_491fb316-de76-4866-ae64-7e0adfba538c"
      decimals="2"
      id="F_a2d94816-f255-4f50-9ec5-b18186ce050d"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_8027ca1b-8c30-4b47-a073-f77aa702b73b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes activity with respect to PSUs during the six months ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested PSUs at January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,165,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeitures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested PSUs at June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,074,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_41f2e884-47b6-44f0-b8af-b6fb07efc6e9"
      decimals="INF"
      id="F_2616b747-073f-4c7f-a7bd-51229824fc77"
      unitRef="U_shares">2165325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_41f2e884-47b6-44f0-b8af-b6fb07efc6e9"
      decimals="2"
      id="F_5c6eb90b-b0a2-491e-9593-f68eaeb12f9c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_c465dc2b-b8fb-4093-a52c-31899dca9507"
      decimals="INF"
      id="F_2b4672b0-e4b8-4df0-8d96-c3b453a32d48"
      unitRef="U_shares">91137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_c465dc2b-b8fb-4093-a52c-31899dca9507"
      decimals="2"
      id="F_3d7d0061-3f9d-459a-9091-c278b1b4d74f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_2ad125fb-5eec-4263-bb8f-8a0e750525f8"
      decimals="INF"
      id="F_b06a00a6-a81c-4d67-8a5f-15a9be59768b"
      unitRef="U_shares">2074188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_2ad125fb-5eec-4263-bb8f-8a0e750525f8"
      decimals="2"
      id="F_24edfb14-71a6-4f45-95ed-24aab36c10ac"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="C_2f3b7b59-d24f-40f5-8461-a913f95f8f17"
      decimals="-5"
      id="F_64f89125-eef0-47ba-959d-2b32f317603d"
      unitRef="U_USD">800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_47b90c1a-3b38-4665-b877-e9472f8c44fd"
      decimals="-5"
      id="F_85c48285-000c-43b3-a335-f09ad234c352"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_c465dc2b-b8fb-4093-a52c-31899dca9507"
      decimals="-5"
      id="F_ab266467-608c-4c0a-8175-4088c962f5d4"
      unitRef="U_USD">1800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_00a86f62-54eb-4a64-af3c-51b16552e396"
      decimals="-5"
      id="F_be585ba4-e217-454e-b1b4-e40122c1dbfe"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_2ad125fb-5eec-4263-bb8f-8a0e750525f8"
      decimals="-5"
      id="F_de12b510-0a05-4a8d-92fc-cead7dcfcbab"
      unitRef="U_USD">3800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_c465dc2b-b8fb-4093-a52c-31899dca9507"
      id="F_b9a3cf54-b412-45f1-9cbc-e50c6a6527d0">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_b983c86a-f948-4a41-89e9-73f4e9e3be43">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Letter of Credit&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had an outstanding letter of credit in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million at June 30, 2025 and December 31, 2024, respectively, which is required as a condition of the Company&#x2019;s office and laboratory lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Indemnification Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with its executive officers and members of its Board that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as executive officers or directors of the Company. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of June 30, 2025 and December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which the Company is focused. The Company is not aware of any material legal proceedings or claims as of June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_fb4b367c-a294-43f5-af08-b0aea809fc01"
      decimals="-5"
      id="F_18ec3cd7-3014-4a85-bb8b-2ac6babe07d3"
      unitRef="U_USD">1900000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_8bf9e100-f231-4586-b5dd-838b0884dd87"
      decimals="-5"
      id="F_ee08599b-85a4-45d1-9cfe-5b2a9442cb8f"
      unitRef="U_USD">2000000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_2625c529-f4e6-4d7c-a2ed-fb21ff0dbc94">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of the Company's basic and diluted net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:42.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares used to compute net loss per share, basic and &lt;br/&gt;&#160;&#160;&#160;diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average shares of common stock &lt;br/&gt;&#160;&#160;&#160;outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,539,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,221,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,476,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,981,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average shares of pre-funded warrants to &lt;br/&gt;&#160;&#160;&#160;purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,600,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,712,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,840,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,563,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average shares of common stock &lt;br/&gt;&#160;&#160;&#160;outstanding used to compute basic and diluted &lt;br/&gt;&#160;&#160;&#160;net loss per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,140,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,934,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,317,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,544,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Included within weighted average shares of common stock outstanding for the three and six months ended June 30, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,600,818&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,712,478&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock issuable upon the exercise of the pre-funded warrants, respectively. The pre-funded warrants are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The outstanding securities presented below were excluded from the calculation of net loss per share because the inclusion of such securities would have been anti-dilutive due to the Company&#x2019;s net loss per share during the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:59.552%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.903%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.903%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three and Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,324,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,890,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,102,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,397,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested performance stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,074,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,165,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares subject to employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;216,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,719,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,711,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_17288e05-e2de-4397-953a-e0e71b1aaa13">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of the Company's basic and diluted net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:42.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares used to compute net loss per share, basic and &lt;br/&gt;&#160;&#160;&#160;diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average shares of common stock &lt;br/&gt;&#160;&#160;&#160;outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,539,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,221,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,476,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,981,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average shares of pre-funded warrants to &lt;br/&gt;&#160;&#160;&#160;purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,600,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,712,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,840,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,563,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average shares of common stock &lt;br/&gt;&#160;&#160;&#160;outstanding used to compute basic and diluted &lt;br/&gt;&#160;&#160;&#160;net loss per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,140,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,934,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,317,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,544,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="-3"
      id="F_9984bfba-9706-43eb-92c2-7017bed768fb"
      unitRef="U_USD">-39480000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="-3"
      id="F_21bee669-8edb-4632-ae3e-f59fd0d7bba7"
      unitRef="U_USD">-25072000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="-3"
      id="F_44f2c5ad-eb53-42aa-a7c5-06c4c17977e2"
      unitRef="U_USD">-78762000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="-3"
      id="F_bfe6e9ab-4544-4b80-af5c-9dcedb6ed904"
      unitRef="U_USD">-49375000</us-gaap:ProfitLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_aa5bd7ea-c156-4475-926c-e8eddecefd5c"
      decimals="0"
      id="F_f1e6318d-5aff-4984-97c4-0b02053b43bf"
      unitRef="U_shares">77539468</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_aa5bd7ea-c156-4475-926c-e8eddecefd5c"
      decimals="0"
      id="F_f10af600-4828-4a24-b98c-e2c41d0c5d92"
      unitRef="U_shares">77539468</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_07264e86-c26a-42ce-a8e5-89f7da5029a5"
      decimals="0"
      id="F_4a52403e-64a5-4aca-9c52-0fd2789f15ae"
      unitRef="U_shares">38221883</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_07264e86-c26a-42ce-a8e5-89f7da5029a5"
      decimals="0"
      id="F_5ba97e2d-35f0-4678-b814-022abdc85762"
      unitRef="U_shares">38221883</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6573f6ee-fbf9-4133-87fb-c760c893c038"
      decimals="0"
      id="F_a4b407a5-5faf-4c59-a61e-3f956a1d1b3e"
      unitRef="U_shares">67476597</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6573f6ee-fbf9-4133-87fb-c760c893c038"
      decimals="0"
      id="F_6444e267-77b4-41c1-9bd5-61a4829b989b"
      unitRef="U_shares">67476597</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7b3b5780-a030-4090-8d67-27c854d7392e"
      decimals="0"
      id="F_87b100d6-6df8-4029-999d-9af57245fe0a"
      unitRef="U_shares">36981426</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7b3b5780-a030-4090-8d67-27c854d7392e"
      decimals="0"
      id="F_1a604e4b-f43e-4afa-975a-4adf2851527f"
      unitRef="U_shares">36981426</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_9afdb802-6737-49db-88fa-ef76a745ff30"
      decimals="0"
      id="F_371965e6-2c42-44f3-8ea3-4871f2644358"
      unitRef="U_shares">16600818</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_9afdb802-6737-49db-88fa-ef76a745ff30"
      decimals="0"
      id="F_d23eb371-19a5-478e-af53-73ee937c9f3d"
      unitRef="U_shares">16600818</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_8353f2de-6a98-4421-bb84-ff19b77babb2"
      decimals="0"
      id="F_f34e7078-ac73-4e72-b62e-6f28baa33cdb"
      unitRef="U_shares">2712478</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_8353f2de-6a98-4421-bb84-ff19b77babb2"
      decimals="0"
      id="F_c24fc963-11fc-4042-a66f-9744ba7ec738"
      unitRef="U_shares">2712478</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7aca4bd1-bcd1-48cc-9174-dd70c602d117"
      decimals="0"
      id="F_01417785-92e6-46f0-a2a6-65d27e3e19fd"
      unitRef="U_shares">12840991</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7aca4bd1-bcd1-48cc-9174-dd70c602d117"
      decimals="0"
      id="F_c84a9568-f0c2-4fc7-ae37-14cabd672da7"
      unitRef="U_shares">12840991</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_dd44ede6-4ec4-41dd-9ad2-bab26319cb0f"
      decimals="0"
      id="F_7215235a-bfe4-47b3-8bde-740d0ac8cdcc"
      unitRef="U_shares">2563441</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_dd44ede6-4ec4-41dd-9ad2-bab26319cb0f"
      decimals="0"
      id="F_fff0958a-9967-4944-8dee-256395c965d5"
      unitRef="U_shares">2563441</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="0"
      id="F_92b3ba36-eef2-430d-8109-5684deb7f0f5"
      unitRef="U_shares">94140286</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="0"
      id="F_136f44e0-4706-4b3a-ae8e-37be384df7a8"
      unitRef="U_shares">94140286</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="0"
      id="F_fc418fe8-d8ee-49c6-ac28-16ac9301df9d"
      unitRef="U_shares">40934361</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="0"
      id="F_c6bccac1-1f05-47b4-bb92-758cb76a3de2"
      unitRef="U_shares">40934361</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="0"
      id="F_868e13a2-bea5-48ec-a378-9c662cc17e19"
      unitRef="U_shares">80317588</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="0"
      id="F_3b0b4ef2-0809-43f7-aef3-3f6e621f0208"
      unitRef="U_shares">80317588</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="0"
      id="F_2f2c074a-98e0-4607-9bbd-e22cab09728b"
      unitRef="U_shares">39544867</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="0"
      id="F_85f79d0f-f51a-4df9-8ef9-adf77e53e08c"
      unitRef="U_shares">39544867</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="2"
      id="F_eb1e9320-e860-42b5-9e54-70eadf3f4b2d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0c822986-4362-4137-a232-16bb78f035a6"
      decimals="2"
      id="F_09c44849-9bd3-43ea-a472-682ceef0760d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="2"
      id="F_7b21749b-8f15-47b5-994e-87dc4803f6ed"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="2"
      id="F_bd3b303e-c397-4b8c-8d7c-8b93d5b733d9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="2"
      id="F_5ea5ac8a-a58c-4126-a573-cef4d5589f8e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="2"
      id="F_6d48da99-786f-4a14-8741-85ed6289946d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="2"
      id="F_62e4f518-d87b-4eb2-9504-e1de7aa9904b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="2"
      id="F_de6f7b60-bb51-49bc-8a4f-ff259759a8ee"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.25</us-gaap:EarningsPerShareDiluted>
    <sldb:CommonStockIssuableUponExerciseOfPrefundedWarrants
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="INF"
      id="F_d64ae1c0-7bc4-4f1d-9561-9bc1148b95f1"
      unitRef="U_shares">16600818</sldb:CommonStockIssuableUponExerciseOfPrefundedWarrants>
    <sldb:CommonStockIssuableUponExerciseOfPrefundedWarrants
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="INF"
      id="F_ea135f90-6c89-4e71-ac49-02ae352ecdf8"
      unitRef="U_shares">2712478</sldb:CommonStockIssuableUponExerciseOfPrefundedWarrants>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_fd8d6e92-48fb-4c03-97b4-f103d27c6750">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The outstanding securities presented below were excluded from the calculation of net loss per share because the inclusion of such securities would have been anti-dilutive due to the Company&#x2019;s net loss per share during the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:59.552%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.903%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.903%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three and Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,324,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,890,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,102,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,397,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested performance stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,074,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,165,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares subject to employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;216,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,719,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,711,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3b99cdb3-b726-4538-afce-a3801788fd13"
      decimals="INF"
      id="F_0474c261-e7de-47d9-a646-ec2e06d62ad4"
      unitRef="U_shares">3324305</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e39737d4-96a5-4208-8dd7-4b8993b23f93"
      decimals="INF"
      id="F_8d2c1eb5-bb42-47a6-bec6-49745163cfd5"
      unitRef="U_shares">3324305</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_78d04ead-7986-4a8d-8aac-14a63c569702"
      decimals="INF"
      id="F_92df6ff6-8265-467d-ac19-db3445baee42"
      unitRef="U_shares">2890045</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_176c63c3-fc59-41a1-a932-f7bf7ba8d013"
      decimals="INF"
      id="F_b2a787c3-d400-4db6-9f8b-51023d455996"
      unitRef="U_shares">2890045</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_467782df-d0fd-4099-acab-ff5bc1e9ec7f"
      decimals="INF"
      id="F_ca1ec4c0-b2e5-4f1a-9868-45ec41de0af3"
      unitRef="U_shares">3102124</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a14e5cf5-aed7-466a-9751-7832ebbdde1c"
      decimals="INF"
      id="F_8c721f50-413c-4ff1-bf11-e72f6b40b407"
      unitRef="U_shares">3102124</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_55f5bc14-0f86-46cb-af50-0c8b568c21fb"
      decimals="INF"
      id="F_ba1914db-8523-4129-9e1d-4add5b9a790d"
      unitRef="U_shares">1397063</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4a834eb1-0754-4f74-8286-ff19658ed3c2"
      decimals="INF"
      id="F_09f2ae1f-ce53-4fc6-bf83-e36d906ec7a8"
      unitRef="U_shares">1397063</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bdad8e63-34f9-4989-b0b3-c9137d6a4917"
      decimals="INF"
      id="F_bfeb0b60-8084-4e81-9649-281426e4680a"
      unitRef="U_shares">2074188</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2724230e-7cdb-46f3-a217-d029bcdf1d1f"
      decimals="INF"
      id="F_c015a2c6-abee-4201-8438-85f9226efcb7"
      unitRef="U_shares">2074188</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_27139884-7a96-4e34-a577-e29115f6dc2f"
      decimals="INF"
      id="F_bb1821ec-b29c-4111-bb1f-138d1a1c6fea"
      unitRef="U_shares">2165325</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a698c408-5f01-47f3-97e9-aa9f2ef0cb86"
      decimals="INF"
      id="F_858d7f62-72ed-49e1-8b9f-b4712e6665fe"
      unitRef="U_shares">2165325</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cfc39ec9-d790-474a-94f7-86f38a3344d7"
      decimals="INF"
      id="F_3f481283-5528-4fee-ae5f-e275460b395d"
      unitRef="U_shares">216802</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_be43a57e-e5c9-467b-9ef0-ad48c48eb300"
      decimals="INF"
      id="F_d98505ea-3f9f-40c7-97be-2b11a4e39805"
      unitRef="U_shares">216802</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f540fe1f-6760-4c9b-902f-500441ab7298"
      decimals="INF"
      id="F_ee645c94-473b-4060-87fa-6007621da35a"
      unitRef="U_shares">250188</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5a01998c-63bd-4627-945b-11d0879cf70c"
      decimals="INF"
      id="F_74a47298-98fb-4a67-913e-ded32c5a26af"
      unitRef="U_shares">250188</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1e06cedf-6a5d-4473-b93f-a7e7df103a67"
      decimals="INF"
      id="F_23c7e743-8a68-43cf-bb44-a14018ba5289"
      unitRef="U_shares">2563</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8930ba8b-d153-4438-8796-eeb7f6030e7f"
      decimals="INF"
      id="F_ee0684d7-ed0f-42d2-ac72-2e77635039b8"
      unitRef="U_shares">2563</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cc99c4e5-1df8-4c44-830a-6d130cb72576"
      decimals="INF"
      id="F_919b8c95-662d-4c4a-ba35-32608b096664"
      unitRef="U_shares">9230</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_fe6f9f56-6572-4eb9-ab24-7440ff654b29"
      decimals="INF"
      id="F_84dc57db-eedd-4aba-b69d-0360f4f432b0"
      unitRef="U_shares">9230</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      decimals="INF"
      id="F_664fab99-4741-45d3-977c-8057180aab7d"
      unitRef="U_shares">8719982</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="INF"
      id="F_ee157183-566d-4467-94d5-02cfb3d51952"
      unitRef="U_shares">8719982</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9a594a20-a7ac-4b49-ae92-d855f2517334"
      decimals="INF"
      id="F_3162e0ba-03a6-4df5-8216-ea960fecc45b"
      unitRef="U_shares">6711851</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_84148e2b-261e-4a0d-b76f-daecd9f88a20"
      decimals="INF"
      id="F_432aa69f-6320-4b1a-9737-4846d28fd443"
      unitRef="U_shares">6711851</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_2e36c46e-950c-457f-84ef-35af221e2199">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#2d2d2d;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#2d2d2d;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment and manages its business activities primarily in North America and on a consolidated basis. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. All of the Company&#x2019;s tangible assets are held in the United States.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accounting policies of the Company are the same as those described in the summary of significant accounting policies.&lt;/span&gt;&lt;span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s chief operating decision maker ("CODM") is its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_1cf5d347-81ef-4291-87b4-2b55905c5532;"&gt;&lt;span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;chief executive officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM assesses performance for the Company and decides how to allocate resources based on net loss as reported on the condensed consolidated statements of operations. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The annual budgeting process is the primary mechanism used to make these decisions.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The financial information also helps in making performance assessments using budgeted versus actual results.&lt;/span&gt;&lt;span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents segment expenses, other segment items, and segment net loss for the periods presented:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.05%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.402%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.402%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.402%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.742%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Segment expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;SGT-003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;SGT-501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External R&amp;amp;D other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Internal R&amp;amp;D expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,608&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External G&amp;amp;A expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Internal G&amp;amp;A expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Condensed consolidated net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:4.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:95.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Internal expenses consisted primarily of payroll and related costs, temporary services, and travel and entertainment.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items primarily included other program costs, equity-based compensation expense, and depreciation and amortization expense.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The measure of segment assets is reported on the balance sheet as total condensed consolidated assets.&lt;/span&gt;&lt;span style="color:#2d2d2d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="INF"
      id="F_f94fdb48-74a3-4424-b60d-c07b4d40f000"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      decimals="INF"
      id="F_215f1864-17fc-420e-b501-76419930b86d"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_52aa506c-ec71-417c-9c37-cf9483397723">The CODM assesses performance for the Company and decides how to allocate resources based on net loss as reported on the condensed consolidated statements of operations. The annual budgeting process is the primary mechanism used to make these decisions.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_19264942-c904-4880-a469-940fad2f6bc6">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents segment expenses, other segment items, and segment net loss for the periods presented:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.05%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.402%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.402%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.402%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.742%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Segment expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;SGT-003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;SGT-501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External R&amp;amp;D other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Internal R&amp;amp;D expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,608&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External G&amp;amp;A expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Internal G&amp;amp;A expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Condensed consolidated net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:4.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:95.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Internal expenses consisted primarily of payroll and related costs, temporary services, and travel and entertainment.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items primarily included other program costs, equity-based compensation expense, and depreciation and amortization expense.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_944b7695-ad9e-4285-960c-d72aec8f998b"
      decimals="-3"
      id="F_7459fdda-7bce-4879-8600-a821268514f1"
      unitRef="U_USD">12219000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0fbb6db9-57f0-4f7f-b13e-14af89636f51"
      decimals="-3"
      id="F_afabd80b-4adf-494c-9493-aecc3cb69ab2"
      unitRef="U_USD">2434000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a1407b45-da9f-427b-a243-aed2688829bf"
      decimals="-3"
      id="F_d5645fc3-0f3b-45df-8fe9-f0b658cfff4f"
      unitRef="U_USD">21385000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_64acb9d0-11e7-4835-9467-65098353bd5a"
      decimals="-3"
      id="F_9bdc08e2-015e-4f7c-bc53-828543afa10b"
      unitRef="U_USD">4340000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a81e0a2f-1838-4bd5-b00c-b952678b1b8f"
      decimals="-3"
      id="F_6d0b7667-2f19-4135-956b-cb89ceb55c6a"
      unitRef="U_USD">2223000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0ba68b2f-2dd1-4b87-be43-3f478cee6225"
      decimals="-3"
      id="F_cd34f12b-a8d4-4db8-bbe2-d17c3870aaf2"
      unitRef="U_USD">3422000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7ad823ef-64bf-4820-ae9b-3a36a9790d50"
      decimals="-3"
      id="F_0b144290-8ec8-4a6f-b7db-0fd4ce90439f"
      unitRef="U_USD">6689000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3a78b22e-0dc9-4c13-a887-682de9fd6013"
      decimals="-3"
      id="F_e157846f-1643-4225-82e3-6ad4d481fa0e"
      unitRef="U_USD">7229000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_4f06942d-922b-469e-b680-72ee9ddfb246"
      decimals="-3"
      id="F_f0f3808c-eee7-4914-89dc-62a3b26682a8"
      unitRef="U_USD">3116000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_0bea57c3-1523-47ea-b446-8474ebbcbd5b"
      decimals="-3"
      id="F_7aa4532e-66ee-44c5-9191-d258d65f8070"
      unitRef="U_USD">1845000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_51655aef-3697-4608-9eff-6b7264ab13cf"
      decimals="-3"
      id="F_a0c89137-4bf5-4df2-b701-09ff167d2cde"
      unitRef="U_USD">5886000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_b4ad5fd9-ef1a-4596-931b-e54dc3cf2c0f"
      decimals="-3"
      id="F_3b6423eb-cbbe-4e80-a654-b174678e6acc"
      unitRef="U_USD">4573000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8b6d4398-1614-4734-94af-3cd9579e2b1f"
      decimals="-3"
      id="F_bd0488a2-5982-4c0d-8427-7cd764b1afaa"
      unitRef="U_USD">6765000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c96a2be2-695f-4030-9b68-3a5f63eb3737"
      decimals="-3"
      id="F_7803374c-5d25-4f3d-842d-d0c64bcd986d"
      unitRef="U_USD">4921000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_77693677-27d9-4472-b43c-7dbe442a2eb4"
      decimals="-3"
      id="F_1fdbb3f3-306e-4a07-872a-ef5e8888e888"
      unitRef="U_USD">13608000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_50c05ebc-0ef9-47a4-a21f-7d16f9e48827"
      decimals="-3"
      id="F_1e814cac-ab32-4e76-abde-3b3858347347"
      unitRef="U_USD">10298000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_b83fb99f-5542-4814-ad4c-4ef8642b65e7"
      decimals="-3"
      id="F_d3b5628e-baee-4939-bdb8-43490a8af74c"
      unitRef="U_USD">5279000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_b1d34379-d268-419a-8067-a8edfa178a20"
      decimals="-3"
      id="F_065e0b9f-c216-48e8-a982-0a3351d043c4"
      unitRef="U_USD">5449000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_3189d97a-043c-49ab-94df-6b80295ced76"
      decimals="-3"
      id="F_197f461c-18fd-41a3-9dc4-66095d8f35e6"
      unitRef="U_USD">10156000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_d8ff73cd-5ef2-4164-872f-1f12e3c684c1"
      decimals="-3"
      id="F_bf1ab42d-5a25-4c15-9742-06b22d4b47d9"
      unitRef="U_USD">10883000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_6d7a65a2-794d-4455-9e96-273e3ca49062"
      decimals="-3"
      id="F_cc3b7589-324b-4fc5-935a-9ea4f75dbd7a"
      unitRef="U_USD">3360000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_3bc4e127-2055-433c-a159-d00bb0f66d84"
      decimals="-3"
      id="F_8fa2a1c1-f4c7-485e-9cfd-c80a924130fb"
      unitRef="U_USD">3037000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_1159e041-c22c-4bf8-b89b-c533c983f202"
      decimals="-3"
      id="F_fb7956d3-803a-40b6-9b94-a33c7013c2a1"
      unitRef="U_USD">6823000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0dbb79eb-088e-4b58-8b14-1c279ad90bd4"
      decimals="-3"
      id="F_df3340fb-8bbd-4a63-a6d4-485e71013839"
      unitRef="U_USD">6003000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_cd72c633-01e1-43fb-bc8c-26f766ba3391"
      decimals="-3"
      id="F_5e808d49-9bf4-474c-b7b5-953f005e5ca6"
      unitRef="U_USD">8731000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_0afad434-c6ec-493a-ad86-7a15c47c34be"
      decimals="-3"
      id="F_934fd9bd-c27c-4de6-9da1-3c287bc2738a"
      unitRef="U_USD">6680000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_253f834d-9848-47a4-80e2-b6033edab9fc"
      decimals="-3"
      id="F_7e836d7f-60dc-40af-81c0-d5cf21feed01"
      unitRef="U_USD">17198000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_96ed23d1-a1e6-4659-bc21-14e675a602f3"
      decimals="-3"
      id="F_a443cd96-bd52-4a95-ae9b-d6a38df5d2fc"
      unitRef="U_USD">11324000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_cd72c633-01e1-43fb-bc8c-26f766ba3391"
      decimals="-3"
      id="F_c1726ca6-d014-4e93-94b0-08241bbf416c"
      unitRef="U_USD">-2213000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0afad434-c6ec-493a-ad86-7a15c47c34be"
      decimals="-3"
      id="F_085df943-29d9-44d2-8b6e-fca459e21eb8"
      unitRef="U_USD">-2716000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_253f834d-9848-47a4-80e2-b6033edab9fc"
      decimals="-3"
      id="F_f462104b-98e6-46d9-8aad-46ae9d64b4d6"
      unitRef="U_USD">-2983000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_96ed23d1-a1e6-4659-bc21-14e675a602f3"
      decimals="-3"
      id="F_4c362931-d495-46af-bcdc-601c8576a63a"
      unitRef="U_USD">-5275000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="C_cd72c633-01e1-43fb-bc8c-26f766ba3391"
      decimals="-3"
      id="F_a04a2774-3018-4a26-8cef-f5ea4f2fbbbe"
      unitRef="U_USD">-39480000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0afad434-c6ec-493a-ad86-7a15c47c34be"
      decimals="-3"
      id="F_c03a103b-6ac8-4ede-852d-1e8deaa2b34d"
      unitRef="U_USD">-25072000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_253f834d-9848-47a4-80e2-b6033edab9fc"
      decimals="-3"
      id="F_699a386a-fa15-4918-b656-d06668a2633b"
      unitRef="U_USD">-78762000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_96ed23d1-a1e6-4659-bc21-14e675a602f3"
      decimals="-3"
      id="F_cda64691-eb27-4149-8bf7-6999ad7f7e24"
      unitRef="U_USD">-49375000</us-gaap:ProfitLoss>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_020b0edf-b857-4f10-ac8b-229a8c436b55"
      id="F_fcc499b8-43a9-4433-a575-04dc61a9d9fb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. Subsequent Events&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On July 4, 2025, the One Big Beautiful Bill Act (the "OBBBA") was enacted in the United States. The OBBBA includes significant changes to federal tax law and other regulatory provisions that may impact the Company. As this legislation was not signed into law until the third quarter of 2025, the impacts are not included in the Company's operating results for the three and six months ended June 30, 2025. The Company will evaluate the impact of the newly enacted tax law and its impact on the Company's forecasted annual effective tax rate in subsequent periods as required.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      id="F_0f803b07-bebc-4c3f-86b4-f9ca688b392d">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      id="F_eb7ef3cb-7af6-4b0b-a350-712b07fdc236">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      id="F_7225c11b-390e-4c31-b799-d859f72e3c34">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_583bdf28-4c22-41d2-bf7a-5f216b481995"
      id="F_6fa49657-f60c-4268-832d-a0ef4d25e08d">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
